{"idB": "906709_12_item1_p0_s1", "idA": "906709_11_item1_p0_s1", "sentA": "Our current proprietary product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.", "sentB": "Our current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.", "type": 2, "words": ["<tag1>", "Our", "current", "proprietary", "product", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology.", "<tag2>", "Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology.", "<tag3>"], "wordsA": ["Our", "current", "proprietary", "product", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology."], "wordsB": ["Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s8", "idA": "906709_11_item1_p101_s2", "sentA": "The agreement expires on the later of ten years from the grant of first marketing authorization in the designated territory, which occurred in March 2003, or the expiration of our last relevant patent containing a valid claim.", "sentB": "We are currently in the process of compiling and performing verification procedures on the preliminary interim results from the patients enrolled to date in this study.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "on", "the", "later", "of", "ten", "years", "from", "the", "grant", "of", "first", "marketing", "authorization", "in", "the", "designated", "territory,", "which", "occurred", "in", "March", "2003,", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "We", "are", "currently", "in", "the", "process", "of", "compiling", "and", "performing", "verification", "procedures", "on", "the", "preliminary", "interim", "results", "from", "the", "patients", "enrolled", "to", "date", "in", "this", "study.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "on", "the", "later", "of", "ten", "years", "from", "the", "grant", "of", "first", "marketing", "authorization", "in", "the", "designated", "territory,", "which", "occurred", "in", "March", "2003,", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["We", "are", "currently", "in", "the", "process", "of", "compiling", "and", "performing", "verification", "procedures", "on", "the", "preliminary", "interim", "results", "from", "the", "patients", "enrolled", "to", "date", "in", "this", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s9", "idA": "906709_11_item1_p104_s0", "sentA": "a PEGylated anti-vascular endothelial growth factor aptamer currently approved in the U.S. and E.U. for use in treating age-related macular degeneration.", "sentB": "Results from this study and communication with government health authorities in both the U.S. and E.U. will guide our future development and regulatory strategy for NKTR-102 in ovarian cancer.", "type": 2, "words": ["<tag1>", "a", "PEGylated", "anti-vascular", "endothelial", "growth", "factor", "aptamer", "currently", "approved", "in", "the", "U.S.", "and", "E.U.", "for", "use", "in", "treating", "age-related", "macular", "degeneration.", "<tag2>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "U.S.", "and", "E.U.", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "NKTR-102", "in", "ovarian", "cancer.", "<tag3>"], "wordsA": ["a", "PEGylated", "anti-vascular", "endothelial", "growth", "factor", "aptamer", "currently", "approved", "in", "the", "U.S.", "and", "E.U.", "for", "use", "in", "treating", "age-related", "macular", "degeneration."], "wordsB": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "U.S.", "and", "E.U.", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "NKTR-102", "in", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s3", "idA": "906709_11_item1_p105_s2", "sentA": "We have the right to receive manufacturing revenue on a cost-plus basis and royalties on net product sales.", "sentB": "Patients in the BEACON study will be randomized on a 1:1 basis to receive either single-agent NKTR-102 or a single agent of physician s choice.", "type": 2, "words": ["<tag1>", "We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "a", "cost-plus", "basis", "and", "royalties", "on", "net", "product", "sales.", "<tag2>", "Patients", "in", "the", "BEACON", "study", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "NKTR-102", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag3>"], "wordsA": ["We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "a", "cost-plus", "basis", "and", "royalties", "on", "net", "product", "sales."], "wordsB": ["Patients", "in", "the", "BEACON", "study", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "NKTR-102", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p57_s4", "idA": "906709_11_item1_p105_s2", "sentA": "We have the right to receive manufacturing revenue on a cost-plus basis and royalties on net product sales.", "sentB": "This study will randomize patients on a 1:1 basis to receive single-agent NKTR-102 or a single agent chosen from a defined set of physician s choice alternatives.", "type": 2, "words": ["<tag1>", "We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "a", "cost-plus", "basis", "and", "royalties", "on", "net", "product", "sales.", "<tag2>", "This", "study", "will", "randomize", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "NKTR-102", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives.", "<tag3>"], "wordsA": ["We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "a", "cost-plus", "basis", "and", "royalties", "on", "net", "product", "sales."], "wordsB": ["This", "study", "will", "randomize", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "NKTR-102", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p14_s6", "idA": "906709_11_item1_p10_s0", "sentA": "With our expertise as a leader in the PEGylation field, we have advanced our technology platform to include first-generation PEGylation as well as new advanced polymer conjugate chemistries that can be tailored in very specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs useful in many disease areas.", "sentB": "Our Technology Platform As a leader in the PEGylation field, we have advanced our technology platform to include first-generation PEGylation technology as well as new advanced polymer conjugate chemistries that can be tailored in very specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs useful in many disease areas.", "type": 2, "words": ["<tag1>", "With", "our", "expertise", "as", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "first-generation", "PEGylation", "as", "well", "as", "new", "advanced", "polymer", "conjugate", "chemistries", "that", "can", "be", "tailored", "in", "very", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "useful", "in", "many", "disease", "areas.", "<tag2>", "Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "first-generation", "PEGylation", "technology", "as", "well", "as", "new", "advanced", "polymer", "conjugate", "chemistries", "that", "can", "be", "tailored", "in", "very", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "useful", "in", "many", "disease", "areas.", "<tag3>"], "wordsA": ["With", "our", "expertise", "as", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "first-generation", "PEGylation", "as", "well", "as", "new", "advanced", "polymer", "conjugate", "chemistries", "that", "can", "be", "tailored", "in", "very", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "useful", "in", "many", "disease", "areas."], "wordsB": ["Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "first-generation", "PEGylation", "technology", "as", "well", "as", "new", "advanced", "polymer", "conjugate", "chemistries", "that", "can", "be", "tailored", "in", "very", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "useful", "in", "many", "disease", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p23_s0", "idA": "906709_11_item1_p111_s0", "sentA": "is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis.", "sentB": "Peginesatide has completed Phase 3 clinical studies and has been filed for approval with the FDA to treat renal anemia in patients with chronic kidney disease on dialysis by our partner Affymax, Inc.", "type": 2, "words": ["<tag1>", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis.", "<tag2>", "Peginesatide", "has", "completed", "Phase", "3", "clinical", "studies", "and", "has", "been", "filed", "for", "approval", "with", "the", "FDA", "to", "treat", "renal", "anemia", "in", "patients", "with", "chronic", "kidney", "disease", "on", "dialysis", "by", "our", "partner", "Affymax,", "Inc.", "<tag3>"], "wordsA": ["is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis."], "wordsB": ["Peginesatide", "has", "completed", "Phase", "3", "clinical", "studies", "and", "has", "been", "filed", "for", "approval", "with", "the", "FDA", "to", "treat", "renal", "anemia", "in", "patients", "with", "chronic", "kidney", "disease", "on", "dialysis", "by", "our", "partner", "Affymax,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p15_s1", "idA": "906709_11_item1_p11_s0", "sentA": "The majority of PEGylated drugs approved over the last fourteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of pharmaceutical companies.", "sentB": "Nearly all of the PEGylated drugs approved over the last fifteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of biotechnology and pharmaceutical companies.", "type": 2, "words": ["<tag1>", "The", "majority", "of", "PEGylated", "drugs", "approved", "over", "the", "last", "fourteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "pharmaceutical", "companies.", "<tag2>", "Nearly", "all", "of", "the", "PEGylated", "drugs", "approved", "over", "the", "last", "fifteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "biotechnology", "and", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["The", "majority", "of", "PEGylated", "drugs", "approved", "over", "the", "last", "fourteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "pharmaceutical", "companies."], "wordsB": ["Nearly", "all", "of", "the", "PEGylated", "drugs", "approved", "over", "the", "last", "fifteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "biotechnology", "and", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p34_s2", "idA": "906709_11_item1_p11_s0", "sentA": "The majority of PEGylated drugs approved over the last fourteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of pharmaceutical companies.", "sentB": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property.", "type": 2, "words": ["<tag1>", "The", "majority", "of", "PEGylated", "drugs", "approved", "over", "the", "last", "fourteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "pharmaceutical", "companies.", "<tag2>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property.", "<tag3>"], "wordsA": ["The", "majority", "of", "PEGylated", "drugs", "approved", "over", "the", "last", "fourteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "pharmaceutical", "companies."], "wordsB": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p16_s0", "idA": "906709_11_item1_p12_s0", "sentA": "PEGylation is a versatile technology since PEG (polyethylene glycol) is a water soluble, amphiphilic, non-toxic, non-immunogenic compound that is safely cleared from the body.", "sentB": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that is safely cleared from the body.", "type": 2, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "since", "PEG", "(polyethylene", "glycol)", "is", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body.", "<tag2>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "since", "PEG", "(polyethylene", "glycol)", "is", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body."], "wordsB": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p16_s2", "idA": "906709_11_item1_p12_s2", "sentA": "However, in spite of its widespread success in commercial drugs, there are limitations with the first-generation PEGylation approaches used with biologics.", "sentB": "However, in spite of its widespread success in commercial drugs, there are limitations with the first-generation PEGylation approaches that have been used with biologics.", "type": 2, "words": ["<tag1>", "However,", "in", "spite", "of", "its", "widespread", "success", "in", "commercial", "drugs,", "there", "are", "limitations", "with", "the", "first-generation", "PEGylation", "approaches", "used", "with", "biologics.", "<tag2>", "However,", "in", "spite", "of", "its", "widespread", "success", "in", "commercial", "drugs,", "there", "are", "limitations", "with", "the", "first-generation", "PEGylation", "approaches", "that", "have", "been", "used", "with", "biologics.", "<tag3>"], "wordsA": ["However,", "in", "spite", "of", "its", "widespread", "success", "in", "commercial", "drugs,", "there", "are", "limitations", "with", "the", "first-generation", "PEGylation", "approaches", "used", "with", "biologics."], "wordsB": ["However,", "in", "spite", "of", "its", "widespread", "success", "in", "commercial", "drugs,", "there", "are", "limitations", "with", "the", "first-generation", "PEGylation", "approaches", "that", "have", "been", "used", "with", "biologics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p16_s3", "idA": "906709_11_item1_p12_s3", "sentA": "Earlier PEGylation approaches were limited, in that they could not be used successfully to improve small molecule drugs, antibody fragments and peptides, all of which could potentially benefit from the application of the technology.", "sentB": "Earlier PEGylation technology applications were limited, in that they could not be used successfully to improve small molecule drugs, antibody fragments and peptides, all of which could potentially benefit from the application of the technology.", "type": 2, "words": ["<tag1>", "Earlier", "PEGylation", "approaches", "were", "limited,", "in", "that", "they", "could", "not", "be", "used", "successfully", "to", "improve", "small", "molecule", "drugs,", "antibody", "fragments", "and", "peptides,", "all", "of", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology.", "<tag2>", "Earlier", "PEGylation", "technology", "applications", "were", "limited,", "in", "that", "they", "could", "not", "be", "used", "successfully", "to", "improve", "small", "molecule", "drugs,", "antibody", "fragments", "and", "peptides,", "all", "of", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology.", "<tag3>"], "wordsA": ["Earlier", "PEGylation", "approaches", "were", "limited,", "in", "that", "they", "could", "not", "be", "used", "successfully", "to", "improve", "small", "molecule", "drugs,", "antibody", "fragments", "and", "peptides,", "all", "of", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology."], "wordsB": ["Earlier", "PEGylation", "technology", "applications", "were", "limited,", "in", "that", "they", "could", "not", "be", "used", "successfully", "to", "improve", "small", "molecule", "drugs,", "antibody", "fragments", "and", "peptides,", "all", "of", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p16_s4", "idA": "906709_11_item1_p12_s4", "sentA": "Other limitations of the early approaches of PEGylation technology include resulting sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs.", "sentB": "Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs.", "type": 2, "words": ["<tag1>", "Other", "limitations", "of", "the", "early", "approaches", "of", "PEGylation", "technology", "include", "resulting", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs.", "<tag2>", "Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs.", "<tag3>"], "wordsA": ["Other", "limitations", "of", "the", "early", "approaches", "of", "PEGylation", "technology", "include", "resulting", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs."], "wordsB": ["Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p45_s3", "idA": "906709_11_item1_p142_s0", "sentA": "The assessment of jurisdiction within the FDA is based upon the primary mode of action of the drug or the location of the specific expertise in one of the centers.", "sentB": "There is a three month safety extension following one of the two 12-week studies.", "type": 2, "words": ["<tag1>", "The", "assessment", "of", "jurisdiction", "within", "the", "FDA", "is", "based", "upon", "the", "primary", "mode", "of", "action", "of", "the", "drug", "or", "the", "location", "of", "the", "specific", "expertise", "in", "one", "of", "the", "centers.", "<tag2>", "There", "is", "a", "three", "month", "safety", "extension", "following", "one", "of", "the", "two", "12-week", "studies.", "<tag3>"], "wordsA": ["The", "assessment", "of", "jurisdiction", "within", "the", "FDA", "is", "based", "upon", "the", "primary", "mode", "of", "action", "of", "the", "drug", "or", "the", "location", "of", "the", "specific", "expertise", "in", "one", "of", "the", "centers."], "wordsB": ["There", "is", "a", "three", "month", "safety", "extension", "following", "one", "of", "the", "two", "12-week", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p45_s0", "idA": "906709_11_item1_p171_s0", "sentA": "There are no oral drugs approved specifically for the treatment of opioid-induced constipation (OIC) or opioid bowel dysfunction (OBD).", "sentB": "efficacy and safety of NKTR-118 for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "type": 2, "words": ["<tag1>", "There", "are", "no", "oral", "drugs", "approved", "specifically", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "or", "opioid", "bowel", "dysfunction", "(OBD).", "<tag2>", "efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag3>"], "wordsA": ["There", "are", "no", "oral", "drugs", "approved", "specifically", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "or", "opioid", "bowel", "dysfunction", "(OBD)."], "wordsB": ["efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s0", "idA": "906709_11_item1_p178_s0", "sentA": "There are currently no approved drugs on the market for adjunctive treatment or prevention of Gram-negative pneumonias in mechanically ventilated patients which are also administered via the pulmonary route.", "sentB": "There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "no", "approved", "drugs", "on", "the", "market", "for", "adjunctive", "treatment", "or", "prevention", "of", "Gram-negative", "pneumonias", "in", "mechanically", "ventilated", "patients", "which", "are", "also", "administered", "via", "the", "pulmonary", "route.", "<tag2>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "to", "treat", "breast", "cancer.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "approved", "drugs", "on", "the", "market", "for", "adjunctive", "treatment", "or", "prevention", "of", "Gram-negative", "pneumonias", "in", "mechanically", "ventilated", "patients", "which", "are", "also", "administered", "via", "the", "pulmonary", "route."], "wordsB": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "to", "treat", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p18_s1", "idA": "906709_11_item1_p17_s0", "sentA": "Our customized approaches for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit.", "sentB": "We have a broad range of approaches that we may use when designing our own drug candidates, some of which are outlined below: Small Molecule Stable Polymer Conjugates Our customized approaches for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit.", "type": 2, "words": ["<tag1>", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit.", "<tag2>", "We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "outlined", "below:", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit.", "<tag3>"], "wordsA": ["Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit."], "wordsB": ["We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "outlined", "below:", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p18_s2", "idA": "906709_11_item1_p17_s1", "sentA": "In addition, this approach can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that havelow bioavailability when delivered orally.", "sentB": "In addition, this approach can enable oral administration of subcutaneously or intravenously delivered small molecule drugs that have low bioavailability when delivered orally.", "type": 2, "words": ["<tag1>", "In", "addition,", "this", "approach", "can", "enable", "oral", "administration", "of", "subcutaneously", "or", "intravenously", "delivered", "small", "molecule", "drugs", "that", "havelow", "bioavailability", "when", "delivered", "orally.", "<tag2>", "In", "addition,", "this", "approach", "can", "enable", "oral", "administration", "of", "subcutaneously", "or", "intravenously", "delivered", "small", "molecule", "drugs", "that", "have", "low", "bioavailability", "when", "delivered", "orally.", "<tag3>"], "wordsA": ["In", "addition,", "this", "approach", "can", "enable", "oral", "administration", "of", "subcutaneously", "or", "intravenously", "delivered", "small", "molecule", "drugs", "that", "havelow", "bioavailability", "when", "delivered", "orally."], "wordsB": ["In", "addition,", "this", "approach", "can", "enable", "oral", "administration", "of", "subcutaneously", "or", "intravenously", "delivered", "small", "molecule", "drugs", "that", "have", "low", "bioavailability", "when", "delivered", "orally."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p18_s3", "idA": "906709_11_item1_p17_s2", "sentA": "The benefits of this approach can also include: improved potency, increased oral bioavailability, modified biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane barriers in the body, such as the blood-brain barrier.", "sentB": "The benefits of this approach can also include: improved potency, modified biodistribution with enhanced pharmacodynamics, and reduced transport across specific membrane barriers in the body, such as the blood-brain barrier.", "type": 2, "words": ["<tag1>", "The", "benefits", "of", "this", "approach", "can", "also", "include:", "improved", "potency,", "increased", "oral", "bioavailability,", "modified", "biodistribution", "with", "enhanced", "pharmacodynamics,", "and", "reduced", "transport", "across", "specific", "membrane", "barriers", "in", "the", "body,", "such", "as", "the", "blood-brain", "barrier.", "<tag2>", "The", "benefits", "of", "this", "approach", "can", "also", "include:", "improved", "potency,", "modified", "biodistribution", "with", "enhanced", "pharmacodynamics,", "and", "reduced", "transport", "across", "specific", "membrane", "barriers", "in", "the", "body,", "such", "as", "the", "blood-brain", "barrier.", "<tag3>"], "wordsA": ["The", "benefits", "of", "this", "approach", "can", "also", "include:", "improved", "potency,", "increased", "oral", "bioavailability,", "modified", "biodistribution", "with", "enhanced", "pharmacodynamics,", "and", "reduced", "transport", "across", "specific", "membrane", "barriers", "in", "the", "body,", "such", "as", "the", "blood-brain", "barrier."], "wordsB": ["The", "benefits", "of", "this", "approach", "can", "also", "include:", "improved", "potency,", "modified", "biodistribution", "with", "enhanced", "pharmacodynamics,", "and", "reduced", "transport", "across", "specific", "membrane", "barriers", "in", "the", "body,", "such", "as", "the", "blood-brain", "barrier."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p18_s4", "idA": "906709_11_item1_p17_s3", "sentA": "A primary example of the application of membrane transport inhibition, specifically reducing transport across the blood-brain barrier is NKTR-118 (oral PEG-naloxol), a novel peripheral opioid antagonist that completed Phase 2 clinical development in 2009.", "sentB": "A primary example of reducing transport across the blood-brain barrier is NKTR-118, an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies with our partner AstraZeneca.", "type": 2, "words": ["<tag1>", "A", "primary", "example", "of", "the", "application", "of", "membrane", "transport", "inhibition,", "specifically", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118", "(oral", "PEG-naloxol),", "a", "novel", "peripheral", "opioid", "antagonist", "that", "completed", "Phase", "2", "clinical", "development", "in", "2009.", "<tag2>", "A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca.", "<tag3>"], "wordsA": ["A", "primary", "example", "of", "the", "application", "of", "membrane", "transport", "inhibition,", "specifically", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118", "(oral", "PEG-naloxol),", "a", "novel", "peripheral", "opioid", "antagonist", "that", "completed", "Phase", "2", "clinical", "development", "in", "2009."], "wordsB": ["A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p18_s5", "idA": "906709_11_item1_p17_s3", "sentA": "A primary example of the application of membrane transport inhibition, specifically reducing transport across the blood-brain barrier is NKTR-118 (oral PEG-naloxol), a novel peripheral opioid antagonist that completed Phase 2 clinical development in 2009.", "sentB": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that has completed Phase 1 clinical development.", "type": 2, "words": ["<tag1>", "A", "primary", "example", "of", "the", "application", "of", "membrane", "transport", "inhibition,", "specifically", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118", "(oral", "PEG-naloxol),", "a", "novel", "peripheral", "opioid", "antagonist", "that", "completed", "Phase", "2", "clinical", "development", "in", "2009.", "<tag2>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "has", "completed", "Phase", "1", "clinical", "development.", "<tag3>"], "wordsA": ["A", "primary", "example", "of", "the", "application", "of", "membrane", "transport", "inhibition,", "specifically", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118", "(oral", "PEG-naloxol),", "a", "novel", "peripheral", "opioid", "antagonist", "that", "completed", "Phase", "2", "clinical", "development", "in", "2009."], "wordsB": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "has", "completed", "Phase", "1", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p18_s6", "idA": "906709_11_item1_p17_s4", "sentA": "An example of a drug candidate that uses this approach to avoid first-pass metabolism is NKTR-140, a protease inhibitor in the early stages of discovery research.", "sentB": "An example of a drug candidate that uses this approach to avoid first-pass metabolism is NKTR-140, a protease inhibitor that is in the early stages of discovery research.", "type": 2, "words": ["<tag1>", "An", "example", "of", "a", "drug", "candidate", "that", "uses", "this", "approach", "to", "avoid", "first-pass", "metabolism", "is", "NKTR-140,", "a", "protease", "inhibitor", "in", "the", "early", "stages", "of", "discovery", "research.", "<tag2>", "An", "example", "of", "a", "drug", "candidate", "that", "uses", "this", "approach", "to", "avoid", "first-pass", "metabolism", "is", "NKTR-140,", "a", "protease", "inhibitor", "that", "is", "in", "the", "early", "stages", "of", "discovery", "research.", "<tag3>"], "wordsA": ["An", "example", "of", "a", "drug", "candidate", "that", "uses", "this", "approach", "to", "avoid", "first-pass", "metabolism", "is", "NKTR-140,", "a", "protease", "inhibitor", "in", "the", "early", "stages", "of", "discovery", "research."], "wordsB": ["An", "example", "of", "a", "drug", "candidate", "that", "uses", "this", "approach", "to", "avoid", "first-pass", "metabolism", "is", "NKTR-140,", "a", "protease", "inhibitor", "that", "is", "in", "the", "early", "stages", "of", "discovery", "research."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p19_s0", "idA": "906709_11_item1_p18_s0", "sentA": "The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase both its efficacy and side effect profile.", "sentB": "Small Molecule Pro-Drug Releasable Polymer Conjugates The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase both its efficacy and side effect profile.", "type": 2, "words": ["<tag1>", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "both", "its", "efficacy", "and", "side", "effect", "profile.", "<tag2>", "Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "both", "its", "efficacy", "and", "side", "effect", "profile.", "<tag3>"], "wordsA": ["The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "both", "its", "efficacy", "and", "side", "effect", "profile."], "wordsB": ["Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "both", "its", "efficacy", "and", "side", "effect", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p54_s1", "idA": "906709_11_item1_p18_s2", "sentA": "With our technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "Over time, the body s natural enzymatic processes slowly metabolize the linkers within the molecule, continuously freeing active drug that then can work to stop tumor cell division through topo I inhibition.", "type": 2, "words": ["<tag1>", "With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "Over", "time,", "the", "body", "s", "natural", "enzymatic", "processes", "slowly", "metabolize", "the", "linkers", "within", "the", "molecule,", "continuously", "freeing", "active", "drug", "that", "then", "can", "work", "to", "stop", "tumor", "cell", "division", "through", "topo", "I", "inhibition.", "<tag3>"], "wordsA": ["With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["Over", "time,", "the", "body", "s", "natural", "enzymatic", "processes", "slowly", "metabolize", "the", "linkers", "within", "the", "molecule,", "continuously", "freeing", "active", "drug", "that", "then", "can", "work", "to", "stop", "tumor", "cell", "division", "through", "topo", "I", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p55_s1", "idA": "906709_11_item1_p18_s2", "sentA": "With our technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "Because NKTR-102 is a large molecule, based on preclinical studies we believe that it may penetrate the leaky vasculature within the tumor environment more readily than normal vasculature, concentrating and trapping NKTR-102 in tumor tissue.", "type": 2, "words": ["<tag1>", "With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "Because", "NKTR-102", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "NKTR-102", "in", "tumor", "tissue.", "<tag3>"], "wordsA": ["With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["Because", "NKTR-102", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "NKTR-102", "in", "tumor", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p10_s0", "idA": "906709_11_item1_p18_s3", "sentA": "We are using this approach with the two oncolytic candidates in our pipeline, NKTR-102, a topoisomerase I inhibitor-polymer conjugate currently in Phase 2 clinical development, and NKTR-105, a polymer conjugate form of docetaxel that is currently in Phase 1 clinical development.", "sentB": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein in Phase 1 clinical development in patients with hemophilia A.", "type": 2, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "the", "two", "oncolytic", "candidates", "in", "our", "pipeline,", "NKTR-102,", "a", "topoisomerase", "I", "inhibitor-polymer", "conjugate", "currently", "in", "Phase", "2", "clinical", "development,", "and", "NKTR-105,", "a", "polymer", "conjugate", "form", "of", "docetaxel", "that", "is", "currently", "in", "Phase", "1", "clinical", "development.", "<tag2>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "in", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "the", "two", "oncolytic", "candidates", "in", "our", "pipeline,", "NKTR-102,", "a", "topoisomerase", "I", "inhibitor-polymer", "conjugate", "currently", "in", "Phase", "2", "clinical", "development,", "and", "NKTR-105,", "a", "polymer", "conjugate", "form", "of", "docetaxel", "that", "is", "currently", "in", "Phase", "1", "clinical", "development."], "wordsB": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "in", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p19_s3", "idA": "906709_11_item1_p18_s3", "sentA": "We are using this approach with the two oncolytic candidates in our pipeline, NKTR-102, a topoisomerase I inhibitor-polymer conjugate currently in Phase 2 clinical development, and NKTR-105, a polymer conjugate form of docetaxel that is currently in Phase 1 clinical development.", "sentB": "We are using this approach with the oncolytic drug candidate in our pipeline, NKTR-102, a next-generation topoisomerase I-inhibitor, currently in Phase 3 clinical development in metastatic breast cancer, and Phase 2 development in ovarian and colorectal cancers.", "type": 2, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "the", "two", "oncolytic", "candidates", "in", "our", "pipeline,", "NKTR-102,", "a", "topoisomerase", "I", "inhibitor-polymer", "conjugate", "currently", "in", "Phase", "2", "clinical", "development,", "and", "NKTR-105,", "a", "polymer", "conjugate", "form", "of", "docetaxel", "that", "is", "currently", "in", "Phase", "1", "clinical", "development.", "<tag2>", "We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "development", "in", "ovarian", "and", "colorectal", "cancers.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "the", "two", "oncolytic", "candidates", "in", "our", "pipeline,", "NKTR-102,", "a", "topoisomerase", "I", "inhibitor-polymer", "conjugate", "currently", "in", "Phase", "2", "clinical", "development,", "and", "NKTR-105,", "a", "polymer", "conjugate", "form", "of", "docetaxel", "that", "is", "currently", "in", "Phase", "1", "clinical", "development."], "wordsB": ["We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "development", "in", "ovarian", "and", "colorectal", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p9_s1", "idA": "906709_11_item1_p1_s1", "sentA": "Additionally, we may utilize established pharmacologic targets to engineer a new drug candidate relying on a combination of the known properties of these targets and our proprietary polymer chemistry technology and expertise.", "sentB": "We are providing our PEGylation technology and expertise.", "type": 2, "words": ["<tag1>", "Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise.", "<tag2>", "We", "are", "providing", "our", "PEGylation", "technology", "and", "expertise.", "<tag3>"], "wordsA": ["Additionally,", "we", "may", "utilize", "established", "pharmacologic", "targets", "to", "engineer", "a", "new", "drug", "candidate", "relying", "on", "a", "combination", "of", "the", "known", "properties", "of", "these", "targets", "and", "our", "proprietary", "polymer", "chemistry", "technology", "and", "expertise."], "wordsB": ["We", "are", "providing", "our", "PEGylation", "technology", "and", "expertise."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p1_s3", "idA": "906709_11_item1_p1_s3", "sentA": "Our objective is to apply our advanced polymer conjugate technology platform to create new drugs in multiple therapeutic areas.", "sentB": "Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas that address large potential markets.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drugs", "in", "multiple", "therapeutic", "areas.", "<tag2>", "Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas", "that", "address", "large", "potential", "markets.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drugs", "in", "multiple", "therapeutic", "areas."], "wordsB": ["Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas", "that", "address", "large", "potential", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p61_s0", "idA": "906709_11_item1_p21_s0", "sentA": "Peptides are important in modulating many physiological processes in the body.", "sentB": "Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.", "type": 2, "words": ["<tag1>", "Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body.", "<tag2>", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body.", "<tag3>"], "wordsA": ["Peptides", "are", "important", "in", "modulating", "many", "physiological", "processes", "in", "the", "body."], "wordsB": ["Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p21_s3", "idA": "906709_11_item1_p22_s0", "sentA": "Based on our knowledge of the technology and biologics, our scientists have designed a novel hydrolyzable linker that can be used to optimize the bioactivity of a peptide.", "sentB": "Based on our knowledge of the technology and biologics, our scientists have designed novel hydrolyzable linkers that in many cases can be used to optimize bioactivity.", "type": 2, "words": ["<tag1>", "Based", "on", "our", "knowledge", "of", "the", "technology", "and", "biologics,", "our", "scientists", "have", "designed", "a", "novel", "hydrolyzable", "linker", "that", "can", "be", "used", "to", "optimize", "the", "bioactivity", "of", "a", "peptide.", "<tag2>", "Based", "on", "our", "knowledge", "of", "the", "technology", "and", "biologics,", "our", "scientists", "have", "designed", "novel", "hydrolyzable", "linkers", "that", "in", "many", "cases", "can", "be", "used", "to", "optimize", "bioactivity.", "<tag3>"], "wordsA": ["Based", "on", "our", "knowledge", "of", "the", "technology", "and", "biologics,", "our", "scientists", "have", "designed", "a", "novel", "hydrolyzable", "linker", "that", "can", "be", "used", "to", "optimize", "the", "bioactivity", "of", "a", "peptide."], "wordsB": ["Based", "on", "our", "knowledge", "of", "the", "technology", "and", "biologics,", "our", "scientists", "have", "designed", "novel", "hydrolyzable", "linkers", "that", "in", "many", "cases", "can", "be", "used", "to", "optimize", "bioactivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p21_s4", "idA": "906709_11_item1_p22_s1", "sentA": "Through rational drug design and the use of our approach, a peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "sentB": "Through rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "type": 2, "words": ["<tag1>", "Through", "rational", "drug", "design", "and", "the", "use", "of", "our", "approach,", "a", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag2>", "Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag3>"], "wordsA": ["Through", "rational", "drug", "design", "and", "the", "use", "of", "our", "approach,", "a", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "wordsB": ["Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p24_s0", "idA": "906709_11_item1_p23_s0", "sentA": "This approach uses a large molecular weight polyethylene glycol (PEG) conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "sentB": "Antibody Fragment Polymer Conjugates This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "type": 2, "words": ["<tag1>", "This", "approach", "uses", "a", "large", "molecular", "weight", "polyethylene", "glycol", "(PEG)", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag2>", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag3>"], "wordsA": ["This", "approach", "uses", "a", "large", "molecular", "weight", "polyethylene", "glycol", "(PEG)", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "wordsB": ["Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p24_s1", "idA": "906709_11_item1_p24_s0", "sentA": "branched architecture PEG with either stable or degradable linkage.", "sentB": "The specially designed PEG replaces the function of the Fc domain of full length antibodies with a branched architecture PEG with either stable or degradable linkage.", "type": 2, "words": ["<tag1>", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage.", "<tag2>", "The", "specially", "designed", "PEG", "replaces", "the", "function", "of", "the", "Fc", "domain", "of", "full", "length", "antibodies", "with", "a", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage.", "<tag3>"], "wordsA": ["branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage."], "wordsB": ["The", "specially", "designed", "PEG", "replaces", "the", "function", "of", "the", "Fc", "domain", "of", "full", "length", "antibodies", "with", "a", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p25_s0", "idA": "906709_11_item1_p25_s0", "sentA": "(certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease in the U.S. and Rheumatoid Arthritis in the U.S. and Europe.", "sentB": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease in the U.S. and rheumatoid arthritis in the U.S. and E.U.", "type": 2, "words": ["<tag1>", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "Rheumatoid", "Arthritis", "in", "the", "U.S.", "and", "Europe.", "<tag2>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U.", "<tag3>"], "wordsA": ["(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "Rheumatoid", "Arthritis", "in", "the", "U.S.", "and", "Europe."], "wordsB": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p27_s1", "idA": "906709_11_item1_p27_s1", "sentA": "To support this strategy, over the past three years we have significantly expanded and added expertise to our internal clinical development and regulatory departments.", "sentB": "To support this strategy, over the past four years we have significantly expanded and added expertise to our internal clinical development and regulatory departments.", "type": 2, "words": ["<tag1>", "To", "support", "this", "strategy,", "over", "the", "past", "three", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "clinical", "development", "and", "regulatory", "departments.", "<tag2>", "To", "support", "this", "strategy,", "over", "the", "past", "four", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "clinical", "development", "and", "regulatory", "departments.", "<tag3>"], "wordsA": ["To", "support", "this", "strategy,", "over", "the", "past", "three", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "clinical", "development", "and", "regulatory", "departments."], "wordsB": ["To", "support", "this", "strategy,", "over", "the", "past", "four", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "clinical", "development", "and", "regulatory", "departments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p28_s0", "idA": "906709_11_item1_p27_s3", "sentA": "For many of our novel drug candidates, we may seek approval in indications for which the parent drugs have not been studied or approved.", "sentB": "For many of our novel drug candidates, we may seek to study the drug candidates in indications for which the parent drugs have not been studied or approved.", "type": 2, "words": ["<tag1>", "For", "many", "of", "our", "novel", "drug", "candidates,", "we", "may", "seek", "approval", "in", "indications", "for", "which", "the", "parent", "drugs", "have", "not", "been", "studied", "or", "approved.", "<tag2>", "For", "many", "of", "our", "novel", "drug", "candidates,", "we", "may", "seek", "to", "study", "the", "drug", "candidates", "in", "indications", "for", "which", "the", "parent", "drugs", "have", "not", "been", "studied", "or", "approved.", "<tag3>"], "wordsA": ["For", "many", "of", "our", "novel", "drug", "candidates,", "we", "may", "seek", "approval", "in", "indications", "for", "which", "the", "parent", "drugs", "have", "not", "been", "studied", "or", "approved."], "wordsB": ["For", "many", "of", "our", "novel", "drug", "candidates,", "we", "may", "seek", "to", "study", "the", "drug", "candidates", "in", "indications", "for", "which", "the", "parent", "drugs", "have", "not", "been", "studied", "or", "approved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p28_s1", "idA": "906709_11_item1_p27_s4", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies, and allow for approval to provide new treatments for patients for which the parent drugs are not currently approved.", "sentB": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies,", "and", "allow", "for", "approval", "to", "provide", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved.", "<tag2>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies,", "and", "allow", "for", "approval", "to", "provide", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved."], "wordsB": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p28_s2", "idA": "906709_11_item1_p27_s4", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies, and allow for approval to provide new treatments for patients for which the parent drugs are not currently approved.", "sentB": "In addition, in certain instances we have the opportunity to develop new treatments for patients for which the parent drugs are not currently approved.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies,", "and", "allow", "for", "approval", "to", "provide", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved.", "<tag2>", "In", "addition,", "in", "certain", "instances", "we", "have", "the", "opportunity", "to", "develop", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies,", "and", "allow", "for", "approval", "to", "provide", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved."], "wordsB": ["In", "addition,", "in", "certain", "instances", "we", "have", "the", "opportunity", "to", "develop", "new", "treatments", "for", "patients", "for", "which", "the", "parent", "drugs", "are", "not", "currently", "approved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p28_s5", "idA": "906709_11_item1_p28_s2", "sentA": "We continue to advance our most promising early research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.", "sentB": "We continue to advance our most promising research drug candidates into preclinical development with the objective to advance these early stage research programs to human clinical studies over the next several years.", "type": 2, "words": ["<tag1>", "We", "continue", "to", "advance", "our", "most", "promising", "early", "research", "drug", "candidates", "into", "preclinical", "development", "with", "the", "objective", "to", "advance", "these", "early", "stage", "research", "programs", "to", "human", "clinical", "studies", "over", "the", "next", "several", "years.", "<tag2>", "We", "continue", "to", "advance", "our", "most", "promising", "research", "drug", "candidates", "into", "preclinical", "development", "with", "the", "objective", "to", "advance", "these", "early", "stage", "research", "programs", "to", "human", "clinical", "studies", "over", "the", "next", "several", "years.", "<tag3>"], "wordsA": ["We", "continue", "to", "advance", "our", "most", "promising", "early", "research", "drug", "candidates", "into", "preclinical", "development", "with", "the", "objective", "to", "advance", "these", "early", "stage", "research", "programs", "to", "human", "clinical", "studies", "over", "the", "next", "several", "years."], "wordsB": ["We", "continue", "to", "advance", "our", "most", "promising", "research", "drug", "candidates", "into", "preclinical", "development", "with", "the", "objective", "to", "advance", "these", "early", "stage", "research", "programs", "to", "human", "clinical", "studies", "over", "the", "next", "several", "years."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p28_s6", "idA": "906709_11_item1_p29_s0", "sentA": "We decide on a product-by-product basis whether to continue development into Phase 3 pivotal clinical trials and commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "sentB": "Enter into Strategic and High-Value Partnerships to Bring Certain of Our Drug Candidates to Market We decide on a drug candidate-by-drug candidate basis how far to advance clinical development (e.g. Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "type": 2, "words": ["<tag1>", "We", "decide", "on", "a", "product-by-product", "basis", "whether", "to", "continue", "development", "into", "Phase", "3", "pivotal", "clinical", "trials", "and", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag2>", "Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag3>"], "wordsA": ["We", "decide", "on", "a", "product-by-product", "basis", "whether", "to", "continue", "development", "into", "Phase", "3", "pivotal", "clinical", "trials", "and", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "wordsB": ["Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p28_s7", "idA": "906709_11_item1_p29_s1", "sentA": "For example, in December 2010, we decided that we would move NKTR-102 into Phase 3 development prior to completing a collaboration for this drug candidate.", "sentB": "For example, in December 2010, we decided that we would move NKTR-102 into Phase 3 development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate.", "type": 2, "words": ["<tag1>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "NKTR-102", "into", "Phase", "3", "development", "prior", "to", "completing", "a", "collaboration", "for", "this", "drug", "candidate.", "<tag2>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "NKTR-102", "into", "Phase", "3", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate.", "<tag3>"], "wordsA": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "NKTR-102", "into", "Phase", "3", "development", "prior", "to", "completing", "a", "collaboration", "for", "this", "drug", "candidate."], "wordsB": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "NKTR-102", "into", "Phase", "3", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p29_s0", "idA": "906709_11_item1_p29_s3", "sentA": "The options for future collaboration arrangements range from comprehensive licensing and commercialization arrangements to co-promotion and co-development agreements with the structure of the collaboration depending on factors such as the cost and complexity of development, marketing and commercialization needs, therapeutic area and geographic capabilities.", "sentB": "comprehensive licensing and commercialization arrangements to co-promotion and co-development agreements with the structure of the collaboration depending on factors such as the structure of economic risk sharing, the cost and complexity of development, marketing and commercialization needs, therapeutic area and geographic capabilities.", "type": 2, "words": ["<tag1>", "The", "options", "for", "future", "collaboration", "arrangements", "range", "from", "comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities.", "<tag2>", "comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "structure", "of", "economic", "risk", "sharing,", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities.", "<tag3>"], "wordsA": ["The", "options", "for", "future", "collaboration", "arrangements", "range", "from", "comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities."], "wordsB": ["comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "structure", "of", "economic", "risk", "sharing,", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p2_s0", "idA": "906709_11_item1_p2_s2", "sentA": "Our most advanced proprietary product candidate, NKTR-118 (oral PEG-naloxol), is a peripheral opioid antagonist that is currently being evaluated for the treatment of opioid-induced constipation.", "sentB": "Our most advanced proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "type": 2, "words": ["<tag1>", "Our", "most", "advanced", "proprietary", "product", "candidate,", "NKTR-118", "(oral", "PEG-naloxol),", "is", "a", "peripheral", "opioid", "antagonist", "that", "is", "currently", "being", "evaluated", "for", "the", "treatment", "of", "opioid-induced", "constipation.", "<tag2>", "Our", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-118,", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "currently", "in", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag3>"], "wordsA": ["Our", "most", "advanced", "proprietary", "product", "candidate,", "NKTR-118", "(oral", "PEG-naloxol),", "is", "a", "peripheral", "opioid", "antagonist", "that", "is", "currently", "being", "evaluated", "for", "the", "treatment", "of", "opioid-induced", "constipation."], "wordsB": ["Our", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-118,", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "currently", "in", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p44_s0", "idA": "906709_11_item1_p2_s2", "sentA": "Our most advanced proprietary product candidate, NKTR-118 (oral PEG-naloxol), is a peripheral opioid antagonist that is currently being evaluated for the treatment of opioid-induced constipation.", "sentB": "NKTR-118 is an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies being conducted by AstraZeneca which AstraZeneca calls the KODIAC study.", "type": 2, "words": ["<tag1>", "Our", "most", "advanced", "proprietary", "product", "candidate,", "NKTR-118", "(oral", "PEG-naloxol),", "is", "a", "peripheral", "opioid", "antagonist", "that", "is", "currently", "being", "evaluated", "for", "the", "treatment", "of", "opioid-induced", "constipation.", "<tag2>", "NKTR-118", "is", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "being", "conducted", "by", "AstraZeneca", "which", "AstraZeneca", "calls", "the", "KODIAC", "study.", "<tag3>"], "wordsA": ["Our", "most", "advanced", "proprietary", "product", "candidate,", "NKTR-118", "(oral", "PEG-naloxol),", "is", "a", "peripheral", "opioid", "antagonist", "that", "is", "currently", "being", "evaluated", "for", "the", "treatment", "of", "opioid-induced", "constipation."], "wordsB": ["NKTR-118", "is", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "being", "conducted", "by", "AstraZeneca", "which", "AstraZeneca", "calls", "the", "KODIAC", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p3_s0", "idA": "906709_11_item1_p2_s3", "sentA": "In September 2009, we entered into a license agreement with AstraZeneca AB for the global development and commercialization of NKTR-118 and NKTR-119.", "sentB": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of NKTR-118 and NKTR-119.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "license", "agreement", "with", "AstraZeneca", "AB", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119.", "<tag2>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "license", "agreement", "with", "AstraZeneca", "AB", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119."], "wordsB": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p9_s0", "idA": "906709_11_item1_p30_s1", "sentA": "To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others, polymer materials, conjugates, formulations, synthesis, therapeutic areas and methods of treatment.", "sentB": "We have a significant collaboration with Baxter Healthcare to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients.", "type": 2, "words": ["<tag1>", "To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas", "and", "methods", "of", "treatment.", "<tag2>", "We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients.", "<tag3>"], "wordsA": ["To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas", "and", "methods", "of", "treatment."], "wordsB": ["We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p30_s2", "idA": "906709_11_item1_p31_s0", "sentA": "The following table summarizes our proprietary product candidate pipeline and Nektar-discovered drug candidates that are being developed by us or in partnerships with pharmaceutical companies.", "sentB": "The following table summarizes our proprietary Nektar-discovered drug candidates that are being developed by us or in collaboration with other pharmaceutical companies.", "type": 2, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "product", "candidate", "pipeline", "and", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "partnerships", "with", "pharmaceutical", "companies.", "<tag2>", "The", "following", "table", "summarizes", "our", "proprietary", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "product", "candidate", "pipeline", "and", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "partnerships", "with", "pharmaceutical", "companies."], "wordsB": ["The", "following", "table", "summarizes", "our", "proprietary", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p5_s0", "idA": "906709_11_item1_p31_s0", "sentA": "The following table summarizes our proprietary product candidate pipeline and Nektar-discovered drug candidates that are being developed by us or in partnerships with pharmaceutical companies.", "sentB": "We also have several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area.", "type": 2, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "product", "candidate", "pipeline", "and", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "partnerships", "with", "pharmaceutical", "companies.", "<tag2>", "We", "also", "have", "several", "proprietary", "pre-clinical", "and", "clinical", "drug", "candidates", "that", "are", "in", "the", "pain", "therapeutic", "area.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "product", "candidate", "pipeline", "and", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "partnerships", "with", "pharmaceutical", "companies."], "wordsB": ["We", "also", "have", "several", "proprietary", "pre-clinical", "and", "clinical", "drug", "candidates", "that", "are", "in", "the", "pain", "therapeutic", "area."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p30_s3", "idA": "906709_11_item1_p31_s1", "sentA": "The table includes the type of molecule or drug, the target indications for the product or product candidate, and the clinical trial status of the program.", "sentB": "The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.", "type": 2, "words": ["<tag1>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "product", "or", "product", "candidate,", "and", "the", "clinical", "trial", "status", "of", "the", "program.", "<tag2>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program.", "<tag3>"], "wordsA": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "product", "or", "product", "candidate,", "and", "the", "clinical", "trial", "status", "of", "the", "program."], "wordsB": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p31_s1", "idA": "906709_11_item1_p33_s0", "sentA": "Phase 2 product in clinical trials to establish dosing and efficacy in patients.", "sentB": "Phase 2 a drug candidate in clinical trials to establish dosing and efficacy in patients.", "type": 2, "words": ["<tag1>", "Phase", "2", "product", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag2>", "Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag3>"], "wordsA": ["Phase", "2", "product", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "wordsB": ["Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p38_s0", "idA": "906709_11_item1_p33_s0", "sentA": "Phase 2 product in clinical trials to establish dosing and efficacy in patients.", "sentB": "Phase 2 a drug candidate in clinical trials to establish dosing and efficacy in patients.", "type": 2, "words": ["<tag1>", "Phase", "2", "product", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag2>", "Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag3>"], "wordsA": ["Phase", "2", "product", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "wordsB": ["Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p33_s0", "idA": "906709_11_item1_p35_s0", "sentA": "Research/Preclinical product is being studied in research by way of in-vitro studies and/or animal studies.", "sentB": "Research/Preclinical a drug candidate being studied in research by way of in-vitro studies and/or animal studies.", "type": 2, "words": ["<tag1>", "Research/Preclinical", "product", "is", "being", "studied", "in", "research", "by", "way", "of", "in-vitro", "studies", "and/or", "animal", "studies.", "<tag2>", "Research/Preclinical", "a", "drug", "candidate", "being", "studied", "in", "research", "by", "way", "of", "in-vitro", "studies", "and/or", "animal", "studies.", "<tag3>"], "wordsA": ["Research/Preclinical", "product", "is", "being", "studied", "in", "research", "by", "way", "of", "in-vitro", "studies", "and/or", "animal", "studies."], "wordsB": ["Research/Preclinical", "a", "drug", "candidate", "being", "studied", "in", "research", "by", "way", "of", "in-vitro", "studies", "and/or", "animal", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p34_s0", "idA": "906709_11_item1_p36_s0", "sentA": "This product candidate uses a liquid aerosol technology platform that was transferred to Novartis in the pulmonary asset sale transaction that was completed on December 31, 2008.", "sentB": "* This drug candidate uses a liquid aerosol technology platform that was transferred to Novartis by us in the pulmonary asset sale transaction that was completed on December 31, 2008.", "type": 2, "words": ["<tag1>", "This", "product", "candidate", "uses", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008.", "<tag2>", "*", "This", "drug", "candidate", "uses", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008.", "<tag3>"], "wordsA": ["This", "product", "candidate", "uses", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008."], "wordsB": ["*", "This", "drug", "candidate", "uses", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p35_s2", "idA": "906709_11_item1_p38_s2", "sentA": "These collaborations generally contain one or more elements including license rights to our proprietary technology, manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or product royalties on commercial sales.", "sentB": "These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.", "type": 2, "words": ["<tag1>", "These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "license", "rights", "to", "our", "proprietary", "technology,", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "product", "royalties", "on", "commercial", "sales.", "<tag2>", "These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products.", "<tag3>"], "wordsA": ["These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "license", "rights", "to", "our", "proprietary", "technology,", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "product", "royalties", "on", "commercial", "sales."], "wordsB": ["These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p36_s0", "idA": "906709_11_item1_p39_s0", "sentA": "Approved regulatory approval to market and sell product obtained in the U.S., EU and other countries.", "sentB": "(1) Status definitions are: Approved regulatory approval to market and sell product obtained in the U.S., EU and other countries.", "type": 2, "words": ["<tag1>", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "the", "U.S.,", "EU", "and", "other", "countries.", "<tag2>", "(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "the", "U.S.,", "EU", "and", "other", "countries.", "<tag3>"], "wordsA": ["Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "the", "U.S.,", "EU", "and", "other", "countries."], "wordsB": ["(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "the", "U.S.,", "EU", "and", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s7", "idA": "906709_11_item1_p3_s1", "sentA": "In June 2010, we announced that we expanded the Phase 2 clinical study by 50 patients in platinum resistant/refractory ovarian cancer to evaluate NKTR-102 in a subset of women who had progressed after prior treatment with Doxil.", "sentB": "The study was further expanded to enroll up to 110 additional women with platinum-resistant ovarian cancer whose disease had progressed after prior treatment with Doxil (doxorubicin HCl liposome injection).", "type": 2, "words": ["<tag1>", "In", "June", "2010,", "we", "announced", "that", "we", "expanded", "the", "Phase", "2", "clinical", "study", "by", "50", "patients", "in", "platinum", "resistant/refractory", "ovarian", "cancer", "to", "evaluate", "NKTR-102", "in", "a", "subset", "of", "women", "who", "had", "progressed", "after", "prior", "treatment", "with", "Doxil.", "<tag2>", "The", "study", "was", "further", "expanded", "to", "enroll", "up", "to", "110", "additional", "women", "with", "platinum-resistant", "ovarian", "cancer", "whose", "disease", "had", "progressed", "after", "prior", "treatment", "with", "Doxil", "(doxorubicin", "HCl", "liposome", "injection).", "<tag3>"], "wordsA": ["In", "June", "2010,", "we", "announced", "that", "we", "expanded", "the", "Phase", "2", "clinical", "study", "by", "50", "patients", "in", "platinum", "resistant/refractory", "ovarian", "cancer", "to", "evaluate", "NKTR-102", "in", "a", "subset", "of", "women", "who", "had", "progressed", "after", "prior", "treatment", "with", "Doxil."], "wordsB": ["The", "study", "was", "further", "expanded", "to", "enroll", "up", "to", "110", "additional", "women", "with", "platinum-resistant", "ovarian", "cancer", "whose", "disease", "had", "progressed", "after", "prior", "treatment", "with", "Doxil", "(doxorubicin", "HCl", "liposome", "injection)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s12", "idA": "906709_11_item1_p3_s4", "sentA": "The Phase 2 clinical trial in colorectal cancer is still enrolling patients.", "sentB": "A Phase 2 clinical trial in patients with metastatic colorectal cancer is still enrolling patients, and a Phase 1 study of NKTR-102 in combination with F-fluorouracil/leucovorin is also continuing to enroll patients.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "trial", "in", "colorectal", "cancer", "is", "still", "enrolling", "patients.", "<tag2>", "A", "Phase", "2", "clinical", "trial", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "still", "enrolling", "patients,", "and", "a", "Phase", "1", "study", "of", "NKTR-102", "in", "combination", "with", "F-fluorouracil/leucovorin", "is", "also", "continuing", "to", "enroll", "patients.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "trial", "in", "colorectal", "cancer", "is", "still", "enrolling", "patients."], "wordsB": ["A", "Phase", "2", "clinical", "trial", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "still", "enrolling", "patients,", "and", "a", "Phase", "1", "study", "of", "NKTR-102", "in", "combination", "with", "F-fluorouracil/leucovorin", "is", "also", "continuing", "to", "enroll", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s11", "idA": "906709_11_item1_p3_s5", "sentA": "In December 2010, we announced that we would advance NKTR-102 into Phase 3 development in metastatic breast cancer and we are also exploring various Phase 3 clinical trial alternatives for NKTR-102 in platinum resistant/refractory ovarian cancer.", "sentB": "Results from this study and communication with government health authorities in both the United States and European Union (E.U.) will guide our future development and regulatory strategy for NKTR-102 in ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "December", "2010,", "we", "announced", "that", "we", "would", "advance", "NKTR-102", "into", "Phase", "3", "development", "in", "metastatic", "breast", "cancer", "and", "we", "are", "also", "exploring", "various", "Phase", "3", "clinical", "trial", "alternatives", "for", "NKTR-102", "in", "platinum", "resistant/refractory", "ovarian", "cancer.", "<tag2>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "NKTR-102", "in", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "December", "2010,", "we", "announced", "that", "we", "would", "advance", "NKTR-102", "into", "Phase", "3", "development", "in", "metastatic", "breast", "cancer", "and", "we", "are", "also", "exploring", "various", "Phase", "3", "clinical", "trial", "alternatives", "for", "NKTR-102", "in", "platinum", "resistant/refractory", "ovarian", "cancer."], "wordsB": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "NKTR-102", "in", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p36_s1", "idA": "906709_11_item1_p40_s0", "sentA": "Filed products for which a New Drug Application (NDA) or Biologics License Application (BLA) has been filed.", "sentB": "Filed an application for approval and marketing has been filed with the applicable government health authority.", "type": 2, "words": ["<tag1>", "Filed", "products", "for", "which", "a", "New", "Drug", "Application", "(NDA)", "or", "Biologics", "License", "Application", "(BLA)", "has", "been", "filed.", "<tag2>", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority.", "<tag3>"], "wordsA": ["Filed", "products", "for", "which", "a", "New", "Drug", "Application", "(NDA)", "or", "Biologics", "License", "Application", "(BLA)", "has", "been", "filed."], "wordsB": ["Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p31_s0", "idA": "906709_11_item1_p41_s0", "sentA": "Phase 3 or Pivotal product in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).", "sentB": "(1) Status definitions are: Phase 3 or Pivotal a drug candidate in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).", "type": 2, "words": ["<tag1>", "Phase", "3", "or", "Pivotal", "product", "in", "large-scale", "clinical", "trials", "conducted", "to", "obtain", "regulatory", "approval", "to", "market", "and", "sell", "the", "drug", "(these", "trials", "are", "typically", "initiated", "following", "encouraging", "Phase", "2", "trial", "results).", "<tag2>", "(1)", "Status", "definitions", "are:", "Phase", "3", "or", "Pivotal", "a", "drug", "candidate", "in", "large-scale", "clinical", "trials", "conducted", "to", "obtain", "regulatory", "approval", "to", "market", "and", "sell", "the", "drug", "(these", "trials", "are", "typically", "initiated", "following", "encouraging", "Phase", "2", "trial", "results).", "<tag3>"], "wordsA": ["Phase", "3", "or", "Pivotal", "product", "in", "large-scale", "clinical", "trials", "conducted", "to", "obtain", "regulatory", "approval", "to", "market", "and", "sell", "the", "drug", "(these", "trials", "are", "typically", "initiated", "following", "encouraging", "Phase", "2", "trial", "results)."], "wordsB": ["(1)", "Status", "definitions", "are:", "Phase", "3", "or", "Pivotal", "a", "drug", "candidate", "in", "large-scale", "clinical", "trials", "conducted", "to", "obtain", "regulatory", "approval", "to", "market", "and", "sell", "the", "drug", "(these", "trials", "are", "typically", "initiated", "following", "encouraging", "Phase", "2", "trial", "results)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p32_s0", "idA": "906709_11_item1_p43_s0", "sentA": "Phase 1 product in clinical trials, typically in healthy subjects, to test safety.", "sentB": "Phase 1 a drug candidate in clinical trials, typically in healthy subjects, to test safety.", "type": 2, "words": ["<tag1>", "Phase", "1", "product", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety.", "<tag2>", "Phase", "1", "a", "drug", "candidate", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety.", "<tag3>"], "wordsA": ["Phase", "1", "product", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety."], "wordsB": ["Phase", "1", "a", "drug", "candidate", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p38_s1", "idA": "906709_11_item1_p43_s0", "sentA": "Phase 1 product in clinical trials, typically in healthy subjects, to test safety.", "sentB": "Phase 1 a drug candidate in clinical trials, typically in healthy subjects, to test safety.", "type": 2, "words": ["<tag1>", "Phase", "1", "product", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety.", "<tag2>", "Phase", "1", "a", "drug", "candidate", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety.", "<tag3>"], "wordsA": ["Phase", "1", "product", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety."], "wordsB": ["Phase", "1", "a", "drug", "candidate", "in", "clinical", "trials,", "typically", "in", "healthy", "subjects,", "to", "test", "safety."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p40_s0", "idA": "906709_11_item1_p44_s0", "sentA": "in the U.S until July 2014.", "sentB": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA in the U.S until July 2014.", "type": 2, "words": ["<tag1>", "in", "the", "U.S", "until", "July", "2014.", "<tag2>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S", "until", "July", "2014.", "<tag3>"], "wordsA": ["in", "the", "U.S", "until", "July", "2014."], "wordsB": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S", "until", "July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p41_s0", "idA": "906709_11_item1_p45_s0", "sentA": "This product candidate was developed using our proprietary pulmonary delivery technology that was transferred to Novartis in an asset sale transaction that closed on December 31, 2008.", "sentB": "This drug candidate was developed using our proprietary pulmonary delivery technology that was transferred by us to Novartis in an asset sale transaction that closed on December 31, 2008.", "type": 2, "words": ["<tag1>", "This", "product", "candidate", "was", "developed", "using", "our", "proprietary", "pulmonary", "delivery", "technology", "that", "was", "transferred", "to", "Novartis", "in", "an", "asset", "sale", "transaction", "that", "closed", "on", "December", "31,", "2008.", "<tag2>", "This", "drug", "candidate", "was", "developed", "using", "our", "proprietary", "pulmonary", "delivery", "technology", "that", "was", "transferred", "by", "us", "to", "Novartis", "in", "an", "asset", "sale", "transaction", "that", "closed", "on", "December", "31,", "2008.", "<tag3>"], "wordsA": ["This", "product", "candidate", "was", "developed", "using", "our", "proprietary", "pulmonary", "delivery", "technology", "that", "was", "transferred", "to", "Novartis", "in", "an", "asset", "sale", "transaction", "that", "closed", "on", "December", "31,", "2008."], "wordsB": ["This", "drug", "candidate", "was", "developed", "using", "our", "proprietary", "pulmonary", "delivery", "technology", "that", "was", "transferred", "by", "us", "to", "Novartis", "in", "an", "asset", "sale", "transaction", "that", "closed", "on", "December", "31,", "2008."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p41_s1", "idA": "906709_11_item1_p45_s1", "sentA": "As part of the transaction, Novartis assumed our rights and obligations for our Cipro Inhale agreements with Bayer Schering Pharma AG; however, we maintained the rights to receive certain royalties on commercial sales of Cipro Inhale if the product candidate is approved.", "sentB": "As part of the transaction, Novartis assumed our rights and obligations for our Cipro Inhale agreements with Bayer Schering Pharma AG; however, we maintained the rights to receive certain royalties on commercial sales of Cipro Inhale if the drug candidate is approved.", "type": 2, "words": ["<tag1>", "As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "our", "Cipro", "Inhale", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "certain", "royalties", "on", "commercial", "sales", "of", "Cipro", "Inhale", "if", "the", "product", "candidate", "is", "approved.", "<tag2>", "As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "our", "Cipro", "Inhale", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "certain", "royalties", "on", "commercial", "sales", "of", "Cipro", "Inhale", "if", "the", "drug", "candidate", "is", "approved.", "<tag3>"], "wordsA": ["As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "our", "Cipro", "Inhale", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "certain", "royalties", "on", "commercial", "sales", "of", "Cipro", "Inhale", "if", "the", "product", "candidate", "is", "approved."], "wordsB": ["As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "our", "Cipro", "Inhale", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "certain", "royalties", "on", "commercial", "sales", "of", "Cipro", "Inhale", "if", "the", "drug", "candidate", "is", "approved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p43_s0", "idA": "906709_11_item1_p47_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell NKTR-118 and NKTR-119.", "sentB": "Overview of Selected Nektar Proprietary Drug Development Programs and Significant Partnered Drug Development Programs NKTR-118 and NKTR-119, License Agreement with AstraZeneca AB In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell NKTR-118 and NKTR-119.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "NKTR-118", "and", "NKTR-119.", "<tag2>", "Overview", "of", "Selected", "Nektar", "Proprietary", "Drug", "Development", "Programs", "and", "Significant", "Partnered", "Drug", "Development", "Programs", "NKTR-118", "and", "NKTR-119,", "License", "Agreement", "with", "AstraZeneca", "AB", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "NKTR-118", "and", "NKTR-119.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "NKTR-118", "and", "NKTR-119."], "wordsB": ["Overview", "of", "Selected", "Nektar", "Proprietary", "Drug", "Development", "Programs", "and", "Significant", "Partnered", "Drug", "Development", "Programs", "NKTR-118", "and", "NKTR-119,", "License", "Agreement", "with", "AstraZeneca", "AB", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "NKTR-118", "and", "NKTR-119."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p43_s1", "idA": "906709_11_item1_p47_s1", "sentA": "Under the terms of this agreement, AstraZeneca made a license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bear all costs associated with research, development and commercialization for NKTR-118 and NKTR-119.", "sentB": "Under the terms of this agreement, AstraZeneca made a license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for NKTR-118 and NKTR-119.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "a", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bear", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "NKTR-118", "and", "NKTR-119.", "<tag2>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "a", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "NKTR-118", "and", "NKTR-119.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "a", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bear", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "NKTR-118", "and", "NKTR-119."], "wordsB": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "a", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "NKTR-118", "and", "NKTR-119."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p43_s2", "idA": "906709_11_item1_p48_s0", "sentA": "For NKTR-118 and NKTR-119, we are eligible to receive significant development milestones and significant sales milestones if the products achieve certain annual commercial sales levels.", "sentB": "For NKTR-118, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones for NKTR-118, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "NKTR-118", "and", "NKTR-119,", "we", "are", "eligible", "to", "receive", "significant", "development", "milestones", "and", "significant", "sales", "milestones", "if", "the", "products", "achieve", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "NKTR-118,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "NKTR-118", "and", "NKTR-119,", "we", "are", "eligible", "to", "receive", "significant", "development", "milestones", "and", "significant", "sales", "milestones", "if", "the", "products", "achieve", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "NKTR-118,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p43_s5", "idA": "906709_11_item1_p48_s0", "sentA": "For NKTR-118 and NKTR-119, we are eligible to receive significant development milestones and significant sales milestones if the products achieve certain annual commercial sales levels.", "sentB": "For NKTR-119, we are also eligible to receive significant development milestones as well as significant sales milestones if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "NKTR-118", "and", "NKTR-119,", "we", "are", "eligible", "to", "receive", "significant", "development", "milestones", "and", "significant", "sales", "milestones", "if", "the", "products", "achieve", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "NKTR-119,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestones", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "NKTR-118", "and", "NKTR-119,", "we", "are", "eligible", "to", "receive", "significant", "development", "milestones", "and", "significant", "sales", "milestones", "if", "the", "products", "achieve", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "NKTR-119,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestones", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p46_s0", "idA": "906709_11_item1_p49_s3", "sentA": "The data presented from the Phase 2 study showed that NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements in patients taking opiates.", "sentB": "Data from a Phase 2 study conducted by us showed that NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements in patients taking opioids with chronic OIC.", "type": 2, "words": ["<tag1>", "The", "data", "presented", "from", "the", "Phase", "2", "study", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opiates.", "<tag2>", "Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC.", "<tag3>"], "wordsA": ["The", "data", "presented", "from", "the", "Phase", "2", "study", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opiates."], "wordsB": ["Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p46_s1", "idA": "906709_11_item1_p49_s4", "sentA": "The study also showed there was no apparent reversal of opioid-mediated analgesia with any of the NKTR-118 dose groups, as measured by no change in Numeric Rating Scale (NRS) pain scores and no increase in mean daily opiate use.", "sentB": "The study also showed that there was no apparent reversal of opioid-mediated analgesia with any of the NKTR-118 dose groups, as measured by no change in Numeric Rating Scale pain scores, no evidence of opioid withdrawal, and no increase in mean daily opioid use.", "type": 2, "words": ["<tag1>", "The", "study", "also", "showed", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "(NRS)", "pain", "scores", "and", "no", "increase", "in", "mean", "daily", "opiate", "use.", "<tag2>", "The", "study", "also", "showed", "that", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "pain", "scores,", "no", "evidence", "of", "opioid", "withdrawal,", "and", "no", "increase", "in", "mean", "daily", "opioid", "use.", "<tag3>"], "wordsA": ["The", "study", "also", "showed", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "(NRS)", "pain", "scores", "and", "no", "increase", "in", "mean", "daily", "opiate", "use."], "wordsB": ["The", "study", "also", "showed", "that", "there", "was", "no", "apparent", "reversal", "of", "opioid-mediated", "analgesia", "with", "any", "of", "the", "NKTR-118", "dose", "groups,", "as", "measured", "by", "no", "change", "in", "Numeric", "Rating", "Scale", "pain", "scores,", "no", "evidence", "of", "opioid", "withdrawal,", "and", "no", "increase", "in", "mean", "daily", "opioid", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p8_s2", "idA": "906709_11_item1_p4_s0", "sentA": "We have a number of license, manufacturing and supply agreements for our technology with leading biotechnology and pharmaceutical companies, including Affymax, Amgen, Baxter, Roche, Merck (through its acquisition of Schering Plough), Pfizer and UCB Pharma.", "sentB": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Affymax, Inc., Amgen Inc., Baxter Healthcare, MAP Pharmaceuticals, Inc., Merck Co., Inc. (through its acquisition of Schering Plough), Pfizer Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "type": 2, "words": ["<tag1>", "We", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "for", "our", "technology", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Amgen,", "Baxter,", "Roche,", "Merck", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "and", "UCB", "Pharma.", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "Baxter", "Healthcare,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag3>"], "wordsA": ["We", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "for", "our", "technology", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Amgen,", "Baxter,", "Roche,", "Merck", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "and", "UCB", "Pharma."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "Baxter", "Healthcare,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p8_s3", "idA": "906709_11_item1_p4_s1", "sentA": "A total of seven products using our PEGylation technology platform have received regulatory approval in the U.S. or Europe, and are currently marketed by our collaboration partners.", "sentB": "A total of seven products using our PEGylation technology have received regulatory approval in the U.S. or EU, and are currently marketed by our collaboration partners.", "type": 2, "words": ["<tag1>", "A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "platform", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe,", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners.", "<tag2>", "A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU,", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners.", "<tag3>"], "wordsA": ["A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "platform", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe,", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners."], "wordsB": ["A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU,", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p8_s4", "idA": "906709_11_item1_p4_s2", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technology platforms.", "sentB": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms.", "<tag2>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms."], "wordsB": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p47_s0", "idA": "906709_11_item1_p50_s0", "sentA": "The most commonly reported side effects from this Phase 2 clinical study of NKTR-118 were dose dependent gastrointestinal-related effects.", "sentB": "The most commonly reported side effects from the Phase 2 clinical study of NKTR-118 were dose dependent gastrointestinal-related effects, which were mild and transient.", "type": 2, "words": ["<tag1>", "The", "most", "commonly", "reported", "side", "effects", "from", "this", "Phase", "2", "clinical", "study", "of", "NKTR-118", "were", "dose", "dependent", "gastrointestinal-related", "effects.", "<tag2>", "The", "most", "commonly", "reported", "side", "effects", "from", "the", "Phase", "2", "clinical", "study", "of", "NKTR-118", "were", "dose", "dependent", "gastrointestinal-related", "effects,", "which", "were", "mild", "and", "transient.", "<tag3>"], "wordsA": ["The", "most", "commonly", "reported", "side", "effects", "from", "this", "Phase", "2", "clinical", "study", "of", "NKTR-118", "were", "dose", "dependent", "gastrointestinal-related", "effects."], "wordsB": ["The", "most", "commonly", "reported", "side", "effects", "from", "the", "Phase", "2", "clinical", "study", "of", "NKTR-118", "were", "dose", "dependent", "gastrointestinal-related", "effects,", "which", "were", "mild", "and", "transient."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p11_s2", "idA": "906709_11_item1_p51_s0", "sentA": "AstraZeneca has informed us that they intend to start the Phase 3 clinical study for NKTR-118 in the first quarter of 2011.", "sentB": "If the Phase 1 clinical study is successful, Baxter plans to then initiate Phase 3 studies for BAX 855.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011.", "<tag2>", "If", "the", "Phase", "1", "clinical", "study", "is", "successful,", "Baxter", "plans", "to", "then", "initiate", "Phase", "3", "studies", "for", "BAX", "855.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011."], "wordsB": ["If", "the", "Phase", "1", "clinical", "study", "is", "successful,", "Baxter", "plans", "to", "then", "initiate", "Phase", "3", "studies", "for", "BAX", "855."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p45_s4", "idA": "906709_11_item1_p51_s0", "sentA": "AstraZeneca has informed us that they intend to start the Phase 3 clinical study for NKTR-118 in the first quarter of 2011.", "sentB": "AstraZeneca is planning global regulatory submissions for NKTR-118, with first regulatory filings for NKTR-118 in the US and EU planned for 2013 if the KODIAC studies are successful.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011.", "<tag2>", "AstraZeneca", "is", "planning", "global", "regulatory", "submissions", "for", "NKTR-118,", "with", "first", "regulatory", "filings", "for", "NKTR-118", "in", "the", "US", "and", "EU", "planned", "for", "2013", "if", "the", "KODIAC", "studies", "are", "successful.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011."], "wordsB": ["AstraZeneca", "is", "planning", "global", "regulatory", "submissions", "for", "NKTR-118,", "with", "first", "regulatory", "filings", "for", "NKTR-118", "in", "the", "US", "and", "EU", "planned", "for", "2013", "if", "the", "KODIAC", "studies", "are", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s1", "idA": "906709_11_item1_p51_s0", "sentA": "AstraZeneca has informed us that they intend to start the Phase 3 clinical study for NKTR-118 in the first quarter of 2011.", "sentB": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), was initiated by us in December 2011.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011.", "<tag2>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "by", "us", "in", "December", "2011.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011."], "wordsB": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "by", "us", "in", "December", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p57_s1", "idA": "906709_11_item1_p51_s0", "sentA": "AstraZeneca has informed us that they intend to start the Phase 3 clinical study for NKTR-118 in the first quarter of 2011.", "sentB": "This Phase 3 clinical study, which we call BEACON (BrEAst Cancer Outcomes with NKTR-102), was initiated in December 2011.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011.", "<tag2>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "BEACON", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "in", "December", "2011.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011."], "wordsB": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "BEACON", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "in", "December", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p76_s4", "idA": "906709_11_item1_p51_s0", "sentA": "AstraZeneca has informed us that they intend to start the Phase 3 clinical study for NKTR-118 in the first quarter of 2011.", "sentB": "if the Phase 3 clinical study commences and is successful.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011.", "<tag2>", "if", "the", "Phase", "3", "clinical", "study", "commences", "and", "is", "successful.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "informed", "us", "that", "they", "intend", "to", "start", "the", "Phase", "3", "clinical", "study", "for", "NKTR-118", "in", "the", "first", "quarter", "of", "2011."], "wordsB": ["if", "the", "Phase", "3", "clinical", "study", "commences", "and", "is", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p50_s0", "idA": "906709_11_item1_p52_s0", "sentA": "NKTR-119 is an early stage drug development program that is intended to combine NKTR-118 with selected opioids, with the goal of treating pain without the side effect of constipation traditionally associated with opioid therapy.", "sentB": "Clinically, OIC is the most prevalent side effect of opioid therapy.", "type": 2, "words": ["<tag1>", "NKTR-119", "is", "an", "early", "stage", "drug", "development", "program", "that", "is", "intended", "to", "combine", "NKTR-118", "with", "selected", "opioids,", "with", "the", "goal", "of", "treating", "pain", "without", "the", "side", "effect", "of", "constipation", "traditionally", "associated", "with", "opioid", "therapy.", "<tag2>", "Clinically,", "OIC", "is", "the", "most", "prevalent", "side", "effect", "of", "opioid", "therapy.", "<tag3>"], "wordsA": ["NKTR-119", "is", "an", "early", "stage", "drug", "development", "program", "that", "is", "intended", "to", "combine", "NKTR-118", "with", "selected", "opioids,", "with", "the", "goal", "of", "treating", "pain", "without", "the", "side", "effect", "of", "constipation", "traditionally", "associated", "with", "opioid", "therapy."], "wordsB": ["Clinically,", "OIC", "is", "the", "most", "prevalent", "side", "effect", "of", "opioid", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p52_s1", "idA": "906709_11_item1_p52_s1", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one product based on NKTR-119 and has the right to develop multiple products based on NKTR-119.", "sentB": "AstraZeneca has agreed to use commercially reasonable efforts to develop one product based on NKTR-119 and has the right to develop multiple products which combine NKTR-118 with other opioids.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "product", "based", "on", "NKTR-119", "and", "has", "the", "right", "to", "develop", "multiple", "products", "based", "on", "NKTR-119.", "<tag2>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "product", "based", "on", "NKTR-119", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "NKTR-118", "with", "other", "opioids.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "product", "based", "on", "NKTR-119", "and", "has", "the", "right", "to", "develop", "multiple", "products", "based", "on", "NKTR-119."], "wordsB": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "product", "based", "on", "NKTR-119", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "NKTR-118", "with", "other", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p49_s0", "idA": "906709_11_item1_p54_s0", "sentA": "Depending on the population studied and the definitions used, constipation occurs in up to 90% of patients taking opioids.", "sentB": "Depending on the population studied and the definitions used, OIC occurs in up to 40-90% of patients taking opioids.", "type": 2, "words": ["<tag1>", "Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "constipation", "occurs", "in", "up", "to", "90%", "of", "patients", "taking", "opioids.", "<tag2>", "Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "OIC", "occurs", "in", "up", "to", "40-90%", "of", "patients", "taking", "opioids.", "<tag3>"], "wordsA": ["Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "constipation", "occurs", "in", "up", "to", "90%", "of", "patients", "taking", "opioids."], "wordsB": ["Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "OIC", "occurs", "in", "up", "to", "40-90%", "of", "patients", "taking", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p51_s0", "idA": "906709_11_item1_p55_s0", "sentA": "Currently, there are no specific oral drugs approved or specifically indicated to treat opioid induced constipation or opioid bowel dysfunction.", "sentB": "Currently, there are no specific oral drugs approved or specifically indicated to treat OIC.", "type": 2, "words": ["<tag1>", "Currently,", "there", "are", "no", "specific", "oral", "drugs", "approved", "or", "specifically", "indicated", "to", "treat", "opioid", "induced", "constipation", "or", "opioid", "bowel", "dysfunction.", "<tag2>", "Currently,", "there", "are", "no", "specific", "oral", "drugs", "approved", "or", "specifically", "indicated", "to", "treat", "OIC.", "<tag3>"], "wordsA": ["Currently,", "there", "are", "no", "specific", "oral", "drugs", "approved", "or", "specifically", "indicated", "to", "treat", "opioid", "induced", "constipation", "or", "opioid", "bowel", "dysfunction."], "wordsB": ["Currently,", "there", "are", "no", "specific", "oral", "drugs", "approved", "or", "specifically", "indicated", "to", "treat", "OIC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p11_s5", "idA": "906709_11_item1_p56_s1", "sentA": "We are responsible for all future development of the nebulizer device used in BAY41-6551 through the completion of Phase 3 clinical trials and for clinical and commercial manufacturing and supply of the nebulizer device.", "sentB": "Under the collaboration agreement, we are responsible for all future development of the nebulizer device and clinical and commercial manufacturing and supply of the device.", "type": 2, "words": ["<tag1>", "We", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "used", "in", "BAY41-6551", "through", "the", "completion", "of", "Phase", "3", "clinical", "trials", "and", "for", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device.", "<tag2>", "Under", "the", "collaboration", "agreement,", "we", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "and", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "device.", "<tag3>"], "wordsA": ["We", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "used", "in", "BAY41-6551", "through", "the", "completion", "of", "Phase", "3", "clinical", "trials", "and", "for", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device."], "wordsB": ["Under", "the", "collaboration", "agreement,", "we", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "and", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "device."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p73_s2", "idA": "906709_11_item1_p56_s1", "sentA": "We are responsible for all future development of the nebulizer device used in BAY41-6551 through the completion of Phase 3 clinical trials and for clinical and commercial manufacturing and supply of the nebulizer device.", "sentB": "We are responsible for all future development of the nebulizer device through the completion of Phase 3 clinical studies and for clinical and commercial manufacturing and supply of the nebulizer device.", "type": 2, "words": ["<tag1>", "We", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "used", "in", "BAY41-6551", "through", "the", "completion", "of", "Phase", "3", "clinical", "trials", "and", "for", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device.", "<tag2>", "We", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "through", "the", "completion", "of", "Phase", "3", "clinical", "studies", "and", "for", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device.", "<tag3>"], "wordsA": ["We", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "used", "in", "BAY41-6551", "through", "the", "completion", "of", "Phase", "3", "clinical", "trials", "and", "for", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device."], "wordsB": ["We", "are", "responsible", "for", "all", "future", "development", "of", "the", "nebulizer", "device", "through", "the", "completion", "of", "Phase", "3", "clinical", "studies", "and", "for", "clinical", "and", "commercial", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p73_s4", "idA": "906709_11_item1_p56_s3", "sentA": "Under the terms of the agreement, we are entitled to development and sales milestone payments upon achievement of certain annual sales targets.", "sentB": "We are entitled to up to $60.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "development", "and", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$60.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "are", "entitled", "to", "development", "and", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$60.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p75_s1", "idA": "906709_11_item1_p58_s1", "sentA": "Gram-negative pneumonia carries a mortality risk that can exceed 50% in mechanically-ventilated patients and accounts for a substantial proportion of the pneumonias in intensive care units today.", "sentB": "Gram-negative pneumonias carry a mortality risk that can exceed 50% in mechanically-ventilated patients and accounts for a substantial proportion of the pneumonias in intensive care units today.", "type": 2, "words": ["<tag1>", "Gram-negative", "pneumonia", "carries", "a", "mortality", "risk", "that", "can", "exceed", "50%", "in", "mechanically-ventilated", "patients", "and", "accounts", "for", "a", "substantial", "proportion", "of", "the", "pneumonias", "in", "intensive", "care", "units", "today.", "<tag2>", "Gram-negative", "pneumonias", "carry", "a", "mortality", "risk", "that", "can", "exceed", "50%", "in", "mechanically-ventilated", "patients", "and", "accounts", "for", "a", "substantial", "proportion", "of", "the", "pneumonias", "in", "intensive", "care", "units", "today.", "<tag3>"], "wordsA": ["Gram-negative", "pneumonia", "carries", "a", "mortality", "risk", "that", "can", "exceed", "50%", "in", "mechanically-ventilated", "patients", "and", "accounts", "for", "a", "substantial", "proportion", "of", "the", "pneumonias", "in", "intensive", "care", "units", "today."], "wordsB": ["Gram-negative", "pneumonias", "carry", "a", "mortality", "risk", "that", "can", "exceed", "50%", "in", "mechanically-ventilated", "patients", "and", "accounts", "for", "a", "substantial", "proportion", "of", "the", "pneumonias", "in", "intensive", "care", "units", "today."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p76_s2", "idA": "906709_11_item1_p59_s2", "sentA": "This product candidate can be integrated with conventional mechanical ventilators or used as a hand-held off-vent device for patients no longer requiring breathing assistance.", "sentB": "This drug candidate can be integrated with conventional mechanical ventilators or used as a hand-held off-vent device for patients no longer requiring breathing assistance.", "type": 2, "words": ["<tag1>", "This", "product", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance.", "<tag2>", "This", "drug", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance.", "<tag3>"], "wordsA": ["This", "product", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance."], "wordsB": ["This", "drug", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p76_s3", "idA": "906709_11_item1_p59_s3", "sentA": "This product candidate has completed Phase 2 clinical development.", "sentB": "This drug candidate has completed Phase 2 clinical development.", "type": 2, "words": ["<tag1>", "This", "product", "candidate", "has", "completed", "Phase", "2", "clinical", "development.", "<tag2>", "This", "drug", "candidate", "has", "completed", "Phase", "2", "clinical", "development.", "<tag3>"], "wordsA": ["This", "product", "candidate", "has", "completed", "Phase", "2", "clinical", "development."], "wordsB": ["This", "drug", "candidate", "has", "completed", "Phase", "2", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p11_s3", "idA": "906709_11_item1_p5_s0", "sentA": "We have a collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "We also have a significant collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "type": 2, "words": ["<tag1>", "We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag3>"], "wordsA": ["We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p73_s0", "idA": "906709_11_item1_p5_s0", "sentA": "We have a collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly called NKTR-061).", "type": 2, "words": ["<tag1>", "We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061).", "<tag3>"], "wordsA": ["We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p12_s0", "idA": "906709_11_item1_p60_s0", "sentA": "Bayer and Nektar have been working together to prepare for the pivotal studies of BAY41-6551 following the consummation of the collaboration in August 2007.", "sentB": "Bayer and Nektar have been working together to prepare for Phase 3 clinical program for BAY41-6551 following the consummation of the collaboration in August 2007.", "type": 2, "words": ["<tag1>", "Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "the", "pivotal", "studies", "of", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007.", "<tag2>", "Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "Phase", "3", "clinical", "program", "for", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007.", "<tag3>"], "wordsA": ["Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "the", "pivotal", "studies", "of", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007."], "wordsB": ["Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "Phase", "3", "clinical", "program", "for", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p77_s0", "idA": "906709_11_item1_p60_s0", "sentA": "Bayer and Nektar have been working together to prepare for the pivotal studies of BAY41-6551 following the consummation of the collaboration in August 2007.", "sentB": "Bayer and Nektar have been working together to prepare for Phase 3 clinical studies of BAY41-6551 following the consummation of the collaboration in August 2007.", "type": 2, "words": ["<tag1>", "Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "the", "pivotal", "studies", "of", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007.", "<tag2>", "Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007.", "<tag3>"], "wordsA": ["Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "the", "pivotal", "studies", "of", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007."], "wordsB": ["Bayer", "and", "Nektar", "have", "been", "working", "together", "to", "prepare", "for", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "following", "the", "consummation", "of", "the", "collaboration", "in", "August", "2007."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p12_s1", "idA": "906709_11_item1_p60_s1", "sentA": "The reason for this is that Bayer and Nektar decided to finalize the design of the device for commercial manufacturing prior to initiating Phase 3 clinical development with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work.", "sentB": "This program is significantly behind schedule due to the fact that Bayer and Nektar decided to finalize the design of the device for commercial manufacturing prior to initiating Phase 3 clinical development.", "type": 2, "words": ["<tag1>", "The", "reason", "for", "this", "is", "that", "Bayer", "and", "Nektar", "decided", "to", "finalize", "the", "design", "of", "the", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work.", "<tag2>", "This", "program", "is", "significantly", "behind", "schedule", "due", "to", "the", "fact", "that", "Bayer", "and", "Nektar", "decided", "to", "finalize", "the", "design", "of", "the", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development.", "<tag3>"], "wordsA": ["The", "reason", "for", "this", "is", "that", "Bayer", "and", "Nektar", "decided", "to", "finalize", "the", "design", "of", "the", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work."], "wordsB": ["This", "program", "is", "significantly", "behind", "schedule", "due", "to", "the", "fact", "that", "Bayer", "and", "Nektar", "decided", "to", "finalize", "the", "design", "of", "the", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p12_s2", "idA": "906709_11_item1_p60_s1", "sentA": "The reason for this is that Bayer and Nektar decided to finalize the design of the device for commercial manufacturing prior to initiating Phase 3 clinical development with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work.", "sentB": "In 2011, Bayer received agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "type": 2, "words": ["<tag1>", "The", "reason", "for", "this", "is", "that", "Bayer", "and", "Nektar", "decided", "to", "finalize", "the", "design", "of", "the", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work.", "<tag2>", "In", "2011,", "Bayer", "received", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag3>"], "wordsA": ["The", "reason", "for", "this", "is", "that", "Bayer", "and", "Nektar", "decided", "to", "finalize", "the", "design", "of", "the", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work."], "wordsB": ["In", "2011,", "Bayer", "received", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p53_s0", "idA": "906709_11_item1_p62_s0", "sentA": "We are developing NKTR-102, a novel topoisomerase I inhibitor-polymer conjugate that was designed using our advanced polymer conjugate technology platform.", "sentB": "We are developing NKTR-102, a next generation topoisomerase I (topo I) inhibitor, that was designed using our PEGylation technology.", "type": 2, "words": ["<tag1>", "We", "are", "developing", "NKTR-102,", "a", "novel", "topoisomerase", "I", "inhibitor-polymer", "conjugate", "that", "was", "designed", "using", "our", "advanced", "polymer", "conjugate", "technology", "platform.", "<tag2>", "We", "are", "developing", "NKTR-102,", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor,", "that", "was", "designed", "using", "our", "PEGylation", "technology.", "<tag3>"], "wordsA": ["We", "are", "developing", "NKTR-102,", "a", "novel", "topoisomerase", "I", "inhibitor-polymer", "conjugate", "that", "was", "designed", "using", "our", "advanced", "polymer", "conjugate", "technology", "platform."], "wordsB": ["We", "are", "developing", "NKTR-102,", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor,", "that", "was", "designed", "using", "our", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p2_s1", "idA": "906709_11_item1_p63_s0", "sentA": "is a topoisomerase I inhibitor used for the treatment of solid tumors.", "sentB": "OIC is a common side effect of prescription opioids when used for chronic pain management.", "type": 2, "words": ["<tag1>", "is", "a", "topoisomerase", "I", "inhibitor", "used", "for", "the", "treatment", "of", "solid", "tumors.", "<tag2>", "OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management.", "<tag3>"], "wordsA": ["is", "a", "topoisomerase", "I", "inhibitor", "used", "for", "the", "treatment", "of", "solid", "tumors."], "wordsB": ["OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s2", "idA": "906709_11_item1_p64_s0", "sentA": "The NKTR-102 Phase 2 study in metastatic breast cancer patients is an open label, randomized, study evaluating two treatment schedules of single-agent NKTR-102 (145 mg/m2 every 14 days or every 21 days).", "sentB": "This clinical study is an open label, randomized, study evaluating two treatment schedules of single-agent NKTR-102 (145 mg/m2 every 14 days or every 21 days).", "type": 2, "words": ["<tag1>", "The", "NKTR-102", "Phase", "2", "study", "in", "metastatic", "breast", "cancer", "patients", "is", "an", "open", "label,", "randomized,", "study", "evaluating", "two", "treatment", "schedules", "of", "single-agent", "NKTR-102", "(145", "mg/m2", "every", "14", "days", "or", "every", "21", "days).", "<tag2>", "This", "clinical", "study", "is", "an", "open", "label,", "randomized,", "study", "evaluating", "two", "treatment", "schedules", "of", "single-agent", "NKTR-102", "(145", "mg/m2", "every", "14", "days", "or", "every", "21", "days).", "<tag3>"], "wordsA": ["The", "NKTR-102", "Phase", "2", "study", "in", "metastatic", "breast", "cancer", "patients", "is", "an", "open", "label,", "randomized,", "study", "evaluating", "two", "treatment", "schedules", "of", "single-agent", "NKTR-102", "(145", "mg/m2", "every", "14", "days", "or", "every", "21", "days)."], "wordsB": ["This", "clinical", "study", "is", "an", "open", "label,", "randomized,", "study", "evaluating", "two", "treatment", "schedules", "of", "single-agent", "NKTR-102", "(145", "mg/m2", "every", "14", "days", "or", "every", "21", "days)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s9", "idA": "906709_11_item1_p64_s1", "sentA": "Patients enrolled in the study included those with metastatic breast cancer with prior taxane therapy.", "sentB": "As of February 2012, approximately 94 of the planned 110 patients had been enrolled in the study.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "the", "study", "included", "those", "with", "metastatic", "breast", "cancer", "with", "prior", "taxane", "therapy.", "<tag2>", "As", "of", "February", "2012,", "approximately", "94", "of", "the", "planned", "110", "patients", "had", "been", "enrolled", "in", "the", "study.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "the", "study", "included", "those", "with", "metastatic", "breast", "cancer", "with", "prior", "taxane", "therapy."], "wordsB": ["As", "of", "February", "2012,", "approximately", "94", "of", "the", "planned", "110", "patients", "had", "been", "enrolled", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p57_s3", "idA": "906709_11_item1_p64_s1", "sentA": "Patients enrolled in the study included those with metastatic breast cancer with prior taxane therapy.", "sentB": "The BEACON study plans to enroll approximately 840 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "the", "study", "included", "those", "with", "metastatic", "breast", "cancer", "with", "prior", "taxane", "therapy.", "<tag2>", "The", "BEACON", "study", "plans", "to", "enroll", "approximately", "840", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "the", "study", "included", "those", "with", "metastatic", "breast", "cancer", "with", "prior", "taxane", "therapy."], "wordsB": ["The", "BEACON", "study", "plans", "to", "enroll", "approximately", "840", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s7", "idA": "906709_11_item1_p64_s1", "sentA": "Patients enrolled in the study included those with metastatic breast cancer with prior taxane therapy.", "sentB": "As of February 2012, approximately 94 patients of the 110 patients had been enrolled in the study.", "type": 2, "words": ["<tag1>", "Patients", "enrolled", "in", "the", "study", "included", "those", "with", "metastatic", "breast", "cancer", "with", "prior", "taxane", "therapy.", "<tag2>", "As", "of", "February", "2012,", "approximately", "94", "patients", "of", "the", "110", "patients", "had", "been", "enrolled", "in", "the", "study.", "<tag3>"], "wordsA": ["Patients", "enrolled", "in", "the", "study", "included", "those", "with", "metastatic", "breast", "cancer", "with", "prior", "taxane", "therapy."], "wordsB": ["As", "of", "February", "2012,", "approximately", "94", "patients", "of", "the", "110", "patients", "had", "been", "enrolled", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s0", "idA": "906709_11_item1_p65_s0", "sentA": "We have begun the planning of a comparative Phase 3 clinical study for single-agent NKTR-102 in metastatic breast cancer patients and plan to start this study in late 2011.", "sentB": "Our second most advanced drug candidate, NKTR-102, is a next-generation topoisomerase I inhibitor, currently being evaluated as a single-agent therapy in a Phase 3 clinical study in patients with metastatic breast cancer.", "type": 2, "words": ["<tag1>", "We", "have", "begun", "the", "planning", "of", "a", "comparative", "Phase", "3", "clinical", "study", "for", "single-agent", "NKTR-102", "in", "metastatic", "breast", "cancer", "patients", "and", "plan", "to", "start", "this", "study", "in", "late", "2011.", "<tag2>", "Our", "second", "most", "advanced", "drug", "candidate,", "NKTR-102,", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "in", "a", "Phase", "3", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["We", "have", "begun", "the", "planning", "of", "a", "comparative", "Phase", "3", "clinical", "study", "for", "single-agent", "NKTR-102", "in", "metastatic", "breast", "cancer", "patients", "and", "plan", "to", "start", "this", "study", "in", "late", "2011."], "wordsB": ["Our", "second", "most", "advanced", "drug", "candidate,", "NKTR-102,", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "in", "a", "Phase", "3", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p63_s2", "idA": "906709_11_item1_p67_s0", "sentA": "Breast cancer is the most common cancer among women in the United States, other than skin cancer.", "sentB": "Ovarian cancer is the ninth most common cancer among women, excluding non-melanoma skin cancers.", "type": 2, "words": ["<tag1>", "Breast", "cancer", "is", "the", "most", "common", "cancer", "among", "women", "in", "the", "United", "States,", "other", "than", "skin", "cancer.", "<tag2>", "Ovarian", "cancer", "is", "the", "ninth", "most", "common", "cancer", "among", "women,", "excluding", "non-melanoma", "skin", "cancers.", "<tag3>"], "wordsA": ["Breast", "cancer", "is", "the", "most", "common", "cancer", "among", "women", "in", "the", "United", "States,", "other", "than", "skin", "cancer."], "wordsB": ["Ovarian", "cancer", "is", "the", "ninth", "most", "common", "cancer", "among", "women,", "excluding", "non-melanoma", "skin", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s3", "idA": "906709_11_item1_p69_s1", "sentA": "Each schedule originally followed a two-stage Simon design and a total of 71 patients were initially enrolled and dosed.", "sentB": "Each schedule originally followed a two-stage Simon design and a total of 71 patients were initially included in the study that was completed in the first half of 2010.", "type": 2, "words": ["<tag1>", "Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "enrolled", "and", "dosed.", "<tag2>", "Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "included", "in", "the", "study", "that", "was", "completed", "in", "the", "first", "half", "of", "2010.", "<tag3>"], "wordsA": ["Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "enrolled", "and", "dosed."], "wordsB": ["Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "included", "in", "the", "study", "that", "was", "completed", "in", "the", "first", "half", "of", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s4", "idA": "906709_11_item1_p69_s3", "sentA": "The primary endpoint of the study was ORR based on RECIST 1.0.", "sentB": "The primary endpoint of the BEACON study will be overall survival, and secondary endpoints will include progression-free survival and objective tumor response rate.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "study", "was", "ORR", "based", "on", "RECIST", "1.0.", "<tag2>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "will", "be", "overall", "survival,", "and", "secondary", "endpoints", "will", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "study", "was", "ORR", "based", "on", "RECIST", "1.0."], "wordsB": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "will", "be", "overall", "survival,", "and", "secondary", "endpoints", "will", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p58_s1", "idA": "906709_11_item1_p69_s3", "sentA": "The primary endpoint of the study was ORR based on RECIST 1.0.", "sentB": "The primary endpoint of the BEACON study will be overall survival, and secondary endpoints will include progression-free survival and objective tumor response rate.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "study", "was", "ORR", "based", "on", "RECIST", "1.0.", "<tag2>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "will", "be", "overall", "survival,", "and", "secondary", "endpoints", "will", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "study", "was", "ORR", "based", "on", "RECIST", "1.0."], "wordsB": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "will", "be", "overall", "survival,", "and", "secondary", "endpoints", "will", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p58_s3", "idA": "906709_11_item1_p69_s4", "sentA": "Secondary endpoints in the study included best clinical response, clinical benefit, CA-125 response (a known ovarian cancer blood marker) safety, progression-free survival and overall survival.", "sentB": "Exploratory objectives of the study will include collecting specific biomarker data to correlate with objective tumor response rate, progression-free survival, overall survival and selected toxicities.", "type": 2, "words": ["<tag1>", "Secondary", "endpoints", "in", "the", "study", "included", "best", "clinical", "response,", "clinical", "benefit,", "CA-125", "response", "(a", "known", "ovarian", "cancer", "blood", "marker)", "safety,", "progression-free", "survival", "and", "overall", "survival.", "<tag2>", "Exploratory", "objectives", "of", "the", "study", "will", "include", "collecting", "specific", "biomarker", "data", "to", "correlate", "with", "objective", "tumor", "response", "rate,", "progression-free", "survival,", "overall", "survival", "and", "selected", "toxicities.", "<tag3>"], "wordsA": ["Secondary", "endpoints", "in", "the", "study", "included", "best", "clinical", "response,", "clinical", "benefit,", "CA-125", "response", "(a", "known", "ovarian", "cancer", "blood", "marker)", "safety,", "progression-free", "survival", "and", "overall", "survival."], "wordsB": ["Exploratory", "objectives", "of", "the", "study", "will", "include", "collecting", "specific", "biomarker", "data", "to", "correlate", "with", "objective", "tumor", "response", "rate,", "progression-free", "survival,", "overall", "survival", "and", "selected", "toxicities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s4", "idA": "906709_11_item1_p69_s5", "sentA": "In 2010, we announced that we are expanding this Phase 2 study to include approximately 50 additional women who had previously received PLD therapy to continue to evaluate the every 21-day dose schedule of single-agent NKTR-102 in this subset of women.", "sentB": "In the second half of 2010, we expanded this Phase 2 study to include approximately 50 additional women who had previously received Doxil therapy to continue to evaluate the every 21-day dose schedule of single-agent NKTR-102 in this subset of women.", "type": 2, "words": ["<tag1>", "In", "2010,", "we", "announced", "that", "we", "are", "expanding", "this", "Phase", "2", "study", "to", "include", "approximately", "50", "additional", "women", "who", "had", "previously", "received", "PLD", "therapy", "to", "continue", "to", "evaluate", "the", "every", "21-day", "dose", "schedule", "of", "single-agent", "NKTR-102", "in", "this", "subset", "of", "women.", "<tag2>", "In", "the", "second", "half", "of", "2010,", "we", "expanded", "this", "Phase", "2", "study", "to", "include", "approximately", "50", "additional", "women", "who", "had", "previously", "received", "Doxil", "therapy", "to", "continue", "to", "evaluate", "the", "every", "21-day", "dose", "schedule", "of", "single-agent", "NKTR-102", "in", "this", "subset", "of", "women.", "<tag3>"], "wordsA": ["In", "2010,", "we", "announced", "that", "we", "are", "expanding", "this", "Phase", "2", "study", "to", "include", "approximately", "50", "additional", "women", "who", "had", "previously", "received", "PLD", "therapy", "to", "continue", "to", "evaluate", "the", "every", "21-day", "dose", "schedule", "of", "single-agent", "NKTR-102", "in", "this", "subset", "of", "women."], "wordsB": ["In", "the", "second", "half", "of", "2010,", "we", "expanded", "this", "Phase", "2", "study", "to", "include", "approximately", "50", "additional", "women", "who", "had", "previously", "received", "Doxil", "therapy", "to", "continue", "to", "evaluate", "the", "every", "21-day", "dose", "schedule", "of", "single-agent", "NKTR-102", "in", "this", "subset", "of", "women."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s8", "idA": "906709_11_item1_p69_s6", "sentA": "On March 1, 2011, we announced that we intended to further expand this Phase 2 clinical study by approximately 60 patients.", "sentB": "In November 2011, we announced that enrollment in this expanded Phase 2 study had significantly slowed due to a shortage of Doxil resulting from serious manufacturing issues being experienced by the manufacturer and supplier of Doxil .", "type": 2, "words": ["<tag1>", "On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "patients.", "<tag2>", "In", "November", "2011,", "we", "announced", "that", "enrollment", "in", "this", "expanded", "Phase", "2", "study", "had", "significantly", "slowed", "due", "to", "a", "shortage", "of", "Doxil", "resulting", "from", "serious", "manufacturing", "issues", "being", "experienced", "by", "the", "manufacturer", "and", "supplier", "of", "Doxil", ".", "<tag3>"], "wordsA": ["On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "patients."], "wordsB": ["In", "November", "2011,", "we", "announced", "that", "enrollment", "in", "this", "expanded", "Phase", "2", "study", "had", "significantly", "slowed", "due", "to", "a", "shortage", "of", "Doxil", "resulting", "from", "serious", "manufacturing", "issues", "being", "experienced", "by", "the", "manufacturer", "and", "supplier", "of", "Doxil", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s5", "idA": "906709_11_item1_p69_s6", "sentA": "On March 1, 2011, we announced that we intended to further expand this Phase 2 clinical study by approximately 60 patients.", "sentB": "On March 1, 2011, we announced that we intended to further expand this Phase 2 clinical study by approximately 60 additional patients.", "type": 2, "words": ["<tag1>", "On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "patients.", "<tag2>", "On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "additional", "patients.", "<tag3>"], "wordsA": ["On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "patients."], "wordsB": ["On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "additional", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s6", "idA": "906709_11_item1_p69_s6", "sentA": "On March 1, 2011, we announced that we intended to further expand this Phase 2 clinical study by approximately 60 patients.", "sentB": "In November 2011, we announced that enrollment in this expanded study had significantly slowed due to a shortage of Doxil resulting from serious manufacturing issues being experienced by the manufacturer and supplier of Doxil .", "type": 2, "words": ["<tag1>", "On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "patients.", "<tag2>", "In", "November", "2011,", "we", "announced", "that", "enrollment", "in", "this", "expanded", "study", "had", "significantly", "slowed", "due", "to", "a", "shortage", "of", "Doxil", "resulting", "from", "serious", "manufacturing", "issues", "being", "experienced", "by", "the", "manufacturer", "and", "supplier", "of", "Doxil", ".", "<tag3>"], "wordsA": ["On", "March", "1,", "2011,", "we", "announced", "that", "we", "intended", "to", "further", "expand", "this", "Phase", "2", "clinical", "study", "by", "approximately", "60", "patients."], "wordsB": ["In", "November", "2011,", "we", "announced", "that", "enrollment", "in", "this", "expanded", "study", "had", "significantly", "slowed", "due", "to", "a", "shortage", "of", "Doxil", "resulting", "from", "serious", "manufacturing", "issues", "being", "experienced", "by", "the", "manufacturer", "and", "supplier", "of", "Doxil", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p11_s4", "idA": "906709_11_item1_p6_s0", "sentA": "We originally developed the liquid aerosol inhalation platform and product and entered into a collaboration agreement with Bayer Healthcare LLC in August 2007 for its further development and commercialization.", "sentB": "We originally developed the liquid aerosol inhalation platform and NKTR-061 drug candidate and entered into a collaboration agreement with Bayer in August 2007 to further advance the drug candidate s development and potential commercialization.", "type": 2, "words": ["<tag1>", "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "product", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "Healthcare", "LLC", "in", "August", "2007", "for", "its", "further", "development", "and", "commercialization.", "<tag2>", "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "in", "August", "2007", "to", "further", "advance", "the", "drug", "candidate", "s", "development", "and", "potential", "commercialization.", "<tag3>"], "wordsA": ["We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "product", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "Healthcare", "LLC", "in", "August", "2007", "for", "its", "further", "development", "and", "commercialization."], "wordsB": ["We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "in", "August", "2007", "to", "further", "advance", "the", "drug", "candidate", "s", "development", "and", "potential", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p6_s2", "idA": "906709_11_item1_p6_s1", "sentA": "BAY41-6551 completed Phase 2 development and we and Bayer are currently preparing for the start of a Phase 3 clinical study.", "sentB": "We have completed two separate Phase 1 clinical studies for NKTR-181 and we are currently preparing for a Phase 2 clinical study that we plan to initiate in mid-2012.", "type": 2, "words": ["<tag1>", "BAY41-6551", "completed", "Phase", "2", "development", "and", "we", "and", "Bayer", "are", "currently", "preparing", "for", "the", "start", "of", "a", "Phase", "3", "clinical", "study.", "<tag2>", "We", "have", "completed", "two", "separate", "Phase", "1", "clinical", "studies", "for", "NKTR-181", "and", "we", "are", "currently", "preparing", "for", "a", "Phase", "2", "clinical", "study", "that", "we", "plan", "to", "initiate", "in", "mid-2012.", "<tag3>"], "wordsA": ["BAY41-6551", "completed", "Phase", "2", "development", "and", "we", "and", "Bayer", "are", "currently", "preparing", "for", "the", "start", "of", "a", "Phase", "3", "clinical", "study."], "wordsB": ["We", "have", "completed", "two", "separate", "Phase", "1", "clinical", "studies", "for", "NKTR-181", "and", "we", "are", "currently", "preparing", "for", "a", "Phase", "2", "clinical", "study", "that", "we", "plan", "to", "initiate", "in", "mid-2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p59_s0", "idA": "906709_11_item1_p71_s1", "sentA": "According to the American Cancer Society, in 2010, there were an estimated 21,880 new cases of ovarian cancer diagnosed and an estimated 13,850 deaths from ovarian cancer in the United States.", "sentB": "According to the American Cancer Society and World Health Organization, more than one million women worldwide are diagnosed with breast cancer globally every year.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Cancer", "Society,", "in", "2010,", "there", "were", "an", "estimated", "21,880", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "13,850", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "American", "Cancer", "Society", "and", "World", "Health", "Organization,", "more", "than", "one", "million", "women", "worldwide", "are", "diagnosed", "with", "breast", "cancer", "globally", "every", "year.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Cancer", "Society,", "in", "2010,", "there", "were", "an", "estimated", "21,880", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "13,850", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "American", "Cancer", "Society", "and", "World", "Health", "Organization,", "more", "than", "one", "million", "women", "worldwide", "are", "diagnosed", "with", "breast", "cancer", "globally", "every", "year."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p60_s0", "idA": "906709_11_item1_p71_s1", "sentA": "According to the American Cancer Society, in 2010, there were an estimated 21,880 new cases of ovarian cancer diagnosed and an estimated 13,850 deaths from ovarian cancer in the United States.", "sentB": "In 2011, there were an estimated 230,000 new cases of breast cancer in the United States and 460,000 new cases in Europe.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Cancer", "Society,", "in", "2010,", "there", "were", "an", "estimated", "21,880", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "13,850", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States.", "<tag2>", "In", "2011,", "there", "were", "an", "estimated", "230,000", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States", "and", "460,000", "new", "cases", "in", "Europe.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Cancer", "Society,", "in", "2010,", "there", "were", "an", "estimated", "21,880", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "13,850", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States."], "wordsB": ["In", "2011,", "there", "were", "an", "estimated", "230,000", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States", "and", "460,000", "new", "cases", "in", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p63_s1", "idA": "906709_11_item1_p71_s1", "sentA": "According to the American Cancer Society, in 2010, there were an estimated 21,880 new cases of ovarian cancer diagnosed and an estimated 13,850 deaths from ovarian cancer in the United States.", "sentB": "According to the American Cancer Society, in 2012, there will be an estimated 22,280 new cases of ovarian cancer diagnosed and an estimated 15,500 deaths from ovarian cancer in the United States.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Cancer", "Society,", "in", "2010,", "there", "were", "an", "estimated", "21,880", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "13,850", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States.", "<tag2>", "According", "to", "the", "American", "Cancer", "Society,", "in", "2012,", "there", "will", "be", "an", "estimated", "22,280", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "15,500", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Cancer", "Society,", "in", "2010,", "there", "were", "an", "estimated", "21,880", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "13,850", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States."], "wordsB": ["According", "to", "the", "American", "Cancer", "Society,", "in", "2012,", "there", "will", "be", "an", "estimated", "22,280", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "15,500", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p63_s3", "idA": "906709_11_item1_p71_s2", "sentA": "Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.", "sentB": "It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system.", "type": 2, "words": ["<tag1>", "Ovarian", "cancer", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system.", "<tag2>", "It", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system.", "<tag3>"], "wordsA": ["Ovarian", "cancer", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system."], "wordsB": ["It", "ranks", "fifth", "in", "cancer", "deaths", "among", "women,", "accounting", "for", "more", "deaths", "than", "any", "other", "cancer", "of", "the", "female", "reproductive", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p64_s1", "idA": "906709_11_item1_p71_s4", "sentA": "About 230,000 women globally are diagnosed each year with ovarian cancer.", "sentB": "According to the World Health Organization, about 230,000 women globally are diagnosed each year with ovarian cancer.", "type": 2, "words": ["<tag1>", "About", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer.", "<tag2>", "According", "to", "the", "World", "Health", "Organization,", "about", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer.", "<tag3>"], "wordsA": ["About", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer."], "wordsB": ["According", "to", "the", "World", "Health", "Organization,", "about", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p65_s0", "idA": "906709_11_item1_p72_s0", "sentA": "A NKTR-102 Phase 2 clinical study was initiated in early 2009 to evaluate the efficacy and safety of NKTR-102 monotherapy versus irinotecan in second-line colorectal cancer patients with the KRAS mutant gene.", "sentB": "A NKTR-102 Phase 2 clinical study was initiated in June 2008 to evaluate the efficacy and safety of NKTR-102 monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "type": 2, "words": ["<tag1>", "A", "NKTR-102", "Phase", "2", "clinical", "study", "was", "initiated", "in", "early", "2009", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "A", "NKTR-102", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag3>"], "wordsA": ["A", "NKTR-102", "Phase", "2", "clinical", "study", "was", "initiated", "in", "early", "2009", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["A", "NKTR-102", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p55_s0", "idA": "906709_11_item1_p72_s1", "sentA": "The primary endpoint of the Phase 2 placebo-controlled trial of NKTR-102 in colorectal cancer is progression-free survival as compared to standard irinotecan monotherapy.", "sentB": "In preclinical models, NKTR-102 achieved a 300-fold increase in tumor concentration as compared to irinotecan.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "Phase", "2", "placebo-controlled", "trial", "of", "NKTR-102", "in", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy.", "<tag2>", "In", "preclinical", "models,", "NKTR-102", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "Phase", "2", "placebo-controlled", "trial", "of", "NKTR-102", "in", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy."], "wordsB": ["In", "preclinical", "models,", "NKTR-102", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p65_s1", "idA": "906709_11_item1_p72_s1", "sentA": "The primary endpoint of the Phase 2 placebo-controlled trial of NKTR-102 in colorectal cancer is progression-free survival as compared to standard irinotecan monotherapy.", "sentB": "The primary endpoint of the Phase 2 clinical study in metastatic colorectal cancer is progression-free survival as compared to standard irinotecan monotherapy.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "Phase", "2", "placebo-controlled", "trial", "of", "NKTR-102", "in", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy.", "<tag2>", "The", "primary", "endpoint", "of", "the", "Phase", "2", "clinical", "study", "in", "metastatic", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "Phase", "2", "placebo-controlled", "trial", "of", "NKTR-102", "in", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy."], "wordsB": ["The", "primary", "endpoint", "of", "the", "Phase", "2", "clinical", "study", "in", "metastatic", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s2", "idA": "906709_11_item1_p73_s0", "sentA": "The Phase 2 clinical study is designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "The BEACON study is designed to enroll approximately 840 women with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s5", "idA": "906709_11_item1_p73_s0", "sentA": "The Phase 2 clinical study is designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "NKTR-102 is also being evaluated in a Phase 2 clinical study in patients with platinum-resistant ovarian cancer and a Phase 2 clinical study in patients with metastatic colorectal cancer.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "and", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "and", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "metastatic", "colorectal", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p4_s6", "idA": "906709_11_item1_p73_s0", "sentA": "The Phase 2 clinical study is designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "The Phase 2 clinical study of NKTR-102 in patients with platinum-resistant ovarian cancer completed enrollment of 71 patients in 2009.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "The", "Phase", "2", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "completed", "enrollment", "of", "71", "patients", "in", "2009.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["The", "Phase", "2", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "completed", "enrollment", "of", "71", "patients", "in", "2009."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p62_s1", "idA": "906709_11_item1_p73_s0", "sentA": "The Phase 2 clinical study is designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "NKTR-102 is also being evaluated in a Phase 2 clinical study in patients with platinum-resistant ovarian cancer.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p7_s0", "idA": "906709_11_item1_p73_s0", "sentA": "The Phase 2 clinical study is designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "The Phase 2 clinical study design is a randomized, double-blind, efficacy and safety study of NKTR-181 as compared to placebo in patients with chronic pain.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "The", "Phase", "2", "clinical", "study", "design", "is", "a", "randomized,", "double-blind,", "efficacy", "and", "safety", "study", "of", "NKTR-181", "as", "compared", "to", "placebo", "in", "patients", "with", "chronic", "pain.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "is", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["The", "Phase", "2", "clinical", "study", "design", "is", "a", "randomized,", "double-blind,", "efficacy", "and", "safety", "study", "of", "NKTR-181", "as", "compared", "to", "placebo", "in", "patients", "with", "chronic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p67_s0", "idA": "906709_11_item1_p73_s1", "sentA": "The study is still enrolling and we do not currently have an estimate for the projected end of this trial.", "sentB": "and the study is still ongoing.", "type": 2, "words": ["<tag1>", "The", "study", "is", "still", "enrolling", "and", "we", "do", "not", "currently", "have", "an", "estimate", "for", "the", "projected", "end", "of", "this", "trial.", "<tag2>", "and", "the", "study", "is", "still", "ongoing.", "<tag3>"], "wordsA": ["The", "study", "is", "still", "enrolling", "and", "we", "do", "not", "currently", "have", "an", "estimate", "for", "the", "projected", "end", "of", "this", "trial."], "wordsB": ["and", "the", "study", "is", "still", "ongoing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p66_s1", "idA": "906709_11_item1_p73_s2", "sentA": "Patient enrollment in this study has been challenging due to the fact that the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the United States or European Union.", "sentB": "The study is still enrolling and patient enrollment in this study has been challenging due to the fact that the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or EU.", "type": 2, "words": ["<tag1>", "Patient", "enrollment", "in", "this", "study", "has", "been", "challenging", "due", "to", "the", "fact", "that", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "United", "States", "or", "European", "Union.", "<tag2>", "The", "study", "is", "still", "enrolling", "and", "patient", "enrollment", "in", "this", "study", "has", "been", "challenging", "due", "to", "the", "fact", "that", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "EU.", "<tag3>"], "wordsA": ["Patient", "enrollment", "in", "this", "study", "has", "been", "challenging", "due", "to", "the", "fact", "that", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "United", "States", "or", "European", "Union."], "wordsB": ["The", "study", "is", "still", "enrolling", "and", "patient", "enrollment", "in", "this", "study", "has", "been", "challenging", "due", "to", "the", "fact", "that", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p69_s1", "idA": "906709_11_item1_p76_s1", "sentA": "According to the American Cancer Society, nearly 142,750 new cases of colon and rectal cancer were diagnosed in the U.S. in 2010, and about 50,000 people will die annually of the disease.", "sentB": "According to the American Cancer Society, nearly 141,210 new cases of colon and rectal cancer were diagnosed in the U.S. in 2011, and about 49,000 people will die annually of the disease.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Cancer", "Society,", "nearly", "142,750", "new", "cases", "of", "colon", "and", "rectal", "cancer", "were", "diagnosed", "in", "the", "U.S.", "in", "2010,", "and", "about", "50,000", "people", "will", "die", "annually", "of", "the", "disease.", "<tag2>", "According", "to", "the", "American", "Cancer", "Society,", "nearly", "141,210", "new", "cases", "of", "colon", "and", "rectal", "cancer", "were", "diagnosed", "in", "the", "U.S.", "in", "2011,", "and", "about", "49,000", "people", "will", "die", "annually", "of", "the", "disease.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Cancer", "Society,", "nearly", "142,750", "new", "cases", "of", "colon", "and", "rectal", "cancer", "were", "diagnosed", "in", "the", "U.S.", "in", "2010,", "and", "about", "50,000", "people", "will", "die", "annually", "of", "the", "disease."], "wordsB": ["According", "to", "the", "American", "Cancer", "Society,", "nearly", "141,210", "new", "cases", "of", "colon", "and", "rectal", "cancer", "were", "diagnosed", "in", "the", "U.S.", "in", "2011,", "and", "about", "49,000", "people", "will", "die", "annually", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p71_s0", "idA": "906709_11_item1_p78_s0", "sentA": "patients receive irinotecan-based regimens, primarily in combination with 5-FU/leucovorin.", "sentB": "The majority of metastatic colorectal cancer patients receive irinotecan-based regimens, primarily in combination with 5-FU/leucovorin.", "type": 2, "words": ["<tag1>", "patients", "receive", "irinotecan-based", "regimens,", "primarily", "in", "combination", "with", "5-FU/leucovorin.", "<tag2>", "The", "majority", "of", "metastatic", "colorectal", "cancer", "patients", "receive", "irinotecan-based", "regimens,", "primarily", "in", "combination", "with", "5-FU/leucovorin.", "<tag3>"], "wordsA": ["patients", "receive", "irinotecan-based", "regimens,", "primarily", "in", "combination", "with", "5-FU/leucovorin."], "wordsB": ["The", "majority", "of", "metastatic", "colorectal", "cancer", "patients", "receive", "irinotecan-based", "regimens,", "primarily", "in", "combination", "with", "5-FU/leucovorin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p72_s1", "idA": "906709_11_item1_p79_s1", "sentA": "It was expected to cause about 51,370 deaths (26,580 in men and 24,790 in women) during 2010 in the U.S. Worldwide, according to the World Health Organization, there are 690,000 deaths annually from colorectal cancers.", "sentB": "It was expected to cause about 49,380 deaths (29,001 in men and 20,379 in women) during 2011 in the U.S. Worldwide, according to the World Health Organization, there are 690,000 deaths annually from colorectal cancers.", "type": 2, "words": ["<tag1>", "It", "was", "expected", "to", "cause", "about", "51,370", "deaths", "(26,580", "in", "men", "and", "24,790", "in", "women)", "during", "2010", "in", "the", "U.S.", "Worldwide,", "according", "to", "the", "World", "Health", "Organization,", "there", "are", "690,000", "deaths", "annually", "from", "colorectal", "cancers.", "<tag2>", "It", "was", "expected", "to", "cause", "about", "49,380", "deaths", "(29,001", "in", "men", "and", "20,379", "in", "women)", "during", "2011", "in", "the", "U.S.", "Worldwide,", "according", "to", "the", "World", "Health", "Organization,", "there", "are", "690,000", "deaths", "annually", "from", "colorectal", "cancers.", "<tag3>"], "wordsA": ["It", "was", "expected", "to", "cause", "about", "51,370", "deaths", "(26,580", "in", "men", "and", "24,790", "in", "women)", "during", "2010", "in", "the", "U.S.", "Worldwide,", "according", "to", "the", "World", "Health", "Organization,", "there", "are", "690,000", "deaths", "annually", "from", "colorectal", "cancers."], "wordsB": ["It", "was", "expected", "to", "cause", "about", "49,380", "deaths", "(29,001", "in", "men", "and", "20,379", "in", "women)", "during", "2011", "in", "the", "U.S.", "Worldwide,", "according", "to", "the", "World", "Health", "Organization,", "there", "are", "690,000", "deaths", "annually", "from", "colorectal", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p78_s0", "idA": "906709_11_item1_p7_s0", "sentA": "device for commercial manufacturing prior to initiating Phase 3 clinical development with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work.", "sentB": "manufacturing prior to initiating Phase 3 clinical development with the objective of commencing Phase 3 clinical trials as soon as possible following completion of this work.", "type": 2, "words": ["<tag1>", "device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work.", "<tag2>", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work.", "<tag3>"], "wordsA": ["device", "for", "commercial", "manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work."], "wordsB": ["manufacturing", "prior", "to", "initiating", "Phase", "3", "clinical", "development", "with", "the", "objective", "of", "commencing", "Phase", "3", "clinical", "trials", "as", "soon", "as", "possible", "following", "completion", "of", "this", "work."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p21_s5", "idA": "906709_11_item1_p84_s0", "sentA": "NKTR-105 is currently being evaluated in a Phase 1 clinical trial in cancer patients.", "sentB": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which is currently being evaluated in Phase 1 clinical development by our partner Baxter for the treatment of hemophilia A.", "type": 2, "words": ["<tag1>", "NKTR-105", "is", "currently", "being", "evaluated", "in", "a", "Phase", "1", "clinical", "trial", "in", "cancer", "patients.", "<tag2>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "1", "clinical", "development", "by", "our", "partner", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "<tag3>"], "wordsA": ["NKTR-105", "is", "currently", "being", "evaluated", "in", "a", "Phase", "1", "clinical", "trial", "in", "cancer", "patients."], "wordsB": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "1", "clinical", "development", "by", "our", "partner", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p57_s0", "idA": "906709_11_item1_p84_s0", "sentA": "NKTR-105 is currently being evaluated in a Phase 1 clinical trial in cancer patients.", "sentB": "NKTR-102 is currently being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "type": 2, "words": ["<tag1>", "NKTR-105", "is", "currently", "being", "evaluated", "in", "a", "Phase", "1", "clinical", "trial", "in", "cancer", "patients.", "<tag2>", "NKTR-102", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["NKTR-105", "is", "currently", "being", "evaluated", "in", "a", "Phase", "1", "clinical", "trial", "in", "cancer", "patients."], "wordsB": ["NKTR-102", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p6_s0", "idA": "906709_11_item1_p85_s0", "sentA": "NKTR-181 is being developed as a safer, mu opioid analgesic with reduced potential for abuse and fewer side effects than traditional opioid therapies.", "sentB": "NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "being", "developed", "as", "a", "safer,", "mu", "opioid", "analgesic", "with", "reduced", "potential", "for", "abuse", "and", "fewer", "side", "effects", "than", "traditional", "opioid", "therapies.", "<tag2>", "NKTR-181", "is", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "with", "a", "long-acting", "profile", "to", "treat", "chronic", "pain", "that", "has", "been", "designed", "with", "the", "objective", "of", "addressing", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "opioid", "therapies.", "<tag3>"], "wordsA": ["NKTR-181", "is", "being", "developed", "as", "a", "safer,", "mu", "opioid", "analgesic", "with", "reduced", "potential", "for", "abuse", "and", "fewer", "side", "effects", "than", "traditional", "opioid", "therapies."], "wordsB": ["NKTR-181", "is", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "with", "a", "long-acting", "profile", "to", "treat", "chronic", "pain", "that", "has", "been", "designed", "with", "the", "objective", "of", "addressing", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p6_s1", "idA": "906709_11_item1_p85_s2", "sentA": "With a reduced rate of entry into the CNS, NKTR-181 has the potential to substantially reduce not only the euphoria that underlies opioid abuse liability and dependence but also the serious CNS-related side effects of respiratory depression and sedation.", "sentB": "These CNS-related side effects include abuse liability, sedation and respiratory depression.", "type": 2, "words": ["<tag1>", "With", "a", "reduced", "rate", "of", "entry", "into", "the", "CNS,", "NKTR-181", "has", "the", "potential", "to", "substantially", "reduce", "not", "only", "the", "euphoria", "that", "underlies", "opioid", "abuse", "liability", "and", "dependence", "but", "also", "the", "serious", "CNS-related", "side", "effects", "of", "respiratory", "depression", "and", "sedation.", "<tag2>", "These", "CNS-related", "side", "effects", "include", "abuse", "liability,", "sedation", "and", "respiratory", "depression.", "<tag3>"], "wordsA": ["With", "a", "reduced", "rate", "of", "entry", "into", "the", "CNS,", "NKTR-181", "has", "the", "potential", "to", "substantially", "reduce", "not", "only", "the", "euphoria", "that", "underlies", "opioid", "abuse", "liability", "and", "dependence", "but", "also", "the", "serious", "CNS-related", "side", "effects", "of", "respiratory", "depression", "and", "sedation."], "wordsB": ["These", "CNS-related", "side", "effects", "include", "abuse", "liability,", "sedation", "and", "respiratory", "depression."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p8_s0", "idA": "906709_11_item1_p85_s2", "sentA": "With a reduced rate of entry into the CNS, NKTR-181 has the potential to substantially reduce not only the euphoria that underlies opioid abuse liability and dependence but also the serious CNS-related side effects of respiratory depression and sedation.", "sentB": "NKTR-192 is an orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain that has been designed with the objective to also address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "type": 2, "words": ["<tag1>", "With", "a", "reduced", "rate", "of", "entry", "into", "the", "CNS,", "NKTR-181", "has", "the", "potential", "to", "substantially", "reduce", "not", "only", "the", "euphoria", "that", "underlies", "opioid", "abuse", "liability", "and", "dependence", "but", "also", "the", "serious", "CNS-related", "side", "effects", "of", "respiratory", "depression", "and", "sedation.", "<tag2>", "NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag3>"], "wordsA": ["With", "a", "reduced", "rate", "of", "entry", "into", "the", "CNS,", "NKTR-181", "has", "the", "potential", "to", "substantially", "reduce", "not", "only", "the", "euphoria", "that", "underlies", "opioid", "abuse", "liability", "and", "dependence", "but", "also", "the", "serious", "CNS-related", "side", "effects", "of", "respiratory", "depression", "and", "sedation."], "wordsB": ["NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p11_s1", "idA": "906709_11_item1_p86_s0", "sentA": "We filed an Investigational New Drug application (IND) with the FDA and plan to begin Phase 1 clinical studies in the first part of 2011.", "sentB": "This Phase 1 clinical study is the first step in assessing whether BAX 855 can be infused less frequently in patients while achieving a similar efficacy and safety profile.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "Investigational", "New", "Drug", "application", "(IND)", "with", "the", "FDA", "and", "plan", "to", "begin", "Phase", "1", "clinical", "studies", "in", "the", "first", "part", "of", "2011.", "<tag2>", "This", "Phase", "1", "clinical", "study", "is", "the", "first", "step", "in", "assessing", "whether", "BAX", "855", "can", "be", "infused", "less", "frequently", "in", "patients", "while", "achieving", "a", "similar", "efficacy", "and", "safety", "profile.", "<tag3>"], "wordsA": ["We", "filed", "an", "Investigational", "New", "Drug", "application", "(IND)", "with", "the", "FDA", "and", "plan", "to", "begin", "Phase", "1", "clinical", "studies", "in", "the", "first", "part", "of", "2011."], "wordsB": ["This", "Phase", "1", "clinical", "study", "is", "the", "first", "step", "in", "assessing", "whether", "BAX", "855", "can", "be", "infused", "less", "frequently", "in", "patients", "while", "achieving", "a", "similar", "efficacy", "and", "safety", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p8_s1", "idA": "906709_11_item1_p86_s0", "sentA": "We filed an Investigational New Drug application (IND) with the FDA and plan to begin Phase 1 clinical studies in the first part of 2011.", "sentB": "NKTR-192 completed preclinical work in 2011 and we plan to begin a Phase 1 clinical study in 2012 subject to our investigational new drug application (IND) clearing the FDA review period.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "Investigational", "New", "Drug", "application", "(IND)", "with", "the", "FDA", "and", "plan", "to", "begin", "Phase", "1", "clinical", "studies", "in", "the", "first", "part", "of", "2011.", "<tag2>", "NKTR-192", "completed", "preclinical", "work", "in", "2011", "and", "we", "plan", "to", "begin", "a", "Phase", "1", "clinical", "study", "in", "2012", "subject", "to", "our", "investigational", "new", "drug", "application", "(IND)", "clearing", "the", "FDA", "review", "period.", "<tag3>"], "wordsA": ["We", "filed", "an", "Investigational", "New", "Drug", "application", "(IND)", "with", "the", "FDA", "and", "plan", "to", "begin", "Phase", "1", "clinical", "studies", "in", "the", "first", "part", "of", "2011."], "wordsB": ["NKTR-192", "completed", "preclinical", "work", "in", "2011", "and", "we", "plan", "to", "begin", "a", "Phase", "1", "clinical", "study", "in", "2012", "subject", "to", "our", "investigational", "new", "drug", "application", "(IND)", "clearing", "the", "FDA", "review", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p14_s0", "idA": "906709_11_item1_p8_s1", "sentA": "We retained all of our rights to BAY41-6551 and certain rights to receive royalties on net sales of the Cipro Inhale (also known as Ciprofloxacin Inhaled Powder or CIP) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "royalties on net sales of the Cipro Inhale (also known as Ciprofloxacin Inhaled Powder or CIP) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "type": 2, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "certain", "rights", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "certain", "rights", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p39_s0", "idA": "906709_11_item1_p8_s1", "sentA": "We retained all of our rights to BAY41-6551 and certain rights to receive royalties on net sales of the Cipro Inhale (also known as Ciprofloxacin Inhaled Powder or CIP) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "* In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012 until the agreement with UCB is terminated or expires.", "type": 2, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "certain", "rights", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "UCB", "is", "terminated", "or", "expires.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "certain", "rights", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "UCB", "is", "terminated", "or", "expires."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p40_s1", "idA": "906709_11_item1_p8_s1", "sentA": "We retained all of our rights to BAY41-6551 and certain rights to receive royalties on net sales of the Cipro Inhale (also known as Ciprofloxacin Inhaled Powder or CIP) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "In February 2012, we sold our rights to receive royalties on future worldwide net sales of MIRCERA effective as of January 1, 2012 until the agreement with Roche is terminated or expires.", "type": 2, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "certain", "rights", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "Roche", "is", "terminated", "or", "expires.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "certain", "rights", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "Roche", "is", "terminated", "or", "expires."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p14_s1", "idA": "906709_11_item1_p8_s2", "sentA": "We also retained certain intellectual property rights to patents specific to inhaled insulin.", "sentB": "We also retained certain rights to patents specific to inhaled insulin.", "type": 2, "words": ["<tag1>", "We", "also", "retained", "certain", "intellectual", "property", "rights", "to", "patents", "specific", "to", "inhaled", "insulin.", "<tag2>", "We", "also", "retained", "certain", "rights", "to", "patents", "specific", "to", "inhaled", "insulin.", "<tag3>"], "wordsA": ["We", "also", "retained", "certain", "intellectual", "property", "rights", "to", "patents", "specific", "to", "inhaled", "insulin."], "wordsB": ["We", "also", "retained", "certain", "rights", "to", "patents", "specific", "to", "inhaled", "insulin."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p3_s2", "idA": "906709_11_item1_p92_s3", "sentA": "Baxter is responsible for all clinical development, regulatory, and commercialization expenses.", "sentB": "AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119.", "type": 2, "words": ["<tag1>", "Baxter", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag2>", "AstraZeneca", "is", "responsible", "for", "all", "clinical,", "regulatory", "and", "commercialization", "costs", "for", "NKTR-118", "and", "NKTR-119.", "<tag3>"], "wordsA": ["Baxter", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "wordsB": ["AstraZeneca", "is", "responsible", "for", "all", "clinical,", "regulatory", "and", "commercialization", "costs", "for", "NKTR-118", "and", "NKTR-119."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_12_item1_p9_s2", "idA": "906709_11_item1_p92_s3", "sentA": "Baxter is responsible for all clinical development, regulatory, and commercialization expenses.", "sentB": "Baxter is responsible for all clinical development.", "type": 2, "words": ["<tag1>", "Baxter", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag2>", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag3>"], "wordsA": ["Baxter", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "wordsB": ["Baxter", "is", "responsible", "for", "all", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p1_s0", "idA": "906709_12_item1_p0_s1", "sentA": "Our current proprietary pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.", "sentB": "Our current proprietary pipeline is comprised of drug candidates across several therapeutic areas including oncology, pain, anti-infectives and immunology.", "type": 2, "words": ["<tag1>", "Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology.", "<tag2>", "Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "several", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives", "and", "immunology.", "<tag3>"], "wordsA": ["Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "a", "number", "of", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives,", "anti-viral", "and", "immunology."], "wordsB": ["Our", "current", "proprietary", "pipeline", "is", "comprised", "of", "drug", "candidates", "across", "several", "therapeutic", "areas", "including", "oncology,", "pain,", "anti-infectives", "and", "immunology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p1_s1", "idA": "906709_12_item1_p0_s2", "sentA": "Our research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates.", "sentB": "Our research and development activities involve both small molecule and biologic drug candidates.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates.", "<tag2>", "Our", "research", "and", "development", "activities", "involve", "both", "small", "molecule", "and", "biologic", "drug", "candidates.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "potential", "biologic", "drug", "candidates."], "wordsB": ["Our", "research", "and", "development", "activities", "involve", "both", "small", "molecule", "and", "biologic", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p0_s0", "idA": "906709_12_item1_p0_s3", "sentA": "We create our innovative drug candidates by using our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities.", "sentB": "development of new molecular entities that target known mechanisms of action.", "type": 2, "words": ["<tag1>", "We", "create", "our", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "drugs", "to", "create", "new", "molecular", "entities.", "<tag2>", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag3>"], "wordsA": ["We", "create", "our", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "drugs", "to", "create", "new", "molecular", "entities."], "wordsB": ["development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p1_s2", "idA": "906709_12_item1_p0_s3", "sentA": "We create our innovative drug candidates by using our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of drugs to create new molecular entities.", "sentB": "We create innovative drug candidates by using our proprietary advanced polymer conjugate technologies and expertise to modify the chemical structure of pharmacophores to create new molecular entities.", "type": 2, "words": ["<tag1>", "We", "create", "our", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "drugs", "to", "create", "new", "molecular", "entities.", "<tag2>", "We", "create", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "pharmacophores", "to", "create", "new", "molecular", "entities.", "<tag3>"], "wordsA": ["We", "create", "our", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "drugs", "to", "create", "new", "molecular", "entities."], "wordsB": ["We", "create", "innovative", "drug", "candidates", "by", "using", "our", "proprietary", "advanced", "polymer", "conjugate", "technologies", "and", "expertise", "to", "modify", "the", "chemical", "structure", "of", "pharmacophores", "to", "create", "new", "molecular", "entities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p13_s5", "idA": "906709_12_item1_p10_s0", "sentA": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein in Phase 1 clinical development in patients with hemophilia A.", "sentB": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein which has completed Phase 1 clinical development in patients with hemophilia A.", "type": 2, "words": ["<tag1>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "in", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag2>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag3>"], "wordsA": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "in", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "wordsB": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p13_s6", "idA": "906709_12_item1_p11_s0", "sentA": "The Phase 1 clinical study is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A. When used for prophylaxis, Baxter s ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes.", "sentB": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE that will enroll more than 100 previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "type": 2, "words": ["<tag1>", "The", "Phase", "1", "clinical", "study", "is", "a", "prospective,", "open-label", "study", "that", "will", "assess", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "previously-treated", "patients", "aged", "12", "years", "or", "older", "with", "severe", "hemophilia", "A.", "When", "used", "for", "prophylaxis,", "Baxter", "s", "ADVATE", "requires", "patients", "to", "infuse", "every", "two", "to", "three", "days", "to", "reduce", "the", "occurrence", "of", "bleeding", "episodes.", "<tag2>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag3>"], "wordsA": ["The", "Phase", "1", "clinical", "study", "is", "a", "prospective,", "open-label", "study", "that", "will", "assess", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "previously-treated", "patients", "aged", "12", "years", "or", "older", "with", "severe", "hemophilia", "A.", "When", "used", "for", "prophylaxis,", "Baxter", "s", "ADVATE", "requires", "patients", "to", "infuse", "every", "two", "to", "three", "days", "to", "reduce", "the", "occurrence", "of", "bleeding", "episodes."], "wordsB": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p14_s0", "idA": "906709_12_item1_p11_s3", "sentA": "We also have a significant collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "We also have a significant collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(NKTR-061,", "Amikacin", "Inhale),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p15_s0", "idA": "906709_12_item1_p12_s2", "sentA": "In 2011, Bayer received agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "type": 2, "words": ["<tag1>", "In", "2011,", "Bayer", "received", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "received", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p16_s3", "idA": "906709_12_item1_p14_s0", "sentA": "royalties on net sales of the Cipro Inhale (also known as Ciprofloxacin Inhaled Powder or CIP) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "We retained all of our rights to BAY41-6551 and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "type": 2, "words": ["<tag1>", "royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag3>"], "wordsA": ["royalties", "on", "net", "sales", "of", "the", "Cipro", "Inhale", "(also", "known", "as", "Ciprofloxacin", "Inhaled", "Powder", "or", "CIP)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p18_s4", "idA": "906709_12_item1_p14_s6", "sentA": "Our Technology Platform As a leader in the PEGylation field, we have advanced our technology platform to include first-generation PEGylation technology as well as new advanced polymer conjugate chemistries that can be tailored in very specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs useful in many disease areas.", "sentB": "Our Technology Platform As a leader in the PEGylation field, we have advanced our technology platform to include new advanced polymer conjugate chemistries and polymer technologies that can be tailored in specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs targeting many disease areas.", "type": 2, "words": ["<tag1>", "Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "first-generation", "PEGylation", "technology", "as", "well", "as", "new", "advanced", "polymer", "conjugate", "chemistries", "that", "can", "be", "tailored", "in", "very", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "useful", "in", "many", "disease", "areas.", "<tag2>", "Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "conjugate", "chemistries", "and", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "many", "disease", "areas.", "<tag3>"], "wordsA": ["Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "first-generation", "PEGylation", "technology", "as", "well", "as", "new", "advanced", "polymer", "conjugate", "chemistries", "that", "can", "be", "tailored", "in", "very", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "useful", "in", "many", "disease", "areas."], "wordsB": ["Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "conjugate", "chemistries", "and", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "many", "disease", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p19_s0", "idA": "906709_12_item1_p15_s0", "sentA": "PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Roche s PEGASYS (PEG-interferon alfa-2a) and Amgen s Neulasta (pegfilgrastim).", "sentB": "PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen s Neulasta (pegfilgrastim) and Roche s PEGASYS (PEG-interferon alfa-2a).", "type": 2, "words": ["<tag1>", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)", "and", "Amgen", "s", "Neulasta", "(pegfilgrastim).", "<tag2>", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a).", "<tag3>"], "wordsA": ["PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)", "and", "Amgen", "s", "Neulasta", "(pegfilgrastim)."], "wordsB": ["PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p20_s0", "idA": "906709_12_item1_p16_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that is safely cleared from the body.", "sentB": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "type": 2, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body.", "<tag2>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body."], "wordsB": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p50_s0", "idA": "906709_12_item1_p16_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that is safely cleared from the body.", "sentB": "OIC is a result of decreased fluid absorption and lower gastrointestinal motility due to opioid receptor binding in the gastrointestinal tract.", "type": 2, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body.", "<tag2>", "OIC", "is", "a", "result", "of", "decreased", "fluid", "absorption", "and", "lower", "gastrointestinal", "motility", "due", "to", "opioid", "receptor", "binding", "in", "the", "gastrointestinal", "tract.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "is", "safely", "cleared", "from", "the", "body."], "wordsB": ["OIC", "is", "a", "result", "of", "decreased", "fluid", "absorption", "and", "lower", "gastrointestinal", "motility", "due", "to", "opioid", "receptor", "binding", "in", "the", "gastrointestinal", "tract."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p20_s3", "idA": "906709_12_item1_p16_s3", "sentA": "Earlier PEGylation technology applications were limited, in that they could not be used successfully to improve small molecule drugs, antibody fragments and peptides, all of which could potentially benefit from the application of the technology.", "sentB": "These techniques cannot be used successfully to create small molecule drugs which could potentially benefit from the application of the technology.", "type": 2, "words": ["<tag1>", "Earlier", "PEGylation", "technology", "applications", "were", "limited,", "in", "that", "they", "could", "not", "be", "used", "successfully", "to", "improve", "small", "molecule", "drugs,", "antibody", "fragments", "and", "peptides,", "all", "of", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology.", "<tag2>", "These", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology.", "<tag3>"], "wordsA": ["Earlier", "PEGylation", "technology", "applications", "were", "limited,", "in", "that", "they", "could", "not", "be", "used", "successfully", "to", "improve", "small", "molecule", "drugs,", "antibody", "fragments", "and", "peptides,", "all", "of", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology."], "wordsB": ["These", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p22_s1", "idA": "906709_12_item1_p18_s1", "sentA": "We have a broad range of approaches that we may use when designing our own drug candidates, some of which are outlined below: Small Molecule Stable Polymer Conjugates Our customized approaches for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit.", "sentB": "We have a broad range of approaches that we may use when designing our own drug candidates, some of which are further described below.", "type": 2, "words": ["<tag1>", "We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "outlined", "below:", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit.", "<tag2>", "We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "further", "described", "below.", "<tag3>"], "wordsA": ["We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "outlined", "below:", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit."], "wordsB": ["We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "further", "described", "below."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p23_s0", "idA": "906709_12_item1_p18_s1", "sentA": "We have a broad range of approaches that we may use when designing our own drug candidates, some of which are outlined below: Small Molecule Stable Polymer Conjugates Our customized approaches for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit.", "sentB": "Small Molecule Stable Polymer Conjugates Our customized approaches for small molecule polymer conjugates allows for the fine-tuning of the physicochemical and pharmacological properties of small molecule oral drugs to potentially increase their therapeutic benefit.", "type": 2, "words": ["<tag1>", "We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "outlined", "below:", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit.", "<tag2>", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit.", "<tag3>"], "wordsA": ["We", "have", "a", "broad", "range", "of", "approaches", "that", "we", "may", "use", "when", "designing", "our", "own", "drug", "candidates,", "some", "of", "which", "are", "outlined", "below:", "Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit."], "wordsB": ["Small", "Molecule", "Stable", "Polymer", "Conjugates", "Our", "customized", "approaches", "for", "small", "molecule", "polymer", "conjugates", "allows", "for", "the", "fine-tuning", "of", "the", "physicochemical", "and", "pharmacological", "properties", "of", "small", "molecule", "oral", "drugs", "to", "potentially", "increase", "their", "therapeutic", "benefit."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p23_s3", "idA": "906709_12_item1_p18_s4", "sentA": "A primary example of reducing transport across the blood-brain barrier is NKTR-118, an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies with our partner AstraZeneca.", "sentB": "Two primary examples of reducing transport across the blood-brain barrier are naloxegol, an orally-available peripherally-acting opioid antagonist that is in late stage clinical development in collaboration with AstraZeneca, and NKTR-171, a novel peripherally-acting sodium channel blocker that is currently in IND-enabling studies for the treatment of neuropathic pain.", "type": 2, "words": ["<tag1>", "A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca.", "<tag2>", "Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "in", "late", "stage", "clinical", "development", "in", "collaboration", "with", "AstraZeneca,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "IND-enabling", "studies", "for", "the", "treatment", "of", "neuropathic", "pain.", "<tag3>"], "wordsA": ["A", "primary", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-118,", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "with", "our", "partner", "AstraZeneca."], "wordsB": ["Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "in", "late", "stage", "clinical", "development", "in", "collaboration", "with", "AstraZeneca,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "IND-enabling", "studies", "for", "the", "treatment", "of", "neuropathic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p23_s4", "idA": "906709_12_item1_p18_s5", "sentA": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that has completed Phase 1 clinical development.", "sentB": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that is being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "type": 2, "words": ["<tag1>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "has", "completed", "Phase", "1", "clinical", "development.", "<tag2>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag3>"], "wordsA": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "has", "completed", "Phase", "1", "clinical", "development."], "wordsB": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p24_s3", "idA": "906709_12_item1_p19_s3", "sentA": "We are using this approach with the oncolytic drug candidate in our pipeline, NKTR-102, a next-generation topoisomerase I-inhibitor, currently in Phase 3 clinical development in metastatic breast cancer, and Phase 2 development in ovarian and colorectal cancers.", "sentB": "We are using this approach with the oncolytic drug candidate in our pipeline, etirinotecan pegol, a next-generation topoisomerase I-inhibitor, currently in Phase 3 clinical development in metastatic breast cancer, and Phase 2 clinical development in ovarian and colorectal cancers.", "type": 2, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "development", "in", "ovarian", "and", "colorectal", "cancers.", "<tag2>", "We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "clinical", "development", "in", "ovarian", "and", "colorectal", "cancers.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "development", "in", "ovarian", "and", "colorectal", "cancers."], "wordsB": ["We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "clinical", "development", "in", "ovarian", "and", "colorectal", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p3_s0", "idA": "906709_12_item1_p1_s2", "sentA": "Our drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.", "sentB": "Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life and/or bioavailability of drugs.", "type": 2, "words": ["<tag1>", "Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "pharmacokinetics,", "pharmacodynamics,", "half-life,", "bioavailability,", "metabolism", "or", "distribution", "of", "drugs", "and", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "the", "patient.", "<tag2>", "Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life", "and/or", "bioavailability", "of", "drugs.", "<tag3>"], "wordsA": ["Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "pharmacokinetics,", "pharmacodynamics,", "half-life,", "bioavailability,", "metabolism", "or", "distribution", "of", "drugs", "and", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "the", "patient."], "wordsB": ["Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life", "and/or", "bioavailability", "of", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p25_s0", "idA": "906709_12_item1_p21_s4", "sentA": "Through rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "sentB": "rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "type": 2, "words": ["<tag1>", "Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag2>", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag3>"], "wordsA": ["Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "wordsB": ["rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p25_s1", "idA": "906709_12_item1_p24_s0", "sentA": "Antibody Fragment Polymer Conjugates This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "sentB": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which is currently being evaluated in Phase 3 clinical development in collaboration with Baxter for the treatment of hemophilia A. Antibody Fragment Polymer Conjugates This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "type": 2, "words": ["<tag1>", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag2>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "3", "clinical", "development", "in", "collaboration", "with", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag3>"], "wordsA": ["Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "wordsB": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "3", "clinical", "development", "in", "collaboration", "with", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p28_s1", "idA": "906709_12_item1_p27_s1", "sentA": "To support this strategy, over the past four years we have significantly expanded and added expertise to our internal clinical development and regulatory departments.", "sentB": "To support this strategy, over the past five years we have significantly expanded and added expertise to our internal preclinical, clinical development and regulatory departments.", "type": 2, "words": ["<tag1>", "To", "support", "this", "strategy,", "over", "the", "past", "four", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "clinical", "development", "and", "regulatory", "departments.", "<tag2>", "To", "support", "this", "strategy,", "over", "the", "past", "five", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments.", "<tag3>"], "wordsA": ["To", "support", "this", "strategy,", "over", "the", "past", "four", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "clinical", "development", "and", "regulatory", "departments."], "wordsB": ["To", "support", "this", "strategy,", "over", "the", "past", "five", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p29_s4", "idA": "906709_12_item1_p28_s4", "sentA": "Our discovery research organization is identifying new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas.", "sentB": "Our discovery research organization is continuing to identify new drug candidates by applying our technology platform to a wide range of molecule classes, including small molecules and large proteins, peptides and antibodies, across multiple therapeutic areas.", "type": 2, "words": ["<tag1>", "Our", "discovery", "research", "organization", "is", "identifying", "new", "drug", "candidates", "by", "applying", "our", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes,", "including", "small", "molecules", "and", "large", "proteins,", "peptides", "and", "antibodies,", "across", "multiple", "therapeutic", "areas.", "<tag2>", "Our", "discovery", "research", "organization", "is", "continuing", "to", "identify", "new", "drug", "candidates", "by", "applying", "our", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes,", "including", "small", "molecules", "and", "large", "proteins,", "peptides", "and", "antibodies,", "across", "multiple", "therapeutic", "areas.", "<tag3>"], "wordsA": ["Our", "discovery", "research", "organization", "is", "identifying", "new", "drug", "candidates", "by", "applying", "our", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes,", "including", "small", "molecules", "and", "large", "proteins,", "peptides", "and", "antibodies,", "across", "multiple", "therapeutic", "areas."], "wordsB": ["Our", "discovery", "research", "organization", "is", "continuing", "to", "identify", "new", "drug", "candidates", "by", "applying", "our", "technology", "platform", "to", "a", "wide", "range", "of", "molecule", "classes,", "including", "small", "molecules", "and", "large", "proteins,", "peptides", "and", "antibodies,", "across", "multiple", "therapeutic", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p29_s7", "idA": "906709_12_item1_p28_s7", "sentA": "For example, in December 2010, we decided that we would move NKTR-102 into Phase 3 development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate.", "sentB": "For example, in December 2010, we decided that we would move etirinotecan pegol (NKTR-102) into Phase 3 clinical development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate.", "type": 2, "words": ["<tag1>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "NKTR-102", "into", "Phase", "3", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate.", "<tag2>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate.", "<tag3>"], "wordsA": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "NKTR-102", "into", "Phase", "3", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate."], "wordsB": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p30_s0", "idA": "906709_12_item1_p28_s8", "sentA": "When we determine to seek a partner, our strategy is to enter into collaborations with leading pharmaceutical and biotechnology companies to fund further clinical development, manage the global regulatory filing process, and market and sell drugs in one or more geographies.", "sentB": "regulatory filing process, and market and sell drugs in one or more geographies.", "type": 2, "words": ["<tag1>", "When", "we", "determine", "to", "seek", "a", "partner,", "our", "strategy", "is", "to", "enter", "into", "collaborations", "with", "leading", "pharmaceutical", "and", "biotechnology", "companies", "to", "fund", "further", "clinical", "development,", "manage", "the", "global", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies.", "<tag2>", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies.", "<tag3>"], "wordsA": ["When", "we", "determine", "to", "seek", "a", "partner,", "our", "strategy", "is", "to", "enter", "into", "collaborations", "with", "leading", "pharmaceutical", "and", "biotechnology", "companies", "to", "fund", "further", "clinical", "development,", "manage", "the", "global", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies."], "wordsB": ["regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p30_s1", "idA": "906709_12_item1_p29_s0", "sentA": "comprehensive licensing and commercialization arrangements to co-promotion and co-development agreements with the structure of the collaboration depending on factors such as the structure of economic risk sharing, the cost and complexity of development, marketing and commercialization needs, therapeutic area and geographic capabilities.", "sentB": "The options for future collaboration arrangements range from comprehensive licensing and commercialization arrangements to co-promotion and co-development agreements with the structure of the collaboration depending on factors such as the structure of economic risk sharing, the cost and complexity of development, marketing and commercialization needs, therapeutic area and geographic capabilities.", "type": 2, "words": ["<tag1>", "comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "structure", "of", "economic", "risk", "sharing,", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities.", "<tag2>", "The", "options", "for", "future", "collaboration", "arrangements", "range", "from", "comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "structure", "of", "economic", "risk", "sharing,", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities.", "<tag3>"], "wordsA": ["comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "structure", "of", "economic", "risk", "sharing,", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities."], "wordsB": ["The", "options", "for", "future", "collaboration", "arrangements", "range", "from", "comprehensive", "licensing", "and", "commercialization", "arrangements", "to", "co-promotion", "and", "co-development", "agreements", "with", "the", "structure", "of", "the", "collaboration", "depending", "on", "factors", "such", "as", "the", "structure", "of", "economic", "risk", "sharing,", "the", "cost", "and", "complexity", "of", "development,", "marketing", "and", "commercialization", "needs,", "therapeutic", "area", "and", "geographic", "capabilities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p17_s0", "idA": "906709_12_item1_p2_s0", "sentA": "Our most advanced proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "In August 2012, Bayer initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis.", "type": 2, "words": ["<tag1>", "Our", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-118,", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "currently", "in", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "In", "August", "2012,", "Bayer", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag3>"], "wordsA": ["Our", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-118,", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "currently", "in", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["In", "August", "2012,", "Bayer", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p4_s0", "idA": "906709_12_item1_p2_s0", "sentA": "Our most advanced proprietary drug candidate, NKTR-118, is an oral peripherally-acting opioid antagonist, currently in Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "type": 2, "words": ["<tag1>", "Our", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-118,", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "currently", "in", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag3>"], "wordsA": ["Our", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-118,", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "currently", "in", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p48_s0", "idA": "906709_12_item1_p2_s1", "sentA": "OIC is a common side effect of prescription opioids when used for chronic pain management.", "sentB": "Naloxegol is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC) which is a common side effect of prescription opioid medications.", "type": 2, "words": ["<tag1>", "OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management.", "<tag2>", "Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag3>"], "wordsA": ["OIC", "is", "a", "common", "side", "effect", "of", "prescription", "opioids", "when", "used", "for", "chronic", "pain", "management."], "wordsB": ["Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p31_s1", "idA": "906709_12_item1_p30_s1", "sentA": "To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others, polymer materials, conjugates, formulations, synthesis, therapeutic areas and methods of treatment.", "sentB": "To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others, polymer materials, conjugates, formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture.", "type": 2, "words": ["<tag1>", "To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas", "and", "methods", "of", "treatment.", "<tag2>", "To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas,", "methods", "of", "treatment", "and", "methods", "of", "manufacture.", "<tag3>"], "wordsA": ["To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas", "and", "methods", "of", "treatment."], "wordsB": ["To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas,", "methods", "of", "treatment", "and", "methods", "of", "manufacture."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p31_s2", "idA": "906709_12_item1_p30_s2", "sentA": "The following table summarizes our proprietary Nektar-discovered drug candidates that are being developed by us or in collaboration with other pharmaceutical companies.", "sentB": "The following table summarizes our proprietary drug candidates that are being developed by us or in collaboration with other pharmaceutical companies.", "type": 2, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies.", "<tag2>", "The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "Nektar-discovered", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies."], "wordsB": ["The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p35_s0", "idA": "906709_12_item1_p34_s0", "sentA": "* This drug candidate uses a liquid aerosol technology platform that was transferred to Novartis by us in the pulmonary asset sale transaction that was completed on December 31, 2008.", "sentB": "This drug candidate uses, in part, a liquid aerosol technology platform that was transferred to Novartis by us in the pulmonary asset sale transaction that was completed on December 31, 2008.", "type": 2, "words": ["<tag1>", "*", "This", "drug", "candidate", "uses", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008.", "<tag2>", "This", "drug", "candidate", "uses,", "in", "part,", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008.", "<tag3>"], "wordsA": ["*", "This", "drug", "candidate", "uses", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008."], "wordsB": ["This", "drug", "candidate", "uses,", "in", "part,", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p36_s0", "idA": "906709_12_item1_p34_s2", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property.", "sentB": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property.", "<tag2>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property."], "wordsB": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p37_s0", "idA": "906709_12_item1_p35_s0", "sentA": "A total of seven products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "type": 2, "words": ["<tag1>", "A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag3>"], "wordsA": ["A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p57_s3", "idA": "906709_12_item1_p35_s0", "sentA": "A total of seven products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "type": 2, "words": ["<tag1>", "A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag3>"], "wordsA": ["A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p42_s0", "idA": "906709_12_item1_p39_s0", "sentA": "* In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012 until the agreement with UCB is terminated or expires.", "sentB": "* In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012.", "type": 2, "words": ["<tag1>", "*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "UCB", "is", "terminated", "or", "expires.", "<tag2>", "*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012.", "<tag3>"], "wordsA": ["*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "UCB", "is", "terminated", "or", "expires."], "wordsB": ["*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p5_s0", "idA": "906709_12_item1_p3_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of NKTR-118 and NKTR-119.", "sentB": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119.", "<tag2>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "NKTR-118", "and", "NKTR-119."], "wordsB": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p6_s0", "idA": "906709_12_item1_p3_s1", "sentA": "NKTR-119 is an early stage research and development program that is designed to combine various opioids with NKTR-118.", "sentB": "The naloxegol fixed-dose combination program, formerly known as the NKTR-119 program, is an early stage research and development program that is designed to combine various opioids with naloxegol.", "type": 2, "words": ["<tag1>", "NKTR-119", "is", "an", "early", "stage", "research", "and", "development", "program", "that", "is", "designed", "to", "combine", "various", "opioids", "with", "NKTR-118.", "<tag2>", "The", "naloxegol", "fixed-dose", "combination", "program,", "formerly", "known", "as", "the", "NKTR-119", "program,", "is", "an", "early", "stage", "research", "and", "development", "program", "that", "is", "designed", "to", "combine", "various", "opioids", "with", "naloxegol.", "<tag3>"], "wordsA": ["NKTR-119", "is", "an", "early", "stage", "research", "and", "development", "program", "that", "is", "designed", "to", "combine", "various", "opioids", "with", "NKTR-118."], "wordsB": ["The", "naloxegol", "fixed-dose", "combination", "program,", "formerly", "known", "as", "the", "NKTR-119", "program,", "is", "an", "early", "stage", "research", "and", "development", "program", "that", "is", "designed", "to", "combine", "various", "opioids", "with", "naloxegol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p6_s1", "idA": "906709_12_item1_p3_s2", "sentA": "AstraZeneca is responsible for all clinical, regulatory and commercialization costs for NKTR-118 and NKTR-119.", "sentB": "AstraZeneca is responsible for all clinical, regulatory and commercialization costs for both the naloxegol drug candidate and all drug candidates within the naloxegol fixed-dose combination program.", "type": 2, "words": ["<tag1>", "AstraZeneca", "is", "responsible", "for", "all", "clinical,", "regulatory", "and", "commercialization", "costs", "for", "NKTR-118", "and", "NKTR-119.", "<tag2>", "AstraZeneca", "is", "responsible", "for", "all", "clinical,", "regulatory", "and", "commercialization", "costs", "for", "both", "the", "naloxegol", "drug", "candidate", "and", "all", "drug", "candidates", "within", "the", "naloxegol", "fixed-dose", "combination", "program.", "<tag3>"], "wordsA": ["AstraZeneca", "is", "responsible", "for", "all", "clinical,", "regulatory", "and", "commercialization", "costs", "for", "NKTR-118", "and", "NKTR-119."], "wordsB": ["AstraZeneca", "is", "responsible", "for", "all", "clinical,", "regulatory", "and", "commercialization", "costs", "for", "both", "the", "naloxegol", "drug", "candidate", "and", "all", "drug", "candidates", "within", "the", "naloxegol", "fixed-dose", "combination", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p57_s0", "idA": "906709_12_item1_p40_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA in the U.S until July 2014.", "sentB": "Naloxegol is currently considered a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA) based on structural relatedness to noroxymorphone.", "type": 2, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S", "until", "July", "2014.", "<tag2>", "Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S", "until", "July", "2014."], "wordsB": ["Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p44_s1", "idA": "906709_12_item1_p41_s1", "sentA": "As part of the transaction, Novartis assumed our rights and obligations for our Cipro Inhale agreements with Bayer Schering Pharma AG; however, we maintained the rights to receive certain royalties on commercial sales of Cipro Inhale if the drug candidate is approved.", "sentB": "As part of the transaction, Novartis assumed our rights and obligations for Cipro DPI (formerly known as Cipro Inhale) under our agreements with Bayer Schering Pharma AG; however, we maintained the rights to receive royalties on commercial sales of Cipro DPI if the drug candidate is approved.", "type": 2, "words": ["<tag1>", "As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "our", "Cipro", "Inhale", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "certain", "royalties", "on", "commercial", "sales", "of", "Cipro", "Inhale", "if", "the", "drug", "candidate", "is", "approved.", "<tag2>", "As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "under", "our", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "royalties", "on", "commercial", "sales", "of", "Cipro", "DPI", "if", "the", "drug", "candidate", "is", "approved.", "<tag3>"], "wordsA": ["As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "our", "Cipro", "Inhale", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "certain", "royalties", "on", "commercial", "sales", "of", "Cipro", "Inhale", "if", "the", "drug", "candidate", "is", "approved."], "wordsB": ["As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "under", "our", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "royalties", "on", "commercial", "sales", "of", "Cipro", "DPI", "if", "the", "drug", "candidate", "is", "approved."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s0", "idA": "906709_12_item1_p43_s0", "sentA": "Overview of Selected Nektar Proprietary Drug Development Programs and Significant Partnered Drug Development Programs NKTR-118 and NKTR-119, License Agreement with AstraZeneca AB In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell NKTR-118 and NKTR-119.", "sentB": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "type": 2, "words": ["<tag1>", "Overview", "of", "Selected", "Nektar", "Proprietary", "Drug", "Development", "Programs", "and", "Significant", "Partnered", "Drug", "Development", "Programs", "NKTR-118", "and", "NKTR-119,", "License", "Agreement", "with", "AstraZeneca", "AB", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "NKTR-118", "and", "NKTR-119.", "<tag2>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["Overview", "of", "Selected", "Nektar", "Proprietary", "Drug", "Development", "Programs", "and", "Significant", "Partnered", "Drug", "Development", "Programs", "NKTR-118", "and", "NKTR-119,", "License", "Agreement", "with", "AstraZeneca", "AB", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "NKTR-118", "and", "NKTR-119."], "wordsB": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s1", "idA": "906709_12_item1_p43_s1", "sentA": "Under the terms of this agreement, AstraZeneca made a license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for NKTR-118 and NKTR-119.", "sentB": "Under the terms of this agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for naloxegol and naloxegol fixed-dose combination products.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "a", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "NKTR-118", "and", "NKTR-119.", "<tag2>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "a", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "NKTR-118", "and", "NKTR-119."], "wordsB": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s2", "idA": "906709_12_item1_p43_s2", "sentA": "For NKTR-118, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones for NKTR-118, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "For naloxegol, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "NKTR-118,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "NKTR-118,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s3", "idA": "906709_12_item1_p43_s3", "sentA": "With respect to the $235.0 million in milestones due upon certain filings and commercial launch milestones for NKTR-118, when filing occurs in the US and in the EU or Japan, Nektar will be entitled to up to $95.0 million of those milestones.", "sentB": "With respect to the $235.0 million in milestone payments due upon certain filings and commercial launch milestones for naloxegol, when filing occurs in the U.S. and in the E.U., we will be entitled to receive $95.0 million of those milestones.", "type": 2, "words": ["<tag1>", "With", "respect", "to", "the", "$235.0", "million", "in", "milestones", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "when", "filing", "occurs", "in", "the", "US", "and", "in", "the", "EU", "or", "Japan,", "Nektar", "will", "be", "entitled", "to", "up", "to", "$95.0", "million", "of", "those", "milestones.", "<tag2>", "With", "respect", "to", "the", "$235.0", "million", "in", "milestone", "payments", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "naloxegol,", "when", "filing", "occurs", "in", "the", "U.S.", "and", "in", "the", "E.U.,", "we", "will", "be", "entitled", "to", "receive", "$95.0", "million", "of", "those", "milestones.", "<tag3>"], "wordsA": ["With", "respect", "to", "the", "$235.0", "million", "in", "milestones", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "NKTR-118,", "when", "filing", "occurs", "in", "the", "US", "and", "in", "the", "EU", "or", "Japan,", "Nektar", "will", "be", "entitled", "to", "up", "to", "$95.0", "million", "of", "those", "milestones."], "wordsB": ["With", "respect", "to", "the", "$235.0", "million", "in", "milestone", "payments", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "naloxegol,", "when", "filing", "occurs", "in", "the", "U.S.", "and", "in", "the", "E.U.,", "we", "will", "be", "entitled", "to", "receive", "$95.0", "million", "of", "those", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s4", "idA": "906709_12_item1_p43_s4", "sentA": "The remaining milestone payments are due upon the commercial launches of NKTR-118 in those regions.", "sentB": "The remaining milestone payments are due upon the commercial launches of naloxegol in those regions.", "type": 2, "words": ["<tag1>", "The", "remaining", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "NKTR-118", "in", "those", "regions.", "<tag2>", "The", "remaining", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "those", "regions.", "<tag3>"], "wordsA": ["The", "remaining", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "NKTR-118", "in", "those", "regions."], "wordsB": ["The", "remaining", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "those", "regions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s5", "idA": "906709_12_item1_p43_s5", "sentA": "For NKTR-119, we are also eligible to receive significant development milestones as well as significant sales milestones if the program achieves certain annual commercial sales levels.", "sentB": "For the naloxegol fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "NKTR-119,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestones", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "NKTR-119,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestones", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p46_s6", "idA": "906709_12_item1_p43_s6", "sentA": "For both NKTR-118 and NKTR-119, we are also entitled to significant double-digit royalty payments, varying by country of sale and level of annual net sales.", "sentB": "For both naloxegol and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments, varying by country of sale and level of annual net sales.", "type": 2, "words": ["<tag1>", "For", "both", "NKTR-118", "and", "NKTR-119,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag3>"], "wordsA": ["For", "both", "NKTR-118", "and", "NKTR-119,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p52_s0", "idA": "906709_12_item1_p44_s0", "sentA": "NKTR-118 is an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies being conducted by AstraZeneca which AstraZeneca calls the KODIAC study.", "sentB": "AstraZeneca has completed a Phase 3 clinical program for naloxegol AstraZeneca calls the KODIAC studies.", "type": 2, "words": ["<tag1>", "NKTR-118", "is", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "being", "conducted", "by", "AstraZeneca", "which", "AstraZeneca", "calls", "the", "KODIAC", "study.", "<tag2>", "AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies.", "<tag3>"], "wordsA": ["NKTR-118", "is", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "being", "conducted", "by", "AstraZeneca", "which", "AstraZeneca", "calls", "the", "KODIAC", "study."], "wordsB": ["AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p5_s1", "idA": "906709_12_item1_p44_s0", "sentA": "NKTR-118 is an orally-available peripheral opioid antagonist that is in Phase 3 clinical studies being conducted by AstraZeneca which AstraZeneca calls the KODIAC study.", "sentB": "On November 12, 2012, AstraZeneca announced positive top-line results for naloxegol from two Phase 3 clinical studies and one safety extension study.", "type": 2, "words": ["<tag1>", "NKTR-118", "is", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "being", "conducted", "by", "AstraZeneca", "which", "AstraZeneca", "calls", "the", "KODIAC", "study.", "<tag2>", "On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study.", "<tag3>"], "wordsA": ["NKTR-118", "is", "an", "orally-available", "peripheral", "opioid", "antagonist", "that", "is", "in", "Phase", "3", "clinical", "studies", "being", "conducted", "by", "AstraZeneca", "which", "AstraZeneca", "calls", "the", "KODIAC", "study."], "wordsB": ["On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p11_s0", "idA": "906709_12_item1_p45_s0", "sentA": "efficacy and safety of NKTR-118 for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "type": 2, "words": ["<tag1>", "efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag3>"], "wordsA": ["efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p52_s1", "idA": "906709_12_item1_p45_s0", "sentA": "efficacy and safety of NKTR-118 for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "The KODIAC studies (KODIAC-04, KODIAC-05, KODIAC-07 and KODIAC-08) evaluated the efficacy and safety of naloxegol for treating OIC in patients with non-cancer pain.", "type": 2, "words": ["<tag1>", "efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "The", "KODIAC", "studies", "(KODIAC-04,", "KODIAC-05,", "KODIAC-07", "and", "KODIAC-08)", "evaluated", "the", "efficacy", "and", "safety", "of", "naloxegol", "for", "treating", "OIC", "in", "patients", "with", "non-cancer", "pain.", "<tag3>"], "wordsA": ["efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["The", "KODIAC", "studies", "(KODIAC-04,", "KODIAC-05,", "KODIAC-07", "and", "KODIAC-08)", "evaluated", "the", "efficacy", "and", "safety", "of", "naloxegol", "for", "treating", "OIC", "in", "patients", "with", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s1", "idA": "906709_12_item1_p45_s0", "sentA": "efficacy and safety of NKTR-118 for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "All three studies were conducted in patients with non-cancer pain and documented OIC, who required daily opioid therapy.", "type": 2, "words": ["<tag1>", "efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "All", "three", "studies", "were", "conducted", "in", "patients", "with", "non-cancer", "pain", "and", "documented", "OIC,", "who", "required", "daily", "opioid", "therapy.", "<tag3>"], "wordsA": ["efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["All", "three", "studies", "were", "conducted", "in", "patients", "with", "non-cancer", "pain", "and", "documented", "OIC,", "who", "required", "daily", "opioid", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s2", "idA": "906709_12_item1_p45_s0", "sentA": "efficacy and safety of NKTR-118 for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "On November 12, 2012, AstraZeneca reported top-line efficacy and safety results from KODIAC-04, -05 and -07.", "type": 2, "words": ["<tag1>", "efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "On", "November", "12,", "2012,", "AstraZeneca", "reported", "top-line", "efficacy", "and", "safety", "results", "from", "KODIAC-04,", "-05", "and", "-07.", "<tag3>"], "wordsA": ["efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["On", "November", "12,", "2012,", "AstraZeneca", "reported", "top-line", "efficacy", "and", "safety", "results", "from", "KODIAC-04,", "-05", "and", "-07."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p54_s0", "idA": "906709_12_item1_p45_s0", "sentA": "efficacy and safety of NKTR-118 for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain and cancer pain.", "sentB": "KODIAC-08 was an open-label, randomized, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and OIC.", "type": 2, "words": ["<tag1>", "efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain.", "<tag2>", "KODIAC-08", "was", "an", "open-label,", "randomized,", "52-week,", "long-term", "safety", "trial", "of", "naloxegol", "versus", "usual", "care", "(UC)", "in", "patients", "with", "non-cancer", "related", "pain", "and", "OIC.", "<tag3>"], "wordsA": ["efficacy", "and", "safety", "of", "NKTR-118", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain", "and", "cancer", "pain."], "wordsB": ["KODIAC-08", "was", "an", "open-label,", "randomized,", "52-week,", "long-term", "safety", "trial", "of", "naloxegol", "versus", "usual", "care", "(UC)", "in", "patients", "with", "non-cancer", "related", "pain", "and", "OIC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s0", "idA": "906709_12_item1_p45_s3", "sentA": "There is a three month safety extension following one of the two 12-week studies.", "sentB": "KODIAC-07 was a three-month safety extension of KODIAC-04.", "type": 2, "words": ["<tag1>", "There", "is", "a", "three", "month", "safety", "extension", "following", "one", "of", "the", "two", "12-week", "studies.", "<tag2>", "KODIAC-07", "was", "a", "three-month", "safety", "extension", "of", "KODIAC-04.", "<tag3>"], "wordsA": ["There", "is", "a", "three", "month", "safety", "extension", "following", "one", "of", "the", "two", "12-week", "studies."], "wordsB": ["KODIAC-07", "was", "a", "three-month", "safety", "extension", "of", "KODIAC-04."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p53_s9", "idA": "906709_12_item1_p46_s0", "sentA": "Data from a Phase 2 study conducted by us showed that NKTR-118 achieved the primary endpoint of change from baseline in spontaneous bowel movements in patients taking opioids with chronic OIC.", "sentB": "In KODIAC-04 and -05 for either naloxegol dose, compared to placebo, there were no significant differences in change from baseline in mean daily pain scores or mean total daily opioid dose.", "type": 2, "words": ["<tag1>", "Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC.", "<tag2>", "In", "KODIAC-04", "and", "-05", "for", "either", "naloxegol", "dose,", "compared", "to", "placebo,", "there", "were", "no", "significant", "differences", "in", "change", "from", "baseline", "in", "mean", "daily", "pain", "scores", "or", "mean", "total", "daily", "opioid", "dose.", "<tag3>"], "wordsA": ["Data", "from", "a", "Phase", "2", "study", "conducted", "by", "us", "showed", "that", "NKTR-118", "achieved", "the", "primary", "endpoint", "of", "change", "from", "baseline", "in", "spontaneous", "bowel", "movements", "in", "patients", "taking", "opioids", "with", "chronic", "OIC."], "wordsB": ["In", "KODIAC-04", "and", "-05", "for", "either", "naloxegol", "dose,", "compared", "to", "placebo,", "there", "were", "no", "significant", "differences", "in", "change", "from", "baseline", "in", "mean", "daily", "pain", "scores", "or", "mean", "total", "daily", "opioid", "dose."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p55_s5", "idA": "906709_12_item1_p47_s0", "sentA": "The most commonly reported side effects from the Phase 2 clinical study of NKTR-118 were dose dependent gastrointestinal-related effects, which were mild and transient.", "sentB": "The most commonly reported AEs occurring more frequently on naloxegol than on UC included abdominal pain, diarrhea, nausea and headache.", "type": 2, "words": ["<tag1>", "The", "most", "commonly", "reported", "side", "effects", "from", "the", "Phase", "2", "clinical", "study", "of", "NKTR-118", "were", "dose", "dependent", "gastrointestinal-related", "effects,", "which", "were", "mild", "and", "transient.", "<tag2>", "The", "most", "commonly", "reported", "AEs", "occurring", "more", "frequently", "on", "naloxegol", "than", "on", "UC", "included", "abdominal", "pain,", "diarrhea,", "nausea", "and", "headache.", "<tag3>"], "wordsA": ["The", "most", "commonly", "reported", "side", "effects", "from", "the", "Phase", "2", "clinical", "study", "of", "NKTR-118", "were", "dose", "dependent", "gastrointestinal-related", "effects,", "which", "were", "mild", "and", "transient."], "wordsB": ["The", "most", "commonly", "reported", "AEs", "occurring", "more", "frequently", "on", "naloxegol", "than", "on", "UC", "included", "abdominal", "pain,", "diarrhea,", "nausea", "and", "headache."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p51_s0", "idA": "906709_12_item1_p49_s0", "sentA": "Depending on the population studied and the definitions used, OIC occurs in up to 40-90% of patients taking opioids.", "sentB": "Globally, approximately 40 50% (28-35 million) patients taking opioids for long-term pain develop constipation.", "type": 2, "words": ["<tag1>", "Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "OIC", "occurs", "in", "up", "to", "40-90%", "of", "patients", "taking", "opioids.", "<tag2>", "Globally,", "approximately", "40", "50%", "(28-35", "million)", "patients", "taking", "opioids", "for", "long-term", "pain", "develop", "constipation.", "<tag3>"], "wordsA": ["Depending", "on", "the", "population", "studied", "and", "the", "definitions", "used,", "OIC", "occurs", "in", "up", "to", "40-90%", "of", "patients", "taking", "opioids."], "wordsB": ["Globally,", "approximately", "40", "50%", "(28-35", "million)", "patients", "taking", "opioids", "for", "long-term", "pain", "develop", "constipation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p7_s0", "idA": "906709_12_item1_p4_s0", "sentA": "Our second most advanced drug candidate, NKTR-102, is a next-generation topoisomerase I inhibitor, currently being evaluated as a single-agent therapy in a Phase 3 clinical study in patients with metastatic breast cancer.", "sentB": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "type": 2, "words": ["<tag1>", "Our", "second", "most", "advanced", "drug", "candidate,", "NKTR-102,", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "in", "a", "Phase", "3", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["Our", "second", "most", "advanced", "drug", "candidate,", "NKTR-102,", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "in", "a", "Phase", "3", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p8_s2", "idA": "906709_12_item1_p4_s11", "sentA": "Results from this study and communication with government health authorities in both the United States and European Union (E.U.) will guide our future development and regulatory strategy for NKTR-102 in ovarian cancer.", "sentB": "Results from this study and communication with government health authorities in both the United States (U.S.) and European Union (E.U.) will guide our future development and regulatory strategy for etirinotecan pegol in ovarian cancer.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "NKTR-102", "in", "ovarian", "cancer.", "<tag2>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "NKTR-102", "in", "ovarian", "cancer."], "wordsB": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p8_s3", "idA": "906709_12_item1_p4_s12", "sentA": "A Phase 2 clinical trial in patients with metastatic colorectal cancer is still enrolling patients, and a Phase 1 study of NKTR-102 in combination with F-fluorouracil/leucovorin is also continuing to enroll patients.", "sentB": "A Phase 1 study to evaluate etirinotecan pegol in combination with 5-Fluorouracil/leucovorin in refractory solid tumor cancers has also been completed, and a Phase 2 clinical trial evaluating etirinotecan pegol as a single agent in patients with metastatic colorectal cancer is enrolling patients.", "type": 2, "words": ["<tag1>", "A", "Phase", "2", "clinical", "trial", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "still", "enrolling", "patients,", "and", "a", "Phase", "1", "study", "of", "NKTR-102", "in", "combination", "with", "F-fluorouracil/leucovorin", "is", "also", "continuing", "to", "enroll", "patients.", "<tag2>", "A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients.", "<tag3>"], "wordsA": ["A", "Phase", "2", "clinical", "trial", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "still", "enrolling", "patients,", "and", "a", "Phase", "1", "study", "of", "NKTR-102", "in", "combination", "with", "F-fluorouracil/leucovorin", "is", "also", "continuing", "to", "enroll", "patients."], "wordsB": ["A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p9_s3", "idA": "906709_12_item1_p4_s2", "sentA": "The BEACON study is designed to enroll approximately 840 women with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "Enrollment in this study is ongoing with a design to enroll approximately 200 patients in a randomized controlled study to receive either NKTR-181 or placebo.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p7_s3", "idA": "906709_12_item1_p4_s3", "sentA": "Patients in the BEACON study will be randomized on a 1:1 basis to receive either single-agent NKTR-102 or a single agent of physician s choice.", "sentB": "Patients in the BEACON study are randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "NKTR-102", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "NKTR-102", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p9_s1", "idA": "906709_12_item1_p4_s5", "sentA": "NKTR-102 is also being evaluated in a Phase 2 clinical study in patients with platinum-resistant ovarian cancer and a Phase 2 clinical study in patients with metastatic colorectal cancer.", "sentB": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "type": 2, "words": ["<tag1>", "NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "and", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag3>"], "wordsA": ["NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "and", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p5_s2", "idA": "906709_12_item1_p4_s6", "sentA": "The Phase 2 clinical study of NKTR-102 in patients with platinum-resistant ovarian cancer completed enrollment of 71 patients in 2009.", "sentB": "On February 26, 2013, AstraZeneca announced positive top-line results from the long-term safety clinical study of naloxegol in patients with OIC.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "completed", "enrollment", "of", "71", "patients", "in", "2009.", "<tag2>", "On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "the", "long-term", "safety", "clinical", "study", "of", "naloxegol", "in", "patients", "with", "OIC.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "completed", "enrollment", "of", "71", "patients", "in", "2009."], "wordsB": ["On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "the", "long-term", "safety", "clinical", "study", "of", "naloxegol", "in", "patients", "with", "OIC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p9_s0", "idA": "906709_12_item1_p4_s6", "sentA": "The Phase 2 clinical study of NKTR-102 in patients with platinum-resistant ovarian cancer completed enrollment of 71 patients in 2009.", "sentB": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "completed", "enrollment", "of", "71", "patients", "in", "2009.", "<tag2>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer", "completed", "enrollment", "of", "71", "patients", "in", "2009."], "wordsB": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p47_s0", "idA": "906709_12_item1_p52_s1", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one product based on NKTR-119 and has the right to develop multiple products which combine NKTR-118 with other opioids.", "sentB": "AstraZeneca has agreed to use commercially reasonable efforts to develop one naloxegol fixed-dose combination product and has the right to develop multiple products which combine naloxegol with other opioids.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "product", "based", "on", "NKTR-119", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "NKTR-118", "with", "other", "opioids.", "<tag2>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "product", "based", "on", "NKTR-119", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "NKTR-118", "with", "other", "opioids."], "wordsB": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p8_s0", "idA": "906709_12_item1_p57_s3", "sentA": "The BEACON study plans to enroll approximately 840 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "In November 2012, the U.S. Food and Drug Administration (FDA) designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "plans", "to", "enroll", "approximately", "840", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "plans", "to", "enroll", "approximately", "840", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p7_s4", "idA": "906709_12_item1_p58_s1", "sentA": "The primary endpoint of the BEACON study will be overall survival, and secondary endpoints will include progression-free survival and objective tumor response rate.", "sentB": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "will", "be", "overall", "survival,", "and", "secondary", "endpoints", "will", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "will", "be", "overall", "survival,", "and", "secondary", "endpoints", "will", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p11_s1", "idA": "906709_12_item1_p5_s0", "sentA": "We also have several proprietary pre-clinical and clinical drug candidates that are in the pain therapeutic area.", "sentB": "We also have additional proprietary preclinical and clinical drug candidates being developed for pain relief.", "type": 2, "words": ["<tag1>", "We", "also", "have", "several", "proprietary", "pre-clinical", "and", "clinical", "drug", "candidates", "that", "are", "in", "the", "pain", "therapeutic", "area.", "<tag2>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief.", "<tag3>"], "wordsA": ["We", "also", "have", "several", "proprietary", "pre-clinical", "and", "clinical", "drug", "candidates", "that", "are", "in", "the", "pain", "therapeutic", "area."], "wordsB": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p8_s1", "idA": "906709_12_item1_p62_s1", "sentA": "NKTR-102 is also being evaluated in a Phase 2 clinical study in patients with platinum-resistant ovarian cancer.", "sentB": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "type": 2, "words": ["<tag1>", "NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag3>"], "wordsA": ["NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p9_s2", "idA": "906709_12_item1_p62_s1", "sentA": "NKTR-102 is also being evaluated in a Phase 2 clinical study in patients with platinum-resistant ovarian cancer.", "sentB": "Our third-most-advanced proprietary drug candidate, NKTR-181, is currently being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "type": 2, "words": ["<tag1>", "NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer.", "<tag2>", "Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag3>"], "wordsA": ["NKTR-102", "is", "also", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "platinum-resistant", "ovarian", "cancer."], "wordsB": ["Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p52_s3", "idA": "906709_12_item1_p65_s1", "sentA": "The primary endpoint of the Phase 2 clinical study in metastatic colorectal cancer is progression-free survival as compared to standard irinotecan monotherapy.", "sentB": "The primary endpoint in both trials was percentage of OIC responders versus placebo over 12 weeks of treatment.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "Phase", "2", "clinical", "study", "in", "metastatic", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy.", "<tag2>", "The", "primary", "endpoint", "in", "both", "trials", "was", "percentage", "of", "OIC", "responders", "versus", "placebo", "over", "12", "weeks", "of", "treatment.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "Phase", "2", "clinical", "study", "in", "metastatic", "colorectal", "cancer", "is", "progression-free", "survival", "as", "compared", "to", "standard", "irinotecan", "monotherapy."], "wordsB": ["The", "primary", "endpoint", "in", "both", "trials", "was", "percentage", "of", "OIC", "responders", "versus", "placebo", "over", "12", "weeks", "of", "treatment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p54_s3", "idA": "906709_12_item1_p68_s0", "sentA": "The chemotherapy agent 5-FU is currently used as a part of a combination treatment regimen for colorectal cancer in combination with irinotecan, which is also known as the FOLFIRI regimen.", "sentB": "UC was defined as the investigator s choice of an existing laxative treatment regimen for OIC.", "type": 2, "words": ["<tag1>", "The", "chemotherapy", "agent", "5-FU", "is", "currently", "used", "as", "a", "part", "of", "a", "combination", "treatment", "regimen", "for", "colorectal", "cancer", "in", "combination", "with", "irinotecan,", "which", "is", "also", "known", "as", "the", "FOLFIRI", "regimen.", "<tag2>", "UC", "was", "defined", "as", "the", "investigator", "s", "choice", "of", "an", "existing", "laxative", "treatment", "regimen", "for", "OIC.", "<tag3>"], "wordsA": ["The", "chemotherapy", "agent", "5-FU", "is", "currently", "used", "as", "a", "part", "of", "a", "combination", "treatment", "regimen", "for", "colorectal", "cancer", "in", "combination", "with", "irinotecan,", "which", "is", "also", "known", "as", "the", "FOLFIRI", "regimen."], "wordsB": ["UC", "was", "defined", "as", "the", "investigator", "s", "choice", "of", "an", "existing", "laxative", "treatment", "regimen", "for", "OIC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p56_s0", "idA": "906709_12_item1_p69_s0", "sentA": "Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer death in the U.S.", "sentB": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "type": 2, "words": ["<tag1>", "Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "second", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S.", "<tag2>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag3>"], "wordsA": ["Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "second", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S."], "wordsB": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p10_s0", "idA": "906709_12_item1_p6_s0", "sentA": "NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies.", "sentB": "NKTR-181 is designed to be a novel, orally-available mu-opioid agonist molecule with a long-acting profile.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "with", "a", "long-acting", "profile", "to", "treat", "chronic", "pain", "that", "has", "been", "designed", "with", "the", "objective", "of", "addressing", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile.", "<tag3>"], "wordsA": ["NKTR-181", "is", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "with", "a", "long-acting", "profile", "to", "treat", "chronic", "pain", "that", "has", "been", "designed", "with", "the", "objective", "of", "addressing", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p10_s1", "idA": "906709_12_item1_p6_s0", "sentA": "NKTR-181 is an orally-available mu-opioid analgesic molecule with a long-acting profile to treat chronic pain that has been designed with the objective of addressing serious CNS-related side effects associated with standard opioid therapies.", "sentB": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system (CNS)-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "with", "a", "long-acting", "profile", "to", "treat", "chronic", "pain", "that", "has", "been", "designed", "with", "the", "objective", "of", "addressing", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag3>"], "wordsA": ["NKTR-181", "is", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "with", "a", "long-acting", "profile", "to", "treat", "chronic", "pain", "that", "has", "been", "designed", "with", "the", "objective", "of", "addressing", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p14_s2", "idA": "906709_12_item1_p76_s4", "sentA": "if the Phase 3 clinical study commences and is successful.", "sentB": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "type": 2, "words": ["<tag1>", "if", "the", "Phase", "3", "clinical", "study", "commences", "and", "is", "successful.", "<tag2>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag3>"], "wordsA": ["if", "the", "Phase", "3", "clinical", "study", "commences", "and", "is", "successful."], "wordsB": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p14_s3", "idA": "906709_12_item1_p76_s4", "sentA": "if the Phase 3 clinical study commences and is successful.", "sentB": "The Phase 3 clinical program is expected to be initiated by Bayer in March 2013.", "type": 2, "words": ["<tag1>", "if", "the", "Phase", "3", "clinical", "study", "commences", "and", "is", "successful.", "<tag2>", "The", "Phase", "3", "clinical", "program", "is", "expected", "to", "be", "initiated", "by", "Bayer", "in", "March", "2013.", "<tag3>"], "wordsA": ["if", "the", "Phase", "3", "clinical", "study", "commences", "and", "is", "successful."], "wordsB": ["The", "Phase", "3", "clinical", "program", "is", "expected", "to", "be", "initiated", "by", "Bayer", "in", "March", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p13_s0", "idA": "906709_12_item1_p7_s0", "sentA": "The Phase 2 clinical study design is a randomized, double-blind, efficacy and safety study of NKTR-181 as compared to placebo in patients with chronic pain.", "sentB": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "design", "is", "a", "randomized,", "double-blind,", "efficacy", "and", "safety", "study", "of", "NKTR-181", "as", "compared", "to", "placebo", "in", "patients", "with", "chronic", "pain.", "<tag2>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "design", "is", "a", "randomized,", "double-blind,", "efficacy", "and", "safety", "study", "of", "NKTR-181", "as", "compared", "to", "placebo", "in", "patients", "with", "chronic", "pain."], "wordsB": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p54_s1", "idA": "906709_12_item1_p7_s0", "sentA": "The Phase 2 clinical study design is a randomized, double-blind, efficacy and safety study of NKTR-181 as compared to placebo in patients with chronic pain.", "sentB": "This trial was designed to evaluate the long-term safety and adverse event profile of naloxegol in patients taking 25 mg of naloxegol once daily, as compared to UC.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "design", "is", "a", "randomized,", "double-blind,", "efficacy", "and", "safety", "study", "of", "NKTR-181", "as", "compared", "to", "placebo", "in", "patients", "with", "chronic", "pain.", "<tag2>", "This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "design", "is", "a", "randomized,", "double-blind,", "efficacy", "and", "safety", "study", "of", "NKTR-181", "as", "compared", "to", "placebo", "in", "patients", "with", "chronic", "pain."], "wordsB": ["This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p12_s0", "idA": "906709_12_item1_p8_s0", "sentA": "NKTR-192 is an orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain that has been designed with the objective to also address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "NKTR-192 is designed to be a novel orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain.", "<tag3>"], "wordsA": ["NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p12_s1", "idA": "906709_12_item1_p8_s0", "sentA": "NKTR-192 is an orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain that has been designed with the objective to also address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "This molecule is designed to address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag3>"], "wordsA": ["NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p13_s1", "idA": "906709_12_item1_p8_s0", "sentA": "NKTR-192 is an orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain that has been designed with the objective to also address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "NKTR-171 is designed to be peripherally-acting in order to avoid the serious CNS-related side effects associated with existing sodium channel blockers.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers.", "<tag3>"], "wordsA": ["NKTR-192", "is", "an", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain", "that", "has", "been", "designed", "with", "the", "objective", "to", "also", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p13_s2", "idA": "906709_12_item1_p8_s1", "sentA": "NKTR-192 completed preclinical work in 2011 and we plan to begin a Phase 1 clinical study in 2012 subject to our investigational new drug application (IND) clearing the FDA review period.", "sentB": "The product candidate is currently undergoing investigational new drug application (IND)-enabling studies in preparation for clinical studies in healthy volunteers.", "type": 2, "words": ["<tag1>", "NKTR-192", "completed", "preclinical", "work", "in", "2011", "and", "we", "plan", "to", "begin", "a", "Phase", "1", "clinical", "study", "in", "2012", "subject", "to", "our", "investigational", "new", "drug", "application", "(IND)", "clearing", "the", "FDA", "review", "period.", "<tag2>", "The", "product", "candidate", "is", "currently", "undergoing", "investigational", "new", "drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "healthy", "volunteers.", "<tag3>"], "wordsA": ["NKTR-192", "completed", "preclinical", "work", "in", "2011", "and", "we", "plan", "to", "begin", "a", "Phase", "1", "clinical", "study", "in", "2012", "subject", "to", "our", "investigational", "new", "drug", "application", "(IND)", "clearing", "the", "FDA", "review", "period."], "wordsB": ["The", "product", "candidate", "is", "currently", "undergoing", "investigational", "new", "drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "healthy", "volunteers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p15_s1", "idA": "906709_12_item1_p8_s2", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Affymax, Inc., Amgen Inc., Baxter Healthcare, MAP Pharmaceuticals, Inc., Merck Co., Inc. (through its acquisition of Schering Plough), Pfizer Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "sentB": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Affymax, Inc., Amgen Inc., MAP Pharmaceuticals, Inc., Merck Co., Inc. (through its acquisition of Schering Plough), Pfizer Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "Baxter", "Healthcare,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "Baxter", "Healthcare,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p16_s0", "idA": "906709_12_item1_p8_s3", "sentA": "A total of seven products using our PEGylation technology have received regulatory approval in the U.S. or EU, and are currently marketed by our collaboration partners.", "sentB": "and are currently marketed by our collaboration partners.", "type": 2, "words": ["<tag1>", "A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU,", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners.", "<tag2>", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners.", "<tag3>"], "wordsA": ["A", "total", "of", "seven", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU,", "and", "are", "currently", "marketed", "by", "our", "collaboration", "partners."], "wordsB": ["and", "are", "currently", "marketed", "by", "our", "collaboration", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p12_s2", "idA": "906709_12_item1_p9_s2", "sentA": "Baxter is responsible for all clinical development.", "sentB": "NKTR-192 is in Phase 1 clinical development.", "type": 2, "words": ["<tag1>", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag2>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag3>"], "wordsA": ["Baxter", "is", "responsible", "for", "all", "clinical", "development."], "wordsB": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_13_item1_p13_s4", "idA": "906709_12_item1_p9_s2", "sentA": "Baxter is responsible for all clinical development.", "sentB": "Under the terms of this collaboration, we are providing our PEGylation technology and expertise and Baxter is responsible for all clinical development.", "type": 2, "words": ["<tag1>", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag2>", "Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag3>"], "wordsA": ["Baxter", "is", "responsible", "for", "all", "clinical", "development."], "wordsB": ["Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p82_s0", "idA": "906709_13_item1_p10_s0", "sentA": "NKTR-181 is designed to be a novel, orally-available mu-opioid agonist molecule with a long-acting profile.", "sentB": "Amikacin Inhale is designed to be an adjunctive therapy to the current antibiotic therapies administered intravenously as standard of care.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile.", "<tag2>", "Amikacin", "Inhale", "is", "designed", "to", "be", "an", "adjunctive", "therapy", "to", "the", "current", "antibiotic", "therapies", "administered", "intravenously", "as", "standard", "of", "care.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile."], "wordsB": ["Amikacin", "Inhale", "is", "designed", "to", "be", "an", "adjunctive", "therapy", "to", "the", "current", "antibiotic", "therapies", "administered", "intravenously", "as", "standard", "of", "care."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p85_s0", "idA": "906709_13_item1_p10_s0", "sentA": "NKTR-181 is designed to be a novel, orally-available mu-opioid agonist molecule with a long-acting profile.", "sentB": "NKTR-181 is an orally-available mu-opioid drug candidate in development as a long-acting analgesic to treat chronic pain.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile.", "<tag2>", "NKTR-181", "is", "an", "orally-available", "mu-opioid", "drug", "candidate", "in", "development", "as", "a", "long-acting", "analgesic", "to", "treat", "chronic", "pain.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile."], "wordsB": ["NKTR-181", "is", "an", "orally-available", "mu-opioid", "drug", "candidate", "in", "development", "as", "a", "long-acting", "analgesic", "to", "treat", "chronic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p86_s0", "idA": "906709_13_item1_p10_s0", "sentA": "NKTR-181 is designed to be a novel, orally-available mu-opioid agonist molecule with a long-acting profile.", "sentB": "NKTR-181 is a novel mu-opioid analgesic molecule created using Nektar s proprietary polymer conjugate technology, which provides it with a long-acting profile and slows its entry into the CNS.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile.", "<tag2>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "molecule", "created", "using", "Nektar", "s", "proprietary", "polymer", "conjugate", "technology,", "which", "provides", "it", "with", "a", "long-acting", "profile", "and", "slows", "its", "entry", "into", "the", "CNS.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "to", "be", "a", "novel,", "orally-available", "mu-opioid", "agonist", "molecule", "with", "a", "long-acting", "profile."], "wordsB": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "molecule", "created", "using", "Nektar", "s", "proprietary", "polymer", "conjugate", "technology,", "which", "provides", "it", "with", "a", "long-acting", "profile", "and", "slows", "its", "entry", "into", "the", "CNS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p7_s1", "idA": "906709_13_item1_p10_s1", "sentA": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system (CNS)-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "sentB": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "type": 2, "words": ["<tag1>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag3>"], "wordsA": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system", "(CNS)-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p101_s3", "idA": "906709_13_item1_p10_s2", "sentA": "As a new molecular structure, NKTR-181 s abuse deterrent property does not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "sentB": "Its differentiating properties are inherent to the design of the new molecule and as a new molecular structure, NKTR-192 does not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "type": 2, "words": ["<tag1>", "As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag2>", "Its", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and", "as", "a", "new", "molecular", "structure,", "NKTR-192", "does", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag3>"], "wordsA": ["As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "wordsB": ["Its", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and", "as", "a", "new", "molecular", "structure,", "NKTR-192", "does", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p7_s2", "idA": "906709_13_item1_p10_s2", "sentA": "As a new molecular structure, NKTR-181 s abuse deterrent property does not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "sentB": "Its potential differentiating properties are inherent to the design of the new molecule and, as a new molecular structure, NKTR-181 s abuse deterrent property does not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "type": 2, "words": ["<tag1>", "As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag2>", "Its", "potential", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and,", "as", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag3>"], "wordsA": ["As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "wordsB": ["Its", "potential", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and,", "as", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p86_s2", "idA": "906709_13_item1_p10_s2", "sentA": "As a new molecular structure, NKTR-181 s abuse deterrent property does not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "sentB": "NKTR-181 s abuse deterrent property does not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "type": 2, "words": ["<tag1>", "As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag2>", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag3>"], "wordsA": ["As", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "wordsB": ["NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p109_s2", "idA": "906709_13_item1_p11_s0", "sentA": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "sentB": "In December 2012, MAP announced that its NDA resubmission for LEVADEX was accepted for filing by the FDA.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag2>", "In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "wordsB": ["In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p87_s0", "idA": "906709_13_item1_p11_s0", "sentA": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "sentB": "In May 2012, the FDA granted Fast Track designation for the NKTR-181 development program.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag2>", "In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "wordsB": ["In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p8_s0", "idA": "906709_13_item1_p11_s0", "sentA": "In May 2012, the development program for NKTR-181 for the treatment of moderate to severe chronic pain was granted Fast Track designation by the FDA.", "sentB": "In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA.", "<tag2>", "In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "development", "program", "for", "NKTR-181", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain", "was", "granted", "Fast", "Track", "designation", "by", "the", "FDA."], "wordsB": ["In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p101_s0", "idA": "906709_13_item1_p12_s0", "sentA": "NKTR-192 is designed to be a novel orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain.", "sentB": "NKTR-192 is a mu-opioid analgesic molecule in preclinical development that is intended to be a short-acting analgesic to treat acute pain.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain.", "<tag2>", "NKTR-192", "is", "a", "mu-opioid", "analgesic", "molecule", "in", "preclinical", "development", "that", "is", "intended", "to", "be", "a", "short-acting", "analgesic", "to", "treat", "acute", "pain.", "<tag3>"], "wordsA": ["NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain."], "wordsB": ["NKTR-192", "is", "a", "mu-opioid", "analgesic", "molecule", "in", "preclinical", "development", "that", "is", "intended", "to", "be", "a", "short-acting", "analgesic", "to", "treat", "acute", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p101_s2", "idA": "906709_13_item1_p12_s0", "sentA": "NKTR-192 is designed to be a novel orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain.", "sentB": "NKTR-192 is also designed to have slow entry into the CNS.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain.", "<tag2>", "NKTR-192", "is", "also", "designed", "to", "have", "slow", "entry", "into", "the", "CNS.", "<tag3>"], "wordsA": ["NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain."], "wordsB": ["NKTR-192", "is", "also", "designed", "to", "have", "slow", "entry", "into", "the", "CNS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p58_s1", "idA": "906709_13_item1_p12_s0", "sentA": "NKTR-192 is designed to be a novel orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain.", "sentB": "Etirinotecan pegol is a novel macromolecular chemotherapeutic designed to enhance the anti-cancer effects of topo I inhibition while minimizing its toxicities.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain.", "<tag2>", "Etirinotecan", "pegol", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities.", "<tag3>"], "wordsA": ["NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain."], "wordsB": ["Etirinotecan", "pegol", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p97_s0", "idA": "906709_13_item1_p12_s0", "sentA": "NKTR-192 is designed to be a novel orally available mu-opioid analgesic molecule with a short-acting profile to treat acute pain.", "sentB": "Opioids are considered to be the most effective therapeutic option for pain.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain.", "<tag2>", "Opioids", "are", "considered", "to", "be", "the", "most", "effective", "therapeutic", "option", "for", "pain.", "<tag3>"], "wordsA": ["NKTR-192", "is", "designed", "to", "be", "a", "novel", "orally", "available", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "to", "treat", "acute", "pain."], "wordsB": ["Opioids", "are", "considered", "to", "be", "the", "most", "effective", "therapeutic", "option", "for", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p101_s1", "idA": "906709_13_item1_p12_s1", "sentA": "This molecule is designed to address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "NKTR-192 is also designed to address the abuse liability and serious CNS side effects associated with current opioid therapies.", "type": 2, "words": ["<tag1>", "This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "NKTR-192", "is", "also", "designed", "to", "address", "the", "abuse", "liability", "and", "serious", "CNS", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag3>"], "wordsA": ["This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["NKTR-192", "is", "also", "designed", "to", "address", "the", "abuse", "liability", "and", "serious", "CNS", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s2", "idA": "906709_13_item1_p12_s1", "sentA": "This molecule is designed to address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "In addition, we are also developing NKTR-192, a novel mu-opioid analgesic molecule with a short-acting profile designed to treat acute pain while addressing the serious CNS-related side effects associated with standard short-acting opioid therapies.", "type": 2, "words": ["<tag1>", "This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "In", "addition,", "we", "are", "also", "developing", "NKTR-192,", "a", "novel", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "designed", "to", "treat", "acute", "pain", "while", "addressing", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag3>"], "wordsA": ["This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["In", "addition,", "we", "are", "also", "developing", "NKTR-192,", "a", "novel", "mu-opioid", "analgesic", "molecule", "with", "a", "short-acting", "profile", "designed", "to", "treat", "acute", "pain", "while", "addressing", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s4", "idA": "906709_13_item1_p12_s1", "sentA": "This molecule is designed to address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "REG1 is designed to increase therapeutic flexibility while reducing side effects and improving outcomes experienced by patients in this setting.", "type": 2, "words": ["<tag1>", "This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "REG1", "is", "designed", "to", "increase", "therapeutic", "flexibility", "while", "reducing", "side", "effects", "and", "improving", "outcomes", "experienced", "by", "patients", "in", "this", "setting.", "<tag3>"], "wordsA": ["This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["REG1", "is", "designed", "to", "increase", "therapeutic", "flexibility", "while", "reducing", "side", "effects", "and", "improving", "outcomes", "experienced", "by", "patients", "in", "this", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p85_s1", "idA": "906709_13_item1_p12_s1", "sentA": "This molecule is designed to address the serious CNS-related side effects associated with standard short-acting opioid therapies.", "sentB": "NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies.", "type": 2, "words": ["<tag1>", "This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies.", "<tag2>", "NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag3>"], "wordsA": ["This", "molecule", "is", "designed", "to", "address", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "standard", "short-acting", "opioid", "therapies."], "wordsB": ["NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p100_s4", "idA": "906709_13_item1_p12_s2", "sentA": "NKTR-192 is in Phase 1 clinical development.", "sentB": "In January 2014, a single-ascending dose Phase 1 clinical study of NKTR-171 was initiated to assess its pharmacokinetics, tolerability, and safety in up to 75 healthy subjects.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag2>", "In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects.", "<tag3>"], "wordsA": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "wordsB": ["In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p102_s0", "idA": "906709_13_item1_p12_s2", "sentA": "NKTR-192 is in Phase 1 clinical development.", "sentB": "NKTR-192 entered Phase 1 clinical development in 2012.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag2>", "NKTR-192", "entered", "Phase", "1", "clinical", "development", "in", "2012.", "<tag3>"], "wordsA": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "wordsB": ["NKTR-192", "entered", "Phase", "1", "clinical", "development", "in", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p10_s4", "idA": "906709_13_item1_p12_s2", "sentA": "NKTR-192 is in Phase 1 clinical development.", "sentB": "This single-ascending dose Phase 1 clinical study of NKTR-171 will assess its pharmacokinetics, tolerability, and safety in up to 75 healthy subjects.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag2>", "This", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "will", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects.", "<tag3>"], "wordsA": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "wordsB": ["This", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "will", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p115_s1", "idA": "906709_13_item1_p12_s2", "sentA": "NKTR-192 is in Phase 1 clinical development.", "sentB": "In January 2013, Baxter announced the top level results from this Phase 1 clinical study.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag2>", "In", "January", "2013,", "Baxter", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study.", "<tag3>"], "wordsA": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "wordsB": ["In", "January", "2013,", "Baxter", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p88_s0", "idA": "906709_13_item1_p12_s2", "sentA": "NKTR-192 is in Phase 1 clinical development.", "sentB": "In 2011, we completed two separate Phase 1 clinical studies of NKTR-181.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag2>", "In", "2011,", "we", "completed", "two", "separate", "Phase", "1", "clinical", "studies", "of", "NKTR-181.", "<tag3>"], "wordsA": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "wordsB": ["In", "2011,", "we", "completed", "two", "separate", "Phase", "1", "clinical", "studies", "of", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p89_s0", "idA": "906709_13_item1_p12_s2", "sentA": "NKTR-192 is in Phase 1 clinical development.", "sentB": "In this multiple dose Phase 1 clinical study, NKTR-181 exhibited a sustained analgesic response.", "type": 2, "words": ["<tag1>", "NKTR-192", "is", "in", "Phase", "1", "clinical", "development.", "<tag2>", "In", "this", "multiple", "dose", "Phase", "1", "clinical", "study,", "NKTR-181", "exhibited", "a", "sustained", "analgesic", "response.", "<tag3>"], "wordsA": ["NKTR-192", "is", "in", "Phase", "1", "clinical", "development."], "wordsB": ["In", "this", "multiple", "dose", "Phase", "1", "clinical", "study,", "NKTR-181", "exhibited", "a", "sustained", "analgesic", "response."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p10_s3", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "On January 14, 2014, we announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "On", "January", "14,", "2014,", "we", "announced", "that", "the", "first", "subjects", "were", "dosed", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-171,", "a", "new", "sodium", "channel", "blocker", "being", "developed", "as", "an", "oral", "therapy", "for", "the", "treatment", "of", "peripheral", "neuropathic", "pain.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["On", "January", "14,", "2014,", "we", "announced", "that", "the", "first", "subjects", "were", "dosed", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-171,", "a", "new", "sodium", "channel", "blocker", "being", "developed", "as", "an", "oral", "therapy", "for", "the", "treatment", "of", "peripheral", "neuropathic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s0", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "NKTR-171 is a new molecular entity that is specifically designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "specifically", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "specifically", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p139_s1", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "PEG-Intron is a treatment for patients with Hepatitis C. Schering was acquired by, and became a wholly-owned subsidiary of, Merck Co., Inc.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p99_s0", "idA": "906709_13_item1_p13_s0", "sentA": "NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "NKTR-171 (neuropathic pain) NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p100_s3", "idA": "906709_13_item1_p13_s1", "sentA": "NKTR-171 is designed to be peripherally-acting in order to avoid the serious CNS-related side effects associated with existing sodium channel blockers.", "sentB": "NKTR-171 is designed to be a peripherally-restricted molecule which selectively blocks hyper-excitable sodium channels without causing the CNS side effects that limit usage of existing therapies.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers.", "<tag2>", "NKTR-171", "is", "designed", "to", "be", "a", "peripherally-restricted", "molecule", "which", "selectively", "blocks", "hyper-excitable", "sodium", "channels", "without", "causing", "the", "CNS", "side", "effects", "that", "limit", "usage", "of", "existing", "therapies.", "<tag3>"], "wordsA": ["NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers."], "wordsB": ["NKTR-171", "is", "designed", "to", "be", "a", "peripherally-restricted", "molecule", "which", "selectively", "blocks", "hyper-excitable", "sodium", "channels", "without", "causing", "the", "CNS", "side", "effects", "that", "limit", "usage", "of", "existing", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s1", "idA": "906709_13_item1_p13_s1", "sentA": "NKTR-171 is designed to be peripherally-acting in order to avoid the serious CNS-related side effects associated with existing sodium channel blockers.", "sentB": "NKTR-171 is designed to be a peripherally-restricted molecule, with the aim of not causing central nervous system (CNS) side effects that limit usage of existing therapies.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers.", "<tag2>", "NKTR-171", "is", "designed", "to", "be", "a", "peripherally-restricted", "molecule,", "with", "the", "aim", "of", "not", "causing", "central", "nervous", "system", "(CNS)", "side", "effects", "that", "limit", "usage", "of", "existing", "therapies.", "<tag3>"], "wordsA": ["NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers."], "wordsB": ["NKTR-171", "is", "designed", "to", "be", "a", "peripherally-restricted", "molecule,", "with", "the", "aim", "of", "not", "causing", "central", "nervous", "system", "(CNS)", "side", "effects", "that", "limit", "usage", "of", "existing", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p99_s1", "idA": "906709_13_item1_p13_s1", "sentA": "NKTR-171 is designed to be peripherally-acting in order to avoid the serious CNS-related side effects associated with existing sodium channel blockers.", "sentB": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers.", "<tag2>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag3>"], "wordsA": ["NKTR-171", "is", "designed", "to", "be", "peripherally-acting", "in", "order", "to", "avoid", "the", "serious", "CNS-related", "side", "effects", "associated", "with", "existing", "sodium", "channel", "blockers."], "wordsB": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p104_s3", "idA": "906709_13_item1_p13_s2", "sentA": "The product candidate is currently undergoing investigational new drug application (IND)-enabling studies in preparation for clinical studies in healthy volunteers.", "sentB": "The product candidate is currently in Investigational New Drug application (IND)-enabling studies in preparation for clinical studies in cancer patients.", "type": 2, "words": ["<tag1>", "The", "product", "candidate", "is", "currently", "undergoing", "investigational", "new", "drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "healthy", "volunteers.", "<tag2>", "The", "product", "candidate", "is", "currently", "in", "Investigational", "New", "Drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "cancer", "patients.", "<tag3>"], "wordsA": ["The", "product", "candidate", "is", "currently", "undergoing", "investigational", "new", "drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "healthy", "volunteers."], "wordsB": ["The", "product", "candidate", "is", "currently", "in", "Investigational", "New", "Drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "cancer", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s6", "idA": "906709_13_item1_p13_s3", "sentA": "We have a significant collaboration with Baxter Healthcare to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients.", "sentB": "We have a significant collaboration with Baxter Healthcare (Baxter), to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients.", "type": 2, "words": ["<tag1>", "We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients.", "<tag2>", "We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "(Baxter),", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients.", "<tag3>"], "wordsA": ["We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients."], "wordsB": ["We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "(Baxter),", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s2", "idA": "906709_13_item1_p13_s3", "sentA": "We have a significant collaboration with Baxter Healthcare to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients.", "sentB": "Roche entered into the toll-manufacturing agreement with the objective of establishing us as a secondary back-up source on a non-exclusive basis.", "type": 2, "words": ["<tag1>", "We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients.", "<tag2>", "Roche", "entered", "into", "the", "toll-manufacturing", "agreement", "with", "the", "objective", "of", "establishing", "us", "as", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis.", "<tag3>"], "wordsA": ["We", "have", "a", "significant", "collaboration", "with", "Baxter", "Healthcare", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients."], "wordsB": ["Roche", "entered", "into", "the", "toll-manufacturing", "agreement", "with", "the", "objective", "of", "establishing", "us", "as", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p133_s1", "idA": "906709_13_item1_p13_s4", "sentA": "Under the terms of this collaboration, we are providing our PEGylation technology and expertise and Baxter is responsible for all clinical development.", "sentB": "Under the terms of the 2010 Agreement, we guarantee the manufacture and supply of our proprietary PEGylation materials (Polymer Materials) to Amgen in an existing manufacturing suite to be used exclusively for the manufacture of Polymer Materials for Amgen in our manufacturing facility in Huntsville, Alabama.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag2>", "Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "guarantee", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "(Polymer", "Materials)", "to", "Amgen", "in", "an", "existing", "manufacturing", "suite", "to", "be", "used", "exclusively", "for", "the", "manufacture", "of", "Polymer", "Materials", "for", "Amgen", "in", "our", "manufacturing", "facility", "in", "Huntsville,", "Alabama.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development."], "wordsB": ["Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "guarantee", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "(Polymer", "Materials)", "to", "Amgen", "in", "an", "existing", "manufacturing", "suite", "to", "be", "used", "exclusively", "for", "the", "manufacture", "of", "Polymer", "Materials", "for", "Amgen", "in", "our", "manufacturing", "facility", "in", "Huntsville,", "Alabama."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s1", "idA": "906709_13_item1_p13_s4", "sentA": "Under the terms of this collaboration, we are providing our PEGylation technology and expertise and Baxter is responsible for all clinical development.", "sentB": "Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p79_s1", "idA": "906709_13_item1_p13_s4", "sentA": "Under the terms of this collaboration, we are providing our PEGylation technology and expertise and Baxter is responsible for all clinical development.", "sentB": "Under the terms of the agreement, Bayer is responsible for most future clinical development and commercialization costs, all activities to support worldwide regulatory filings, approvals and related activities, further development of formulated Amikacin and final product packaging for Amikacin Inhale.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "Bayer", "is", "responsible", "for", "most", "future", "clinical", "development", "and", "commercialization", "costs,", "all", "activities", "to", "support", "worldwide", "regulatory", "filings,", "approvals", "and", "related", "activities,", "further", "development", "of", "formulated", "Amikacin", "and", "final", "product", "packaging", "for", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "collaboration,", "we", "are", "providing", "our", "PEGylation", "technology", "and", "expertise", "and", "Baxter", "is", "responsible", "for", "all", "clinical", "development."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "Bayer", "is", "responsible", "for", "most", "future", "clinical", "development", "and", "commercialization", "costs,", "all", "activities", "to", "support", "worldwide", "regulatory", "filings,", "approvals", "and", "related", "activities,", "further", "development", "of", "formulated", "Amikacin", "and", "final", "product", "packaging", "for", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p112_s1", "idA": "906709_13_item1_p13_s5", "sentA": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein which has completed Phase 1 clinical development in patients with hemophilia A.", "sentB": "The first product in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "type": 2, "words": ["<tag1>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag2>", "The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag3>"], "wordsA": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "wordsB": ["The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p113_s0", "idA": "906709_13_item1_p13_s5", "sentA": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein which has completed Phase 1 clinical development in patients with hemophilia A.", "sentB": "BAX 855 is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "type": 2, "words": ["<tag1>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag2>", "BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag3>"], "wordsA": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "wordsB": ["BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p115_s0", "idA": "906709_13_item1_p13_s6", "sentA": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE that will enroll more than 100 previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "In 2012, Baxter completed a Phase 1 clinical study for BAX 855 that was a prospective, open-label study assessing the safety, tolerability and pharmacokinetics of BAX 855 in 19 previously treated patients age 18 years or older with severe hemophilia A.", "type": 2, "words": ["<tag1>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "In", "2012,", "Baxter", "completed", "a", "Phase", "1", "clinical", "study", "for", "BAX", "855", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "hemophilia", "A.", "<tag3>"], "wordsA": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["In", "2012,", "Baxter", "completed", "a", "Phase", "1", "clinical", "study", "for", "BAX", "855", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p116_s1", "idA": "906709_13_item1_p13_s6", "sentA": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE that will enroll more than 100 previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "The Phase 3 clinical study is ongoing and is as a multi-center, open-label study called PROLONG-ATE and enrolled 146 previously treated adult patients with severe hemophilia A in order to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "type": 2, "words": ["<tag1>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "The", "Phase", "3", "clinical", "study", "is", "ongoing", "and", "is", "as", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE", "and", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag3>"], "wordsA": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["The", "Phase", "3", "clinical", "study", "is", "ongoing", "and", "is", "as", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE", "and", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s9", "idA": "906709_13_item1_p13_s6", "sentA": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE that will enroll more than 100 previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "In February 2013, Baxter initiated a Phase 3 multi-center, open-label clinical study called PROLONG-ATE in previously treated adult patients with severe hemophilia A to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "type": 2, "words": ["<tag1>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "in", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag3>"], "wordsA": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "that", "will", "enroll", "more", "than", "100", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["In", "February", "2013,", "Baxter", "initiated", "a", "Phase", "3", "multi-center,", "open-label", "clinical", "study", "called", "PROLONG-ATE", "in", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p79_s0", "idA": "906709_13_item1_p14_s0", "sentA": "We also have a significant collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly called NKTR-061) for the treatment of gram negative pneumonias.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)", "for", "the", "treatment", "of", "gram", "negative", "pneumonias.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)", "for", "the", "treatment", "of", "gram", "negative", "pneumonias."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p109_s1", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "In March of 2012, the FDA issued a complete response letter identifying issues relating to chemistry, manufacturing and controls deficiencies at a third party manufacturer that needed to be resolved to the FDA s satisfaction as well as citing the need for additional time to complete review of inhaler usability information.", "type": 2, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "In", "March", "of", "2012,", "the", "FDA", "issued", "a", "complete", "response", "letter", "identifying", "issues", "relating", "to", "chemistry,", "manufacturing", "and", "controls", "deficiencies", "at", "a", "third", "party", "manufacturer", "that", "needed", "to", "be", "resolved", "to", "the", "FDA", "s", "satisfaction", "as", "well", "as", "citing", "the", "need", "for", "additional", "time", "to", "complete", "review", "of", "inhaler", "usability", "information.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["In", "March", "of", "2012,", "the", "FDA", "issued", "a", "complete", "response", "letter", "identifying", "issues", "relating", "to", "chemistry,", "manufacturing", "and", "controls", "deficiencies", "at", "a", "third", "party", "manufacturer", "that", "needed", "to", "be", "resolved", "to", "the", "FDA", "s", "satisfaction", "as", "well", "as", "citing", "the", "need", "for", "additional", "time", "to", "complete", "review", "of", "inhaler", "usability", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p10_s0", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 clinical study design.", "type": 2, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p116_s0", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "type": 2, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p79_s2", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "We are responsible for all future development, manufacturing and supply of the nebulizer device for clinical and commercial use.", "type": 2, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p83_s0", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "The aerosol generator within the nebulizer for Amikacin Inhale delivers a fine aerosol of the antimicrobial agent directly to the site of infection in the lungs.", "type": 2, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "The", "aerosol", "generator", "within", "the", "nebulizer", "for", "Amikacin", "Inhale", "delivers", "a", "fine", "aerosol", "of", "the", "antimicrobial", "agent", "directly", "to", "the", "site", "of", "infection", "in", "the", "lungs.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["The", "aerosol", "generator", "within", "the", "nebulizer", "for", "Amikacin", "Inhale", "delivers", "a", "fine", "aerosol", "of", "the", "antimicrobial", "agent", "directly", "to", "the", "site", "of", "infection", "in", "the", "lungs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p92_s0", "idA": "906709_13_item1_p14_s2", "sentA": "The stability studies on the nebulizer device that needed to be completed prior to the start of the Phase 3 clinical study were successfully completed in February 2013.", "sentB": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 study design.", "type": 2, "words": ["<tag1>", "The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013.", "<tag2>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design.", "<tag3>"], "wordsA": ["The", "stability", "studies", "on", "the", "nebulizer", "device", "that", "needed", "to", "be", "completed", "prior", "to", "the", "start", "of", "the", "Phase", "3", "clinical", "study", "were", "successfully", "completed", "in", "February", "2013."], "wordsB": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p10_s1", "idA": "906709_13_item1_p15_s0", "sentA": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "We are currently evaluating the appropriate Phase 3 clinical study design for NKTR-181 and expect to start a Phase 3 clinical study in mid-2014, following the completion of an end-of-Phase 2 meeting with the FDA planned to occur in the first half of 2014.", "type": 2, "words": ["<tag1>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "study", "design", "for", "NKTR-181", "and", "expect", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "study", "design", "for", "NKTR-181", "and", "expect", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p12_s3", "idA": "906709_13_item1_p15_s0", "sentA": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "Bayer is conducting this study under a Special Protocol Assessment process that was agreed to with the FDA in 2011.", "type": 2, "words": ["<tag1>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "Bayer", "is", "conducting", "this", "study", "under", "a", "Special", "Protocol", "Assessment", "process", "that", "was", "agreed", "to", "with", "the", "FDA", "in", "2011.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["Bayer", "is", "conducting", "this", "study", "under", "a", "Special", "Protocol", "Assessment", "process", "that", "was", "agreed", "to", "with", "the", "FDA", "in", "2011."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p84_s2", "idA": "906709_13_item1_p15_s0", "sentA": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "The INHALE development program is being conducted by Bayer under a Special Protocol Assessment agreement with the FDA that is intended to support the submission of an NDA if the INHALE clinical studies are successful.", "type": 2, "words": ["<tag1>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "The", "INHALE", "development", "program", "is", "being", "conducted", "by", "Bayer", "under", "a", "Special", "Protocol", "Assessment", "agreement", "with", "the", "FDA", "that", "is", "intended", "to", "support", "the", "submission", "of", "an", "NDA", "if", "the", "INHALE", "clinical", "studies", "are", "successful.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["The", "INHALE", "development", "program", "is", "being", "conducted", "by", "Bayer", "under", "a", "Special", "Protocol", "Assessment", "agreement", "with", "the", "FDA", "that", "is", "intended", "to", "support", "the", "submission", "of", "an", "NDA", "if", "the", "INHALE", "clinical", "studies", "are", "successful."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p86_s1", "idA": "906709_13_item1_p15_s0", "sentA": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "Its potential differentiating properties are inherent to the design of the new molecule and as a new molecular structure.", "type": 2, "words": ["<tag1>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "Its", "potential", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and", "as", "a", "new", "molecular", "structure.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["Its", "potential", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and", "as", "a", "new", "molecular", "structure."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p92_s1", "idA": "906709_13_item1_p15_s0", "sentA": "In 2011, Bayer achieved agreement with the FDA on the design of the planned Phase 3 clinical studies of BAY41-6551 under the Special Protocol Assessment process that is intended to support the submission of a New Drug Application (NDA) if the planned Phase 3 clinical study is successful.", "sentB": "We are currently evaluating the appropriate Phase 3 clinical trial design for NKTR-181 and plan to start a Phase 3 clinical study in mid-2014, following the completion of an end-of-Phase 2 meeting with the FDA planned to occur in the first half of 2014.", "type": 2, "words": ["<tag1>", "In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful.", "<tag2>", "We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "trial", "design", "for", "NKTR-181", "and", "plan", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014.", "<tag3>"], "wordsA": ["In", "2011,", "Bayer", "achieved", "agreement", "with", "the", "FDA", "on", "the", "design", "of", "the", "planned", "Phase", "3", "clinical", "studies", "of", "BAY41-6551", "under", "the", "Special", "Protocol", "Assessment", "process", "that", "is", "intended", "to", "support", "the", "submission", "of", "a", "New", "Drug", "Application", "(NDA)", "if", "the", "planned", "Phase", "3", "clinical", "study", "is", "successful."], "wordsB": ["We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "trial", "design", "for", "NKTR-181", "and", "plan", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p12_s4", "idA": "906709_13_item1_p15_s1", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Affymax, Inc., Amgen Inc., MAP Pharmaceuticals, Inc., Merck Co., Inc. (through its acquisition of Schering Plough), Pfizer Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "sentB": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., MAP Pharmaceuticals, Inc., Merck Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), Regado Biosciences, Inc., and UCB Pharma.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "Regado", "Biosciences,", "Inc.,", "and", "UCB", "Pharma.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "Regado", "Biosciences,", "Inc.,", "and", "UCB", "Pharma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p145_s0", "idA": "906709_13_item1_p15_s1", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Affymax, Inc., Amgen Inc., MAP Pharmaceuticals, Inc., Merck Co., Inc. (through its acquisition of Schering Plough), Pfizer Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "sentB": "In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), which was amended and restated in its entirety in December 2005.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag2>", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Affymax,", "Inc.,", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.", "(through", "its", "acquisition", "of", "Schering", "Plough),", "Pfizer", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "wordsB": ["In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p105_s0", "idA": "906709_13_item1_p16_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "Overview of Select Technology Licensing Collaborations and Programs We have a number of product candidates in clinical development and approved products in collaboration with our partners that use our technology or involve rights over which we have patents or other proprietary intellectual property.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "Overview", "of", "Select", "Technology", "Licensing", "Collaborations", "and", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "that", "use", "our", "technology", "or", "involve", "rights", "over", "which", "we", "have", "patents", "or", "other", "proprietary", "intellectual", "property.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["Overview", "of", "Select", "Technology", "Licensing", "Collaborations", "and", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "that", "use", "our", "technology", "or", "involve", "rights", "over", "which", "we", "have", "patents", "or", "other", "proprietary", "intellectual", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p126_s1", "idA": "906709_13_item1_p16_s2", "sentA": "On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 of our dedicated pulmonary personnel and operations to Novartis Pharma AG.", "sentB": "On December 31, 2008, we assigned the agreement to Novartis Pharma AG in connection with the completion of the pulmonary asset sale transaction.", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "of", "our", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG.", "<tag2>", "On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction.", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "of", "our", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG."], "wordsB": ["On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p13_s2", "idA": "906709_13_item1_p16_s2", "sentA": "On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 of our dedicated pulmonary personnel and operations to Novartis Pharma AG.", "sentB": "On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 dedicated pulmonary personnel and operations to Novartis Pharma AG.", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "of", "our", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG.", "<tag2>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG.", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "of", "our", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG."], "wordsB": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p106_s2", "idA": "906709_13_item1_p16_s3", "sentA": "We retained all of our rights to BAY41-6551 and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of LEVADEX .", "type": 2, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", ".", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p13_s3", "idA": "906709_13_item1_p16_s3", "sentA": "We retained all of our rights to BAY41-6551 and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "We retained all of our rights to Amikacin Inhale and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "type": 2, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "We", "retained", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "BAY41-6551", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["We", "retained", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p127_s1", "idA": "906709_13_item1_p17_s0", "sentA": "In August 2012, Bayer initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis.", "sentB": "In August 2012, Bayer initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis.", "type": 2, "words": ["<tag1>", "In", "August", "2012,", "Bayer", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag2>", "In", "August", "2012,", "Bayer", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag3>"], "wordsA": ["In", "August", "2012,", "Bayer", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "wordsB": ["In", "August", "2012,", "Bayer", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p129_s0", "idA": "906709_13_item1_p17_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "In the two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, Bayer plans to enroll up to 600 patients and to evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "type": 2, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "In", "the", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "Bayer", "plans", "to", "enroll", "up", "to", "600", "patients", "and", "to", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["In", "the", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "Bayer", "plans", "to", "enroll", "up", "to", "600", "patients", "and", "to", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s7", "idA": "906709_13_item1_p18_s1", "sentA": "We maintain our executive offices at 455 Mission Bay Boulevard South, San Francisco, California 94158, and our main telephone number is (415) 482-5300.", "sentB": "On January 18, 2014, we presented data from this study at the 2014 Gastrointestinal Cancers Symposium in San Francisco, California.", "type": 2, "words": ["<tag1>", "We", "maintain", "our", "executive", "offices", "at", "455", "Mission", "Bay", "Boulevard", "South,", "San", "Francisco,", "California", "94158,", "and", "our", "main", "telephone", "number", "is", "(415)", "482-5300.", "<tag2>", "On", "January", "18,", "2014,", "we", "presented", "data", "from", "this", "study", "at", "the", "2014", "Gastrointestinal", "Cancers", "Symposium", "in", "San", "Francisco,", "California.", "<tag3>"], "wordsA": ["We", "maintain", "our", "executive", "offices", "at", "455", "Mission", "Bay", "Boulevard", "South,", "San", "Francisco,", "California", "94158,", "and", "our", "main", "telephone", "number", "is", "(415)", "482-5300."], "wordsB": ["On", "January", "18,", "2014,", "we", "presented", "data", "from", "this", "study", "at", "the", "2014", "Gastrointestinal", "Cancers", "Symposium", "in", "San", "Francisco,", "California."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p1_s1", "idA": "906709_13_item1_p1_s1", "sentA": "Our research and development activities involve both small molecule and biologic drug candidates.", "sentB": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "both", "small", "molecule", "and", "biologic", "drug", "candidates.", "<tag2>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "both", "small", "molecule", "and", "biologic", "drug", "candidates."], "wordsB": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p68_s0", "idA": "906709_13_item1_p20_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "sentB": "Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.", "type": 2, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag2>", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "wordsB": ["Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p105_s1", "idA": "906709_13_item1_p20_s4", "sentA": "Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs.", "sentB": "In a typical collaboration involving our PEGylation technology, we license our proprietary intellectual property related to our PEGylation technology or proprietary conjugated drug molecules in exchange for upfront payments, development milestone payments and royalties from sales of the resulting commercial product as well as sales milestones.", "type": 2, "words": ["<tag1>", "Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs.", "<tag2>", "In", "a", "typical", "collaboration", "involving", "our", "PEGylation", "technology,", "we", "license", "our", "proprietary", "intellectual", "property", "related", "to", "our", "PEGylation", "technology", "or", "proprietary", "conjugated", "drug", "molecules", "in", "exchange", "for", "upfront", "payments,", "development", "milestone", "payments", "and", "royalties", "from", "sales", "of", "the", "resulting", "commercial", "product", "as", "well", "as", "sales", "milestones.", "<tag3>"], "wordsA": ["Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs."], "wordsB": ["In", "a", "typical", "collaboration", "involving", "our", "PEGylation", "technology,", "we", "license", "our", "proprietary", "intellectual", "property", "related", "to", "our", "PEGylation", "technology", "or", "proprietary", "conjugated", "drug", "molecules", "in", "exchange", "for", "upfront", "payments,", "development", "milestone", "payments", "and", "royalties", "from", "sales", "of", "the", "resulting", "commercial", "product", "as", "well", "as", "sales", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s4", "idA": "906709_13_item1_p20_s4", "sentA": "Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs.", "sentB": "Secondary endpoints of the study included quality-of-life assessment, sleep and motor activity scoring, as well as tolerability endpoints.", "type": 2, "words": ["<tag1>", "Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs.", "<tag2>", "Secondary", "endpoints", "of", "the", "study", "included", "quality-of-life", "assessment,", "sleep", "and", "motor", "activity", "scoring,", "as", "well", "as", "tolerability", "endpoints.", "<tag3>"], "wordsA": ["Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs."], "wordsB": ["Secondary", "endpoints", "of", "the", "study", "included", "quality-of-life", "assessment,", "sleep", "and", "motor", "activity", "scoring,", "as", "well", "as", "tolerability", "endpoints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p19_s0", "idA": "906709_13_item1_p21_s1", "sentA": "Our advanced polymer conjugate technology platform is designed to overcome the limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "sentB": "limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "type": 2, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag2>", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "wordsB": ["limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p21_s3", "idA": "906709_13_item1_p23_s3", "sentA": "Two primary examples of reducing transport across the blood-brain barrier are naloxegol, an orally-available peripherally-acting opioid antagonist that is in late stage clinical development in collaboration with AstraZeneca, and NKTR-171, a novel peripherally-acting sodium channel blocker that is currently in IND-enabling studies for the treatment of neuropathic pain.", "sentB": "Two primary examples of reducing transport across the blood-brain barrier are naloxegol, an orally-available peripherally-acting opioid antagonist that AstraZeneca has filed applications for marketing authorizations, and NKTR-171, a novel peripherally-acting sodium channel blocker that is currently in a Phase 1 clinical study for the treatment of neuropathic pain.", "type": 2, "words": ["<tag1>", "Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "in", "late", "stage", "clinical", "development", "in", "collaboration", "with", "AstraZeneca,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "IND-enabling", "studies", "for", "the", "treatment", "of", "neuropathic", "pain.", "<tag2>", "Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "AstraZeneca", "has", "filed", "applications", "for", "marketing", "authorizations,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "a", "Phase", "1", "clinical", "study", "for", "the", "treatment", "of", "neuropathic", "pain.", "<tag3>"], "wordsA": ["Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "in", "late", "stage", "clinical", "development", "in", "collaboration", "with", "AstraZeneca,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "IND-enabling", "studies", "for", "the", "treatment", "of", "neuropathic", "pain."], "wordsB": ["Two", "primary", "examples", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "are", "naloxegol,", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "AstraZeneca", "has", "filed", "applications", "for", "marketing", "authorizations,", "and", "NKTR-171,", "a", "novel", "peripherally-acting", "sodium", "channel", "blocker", "that", "is", "currently", "in", "a", "Phase", "1", "clinical", "study", "for", "the", "treatment", "of", "neuropathic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p21_s4", "idA": "906709_13_item1_p23_s4", "sentA": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that is being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that we plan to initiate Phase 3 clinical studies starting in mid-2014, following the completion of an end-of-Phase 2 meeting with the FDA in the first half of 2014.", "type": 2, "words": ["<tag1>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "we", "plan", "to", "initiate", "Phase", "3", "clinical", "studies", "starting", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "in", "the", "first", "half", "of", "2014.", "<tag3>"], "wordsA": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "we", "plan", "to", "initiate", "Phase", "3", "clinical", "studies", "starting", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "in", "the", "first", "half", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p88_s1", "idA": "906709_13_item1_p24_s0", "sentA": "Small Molecule Pro-Drug Releasable Polymer Conjugates The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase its efficacy and improve its side effect profile.", "sentB": "The first study, a single-ascending dose study of NKTR-181 evaluated the pharmacokinetics and pharmacodynamics of a 50-fold range of single oral doses of NKTR-181 in 84 healthy subjects at up to 500 mg dose levels.", "type": 2, "words": ["<tag1>", "Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "its", "efficacy", "and", "improve", "its", "side", "effect", "profile.", "<tag2>", "The", "first", "study,", "a", "single-ascending", "dose", "study", "of", "NKTR-181", "evaluated", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "50-fold", "range", "of", "single", "oral", "doses", "of", "NKTR-181", "in", "84", "healthy", "subjects", "at", "up", "to", "500", "mg", "dose", "levels.", "<tag3>"], "wordsA": ["Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "its", "efficacy", "and", "improve", "its", "side", "effect", "profile."], "wordsB": ["The", "first", "study,", "a", "single-ascending", "dose", "study", "of", "NKTR-181", "evaluated", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "50-fold", "range", "of", "single", "oral", "doses", "of", "NKTR-181", "in", "84", "healthy", "subjects", "at", "up", "to", "500", "mg", "dose", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p88_s2", "idA": "906709_13_item1_p24_s0", "sentA": "Small Molecule Pro-Drug Releasable Polymer Conjugates The pro-drug polymer conjugation approach can be used to optimize the pharmacokinetics and pharmacodynamics of a small molecule drug to substantially increase its efficacy and improve its side effect profile.", "sentB": "The second study, a multiple-ascending dose study of NKTR-181 evaluated the pharmacokinetics and pharmacodynamics of four separate dose cohorts of NKTR-181 (100 mg 400 mg) administered orally twice- daily.", "type": 2, "words": ["<tag1>", "Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "its", "efficacy", "and", "improve", "its", "side", "effect", "profile.", "<tag2>", "The", "second", "study,", "a", "multiple-ascending", "dose", "study", "of", "NKTR-181", "evaluated", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "four", "separate", "dose", "cohorts", "of", "NKTR-181", "(100", "mg", "400", "mg)", "administered", "orally", "twice-", "daily.", "<tag3>"], "wordsA": ["Small", "Molecule", "Pro-Drug", "Releasable", "Polymer", "Conjugates", "The", "pro-drug", "polymer", "conjugation", "approach", "can", "be", "used", "to", "optimize", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "a", "small", "molecule", "drug", "to", "substantially", "increase", "its", "efficacy", "and", "improve", "its", "side", "effect", "profile."], "wordsB": ["The", "second", "study,", "a", "multiple-ascending", "dose", "study", "of", "NKTR-181", "evaluated", "the", "pharmacokinetics", "and", "pharmacodynamics", "of", "four", "separate", "dose", "cohorts", "of", "NKTR-181", "(100", "mg", "400", "mg)", "administered", "orally", "twice-", "daily."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p23_s0", "idA": "906709_13_item1_p24_s2", "sentA": "With our technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "With our releasable polymer conjugate technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "type": 2, "words": ["<tag1>", "With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag3>"], "wordsA": ["With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p59_s1", "idA": "906709_13_item1_p24_s2", "sentA": "With our technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "Over time, the body s natural enzymatic processes slowly metabolize the linkers within the molecule, continuously freeing active drug that then can work to stop tumor cell division through topo I inhibition.", "type": 2, "words": ["<tag1>", "With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "Over", "time,", "the", "body", "s", "natural", "enzymatic", "processes", "slowly", "metabolize", "the", "linkers", "within", "the", "molecule,", "continuously", "freeing", "active", "drug", "that", "then", "can", "work", "to", "stop", "tumor", "cell", "division", "through", "topo", "I", "inhibition.", "<tag3>"], "wordsA": ["With", "our", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["Over", "time,", "the", "body", "s", "natural", "enzymatic", "processes", "slowly", "metabolize", "the", "linkers", "within", "the", "molecule,", "continuously", "freeing", "active", "drug", "that", "then", "can", "work", "to", "stop", "tumor", "cell", "division", "through", "topo", "I", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p23_s1", "idA": "906709_13_item1_p24_s3", "sentA": "We are using this approach with the oncolytic drug candidate in our pipeline, etirinotecan pegol, a next-generation topoisomerase I-inhibitor, currently in Phase 3 clinical development in metastatic breast cancer, and Phase 2 clinical development in ovarian and colorectal cancers.", "sentB": "We are using this approach with our lead oncolytic drug candidate, etirinotecan pegol, a next-generation topoisomerase I-inhibitor currently in the Phase 3 BEACON clinical study for treatment of metastatic breast cancer.", "type": 2, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "clinical", "development", "in", "ovarian", "and", "colorectal", "cancers.", "<tag2>", "We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "the", "oncolytic", "drug", "candidate", "in", "our", "pipeline,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor,", "currently", "in", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer,", "and", "Phase", "2", "clinical", "development", "in", "ovarian", "and", "colorectal", "cancers."], "wordsB": ["We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p23_s4", "idA": "906709_13_item1_p25_s0", "sentA": "rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "sentB": "Through rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "type": 2, "words": ["<tag1>", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag2>", "Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag3>"], "wordsA": ["rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "wordsB": ["Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p23_s6", "idA": "906709_13_item1_p25_s2", "sentA": "The specially designed PEG replaces the function of the Fc domain of full length antibodies with a branched architecture PEG with either stable or degradable linkage.", "sentB": "The specially designed PEG replaces the function of the fragment crystallizable (Fc) domain of full length antibodies with a branched architecture PEG with either stable or degradable linkage.", "type": 2, "words": ["<tag1>", "The", "specially", "designed", "PEG", "replaces", "the", "function", "of", "the", "Fc", "domain", "of", "full", "length", "antibodies", "with", "a", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage.", "<tag2>", "The", "specially", "designed", "PEG", "replaces", "the", "function", "of", "the", "fragment", "crystallizable", "(Fc)", "domain", "of", "full", "length", "antibodies", "with", "a", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage.", "<tag3>"], "wordsA": ["The", "specially", "designed", "PEG", "replaces", "the", "function", "of", "the", "Fc", "domain", "of", "full", "length", "antibodies", "with", "a", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage."], "wordsB": ["The", "specially", "designed", "PEG", "replaces", "the", "function", "of", "the", "fragment", "crystallizable", "(Fc)", "domain", "of", "full", "length", "antibodies", "with", "a", "branched", "architecture", "PEG", "with", "either", "stable", "or", "degradable", "linkage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p136_s0", "idA": "906709_13_item1_p26_s0", "sentA": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease in the U.S. and rheumatoid arthritis in the U.S. and E.U.", "sentB": "PEGASYS is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "type": 2, "words": ["<tag1>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U.", "<tag2>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag3>"], "wordsA": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U."], "wordsB": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p24_s0", "idA": "906709_13_item1_p26_s0", "sentA": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease in the U.S. and rheumatoid arthritis in the U.S. and E.U.", "sentB": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease, psoriatic arthritis and ankylosing spondylitis in the U.S. and rheumatoid arthritis in the U.S. and E.U.", "type": 2, "words": ["<tag1>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U.", "<tag2>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease,", "psoriatic", "arthritis", "and", "ankylosing", "spondylitis", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U.", "<tag3>"], "wordsA": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U."], "wordsB": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease,", "psoriatic", "arthritis", "and", "ankylosing", "spondylitis", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s5", "idA": "906709_13_item1_p28_s0", "sentA": "Our objective is to create value by advancing our lead drug candidates through various stages of clinical development.", "sentB": "In addition, we are also advancing other acute pain drug candidates in preclinical development.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "create", "value", "by", "advancing", "our", "lead", "drug", "candidates", "through", "various", "stages", "of", "clinical", "development.", "<tag2>", "In", "addition,", "we", "are", "also", "advancing", "other", "acute", "pain", "drug", "candidates", "in", "preclinical", "development.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "create", "value", "by", "advancing", "our", "lead", "drug", "candidates", "through", "various", "stages", "of", "clinical", "development."], "wordsB": ["In", "addition,", "we", "are", "also", "advancing", "other", "acute", "pain", "drug", "candidates", "in", "preclinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p26_s1", "idA": "906709_13_item1_p28_s1", "sentA": "To support this strategy, over the past five years we have significantly expanded and added expertise to our internal preclinical, clinical development and regulatory departments.", "sentB": "To support this strategy, we have significantly expanded and added expertise to our internal preclinical, clinical development and regulatory departments.", "type": 2, "words": ["<tag1>", "To", "support", "this", "strategy,", "over", "the", "past", "five", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments.", "<tag2>", "To", "support", "this", "strategy,", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments.", "<tag3>"], "wordsA": ["To", "support", "this", "strategy,", "over", "the", "past", "five", "years", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments."], "wordsB": ["To", "support", "this", "strategy,", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p28_s1", "idA": "906709_13_item1_p29_s7", "sentA": "For example, in December 2010, we decided that we would move etirinotecan pegol (NKTR-102) into Phase 3 clinical development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate.", "sentB": "For example, in December 2010, we decided that we would move etirinotecan pegol (also known as NKTR-102) into Phase 3 clinical development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate.", "type": 2, "words": ["<tag1>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate.", "<tag2>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate.", "<tag3>"], "wordsA": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate."], "wordsB": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p71_s1", "idA": "906709_13_item1_p29_s7", "sentA": "For example, in December 2010, we decided that we would move etirinotecan pegol (NKTR-102) into Phase 3 clinical development in metastatic breast cancer prior to completing a collaboration partnership for this drug candidate.", "sentB": "In September 2013, the FDA advised us that a Phase 3 clinical study would be required in order to support an NDA filing for etirinotecan pegol in ovarian cancer; however the FDA also indicated that a positive interim over-all survival analysis in a Phase 3 clinical study could potentially support an accelerated NDA filing prior to completing a Phase 3 clinical study.", "type": 2, "words": ["<tag1>", "For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate.", "<tag2>", "In", "September", "2013,", "the", "FDA", "advised", "us", "that", "a", "Phase", "3", "clinical", "study", "would", "be", "required", "in", "order", "to", "support", "an", "NDA", "filing", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer;", "however", "the", "FDA", "also", "indicated", "that", "a", "positive", "interim", "over-all", "survival", "analysis", "in", "a", "Phase", "3", "clinical", "study", "could", "potentially", "support", "an", "accelerated", "NDA", "filing", "prior", "to", "completing", "a", "Phase", "3", "clinical", "study.", "<tag3>"], "wordsA": ["For", "example,", "in", "December", "2010,", "we", "decided", "that", "we", "would", "move", "etirinotecan", "pegol", "(NKTR-102)", "into", "Phase", "3", "clinical", "development", "in", "metastatic", "breast", "cancer", "prior", "to", "completing", "a", "collaboration", "partnership", "for", "this", "drug", "candidate."], "wordsB": ["In", "September", "2013,", "the", "FDA", "advised", "us", "that", "a", "Phase", "3", "clinical", "study", "would", "be", "required", "in", "order", "to", "support", "an", "NDA", "filing", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer;", "however", "the", "FDA", "also", "indicated", "that", "a", "positive", "interim", "over-all", "survival", "analysis", "in", "a", "Phase", "3", "clinical", "study", "could", "potentially", "support", "an", "accelerated", "NDA", "filing", "prior", "to", "completing", "a", "Phase", "3", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p28_s2", "idA": "906709_13_item1_p30_s0", "sentA": "regulatory filing process, and market and sell drugs in one or more geographies.", "sentB": "When we determine to seek a partner, our strategy is to enter into collaborations with leading pharmaceutical and biotechnology companies to fund further clinical development, manage the global regulatory filing process, and market and sell drugs in one or more geographies.", "type": 2, "words": ["<tag1>", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies.", "<tag2>", "When", "we", "determine", "to", "seek", "a", "partner,", "our", "strategy", "is", "to", "enter", "into", "collaborations", "with", "leading", "pharmaceutical", "and", "biotechnology", "companies", "to", "fund", "further", "clinical", "development,", "manage", "the", "global", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies.", "<tag3>"], "wordsA": ["regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies."], "wordsB": ["When", "we", "determine", "to", "seek", "a", "partner,", "our", "strategy", "is", "to", "enter", "into", "collaborations", "with", "leading", "pharmaceutical", "and", "biotechnology", "companies", "to", "fund", "further", "clinical", "development,", "manage", "the", "global", "regulatory", "filing", "process,", "and", "market", "and", "sell", "drugs", "in", "one", "or", "more", "geographies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p29_s2", "idA": "906709_13_item1_p31_s2", "sentA": "The following table summarizes our proprietary drug candidates that are being developed by us or in collaboration with other pharmaceutical companies.", "sentB": "The following table summarizes our proprietary drug candidates that are being developed by us or in collaboration with other pharmaceutical companies or independent investigators.", "type": 2, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies.", "<tag2>", "The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies."], "wordsB": ["The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p36_s0", "idA": "906709_13_item1_p32_s0", "sentA": "(1) Status definitions are: Approved regulatory approval to market and sell product obtained in the U.S., EU and other countries.", "sentB": "(1) Status definitions are: Approved regulatory approval to market and sell product obtained in one or more of the U.S., E.U. or other countries.", "type": 2, "words": ["<tag1>", "(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "the", "U.S.,", "EU", "and", "other", "countries.", "<tag2>", "(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries.", "<tag3>"], "wordsA": ["(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "the", "U.S.,", "EU", "and", "other", "countries."], "wordsB": ["(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p32_s2", "idA": "906709_13_item1_p34_s0", "sentA": "Phase 2 a drug candidate in clinical trials to establish dosing and efficacy in patients.", "sentB": "Research/Preclinical a drug candidate is being studied in research by way of in vitro studies and/or animal studies ISS Investigator sponsored study for which the Company is providing support.", "type": 2, "words": ["<tag1>", "Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag2>", "Research/Preclinical", "a", "drug", "candidate", "is", "being", "studied", "in", "research", "by", "way", "of", "in", "vitro", "studies", "and/or", "animal", "studies", "ISS", "Investigator", "sponsored", "study", "for", "which", "the", "Company", "is", "providing", "support.", "<tag3>"], "wordsA": ["Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "wordsB": ["Research/Preclinical", "a", "drug", "candidate", "is", "being", "studied", "in", "research", "by", "way", "of", "in", "vitro", "studies", "and/or", "animal", "studies", "ISS", "Investigator", "sponsored", "study", "for", "which", "the", "Company", "is", "providing", "support."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p70_s1", "idA": "906709_13_item1_p35_s0", "sentA": "This drug candidate uses, in part, a liquid aerosol technology platform that was transferred to Novartis by us in the pulmonary asset sale transaction that was completed on December 31, 2008.", "sentB": "Each schedule originally followed a two-stage Simon design and a total of 71 patients were initially included in the study that was completed in the first half of 2010.", "type": 2, "words": ["<tag1>", "This", "drug", "candidate", "uses,", "in", "part,", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008.", "<tag2>", "Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "included", "in", "the", "study", "that", "was", "completed", "in", "the", "first", "half", "of", "2010.", "<tag3>"], "wordsA": ["This", "drug", "candidate", "uses,", "in", "part,", "a", "liquid", "aerosol", "technology", "platform", "that", "was", "transferred", "to", "Novartis", "by", "us", "in", "the", "pulmonary", "asset", "sale", "transaction", "that", "was", "completed", "on", "December", "31,", "2008."], "wordsB": ["Each", "schedule", "originally", "followed", "a", "two-stage", "Simon", "design", "and", "a", "total", "of", "71", "patients", "were", "initially", "included", "in", "the", "study", "that", "was", "completed", "in", "the", "first", "half", "of", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p134_s1", "idA": "906709_13_item1_p35_s1", "sentA": "As part of that transaction, we retained an exclusive license to this technology for the development and commercialization of this drug candidate originally developed by us.", "sentB": "Amgen may terminate the 2010 Agreement for convenience or due to an uncured material default by us.", "type": 2, "words": ["<tag1>", "As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us.", "<tag2>", "Amgen", "may", "terminate", "the", "2010", "Agreement", "for", "convenience", "or", "due", "to", "an", "uncured", "material", "default", "by", "us.", "<tag3>"], "wordsA": ["As", "part", "of", "that", "transaction,", "we", "retained", "an", "exclusive", "license", "to", "this", "technology", "for", "the", "development", "and", "commercialization", "of", "this", "drug", "candidate", "originally", "developed", "by", "us."], "wordsB": ["Amgen", "may", "terminate", "the", "2010", "Agreement", "for", "convenience", "or", "due", "to", "an", "uncured", "material", "default", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p105_s2", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "In certain cases, we also manufacture and supply our proprietary PEGylation materials to our partners.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p136_s1", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "As a result of Roche exercising a license extension option in December 2009, beginning in 2010 Roche has the right to manufacture all of its requirements for our proprietary PEGylation materials for PEGASYS and we supply raw materials or perform additional manufacturing, if any, only on a back-up basis.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "As", "a", "result", "of", "Roche", "exercising", "a", "license", "extension", "option", "in", "December", "2009,", "beginning", "in", "2010", "Roche", "has", "the", "right", "to", "manufacture", "all", "of", "its", "requirements", "for", "our", "proprietary", "PEGylation", "materials", "for", "PEGASYS", "and", "we", "supply", "raw", "materials", "or", "perform", "additional", "manufacturing,", "if", "any,", "only", "on", "a", "back-up", "basis.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["As", "a", "result", "of", "Roche", "exercising", "a", "license", "extension", "option", "in", "December", "2009,", "beginning", "in", "2010", "Roche", "has", "the", "right", "to", "manufacture", "all", "of", "its", "requirements", "for", "our", "proprietary", "PEGylation", "materials", "for", "PEGASYS", "and", "we", "supply", "raw", "materials", "or", "perform", "additional", "manufacturing,", "if", "any,", "only", "on", "a", "back-up", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p139_s2", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "We currently manufacture our proprietary PEGylation materials for Schering on a price per gram basis.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p142_s0", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "PEGylation materials for Valeant on a price per gram basis.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s0", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "CIMZIA , Agreement with UCB Pharma In December 2000, we entered into a license, manufacturing and supply agreement covering our proprietary PEGylation materials for use in CIMZIA (certolizumab pegol) with Celltech Chiroscience Ltd., which was acquired by UCB Pharma (UCB) in 2004.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "CIMZIA", ",", "Agreement", "with", "UCB", "Pharma", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "covering", "our", "proprietary", "PEGylation", "materials", "for", "use", "in", "CIMZIA", "(certolizumab", "pegol)", "with", "Celltech", "Chiroscience", "Ltd.,", "which", "was", "acquired", "by", "UCB", "Pharma", "(UCB)", "in", "2004.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["CIMZIA", ",", "Agreement", "with", "UCB", "Pharma", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "covering", "our", "proprietary", "PEGylation", "materials", "for", "use", "in", "CIMZIA", "(certolizumab", "pegol)", "with", "Celltech", "Chiroscience", "Ltd.,", "which", "was", "acquired", "by", "UCB", "Pharma", "(UCB)", "in", "2004."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p145_s1", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "Pursuant to the agreement, we license our intellectual property related to our proprietary PEGylation materials for the manufacture and commercialization of Roche s MIRCERA product.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "Pursuant", "to", "the", "agreement,", "we", "license", "our", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "materials", "for", "the", "manufacture", "and", "commercialization", "of", "Roche", "s", "MIRCERA", "product.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["Pursuant", "to", "the", "agreement,", "we", "license", "our", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "materials", "for", "the", "manufacture", "and", "commercialization", "of", "Roche", "s", "MIRCERA", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s0", "idA": "906709_13_item1_p36_s0", "sentA": "The following table outlines our collaborations with a number of pharmaceutical companies that license our intellectual property and, in some cases, purchase our proprietary PEGylation materials for their drug products.", "sentB": "As of the end of 2006, we were no longer required to manufacture and supply our proprietary PEGylation materials for MIRCERA under our original agreement.", "type": 2, "words": ["<tag1>", "The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products.", "<tag2>", "As", "of", "the", "end", "of", "2006,", "we", "were", "no", "longer", "required", "to", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "for", "MIRCERA", "under", "our", "original", "agreement.", "<tag3>"], "wordsA": ["The", "following", "table", "outlines", "our", "collaborations", "with", "a", "number", "of", "pharmaceutical", "companies", "that", "license", "our", "intellectual", "property", "and,", "in", "some", "cases,", "purchase", "our", "proprietary", "PEGylation", "materials", "for", "their", "drug", "products."], "wordsB": ["As", "of", "the", "end", "of", "2006,", "we", "were", "no", "longer", "required", "to", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "for", "MIRCERA", "under", "our", "original", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s1", "idA": "906709_13_item1_p37_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "Regado is using our PEGylation technology to develop the REG1 Anticoagulation System, or REG1, which is a two-component system comprising a Factor IXa inhibitor anticoagulant (pegnivacogin, a single-stranded, nucleic acid aptamer) and its specific active control agent.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "Regado", "is", "using", "our", "PEGylation", "technology", "to", "develop", "the", "REG1", "Anticoagulation", "System,", "or", "REG1,", "which", "is", "a", "two-component", "system", "comprising", "a", "Factor", "IXa", "inhibitor", "anticoagulant", "(pegnivacogin,", "a", "single-stranded,", "nucleic", "acid", "aptamer)", "and", "its", "specific", "active", "control", "agent.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["Regado", "is", "using", "our", "PEGylation", "technology", "to", "develop", "the", "REG1", "Anticoagulation", "System,", "or", "REG1,", "which", "is", "a", "two-component", "system", "comprising", "a", "Factor", "IXa", "inhibitor", "anticoagulant", "(pegnivacogin,", "a", "single-stranded,", "nucleic", "acid", "aptamer)", "and", "its", "specific", "active", "control", "agent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p13_s0", "idA": "906709_13_item1_p37_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or E.U.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s8", "idA": "906709_13_item1_p37_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "A total of 213 patients achieved an average 40% reduction in pain and entered the randomized phase of the study.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p30_s0", "idA": "906709_13_item1_p39_s0", "sentA": "Filed an application for approval and marketing has been filed with the applicable government health authority.", "sentB": "(1) Status definitions are: Filed an application for approval and marketing has been filed with the applicable government health authority.", "type": 2, "words": ["<tag1>", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority.", "<tag2>", "(1)", "Status", "definitions", "are:", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority.", "<tag3>"], "wordsA": ["Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority."], "wordsB": ["(1)", "Status", "definitions", "are:", "Filed", "an", "application", "for", "approval", "and", "marketing", "has", "been", "filed", "with", "the", "applicable", "government", "health", "authority."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s7", "idA": "906709_13_item1_p42_s0", "sentA": "* In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012.", "sentB": "We were also entitled to receive royalties on net sales of the MIRCERA product.", "type": 2, "words": ["<tag1>", "*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012.", "<tag2>", "We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "MIRCERA", "product.", "<tag3>"], "wordsA": ["*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012."], "wordsB": ["We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "MIRCERA", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s8", "idA": "906709_13_item1_p42_s0", "sentA": "* In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012.", "sentB": "In February 2012, we sold all of our future rights to receive royalties on future worldwide net sales of MIRCERA effective as of January 1, 2012.", "type": 2, "words": ["<tag1>", "*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012.", "<tag2>", "In", "February", "2012,", "we", "sold", "all", "of", "our", "future", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012.", "<tag3>"], "wordsA": ["*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012."], "wordsB": ["In", "February", "2012,", "we", "sold", "all", "of", "our", "future", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p117_s2", "idA": "906709_13_item1_p43_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA in the U.S. until July 2014.", "sentB": "As a result of this transaction, Ophthotech assumed the license, manufacturing and supply agreement between Eyetech and us.", "type": 2, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag2>", "As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "wordsB": ["As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p39_s0", "idA": "906709_13_item1_p43_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA in the U.S. until July 2014.", "sentB": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA in the U.S. until July 2014.", "type": 2, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag2>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "wordsB": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s4", "idA": "906709_13_item1_p43_s1", "sentA": "In February 2012, we sold our rights to receive royalties on future worldwide net sales of MIRCERA effective as of January 1, 2012 until the agreement with Roche is terminated or expires.", "sentB": "In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012 until the agreement with UCB is terminated or expires.", "type": 2, "words": ["<tag1>", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "Roche", "is", "terminated", "or", "expires.", "<tag2>", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "UCB", "is", "terminated", "or", "expires.", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "Roche", "is", "terminated", "or", "expires."], "wordsB": ["In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "UCB", "is", "terminated", "or", "expires."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s1", "idA": "906709_13_item1_p43_s1", "sentA": "In February 2012, we sold our rights to receive royalties on future worldwide net sales of MIRCERA effective as of January 1, 2012 until the agreement with Roche is terminated or expires.", "sentB": "In February 2012, we entered into a toll-manufacturing agreement with Roche under which we manufactured our proprietary PEGylation material for MIRCERA .", "type": 2, "words": ["<tag1>", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "Roche", "is", "terminated", "or", "expires.", "<tag2>", "In", "February", "2012,", "we", "entered", "into", "a", "toll-manufacturing", "agreement", "with", "Roche", "under", "which", "we", "manufactured", "our", "proprietary", "PEGylation", "material", "for", "MIRCERA", ".", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "MIRCERA", "effective", "as", "of", "January", "1,", "2012", "until", "the", "agreement", "with", "Roche", "is", "terminated", "or", "expires."], "wordsB": ["In", "February", "2012,", "we", "entered", "into", "a", "toll-manufacturing", "agreement", "with", "Roche", "under", "which", "we", "manufactured", "our", "proprietary", "PEGylation", "material", "for", "MIRCERA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p126_s0", "idA": "906709_13_item1_p44_s1", "sentA": "As part of the transaction, Novartis assumed our rights and obligations for Cipro DPI (formerly known as Cipro Inhale) under our agreements with Bayer Schering Pharma AG; however, we maintained the rights to receive royalties on commercial sales of Cipro DPI if the drug candidate is approved.", "sentB": "Cipro DPI (formerly known as Cipro Inhale), Agreement with Bayer Schering Pharma AG Assigned to Novartis as of December 31, 2008 We were a party to a collaborative research, development and commercialization agreement with Bayer Schering Pharma AG, (Bayer), related to the development of an inhaled powder formulation of ciprofloxacin delivered by way of a dry powder inhaler, Cipro DPI (formerly known as Cipro Inhale) for the treatment of chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.", "type": 2, "words": ["<tag1>", "As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "under", "our", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "royalties", "on", "commercial", "sales", "of", "Cipro", "DPI", "if", "the", "drug", "candidate", "is", "approved.", "<tag2>", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale),", "Agreement", "with", "Bayer", "Schering", "Pharma", "AG", "Assigned", "to", "Novartis", "as", "of", "December", "31,", "2008", "We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG,", "(Bayer),", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "ciprofloxacin", "delivered", "by", "way", "of", "a", "dry", "powder", "inhaler,", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients.", "<tag3>"], "wordsA": ["As", "part", "of", "the", "transaction,", "Novartis", "assumed", "our", "rights", "and", "obligations", "for", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "under", "our", "agreements", "with", "Bayer", "Schering", "Pharma", "AG;", "however,", "we", "maintained", "the", "rights", "to", "receive", "royalties", "on", "commercial", "sales", "of", "Cipro", "DPI", "if", "the", "drug", "candidate", "is", "approved."], "wordsB": ["Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale),", "Agreement", "with", "Bayer", "Schering", "Pharma", "AG", "Assigned", "to", "Novartis", "as", "of", "December", "31,", "2008", "We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG,", "(Bayer),", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "ciprofloxacin", "delivered", "by", "way", "of", "a", "dry", "powder", "inhaler,", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p54_s0", "idA": "906709_13_item1_p45_s0", "sentA": "With respect to all of our collaboration and license agreements with third parties, please refer to Item 1A, Risk Factors, including without limitation, We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.", "sentB": "Please refer to Item 1A, Risk Factors, including without limitation, If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.", "type": 2, "words": ["<tag1>", "With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag2>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "we", "or", "our", "partners", "do", "not", "obtain", "regulatory", "approval", "for", "our", "drug", "candidates", "on", "a", "timely", "basis,", "or", "at", "all,", "or", "if", "the", "terms", "of", "any", "approval", "impose", "significant", "restrictions", "or", "limitations", "on", "use,", "our", "business,", "results", "of", "operations", "and", "financial", "condition", "will", "be", "negatively", "affected.", "<tag3>"], "wordsA": ["With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "wordsB": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "we", "or", "our", "partners", "do", "not", "obtain", "regulatory", "approval", "for", "our", "drug", "candidates", "on", "a", "timely", "basis,", "or", "at", "all,", "or", "if", "the", "terms", "of", "any", "approval", "impose", "significant", "restrictions", "or", "limitations", "on", "use,", "our", "business,", "results", "of", "operations", "and", "financial", "condition", "will", "be", "negatively", "affected."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p106_s0", "idA": "906709_13_item1_p46_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In June 2004, we entered into a license agreement with MAP Pharmaceuticals, Inc. (MAP), which includes a worldwide, exclusive license, to certain of our patents and other intellectual property rights to develop and commercialize a formulation of dihydroergotamine (DHE) for administration to patients via the pulmonary or nasal delivery route, which resulted in the development of LEVADEX .", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "June", "2004,", "we", "entered", "into", "a", "license", "agreement", "with", "MAP", "Pharmaceuticals,", "Inc.", "(MAP),", "which", "includes", "a", "worldwide,", "exclusive", "license,", "to", "certain", "of", "our", "patents", "and", "other", "intellectual", "property", "rights", "to", "develop", "and", "commercialize", "a", "formulation", "of", "dihydroergotamine", "(DHE)", "for", "administration", "to", "patients", "via", "the", "pulmonary", "or", "nasal", "delivery", "route,", "which", "resulted", "in", "the", "development", "of", "LEVADEX", ".", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "June", "2004,", "we", "entered", "into", "a", "license", "agreement", "with", "MAP", "Pharmaceuticals,", "Inc.", "(MAP),", "which", "includes", "a", "worldwide,", "exclusive", "license,", "to", "certain", "of", "our", "patents", "and", "other", "intellectual", "property", "rights", "to", "develop", "and", "commercialize", "a", "formulation", "of", "dihydroergotamine", "(DHE)", "for", "administration", "to", "patients", "via", "the", "pulmonary", "or", "nasal", "delivery", "route,", "which", "resulted", "in", "the", "development", "of", "LEVADEX", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p117_s0", "idA": "906709_13_item1_p46_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In September 2006, we entered into a license, manufacturing and supply agreement with (OSI) Eyetech, Inc. (Eyetech) under which we granted Eyetech a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked with the active ingredient in Fovista .", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "September", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "(OSI)", "Eyetech,", "Inc.", "(Eyetech)", "under", "which", "we", "granted", "Eyetech", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "with", "the", "active", "ingredient", "in", "Fovista", ".", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "September", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "(OSI)", "Eyetech,", "Inc.", "(Eyetech)", "under", "which", "we", "granted", "Eyetech", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "with", "the", "active", "ingredient", "in", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s0", "idA": "906709_13_item1_p46_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In December 2006, we entered into a license, manufacturing and supply agreement with Regado Biosciences, Inc. (Regado), in which we granted Regado a worldwide, exclusive license to certain of our proprietary PEGylation technology.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "December", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Regado", "Biosciences,", "Inc.", "(Regado),", "in", "which", "we", "granted", "Regado", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "December", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Regado", "Biosciences,", "Inc.", "(Regado),", "in", "which", "we", "granted", "Regado", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p131_s0", "idA": "906709_13_item1_p46_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In July 1995, we entered into a non-exclusive supply and license agreement (the 1995 Agreement) with Amgen, Inc., pursuant to which we licensed our proprietary PEGylation technology to be used in the development and manufacture of Neulasta .", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "July", "1995,", "we", "entered", "into", "a", "non-exclusive", "supply", "and", "license", "agreement", "(the", "1995", "Agreement)", "with", "Amgen,", "Inc.,", "pursuant", "to", "which", "we", "licensed", "our", "proprietary", "PEGylation", "technology", "to", "be", "used", "in", "the", "development", "and", "manufacture", "of", "Neulasta", ".", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "July", "1995,", "we", "entered", "into", "a", "non-exclusive", "supply", "and", "license", "agreement", "(the", "1995", "Agreement)", "with", "Amgen,", "Inc.,", "pursuant", "to", "which", "we", "licensed", "our", "proprietary", "PEGylation", "technology", "to", "be", "used", "in", "the", "development", "and", "manufacture", "of", "Neulasta", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p135_s0", "idA": "906709_13_item1_p46_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In February 1997, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), under which we granted Roche a worldwide, exclusive license to use certain intellectual property related to our PEGylation materials to manufacture and commercialize a certain class of products, of which PEGASYS is the only product currently commercialized.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "February", "1997,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "under", "which", "we", "granted", "Roche", "a", "worldwide,", "exclusive", "license", "to", "use", "certain", "intellectual", "property", "related", "to", "our", "PEGylation", "materials", "to", "manufacture", "and", "commercialize", "a", "certain", "class", "of", "products,", "of", "which", "PEGASYS", "is", "the", "only", "product", "currently", "commercialized.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "February", "1997,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "under", "which", "we", "granted", "Roche", "a", "worldwide,", "exclusive", "license", "to", "use", "certain", "intellectual", "property", "related", "to", "our", "PEGylation", "materials", "to", "manufacture", "and", "commercialize", "a", "certain", "class", "of", "products,", "of", "which", "PEGASYS", "is", "the", "only", "product", "currently", "commercialized."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p147_s3", "idA": "906709_13_item1_p46_s1", "sentA": "Under the terms of this agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for naloxegol and naloxegol fixed-dose combination products.", "sentB": "Under the terms of this agreement, Roche paid us an up-front payment of $5.0 million plus a total of $22.0 million in performance-based milestone payments upon our achievement of certain manufacturing readiness, validation and production milestones, including the delivery of specified quantities of PEGylation materials, all of which were successfully completed by the end of January 2013.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "Under", "the", "terms", "of", "this", "agreement,", "Roche", "paid", "us", "an", "up-front", "payment", "of", "$5.0", "million", "plus", "a", "total", "of", "$22.0", "million", "in", "performance-based", "milestone", "payments", "upon", "our", "achievement", "of", "certain", "manufacturing", "readiness,", "validation", "and", "production", "milestones,", "including", "the", "delivery", "of", "specified", "quantities", "of", "PEGylation", "materials,", "all", "of", "which", "were", "successfully", "completed", "by", "the", "end", "of", "January", "2013.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["Under", "the", "terms", "of", "this", "agreement,", "Roche", "paid", "us", "an", "up-front", "payment", "of", "$5.0", "million", "plus", "a", "total", "of", "$22.0", "million", "in", "performance-based", "milestone", "payments", "upon", "our", "achievement", "of", "certain", "manufacturing", "readiness,", "validation", "and", "production", "milestones,", "including", "the", "delivery", "of", "specified", "quantities", "of", "PEGylation", "materials,", "all", "of", "which", "were", "successfully", "completed", "by", "the", "end", "of", "January", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p55_s0", "idA": "906709_13_item1_p46_s1", "sentA": "Under the terms of this agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for naloxegol and naloxegol fixed-dose combination products.", "sentB": "Under the terms of our license agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for naloxegol and naloxegol fixed-dose combination products.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "this", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p119_s0", "idA": "906709_13_item1_p46_s2", "sentA": "For naloxegol, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "We are entitled to up to $7.5 million in total development and sales milestone payments, low- to mid- single-digit royalties on net sales that vary by sales levels and are subject to reduction in the absence of patent coverage, and additional consideration if Ophthotech grants certain third-party commercialization rights to Fovista .", "type": 2, "words": ["<tag1>", "For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$7.5", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "low-", "to", "mid-", "single-digit", "royalties", "on", "net", "sales", "that", "vary", "by", "sales", "levels", "and", "are", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage,", "and", "additional", "consideration", "if", "Ophthotech", "grants", "certain", "third-party", "commercialization", "rights", "to", "Fovista", ".", "<tag3>"], "wordsA": ["For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$7.5", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "low-", "to", "mid-", "single-digit", "royalties", "on", "net", "sales", "that", "vary", "by", "sales", "levels", "and", "are", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage,", "and", "additional", "consideration", "if", "Ophthotech", "grants", "certain", "third-party", "commercialization", "rights", "to", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s5", "idA": "906709_13_item1_p46_s2", "sentA": "For naloxegol, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "We are entitled to up to $6.5 million in total development and sales milestone payments, mid-single-digit royalties on net sales varying by sales volume and certain additional payments if Regado grants any third parties certain rights to the REG1 product.", "type": 2, "words": ["<tag1>", "For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$6.5", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "mid-single-digit", "royalties", "on", "net", "sales", "varying", "by", "sales", "volume", "and", "certain", "additional", "payments", "if", "Regado", "grants", "any", "third", "parties", "certain", "rights", "to", "the", "REG1", "product.", "<tag3>"], "wordsA": ["For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$6.5", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "mid-single-digit", "royalties", "on", "net", "sales", "varying", "by", "sales", "volume", "and", "certain", "additional", "payments", "if", "Regado", "grants", "any", "third", "parties", "certain", "rights", "to", "the", "REG1", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p55_s1", "idA": "906709_13_item1_p46_s2", "sentA": "For naloxegol, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "For naloxegol, we have received $70.0 million and $25.0 million upon the acceptance for review of naloxegol regulatory approval applications filed by AstraZeneca with the FDA and European Medicines Agency (EMA), respectively, in 2013 and are also entitled to up to an additional $175.0 million upon certain regulatory approval and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "naloxegol,", "we", "have", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "naloxegol", "regulatory", "approval", "applications", "filed", "by", "AstraZeneca", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013", "and", "are", "also", "entitled", "to", "up", "to", "an", "additional", "$175.0", "million", "upon", "certain", "regulatory", "approval", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "naloxegol,", "we", "have", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "naloxegol", "regulatory", "approval", "applications", "filed", "by", "AstraZeneca", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013", "and", "are", "also", "entitled", "to", "up", "to", "an", "additional", "$175.0", "million", "upon", "certain", "regulatory", "approval", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p79_s4", "idA": "906709_13_item1_p46_s2", "sentA": "For naloxegol, we are also entitled to up to $235.0 million upon certain filings and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "type": 2, "words": ["<tag1>", "For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag3>"], "wordsA": ["For", "naloxegol,", "we", "are", "also", "entitled", "to", "up", "to", "$235.0", "million", "upon", "certain", "filings", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p56_s3", "idA": "906709_13_item1_p46_s3", "sentA": "With respect to the $235.0 million in milestone payments due upon certain filings and commercial launch milestones for naloxegol, when filing occurs in the U.S. and in the E.U., we will be entitled to receive $95.0 million of those milestones.", "sentB": "If AstraZeneca elects to terminate the license agreement only with respect to its rights in the U.S., then such repayment amount would be funded through a 50% reduction of non-U.S. royalty amounts otherwise payable to us until the aggregate amount of such royalty reduction equals the total principal amount of $70.0 million plus accumulated interest at 4.5% compounded annually.", "type": 2, "words": ["<tag1>", "With", "respect", "to", "the", "$235.0", "million", "in", "milestone", "payments", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "naloxegol,", "when", "filing", "occurs", "in", "the", "U.S.", "and", "in", "the", "E.U.,", "we", "will", "be", "entitled", "to", "receive", "$95.0", "million", "of", "those", "milestones.", "<tag2>", "If", "AstraZeneca", "elects", "to", "terminate", "the", "license", "agreement", "only", "with", "respect", "to", "its", "rights", "in", "the", "U.S.,", "then", "such", "repayment", "amount", "would", "be", "funded", "through", "a", "50%", "reduction", "of", "non-U.S.", "royalty", "amounts", "otherwise", "payable", "to", "us", "until", "the", "aggregate", "amount", "of", "such", "royalty", "reduction", "equals", "the", "total", "principal", "amount", "of", "$70.0", "million", "plus", "accumulated", "interest", "at", "4.5%", "compounded", "annually.", "<tag3>"], "wordsA": ["With", "respect", "to", "the", "$235.0", "million", "in", "milestone", "payments", "due", "upon", "certain", "filings", "and", "commercial", "launch", "milestones", "for", "naloxegol,", "when", "filing", "occurs", "in", "the", "U.S.", "and", "in", "the", "E.U.,", "we", "will", "be", "entitled", "to", "receive", "$95.0", "million", "of", "those", "milestones."], "wordsB": ["If", "AstraZeneca", "elects", "to", "terminate", "the", "license", "agreement", "only", "with", "respect", "to", "its", "rights", "in", "the", "U.S.,", "then", "such", "repayment", "amount", "would", "be", "funded", "through", "a", "50%", "reduction", "of", "non-U.S.", "royalty", "amounts", "otherwise", "payable", "to", "us", "until", "the", "aggregate", "amount", "of", "such", "royalty", "reduction", "equals", "the", "total", "principal", "amount", "of", "$70.0", "million", "plus", "accumulated", "interest", "at", "4.5%", "compounded", "annually."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p139_s4", "idA": "906709_13_item1_p46_s5", "sentA": "For the naloxegol fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "sentB": "The amended agreement provided for a one-time payment and milestone payments as well as increased pricing for any future manufacturing performed by us.", "type": 2, "words": ["<tag1>", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "The", "amended", "agreement", "provided", "for", "a", "one-time", "payment", "and", "milestone", "payments", "as", "well", "as", "increased", "pricing", "for", "any", "future", "manufacturing", "performed", "by", "us.", "<tag3>"], "wordsA": ["For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["The", "amended", "agreement", "provided", "for", "a", "one-time", "payment", "and", "milestone", "payments", "as", "well", "as", "increased", "pricing", "for", "any", "future", "manufacturing", "performed", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p56_s5", "idA": "906709_13_item1_p46_s5", "sentA": "For the naloxegol fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "sentB": "The remaining $140.0 million of milestone payments are due upon the commercial launches of naloxegol in the U.S. and in the E.U. For the naloxegol fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "The", "remaining", "$140.0", "million", "of", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "the", "U.S.", "and", "in", "the", "E.U.", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["The", "remaining", "$140.0", "million", "of", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "the", "U.S.", "and", "in", "the", "E.U.", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p114_s0", "idA": "906709_13_item1_p46_s6", "sentA": "For both naloxegol and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments, varying by country of sale and level of annual net sales.", "sentB": "We are entitled to up to $73.0 million in total development and sales milestone payments, as well as royalties on net sales varying by product and country of sale.", "type": 2, "words": ["<tag1>", "For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$73.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale.", "<tag3>"], "wordsA": ["For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$73.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p79_s5", "idA": "906709_13_item1_p46_s6", "sentA": "For both naloxegol and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments, varying by country of sale and level of annual net sales.", "sentB": "We are also entitled to royalties based on annual worldwide net sales of Amikacin Inhale.", "type": 2, "words": ["<tag1>", "For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "We", "are", "also", "entitled", "to", "royalties", "based", "on", "annual", "worldwide", "net", "sales", "of", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["We", "are", "also", "entitled", "to", "royalties", "based", "on", "annual", "worldwide", "net", "sales", "of", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p108_s0", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "Our right to receive royalties in any particular country will expire upon the later of (i) 10 years after first commercial sale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p114_s1", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p119_s1", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "Our right to receive royalties in any particular country will expire upon the later of ten years after first commercial sale of the product or expiration of patent rights in the particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p123_s6", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "Our right to receive royalties in any particular country will expire upon the later of ten years after first commercial sale of the product or expiration of patent rights in the particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p136_s3", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "The agreement expires on the later of January 10, 2015 or the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "The", "agreement", "expires", "on", "the", "later", "of", "January", "10,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["The", "agreement", "expires", "on", "the", "later", "of", "January", "10,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p138_s2", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "The agreement expires on the later of ten years from the grant of first marketing authorization in the designated territory, which occurred in March 2003, or the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "The", "agreement", "expires", "on", "the", "later", "of", "ten", "years", "from", "the", "grant", "of", "first", "marketing", "authorization", "in", "the", "designated", "territory,", "which", "occurred", "in", "March", "2003,", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["The", "agreement", "expires", "on", "the", "later", "of", "ten", "years", "from", "the", "grant", "of", "first", "marketing", "authorization", "in", "the", "designated", "territory,", "which", "occurred", "in", "March", "2003,", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p143_s0", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "Under the terms of the agreement, we will receive royalties on net product sales in any particular country for the longer of ten years from the date of the first commercial sale of the product in that country or the duration of patent coverage.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "will", "receive", "royalties", "on", "net", "product", "sales", "in", "any", "particular", "country", "for", "the", "longer", "of", "ten", "years", "from", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "duration", "of", "patent", "coverage.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "will", "receive", "royalties", "on", "net", "product", "sales", "in", "any", "particular", "country", "for", "the", "longer", "of", "ten", "years", "from", "the", "date", "of", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "duration", "of", "patent", "coverage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p143_s2", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "The agreement expires upon the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "The", "agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["The", "agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s3", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "We were also entitled to receive royalties on net sales of the CIMZIA product for the longer of ten years from the first commercial sale of the product anywhere in the world or the expiration of patent rights in a particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "CIMZIA", "product", "for", "the", "longer", "of", "ten", "years", "from", "the", "first", "commercial", "sale", "of", "the", "product", "anywhere", "in", "the", "world", "or", "the", "expiration", "of", "patent", "rights", "in", "a", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "CIMZIA", "product", "for", "the", "longer", "of", "ten", "years", "from", "the", "first", "commercial", "sale", "of", "the", "product", "anywhere", "in", "the", "world", "or", "the", "expiration", "of", "patent", "rights", "in", "a", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s7", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "The agreement expires upon the expiration of all of UCB s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "The", "agreement", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["The", "agreement", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p80_s0", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "product in that country or the expiration of certain patent rights in that particular country, subject to certain exceptions.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "product", "in", "that", "country", "or", "the", "expiration", "of", "certain", "patent", "rights", "in", "that", "particular", "country,", "subject", "to", "certain", "exceptions.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["product", "in", "that", "country", "or", "the", "expiration", "of", "certain", "patent", "rights", "in", "that", "particular", "country,", "subject", "to", "certain", "exceptions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p80_s2", "idA": "906709_13_item1_p46_s7", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "The agreement expires in relation to a particular country upon the expiration of all royalty and payment obligations between the parties related to such country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "The", "agreement", "expires", "in", "relation", "to", "a", "particular", "country", "upon", "the", "expiration", "of", "all", "royalty", "and", "payment", "obligations", "between", "the", "parties", "related", "to", "such", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["The", "agreement", "expires", "in", "relation", "to", "a", "particular", "country", "upon", "the", "expiration", "of", "all", "royalty", "and", "payment", "obligations", "between", "the", "parties", "related", "to", "such", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p144_s2", "idA": "906709_13_item1_p47_s0", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one naloxegol fixed-dose combination product and has the right to develop multiple products which combine naloxegol with other opioids.", "sentB": "We have the right to receive manufacturing revenue on the basis of a fixed price per gram.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids.", "<tag2>", "We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "the", "basis", "of", "a", "fixed", "price", "per", "gram.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids."], "wordsB": ["We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "the", "basis", "of", "a", "fixed", "price", "per", "gram."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p80_s3", "idA": "906709_13_item1_p47_s0", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one naloxegol fixed-dose combination product and has the right to develop multiple products which combine naloxegol with other opioids.", "sentB": "Subject to termination fee payment obligations in certain circumstances, Bayer also has the right to terminate the agreement for convenience.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids.", "<tag2>", "Subject", "to", "termination", "fee", "payment", "obligations", "in", "certain", "circumstances,", "Bayer", "also", "has", "the", "right", "to", "terminate", "the", "agreement", "for", "convenience.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids."], "wordsB": ["Subject", "to", "termination", "fee", "payment", "obligations", "in", "certain", "circumstances,", "Bayer", "also", "has", "the", "right", "to", "terminate", "the", "agreement", "for", "convenience."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p104_s0", "idA": "906709_13_item1_p48_s0", "sentA": "Naloxegol is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC) which is a common side effect of prescription opioid medications.", "sentB": "NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors.", "type": 2, "words": ["<tag1>", "Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag2>", "NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors.", "<tag3>"], "wordsA": ["Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "wordsB": ["NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p118_s0", "idA": "906709_13_item1_p48_s0", "sentA": "Naloxegol is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC) which is a common side effect of prescription opioid medications.", "sentB": "Fovista is an anti-PDGF agent administered in combination with anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of neovascular age-related macular degeneration, (or wet AMD).", "type": 2, "words": ["<tag1>", "Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag2>", "Fovista", "is", "an", "anti-PDGF", "agent", "administered", "in", "combination", "with", "anti-vascular", "endothelial", "growth", "factor", "(anti-VEGF)", "therapy", "for", "the", "treatment", "of", "neovascular", "age-related", "macular", "degeneration,", "(or", "wet", "AMD).", "<tag3>"], "wordsA": ["Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "wordsB": ["Fovista", "is", "an", "anti-PDGF", "agent", "administered", "in", "combination", "with", "anti-vascular", "endothelial", "growth", "factor", "(anti-VEGF)", "therapy", "for", "the", "treatment", "of", "neovascular", "age-related", "macular", "degeneration,", "(or", "wet", "AMD)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p146_s0", "idA": "906709_13_item1_p48_s0", "sentA": "Naloxegol is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC) which is a common side effect of prescription opioid medications.", "sentB": "MIRCERA is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis.", "type": 2, "words": ["<tag1>", "Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag2>", "MIRCERA", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis.", "<tag3>"], "wordsA": ["Naloxegol", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "wordsB": ["MIRCERA", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p3_s1", "idA": "906709_13_item1_p49_s1", "sentA": "When the opioids attach to certain opioid receptors in the gastrointestinal tract, constipation may occur.", "sentB": "Naloxegol has been specifically designed as a once-daily tablet to block the binding of opioids to the opioid receptors in the gastrointestinal tract while not crossing the blood brain barrier and impacting the analgesic activity of opioids binding to opioid receptors in the brain.", "type": 2, "words": ["<tag1>", "When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur.", "<tag2>", "Naloxegol", "has", "been", "specifically", "designed", "as", "a", "once-daily", "tablet", "to", "block", "the", "binding", "of", "opioids", "to", "the", "opioid", "receptors", "in", "the", "gastrointestinal", "tract", "while", "not", "crossing", "the", "blood", "brain", "barrier", "and", "impacting", "the", "analgesic", "activity", "of", "opioids", "binding", "to", "opioid", "receptors", "in", "the", "brain.", "<tag3>"], "wordsA": ["When", "the", "opioids", "attach", "to", "certain", "opioid", "receptors", "in", "the", "gastrointestinal", "tract,", "constipation", "may", "occur."], "wordsB": ["Naloxegol", "has", "been", "specifically", "designed", "as", "a", "once-daily", "tablet", "to", "block", "the", "binding", "of", "opioids", "to", "the", "opioid", "receptors", "in", "the", "gastrointestinal", "tract", "while", "not", "crossing", "the", "blood", "brain", "barrier", "and", "impacting", "the", "analgesic", "activity", "of", "opioids", "binding", "to", "opioid", "receptors", "in", "the", "brain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p103_s0", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "NKTR-192 demonstrated low CNS side effects and achieved the target profile for the treatment of acute pain.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "NKTR-192", "demonstrated", "low", "CNS", "side", "effects", "and", "achieved", "the", "target", "profile", "for", "the", "treatment", "of", "acute", "pain.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["NKTR-192", "demonstrated", "low", "CNS", "side", "effects", "and", "achieved", "the", "target", "profile", "for", "the", "treatment", "of", "acute", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p103_s3", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "We are currently exploring an injectable formulation of NKTR-192 in preclinical development for the treatment of migraine and cancer pain.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "We", "are", "currently", "exploring", "an", "injectable", "formulation", "of", "NKTR-192", "in", "preclinical", "development", "for", "the", "treatment", "of", "migraine", "and", "cancer", "pain.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["We", "are", "currently", "exploring", "an", "injectable", "formulation", "of", "NKTR-192", "in", "preclinical", "development", "for", "the", "treatment", "of", "migraine", "and", "cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p121_s0", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "In September 2013, Ophthotech announced the initiation of patient enrollment in the first of three planned pivotal Phase 3 clinical studies of Fovista in combination with anti-VEGF therapy for the treatment of newly diagnosed patients with wet AMD.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "In", "September", "2013,", "Ophthotech", "announced", "the", "initiation", "of", "patient", "enrollment", "in", "the", "first", "of", "three", "planned", "pivotal", "Phase", "3", "clinical", "studies", "of", "Fovista", "in", "combination", "with", "anti-VEGF", "therapy", "for", "the", "treatment", "of", "newly", "diagnosed", "patients", "with", "wet", "AMD.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["In", "September", "2013,", "Ophthotech", "announced", "the", "initiation", "of", "patient", "enrollment", "in", "the", "first", "of", "three", "planned", "pivotal", "Phase", "3", "clinical", "studies", "of", "Fovista", "in", "combination", "with", "anti-VEGF", "therapy", "for", "the", "treatment", "of", "newly", "diagnosed", "patients", "with", "wet", "AMD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p125_s0", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "trial that plans to enroll 13,200 patients, described by Regado as a PROBE design (Prospective, Randomized, Open-label, Blinded-Endpoint) superiority study comparing the effects of REG1 to bivalirudin in patients undergoing PCI electively or for the treatment of unstable angina or non-ST elevated myocardial infarction.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "trial", "that", "plans", "to", "enroll", "13,200", "patients,", "described", "by", "Regado", "as", "a", "PROBE", "design", "(Prospective,", "Randomized,", "Open-label,", "Blinded-Endpoint)", "superiority", "study", "comparing", "the", "effects", "of", "REG1", "to", "bivalirudin", "in", "patients", "undergoing", "PCI", "electively", "or", "for", "the", "treatment", "of", "unstable", "angina", "or", "non-ST", "elevated", "myocardial", "infarction.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["trial", "that", "plans", "to", "enroll", "13,200", "patients,", "described", "by", "Regado", "as", "a", "PROBE", "design", "(Prospective,", "Randomized,", "Open-label,", "Blinded-Endpoint)", "superiority", "study", "comparing", "the", "effects", "of", "REG1", "to", "bivalirudin", "in", "patients", "undergoing", "PCI", "electively", "or", "for", "the", "treatment", "of", "unstable", "angina", "or", "non-ST", "elevated", "myocardial", "infarction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p127_s0", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "Cipro DPI has completed Phase 2 clinical development for the treatment of chronic lung infections.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p3_s0", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, for the treatment of opioid-induced constipation, or OIC, in patients with non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain medicines.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "in", "patients", "with", "non-cancer", "pain,", "the", "most", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "in", "patients", "with", "non-cancer", "pain,", "the", "most", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p4_s1", "idA": "906709_13_item1_p4_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, which has completed Phase 3 clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain.", "sentB": "The NDA filing was based on comprehensive data from a Phase 3 clinical development program comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "The", "NDA", "filing", "was", "based", "on", "comprehensive", "data", "from", "a", "Phase", "3", "clinical", "development", "program", "comprised", "of", "four", "clinical", "trials", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "naloxegol", "for", "the", "treatment", "of", "OIC.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "which", "has", "completed", "Phase", "3", "clinical", "studies", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["The", "NDA", "filing", "was", "based", "on", "comprehensive", "data", "from", "a", "Phase", "3", "clinical", "development", "program", "comprised", "of", "four", "clinical", "trials", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "naloxegol", "for", "the", "treatment", "of", "OIC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p103_s2", "idA": "906709_13_item1_p50_s0", "sentA": "OIC is a result of decreased fluid absorption and lower gastrointestinal motility due to opioid receptor binding in the gastrointestinal tract.", "sentB": "As a result of these data, NKTR-192 will no longer be developed as an oral formulation.", "type": 2, "words": ["<tag1>", "OIC", "is", "a", "result", "of", "decreased", "fluid", "absorption", "and", "lower", "gastrointestinal", "motility", "due", "to", "opioid", "receptor", "binding", "in", "the", "gastrointestinal", "tract.", "<tag2>", "As", "a", "result", "of", "these", "data,", "NKTR-192", "will", "no", "longer", "be", "developed", "as", "an", "oral", "formulation.", "<tag3>"], "wordsA": ["OIC", "is", "a", "result", "of", "decreased", "fluid", "absorption", "and", "lower", "gastrointestinal", "motility", "due", "to", "opioid", "receptor", "binding", "in", "the", "gastrointestinal", "tract."], "wordsB": ["As", "a", "result", "of", "these", "data,", "NKTR-192", "will", "no", "longer", "be", "developed", "as", "an", "oral", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p46_s0", "idA": "906709_13_item1_p51_s0", "sentA": "Globally, approximately 40 50% (28-35 million) patients taking opioids for long-term pain develop constipation.", "sentB": "Globally, approximately 40 50% (28-35 million) of patients taking opioids for long-term pain develop constipation.", "type": 2, "words": ["<tag1>", "Globally,", "approximately", "40", "50%", "(28-35", "million)", "patients", "taking", "opioids", "for", "long-term", "pain", "develop", "constipation.", "<tag2>", "Globally,", "approximately", "40", "50%", "(28-35", "million)", "of", "patients", "taking", "opioids", "for", "long-term", "pain", "develop", "constipation.", "<tag3>"], "wordsA": ["Globally,", "approximately", "40", "50%", "(28-35", "million)", "patients", "taking", "opioids", "for", "long-term", "pain", "develop", "constipation."], "wordsB": ["Globally,", "approximately", "40", "50%", "(28-35", "million)", "of", "patients", "taking", "opioids", "for", "long-term", "pain", "develop", "constipation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p47_s0", "idA": "906709_13_item1_p52_s0", "sentA": "AstraZeneca has completed a Phase 3 clinical program for naloxegol AstraZeneca calls the KODIAC studies.", "sentB": "AstraZeneca has completed a Phase 3 clinical development program for naloxegol, which AstraZeneca calls the KODIAC studies.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies.", "<tag2>", "AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "development", "program", "for", "naloxegol,", "which", "AstraZeneca", "calls", "the", "KODIAC", "studies.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "program", "for", "naloxegol", "AstraZeneca", "calls", "the", "KODIAC", "studies."], "wordsB": ["AstraZeneca", "has", "completed", "a", "Phase", "3", "clinical", "development", "program", "for", "naloxegol,", "which", "AstraZeneca", "calls", "the", "KODIAC", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p121_s1", "idA": "906709_13_item1_p52_s1", "sentA": "The KODIAC studies (KODIAC-04, KODIAC-05, KODIAC-07 and KODIAC-08) evaluated the efficacy and safety of naloxegol for treating OIC in patients with non-cancer pain.", "sentB": "These three studies plan to enroll a total of approximately 1,866 patients to evaluate the efficacy and safety of Fovista .", "type": 2, "words": ["<tag1>", "The", "KODIAC", "studies", "(KODIAC-04,", "KODIAC-05,", "KODIAC-07", "and", "KODIAC-08)", "evaluated", "the", "efficacy", "and", "safety", "of", "naloxegol", "for", "treating", "OIC", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", ".", "<tag3>"], "wordsA": ["The", "KODIAC", "studies", "(KODIAC-04,", "KODIAC-05,", "KODIAC-07", "and", "KODIAC-08)", "evaluated", "the", "efficacy", "and", "safety", "of", "naloxegol", "for", "treating", "OIC", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p84_s0", "idA": "906709_13_item1_p52_s1", "sentA": "The KODIAC studies (KODIAC-04, KODIAC-05, KODIAC-07 and KODIAC-08) evaluated the efficacy and safety of naloxegol for treating OIC in patients with non-cancer pain.", "sentB": "In April 2013, Bayer initiated enrollment in a global Phase 3 clinical study, which it calls INHALE, to evaluate the efficacy and safety of Amikacin Inhale versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.", "type": 2, "words": ["<tag1>", "The", "KODIAC", "studies", "(KODIAC-04,", "KODIAC-05,", "KODIAC-07", "and", "KODIAC-08)", "evaluated", "the", "efficacy", "and", "safety", "of", "naloxegol", "for", "treating", "OIC", "in", "patients", "with", "non-cancer", "pain.", "<tag2>", "In", "April", "2013,", "Bayer", "initiated", "enrollment", "in", "a", "global", "Phase", "3", "clinical", "study,", "which", "it", "calls", "INHALE,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Amikacin", "Inhale", "versus", "aerosolized", "placebo", "in", "the", "treatment", "of", "intubated", "and", "mechanically", "ventilated", "patients", "with", "Gram-negative", "pneumonia", "receiving", "standard", "of", "care", "intravenous", "antibiotics.", "<tag3>"], "wordsA": ["The", "KODIAC", "studies", "(KODIAC-04,", "KODIAC-05,", "KODIAC-07", "and", "KODIAC-08)", "evaluated", "the", "efficacy", "and", "safety", "of", "naloxegol", "for", "treating", "OIC", "in", "patients", "with", "non-cancer", "pain."], "wordsB": ["In", "April", "2013,", "Bayer", "initiated", "enrollment", "in", "a", "global", "Phase", "3", "clinical", "study,", "which", "it", "calls", "INHALE,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Amikacin", "Inhale", "versus", "aerosolized", "placebo", "in", "the", "treatment", "of", "intubated", "and", "mechanically", "ventilated", "patients", "with", "Gram-negative", "pneumonia", "receiving", "standard", "of", "care", "intravenous", "antibiotics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p52_s1", "idA": "906709_13_item1_p53_s6", "sentA": "The most common adverse events (AEs) in the naloxegol treatment arms in both trials were abdominal pain, diarrhea and nausea.", "sentB": "The PDUFA date for the naloxegol NDA in the US is September 16, 2014.", "type": 2, "words": ["<tag1>", "The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea.", "<tag2>", "The", "PDUFA", "date", "for", "the", "naloxegol", "NDA", "in", "the", "US", "is", "September", "16,", "2014.", "<tag3>"], "wordsA": ["The", "most", "common", "adverse", "events", "(AEs)", "in", "the", "naloxegol", "treatment", "arms", "in", "both", "trials", "were", "abdominal", "pain,", "diarrhea", "and", "nausea."], "wordsB": ["The", "PDUFA", "date", "for", "the", "naloxegol", "NDA", "in", "the", "US", "is", "September", "16,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p70_s0", "idA": "906709_13_item1_p54_s0", "sentA": "KODIAC-08 was an open-label, randomized, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and OIC.", "sentB": "The first phase was an open-label, randomized, study evaluating two treatment schedules of single-agent etirinotecan pegol (145 mg/m2 every 14 days or every 21 days).", "type": 2, "words": ["<tag1>", "KODIAC-08", "was", "an", "open-label,", "randomized,", "52-week,", "long-term", "safety", "trial", "of", "naloxegol", "versus", "usual", "care", "(UC)", "in", "patients", "with", "non-cancer", "related", "pain", "and", "OIC.", "<tag2>", "The", "first", "phase", "was", "an", "open-label,", "randomized,", "study", "evaluating", "two", "treatment", "schedules", "of", "single-agent", "etirinotecan", "pegol", "(145", "mg/m2", "every", "14", "days", "or", "every", "21", "days).", "<tag3>"], "wordsA": ["KODIAC-08", "was", "an", "open-label,", "randomized,", "52-week,", "long-term", "safety", "trial", "of", "naloxegol", "versus", "usual", "care", "(UC)", "in", "patients", "with", "non-cancer", "related", "pain", "and", "OIC."], "wordsB": ["The", "first", "phase", "was", "an", "open-label,", "randomized,", "study", "evaluating", "two", "treatment", "schedules", "of", "single-agent", "etirinotecan", "pegol", "(145", "mg/m2", "every", "14", "days", "or", "every", "21", "days)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p60_s0", "idA": "906709_13_item1_p54_s1", "sentA": "This trial was designed to evaluate the long-term safety and adverse event profile of naloxegol in patients taking 25 mg of naloxegol once daily, as compared to UC.", "sentB": "In preclinical models, etirinotecan pegol achieved a 300-fold increase in tumor concentration as compared to irinotecan.", "type": 2, "words": ["<tag1>", "This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC.", "<tag2>", "In", "preclinical", "models,", "etirinotecan", "pegol", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan.", "<tag3>"], "wordsA": ["This", "trial", "was", "designed", "to", "evaluate", "the", "long-term", "safety", "and", "adverse", "event", "profile", "of", "naloxegol", "in", "patients", "taking", "25", "mg", "of", "naloxegol", "once", "daily,", "as", "compared", "to", "UC."], "wordsB": ["In", "preclinical", "models,", "etirinotecan", "pegol", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s6", "idA": "906709_13_item1_p54_s3", "sentA": "UC was defined as the investigator s choice of an existing laxative treatment regimen for OIC.", "sentB": "The chemotherapy agent 5-FU is currently used as a part of a combination treatment regimen for colorectal cancer in combination with irinotecan, which is also known as the FOLFIRI regimen.", "type": 2, "words": ["<tag1>", "UC", "was", "defined", "as", "the", "investigator", "s", "choice", "of", "an", "existing", "laxative", "treatment", "regimen", "for", "OIC.", "<tag2>", "The", "chemotherapy", "agent", "5-FU", "is", "currently", "used", "as", "a", "part", "of", "a", "combination", "treatment", "regimen", "for", "colorectal", "cancer", "in", "combination", "with", "irinotecan,", "which", "is", "also", "known", "as", "the", "FOLFIRI", "regimen.", "<tag3>"], "wordsA": ["UC", "was", "defined", "as", "the", "investigator", "s", "choice", "of", "an", "existing", "laxative", "treatment", "regimen", "for", "OIC."], "wordsB": ["The", "chemotherapy", "agent", "5-FU", "is", "currently", "used", "as", "a", "part", "of", "a", "combination", "treatment", "regimen", "for", "colorectal", "cancer", "in", "combination", "with", "irinotecan,", "which", "is", "also", "known", "as", "the", "FOLFIRI", "regimen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s5", "idA": "906709_13_item1_p55_s0", "sentA": "On February 26, 2013, AstraZeneca announced positive top-line results from KODIAC-08.", "sentB": "On September 26, 2013, we announced results from this Phase 2 efficacy study.", "type": 2, "words": ["<tag1>", "On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "KODIAC-08.", "<tag2>", "On", "September", "26,", "2013,", "we", "announced", "results", "from", "this", "Phase", "2", "efficacy", "study.", "<tag3>"], "wordsA": ["On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "KODIAC-08."], "wordsB": ["On", "September", "26,", "2013,", "we", "announced", "results", "from", "this", "Phase", "2", "efficacy", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p110_s1", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for LEVADEX in the second quarter of 2014.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p52_s0", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "AstraZeneca submitted an NDA filing in the U.S. on September 25, 2013 and a Marketing Authorization Application (MAA) filing in the E.U. in August 2013.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "AstraZeneca", "submitted", "an", "NDA", "filing", "in", "the", "U.S.", "on", "September", "25,", "2013", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "August", "2013.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["AstraZeneca", "submitted", "an", "NDA", "filing", "in", "the", "U.S.", "on", "September", "25,", "2013", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "August", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p56_s4", "idA": "906709_13_item1_p56_s0", "sentA": "AstraZeneca has stated that it plans to submit an NDA filing in the U.S. and a Marketing Authorization Application (MAA) filing in the E.U. in the third quarter of 2013, pending AstraZeneca s final preparation of the registration package and a pre-NDA meeting with the FDA.", "sentB": "If the FDA requires a post-approval cardiovascular safety study as a condition to approval of the naloxegol NDA, then the royalty rate payable to us from net sales of naloxegol in the U.S. by AstraZeneca would be reduced by two percentage points until the aggregate accumulated amount of such royalty payment reduction is equal to a maximum of $35.0 million.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA.", "<tag2>", "If", "the", "FDA", "requires", "a", "post-approval", "cardiovascular", "safety", "study", "as", "a", "condition", "to", "approval", "of", "the", "naloxegol", "NDA,", "then", "the", "royalty", "rate", "payable", "to", "us", "from", "net", "sales", "of", "naloxegol", "in", "the", "U.S.", "by", "AstraZeneca", "would", "be", "reduced", "by", "two", "percentage", "points", "until", "the", "aggregate", "accumulated", "amount", "of", "such", "royalty", "payment", "reduction", "is", "equal", "to", "a", "maximum", "of", "$35.0", "million.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "stated", "that", "it", "plans", "to", "submit", "an", "NDA", "filing", "in", "the", "U.S.", "and", "a", "Marketing", "Authorization", "Application", "(MAA)", "filing", "in", "the", "E.U.", "in", "the", "third", "quarter", "of", "2013,", "pending", "AstraZeneca", "s", "final", "preparation", "of", "the", "registration", "package", "and", "a", "pre-NDA", "meeting", "with", "the", "FDA."], "wordsB": ["If", "the", "FDA", "requires", "a", "post-approval", "cardiovascular", "safety", "study", "as", "a", "condition", "to", "approval", "of", "the", "naloxegol", "NDA,", "then", "the", "royalty", "rate", "payable", "to", "us", "from", "net", "sales", "of", "naloxegol", "in", "the", "U.S.", "by", "AstraZeneca", "would", "be", "reduced", "by", "two", "percentage", "points", "until", "the", "aggregate", "accumulated", "amount", "of", "such", "royalty", "payment", "reduction", "is", "equal", "to", "a", "maximum", "of", "$35.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p67_s0", "idA": "906709_13_item1_p57_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "In 2014, the American Cancer Society estimates there will be 235,030 new cases of breast cancer in the United States.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p76_s0", "idA": "906709_13_item1_p57_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in the U.S.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p76_s1", "idA": "906709_13_item1_p57_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "According to the American Cancer Society, nearly 137,000 new cases of colon and rectal cancer will be diagnosed in the U.S. in 2014, and about 51,000 people will die annually of the disease.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "According", "to", "the", "American", "Cancer", "Society,", "nearly", "137,000", "new", "cases", "of", "colon", "and", "rectal", "cancer", "will", "be", "diagnosed", "in", "the", "U.S.", "in", "2014,", "and", "about", "51,000", "people", "will", "die", "annually", "of", "the", "disease.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["According", "to", "the", "American", "Cancer", "Society,", "nearly", "137,000", "new", "cases", "of", "colon", "and", "rectal", "cancer", "will", "be", "diagnosed", "in", "the", "U.S.", "in", "2014,", "and", "about", "51,000", "people", "will", "die", "annually", "of", "the", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p96_s0", "idA": "906709_13_item1_p57_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "According to a 2011 report from the National Academy of Sciences, chronic pain conditions, such as osteoarthritis, back pain and cancer pain, affect at least 100 million adults in the U.S. annually and contribute to over $300 billion a year in lost productivity.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "According", "to", "a", "2011", "report", "from", "the", "National", "Academy", "of", "Sciences,", "chronic", "pain", "conditions,", "such", "as", "osteoarthritis,", "back", "pain", "and", "cancer", "pain,", "affect", "at", "least", "100", "million", "adults", "in", "the", "U.S.", "annually", "and", "contribute", "to", "over", "$300", "billion", "a", "year", "in", "lost", "productivity.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["According", "to", "a", "2011", "report", "from", "the", "National", "Academy", "of", "Sciences,", "chronic", "pain", "conditions,", "such", "as", "osteoarthritis,", "back", "pain", "and", "cancer", "pain,", "affect", "at", "least", "100", "million", "adults", "in", "the", "U.S.", "annually", "and", "contribute", "to", "over", "$300", "billion", "a", "year", "in", "lost", "productivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p112_s0", "idA": "906709_13_item1_p5_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "sentB": "In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation (Baxter) to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "Baxter", "Healthcare", "SA", "and", "Baxter", "Healthcare", "Corporation", "(Baxter)", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "Baxter", "Healthcare", "SA", "and", "Baxter", "Healthcare", "Corporation", "(Baxter)", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p138_s0", "idA": "906709_13_item1_p5_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "sentB": "In January 2000, we entered into a license, manufacturing and supply agreement with Sensus Drug Development Corporation (subsequently acquired by Pharmacia Corp. in 2001 and then acquired by Pfizer, Inc. in 2003), for the PEGylation of Somavert (pegvisomant), a human growth hormone receptor antagonist for the treatment of acromegaly.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "January", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Sensus", "Drug", "Development", "Corporation", "(subsequently", "acquired", "by", "Pharmacia", "Corp.", "in", "2001", "and", "then", "acquired", "by", "Pfizer,", "Inc.", "in", "2003),", "for", "the", "PEGylation", "of", "Somavert", "(pegvisomant),", "a", "human", "growth", "hormone", "receptor", "antagonist", "for", "the", "treatment", "of", "acromegaly.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "January", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Sensus", "Drug", "Development", "Corporation", "(subsequently", "acquired", "by", "Pharmacia", "Corp.", "in", "2001", "and", "then", "acquired", "by", "Pfizer,", "Inc.", "in", "2003),", "for", "the", "PEGylation", "of", "Somavert", "(pegvisomant),", "a", "human", "growth", "hormone", "receptor", "antagonist", "for", "the", "treatment", "of", "acromegaly."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p139_s0", "idA": "906709_13_item1_p5_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "sentB": "In February 2000, we entered into a manufacturing and supply agreement with Schering-Plough Corporation (Schering) for the manufacture and supply of our proprietary PEGylation materials to be used by Schering in production of a PEGylated recombinant human interferon-alpha (PEG-Intron).", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "February", "2000,", "we", "entered", "into", "a", "manufacturing", "and", "supply", "agreement", "with", "Schering-Plough", "Corporation", "(Schering)", "for", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "to", "be", "used", "by", "Schering", "in", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron).", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "February", "2000,", "we", "entered", "into", "a", "manufacturing", "and", "supply", "agreement", "with", "Schering-Plough", "Corporation", "(Schering)", "for", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "to", "be", "used", "by", "Schering", "in", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p141_s0", "idA": "906709_13_item1_p5_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) for the global development and commercialization of naloxegol and naloxegol fixed-dose combination products.", "sentB": "In 2002, we entered into a license, manufacturing and supply agreement with Eyetech, Inc. (subsequently acquired by Valeant Pharmaceuticals International, Inc. or Valeant), pursuant to which we license certain intellectual property related to our proprietary PEGylation technology for the development and commercialization of Macugen , a PEGylated anti-vascular endothelial growth factor aptamer currently approved in the U.S. and E.U. for age-related macular degeneration.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "2002,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Eyetech,", "Inc.", "(subsequently", "acquired", "by", "Valeant", "Pharmaceuticals", "International,", "Inc.", "or", "Valeant),", "pursuant", "to", "which", "we", "license", "certain", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "technology", "for", "the", "development", "and", "commercialization", "of", "Macugen", ",", "a", "PEGylated", "anti-vascular", "endothelial", "growth", "factor", "aptamer", "currently", "approved", "in", "the", "U.S.", "and", "E.U.", "for", "age-related", "macular", "degeneration.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "for", "the", "global", "development", "and", "commercialization", "of", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "2002,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Eyetech,", "Inc.", "(subsequently", "acquired", "by", "Valeant", "Pharmaceuticals", "International,", "Inc.", "or", "Valeant),", "pursuant", "to", "which", "we", "license", "certain", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "technology", "for", "the", "development", "and", "commercialization", "of", "Macugen", ",", "a", "PEGylated", "anti-vascular", "endothelial", "growth", "factor", "aptamer", "currently", "approved", "in", "the", "U.S.", "and", "E.U.", "for", "age-related", "macular", "degeneration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s10", "idA": "906709_13_item1_p5_s1", "sentA": "On November 12, 2012, AstraZeneca announced positive top-line results for naloxegol from two Phase 3 clinical studies and one safety extension study.", "sentB": "On November 13, 2013, Baxter announced that it had completed enrollment of 146 patients in the PROLONG-ATE clinical study.", "type": 2, "words": ["<tag1>", "On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study.", "<tag2>", "On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study.", "<tag3>"], "wordsA": ["On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study."], "wordsB": ["On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p124_s0", "idA": "906709_13_item1_p5_s1", "sentA": "On November 12, 2012, AstraZeneca announced positive top-line results for naloxegol from two Phase 3 clinical studies and one safety extension study.", "sentB": "Regado has announced the completion of three Phase 1 and one Phase 2 clinical studies for REG1.", "type": 2, "words": ["<tag1>", "On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study.", "<tag2>", "Regado", "has", "announced", "the", "completion", "of", "three", "Phase", "1", "and", "one", "Phase", "2", "clinical", "studies", "for", "REG1.", "<tag3>"], "wordsA": ["On", "November", "12,", "2012,", "AstraZeneca", "announced", "positive", "top-line", "results", "for", "naloxegol", "from", "two", "Phase", "3", "clinical", "studies", "and", "one", "safety", "extension", "study."], "wordsB": ["Regado", "has", "announced", "the", "completion", "of", "three", "Phase", "1", "and", "one", "Phase", "2", "clinical", "studies", "for", "REG1."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p12_s2", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale that commenced in April 2013.", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale", "that", "commenced", "in", "April", "2013.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale", "that", "commenced", "in", "April", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p58_s0", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "We are developing etirinotecan pegol (also known as NKTR-102), a next generation topoisomerase I (topo I) inhibitor which was designed using our PEGylation technology.", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "We", "are", "developing", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["We", "are", "developing", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p62_s0", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "Etirinotecan pegol is currently being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p66_s1", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "The chance of developing invasive breast cancer at some time in a woman s life is a little less than one in eight (12%).", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(12%).", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(12%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p69_s0", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "to", "treat", "breast", "cancer.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "to", "treat", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p71_s3", "idA": "906709_13_item1_p7_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for patients with metastatic breast cancer.", "sentB": "The EMA also indicated that a positive interim over-all survival analysis in a Phase 3 clinical study could potentially support a conditional approval of etirinotecan pegol for ovarian cancer.", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "The", "EMA", "also", "indicated", "that", "a", "positive", "interim", "over-all", "survival", "analysis", "in", "a", "Phase", "3", "clinical", "study", "could", "potentially", "support", "a", "conditional", "approval", "of", "etirinotecan", "pegol", "for", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["The", "EMA", "also", "indicated", "that", "a", "positive", "interim", "over-all", "survival", "analysis", "in", "a", "Phase", "3", "clinical", "study", "could", "potentially", "support", "a", "conditional", "approval", "of", "etirinotecan", "pegol", "for", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p5_s1", "idA": "906709_13_item1_p7_s1", "sentA": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), was initiated by us in December 2011.", "sentB": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), was initiated by us in December 2011 and enrollment completed in July 2013.", "type": 2, "words": ["<tag1>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "by", "us", "in", "December", "2011.", "<tag2>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "by", "us", "in", "December", "2011", "and", "enrollment", "completed", "in", "July", "2013.", "<tag3>"], "wordsA": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "by", "us", "in", "December", "2011."], "wordsB": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "was", "initiated", "by", "us", "in", "December", "2011", "and", "enrollment", "completed", "in", "July", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p5_s2", "idA": "906709_13_item1_p7_s2", "sentA": "The BEACON study is designed to enroll approximately 840 women with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "The BEACON study enrolled approximately 850 women with locally recurrent or metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "The", "BEACON", "study", "enrolled", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["The", "BEACON", "study", "enrolled", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p62_s2", "idA": "906709_13_item1_p7_s2", "sentA": "The BEACON study is designed to enroll approximately 840 women with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "The BEACON study enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "The", "BEACON", "study", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["The", "BEACON", "study", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p63_s1", "idA": "906709_13_item1_p7_s2", "sentA": "The BEACON study is designed to enroll approximately 840 women with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "Randomization was stratified by geographic region, prior treatment with eribulin and whether or not the patient has triple negative breast cancer.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "Randomization", "was", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "has", "triple", "negative", "breast", "cancer.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "is", "designed", "to", "enroll", "approximately", "840", "women", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["Randomization", "was", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "has", "triple", "negative", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p5_s3", "idA": "906709_13_item1_p7_s3", "sentA": "Patients in the BEACON study are randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "Patients in the BEACON study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p62_s3", "idA": "906709_13_item1_p7_s3", "sentA": "Patients in the BEACON study are randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "We completed enrollment in the BEACON study in late July 2013.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p63_s0", "idA": "906709_13_item1_p7_s3", "sentA": "Patients in the BEACON study are randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "The physician s choice single agents include the following: ixabepilone, vinorelbine, gemcitabine, eribulin, or a taxane.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "The", "physician", "s", "choice", "single", "agents", "include", "the", "following:", "ixabepilone,", "vinorelbine,", "gemcitabine,", "eribulin,", "or", "a", "taxane.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["The", "physician", "s", "choice", "single", "agents", "include", "the", "following:", "ixabepilone,", "vinorelbine,", "gemcitabine,", "eribulin,", "or", "a", "taxane."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s2", "idA": "906709_13_item1_p7_s3", "sentA": "Patients in the BEACON study are randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "Patients that achieved this level of analgesia were then randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive placebo for up to 25 days.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "up", "to", "25", "days.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "are", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "up", "to", "25", "days."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p125_s1", "idA": "906709_13_item1_p7_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "The primary endpoint of the REGULATE-PCI trial is efficacy compared to bivalrudin based on a composite set of endpoints including death, nonfatal myocardial infarction, nonfatal stroke, and urgent target lesion revascularization through day three.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "REGULATE-PCI", "trial", "is", "efficacy", "compared", "to", "bivalrudin", "based", "on", "a", "composite", "set", "of", "endpoints", "including", "death,", "nonfatal", "myocardial", "infarction,", "nonfatal", "stroke,", "and", "urgent", "target", "lesion", "revascularization", "through", "day", "three.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "REGULATE-PCI", "trial", "is", "efficacy", "compared", "to", "bivalrudin", "based", "on", "a", "composite", "set", "of", "endpoints", "including", "death,", "nonfatal", "myocardial", "infarction,", "nonfatal", "stroke,", "and", "urgent", "target", "lesion", "revascularization", "through", "day", "three."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p5_s5", "idA": "906709_13_item1_p7_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "On January 14, 2014, we announced that the Independent Data Monitoring Committee, or the DMC, created to provide safety oversight for the BEACON study recommended continuation of the Phase 3 BEACON study following an interim data analysis which was performed after reaching 50% of the events needed to achieve the primary endpoint of overall survival.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "On", "January", "14,", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee,", "or", "the", "DMC,", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "Phase", "3", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["On", "January", "14,", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee,", "or", "the", "DMC,", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "Phase", "3", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p63_s4", "idA": "906709_13_item1_p7_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "Exploratory objectives of the study include collecting specific biomarker data to correlate with objective tumor response rate, progression-free survival, overall survival and selected toxicities.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "Exploratory", "objectives", "of", "the", "study", "include", "collecting", "specific", "biomarker", "data", "to", "correlate", "with", "objective", "tumor", "response", "rate,", "progression-free", "survival,", "overall", "survival", "and", "selected", "toxicities.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["Exploratory", "objectives", "of", "the", "study", "include", "collecting", "specific", "biomarker", "data", "to", "correlate", "with", "objective", "tumor", "response", "rate,", "progression-free", "survival,", "overall", "survival", "and", "selected", "toxicities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p65_s0", "idA": "906709_13_item1_p7_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "On January 14, 2014, we announced that the Independent Data Monitoring Committee, or the DMC, created to provide safety oversight for the BEACON study recommended continuation of the Phase 3 BEACON study following an interim data analysis which was performed after reaching 50% of the events needed to achieve the primary endpoint of overall survival.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "On", "January", "14,", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee,", "or", "the", "DMC,", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "Phase", "3", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["On", "January", "14,", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee,", "or", "the", "DMC,", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "Phase", "3", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s3", "idA": "906709_13_item1_p7_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "The primary endpoint of the study was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p64_s0", "idA": "906709_13_item1_p8_s0", "sentA": "In November 2012, the U.S. Food and Drug Administration (FDA) designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "sentB": "In November 2012, the FDA designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "type": 2, "words": ["<tag1>", "In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag2>", "In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag3>"], "wordsA": ["In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "wordsB": ["In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p6_s0", "idA": "906709_13_item1_p8_s0", "sentA": "In November 2012, the U.S. Food and Drug Administration (FDA) designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "sentB": "In November 2012, the FDA designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "type": 2, "words": ["<tag1>", "In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag2>", "In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag3>"], "wordsA": ["In", "November", "2012,", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "wordsB": ["In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p69_s1", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "Etirinotecan pegol has also completed a Phase 2 clinical study in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "Etirinotecan", "pegol", "has", "also", "completed", "a", "Phase", "2", "clinical", "study", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["Etirinotecan", "pegol", "has", "also", "completed", "a", "Phase", "2", "clinical", "study", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p69_s2", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "The Phase 2 clinical study included two phases.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "The", "Phase", "2", "clinical", "study", "included", "two", "phases.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["The", "Phase", "2", "clinical", "study", "included", "two", "phases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p71_s0", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "The second phase was an expansion of patients in the every 21 day dosing schedule in women with platinum-resistant/refractory ovarian cancer who had previously received Doxil therapy.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "The", "second", "phase", "was", "an", "expansion", "of", "patients", "in", "the", "every", "21", "day", "dosing", "schedule", "in", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer", "who", "had", "previously", "received", "Doxil", "therapy.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["The", "second", "phase", "was", "an", "expansion", "of", "patients", "in", "the", "every", "21", "day", "dosing", "schedule", "in", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer", "who", "had", "previously", "received", "Doxil", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p71_s2", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "In December 2013, we also received scientific advice and protocol assistance from the EMA indicating that a Phase 3 clinical study would be required to support a marketing application for etirinotecan pegol in ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "In", "December", "2013,", "we", "also", "received", "scientific", "advice", "and", "protocol", "assistance", "from", "the", "EMA", "indicating", "that", "a", "Phase", "3", "clinical", "study", "would", "be", "required", "to", "support", "a", "marketing", "application", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["In", "December", "2013,", "we", "also", "received", "scientific", "advice", "and", "protocol", "assistance", "from", "the", "EMA", "indicating", "that", "a", "Phase", "3", "clinical", "study", "would", "be", "required", "to", "support", "a", "marketing", "application", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p73_s0", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "Historically, less than 40% of women with ovarian cancer are cured.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "Historically,", "less", "than", "40%", "of", "women", "with", "ovarian", "cancer", "are", "cured.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["Historically,", "less", "than", "40%", "of", "women", "with", "ovarian", "cancer", "are", "cured."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p73_s1", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "According to the World Health Organization, about 230,000 women globally are diagnosed each year with ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "According", "to", "the", "World", "Health", "Organization,", "about", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["According", "to", "the", "World", "Health", "Organization,", "about", "230,000", "women", "globally", "are", "diagnosed", "each", "year", "with", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p90_s1", "idA": "906709_13_item1_p8_s1", "sentA": "In the fourth quarter of 2012, we completed a Phase 2 clinical study of single-agent etirinotecan pegol in approximately 170 women with platinum-resistant/refractory ovarian cancer.", "sentB": "The Phase 2 clinical study utilized a double-blind, placebo-controlled, randomized withdrawal, enriched enrollment study design.", "type": 2, "words": ["<tag1>", "In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "The", "Phase", "2", "clinical", "study", "utilized", "a", "double-blind,", "placebo-controlled,", "randomized", "withdrawal,", "enriched", "enrollment", "study", "design.", "<tag3>"], "wordsA": ["In", "the", "fourth", "quarter", "of", "2012,", "we", "completed", "a", "Phase", "2", "clinical", "study", "of", "single-agent", "etirinotecan", "pegol", "in", "approximately", "170", "women", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["The", "Phase", "2", "clinical", "study", "utilized", "a", "double-blind,", "placebo-controlled,", "randomized", "withdrawal,", "enriched", "enrollment", "study", "design."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p4_s2", "idA": "906709_13_item1_p8_s2", "sentA": "Results from this study and communication with government health authorities in both the United States (U.S.) and European Union (E.U.) will guide our future development and regulatory strategy for etirinotecan pegol in ovarian cancer.", "sentB": "AstraZeneca has also filed marketing applications for naloxegol with health authorities in the European Union (E.U.) and Canada.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer.", "<tag2>", "AstraZeneca", "has", "also", "filed", "marketing", "applications", "for", "naloxegol", "with", "health", "authorities", "in", "the", "European", "Union", "(E.U.)", "and", "Canada.", "<tag3>"], "wordsA": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer."], "wordsB": ["AstraZeneca", "has", "also", "filed", "marketing", "applications", "for", "naloxegol", "with", "health", "authorities", "in", "the", "European", "Union", "(E.U.)", "and", "Canada."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p71_s4", "idA": "906709_13_item1_p8_s2", "sentA": "Results from this study and communication with government health authorities in both the United States (U.S.) and European Union (E.U.) will guide our future development and regulatory strategy for etirinotecan pegol in ovarian cancer.", "sentB": "We do not plan to make a decision on future development for etirinotecan pegol in ovarian cancer until we review the top-line data from the BEACON study.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer.", "<tag2>", "We", "do", "not", "plan", "to", "make", "a", "decision", "on", "future", "development", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer", "until", "we", "review", "the", "top-line", "data", "from", "the", "BEACON", "study.", "<tag3>"], "wordsA": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer."], "wordsB": ["We", "do", "not", "plan", "to", "make", "a", "decision", "on", "future", "development", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer", "until", "we", "review", "the", "top-line", "data", "from", "the", "BEACON", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p72_s1", "idA": "906709_13_item1_p8_s2", "sentA": "Results from this study and communication with government health authorities in both the United States (U.S.) and European Union (E.U.) will guide our future development and regulatory strategy for etirinotecan pegol in ovarian cancer.", "sentB": "According to the American Cancer Society, in 2014, there will be an estimated 21,980 new cases of ovarian cancer diagnosed and an estimated 14,270 deaths from ovarian cancer in the United States.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer.", "<tag2>", "According", "to", "the", "American", "Cancer", "Society,", "in", "2014,", "there", "will", "be", "an", "estimated", "21,980", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "14,270", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States.", "<tag3>"], "wordsA": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer."], "wordsB": ["According", "to", "the", "American", "Cancer", "Society,", "in", "2014,", "there", "will", "be", "an", "estimated", "21,980", "new", "cases", "of", "ovarian", "cancer", "diagnosed", "and", "an", "estimated", "14,270", "deaths", "from", "ovarian", "cancer", "in", "the", "United", "States."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s4", "idA": "906709_13_item1_p8_s2", "sentA": "Results from this study and communication with government health authorities in both the United States (U.S.) and European Union (E.U.) will guide our future development and regulatory strategy for etirinotecan pegol in ovarian cancer.", "sentB": "Following the conclusion of the study and completion of data verification and audit procedures, we currently plan to publish the results from this study at a scientific meeting.", "type": 2, "words": ["<tag1>", "Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer.", "<tag2>", "Following", "the", "conclusion", "of", "the", "study", "and", "completion", "of", "data", "verification", "and", "audit", "procedures,", "we", "currently", "plan", "to", "publish", "the", "results", "from", "this", "study", "at", "a", "scientific", "meeting.", "<tag3>"], "wordsA": ["Results", "from", "this", "study", "and", "communication", "with", "government", "health", "authorities", "in", "both", "the", "United", "States", "(U.S.)", "and", "European", "Union", "(E.U.)", "will", "guide", "our", "future", "development", "and", "regulatory", "strategy", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer."], "wordsB": ["Following", "the", "conclusion", "of", "the", "study", "and", "completion", "of", "data", "verification", "and", "audit", "procedures,", "we", "currently", "plan", "to", "publish", "the", "results", "from", "this", "study", "at", "a", "scientific", "meeting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p74_s0", "idA": "906709_13_item1_p8_s3", "sentA": "A Phase 1 study to evaluate etirinotecan pegol in combination with 5-Fluorouracil/leucovorin in refractory solid tumor cancers has also been completed, and a Phase 2 clinical trial evaluating etirinotecan pegol as a single agent in patients with metastatic colorectal cancer is enrolling patients.", "sentB": "An etirinotecan pegol Phase 2 clinical study was initiated in June 2008 to evaluate the efficacy and safety of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "type": 2, "words": ["<tag1>", "A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients.", "<tag2>", "An", "etirinotecan", "pegol", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag3>"], "wordsA": ["A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients."], "wordsB": ["An", "etirinotecan", "pegol", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s5", "idA": "906709_13_item1_p8_s3", "sentA": "A Phase 1 study to evaluate etirinotecan pegol in combination with 5-Fluorouracil/leucovorin in refractory solid tumor cancers has also been completed, and a Phase 2 clinical trial evaluating etirinotecan pegol as a single agent in patients with metastatic colorectal cancer is enrolling patients.", "sentB": "We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate etirinotecan pegol in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.", "type": 2, "words": ["<tag1>", "A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients.", "<tag2>", "We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers.", "<tag3>"], "wordsA": ["A", "Phase", "1", "study", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil/leucovorin", "in", "refractory", "solid", "tumor", "cancers", "has", "also", "been", "completed,", "and", "a", "Phase", "2", "clinical", "trial", "evaluating", "etirinotecan", "pegol", "as", "a", "single", "agent", "in", "patients", "with", "metastatic", "colorectal", "cancer", "is", "enrolling", "patients."], "wordsB": ["We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p120_s0", "idA": "906709_13_item1_p9_s0", "sentA": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "In June 2012, Ophthotech announced completion of a prospective, randomized, controlled Phase 2b clinical study of 449 patients with wet AMD comparing Fovista , administered in combination with Lucentis (ranibizumab injection) anti-VEGF therapy with Lucentis monotherapy.", "type": 2, "words": ["<tag1>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "In", "June", "2012,", "Ophthotech", "announced", "completion", "of", "a", "prospective,", "randomized,", "controlled", "Phase", "2b", "clinical", "study", "of", "449", "patients", "with", "wet", "AMD", "comparing", "Fovista", ",", "administered", "in", "combination", "with", "Lucentis", "(ranibizumab", "injection)", "anti-VEGF", "therapy", "with", "Lucentis", "monotherapy.", "<tag3>"], "wordsA": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["In", "June", "2012,", "Ophthotech", "announced", "completion", "of", "a", "prospective,", "randomized,", "controlled", "Phase", "2b", "clinical", "study", "of", "449", "patients", "with", "wet", "AMD", "comparing", "Fovista", ",", "administered", "in", "combination", "with", "Lucentis", "(ranibizumab", "injection)", "anti-VEGF", "therapy", "with", "Lucentis", "monotherapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s8", "idA": "906709_13_item1_p9_s0", "sentA": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "Results from this Phase 1 clinical study include establishing a dose of 75 mg/m2 of etirinotecan pegol in combination with a standard dose of 5-FU/leucovorin and demonstrating clinical activity of etirinotecan pegol in combination with a standard dose of 5-FU/leucovorin clinical activity.", "type": 2, "words": ["<tag1>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "Results", "from", "this", "Phase", "1", "clinical", "study", "include", "establishing", "a", "dose", "of", "75", "mg/m2", "of", "etirinotecan", "pegol", "in", "combination", "with", "a", "standard", "dose", "of", "5-FU/leucovorin", "and", "demonstrating", "clinical", "activity", "of", "etirinotecan", "pegol", "in", "combination", "with", "a", "standard", "dose", "of", "5-FU/leucovorin", "clinical", "activity.", "<tag3>"], "wordsA": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["Results", "from", "this", "Phase", "1", "clinical", "study", "include", "establishing", "a", "dose", "of", "75", "mg/m2", "of", "etirinotecan", "pegol", "in", "combination", "with", "a", "standard", "dose", "of", "5-FU/leucovorin", "and", "demonstrating", "clinical", "activity", "of", "etirinotecan", "pegol", "in", "combination", "with", "a", "standard", "dose", "of", "5-FU/leucovorin", "clinical", "activity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p77_s1", "idA": "906709_13_item1_p9_s0", "sentA": "investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "On August 7, 2012, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "type": 2, "words": ["<tag1>", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag3>"], "wordsA": ["investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p11_s3", "idA": "906709_13_item1_p9_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "In January 2014, we announced that we observed elevated liver enzymes in some patients at the highest dose in a Phase 1 clinical study for NKTR-192.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "In", "January", "2014,", "we", "announced", "that", "we", "observed", "elevated", "liver", "enzymes", "in", "some", "patients", "at", "the", "highest", "dose", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-192.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["In", "January", "2014,", "we", "announced", "that", "we", "observed", "elevated", "liver", "enzymes", "in", "some", "patients", "at", "the", "highest", "dose", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-192."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p6_s1", "idA": "906709_13_item1_p9_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "We have also studied or provided support for ongoing studies being conducted for etirinotecan pegol in bevacizumab (Avastin)-resistant high-grade glioma, colorectal cancer, metastatic and recurrent non-small cell lung cancer, and ovarian cancer.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "We", "have", "also", "studied", "or", "provided", "support", "for", "ongoing", "studies", "being", "conducted", "for", "etirinotecan", "pegol", "in", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "colorectal", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "ovarian", "cancer.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["We", "have", "also", "studied", "or", "provided", "support", "for", "ongoing", "studies", "being", "conducted", "for", "etirinotecan", "pegol", "in", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "colorectal", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p77_s0", "idA": "906709_13_item1_p9_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "In addition to the clinical studies being conducted by us, there are also three investigator-initiated Phase 2 studies being conducted for etirinotecan pegol.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "In", "addition", "to", "the", "clinical", "studies", "being", "conducted", "by", "us,", "there", "are", "also", "three", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["In", "addition", "to", "the", "clinical", "studies", "being", "conducted", "by", "us,", "there", "are", "also", "three", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p78_s1", "idA": "906709_13_item1_p9_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "On October 24, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p7_s0", "idA": "906709_13_item1_p9_s2", "sentA": "Our third-most-advanced proprietary drug candidate, NKTR-181, is currently being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "Our third most advanced proprietary drug candidate, NKTR-181, is a novel mu-opioid analgesic drug candidate for chronic pain conditions.", "type": 2, "words": ["<tag1>", "Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "Our", "third", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions.", "<tag3>"], "wordsA": ["Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["Our", "third", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p90_s0", "idA": "906709_13_item1_p9_s2", "sentA": "Our third-most-advanced proprietary drug candidate, NKTR-181, is currently being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "type": 2, "words": ["<tag1>", "Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag3>"], "wordsA": ["Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p91_s0", "idA": "906709_13_item1_p9_s2", "sentA": "Our third-most-advanced proprietary drug candidate, NKTR-181, is currently being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "enrolled 213 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication.", "type": 2, "words": ["<tag1>", "Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag3>"], "wordsA": ["Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p9_s2", "idA": "906709_13_item1_p9_s2", "sentA": "Our third-most-advanced proprietary drug candidate, NKTR-181, is currently being evaluated in a Phase 2 clinical study in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "On September 26, 2013, we announced preliminary topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "type": 2, "words": ["<tag1>", "Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "On", "September", "26,", "2013,", "we", "announced", "preliminary", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag3>"], "wordsA": ["Our", "third-most-advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "currently", "being", "evaluated", "in", "a", "Phase", "2", "clinical", "study", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["On", "September", "26,", "2013,", "we", "announced", "preliminary", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_14_item1_p75_s1", "idA": "906709_13_item1_p9_s3", "sentA": "Enrollment in this study is ongoing with a design to enroll approximately 200 patients in a randomized controlled study to receive either NKTR-181 or placebo.", "sentB": "However, due to the low number of patients enrolled in this study, we do not expect the results from this study to be statistically significant.", "type": 2, "words": ["<tag1>", "Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag2>", "However,", "due", "to", "the", "low", "number", "of", "patients", "enrolled", "in", "this", "study,", "we", "do", "not", "expect", "the", "results", "from", "this", "study", "to", "be", "statistically", "significant.", "<tag3>"], "wordsA": ["Enrollment", "in", "this", "study", "is", "ongoing", "with", "a", "design", "to", "enroll", "approximately", "200", "patients", "in", "a", "randomized", "controlled", "study", "to", "receive", "either", "NKTR-181", "or", "placebo."], "wordsB": ["However,", "due", "to", "the", "low", "number", "of", "patients", "enrolled", "in", "this", "study,", "we", "do", "not", "expect", "the", "results", "from", "this", "study", "to", "be", "statistically", "significant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p0_s0", "idA": "906709_14_item1_p0_s0", "sentA": "development of new molecular entities that target known mechanisms of action.", "sentB": "new molecular entities that target known mechanisms of action.", "type": 2, "words": ["<tag1>", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag2>", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag3>"], "wordsA": ["development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "wordsB": ["new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p101_s0", "idA": "906709_14_item1_p100_s2", "sentA": "Existing therapies that block sodium channels have been shown to provide effective pain relief but are typically associated with significant unwanted CNS side effects, including dizziness, ataxia and somnolence.", "sentB": "According to Halozyme, certain cancers, including pancreatic, breast, colon and prostate, have been shown to accumulate high levels of hyaluronan (HA).", "type": 2, "words": ["<tag1>", "Existing", "therapies", "that", "block", "sodium", "channels", "have", "been", "shown", "to", "provide", "effective", "pain", "relief", "but", "are", "typically", "associated", "with", "significant", "unwanted", "CNS", "side", "effects,", "including", "dizziness,", "ataxia", "and", "somnolence.", "<tag2>", "According", "to", "Halozyme,", "certain", "cancers,", "including", "pancreatic,", "breast,", "colon", "and", "prostate,", "have", "been", "shown", "to", "accumulate", "high", "levels", "of", "hyaluronan", "(HA).", "<tag3>"], "wordsA": ["Existing", "therapies", "that", "block", "sodium", "channels", "have", "been", "shown", "to", "provide", "effective", "pain", "relief", "but", "are", "typically", "associated", "with", "significant", "unwanted", "CNS", "side", "effects,", "including", "dizziness,", "ataxia", "and", "somnolence."], "wordsB": ["According", "to", "Halozyme,", "certain", "cancers,", "including", "pancreatic,", "breast,", "colon", "and", "prostate,", "have", "been", "shown", "to", "accumulate", "high", "levels", "of", "hyaluronan", "(HA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p81_s4", "idA": "906709_14_item1_p100_s4", "sentA": "In January 2014, a single-ascending dose Phase 1 clinical study of NKTR-171 was initiated to assess its pharmacokinetics, tolerability, and safety in up to 75 healthy subjects.", "sentB": "In January 2014, a single-ascending dose Phase 1 clinical study of NKTR-171 was completed.", "type": 2, "words": ["<tag1>", "In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects.", "<tag2>", "In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "completed.", "<tag3>"], "wordsA": ["In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects."], "wordsB": ["In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "completed."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p81_s6", "idA": "906709_14_item1_p100_s4", "sentA": "In January 2014, a single-ascending dose Phase 1 clinical study of NKTR-171 was initiated to assess its pharmacokinetics, tolerability, and safety in up to 75 healthy subjects.", "sentB": "In January 2015, a multiple-ascending dose Phase 1 clinical study was initiated to assess its pharmacokinetics, tolerability, and safety of NKTR-171.", "type": 2, "words": ["<tag1>", "In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects.", "<tag2>", "In", "January", "2015,", "a", "multiple-ascending", "dose", "Phase", "1", "clinical", "study", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "of", "NKTR-171.", "<tag3>"], "wordsA": ["In", "January", "2014,", "a", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects."], "wordsB": ["In", "January", "2015,", "a", "multiple-ascending", "dose", "Phase", "1", "clinical", "study", "was", "initiated", "to", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "of", "NKTR-171."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p25_s1", "idA": "906709_14_item1_p103_s3", "sentA": "We are currently exploring an injectable formulation of NKTR-192 in preclinical development for the treatment of migraine and cancer pain.", "sentB": "We are currently using this platform with oncolytics, which typically have sub-optimal half-lives that can limit their therapeutic efficacy.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "exploring", "an", "injectable", "formulation", "of", "NKTR-192", "in", "preclinical", "development", "for", "the", "treatment", "of", "migraine", "and", "cancer", "pain.", "<tag2>", "We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy.", "<tag3>"], "wordsA": ["We", "are", "currently", "exploring", "an", "injectable", "formulation", "of", "NKTR-192", "in", "preclinical", "development", "for", "the", "treatment", "of", "migraine", "and", "cancer", "pain."], "wordsB": ["We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s10", "idA": "906709_14_item1_p104_s0", "sentA": "NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors.", "sentB": "This year we plan to advance NKTR-214, an engineered immune-stimulatory cytokine being developed for the treatment of solid tumors, into a Phase 1 clinical study.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors.", "<tag2>", "This", "year", "we", "plan", "to", "advance", "NKTR-214,", "an", "engineered", "immune-stimulatory", "cytokine", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors,", "into", "a", "Phase", "1", "clinical", "study.", "<tag3>"], "wordsA": ["NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors."], "wordsB": ["This", "year", "we", "plan", "to", "advance", "NKTR-214,", "an", "engineered", "immune-stimulatory", "cytokine", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors,", "into", "a", "Phase", "1", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p128_s0", "idA": "906709_14_item1_p104_s0", "sentA": "NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors.", "sentB": "The compound was discovered by Affymax and is being co-developed and marketed by Affymax and Takeda Pharmaceutical Company Limited (Takeda).", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors.", "<tag2>", "The", "compound", "was", "discovered", "by", "Affymax", "and", "is", "being", "co-developed", "and", "marketed", "by", "Affymax", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda).", "<tag3>"], "wordsA": ["NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors."], "wordsB": ["The", "compound", "was", "discovered", "by", "Affymax", "and", "is", "being", "co-developed", "and", "marketed", "by", "Affymax", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s11", "idA": "906709_14_item1_p104_s1", "sentA": "NKTR-214 is engineered to selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T cells that dampen the immune response to tumors.", "sentB": "NKTR-214 is engineered to selectively activate interlerleukin-2 (IL-2) receptors present on the surface of cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors present on the regulatory T cells that would otherwise dampen the immune response to tumors.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors.", "<tag2>", "NKTR-214", "is", "engineered", "to", "selectively", "activate", "interlerleukin-2", "(IL-2)", "receptors", "present", "on", "the", "surface", "of", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "present", "on", "the", "regulatory", "T", "cells", "that", "would", "otherwise", "dampen", "the", "immune", "response", "to", "tumors.", "<tag3>"], "wordsA": ["NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors."], "wordsB": ["NKTR-214", "is", "engineered", "to", "selectively", "activate", "interlerleukin-2", "(IL-2)", "receptors", "present", "on", "the", "surface", "of", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "present", "on", "the", "regulatory", "T", "cells", "that", "would", "otherwise", "dampen", "the", "immune", "response", "to", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p82_s1", "idA": "906709_14_item1_p104_s1", "sentA": "NKTR-214 is engineered to selectively activate IL-2 receptors on cytotoxic T cells that kill tumor cells, with relatively low affinity for IL-2 receptors on regulatory T cells that dampen the immune response to tumors.", "sentB": "NKTR-214 is engineered to selectively activate IL-2 receptors on the surface of cytotoxic T cells that kill tumor cells while imparting substantially reduced affinity for IL-2 receptors present on the regulatory T cells that would otherwise dampen the immune response to tumors.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors.", "<tag2>", "NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "the", "surface", "of", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells", "while", "imparting", "substantially", "reduced", "affinity", "for", "IL-2", "receptors", "present", "on", "the", "regulatory", "T", "cells", "that", "would", "otherwise", "dampen", "the", "immune", "response", "to", "tumors.", "<tag3>"], "wordsA": ["NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells,", "with", "relatively", "low", "affinity", "for", "IL-2", "receptors", "on", "regulatory", "T", "cells", "that", "dampen", "the", "immune", "response", "to", "tumors."], "wordsB": ["NKTR-214", "is", "engineered", "to", "selectively", "activate", "IL-2", "receptors", "on", "the", "surface", "of", "cytotoxic", "T", "cells", "that", "kill", "tumor", "cells", "while", "imparting", "substantially", "reduced", "affinity", "for", "IL-2", "receptors", "present", "on", "the", "regulatory", "T", "cells", "that", "would", "otherwise", "dampen", "the", "immune", "response", "to", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p82_s3", "idA": "906709_14_item1_p104_s3", "sentA": "The product candidate is currently in Investigational New Drug application (IND)-enabling studies in preparation for clinical studies in cancer patients.", "sentB": "The product candidate is currently in Investigational New Drug application (IND)-enabling studies and we plan to start a Phase 1 clinical study in the second half of 2015.", "type": 2, "words": ["<tag1>", "The", "product", "candidate", "is", "currently", "in", "Investigational", "New", "Drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "cancer", "patients.", "<tag2>", "The", "product", "candidate", "is", "currently", "in", "Investigational", "New", "Drug", "application", "(IND)-enabling", "studies", "and", "we", "plan", "to", "start", "a", "Phase", "1", "clinical", "study", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["The", "product", "candidate", "is", "currently", "in", "Investigational", "New", "Drug", "application", "(IND)-enabling", "studies", "in", "preparation", "for", "clinical", "studies", "in", "cancer", "patients."], "wordsB": ["The", "product", "candidate", "is", "currently", "in", "Investigational", "New", "Drug", "application", "(IND)-enabling", "studies", "and", "we", "plan", "to", "start", "a", "Phase", "1", "clinical", "study", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p106_s0", "idA": "906709_14_item1_p106_s0", "sentA": "In June 2004, we entered into a license agreement with MAP Pharmaceuticals, Inc. (MAP), which includes a worldwide, exclusive license, to certain of our patents and other intellectual property rights to develop and commercialize a formulation of dihydroergotamine (DHE) for administration to patients via the pulmonary or nasal delivery route, which resulted in the development of LEVADEX .", "sentB": "In June 2004, we entered into a license agreement with MAP Pharmaceuticals, Inc. (MAP), which includes a worldwide, exclusive license, to certain of our patents and other intellectual property rights to develop and commercialize a formulation of dihydroergotamine (DHE) for administration to patients via the pulmonary or nasal delivery route, which resulted in the development of SEMPRANA , formerly known as LEVADEX .", "type": 2, "words": ["<tag1>", "In", "June", "2004,", "we", "entered", "into", "a", "license", "agreement", "with", "MAP", "Pharmaceuticals,", "Inc.", "(MAP),", "which", "includes", "a", "worldwide,", "exclusive", "license,", "to", "certain", "of", "our", "patents", "and", "other", "intellectual", "property", "rights", "to", "develop", "and", "commercialize", "a", "formulation", "of", "dihydroergotamine", "(DHE)", "for", "administration", "to", "patients", "via", "the", "pulmonary", "or", "nasal", "delivery", "route,", "which", "resulted", "in", "the", "development", "of", "LEVADEX", ".", "<tag2>", "In", "June", "2004,", "we", "entered", "into", "a", "license", "agreement", "with", "MAP", "Pharmaceuticals,", "Inc.", "(MAP),", "which", "includes", "a", "worldwide,", "exclusive", "license,", "to", "certain", "of", "our", "patents", "and", "other", "intellectual", "property", "rights", "to", "develop", "and", "commercialize", "a", "formulation", "of", "dihydroergotamine", "(DHE)", "for", "administration", "to", "patients", "via", "the", "pulmonary", "or", "nasal", "delivery", "route,", "which", "resulted", "in", "the", "development", "of", "SEMPRANA", ",", "formerly", "known", "as", "LEVADEX", ".", "<tag3>"], "wordsA": ["In", "June", "2004,", "we", "entered", "into", "a", "license", "agreement", "with", "MAP", "Pharmaceuticals,", "Inc.", "(MAP),", "which", "includes", "a", "worldwide,", "exclusive", "license,", "to", "certain", "of", "our", "patents", "and", "other", "intellectual", "property", "rights", "to", "develop", "and", "commercialize", "a", "formulation", "of", "dihydroergotamine", "(DHE)", "for", "administration", "to", "patients", "via", "the", "pulmonary", "or", "nasal", "delivery", "route,", "which", "resulted", "in", "the", "development", "of", "LEVADEX", "."], "wordsB": ["In", "June", "2004,", "we", "entered", "into", "a", "license", "agreement", "with", "MAP", "Pharmaceuticals,", "Inc.", "(MAP),", "which", "includes", "a", "worldwide,", "exclusive", "license,", "to", "certain", "of", "our", "patents", "and", "other", "intellectual", "property", "rights", "to", "develop", "and", "commercialize", "a", "formulation", "of", "dihydroergotamine", "(DHE)", "for", "administration", "to", "patients", "via", "the", "pulmonary", "or", "nasal", "delivery", "route,", "which", "resulted", "in", "the", "development", "of", "SEMPRANA", ",", "formerly", "known", "as", "LEVADEX", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p106_s2", "idA": "906709_14_item1_p106_s2", "sentA": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of LEVADEX .", "sentB": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of SEMPRANA .", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", ".", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", "."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p153_s1", "idA": "906709_14_item1_p106_s2", "sentA": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of LEVADEX .", "sentB": "In certain cases, we have the option to license certain of Enzon s PEGylation patents for use in our proprietary products or for sublicenses to third parties in each case in exchange for payments to Enzon based on manufacturing profits, revenue share or royalties on net sales if a designated product candidate is approved in one or more markets.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", ".", "<tag2>", "In", "certain", "cases,", "we", "have", "the", "option", "to", "license", "certain", "of", "Enzon", "s", "PEGylation", "patents", "for", "use", "in", "our", "proprietary", "products", "or", "for", "sublicenses", "to", "third", "parties", "in", "each", "case", "in", "exchange", "for", "payments", "to", "Enzon", "based", "on", "manufacturing", "profits,", "revenue", "share", "or", "royalties", "on", "net", "sales", "if", "a", "designated", "product", "candidate", "is", "approved", "in", "one", "or", "more", "markets.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "LEVADEX", "."], "wordsB": ["In", "certain", "cases,", "we", "have", "the", "option", "to", "license", "certain", "of", "Enzon", "s", "PEGylation", "patents", "for", "use", "in", "our", "proprietary", "products", "or", "for", "sublicenses", "to", "third", "parties", "in", "each", "case", "in", "exchange", "for", "payments", "to", "Enzon", "based", "on", "manufacturing", "profits,", "revenue", "share", "or", "royalties", "on", "net", "sales", "if", "a", "designated", "product", "candidate", "is", "approved", "in", "one", "or", "more", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s0", "idA": "906709_14_item1_p107_s0", "sentA": "LEVADEX is a self-administered formulation of DHE using an inhaler device.", "sentB": "SEMPRANA is a self-administered formulation of DHE using an inhaler device that is currently under review by the FDA.", "type": 2, "words": ["<tag1>", "LEVADEX", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device.", "<tag2>", "SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA.", "<tag3>"], "wordsA": ["LEVADEX", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device."], "wordsB": ["SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p106_s3", "idA": "906709_14_item1_p108_s0", "sentA": "Our right to receive royalties in any particular country will expire upon the later of (i) 10 years after first commercial sale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "sentB": "Our right to receive royalties for the net sales of SEMPRANA under the license agreement in any particular country will expire upon the later of (i) 10 years after first commercial sale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag2>", "Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "wordsB": ["Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s1", "idA": "906709_14_item1_p109_s0", "sentA": "On May 26, 2011, MAP submitted an NDA to the FDA for LEVADEX .", "sentB": "On May 26, 2011, MAP submitted an NDA to the FDA for SEMPRANA .", "type": 2, "words": ["<tag1>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", ".", "<tag2>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "SEMPRANA", ".", "<tag3>"], "wordsA": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", "."], "wordsB": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "SEMPRANA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p134_s0", "idA": "906709_14_item1_p109_s0", "sentA": "On May 26, 2011, MAP submitted an NDA to the FDA for LEVADEX .", "sentB": "submission to the FDA of an NDA for approval of a drug, a Biological License Application (BLA) for approval of a biological product or a Premarket Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)).", "type": 2, "words": ["<tag1>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", ".", "<tag2>", "submission", "to", "the", "FDA", "of", "an", "NDA", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k)).", "<tag3>"], "wordsA": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", "."], "wordsB": ["submission", "to", "the", "FDA", "of", "an", "NDA", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k))."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s3", "idA": "906709_14_item1_p109_s0", "sentA": "On May 26, 2011, MAP submitted an NDA to the FDA for LEVADEX .", "sentB": "Each protocol is submitted to the FDA in the IND.", "type": 2, "words": ["<tag1>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", ".", "<tag2>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag3>"], "wordsA": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", "."], "wordsB": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p141_s3", "idA": "906709_14_item1_p109_s0", "sentA": "On May 26, 2011, MAP submitted an NDA to the FDA for LEVADEX .", "sentB": "Manufacturing establishments of U.S. marketed products are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements.", "type": 2, "words": ["<tag1>", "On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", ".", "<tag2>", "Manufacturing", "establishments", "of", "U.S.", "marketed", "products", "are", "subject", "to", "inspections", "by", "the", "FDA", "for", "compliance", "with", "cGMP", "and", "other", "U.S.", "regulatory", "requirements.", "<tag3>"], "wordsA": ["On", "May", "26,", "2011,", "MAP", "submitted", "an", "NDA", "to", "the", "FDA", "for", "LEVADEX", "."], "wordsB": ["Manufacturing", "establishments", "of", "U.S.", "marketed", "products", "are", "subject", "to", "inspections", "by", "the", "FDA", "for", "compliance", "with", "cGMP", "and", "other", "U.S.", "regulatory", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s2", "idA": "906709_14_item1_p109_s1", "sentA": "In March of 2012, the FDA issued a complete response letter identifying issues relating to chemistry, manufacturing and controls deficiencies at a third party manufacturer that needed to be resolved to the FDA s satisfaction as well as citing the need for additional time to complete review of inhaler usability information.", "sentB": "In March of 2012, the FDA issued a complete response letter to MAP identifying issues relating to chemistry, manufacturing and controls deficiencies of the product at a contracted third party manufacturer.", "type": 2, "words": ["<tag1>", "In", "March", "of", "2012,", "the", "FDA", "issued", "a", "complete", "response", "letter", "identifying", "issues", "relating", "to", "chemistry,", "manufacturing", "and", "controls", "deficiencies", "at", "a", "third", "party", "manufacturer", "that", "needed", "to", "be", "resolved", "to", "the", "FDA", "s", "satisfaction", "as", "well", "as", "citing", "the", "need", "for", "additional", "time", "to", "complete", "review", "of", "inhaler", "usability", "information.", "<tag2>", "In", "March", "of", "2012,", "the", "FDA", "issued", "a", "complete", "response", "letter", "to", "MAP", "identifying", "issues", "relating", "to", "chemistry,", "manufacturing", "and", "controls", "deficiencies", "of", "the", "product", "at", "a", "contracted", "third", "party", "manufacturer.", "<tag3>"], "wordsA": ["In", "March", "of", "2012,", "the", "FDA", "issued", "a", "complete", "response", "letter", "identifying", "issues", "relating", "to", "chemistry,", "manufacturing", "and", "controls", "deficiencies", "at", "a", "third", "party", "manufacturer", "that", "needed", "to", "be", "resolved", "to", "the", "FDA", "s", "satisfaction", "as", "well", "as", "citing", "the", "need", "for", "additional", "time", "to", "complete", "review", "of", "inhaler", "usability", "information."], "wordsB": ["In", "March", "of", "2012,", "the", "FDA", "issued", "a", "complete", "response", "letter", "to", "MAP", "identifying", "issues", "relating", "to", "chemistry,", "manufacturing", "and", "controls", "deficiencies", "of", "the", "product", "at", "a", "contracted", "third", "party", "manufacturer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p12_s1", "idA": "906709_14_item1_p109_s2", "sentA": "In December 2012, MAP announced that its NDA resubmission for LEVADEX was accepted for filing by the FDA.", "sentB": "In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA.", "<tag2>", "In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855.", "<tag3>"], "wordsA": ["In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA."], "wordsB": ["In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p134_s5", "idA": "906709_14_item1_p109_s2", "sentA": "In December 2012, MAP announced that its NDA resubmission for LEVADEX was accepted for filing by the FDA.", "sentB": "Clinical trials may begin 30 days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA.", "<tag2>", "Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "clarification", "within", "that", "period.", "<tag3>"], "wordsA": ["In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA."], "wordsB": ["Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "clarification", "within", "that", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p90_s3", "idA": "906709_14_item1_p109_s2", "sentA": "In December 2012, MAP announced that its NDA resubmission for LEVADEX was accepted for filing by the FDA.", "sentB": "In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855.", "type": 2, "words": ["<tag1>", "In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA.", "<tag2>", "In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855.", "<tag3>"], "wordsA": ["In", "December", "2012,", "MAP", "announced", "that", "its", "NDA", "resubmission", "for", "LEVADEX", "was", "accepted", "for", "filing", "by", "the", "FDA."], "wordsB": ["In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s0", "idA": "906709_14_item1_p10_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 clinical study design.", "sentB": "In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of certain considerations for the Phase 3 clinical study program.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design.", "<tag2>", "In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "certain", "considerations", "for", "the", "Phase", "3", "clinical", "study", "program.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design."], "wordsB": ["In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "certain", "considerations", "for", "the", "Phase", "3", "clinical", "study", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s7", "idA": "906709_14_item1_p10_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 clinical study design.", "sentB": "We plan to have further interactions with the FDA to finalize the study design for the other clinical studies planned for the Phase 3 program.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design.", "<tag2>", "We", "plan", "to", "have", "further", "interactions", "with", "the", "FDA", "to", "finalize", "the", "study", "design", "for", "the", "other", "clinical", "studies", "planned", "for", "the", "Phase", "3", "program.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design."], "wordsB": ["We", "plan", "to", "have", "further", "interactions", "with", "the", "FDA", "to", "finalize", "the", "study", "design", "for", "the", "other", "clinical", "studies", "planned", "for", "the", "Phase", "3", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s19", "idA": "906709_14_item1_p10_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 clinical study design.", "sentB": "We plan to have further interactions with the FDA to finalize the study design for the other clinical studies planned for the Phase 3 program.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design.", "<tag2>", "We", "plan", "to", "have", "further", "interactions", "with", "the", "FDA", "to", "finalize", "the", "study", "design", "for", "the", "other", "clinical", "studies", "planned", "for", "the", "Phase", "3", "program.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "clinical", "study", "design."], "wordsB": ["We", "plan", "to", "have", "further", "interactions", "with", "the", "FDA", "to", "finalize", "the", "study", "design", "for", "the", "other", "clinical", "studies", "planned", "for", "the", "Phase", "3", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s13", "idA": "906709_14_item1_p10_s1", "sentA": "We are currently evaluating the appropriate Phase 3 clinical study design for NKTR-181 and expect to start a Phase 3 clinical study in mid-2014, following the completion of an end-of-Phase 2 meeting with the FDA planned to occur in the first half of 2014.", "sentB": "In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of the design of the Phase 3 clinical study program.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "study", "design", "for", "NKTR-181", "and", "expect", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014.", "<tag2>", "In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "study", "design", "for", "NKTR-181", "and", "expect", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014."], "wordsB": ["In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s8", "idA": "906709_14_item1_p10_s2", "sentA": "We also have additional proprietary preclinical and clinical drug candidates being developed for pain relief.", "sentB": "We also have additional proprietary preclinical and clinical drug candidates in research and development.", "type": 2, "words": ["<tag1>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief.", "<tag2>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "in", "research", "and", "development.", "<tag3>"], "wordsA": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "being", "developed", "for", "pain", "relief."], "wordsB": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "in", "research", "and", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s9", "idA": "906709_14_item1_p10_s3", "sentA": "On January 14, 2014, we announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.", "sentB": "We have an ongoing Phase 1 clinical development program for NKTR-171, a new sodium channel blocker being developed as a potential oral therapy for the treatment of peripheral neuropathic pain.", "type": 2, "words": ["<tag1>", "On", "January", "14,", "2014,", "we", "announced", "that", "the", "first", "subjects", "were", "dosed", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-171,", "a", "new", "sodium", "channel", "blocker", "being", "developed", "as", "an", "oral", "therapy", "for", "the", "treatment", "of", "peripheral", "neuropathic", "pain.", "<tag2>", "We", "have", "an", "ongoing", "Phase", "1", "clinical", "development", "program", "for", "NKTR-171,", "a", "new", "sodium", "channel", "blocker", "being", "developed", "as", "a", "potential", "oral", "therapy", "for", "the", "treatment", "of", "peripheral", "neuropathic", "pain.", "<tag3>"], "wordsA": ["On", "January", "14,", "2014,", "we", "announced", "that", "the", "first", "subjects", "were", "dosed", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-171,", "a", "new", "sodium", "channel", "blocker", "being", "developed", "as", "an", "oral", "therapy", "for", "the", "treatment", "of", "peripheral", "neuropathic", "pain."], "wordsB": ["We", "have", "an", "ongoing", "Phase", "1", "clinical", "development", "program", "for", "NKTR-171,", "a", "new", "sodium", "channel", "blocker", "being", "developed", "as", "a", "potential", "oral", "therapy", "for", "the", "treatment", "of", "peripheral", "neuropathic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p81_s5", "idA": "906709_14_item1_p10_s4", "sentA": "This single-ascending dose Phase 1 clinical study of NKTR-171 will assess its pharmacokinetics, tolerability, and safety in up to 75 healthy subjects.", "sentB": "This study assessed the pharmacokinetics, tolerability, and safety of NKTR-171 in healthy subjects.", "type": 2, "words": ["<tag1>", "This", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "will", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects.", "<tag2>", "This", "study", "assessed", "the", "pharmacokinetics,", "tolerability,", "and", "safety", "of", "NKTR-171", "in", "healthy", "subjects.", "<tag3>"], "wordsA": ["This", "single-ascending", "dose", "Phase", "1", "clinical", "study", "of", "NKTR-171", "will", "assess", "its", "pharmacokinetics,", "tolerability,", "and", "safety", "in", "up", "to", "75", "healthy", "subjects."], "wordsB": ["This", "study", "assessed", "the", "pharmacokinetics,", "tolerability,", "and", "safety", "of", "NKTR-171", "in", "healthy", "subjects."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s3", "idA": "906709_14_item1_p110_s0", "sentA": "On April 17, 2013, the FDA issued another complete response letter identifying issues related to a supplier that provided the canister filling unit for LEVADEX .", "sentB": "On April 17, 2013, the FDA issued a second complete response letter identifying issues related to a supplier that provided the canister filling unit for SEMPRANA .", "type": 2, "words": ["<tag1>", "On", "April", "17,", "2013,", "the", "FDA", "issued", "another", "complete", "response", "letter", "identifying", "issues", "related", "to", "a", "supplier", "that", "provided", "the", "canister", "filling", "unit", "for", "LEVADEX", ".", "<tag2>", "On", "April", "17,", "2013,", "the", "FDA", "issued", "a", "second", "complete", "response", "letter", "identifying", "issues", "related", "to", "a", "supplier", "that", "provided", "the", "canister", "filling", "unit", "for", "SEMPRANA", ".", "<tag3>"], "wordsA": ["On", "April", "17,", "2013,", "the", "FDA", "issued", "another", "complete", "response", "letter", "identifying", "issues", "related", "to", "a", "supplier", "that", "provided", "the", "canister", "filling", "unit", "for", "LEVADEX", "."], "wordsB": ["On", "April", "17,", "2013,", "the", "FDA", "issued", "a", "second", "complete", "response", "letter", "identifying", "issues", "related", "to", "a", "supplier", "that", "provided", "the", "canister", "filling", "unit", "for", "SEMPRANA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s4", "idA": "906709_14_item1_p110_s1", "sentA": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for LEVADEX in the second quarter of 2014.", "sentB": "In June 2014, Allergan announced that it had received a third complete response letter from the FDA related to specifications around content uniformity on the improved canister filling process and on standards for device actuation.", "type": 2, "words": ["<tag1>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014.", "<tag2>", "In", "June", "2014,", "Allergan", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation.", "<tag3>"], "wordsA": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014."], "wordsB": ["In", "June", "2014,", "Allergan", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s5", "idA": "906709_14_item1_p110_s1", "sentA": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for LEVADEX in the second quarter of 2014.", "sentB": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for SEMPRANA in the second half of 2015.", "type": 2, "words": ["<tag1>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014.", "<tag2>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "SEMPRANA", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014."], "wordsB": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "SEMPRANA", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p51_s0", "idA": "906709_14_item1_p110_s1", "sentA": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for LEVADEX in the second quarter of 2014.", "sentB": "On January 23, 2015, the DEA published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled Substances Act.", "type": 2, "words": ["<tag1>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014.", "<tag2>", "On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act.", "<tag3>"], "wordsA": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "LEVADEX", "in", "the", "second", "quarter", "of", "2014."], "wordsB": ["On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p25_s7", "idA": "906709_14_item1_p112_s1", "sentA": "The first product in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "sentB": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, for which Baxter filed a biologic license application with the United States Food and Drug Administration on December 1, 2014.", "type": 2, "words": ["<tag1>", "The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag2>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014.", "<tag3>"], "wordsA": ["The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "wordsB": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p102_s0", "idA": "906709_14_item1_p113_s0", "sentA": "BAX 855 is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "sentB": "PEGPH20 is an investigational PEGylated form of rHuPH20, under development by Halozyme to increase the half-life of the compound in the blood and allow for intravenous administration.", "type": 2, "words": ["<tag1>", "BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag2>", "PEGPH20", "is", "an", "investigational", "PEGylated", "form", "of", "rHuPH20,", "under", "development", "by", "Halozyme", "to", "increase", "the", "half-life", "of", "the", "compound", "in", "the", "blood", "and", "allow", "for", "intravenous", "administration.", "<tag3>"], "wordsA": ["BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "wordsB": ["PEGPH20", "is", "an", "investigational", "PEGylated", "form", "of", "rHuPH20,", "under", "development", "by", "Halozyme", "to", "increase", "the", "half-life", "of", "the", "compound", "in", "the", "blood", "and", "allow", "for", "intravenous", "administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p88_s0", "idA": "906709_14_item1_p114_s0", "sentA": "We are entitled to up to $73.0 million in total development and sales milestone payments, as well as royalties on net sales varying by product and country of sale.", "sentB": "We are entitled to up to $65.0 million in total development and sales milestone payments, as well as royalties on net sales varying by product and country of sale.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$73.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$65.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$73.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$65.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p67_s6", "idA": "906709_14_item1_p114_s1", "sentA": "Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country.", "sentB": "Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of certain patent rights in that particular country, subject to certain exceptions.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "certain", "patent", "rights", "in", "that", "particular", "country,", "subject", "to", "certain", "exceptions.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "certain", "patent", "rights", "in", "that", "particular", "country,", "subject", "to", "certain", "exceptions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p12_s3", "idA": "906709_14_item1_p115_s2", "sentA": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of BAX 855 was approximately 1.5-fold higher compared to ADVATE.", "sentB": "Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older.", "type": 2, "words": ["<tag1>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE.", "<tag2>", "Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag3>"], "wordsA": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE."], "wordsB": ["Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s0", "idA": "906709_14_item1_p115_s2", "sentA": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of BAX 855 was approximately 1.5-fold higher compared to ADVATE.", "sentB": "Clinical trials involve the administration of the drug to healthy volunteers or patients under the supervision of a qualified, identified medical investigator according to a protocol submitted in the IND for FDA review.", "type": 2, "words": ["<tag1>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE.", "<tag2>", "Clinical", "trials", "involve", "the", "administration", "of", "the", "drug", "to", "healthy", "volunteers", "or", "patients", "under", "the", "supervision", "of", "a", "qualified,", "identified", "medical", "investigator", "according", "to", "a", "protocol", "submitted", "in", "the", "IND", "for", "FDA", "review.", "<tag3>"], "wordsA": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE."], "wordsB": ["Clinical", "trials", "involve", "the", "administration", "of", "the", "drug", "to", "healthy", "volunteers", "or", "patients", "under", "the", "supervision", "of", "a", "qualified,", "identified", "medical", "investigator", "according", "to", "a", "protocol", "submitted", "in", "the", "IND", "for", "FDA", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p12_s2", "idA": "906709_14_item1_p116_s0", "sentA": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "This regulatory submission was based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients.", "type": 2, "words": ["<tag1>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients.", "<tag3>"], "wordsA": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p88_s1", "idA": "906709_14_item1_p116_s0", "sentA": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "The royalties start in the mid-single digits for net sales of BAX 855 up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion.", "type": 2, "words": ["<tag1>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "BAX", "855", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion.", "<tag3>"], "wordsA": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "BAX", "855", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p90_s1", "idA": "906709_14_item1_p116_s1", "sentA": "The Phase 3 clinical study is ongoing and is as a multi-center, open-label study called PROLONG-ATE and enrolled 146 previously treated adult patients with severe hemophilia A in order to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146 previously treated adult patients with severe hemophilia A in order to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "clinical", "study", "is", "ongoing", "and", "is", "as", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE", "and", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag3>"], "wordsA": ["The", "Phase", "3", "clinical", "study", "is", "ongoing", "and", "is", "as", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE", "and", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p100_s0", "idA": "906709_14_item1_p117_s0", "sentA": "In September 2006, we entered into a license, manufacturing and supply agreement with (OSI) Eyetech, Inc. (Eyetech) under which we granted Eyetech a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked with the active ingredient in Fovista .", "sentB": "In December 2006, we entered into a license agreement with Halozyme, Inc. (Halozyme) under which we granted Halozyme a worldwide, limited exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked only with certain qualifying hyaluronidase protein molecules including PEGPH20.", "type": 2, "words": ["<tag1>", "In", "September", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "(OSI)", "Eyetech,", "Inc.", "(Eyetech)", "under", "which", "we", "granted", "Eyetech", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "with", "the", "active", "ingredient", "in", "Fovista", ".", "<tag2>", "In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme,", "Inc.", "(Halozyme)", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20.", "<tag3>"], "wordsA": ["In", "September", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "(OSI)", "Eyetech,", "Inc.", "(Eyetech)", "under", "which", "we", "granted", "Eyetech", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "with", "the", "active", "ingredient", "in", "Fovista", "."], "wordsB": ["In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme,", "Inc.", "(Halozyme)", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p126_s1", "idA": "906709_14_item1_p117_s0", "sentA": "In September 2006, we entered into a license, manufacturing and supply agreement with (OSI) Eyetech, Inc. (Eyetech) under which we granted Eyetech a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked with the active ingredient in Fovista .", "sentB": "In April 2004, we entered into a license, manufacturing and supply agreement with Affymax, Inc. (Affymax), under which we granted Affymax a worldwide, non-exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize OMONTYS .", "type": 2, "words": ["<tag1>", "In", "September", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "(OSI)", "Eyetech,", "Inc.", "(Eyetech)", "under", "which", "we", "granted", "Eyetech", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "with", "the", "active", "ingredient", "in", "Fovista", ".", "<tag2>", "In", "April", "2004,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Affymax,", "Inc.", "(Affymax),", "under", "which", "we", "granted", "Affymax", "a", "worldwide,", "non-exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "OMONTYS", ".", "<tag3>"], "wordsA": ["In", "September", "2006,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "(OSI)", "Eyetech,", "Inc.", "(Eyetech)", "under", "which", "we", "granted", "Eyetech", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "with", "the", "active", "ingredient", "in", "Fovista", "."], "wordsB": ["In", "April", "2004,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Affymax,", "Inc.", "(Affymax),", "under", "which", "we", "granted", "Affymax", "a", "worldwide,", "non-exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "OMONTYS", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p96_s1", "idA": "906709_14_item1_p117_s1", "sentA": "In July 2007, as a result of a divestiture agreement between Eyetech and Ophthotech Corporation (Ophthotech), Opthotech acquired from Eyetech certain technology rights and other assets owned or controlled by Eyetech relating to particular anti-platelet-derived growth factor aptamers, or anti-PDGFs, including Fovista .", "sentB": "In July 2007, as a result of a divestiture agreement between Eyetech and Ophthotech Corporation (Ophthotech), Ophthotech acquired from Eyetech certain technology rights and other assets owned or controlled by Eyetech relating to particular anti-platelet-derived growth factor aptamers, or anti-PDGFs, including Fovista .", "type": 2, "words": ["<tag1>", "In", "July", "2007,", "as", "a", "result", "of", "a", "divestiture", "agreement", "between", "Eyetech", "and", "Ophthotech", "Corporation", "(Ophthotech),", "Opthotech", "acquired", "from", "Eyetech", "certain", "technology", "rights", "and", "other", "assets", "owned", "or", "controlled", "by", "Eyetech", "relating", "to", "particular", "anti-platelet-derived", "growth", "factor", "aptamers,", "or", "anti-PDGFs,", "including", "Fovista", ".", "<tag2>", "In", "July", "2007,", "as", "a", "result", "of", "a", "divestiture", "agreement", "between", "Eyetech", "and", "Ophthotech", "Corporation", "(Ophthotech),", "Ophthotech", "acquired", "from", "Eyetech", "certain", "technology", "rights", "and", "other", "assets", "owned", "or", "controlled", "by", "Eyetech", "relating", "to", "particular", "anti-platelet-derived", "growth", "factor", "aptamers,", "or", "anti-PDGFs,", "including", "Fovista", ".", "<tag3>"], "wordsA": ["In", "July", "2007,", "as", "a", "result", "of", "a", "divestiture", "agreement", "between", "Eyetech", "and", "Ophthotech", "Corporation", "(Ophthotech),", "Opthotech", "acquired", "from", "Eyetech", "certain", "technology", "rights", "and", "other", "assets", "owned", "or", "controlled", "by", "Eyetech", "relating", "to", "particular", "anti-platelet-derived", "growth", "factor", "aptamers,", "or", "anti-PDGFs,", "including", "Fovista", "."], "wordsB": ["In", "July", "2007,", "as", "a", "result", "of", "a", "divestiture", "agreement", "between", "Eyetech", "and", "Ophthotech", "Corporation", "(Ophthotech),", "Ophthotech", "acquired", "from", "Eyetech", "certain", "technology", "rights", "and", "other", "assets", "owned", "or", "controlled", "by", "Eyetech", "relating", "to", "particular", "anti-platelet-derived", "growth", "factor", "aptamers,", "or", "anti-PDGFs,", "including", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p131_s2", "idA": "906709_14_item1_p117_s2", "sentA": "As a result of this transaction, Ophthotech assumed the license, manufacturing and supply agreement between Eyetech and us.", "sentB": "In July 2013, Affymax terminated the license, manufacturing and supply agreement with us.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us.", "<tag2>", "In", "July", "2013,", "Affymax", "terminated", "the", "license,", "manufacturing", "and", "supply", "agreement", "with", "us.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us."], "wordsB": ["In", "July", "2013,", "Affymax", "terminated", "the", "license,", "manufacturing", "and", "supply", "agreement", "with", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p104_s0", "idA": "906709_14_item1_p119_s0", "sentA": "We are entitled to up to $7.5 million in total development and sales milestone payments, low- to mid- single-digit royalties on net sales that vary by sales levels and are subject to reduction in the absence of patent coverage, and additional consideration if Ophthotech grants certain third-party commercialization rights to Fovista .", "sentB": "We are entitled to future development milestones and royalties on net sales subject to reduction in the absence of patent coverage.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$7.5", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "low-", "to", "mid-", "single-digit", "royalties", "on", "net", "sales", "that", "vary", "by", "sales", "levels", "and", "are", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage,", "and", "additional", "consideration", "if", "Ophthotech", "grants", "certain", "third-party", "commercialization", "rights", "to", "Fovista", ".", "<tag2>", "We", "are", "entitled", "to", "future", "development", "milestones", "and", "royalties", "on", "net", "sales", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$7.5", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "low-", "to", "mid-", "single-digit", "royalties", "on", "net", "sales", "that", "vary", "by", "sales", "levels", "and", "are", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage,", "and", "additional", "consideration", "if", "Ophthotech", "grants", "certain", "third-party", "commercialization", "rights", "to", "Fovista", "."], "wordsB": ["We", "are", "entitled", "to", "future", "development", "milestones", "and", "royalties", "on", "net", "sales", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p121_s2", "idA": "906709_14_item1_p119_s2", "sentA": "We are the exclusive supplier of all of Ophthotech s clinical and commercial requirements of our proprietary PEGylation reagent used in the manufacture of Fovista .", "sentB": "We also manufacture and supply UCB with our proprietary PEGylation reagent used in the manufacture of CIMZIA on a fixed price per gram.", "type": 2, "words": ["<tag1>", "We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Ophthotech", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", ".", "<tag2>", "We", "also", "manufacture", "and", "supply", "UCB", "with", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "CIMZIA", "on", "a", "fixed", "price", "per", "gram.", "<tag3>"], "wordsA": ["We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Ophthotech", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", "."], "wordsB": ["We", "also", "manufacture", "and", "supply", "UCB", "with", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "CIMZIA", "on", "a", "fixed", "price", "per", "gram."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p97_s5", "idA": "906709_14_item1_p119_s2", "sentA": "We are the exclusive supplier of all of Ophthotech s clinical and commercial requirements of our proprietary PEGylation reagent used in the manufacture of Fovista .", "sentB": "We are the exclusive supplier for all of Ophthotech s clinical and future commercial requirements of our proprietary PEGylation reagent used in the manufacture of Fovista .", "type": 2, "words": ["<tag1>", "We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Ophthotech", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", ".", "<tag2>", "We", "are", "the", "exclusive", "supplier", "for", "all", "of", "Ophthotech", "s", "clinical", "and", "future", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", ".", "<tag3>"], "wordsA": ["We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Ophthotech", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", "."], "wordsB": ["We", "are", "the", "exclusive", "supplier", "for", "all", "of", "Ophthotech", "s", "clinical", "and", "future", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p131_s1", "idA": "906709_14_item1_p11_s10", "sentA": "On November 13, 2013, Baxter announced that it had completed enrollment of 146 patients in the PROLONG-ATE clinical study.", "sentB": "Effective as of April 1, 2013, Affymax announced that it had amended its collaboration agreement with Takeda to transfer regulatory, manufacturing, and development responsibilities for OMONTYS to Takeda.", "type": 2, "words": ["<tag1>", "On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study.", "<tag2>", "Effective", "as", "of", "April", "1,", "2013,", "Affymax", "announced", "that", "it", "had", "amended", "its", "collaboration", "agreement", "with", "Takeda", "to", "transfer", "regulatory,", "manufacturing,", "and", "development", "responsibilities", "for", "OMONTYS", "to", "Takeda.", "<tag3>"], "wordsA": ["On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study."], "wordsB": ["Effective", "as", "of", "April", "1,", "2013,", "Affymax", "announced", "that", "it", "had", "amended", "its", "collaboration", "agreement", "with", "Takeda", "to", "transfer", "regulatory,", "manufacturing,", "and", "development", "responsibilities", "for", "OMONTYS", "to", "Takeda."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s6", "idA": "906709_14_item1_p11_s10", "sentA": "On November 13, 2013, Baxter announced that it had completed enrollment of 146 patients in the PROLONG-ATE clinical study.", "sentB": "The IRB also reviews and approves the informed consent form to be signed by the trial participants and any significant changes in the clinical study.", "type": 2, "words": ["<tag1>", "On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study.", "<tag2>", "The", "IRB", "also", "reviews", "and", "approves", "the", "informed", "consent", "form", "to", "be", "signed", "by", "the", "trial", "participants", "and", "any", "significant", "changes", "in", "the", "clinical", "study.", "<tag3>"], "wordsA": ["On", "November", "13,", "2013,", "Baxter", "announced", "that", "it", "had", "completed", "enrollment", "of", "146", "patients", "in", "the", "PROLONG-ATE", "clinical", "study."], "wordsB": ["The", "IRB", "also", "reviews", "and", "approves", "the", "informed", "consent", "form", "to", "be", "signed", "by", "the", "trial", "participants", "and", "any", "significant", "changes", "in", "the", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p83_s0", "idA": "906709_14_item1_p11_s3", "sentA": "In January 2014, we announced that we observed elevated liver enzymes in some patients at the highest dose in a Phase 1 clinical study for NKTR-192.", "sentB": "On June 1, 2014, we announced positive preclinical data for NKTR-214 at the ASCO Annual Meeting in Chicago.", "type": 2, "words": ["<tag1>", "In", "January", "2014,", "we", "announced", "that", "we", "observed", "elevated", "liver", "enzymes", "in", "some", "patients", "at", "the", "highest", "dose", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-192.", "<tag2>", "On", "June", "1,", "2014,", "we", "announced", "positive", "preclinical", "data", "for", "NKTR-214", "at", "the", "ASCO", "Annual", "Meeting", "in", "Chicago.", "<tag3>"], "wordsA": ["In", "January", "2014,", "we", "announced", "that", "we", "observed", "elevated", "liver", "enzymes", "in", "some", "patients", "at", "the", "highest", "dose", "in", "a", "Phase", "1", "clinical", "study", "for", "NKTR-192."], "wordsB": ["On", "June", "1,", "2014,", "we", "announced", "positive", "preclinical", "data", "for", "NKTR-214", "at", "the", "ASCO", "Annual", "Meeting", "in", "Chicago."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s12", "idA": "906709_14_item1_p11_s5", "sentA": "In addition, we are also advancing other acute pain drug candidates in preclinical development.", "sentB": "We are also advancing numerous other drug candidates in preclinical development in the areas of cancer immunotherapy, pain and other therapeutic indications.", "type": 2, "words": ["<tag1>", "In", "addition,", "we", "are", "also", "advancing", "other", "acute", "pain", "drug", "candidates", "in", "preclinical", "development.", "<tag2>", "We", "are", "also", "advancing", "numerous", "other", "drug", "candidates", "in", "preclinical", "development", "in", "the", "areas", "of", "cancer", "immunotherapy,", "pain", "and", "other", "therapeutic", "indications.", "<tag3>"], "wordsA": ["In", "addition,", "we", "are", "also", "advancing", "other", "acute", "pain", "drug", "candidates", "in", "preclinical", "development."], "wordsB": ["We", "are", "also", "advancing", "numerous", "other", "drug", "candidates", "in", "preclinical", "development", "in", "the", "areas", "of", "cancer", "immunotherapy,", "pain", "and", "other", "therapeutic", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p12_s0", "idA": "906709_14_item1_p11_s8", "sentA": "The first drug candidate in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein which has completed Phase 1 clinical development in patients with hemophilia A.", "sentB": "The first drug candidate in this collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "type": 2, "words": ["<tag1>", "The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A.", "<tag2>", "The", "first", "drug", "candidate", "in", "this", "collaboration", "is", "BAX", "855,", "an", "investigational,", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag3>"], "wordsA": ["The", "first", "drug", "candidate", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein", "which", "has", "completed", "Phase", "1", "clinical", "development", "in", "patients", "with", "hemophilia", "A."], "wordsB": ["The", "first", "drug", "candidate", "in", "this", "collaboration", "is", "BAX", "855,", "an", "investigational,", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p105_s0", "idA": "906709_14_item1_p123_s6", "sentA": "Our right to receive royalties in any particular country will expire upon the later of ten years after first commercial sale of the product or expiration of patent rights in the particular country.", "sentB": "country will expire upon the later of twelve years after first commercial sale of the product or expiration of patent rights in the particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country.", "<tag2>", "country", "will", "expire", "upon", "the", "later", "of", "twelve", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country."], "wordsB": ["country", "will", "expire", "upon", "the", "later", "of", "twelve", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p105_s1", "idA": "906709_14_item1_p123_s7", "sentA": "We are the exclusive supplier of all of Regado s clinical and commercial requirements of our proprietary PEGylation reagent used in the manufacture of REG1.", "sentB": "We also manufacture and supply Halozyme with clinical and future commercial supply of our proprietary PEGylation reagent used in the manufacture of PEGPH20.", "type": 2, "words": ["<tag1>", "We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Regado", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "REG1.", "<tag2>", "We", "also", "manufacture", "and", "supply", "Halozyme", "with", "clinical", "and", "future", "commercial", "supply", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "PEGPH20.", "<tag3>"], "wordsA": ["We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Regado", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "REG1."], "wordsB": ["We", "also", "manufacture", "and", "supply", "Halozyme", "with", "clinical", "and", "future", "commercial", "supply", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "PEGPH20."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p143_s1", "idA": "906709_14_item1_p123_s7", "sentA": "We are the exclusive supplier of all of Regado s clinical and commercial requirements of our proprietary PEGylation reagent used in the manufacture of REG1.", "sentB": "In the case of our product candidates, CDER in consultation with CDRH could be involved in the review.", "type": 2, "words": ["<tag1>", "We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Regado", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "REG1.", "<tag2>", "In", "the", "case", "of", "our", "product", "candidates,", "CDER", "in", "consultation", "with", "CDRH", "could", "be", "involved", "in", "the", "review.", "<tag3>"], "wordsA": ["We", "are", "the", "exclusive", "supplier", "of", "all", "of", "Regado", "s", "clinical", "and", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "REG1."], "wordsB": ["In", "the", "case", "of", "our", "product", "candidates,", "CDER", "in", "consultation", "with", "CDRH", "could", "be", "involved", "in", "the", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s6", "idA": "906709_14_item1_p124_s0", "sentA": "Regado has announced the completion of three Phase 1 and one Phase 2 clinical studies for REG1.", "sentB": "MOVANTIK was developed using our oral small molecule polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca.", "type": 2, "words": ["<tag1>", "Regado", "has", "announced", "the", "completion", "of", "three", "Phase", "1", "and", "one", "Phase", "2", "clinical", "studies", "for", "REG1.", "<tag2>", "MOVANTIK", "was", "developed", "using", "our", "oral", "small", "molecule", "polymer", "conjugate", "technology", "and", "we", "advanced", "this", "drug", "through", "the", "completion", "of", "Phase", "2", "clinical", "studies", "prior", "to", "licensing", "it", "to", "AstraZeneca.", "<tag3>"], "wordsA": ["Regado", "has", "announced", "the", "completion", "of", "three", "Phase", "1", "and", "one", "Phase", "2", "clinical", "studies", "for", "REG1."], "wordsB": ["MOVANTIK", "was", "developed", "using", "our", "oral", "small", "molecule", "polymer", "conjugate", "technology", "and", "we", "advanced", "this", "drug", "through", "the", "completion", "of", "Phase", "2", "clinical", "studies", "prior", "to", "licensing", "it", "to", "AstraZeneca."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p47_s0", "idA": "906709_14_item1_p124_s0", "sentA": "Regado has announced the completion of three Phase 1 and one Phase 2 clinical studies for REG1.", "sentB": "MOVANTIK TM was developed using our oral small molecule polymer conjugate technology and we advanced this drug through the completion of Phase 2 clinical studies prior to licensing it to AstraZeneca.", "type": 2, "words": ["<tag1>", "Regado", "has", "announced", "the", "completion", "of", "three", "Phase", "1", "and", "one", "Phase", "2", "clinical", "studies", "for", "REG1.", "<tag2>", "MOVANTIK", "TM", "was", "developed", "using", "our", "oral", "small", "molecule", "polymer", "conjugate", "technology", "and", "we", "advanced", "this", "drug", "through", "the", "completion", "of", "Phase", "2", "clinical", "studies", "prior", "to", "licensing", "it", "to", "AstraZeneca.", "<tag3>"], "wordsA": ["Regado", "has", "announced", "the", "completion", "of", "three", "Phase", "1", "and", "one", "Phase", "2", "clinical", "studies", "for", "REG1."], "wordsB": ["MOVANTIK", "TM", "was", "developed", "using", "our", "oral", "small", "molecule", "polymer", "conjugate", "technology", "and", "we", "advanced", "this", "drug", "through", "the", "completion", "of", "Phase", "2", "clinical", "studies", "prior", "to", "licensing", "it", "to", "AstraZeneca."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p154_s1", "idA": "906709_14_item1_p126_s1", "sentA": "On December 31, 2008, we assigned the agreement to Novartis Pharma AG in connection with the completion of the pulmonary asset sale transaction.", "sentB": "In connection with the Novartis Pulmonary Asset Sale, as of December 31, 2008, we entered into an exclusive license agreement with Novartis Pharma AG.", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction.", "<tag2>", "In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "of", "December", "31,", "2008,", "we", "entered", "into", "an", "exclusive", "license", "agreement", "with", "Novartis", "Pharma", "AG.", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction."], "wordsB": ["In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "of", "December", "31,", "2008,", "we", "entered", "into", "an", "exclusive", "license", "agreement", "with", "Novartis", "Pharma", "AG."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s0", "idA": "906709_14_item1_p12_s0", "sentA": "We also have a significant collaboration with Bayer Healthcare LLC (Bayer), to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "program for inhaled vancomycin or are necessary for us to satisfy certain continuing contractual obligations to third parties, including in connection with development, manufacture, sale, and commercialization activities related to BAY41-6551 partnered with Bayer Healthcare LLC.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer),", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "program", "for", "inhaled", "vancomycin", "or", "are", "necessary", "for", "us", "to", "satisfy", "certain", "continuing", "contractual", "obligations", "to", "third", "parties,", "including", "in", "connection", "with", "development,", "manufacture,", "sale,", "and", "commercialization", "activities", "related", "to", "BAY41-6551", "partnered", "with", "Bayer", "Healthcare", "LLC.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "significant", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer),", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["program", "for", "inhaled", "vancomycin", "or", "are", "necessary", "for", "us", "to", "satisfy", "certain", "continuing", "contractual", "obligations", "to", "third", "parties,", "including", "in", "connection", "with", "development,", "manufacture,", "sale,", "and", "commercialization", "activities", "related", "to", "BAY41-6551", "partnered", "with", "Bayer", "Healthcare", "LLC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p13_s1", "idA": "906709_14_item1_p12_s1", "sentA": "We originally developed the liquid aerosol inhalation platform and the NKTR-061 drug candidate and entered into a collaboration agreement with Bayer in August 2007 to further advance the drug candidate s development and potential commercialization.", "sentB": "We originally developed the NKTR-061 drug candidate and the associated liquid aerosol inhalation platform and entered into a collaboration agreement with Bayer to advance the drug candidate into further clinical development and potential commercialization.", "type": 2, "words": ["<tag1>", "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "the", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "in", "August", "2007", "to", "further", "advance", "the", "drug", "candidate", "s", "development", "and", "potential", "commercialization.", "<tag2>", "We", "originally", "developed", "the", "NKTR-061", "drug", "candidate", "and", "the", "associated", "liquid", "aerosol", "inhalation", "platform", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "advance", "the", "drug", "candidate", "into", "further", "clinical", "development", "and", "potential", "commercialization.", "<tag3>"], "wordsA": ["We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "the", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "in", "August", "2007", "to", "further", "advance", "the", "drug", "candidate", "s", "development", "and", "potential", "commercialization."], "wordsB": ["We", "originally", "developed", "the", "NKTR-061", "drug", "candidate", "and", "the", "associated", "liquid", "aerosol", "inhalation", "platform", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "advance", "the", "drug", "candidate", "into", "further", "clinical", "development", "and", "potential", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p13_s2", "idA": "906709_14_item1_p12_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale that commenced in April 2013.", "sentB": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale", "that", "commenced", "in", "April", "2013.", "<tag2>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale", "that", "commenced", "in", "April", "2013."], "wordsB": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p13_s3", "idA": "906709_14_item1_p12_s3", "sentA": "Bayer is conducting this study under a Special Protocol Assessment process that was agreed to with the FDA in 2011.", "sentB": "Bayer is conducting this study under a Special Protocol Assessment process agreed to with the FDA.", "type": 2, "words": ["<tag1>", "Bayer", "is", "conducting", "this", "study", "under", "a", "Special", "Protocol", "Assessment", "process", "that", "was", "agreed", "to", "with", "the", "FDA", "in", "2011.", "<tag2>", "Bayer", "is", "conducting", "this", "study", "under", "a", "Special", "Protocol", "Assessment", "process", "agreed", "to", "with", "the", "FDA.", "<tag3>"], "wordsA": ["Bayer", "is", "conducting", "this", "study", "under", "a", "Special", "Protocol", "Assessment", "process", "that", "was", "agreed", "to", "with", "the", "FDA", "in", "2011."], "wordsB": ["Bayer", "is", "conducting", "this", "study", "under", "a", "Special", "Protocol", "Assessment", "process", "agreed", "to", "with", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p13_s4", "idA": "906709_14_item1_p12_s4", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., MAP Pharmaceuticals, Inc., Merck Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), Regado Biosciences, Inc., and UCB Pharma.", "sentB": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Halozyme Therapeutics, Inc., Merck Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "Regado", "Biosciences,", "Inc.,", "and", "UCB", "Pharma.", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "MAP", "Pharmaceuticals,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "Regado", "Biosciences,", "Inc.,", "and", "UCB", "Pharma."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p153_s0", "idA": "906709_14_item1_p131_s0", "sentA": "In July 1995, we entered into a non-exclusive supply and license agreement (the 1995 Agreement) with Amgen, Inc., pursuant to which we licensed our proprietary PEGylation technology to be used in the development and manufacture of Neulasta .", "sentB": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "type": 2, "words": ["<tag1>", "In", "July", "1995,", "we", "entered", "into", "a", "non-exclusive", "supply", "and", "license", "agreement", "(the", "1995", "Agreement)", "with", "Amgen,", "Inc.,", "pursuant", "to", "which", "we", "licensed", "our", "proprietary", "PEGylation", "technology", "to", "be", "used", "in", "the", "development", "and", "manufacture", "of", "Neulasta", ".", "<tag2>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag3>"], "wordsA": ["In", "July", "1995,", "we", "entered", "into", "a", "non-exclusive", "supply", "and", "license", "agreement", "(the", "1995", "Agreement)", "with", "Amgen,", "Inc.,", "pursuant", "to", "which", "we", "licensed", "our", "proprietary", "PEGylation", "technology", "to", "be", "used", "in", "the", "development", "and", "manufacture", "of", "Neulasta", "."], "wordsB": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p113_s0", "idA": "906709_14_item1_p133_s2", "sentA": "This supply arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from any other third party.", "sentB": "arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from any other third party.", "type": 2, "words": ["<tag1>", "This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party.", "<tag2>", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party.", "<tag3>"], "wordsA": ["This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party."], "wordsB": ["arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s6", "idA": "906709_14_item1_p133_s2", "sentA": "This supply arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from any other third party.", "sentB": "Even if we believe we are free to work with a proprietary drug, we cannot guarantee that we will not be accused of, or determined to be, infringing a third party s rights and be prohibited from working with the drug or found liable for damages.", "type": 2, "words": ["<tag1>", "This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party.", "<tag2>", "Even", "if", "we", "believe", "we", "are", "free", "to", "work", "with", "a", "proprietary", "drug,", "we", "cannot", "guarantee", "that", "we", "will", "not", "be", "accused", "of,", "or", "determined", "to", "be,", "infringing", "a", "third", "party", "s", "rights", "and", "be", "prohibited", "from", "working", "with", "the", "drug", "or", "found", "liable", "for", "damages.", "<tag3>"], "wordsA": ["This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party."], "wordsB": ["Even", "if", "we", "believe", "we", "are", "free", "to", "work", "with", "a", "proprietary", "drug,", "we", "cannot", "guarantee", "that", "we", "will", "not", "be", "accused", "of,", "or", "determined", "to", "be,", "infringing", "a", "third", "party", "s", "rights", "and", "be", "prohibited", "from", "working", "with", "the", "drug", "or", "found", "liable", "for", "damages."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p113_s4", "idA": "906709_14_item1_p133_s6", "sentA": "The term of the Agreement runs through October 29, 2020.", "sentB": "The term of the 2010 Agreement runs through October 29, 2020.", "type": 2, "words": ["<tag1>", "The", "term", "of", "the", "Agreement", "runs", "through", "October", "29,", "2020.", "<tag2>", "The", "term", "of", "the", "2010", "Agreement", "runs", "through", "October", "29,", "2020.", "<tag3>"], "wordsA": ["The", "term", "of", "the", "Agreement", "runs", "through", "October", "29,", "2020."], "wordsB": ["The", "term", "of", "the", "2010", "Agreement", "runs", "through", "October", "29,", "2020."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p113_s5", "idA": "906709_14_item1_p134_s0", "sentA": "the manufacturing facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "sentB": "In the event we become subject to a bankruptcy or insolvency proceeding, we cease to own or control the manufacturing facility in Huntsville, Alabama, we fail to manufacture and supply the Polymer Materials or certain other events occur, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the dedicated equipment and access the manufacturing facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "type": 2, "words": ["<tag1>", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag2>", "In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Alabama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag3>"], "wordsA": ["the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "wordsB": ["In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Alabama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p131_s0", "idA": "906709_14_item1_p134_s2", "sentA": "Either party may terminate the 2010 Agreement in the event of insolvency or bankruptcy of the other party.", "sentB": "Since launch of the drug, more than 25,000 patients have received OMONTYS in the post-marketing setting.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party.", "<tag2>", "Since", "launch", "of", "the", "drug,", "more", "than", "25,000", "patients", "have", "received", "OMONTYS", "in", "the", "post-marketing", "setting.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party."], "wordsB": ["Since", "launch", "of", "the", "drug,", "more", "than", "25,000", "patients", "have", "received", "OMONTYS", "in", "the", "post-marketing", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s4", "idA": "906709_14_item1_p134_s2", "sentA": "Either party may terminate the 2010 Agreement in the event of insolvency or bankruptcy of the other party.", "sentB": "Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party.", "<tag2>", "Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party."], "wordsB": ["Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p158_s0", "idA": "906709_14_item1_p134_s2", "sentA": "Either party may terminate the 2010 Agreement in the event of insolvency or bankruptcy of the other party.", "sentB": "In the event of a claim of infringement, we or our partners may be required to obtain one or more licenses from third parties.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party.", "<tag2>", "In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "third", "parties.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "2010", "Agreement", "in", "the", "event", "of", "insolvency", "or", "bankruptcy", "of", "the", "other", "party."], "wordsB": ["In", "the", "event", "of", "a", "claim", "of", "infringement,", "we", "or", "our", "partners", "may", "be", "required", "to", "obtain", "one", "or", "more", "licenses", "from", "third", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s8", "idA": "906709_14_item1_p136_s0", "sentA": "PEGASYS is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "sentB": "On December 9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG (the naloxegol brand name in the European Union, or EU) as the first once-daily oral PAMORA to be approved in the European Union (EU) for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "type": 2, "words": ["<tag1>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag2>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "European", "Union", "(EU)", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag3>"], "wordsA": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "wordsB": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "European", "Union", "(EU)", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p50_s1", "idA": "906709_14_item1_p136_s0", "sentA": "PEGASYS is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "sentB": "On December 9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG (the naloxegol brand name in the European Union, or EU) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "type": 2, "words": ["<tag1>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag2>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag3>"], "wordsA": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "wordsB": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p97_s2", "idA": "906709_14_item1_p136_s2", "sentA": "In connection with Roche s exercise of the license extension option in December 2009, we received a payment of $31.0 million.", "sentB": "Under our agreement with Ophthotech, in June 2014 we received a $19.75 million payment in connection with this licensing agreement.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million.", "<tag2>", "Under", "our", "agreement", "with", "Ophthotech,", "in", "June", "2014", "we", "received", "a", "$19.75", "million", "payment", "in", "connection", "with", "this", "licensing", "agreement.", "<tag3>"], "wordsA": ["In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million."], "wordsB": ["Under", "our", "agreement", "with", "Ophthotech,", "in", "June", "2014", "we", "received", "a", "$19.75", "million", "payment", "in", "connection", "with", "this", "licensing", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p115_s3", "idA": "906709_14_item1_p136_s3", "sentA": "The agreement expires on the later of January 10, 2015 or the expiration of our last relevant patent containing a valid claim.", "sentB": "The agreement expires on the later of December 31, 2015 or the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "on", "the", "later", "of", "January", "10,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "The", "agreement", "expires", "on", "the", "later", "of", "December", "31,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "on", "the", "later", "of", "January", "10,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["The", "agreement", "expires", "on", "the", "later", "of", "December", "31,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p126_s0", "idA": "906709_14_item1_p137_s0", "sentA": "Somavert , Agreement with Pfizer, Inc.", "sentB": "OMONTYS (Peginesatide), Agreement with Affymax, Inc.", "type": 2, "words": ["<tag1>", "Somavert", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag2>", "OMONTYS", "(Peginesatide),", "Agreement", "with", "Affymax,", "Inc.", "<tag3>"], "wordsA": ["Somavert", ",", "Agreement", "with", "Pfizer,", "Inc."], "wordsB": ["OMONTYS", "(Peginesatide),", "Agreement", "with", "Affymax,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p118_s0", "idA": "906709_14_item1_p139_s0", "sentA": "In February 2000, we entered into a manufacturing and supply agreement with Schering-Plough Corporation (Schering) for the manufacture and supply of our proprietary PEGylation materials to be used by Schering in production of a PEGylated recombinant human interferon-alpha (PEG-Intron).", "sentB": "production of a PEGylated recombinant human interferon-alpha (PEG-Intron).", "type": 2, "words": ["<tag1>", "In", "February", "2000,", "we", "entered", "into", "a", "manufacturing", "and", "supply", "agreement", "with", "Schering-Plough", "Corporation", "(Schering)", "for", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "to", "be", "used", "by", "Schering", "in", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron).", "<tag2>", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron).", "<tag3>"], "wordsA": ["In", "February", "2000,", "we", "entered", "into", "a", "manufacturing", "and", "supply", "agreement", "with", "Schering-Plough", "Corporation", "(Schering)", "for", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "to", "be", "used", "by", "Schering", "in", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron)."], "wordsB": ["production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p120_s1", "idA": "906709_14_item1_p139_s2", "sentA": "We currently manufacture our proprietary PEGylation materials for Schering on a price per gram basis.", "sentB": "We currently manufacture our proprietary PEGylation materials for Valeant on a price per gram basis.", "type": 2, "words": ["<tag1>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis.", "<tag2>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis.", "<tag3>"], "wordsA": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis."], "wordsB": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p14_s0", "idA": "906709_14_item1_p13_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or E.U.", "sentB": "A total of nine products using our PEGylation technology have received regulatory approval in the U.S. or E.U.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U.", "<tag2>", "A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U."], "wordsB": ["A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p150_s0", "idA": "906709_14_item1_p13_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or E.U.", "sentB": "Similar incentives also are available for orphan drugs in the E.U.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U.", "<tag2>", "Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "E.U.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "E.U."], "wordsB": ["Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "E.U."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s0", "idA": "906709_14_item1_p13_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "Patents and Proprietary Rights We own more than 215 U.S. and 750 foreign patents and a number of pending patent applications that cover various aspects of our technologies.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "Patents", "and", "Proprietary", "Rights", "We", "own", "more", "than", "215", "U.S.", "and", "750", "foreign", "patents", "and", "a", "number", "of", "pending", "patent", "applications", "that", "cover", "various", "aspects", "of", "our", "technologies.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["Patents", "and", "Proprietary", "Rights", "We", "own", "more", "than", "215", "U.S.", "and", "750", "foreign", "patents", "and", "a", "number", "of", "pending", "patent", "applications", "that", "cover", "various", "aspects", "of", "our", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p154_s0", "idA": "906709_14_item1_p13_s2", "sentA": "On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 dedicated pulmonary personnel and operations to Novartis Pharma AG.", "sentB": "On December 31, 2008, we completed the sale of certain assets related to our pulmonary business, associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation (together referred to as Novartis) for a purchase price of $115.0 million in cash (Novartis Pulmonary Asset Sale).", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG.", "<tag2>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "of", "certain", "assets", "related", "to", "our", "pulmonary", "business,", "associated", "technology", "and", "intellectual", "property", "to", "Novartis", "Pharma", "AG", "and", "Novartis", "Pharmaceuticals", "Corporation", "(together", "referred", "to", "as", "Novartis)", "for", "a", "purchase", "price", "of", "$115.0", "million", "in", "cash", "(Novartis", "Pulmonary", "Asset", "Sale).", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG."], "wordsB": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "of", "certain", "assets", "related", "to", "our", "pulmonary", "business,", "associated", "technology", "and", "intellectual", "property", "to", "Novartis", "Pharma", "AG", "and", "Novartis", "Pharmaceuticals", "Corporation", "(together", "referred", "to", "as", "Novartis)", "for", "a", "purchase", "price", "of", "$115.0", "million", "in", "cash", "(Novartis", "Pulmonary", "Asset", "Sale)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p15_s0", "idA": "906709_14_item1_p13_s2", "sentA": "On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 dedicated pulmonary personnel and operations to Novartis Pharma AG.", "sentB": "On December 31, 2008, we completed the sale and transfer of certain pulmonary technology rights, certain pulmonary collaboration agreements and approximately 140 dedicated pulmonary personnel and operations to Novartis Pharma AG (Novartis).", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG.", "<tag2>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG", "(Novartis).", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG."], "wordsB": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "and", "transfer", "of", "certain", "pulmonary", "technology", "rights,", "certain", "pulmonary", "collaboration", "agreements", "and", "approximately", "140", "dedicated", "pulmonary", "personnel", "and", "operations", "to", "Novartis", "Pharma", "AG", "(Novartis)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p120_s3", "idA": "906709_14_item1_p143_s1", "sentA": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc. which ends in 2014.", "sentB": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014.", "<tag2>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014."], "wordsB": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s0", "idA": "906709_14_item1_p144_s2", "sentA": "We have the right to receive manufacturing revenue on the basis of a fixed price per gram.", "sentB": "Polymer chemistry is a science focused on the synthesis or bonding of polymer architectures with drug molecules to alter the properties of a molecule.", "type": 2, "words": ["<tag1>", "We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "the", "basis", "of", "a", "fixed", "price", "per", "gram.", "<tag2>", "Polymer", "chemistry", "is", "a", "science", "focused", "on", "the", "synthesis", "or", "bonding", "of", "polymer", "architectures", "with", "drug", "molecules", "to", "alter", "the", "properties", "of", "a", "molecule.", "<tag3>"], "wordsA": ["We", "have", "the", "right", "to", "receive", "manufacturing", "revenue", "on", "the", "basis", "of", "a", "fixed", "price", "per", "gram."], "wordsB": ["Polymer", "chemistry", "is", "a", "science", "focused", "on", "the", "synthesis", "or", "bonding", "of", "polymer", "architectures", "with", "drug", "molecules", "to", "alter", "the", "properties", "of", "a", "molecule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p107_s6", "idA": "906709_14_item1_p144_s3", "sentA": "We were also entitled to receive royalties on net sales of the CIMZIA product for the longer of ten years from the first commercial sale of the product anywhere in the world or the expiration of patent rights in a particular country.", "sentB": "On January 28, 2011, MAP entered into a Collaboration Agreement with Allergan, Inc. pursuant to which Allergan received a co-exclusive license to market and promote SEMPRANA to neurologists and pain specialists in the U.S. Under this arrangement, Allergan paid MAP an upfront payment of $60 million and MAP was also entitled to receive up to an additional $97 million in the form of regulatory milestones, which includes milestones for acceptance of filing of the SEMPRANA NDA and first commercial sale associated with the initial acute migraine indication.", "type": 2, "words": ["<tag1>", "We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "CIMZIA", "product", "for", "the", "longer", "of", "ten", "years", "from", "the", "first", "commercial", "sale", "of", "the", "product", "anywhere", "in", "the", "world", "or", "the", "expiration", "of", "patent", "rights", "in", "a", "particular", "country.", "<tag2>", "On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication.", "<tag3>"], "wordsA": ["We", "were", "also", "entitled", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "CIMZIA", "product", "for", "the", "longer", "of", "ten", "years", "from", "the", "first", "commercial", "sale", "of", "the", "product", "anywhere", "in", "the", "world", "or", "the", "expiration", "of", "patent", "rights", "in", "a", "particular", "country."], "wordsB": ["On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p121_s6", "idA": "906709_14_item1_p144_s6", "sentA": "We share a portion of the payments we receive from UCB with Enzon Pharmaceuticals, Inc. which ends in 2014.", "sentB": "We share a portion of the payments we receive from UCB with Enzon Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014.", "<tag2>", "We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "which", "ends", "in", "2014."], "wordsB": ["We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s2", "idA": "906709_14_item1_p144_s7", "sentA": "The agreement expires upon the expiration of all of UCB s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties.", "sentB": "Even if such data are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy all of the criteria for approval.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag2>", "Even", "if", "such", "data", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "or", "BLA", "does", "not", "satisfy", "all", "of", "the", "criteria", "for", "approval.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties."], "wordsB": ["Even", "if", "such", "data", "are", "submitted,", "the", "FDA", "may", "ultimately", "decide", "that", "the", "NDA", "or", "BLA", "does", "not", "satisfy", "all", "of", "the", "criteria", "for", "approval."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p125_s0", "idA": "906709_14_item1_p147_s2", "sentA": "Roche entered into the toll-manufacturing agreement with the objective of establishing us as a secondary back-up source on a non-exclusive basis.", "sentB": "a secondary back-up source on a non-exclusive basis through December 31, 2016.", "type": 2, "words": ["<tag1>", "Roche", "entered", "into", "the", "toll-manufacturing", "agreement", "with", "the", "objective", "of", "establishing", "us", "as", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis.", "<tag2>", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016.", "<tag3>"], "wordsA": ["Roche", "entered", "into", "the", "toll-manufacturing", "agreement", "with", "the", "objective", "of", "establishing", "us", "as", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis."], "wordsB": ["a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s2", "idA": "906709_14_item1_p17_s4", "sentA": "Other limitations of the early applications of PEGylation technology include sub-optimal bioavailability and bioactivity, and its limited ability to be used to fine-tune properties of the drug, as well as its inability to be used to create oral drugs.", "sentB": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "type": 2, "words": ["<tag1>", "Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs.", "<tag2>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag3>"], "wordsA": ["Other", "limitations", "of", "the", "early", "applications", "of", "PEGylation", "technology", "include", "sub-optimal", "bioavailability", "and", "bioactivity,", "and", "its", "limited", "ability", "to", "be", "used", "to", "fine-tune", "properties", "of", "the", "drug,", "as", "well", "as", "its", "inability", "to", "be", "used", "to", "create", "oral", "drugs."], "wordsB": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p21_s1", "idA": "906709_14_item1_p19_s0", "sentA": "limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "sentB": "Our advanced polymer conjugate technology platform is designed to overcome the limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "type": 2, "words": ["<tag1>", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag2>", "Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag3>"], "wordsA": ["limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "wordsB": ["Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s1", "idA": "906709_14_item1_p19_s2", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates.", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "have", "filed", "patent", "applications,", "and", "plan", "to", "file", "additional", "patent", "applications,", "covering", "various", "aspects", "of", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies", "and", "our", "proprietary", "product", "candidates.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "have", "filed", "patent", "applications,", "and", "plan", "to", "file", "additional", "patent", "applications,", "covering", "various", "aspects", "of", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies", "and", "our", "proprietary", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s3", "idA": "906709_14_item1_p19_s2", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "Our patent portfolio contains patents and patent applications that encompass our PEGylation and advanced polymer conjugate technology platforms, some of which we acquired in our acquisition of Shearwater Corporation in June 2001.", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p132_s1", "idA": "906709_14_item1_p1_s1", "sentA": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "sentB": "These national agencies and other federal, state and local entities regulate, among other things, research and development activities and the testing (in vitro, in animals, and in human clinical trials), manufacture, labeling, storage, recordkeeping, approval, marketing, advertising and promotion of our products.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag2>", "These", "national", "agencies", "and", "other", "federal,", "state", "and", "local", "entities", "regulate,", "among", "other", "things,", "research", "and", "development", "activities", "and", "the", "testing", "(in", "vitro,", "in", "animals,", "and", "in", "human", "clinical", "trials),", "manufacture,", "labeling,", "storage,", "recordkeeping,", "approval,", "marketing,", "advertising", "and", "promotion", "of", "our", "products.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "wordsB": ["These", "national", "agencies", "and", "other", "federal,", "state", "and", "local", "entities", "regulate,", "among", "other", "things,", "research", "and", "development", "activities", "and", "the", "testing", "(in", "vitro,", "in", "animals,", "and", "in", "human", "clinical", "trials),", "manufacture,", "labeling,", "storage,", "recordkeeping,", "approval,", "marketing,", "advertising", "and", "promotion", "of", "our", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p24_s0", "idA": "906709_14_item1_p21_s4", "sentA": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that we plan to initiate Phase 3 clinical studies starting in mid-2014, following the completion of an end-of-Phase 2 meeting with the FDA in the first half of 2014.", "sentB": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that is currently in Phase 3 development.", "type": 2, "words": ["<tag1>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "we", "plan", "to", "initiate", "Phase", "3", "clinical", "studies", "starting", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "in", "the", "first", "half", "of", "2014.", "<tag2>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "development.", "<tag3>"], "wordsA": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "we", "plan", "to", "initiate", "Phase", "3", "clinical", "studies", "starting", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "in", "the", "first", "half", "of", "2014."], "wordsB": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p25_s8", "idA": "906709_14_item1_p23_s5", "sentA": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which is currently being evaluated in Phase 3 clinical development in collaboration with Baxter for the treatment of hemophilia A. Antibody Fragment Polymer Conjugates This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "sentB": "This approach uses a large molecular weight PEG conjugated to antibody fragments in order to potentially improve their toxicity profile, extend their half-life and allow for ease of synthesis with the antibody.", "type": 2, "words": ["<tag1>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "3", "clinical", "development", "in", "collaboration", "with", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag2>", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody.", "<tag3>"], "wordsA": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "is", "currently", "being", "evaluated", "in", "Phase", "3", "clinical", "development", "in", "collaboration", "with", "Baxter", "for", "the", "treatment", "of", "hemophilia", "A.", "Antibody", "Fragment", "Polymer", "Conjugates", "This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "wordsB": ["This", "approach", "uses", "a", "large", "molecular", "weight", "PEG", "conjugated", "to", "antibody", "fragments", "in", "order", "to", "potentially", "improve", "their", "toxicity", "profile,", "extend", "their", "half-life", "and", "allow", "for", "ease", "of", "synthesis", "with", "the", "antibody."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p146_s0", "idA": "906709_14_item1_p26_s1", "sentA": "To support this strategy, we have significantly expanded and added expertise to our internal preclinical, clinical development and regulatory departments.", "sentB": "The clinical and manufacturing, development and regulatory review and approval process generally takes a number of years and requires the expenditure of substantial resources.", "type": 2, "words": ["<tag1>", "To", "support", "this", "strategy,", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments.", "<tag2>", "The", "clinical", "and", "manufacturing,", "development", "and", "regulatory", "review", "and", "approval", "process", "generally", "takes", "a", "number", "of", "years", "and", "requires", "the", "expenditure", "of", "substantial", "resources.", "<tag3>"], "wordsA": ["To", "support", "this", "strategy,", "we", "have", "significantly", "expanded", "and", "added", "expertise", "to", "our", "internal", "preclinical,", "clinical", "development", "and", "regulatory", "departments."], "wordsB": ["The", "clinical", "and", "manufacturing,", "development", "and", "regulatory", "review", "and", "approval", "process", "generally", "takes", "a", "number", "of", "years", "and", "requires", "the", "expenditure", "of", "substantial", "resources."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p30_s0", "idA": "906709_14_item1_p27_s3", "sentA": "We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "sentB": "Ensure Future Growth of our Proprietary Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "type": 2, "words": ["<tag1>", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag2>", "Ensure", "Future", "Growth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag3>"], "wordsA": ["We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "wordsB": ["Ensure", "Future", "Growth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p152_s2", "idA": "906709_14_item1_p29_s1", "sentA": "To that end, we have a comprehensive patent strategy with the objective of developing a patent estate covering a wide range of novel inventions including among others, polymer materials, conjugates, formulations, synthesis, therapeutic areas, methods of treatment and methods of manufacture.", "sentB": "More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, methods of administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates.", "type": 2, "words": ["<tag1>", "To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas,", "methods", "of", "treatment", "and", "methods", "of", "manufacture.", "<tag2>", "More", "specifically,", "our", "patents", "and", "patent", "applications", "cover", "polymer", "architecture,", "drug", "conjugates,", "formulations,", "methods", "of", "making", "polymers", "and", "polymer", "conjugates,", "methods", "of", "administering", "polymer", "conjugates,", "and", "methods", "of", "manufacturing", "polymers", "and", "polymer", "conjugates.", "<tag3>"], "wordsA": ["To", "that", "end,", "we", "have", "a", "comprehensive", "patent", "strategy", "with", "the", "objective", "of", "developing", "a", "patent", "estate", "covering", "a", "wide", "range", "of", "novel", "inventions", "including", "among", "others,", "polymer", "materials,", "conjugates,", "formulations,", "synthesis,", "therapeutic", "areas,", "methods", "of", "treatment", "and", "methods", "of", "manufacture."], "wordsB": ["More", "specifically,", "our", "patents", "and", "patent", "applications", "cover", "polymer", "architecture,", "drug", "conjugates,", "formulations,", "methods", "of", "making", "polymers", "and", "polymer", "conjugates,", "methods", "of", "administering", "polymer", "conjugates,", "and", "methods", "of", "manufacturing", "polymers", "and", "polymer", "conjugates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p146_s1", "idA": "906709_14_item1_p29_s2", "sentA": "The following table summarizes our proprietary drug candidates that are being developed by us or in collaboration with other pharmaceutical companies or independent investigators.", "sentB": "Our ability to manufacture and market products, whether developed by us or under collaboration agreements, ultimately depends upon the completion of satisfactory clinical trials and success in obtaining marketing approvals from the FDA and equivalent foreign health authorities.", "type": 2, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators.", "<tag2>", "Our", "ability", "to", "manufacture", "and", "market", "products,", "whether", "developed", "by", "us", "or", "under", "collaboration", "agreements,", "ultimately", "depends", "upon", "the", "completion", "of", "satisfactory", "clinical", "trials", "and", "success", "in", "obtaining", "marketing", "approvals", "from", "the", "FDA", "and", "equivalent", "foreign", "health", "authorities.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators."], "wordsB": ["Our", "ability", "to", "manufacture", "and", "market", "products,", "whether", "developed", "by", "us", "or", "under", "collaboration", "agreements,", "ultimately", "depends", "upon", "the", "completion", "of", "satisfactory", "clinical", "trials", "and", "success", "in", "obtaining", "marketing", "approvals", "from", "the", "FDA", "and", "equivalent", "foreign", "health", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p31_s2", "idA": "906709_14_item1_p29_s2", "sentA": "The following table summarizes our proprietary drug candidates that are being developed by us or in collaboration with other pharmaceutical companies or independent investigators.", "sentB": "The following table summarizes our proprietary drugs and drug candidates that have either received regulatory approval or are being developed by us or in collaboration with other pharmaceutical companies or independent investigators.", "type": 2, "words": ["<tag1>", "The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators.", "<tag2>", "The", "following", "table", "summarizes", "our", "proprietary", "drugs", "and", "drug", "candidates", "that", "have", "either", "received", "regulatory", "approval", "or", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators.", "<tag3>"], "wordsA": ["The", "following", "table", "summarizes", "our", "proprietary", "drug", "candidates", "that", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators."], "wordsB": ["The", "following", "table", "summarizes", "our", "proprietary", "drugs", "and", "drug", "candidates", "that", "have", "either", "received", "regulatory", "approval", "or", "are", "being", "developed", "by", "us", "or", "in", "collaboration", "with", "other", "pharmaceutical", "companies", "or", "independent", "investigators."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s4", "idA": "906709_14_item1_p29_s3", "sentA": "The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.", "sentB": "Apart from the IND process described above, each clinical study must be reviewed by an independent Institutional Review Board (IRB) and the IRB must be kept current with respect to the status of the clinical study.", "type": 2, "words": ["<tag1>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program.", "<tag2>", "Apart", "from", "the", "IND", "process", "described", "above,", "each", "clinical", "study", "must", "be", "reviewed", "by", "an", "independent", "Institutional", "Review", "Board", "(IRB)", "and", "the", "IRB", "must", "be", "kept", "current", "with", "respect", "to", "the", "status", "of", "the", "clinical", "study.", "<tag3>"], "wordsA": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program."], "wordsB": ["Apart", "from", "the", "IND", "process", "described", "above,", "each", "clinical", "study", "must", "be", "reviewed", "by", "an", "independent", "Institutional", "Review", "Board", "(IRB)", "and", "the", "IRB", "must", "be", "kept", "current", "with", "respect", "to", "the", "status", "of", "the", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p137_s0", "idA": "906709_14_item1_p29_s3", "sentA": "The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.", "sentB": "Phase 1 involves the initial introduction of the drug into healthy human subjects (in most cases) and the product generally is tested for tolerability, pharmacokinetics, absorption, metabolism and excretion.", "type": 2, "words": ["<tag1>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program.", "<tag2>", "Phase", "1", "involves", "the", "initial", "introduction", "of", "the", "drug", "into", "healthy", "human", "subjects", "(in", "most", "cases)", "and", "the", "product", "generally", "is", "tested", "for", "tolerability,", "pharmacokinetics,", "absorption,", "metabolism", "and", "excretion.", "<tag3>"], "wordsA": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program."], "wordsB": ["Phase", "1", "involves", "the", "initial", "introduction", "of", "the", "drug", "into", "healthy", "human", "subjects", "(in", "most", "cases)", "and", "the", "product", "generally", "is", "tested", "for", "tolerability,", "pharmacokinetics,", "absorption,", "metabolism", "and", "excretion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s2", "idA": "906709_14_item1_p2_s0", "sentA": "Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life and/or bioavailability of drugs.", "sentB": "Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life, bioavailability and mechanism of action.", "type": 2, "words": ["<tag1>", "Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life", "and/or", "bioavailability", "of", "drugs.", "<tag2>", "Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life,", "bioavailability", "and", "mechanism", "of", "action.", "<tag3>"], "wordsA": ["Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life", "and/or", "bioavailability", "of", "drugs."], "wordsB": ["Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life,", "bioavailability", "and", "mechanism", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s3", "idA": "906709_14_item1_p2_s1", "sentA": "Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas that address large potential markets.", "sentB": "Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas", "that", "address", "large", "potential", "markets.", "<tag2>", "Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas", "that", "address", "large", "potential", "markets."], "wordsB": ["Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p139_s1", "idA": "906709_14_item1_p31_s0", "sentA": "Phase 3 or Pivotal product in large-scale clinical trials conducted to obtain regulatory approval to market and sell the drug (these trials are typically initiated following encouraging Phase 2 trial results).", "sentB": "In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials.", "type": 2, "words": ["<tag1>", "Phase", "3", "or", "Pivotal", "product", "in", "large-scale", "clinical", "trials", "conducted", "to", "obtain", "regulatory", "approval", "to", "market", "and", "sell", "the", "drug", "(these", "trials", "are", "typically", "initiated", "following", "encouraging", "Phase", "2", "trial", "results).", "<tag2>", "In", "some", "cases,", "the", "FDA", "and", "the", "drug", "sponsor", "may", "determine", "that", "Phase", "2", "trials", "are", "not", "needed", "prior", "to", "entering", "Phase", "3", "trials.", "<tag3>"], "wordsA": ["Phase", "3", "or", "Pivotal", "product", "in", "large-scale", "clinical", "trials", "conducted", "to", "obtain", "regulatory", "approval", "to", "market", "and", "sell", "the", "drug", "(these", "trials", "are", "typically", "initiated", "following", "encouraging", "Phase", "2", "trial", "results)."], "wordsB": ["In", "some", "cases,", "the", "FDA", "and", "the", "drug", "sponsor", "may", "determine", "that", "Phase", "2", "trials", "are", "not", "needed", "prior", "to", "entering", "Phase", "3", "trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p135_s1", "idA": "906709_14_item1_p32_s0", "sentA": "Phase 2 a drug candidate in clinical trials to establish dosing and efficacy in patients.", "sentB": "Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP).", "type": 2, "words": ["<tag1>", "Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients.", "<tag2>", "Drug", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP).", "<tag3>"], "wordsA": ["Phase", "2", "a", "drug", "candidate", "in", "clinical", "trials", "to", "establish", "dosing", "and", "efficacy", "in", "patients."], "wordsB": ["Drug", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p37_s0", "idA": "906709_14_item1_p35_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "A total of nine products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p38_s0", "idA": "906709_14_item1_p35_s0", "sentA": "A total of eight products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "Phase 3 ongoing and filed for approval in U.S.", "type": 2, "words": ["<tag1>", "A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "Phase", "3", "ongoing", "and", "filed", "for", "approval", "in", "U.S.", "<tag3>"], "wordsA": ["A", "total", "of", "eight", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["Phase", "3", "ongoing", "and", "filed", "for", "approval", "in", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p43_s0", "idA": "906709_14_item1_p39_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche is currently prevented from marketing MIRCERA in the U.S. until July 2014.", "sentB": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche was prevented from marketing MIRCERA in the U.S. until July 2014.", "type": 2, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag2>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "is", "currently", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "wordsB": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s5", "idA": "906709_14_item1_p3_s0", "sentA": "Our most-advanced proprietary drug candidate, naloxegol (formerly known as NKTR-118), is an oral peripherally-acting opioid antagonist, for the treatment of opioid-induced constipation, or OIC, in patients with non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain medicines.", "sentB": "MOVANTIK is an oral peripherally-acting mu-opioid antagonist (PAMORA), approved in both the U.S. and Europe for the treatment of opioid-induced constipation, or OIC, a common side effect caused by chronic administration of prescription opioid pain medicines.", "type": 2, "words": ["<tag1>", "Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "in", "patients", "with", "non-cancer", "pain,", "the", "most", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag2>", "MOVANTIK", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag3>"], "wordsA": ["Our", "most-advanced", "proprietary", "drug", "candidate,", "naloxegol", "(formerly", "known", "as", "NKTR-118),", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "in", "patients", "with", "non-cancer", "pain,", "the", "most", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "wordsB": ["MOVANTIK", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s4", "idA": "906709_14_item1_p41_s0", "sentA": "With respect to all of our collaboration and license agreements with third parties, please refer to Item 1A, Risk Factors, including without limitation, We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.", "sentB": "Please refer to Item 1A, Risk Factors, including but not limited to We rely on trade secret protection and other unpatented proprietary rights for important proprietary technologies, and any loss of such rights could harm our business, results of operations and financial condition.", "type": 2, "words": ["<tag1>", "With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag2>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "but", "not", "limited", "to", "We", "rely", "on", "trade", "secret", "protection", "and", "other", "unpatented", "proprietary", "rights", "for", "important", "proprietary", "technologies,", "and", "any", "loss", "of", "such", "rights", "could", "harm", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag3>"], "wordsA": ["With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "wordsB": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "but", "not", "limited", "to", "We", "rely", "on", "trade", "secret", "protection", "and", "other", "unpatented", "proprietary", "rights", "for", "important", "proprietary", "technologies,", "and", "any", "loss", "of", "such", "rights", "could", "harm", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p155_s7", "idA": "906709_14_item1_p41_s0", "sentA": "With respect to all of our collaboration and license agreements with third parties, please refer to Item 1A, Risk Factors, including without limitation, We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.", "sentB": "Any such restriction on access or liability for damages would have a material adverse effect on our business, results of operations and financial condition.", "type": 2, "words": ["<tag1>", "With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag2>", "Any", "such", "restriction", "on", "access", "or", "liability", "for", "damages", "would", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag3>"], "wordsA": ["With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "wordsB": ["Any", "such", "restriction", "on", "access", "or", "liability", "for", "damages", "would", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p158_s2", "idA": "906709_14_item1_p41_s0", "sentA": "With respect to all of our collaboration and license agreements with third parties, please refer to Item 1A, Risk Factors, including without limitation, We are a party to numerous collaboration agreements and other significant agreements which contain complex commercial terms that could result in disputes, litigation or indemnification liability that could adversely affect our business, results of operations and financial condition.", "sentB": "The failure to obtain licenses if needed may have a material adverse effect on our business, results of operations and financial condition.", "type": 2, "words": ["<tag1>", "With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag2>", "The", "failure", "to", "obtain", "licenses", "if", "needed", "may", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition.", "<tag3>"], "wordsA": ["With", "respect", "to", "all", "of", "our", "collaboration", "and", "license", "agreements", "with", "third", "parties,", "please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "are", "a", "party", "to", "numerous", "collaboration", "agreements", "and", "other", "significant", "agreements", "which", "contain", "complex", "commercial", "terms", "that", "could", "result", "in", "disputes,", "litigation", "or", "indemnification", "liability", "that", "could", "adversely", "affect", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "wordsB": ["The", "failure", "to", "obtain", "licenses", "if", "needed", "may", "have", "a", "material", "adverse", "effect", "on", "our", "business,", "results", "of", "operations", "and", "financial", "condition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s4", "idA": "906709_14_item1_p42_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK (previously referred to as naloxegol and NKTR-118), under a global license agreement with AstraZeneca AB (AstraZeneca).", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca).", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p46_s0", "idA": "906709_14_item1_p42_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell naloxegol and naloxegol fixed-dose combination products.", "sentB": "In September 2009, we entered into a global license agreement with AstraZeneca AB pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell MOVANTIK TM and MOVANTIK TM fixed-dose combination products.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p2_s7", "idA": "906709_14_item1_p4_s0", "sentA": "In November 2013, we reported that our collaboration partner AstraZeneca PLC announced that the United States Food and Drug Administration, or FDA, accepted the New Drug Application, or NDA, for naloxegol, with a Prescription Drug User Fee Act, or PDUFA, date of September 16, 2014.", "sentB": "On September 16, 2014, the United States Food and Drug Administration, or FDA, approved MOVANTIK as the first once-daily oral PAMORA medication for the treatment of OIC, in adult patients with chronic, non-cancer pain.", "type": 2, "words": ["<tag1>", "In", "November", "2013,", "we", "reported", "that", "our", "collaboration", "partner", "AstraZeneca", "PLC", "announced", "that", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "accepted", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "naloxegol,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act,", "or", "PDUFA,", "date", "of", "September", "16,", "2014.", "<tag2>", "On", "September", "16,", "2014,", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "approved", "MOVANTIK", "as", "the", "first", "once-daily", "oral", "PAMORA", "medication", "for", "the", "treatment", "of", "OIC,", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag3>"], "wordsA": ["In", "November", "2013,", "we", "reported", "that", "our", "collaboration", "partner", "AstraZeneca", "PLC", "announced", "that", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "accepted", "the", "New", "Drug", "Application,", "or", "NDA,", "for", "naloxegol,", "with", "a", "Prescription", "Drug", "User", "Fee", "Act,", "or", "PDUFA,", "date", "of", "September", "16,", "2014."], "wordsB": ["On", "September", "16,", "2014,", "the", "United", "States", "Food", "and", "Drug", "Administration,", "or", "FDA,", "approved", "MOVANTIK", "as", "the", "first", "once-daily", "oral", "PAMORA", "medication", "for", "the", "treatment", "of", "OIC,", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p134_s2", "idA": "906709_14_item1_p4_s1", "sentA": "The NDA filing was based on comprehensive data from a Phase 3 clinical development program comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC.", "sentB": "Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation.", "type": 2, "words": ["<tag1>", "The", "NDA", "filing", "was", "based", "on", "comprehensive", "data", "from", "a", "Phase", "3", "clinical", "development", "program", "comprised", "of", "four", "clinical", "trials", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "naloxegol", "for", "the", "treatment", "of", "OIC.", "<tag2>", "Preclinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "animal", "studies", "to", "assess", "the", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "chosen", "formulation.", "<tag3>"], "wordsA": ["The", "NDA", "filing", "was", "based", "on", "comprehensive", "data", "from", "a", "Phase", "3", "clinical", "development", "program", "comprised", "of", "four", "clinical", "trials", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "naloxegol", "for", "the", "treatment", "of", "OIC."], "wordsB": ["Preclinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "animal", "studies", "to", "assess", "the", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "chosen", "formulation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p83_s1", "idA": "906709_14_item1_p4_s1", "sentA": "The NDA filing was based on comprehensive data from a Phase 3 clinical development program comprised of four clinical trials designed to investigate the safety and efficacy of naloxegol for the treatment of OIC.", "sentB": "Nektar scientists conducted a series of studies using preclinical models of breast tumors (EMT6) and colon tumors (CT26) to assess the safety and efficacy of both single agent and combination dosing of NKTR-214 with checkpoint inhibitors, either an anti-PD-1 therapy or an anti-CTLA-4 therapy.", "type": 2, "words": ["<tag1>", "The", "NDA", "filing", "was", "based", "on", "comprehensive", "data", "from", "a", "Phase", "3", "clinical", "development", "program", "comprised", "of", "four", "clinical", "trials", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "naloxegol", "for", "the", "treatment", "of", "OIC.", "<tag2>", "Nektar", "scientists", "conducted", "a", "series", "of", "studies", "using", "preclinical", "models", "of", "breast", "tumors", "(EMT6)", "and", "colon", "tumors", "(CT26)", "to", "assess", "the", "safety", "and", "efficacy", "of", "both", "single", "agent", "and", "combination", "dosing", "of", "NKTR-214", "with", "checkpoint", "inhibitors,", "either", "an", "anti-PD-1", "therapy", "or", "an", "anti-CTLA-4", "therapy.", "<tag3>"], "wordsA": ["The", "NDA", "filing", "was", "based", "on", "comprehensive", "data", "from", "a", "Phase", "3", "clinical", "development", "program", "comprised", "of", "four", "clinical", "trials", "designed", "to", "investigate", "the", "safety", "and", "efficacy", "of", "naloxegol", "for", "the", "treatment", "of", "OIC."], "wordsB": ["Nektar", "scientists", "conducted", "a", "series", "of", "studies", "using", "preclinical", "models", "of", "breast", "tumors", "(EMT6)", "and", "colon", "tumors", "(CT26)", "to", "assess", "the", "safety", "and", "efficacy", "of", "both", "single", "agent", "and", "combination", "dosing", "of", "NKTR-214", "with", "checkpoint", "inhibitors,", "either", "an", "anti-PD-1", "therapy", "or", "an", "anti-CTLA-4", "therapy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p90_s2", "idA": "906709_14_item1_p51_s0", "sentA": "On February 26, 2013, AstraZeneca announced positive top-line results from KODIAC-08.", "sentB": "In August 2014, Baxter announced positive top-line results from the PROLONG-ATE clinical study which met the primary endpoint for the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older.", "type": 2, "words": ["<tag1>", "On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "KODIAC-08.", "<tag2>", "In", "August", "2014,", "Baxter", "announced", "positive", "top-line", "results", "from", "the", "PROLONG-ATE", "clinical", "study", "which", "met", "the", "primary", "endpoint", "for", "the", "control", "and", "prevention", "of", "bleeding,", "routine", "prophylaxis", "and", "perioperative", "management", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag3>"], "wordsA": ["On", "February", "26,", "2013,", "AstraZeneca", "announced", "positive", "top-line", "results", "from", "KODIAC-08."], "wordsB": ["In", "August", "2014,", "Baxter", "announced", "positive", "top-line", "results", "from", "the", "PROLONG-ATE", "clinical", "study", "which", "met", "the", "primary", "endpoint", "for", "the", "control", "and", "prevention", "of", "bleeding,", "routine", "prophylaxis", "and", "perioperative", "management", "for", "patients", "who", "were", "12", "years", "or", "older."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p130_s3", "idA": "906709_14_item1_p51_s4", "sentA": "Additionally, there were no reports of opioid withdrawal AEs which could be attributed to naloxegol.", "sentB": "There have been no reports of such reactions following subsequent dosing, or in patients who have completed their dialysis session.", "type": 2, "words": ["<tag1>", "Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol.", "<tag2>", "There", "have", "been", "no", "reports", "of", "such", "reactions", "following", "subsequent", "dosing,", "or", "in", "patients", "who", "have", "completed", "their", "dialysis", "session.", "<tag3>"], "wordsA": ["Additionally,", "there", "were", "no", "reports", "of", "opioid", "withdrawal", "AEs", "which", "could", "be", "attributed", "to", "naloxegol."], "wordsB": ["There", "have", "been", "no", "reports", "of", "such", "reactions", "following", "subsequent", "dosing,", "or", "in", "patients", "who", "have", "completed", "their", "dialysis", "session."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p141_s0", "idA": "906709_14_item1_p53_s0", "sentA": "Naloxegol is currently considered a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA) based on structural relatedness to noroxymorphone.", "sentB": "Each manufacturing establishment producing the active pharmaceutical ingredient and finished drug product for the U.S. market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment.", "type": 2, "words": ["<tag1>", "Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone.", "<tag2>", "Each", "manufacturing", "establishment", "producing", "the", "active", "pharmaceutical", "ingredient", "and", "finished", "drug", "product", "for", "the", "U.S.", "market", "must", "be", "registered", "with", "the", "FDA", "and", "typically", "is", "inspected", "by", "the", "FDA", "prior", "to", "NDA", "or", "BLA", "approval", "of", "a", "drug", "product", "manufactured", "by", "such", "establishment.", "<tag3>"], "wordsA": ["Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone."], "wordsB": ["Each", "manufacturing", "establishment", "producing", "the", "active", "pharmaceutical", "ingredient", "and", "finished", "drug", "product", "for", "the", "U.S.", "market", "must", "be", "registered", "with", "the", "FDA", "and", "typically", "is", "inspected", "by", "the", "FDA", "prior", "to", "NDA", "or", "BLA", "approval", "of", "a", "drug", "product", "manufactured", "by", "such", "establishment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p141_s2", "idA": "906709_14_item1_p53_s0", "sentA": "Naloxegol is currently considered a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA) based on structural relatedness to noroxymorphone.", "sentB": "Establishments handling controlled substances must also be licensed by the U.S. Drug Enforcement Administration.", "type": 2, "words": ["<tag1>", "Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone.", "<tag2>", "Establishments", "handling", "controlled", "substances", "must", "also", "be", "licensed", "by", "the", "U.S.", "Drug", "Enforcement", "Administration.", "<tag3>"], "wordsA": ["Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone."], "wordsB": ["Establishments", "handling", "controlled", "substances", "must", "also", "be", "licensed", "by", "the", "U.S.", "Drug", "Enforcement", "Administration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s6", "idA": "906709_14_item1_p53_s0", "sentA": "Naloxegol is currently considered a Schedule II controlled substance by the U.S. Drug Enforcement Administration (DEA) based on structural relatedness to noroxymorphone.", "sentB": "We may have to participate in interference proceedings declared by the U.S. Patent and Trademark Office, which could result in a loss of the patent and/or substantial cost to us.", "type": 2, "words": ["<tag1>", "Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone.", "<tag2>", "We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us.", "<tag3>"], "wordsA": ["Naloxegol", "is", "currently", "considered", "a", "Schedule", "II", "controlled", "substance", "by", "the", "U.S.", "Drug", "Enforcement", "Administration", "(DEA)", "based", "on", "structural", "relatedness", "to", "noroxymorphone."], "wordsB": ["We", "may", "have", "to", "participate", "in", "interference", "proceedings", "declared", "by", "the", "U.S.", "Patent", "and", "Trademark", "Office,", "which", "could", "result", "in", "a", "loss", "of", "the", "patent", "and/or", "substantial", "cost", "to", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p141_s4", "idA": "906709_14_item1_p53_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance controls, among others.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p147_s0", "idA": "906709_14_item1_p53_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "Sales of our products outside the U.S. are subject to local regulatory requirements governing clinical trials and marketing approval for drugs.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "Sales", "of", "our", "products", "outside", "the", "U.S.", "are", "subject", "to", "local", "regulatory", "requirements", "governing", "clinical", "trials", "and", "marketing", "approval", "for", "drugs.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["Sales", "of", "our", "products", "outside", "the", "U.S.", "are", "subject", "to", "local", "regulatory", "requirements", "governing", "clinical", "trials", "and", "marketing", "approval", "for", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s3", "idA": "906709_14_item1_p53_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "Additionally, issued patents can be subject to opposition or other proceedings that can result in the revocation of the patent or maintenance of the patent in amended form (and potentially in a form that renders the patent without commercially relevant or broad coverage).", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "Additionally,", "issued", "patents", "can", "be", "subject", "to", "opposition", "or", "other", "proceedings", "that", "can", "result", "in", "the", "revocation", "of", "the", "patent", "or", "maintenance", "of", "the", "patent", "in", "amended", "form", "(and", "potentially", "in", "a", "form", "that", "renders", "the", "patent", "without", "commercially", "relevant", "or", "broad", "coverage).", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["Additionally,", "issued", "patents", "can", "be", "subject", "to", "opposition", "or", "other", "proceedings", "that", "can", "result", "in", "the", "revocation", "of", "the", "patent", "or", "maintenance", "of", "the", "patent", "in", "amended", "form", "(and", "potentially", "in", "a", "form", "that", "renders", "the", "patent", "without", "commercially", "relevant", "or", "broad", "coverage)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p157_s3", "idA": "906709_14_item1_p53_s3", "sentA": "Commercialization and launch in the U.S. will be subject to both FDA approval and DEA schedule determination.", "sentB": "Furthermore, parties making such claims may be able to obtain injunctive or other equitable relief, which could effectively block our ability to develop or commercialize some or all of our products in the U.S. and abroad and could result in the award of substantial damages.", "type": 2, "words": ["<tag1>", "Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination.", "<tag2>", "Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages.", "<tag3>"], "wordsA": ["Commercialization", "and", "launch", "in", "the", "U.S.", "will", "be", "subject", "to", "both", "FDA", "approval", "and", "DEA", "schedule", "determination."], "wordsB": ["Furthermore,", "parties", "making", "such", "claims", "may", "be", "able", "to", "obtain", "injunctive", "or", "other", "equitable", "relief,", "which", "could", "effectively", "block", "our", "ability", "to", "develop", "or", "commercialize", "some", "or", "all", "of", "our", "products", "in", "the", "U.S.", "and", "abroad", "and", "could", "result", "in", "the", "award", "of", "substantial", "damages."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p156_s7", "idA": "906709_14_item1_p54_s0", "sentA": "Please refer to Item 1A, Risk Factors, including without limitation, If we or our partners do not obtain regulatory approval for our drug candidates on a timely basis, or at all, or if the terms of any approval impose significant restrictions or limitations on use, our business, results of operations and financial condition will be negatively affected.", "sentB": "Please refer to Item 1A, Risk Factors, including without limitation, If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.", "type": 2, "words": ["<tag1>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "we", "or", "our", "partners", "do", "not", "obtain", "regulatory", "approval", "for", "our", "drug", "candidates", "on", "a", "timely", "basis,", "or", "at", "all,", "or", "if", "the", "terms", "of", "any", "approval", "impose", "significant", "restrictions", "or", "limitations", "on", "use,", "our", "business,", "results", "of", "operations", "and", "financial", "condition", "will", "be", "negatively", "affected.", "<tag2>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "any", "of", "our", "pending", "patent", "applications", "do", "not", "issue,", "or", "are", "deemed", "invalid", "following", "issuance,", "we", "may", "lose", "valuable", "intellectual", "property", "protection.", "<tag3>"], "wordsA": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "we", "or", "our", "partners", "do", "not", "obtain", "regulatory", "approval", "for", "our", "drug", "candidates", "on", "a", "timely", "basis,", "or", "at", "all,", "or", "if", "the", "terms", "of", "any", "approval", "impose", "significant", "restrictions", "or", "limitations", "on", "use,", "our", "business,", "results", "of", "operations", "and", "financial", "condition", "will", "be", "negatively", "affected."], "wordsB": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "any", "of", "our", "pending", "patent", "applications", "do", "not", "issue,", "or", "are", "deemed", "invalid", "following", "issuance,", "we", "may", "lose", "valuable", "intellectual", "property", "protection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s1", "idA": "906709_14_item1_p55_s0", "sentA": "Under the terms of our license agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for naloxegol and naloxegol fixed-dose combination products.", "sentB": "Under the terms of our license agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK TM and MOVANTIK TM fixed-dose combination products.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products.", "<tag2>", "Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "naloxegol", "and", "naloxegol", "fixed-dose", "combination", "products."], "wordsB": ["Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s2", "idA": "906709_14_item1_p55_s1", "sentA": "For naloxegol, we have received $70.0 million and $25.0 million upon the acceptance for review of naloxegol regulatory approval applications filed by AstraZeneca with the FDA and European Medicines Agency (EMA), respectively, in 2013 and are also entitled to up to an additional $175.0 million upon certain regulatory approval and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "We received $70.0 million and $25.0 million upon the acceptance for review of MOVANTIK TM regulatory approval applications filed with the FDA and European Medicines Agency (EMA), respectively, in 2013.", "type": 2, "words": ["<tag1>", "For", "naloxegol,", "we", "have", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "naloxegol", "regulatory", "approval", "applications", "filed", "by", "AstraZeneca", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013", "and", "are", "also", "entitled", "to", "up", "to", "an", "additional", "$175.0", "million", "upon", "certain", "regulatory", "approval", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "MOVANTIK", "TM", "regulatory", "approval", "applications", "filed", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag3>"], "wordsA": ["For", "naloxegol,", "we", "have", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "naloxegol", "regulatory", "approval", "applications", "filed", "by", "AstraZeneca", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013", "and", "are", "also", "entitled", "to", "up", "to", "an", "additional", "$175.0", "million", "upon", "certain", "regulatory", "approval", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "MOVANTIK", "TM", "regulatory", "approval", "applications", "filed", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s5", "idA": "906709_14_item1_p55_s1", "sentA": "For naloxegol, we have received $70.0 million and $25.0 million upon the acceptance for review of naloxegol regulatory approval applications filed by AstraZeneca with the FDA and European Medicines Agency (EMA), respectively, in 2013 and are also entitled to up to an additional $175.0 million upon certain regulatory approval and commercial launch milestones, and $375.0 million in sales milestones if the product achieves certain annual commercial sales levels.", "sentB": "We are also entitled to up to $375.0 million in sales milestones for MOVANTIK TM if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "naloxegol,", "we", "have", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "naloxegol", "regulatory", "approval", "applications", "filed", "by", "AstraZeneca", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013", "and", "are", "also", "entitled", "to", "up", "to", "an", "additional", "$175.0", "million", "upon", "certain", "regulatory", "approval", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "are", "also", "entitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "TM", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "naloxegol,", "we", "have", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "naloxegol", "regulatory", "approval", "applications", "filed", "by", "AstraZeneca", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013", "and", "are", "also", "entitled", "to", "up", "to", "an", "additional", "$175.0", "million", "upon", "certain", "regulatory", "approval", "and", "commercial", "launch", "milestones,", "and", "$375.0", "million", "in", "sales", "milestones", "if", "the", "product", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "are", "also", "entitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "TM", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s3", "idA": "906709_14_item1_p56_s0", "sentA": "If the FDA does not require a future clinical trial or other significant studies to assess the cardiovascular safety (CV Safety Study) of naloxegol prior to an approval decision, AstraZeneca is required to pay us a $35.0 million milestone.", "sentB": "In 2014, we received an additional $35.0 million payment upon the FDA s approval of MOVANTIK TM .", "type": 2, "words": ["<tag1>", "If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(CV", "Safety", "Study)", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "required", "to", "pay", "us", "a", "$35.0", "million", "milestone.", "<tag2>", "In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", ".", "<tag3>"], "wordsA": ["If", "the", "FDA", "does", "not", "require", "a", "future", "clinical", "trial", "or", "other", "significant", "studies", "to", "assess", "the", "cardiovascular", "safety", "(CV", "Safety", "Study)", "of", "naloxegol", "prior", "to", "an", "approval", "decision,", "AstraZeneca", "is", "required", "to", "pay", "us", "a", "$35.0", "million", "milestone."], "wordsB": ["In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s4", "idA": "906709_14_item1_p56_s5", "sentA": "The remaining $140.0 million of milestone payments are due upon the commercial launches of naloxegol in the U.S. and in the E.U. For the naloxegol fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "sentB": "The remaining $140.0 million of development milestone payments are due upon the commercial launches of MOVANTIK TM in the U.S. ($100 million) and in the E.U. ($40 million).", "type": 2, "words": ["<tag1>", "The", "remaining", "$140.0", "million", "of", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "the", "U.S.", "and", "in", "the", "E.U.", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "The", "remaining", "$140.0", "million", "of", "development", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "MOVANTIK", "TM", "in", "the", "U.S.", "($100", "million)", "and", "in", "the", "E.U.", "($40", "million).", "<tag3>"], "wordsA": ["The", "remaining", "$140.0", "million", "of", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "the", "U.S.", "and", "in", "the", "E.U.", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["The", "remaining", "$140.0", "million", "of", "development", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "MOVANTIK", "TM", "in", "the", "U.S.", "($100", "million)", "and", "in", "the", "E.U.", "($40", "million)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s6", "idA": "906709_14_item1_p56_s5", "sentA": "The remaining $140.0 million of milestone payments are due upon the commercial launches of naloxegol in the U.S. and in the E.U. For the naloxegol fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "sentB": "For the MOVANTIK TM fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "The", "remaining", "$140.0", "million", "of", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "the", "U.S.", "and", "in", "the", "E.U.", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "the", "MOVANTIK", "TM", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["The", "remaining", "$140.0", "million", "of", "milestone", "payments", "are", "due", "upon", "the", "commercial", "launches", "of", "naloxegol", "in", "the", "U.S.", "and", "in", "the", "E.U.", "For", "the", "naloxegol", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "the", "MOVANTIK", "TM", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s7", "idA": "906709_14_item1_p56_s6", "sentA": "For both naloxegol and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments, varying by country of sale and level of annual net sales.", "sentB": "For both MOVANTIK TM and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sales in the U.S. and 18% of net sales in the E.U. and rest of world, varying by country of sale and level of annual net sales.", "type": 2, "words": ["<tag1>", "For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "E.U.", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag3>"], "wordsA": ["For", "both", "naloxegol", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "E.U.", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p53_s0", "idA": "906709_14_item1_p57_s0", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one naloxegol fixed-dose combination product and has the right to develop multiple products which combine naloxegol with other opioids.", "sentB": "AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK TM fixed-dose combination product and has the right to develop multiple products which combine MOVANTIK TM with opioids.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids.", "<tag2>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "TM", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "TM", "with", "opioids.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "naloxegol", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "naloxegol", "with", "other", "opioids."], "wordsB": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "TM", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "TM", "with", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p101_s2", "idA": "906709_14_item1_p58_s2", "sentA": "Unlike irinotecan, which is a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, etirinotecan pegol s pro-drug design results in a lower initial peak concentration of active topo I inhibitor in the blood.", "sentB": "However, rHuPH20 acts only locally at the injection site, is rapidly inactivated in the body, and does not survive in the blood.", "type": 2, "words": ["<tag1>", "Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "etirinotecan", "pegol", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood.", "<tag2>", "However,", "rHuPH20", "acts", "only", "locally", "at", "the", "injection", "site,", "is", "rapidly", "inactivated", "in", "the", "body,", "and", "does", "not", "survive", "in", "the", "blood.", "<tag3>"], "wordsA": ["Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "etirinotecan", "pegol", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood."], "wordsB": ["However,", "rHuPH20", "acts", "only", "locally", "at", "the", "injection", "site,", "is", "rapidly", "inactivated", "in", "the", "body,", "and", "does", "not", "survive", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p5_s0", "idA": "906709_14_item1_p5_s0", "sentA": "Our second-most-advanced drug candidate, etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I inhibitor, currently being evaluated in a Phase 3 clinical study as a single-agent therapy for women with metastatic breast cancer.", "sentB": "Etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I (topo I) inhibitor currently being evaluated in a Phase 3 open-label, randomized, multicenter clinical study as a single-agent therapy for women with metastatic breast cancer.", "type": 2, "words": ["<tag1>", "Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "women", "with", "metastatic", "breast", "cancer.", "<tag2>", "Etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "currently", "being", "evaluated", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "women", "with", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["Our", "second-most-advanced", "drug", "candidate,", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "inhibitor,", "currently", "being", "evaluated", "in", "a", "Phase", "3", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "women", "with", "metastatic", "breast", "cancer."], "wordsB": ["Etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "currently", "being", "evaluated", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "women", "with", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p5_s1", "idA": "906709_14_item1_p5_s2", "sentA": "The BEACON study enrolled approximately 850 women with locally recurrent or metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), has completed enrollment of approximately 850 women with locally recurrent or metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "enrolled", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "has", "completed", "enrollment", "of", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "enrolled", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "has", "completed", "enrollment", "of", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p59_s2", "idA": "906709_14_item1_p5_s3", "sentA": "Patients in the BEACON study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "This study randomized patients on a 1:1 basis to receive single-agent etirinotecan pegol or a single agent chosen from a defined set of physician s choice alternatives.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "This", "study", "randomized", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["This", "study", "randomized", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s16", "idA": "906709_14_item1_p5_s3", "sentA": "Patients in the BEACON study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "In this first efficacy study, we plan to enroll approximately 416 patients in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "In", "this", "first", "efficacy", "study,", "we", "plan", "to", "enroll", "approximately", "416", "patients", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["In", "this", "first", "efficacy", "study,", "we", "plan", "to", "enroll", "approximately", "416", "patients", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p7_s1", "idA": "906709_14_item1_p5_s4", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "We have now achieved the necessary number of events in the BEACON study to assess the overall survival primary endpoint and other secondary endpoints.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "We", "have", "now", "achieved", "the", "necessary", "number", "of", "events", "in", "the", "BEACON", "study", "to", "assess", "the", "overall", "survival", "primary", "endpoint", "and", "other", "secondary", "endpoints.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["We", "have", "now", "achieved", "the", "necessary", "number", "of", "events", "in", "the", "BEACON", "study", "to", "assess", "the", "overall", "survival", "primary", "endpoint", "and", "other", "secondary", "endpoints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p7_s0", "idA": "906709_14_item1_p5_s5", "sentA": "On January 14, 2014, we announced that the Independent Data Monitoring Committee, or the DMC, created to provide safety oversight for the BEACON study recommended continuation of the Phase 3 BEACON study following an interim data analysis which was performed after reaching 50% of the events needed to achieve the primary endpoint of overall survival.", "sentB": "In January 2014, we announced that the Independent Data Monitoring Committee created to provide safety oversight for the BEACON study recommended continuation of the BEACON study following an interim data analysis which was performed after reaching 50% of the events needed to achieve the primary endpoint of overall survival.", "type": 2, "words": ["<tag1>", "On", "January", "14,", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee,", "or", "the", "DMC,", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "Phase", "3", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival.", "<tag2>", "In", "January", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival.", "<tag3>"], "wordsA": ["On", "January", "14,", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee,", "or", "the", "DMC,", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "Phase", "3", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival."], "wordsB": ["In", "January", "2014,", "we", "announced", "that", "the", "Independent", "Data", "Monitoring", "Committee", "created", "to", "provide", "safety", "oversight", "for", "the", "BEACON", "study", "recommended", "continuation", "of", "the", "BEACON", "study", "following", "an", "interim", "data", "analysis", "which", "was", "performed", "after", "reaching", "50%", "of", "the", "events", "needed", "to", "achieve", "the", "primary", "endpoint", "of", "overall", "survival."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p102_s1", "idA": "906709_14_item1_p62_s0", "sentA": "Etirinotecan pegol is currently being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "sentB": "Halozyme is currently evaluating PEGPH20 in a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer.", "type": 2, "words": ["<tag1>", "Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer.", "<tag3>"], "wordsA": ["Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p59_s0", "idA": "906709_14_item1_p62_s2", "sentA": "The BEACON study enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p59_s4", "idA": "906709_14_item1_p63_s1", "sentA": "Randomization was stratified by geographic region, prior treatment with eribulin and whether or not the patient has triple negative breast cancer.", "sentB": "Randomization was stratified by geographic region, prior treatment with eribulin and whether or not the patient had triple negative breast cancer.", "type": 2, "words": ["<tag1>", "Randomization", "was", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "has", "triple", "negative", "breast", "cancer.", "<tag2>", "Randomization", "was", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "had", "triple", "negative", "breast", "cancer.", "<tag3>"], "wordsA": ["Randomization", "was", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "has", "triple", "negative", "breast", "cancer."], "wordsB": ["Randomization", "was", "stratified", "by", "geographic", "region,", "prior", "treatment", "with", "eribulin", "and", "whether", "or", "not", "the", "patient", "had", "triple", "negative", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p3_s0", "idA": "906709_14_item1_p67_s0", "sentA": "In 2014, the American Cancer Society estimates there will be 235,030 new cases of breast cancer in the United States.", "sentB": "On January 23, 2015, the United States Drug Enforcement Agency published its final rule in the Federal Register, effective immediately on the date it was published, which removed naloxegol and its salts from the schedules of the Controlled Substances Act.", "type": 2, "words": ["<tag1>", "In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States.", "<tag2>", "On", "January", "23,", "2015,", "the", "United", "States", "Drug", "Enforcement", "Agency", "published", "its", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "which", "removed", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act.", "<tag3>"], "wordsA": ["In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States."], "wordsB": ["On", "January", "23,", "2015,", "the", "United", "States", "Drug", "Enforcement", "Agency", "published", "its", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "which", "removed", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p4_s0", "idA": "906709_14_item1_p67_s0", "sentA": "In 2014, the American Cancer Society estimates there will be 235,030 new cases of breast cancer in the United States.", "sentB": "AstraZeneca is planning the commercial launch of MOVANTIK in the United States late in the first quarter of 2015 and commercial launch of MOVENTIG in Europe in the second half of 2015.", "type": 2, "words": ["<tag1>", "In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States.", "<tag2>", "AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "commercial", "launch", "of", "MOVENTIG", "in", "Europe", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States."], "wordsB": ["AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "commercial", "launch", "of", "MOVENTIG", "in", "Europe", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p52_s0", "idA": "906709_14_item1_p67_s0", "sentA": "In 2014, the American Cancer Society estimates there will be 235,030 new cases of breast cancer in the United States.", "sentB": "AstraZeneca is planning the commercial launch of MOVANTIK in the United States late in the first quarter of 2015 and MOVENTIG in the second half of 2015.", "type": 2, "words": ["<tag1>", "In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States.", "<tag2>", "AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "second", "half", "of", "2015.", "<tag3>"], "wordsA": ["In", "2014,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "235,030", "new", "cases", "of", "breast", "cancer", "in", "the", "United", "States."], "wordsB": ["AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "second", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p63_s0", "idA": "906709_14_item1_p68_s0", "sentA": "Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.", "sentB": "In 2015, the American Cancer Society estimates there will be 231,840 new cases of breast cancer in the U.S. Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.", "type": 2, "words": ["<tag1>", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body.", "<tag2>", "In", "2015,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "231,840", "new", "cases", "of", "breast", "cancer", "in", "the", "U.S.", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body.", "<tag3>"], "wordsA": ["Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body."], "wordsB": ["In", "2015,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "231,840", "new", "cases", "of", "breast", "cancer", "in", "the", "U.S.", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s0", "idA": "906709_14_item1_p69_s0", "sentA": "There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.", "sentB": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "to", "treat", "breast", "cancer.", "<tag2>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "to", "treat", "breast", "cancer."], "wordsB": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s2", "idA": "906709_14_item1_p69_s1", "sentA": "Etirinotecan pegol has also completed a Phase 2 clinical study in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "sentB": "In 2013, we completed a Phase 2 clinical study for etirinotecan pegol in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "type": 2, "words": ["<tag1>", "Etirinotecan", "pegol", "has", "also", "completed", "a", "Phase", "2", "clinical", "study", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag3>"], "wordsA": ["Etirinotecan", "pegol", "has", "also", "completed", "a", "Phase", "2", "clinical", "study", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p136_s0", "idA": "906709_14_item1_p69_s2", "sentA": "The Phase 2 clinical study included two phases.", "sentB": "Clinical trials are typically conducted in three sequential phases.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "included", "two", "phases.", "<tag2>", "Clinical", "trials", "are", "typically", "conducted", "in", "three", "sequential", "phases.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "included", "two", "phases."], "wordsB": ["Clinical", "trials", "are", "typically", "conducted", "in", "three", "sequential", "phases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p137_s1", "idA": "906709_14_item1_p69_s2", "sentA": "The Phase 2 clinical study included two phases.", "sentB": "Phase 2 involves studies in a limited patient population to:", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "included", "two", "phases.", "<tag2>", "Phase", "2", "involves", "studies", "in", "a", "limited", "patient", "population", "to:", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "included", "two", "phases."], "wordsB": ["Phase", "2", "involves", "studies", "in", "a", "limited", "patient", "population", "to:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s4", "idA": "906709_14_item1_p69_s2", "sentA": "The Phase 2 clinical study included two phases.", "sentB": "The Phase 2 clinical study was designed to enroll 174 patients with metastatic colorectal cancer.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "included", "two", "phases.", "<tag2>", "The", "Phase", "2", "clinical", "study", "was", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "included", "two", "phases."], "wordsB": ["The", "Phase", "2", "clinical", "study", "was", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p102_s2", "idA": "906709_14_item1_p6_s0", "sentA": "In November 2012, the FDA designated etirinotecan pegol as a Fast Track development program for the treatment of patients with locally recurrent or metastatic breast cancer progressing after treatment with an anthracycline, a taxane, and capecitabine.", "sentB": "Halozyme is also evaluating PEGPH20 in an on-going Phase 1b multi-center, randomized clinical trial evaluating PEGPH20 as a second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.", "type": 2, "words": ["<tag1>", "In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine.", "<tag2>", "Halozyme", "is", "also", "evaluating", "PEGPH20", "in", "an", "on-going", "Phase", "1b", "multi-center,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "second-line", "therapy", "for", "patients", "with", "locally", "advanced", "or", "metastatic", "non-small", "cell", "lung", "cancer.", "<tag3>"], "wordsA": ["In", "November", "2012,", "the", "FDA", "designated", "etirinotecan", "pegol", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "patients", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "progressing", "after", "treatment", "with", "an", "anthracycline,", "a", "taxane,", "and", "capecitabine."], "wordsB": ["Halozyme", "is", "also", "evaluating", "PEGPH20", "in", "an", "on-going", "Phase", "1b", "multi-center,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "second-line", "therapy", "for", "patients", "with", "locally", "advanced", "or", "metastatic", "non-small", "cell", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s1", "idA": "906709_14_item1_p6_s1", "sentA": "We have also studied or provided support for ongoing studies being conducted for etirinotecan pegol in bevacizumab (Avastin)-resistant high-grade glioma, colorectal cancer, metastatic and recurrent non-small cell lung cancer, and ovarian cancer.", "sentB": "We have also conducted clinical studies for etirinotecan pegol in other solid tumor settings.", "type": 2, "words": ["<tag1>", "We", "have", "also", "studied", "or", "provided", "support", "for", "ongoing", "studies", "being", "conducted", "for", "etirinotecan", "pegol", "in", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "colorectal", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "ovarian", "cancer.", "<tag2>", "We", "have", "also", "conducted", "clinical", "studies", "for", "etirinotecan", "pegol", "in", "other", "solid", "tumor", "settings.", "<tag3>"], "wordsA": ["We", "have", "also", "studied", "or", "provided", "support", "for", "ongoing", "studies", "being", "conducted", "for", "etirinotecan", "pegol", "in", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "colorectal", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "ovarian", "cancer."], "wordsB": ["We", "have", "also", "conducted", "clinical", "studies", "for", "etirinotecan", "pegol", "in", "other", "solid", "tumor", "settings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p8_s1", "idA": "906709_14_item1_p6_s1", "sentA": "We have also studied or provided support for ongoing studies being conducted for etirinotecan pegol in bevacizumab (Avastin)-resistant high-grade glioma, colorectal cancer, metastatic and recurrent non-small cell lung cancer, and ovarian cancer.", "sentB": "We have also studied etirinotecan pegol in colorectal cancer and ovarian cancer and, in addition, have provided or are providing support for investigator initiated research with etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma, relapsed small cell lung cancer, metastatic and recurrent non-small cell lung cancer, and with refractory brain metastases in patients with lung cancer.", "type": 2, "words": ["<tag1>", "We", "have", "also", "studied", "or", "provided", "support", "for", "ongoing", "studies", "being", "conducted", "for", "etirinotecan", "pegol", "in", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "colorectal", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "ovarian", "cancer.", "<tag2>", "We", "have", "also", "studied", "etirinotecan", "pegol", "in", "colorectal", "cancer", "and", "ovarian", "cancer", "and,", "in", "addition,", "have", "provided", "or", "are", "providing", "support", "for", "investigator", "initiated", "research", "with", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "relapsed", "small", "cell", "lung", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "with", "refractory", "brain", "metastases", "in", "patients", "with", "lung", "cancer.", "<tag3>"], "wordsA": ["We", "have", "also", "studied", "or", "provided", "support", "for", "ongoing", "studies", "being", "conducted", "for", "etirinotecan", "pegol", "in", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "colorectal", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "ovarian", "cancer."], "wordsB": ["We", "have", "also", "studied", "etirinotecan", "pegol", "in", "colorectal", "cancer", "and", "ovarian", "cancer", "and,", "in", "addition,", "have", "provided", "or", "are", "providing", "support", "for", "investigator", "initiated", "research", "with", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma,", "relapsed", "small", "cell", "lung", "cancer,", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer,", "and", "with", "refractory", "brain", "metastases", "in", "patients", "with", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p61_s1", "idA": "906709_14_item1_p71_s4", "sentA": "We do not plan to make a decision on future development for etirinotecan pegol in ovarian cancer until we review the top-line data from the BEACON study.", "sentB": "We are now conducting blinded data verification activities and currently plan to unblind and announce the top-line data from the BEACON Study in March 2015.", "type": 2, "words": ["<tag1>", "We", "do", "not", "plan", "to", "make", "a", "decision", "on", "future", "development", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer", "until", "we", "review", "the", "top-line", "data", "from", "the", "BEACON", "study.", "<tag2>", "We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "unblind", "and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015.", "<tag3>"], "wordsA": ["We", "do", "not", "plan", "to", "make", "a", "decision", "on", "future", "development", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer", "until", "we", "review", "the", "top-line", "data", "from", "the", "BEACON", "study."], "wordsB": ["We", "are", "now", "conducting", "blinded", "data", "verification", "activities", "and", "currently", "plan", "to", "unblind", "and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p8_s0", "idA": "906709_14_item1_p71_s4", "sentA": "We do not plan to make a decision on future development for etirinotecan pegol in ovarian cancer until we review the top-line data from the BEACON study.", "sentB": "and announce the top-line data from the BEACON Study in March 2015.", "type": 2, "words": ["<tag1>", "We", "do", "not", "plan", "to", "make", "a", "decision", "on", "future", "development", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer", "until", "we", "review", "the", "top-line", "data", "from", "the", "BEACON", "study.", "<tag2>", "and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015.", "<tag3>"], "wordsA": ["We", "do", "not", "plan", "to", "make", "a", "decision", "on", "future", "development", "for", "etirinotecan", "pegol", "in", "ovarian", "cancer", "until", "we", "review", "the", "top-line", "data", "from", "the", "BEACON", "study."], "wordsB": ["and", "announce", "the", "top-line", "data", "from", "the", "BEACON", "Study", "in", "March", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p138_s1", "idA": "906709_14_item1_p74_s0", "sentA": "An etirinotecan pegol Phase 2 clinical study was initiated in June 2008 to evaluate the efficacy and safety of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "If Phase 2 trials demonstrate that a product appears to be effective and to have an acceptable safety profile, Phase 3 trials are undertaken to evaluate the further clinical efficacy and safety of the drug and formulation within an expanded patient population at geographically dispersed clinical study sites and in large enough trials to provide statistical proof of efficacy and tolerability.", "type": 2, "words": ["<tag1>", "An", "etirinotecan", "pegol", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "If", "Phase", "2", "trials", "demonstrate", "that", "a", "product", "appears", "to", "be", "effective", "and", "to", "have", "an", "acceptable", "safety", "profile,", "Phase", "3", "trials", "are", "undertaken", "to", "evaluate", "the", "further", "clinical", "efficacy", "and", "safety", "of", "the", "drug", "and", "formulation", "within", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "study", "sites", "and", "in", "large", "enough", "trials", "to", "provide", "statistical", "proof", "of", "efficacy", "and", "tolerability.", "<tag3>"], "wordsA": ["An", "etirinotecan", "pegol", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["If", "Phase", "2", "trials", "demonstrate", "that", "a", "product", "appears", "to", "be", "effective", "and", "to", "have", "an", "acceptable", "safety", "profile,", "Phase", "3", "trials", "are", "undertaken", "to", "evaluate", "the", "further", "clinical", "efficacy", "and", "safety", "of", "the", "drug", "and", "formulation", "within", "an", "expanded", "patient", "population", "at", "geographically", "dispersed", "clinical", "study", "sites", "and", "in", "large", "enough", "trials", "to", "provide", "statistical", "proof", "of", "efficacy", "and", "tolerability."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s3", "idA": "906709_14_item1_p74_s0", "sentA": "An etirinotecan pegol Phase 2 clinical study was initiated in June 2008 to evaluate the efficacy and safety of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "We also initiated a Phase 2 clinical study of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "type": 2, "words": ["<tag1>", "An", "etirinotecan", "pegol", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag3>"], "wordsA": ["An", "etirinotecan", "pegol", "Phase", "2", "clinical", "study", "was", "initiated", "in", "June", "2008", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s5", "idA": "906709_14_item1_p75_s0", "sentA": "In February 2014, we decided to close enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or E.U. Based on preliminary data we have collected to date from this study, etirinotecan pegol resulted in numerically improved overall survival, progression-free survival, objective response rate, and duration of response compared to that observed in the irinotecan comparator arm.", "sentB": "In February 2014, we decided to close enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or E.U.", "type": 2, "words": ["<tag1>", "In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U.", "Based", "on", "preliminary", "data", "we", "have", "collected", "to", "date", "from", "this", "study,", "etirinotecan", "pegol", "resulted", "in", "numerically", "improved", "overall", "survival,", "progression-free", "survival,", "objective", "response", "rate,", "and", "duration", "of", "response", "compared", "to", "that", "observed", "in", "the", "irinotecan", "comparator", "arm.", "<tag2>", "In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U.", "<tag3>"], "wordsA": ["In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U.", "Based", "on", "preliminary", "data", "we", "have", "collected", "to", "date", "from", "this", "study,", "etirinotecan", "pegol", "resulted", "in", "numerically", "improved", "overall", "survival,", "progression-free", "survival,", "objective", "response", "rate,", "and", "duration", "of", "response", "compared", "to", "that", "observed", "in", "the", "irinotecan", "comparator", "arm."], "wordsB": ["In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p129_s1", "idA": "906709_14_item1_p76_s0", "sentA": "Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in the U.S.", "sentB": "OMONTYS is the first once-monthly ESA for anemia in CKD for dialysis patients available in the U.S.", "type": 2, "words": ["<tag1>", "Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S.", "<tag2>", "OMONTYS", "is", "the", "first", "once-monthly", "ESA", "for", "anemia", "in", "CKD", "for", "dialysis", "patients", "available", "in", "the", "U.S.", "<tag3>"], "wordsA": ["Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S."], "wordsB": ["OMONTYS", "is", "the", "first", "once-monthly", "ESA", "for", "anemia", "in", "CKD", "for", "dialysis", "patients", "available", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p148_s0", "idA": "906709_14_item1_p76_s0", "sentA": "Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in the U.S.", "sentB": "In the U.S., under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S.", "type": 2, "words": ["<tag1>", "Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S.", "<tag2>", "In", "the", "U.S.,", "under", "the", "Orphan", "Drug", "Act,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "drugs", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "U.S.", "<tag3>"], "wordsA": ["Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S."], "wordsB": ["In", "the", "U.S.,", "under", "the", "Orphan", "Drug", "Act,", "the", "FDA", "may", "grant", "orphan", "drug", "designation", "to", "drugs", "intended", "to", "treat", "a", "rare", "disease", "or", "condition,", "which", "is", "generally", "a", "disease", "or", "condition", "that", "affects", "fewer", "than", "200,000", "individuals", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p97_s1", "idA": "906709_14_item1_p76_s0", "sentA": "Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in the U.S.", "sentB": "On May 19, 2014, Ophthotech entered into a Licensing and Commercialization Agreement with Novartis Pharma AG to develop and commercialize Fovista and related combination products in all countries outside of the U.S.", "type": 2, "words": ["<tag1>", "Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S.", "<tag2>", "On", "May", "19,", "2014,", "Ophthotech", "entered", "into", "a", "Licensing", "and", "Commercialization", "Agreement", "with", "Novartis", "Pharma", "AG", "to", "develop", "and", "commercialize", "Fovista", "and", "related", "combination", "products", "in", "all", "countries", "outside", "of", "the", "U.S.", "<tag3>"], "wordsA": ["Colorectal", "cancer", "is", "the", "third", "most", "commonly", "diagnosed", "cancer", "and", "the", "third", "leading", "cause", "of", "cancer", "death", "in", "the", "U.S."], "wordsB": ["On", "May", "19,", "2014,", "Ophthotech", "entered", "into", "a", "Licensing", "and", "Commercialization", "Agreement", "with", "Novartis", "Pharma", "AG", "to", "develop", "and", "commercialize", "Fovista", "and", "related", "combination", "products", "in", "all", "countries", "outside", "of", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p133_s0", "idA": "906709_14_item1_p76_s1", "sentA": "According to the American Cancer Society, nearly 137,000 new cases of colon and rectal cancer will be diagnosed in the U.S. in 2014, and about 51,000 people will die annually of the disease.", "sentB": "The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S. depends on whether the chemical composition of the product has previously been approved for use in other dosage forms.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Cancer", "Society,", "nearly", "137,000", "new", "cases", "of", "colon", "and", "rectal", "cancer", "will", "be", "diagnosed", "in", "the", "U.S.", "in", "2014,", "and", "about", "51,000", "people", "will", "die", "annually", "of", "the", "disease.", "<tag2>", "The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Cancer", "Society,", "nearly", "137,000", "new", "cases", "of", "colon", "and", "rectal", "cancer", "will", "be", "diagnosed", "in", "the", "U.S.", "in", "2014,", "and", "about", "51,000", "people", "will", "die", "annually", "of", "the", "disease."], "wordsB": ["The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s10", "idA": "906709_14_item1_p77_s0", "sentA": "In addition to the clinical studies being conducted by us, there are also three investigator-initiated Phase 2 studies being conducted for etirinotecan pegol.", "sentB": "In addition to the clinical study of etirinotecan pegol being conducted by us, we are also providing support for four investigator-initiated Phase 2 studies being conducted for etirinotecan pegol.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "studies", "being", "conducted", "by", "us,", "there", "are", "also", "three", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol.", "<tag2>", "In", "addition", "to", "the", "clinical", "study", "of", "etirinotecan", "pegol", "being", "conducted", "by", "us,", "we", "are", "also", "providing", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "studies", "being", "conducted", "by", "us,", "there", "are", "also", "three", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol."], "wordsB": ["In", "addition", "to", "the", "clinical", "study", "of", "etirinotecan", "pegol", "being", "conducted", "by", "us,", "we", "are", "also", "providing", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p66_s0", "idA": "906709_14_item1_p78_s1", "sentA": "On October 24, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute.", "sentB": "to evaluate etirinotecan pegol in patients with brain metastasis from primary lung cancer.", "type": 2, "words": ["<tag1>", "On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute.", "<tag2>", "to", "evaluate", "etirinotecan", "pegol", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer.", "<tag3>"], "wordsA": ["On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute."], "wordsB": ["to", "evaluate", "etirinotecan", "pegol", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s6", "idA": "906709_14_item1_p79_s2", "sentA": "We are responsible for all future development, manufacturing and supply of the nebulizer device for clinical and commercial use.", "sentB": "For our proprietary products, we prepare and submit an IND and are responsible for additional clinical and regulatory procedures for product candidates being developed under an IND.", "type": 2, "words": ["<tag1>", "We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use.", "<tag2>", "For", "our", "proprietary", "products,", "we", "prepare", "and", "submit", "an", "IND", "and", "are", "responsible", "for", "additional", "clinical", "and", "regulatory", "procedures", "for", "product", "candidates", "being", "developed", "under", "an", "IND.", "<tag3>"], "wordsA": ["We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use."], "wordsB": ["For", "our", "proprietary", "products,", "we", "prepare", "and", "submit", "an", "IND", "and", "are", "responsible", "for", "additional", "clinical", "and", "regulatory", "procedures", "for", "product", "candidates", "being", "developed", "under", "an", "IND."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p67_s3", "idA": "906709_14_item1_p79_s3", "sentA": "We have engaged third party contract manufacturers to perform our device manufacturing obligations for this program.", "sentB": "We have engaged third party contract manufacturers to perform our device manufacturing activities for this program.", "type": 2, "words": ["<tag1>", "We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "obligations", "for", "this", "program.", "<tag2>", "We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program.", "<tag3>"], "wordsA": ["We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "obligations", "for", "this", "program."], "wordsB": ["We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p9_s0", "idA": "906709_14_item1_p7_s0", "sentA": "Our third most advanced proprietary drug candidate, NKTR-181, is a novel mu-opioid analgesic drug candidate for chronic pain conditions.", "sentB": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions.", "type": 2, "words": ["<tag1>", "Our", "third", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions.", "<tag2>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions.", "<tag3>"], "wordsA": ["Our", "third", "most", "advanced", "proprietary", "drug", "candidate,", "NKTR-181,", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions."], "wordsB": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p9_s1", "idA": "906709_14_item1_p7_s1", "sentA": "The molecule has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are commonly associated with standard opioid therapies.", "sentB": "NKTR-181 has been designed to have a slow rate of entry into the brain, which is expected to reduce the attractiveness of the molecule as a target of abuse and reduce other serious central nervous system-related side effects, such as sedation and respiratory depression, which are associated with standard opioid therapies.", "type": 2, "words": ["<tag1>", "The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies.", "<tag2>", "NKTR-181", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "associated", "with", "standard", "opioid", "therapies.", "<tag3>"], "wordsA": ["The", "molecule", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "commonly", "associated", "with", "standard", "opioid", "therapies."], "wordsB": ["NKTR-181", "has", "been", "designed", "to", "have", "a", "slow", "rate", "of", "entry", "into", "the", "brain,", "which", "is", "expected", "to", "reduce", "the", "attractiveness", "of", "the", "molecule", "as", "a", "target", "of", "abuse", "and", "reduce", "other", "serious", "central", "nervous", "system-related", "side", "effects,", "such", "as", "sedation", "and", "respiratory", "depression,", "which", "are", "associated", "with", "standard", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p9_s2", "idA": "906709_14_item1_p7_s2", "sentA": "Its potential differentiating properties are inherent to the design of the new molecule and, as a new molecular structure, NKTR-181 s abuse deterrent property does not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "sentB": "NKTR-181 s potential abuse deterrent properties are inherent to its novel molecular structure and do not rely on a formulation approach, a common method used with opioid drugs to reduce their ease of conversion into abusable forms of an opioid.", "type": 2, "words": ["<tag1>", "Its", "potential", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and,", "as", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag2>", "NKTR-181", "s", "potential", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid.", "<tag3>"], "wordsA": ["Its", "potential", "differentiating", "properties", "are", "inherent", "to", "the", "design", "of", "the", "new", "molecule", "and,", "as", "a", "new", "molecular", "structure,", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "wordsB": ["NKTR-181", "s", "potential", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach,", "a", "common", "method", "used", "with", "opioid", "drugs", "to", "reduce", "their", "ease", "of", "conversion", "into", "abusable", "forms", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p70_s1", "idA": "906709_14_item1_p83_s1", "sentA": "This drug candidate can be integrated with conventional mechanical ventilators or used as a hand-held off-vent device for patients no longer requiring breathing assistance.", "sentB": "This nebulizer device containing amikacin can be integrated with conventional mechanical ventilators or used as a hand-held off-vent device for patients no longer requiring breathing assistance.", "type": 2, "words": ["<tag1>", "This", "drug", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance.", "<tag2>", "This", "nebulizer", "device", "containing", "amikacin", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance.", "<tag3>"], "wordsA": ["This", "drug", "candidate", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance."], "wordsB": ["This", "nebulizer", "device", "containing", "amikacin", "can", "be", "integrated", "with", "conventional", "mechanical", "ventilators", "or", "used", "as", "a", "hand-held", "off-vent", "device", "for", "patients", "no", "longer", "requiring", "breathing", "assistance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p72_s0", "idA": "906709_14_item1_p85_s0", "sentA": "NKTR-181 is an orally-available mu-opioid drug candidate in development as a long-acting analgesic to treat chronic pain.", "sentB": "NKTR-181 is an orally-available novel mu-opioid analgesic molecule in development as a long-acting analgesic to treat chronic pain.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "an", "orally-available", "mu-opioid", "drug", "candidate", "in", "development", "as", "a", "long-acting", "analgesic", "to", "treat", "chronic", "pain.", "<tag2>", "NKTR-181", "is", "an", "orally-available", "novel", "mu-opioid", "analgesic", "molecule", "in", "development", "as", "a", "long-acting", "analgesic", "to", "treat", "chronic", "pain.", "<tag3>"], "wordsA": ["NKTR-181", "is", "an", "orally-available", "mu-opioid", "drug", "candidate", "in", "development", "as", "a", "long-acting", "analgesic", "to", "treat", "chronic", "pain."], "wordsB": ["NKTR-181", "is", "an", "orally-available", "novel", "mu-opioid", "analgesic", "molecule", "in", "development", "as", "a", "long-acting", "analgesic", "to", "treat", "chronic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p73_s0", "idA": "906709_14_item1_p85_s1", "sentA": "NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies.", "sentB": "serious central nervous system (CNS) side effects associated with current opioid therapies.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag2>", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag3>"], "wordsA": ["NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "wordsB": ["serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p73_s1", "idA": "906709_14_item1_p86_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic molecule created using Nektar s proprietary polymer conjugate technology, which provides it with a long-acting profile and slows its entry into the CNS.", "sentB": "NKTR-181 was created using Nektar s proprietary polymer conjugate technology, which provides it with a long-acting profile and slows its entry into the CNS.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "molecule", "created", "using", "Nektar", "s", "proprietary", "polymer", "conjugate", "technology,", "which", "provides", "it", "with", "a", "long-acting", "profile", "and", "slows", "its", "entry", "into", "the", "CNS.", "<tag2>", "NKTR-181", "was", "created", "using", "Nektar", "s", "proprietary", "polymer", "conjugate", "technology,", "which", "provides", "it", "with", "a", "long-acting", "profile", "and", "slows", "its", "entry", "into", "the", "CNS.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "molecule", "created", "using", "Nektar", "s", "proprietary", "polymer", "conjugate", "technology,", "which", "provides", "it", "with", "a", "long-acting", "profile", "and", "slows", "its", "entry", "into", "the", "CNS."], "wordsB": ["NKTR-181", "was", "created", "using", "Nektar", "s", "proprietary", "polymer", "conjugate", "technology,", "which", "provides", "it", "with", "a", "long-acting", "profile", "and", "slows", "its", "entry", "into", "the", "CNS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p73_s2", "idA": "906709_14_item1_p86_s2", "sentA": "NKTR-181 s abuse deterrent property does not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "sentB": "NKTR-181 s abuse deterrent properties are inherent to its novel molecular structure and do not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "type": 2, "words": ["<tag1>", "NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag2>", "NKTR-181", "s", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag3>"], "wordsA": ["NKTR-181", "s", "abuse", "deterrent", "property", "does", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "wordsB": ["NKTR-181", "s", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p103_s0", "idA": "906709_14_item1_p87_s0", "sentA": "In May 2012, the FDA granted Fast Track designation for the NKTR-181 development program.", "sentB": "On October 2, 2014, the FDA granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program.", "<tag2>", "On", "October", "2,", "2014,", "the", "FDA", "granted", "Orphan", "Drug", "designation", "for", "PEGPH20", "for", "the", "treatment", "of", "pancreatic", "cancer.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program."], "wordsB": ["On", "October", "2,", "2014,", "the", "FDA", "granted", "Orphan", "Drug", "designation", "for", "PEGPH20", "for", "the", "treatment", "of", "pancreatic", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p71_s3", "idA": "906709_14_item1_p87_s0", "sentA": "In May 2012, the FDA granted Fast Track designation for the NKTR-181 development program.", "sentB": "In November 2014, the FDA granted qualified infectious disease product (QIDP) designation to Amikacin Inhale.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program.", "<tag2>", "In", "November", "2014,", "the", "FDA", "granted", "qualified", "infectious", "disease", "product", "(QIDP)", "designation", "to", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program."], "wordsB": ["In", "November", "2014,", "the", "FDA", "granted", "qualified", "infectious", "disease", "product", "(QIDP)", "designation", "to", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p95_s0", "idA": "906709_14_item1_p87_s0", "sentA": "In May 2012, the FDA granted Fast Track designation for the NKTR-181 development program.", "sentB": "In November 2014, the FDA granted qualified infectious disease product (QIDP) designation to Cipro DPI.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program.", "<tag2>", "In", "November", "2014,", "the", "FDA", "granted", "qualified", "infectious", "disease", "product", "(QIDP)", "designation", "to", "Cipro", "DPI.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "granted", "Fast", "Track", "designation", "for", "the", "NKTR-181", "development", "program."], "wordsB": ["In", "November", "2014,", "the", "FDA", "granted", "qualified", "infectious", "disease", "product", "(QIDP)", "designation", "to", "Cipro", "DPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p83_s5", "idA": "906709_14_item1_p89_s2", "sentA": "NKTR-181 was also well-tolerated at all doses evaluated in both studies.", "sentB": "NKTR-214 was also very well-tolerated when co-dosed with either antibody in these preclinical studies.", "type": 2, "words": ["<tag1>", "NKTR-181", "was", "also", "well-tolerated", "at", "all", "doses", "evaluated", "in", "both", "studies.", "<tag2>", "NKTR-214", "was", "also", "very", "well-tolerated", "when", "co-dosed", "with", "either", "antibody", "in", "these", "preclinical", "studies.", "<tag3>"], "wordsA": ["NKTR-181", "was", "also", "well-tolerated", "at", "all", "doses", "evaluated", "in", "both", "studies."], "wordsB": ["NKTR-214", "was", "also", "very", "well-tolerated", "when", "co-dosed", "with", "either", "antibody", "in", "these", "preclinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p129_s0", "idA": "906709_14_item1_p8_s0", "sentA": "In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain.", "sentB": "In March 2012, the FDA approved OMONTYS for the treatment of dialysis patients with anemia due to chronic kidney disease (CKD).", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain.", "<tag2>", "In", "March", "2012,", "the", "FDA", "approved", "OMONTYS", "for", "the", "treatment", "of", "dialysis", "patients", "with", "anemia", "due", "to", "chronic", "kidney", "disease", "(CKD).", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain."], "wordsB": ["In", "March", "2012,", "the", "FDA", "approved", "OMONTYS", "for", "the", "treatment", "of", "dialysis", "patients", "with", "anemia", "due", "to", "chronic", "kidney", "disease", "(CKD)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s4", "idA": "906709_14_item1_p8_s0", "sentA": "In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain.", "sentB": "Further, as a condition of approval, the FDA may impose post-market surveillance, or Phase 4, studies or risk evaluation and mitigation strategies.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain.", "<tag2>", "Further,", "as", "a", "condition", "of", "approval,", "the", "FDA", "may", "impose", "post-market", "surveillance,", "or", "Phase", "4,", "studies", "or", "risk", "evaluation", "and", "mitigation", "strategies.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain."], "wordsB": ["Further,", "as", "a", "condition", "of", "approval,", "the", "FDA", "may", "impose", "post-market", "surveillance,", "or", "Phase", "4,", "studies", "or", "risk", "evaluation", "and", "mitigation", "strategies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p50_s0", "idA": "906709_14_item1_p8_s0", "sentA": "In May 2012, the FDA designated NKTR-181 as a Fast Track development program for the treatment of moderate to severe chronic pain.", "sentB": "On September 16, 2014, the FDA approved MOVANTIK TM as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "type": 2, "words": ["<tag1>", "In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain.", "<tag2>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag3>"], "wordsA": ["In", "May", "2012,", "the", "FDA", "designated", "NKTR-181", "as", "a", "Fast", "Track", "development", "program", "for", "the", "treatment", "of", "moderate", "to", "severe", "chronic", "pain."], "wordsB": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s3", "idA": "906709_14_item1_p90_s1", "sentA": "The Phase 2 clinical study utilized a double-blind, placebo-controlled, randomized withdrawal, enriched enrollment study design.", "sentB": "In this first efficacy study, we plan to randomize approximately 416 chronic low back pain patients in a clinical study that utilizes an enriched enrollment randomized withdrawal design.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "utilized", "a", "double-blind,", "placebo-controlled,", "randomized", "withdrawal,", "enriched", "enrollment", "study", "design.", "<tag2>", "In", "this", "first", "efficacy", "study,", "we", "plan", "to", "randomize", "approximately", "416", "chronic", "low", "back", "pain", "patients", "in", "a", "clinical", "study", "that", "utilizes", "an", "enriched", "enrollment", "randomized", "withdrawal", "design.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "utilized", "a", "double-blind,", "placebo-controlled,", "randomized", "withdrawal,", "enriched", "enrollment", "study", "design."], "wordsB": ["In", "this", "first", "efficacy", "study,", "we", "plan", "to", "randomize", "approximately", "416", "chronic", "low", "back", "pain", "patients", "in", "a", "clinical", "study", "that", "utilizes", "an", "enriched", "enrollment", "randomized", "withdrawal", "design."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s3", "idA": "906709_14_item1_p91_s0", "sentA": "enrolled 213 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication.", "sentB": "The study enrolled 213 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication.", "type": 2, "words": ["<tag1>", "enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag2>", "The", "study", "enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag3>"], "wordsA": ["enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication."], "wordsB": ["The", "study", "enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p144_s0", "idA": "906709_14_item1_p91_s12", "sentA": "This unusual lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study, which was based upon the average change in a patient s pain score from pre-randomization baseline to the end of the double-blind, randomized treatment period of the study.", "sentB": "The assessment of jurisdiction within the FDA is based upon the primary mode of action of the drug or the location of the specific expertise in one of the centers.", "type": 2, "words": ["<tag1>", "This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study,", "which", "was", "based", "upon", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "pre-randomization", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period", "of", "the", "study.", "<tag2>", "The", "assessment", "of", "jurisdiction", "within", "the", "FDA", "is", "based", "upon", "the", "primary", "mode", "of", "action", "of", "the", "drug", "or", "the", "location", "of", "the", "specific", "expertise", "in", "one", "of", "the", "centers.", "<tag3>"], "wordsA": ["This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study,", "which", "was", "based", "upon", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "pre-randomization", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period", "of", "the", "study."], "wordsB": ["The", "assessment", "of", "jurisdiction", "within", "the", "FDA", "is", "based", "upon", "the", "primary", "mode", "of", "action", "of", "the", "drug", "or", "the", "location", "of", "the", "specific", "expertise", "in", "one", "of", "the", "centers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s12", "idA": "906709_14_item1_p91_s12", "sentA": "This unusual lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study, which was based upon the average change in a patient s pain score from pre-randomization baseline to the end of the double-blind, randomized treatment period of the study.", "sentB": "This unusual lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study.", "type": 2, "words": ["<tag1>", "This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study,", "which", "was", "based", "upon", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "pre-randomization", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period", "of", "the", "study.", "<tag2>", "This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study.", "<tag3>"], "wordsA": ["This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study,", "which", "was", "based", "upon", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "pre-randomization", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period", "of", "the", "study."], "wordsB": ["This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s4", "idA": "906709_14_item1_p91_s2", "sentA": "Patients that achieved this level of analgesia were then randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive placebo for up to 25 days.", "sentB": "The study includes a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, and then is followed by a 12 week double-blind randomized period where a total of approximately 416 patients will be randomized on a 1:1 basis to continue receiving NKTR-181 or crossover to receive placebo.", "type": 2, "words": ["<tag1>", "Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "up", "to", "25", "days.", "<tag2>", "The", "study", "includes", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "and", "then", "is", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "a", "total", "of", "approximately", "416", "patients", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "continue", "receiving", "NKTR-181", "or", "crossover", "to", "receive", "placebo.", "<tag3>"], "wordsA": ["Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "up", "to", "25", "days."], "wordsB": ["The", "study", "includes", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "and", "then", "is", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "a", "total", "of", "approximately", "416", "patients", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "continue", "receiving", "NKTR-181", "or", "crossover", "to", "receive", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s6", "idA": "906709_14_item1_p91_s3", "sentA": "The primary endpoint of the study was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "sentB": "The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of responders ( 30% reduction in pain score) and patient impression of change.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag2>", "The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "wordsB": ["The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s18", "idA": "906709_14_item1_p91_s3", "sentA": "The primary endpoint of the study was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "sentB": "The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of responders ( 30% reduction in pain score) and patient impression of change.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag2>", "The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "wordsB": ["The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p145_s3", "idA": "906709_14_item1_p91_s5", "sentA": "On September 26, 2013, we announced results from this Phase 2 efficacy study.", "sentB": "Some low risk devices are exempted from this requirement.", "type": 2, "words": ["<tag1>", "On", "September", "26,", "2013,", "we", "announced", "results", "from", "this", "Phase", "2", "efficacy", "study.", "<tag2>", "Some", "low", "risk", "devices", "are", "exempted", "from", "this", "requirement.", "<tag3>"], "wordsA": ["On", "September", "26,", "2013,", "we", "announced", "results", "from", "this", "Phase", "2", "efficacy", "study."], "wordsB": ["Some", "low", "risk", "devices", "are", "exempted", "from", "this", "requirement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s2", "idA": "906709_14_item1_p92_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 study design.", "sentB": "We enrolled the first patient in this first Phase 3 study on February 24, 2015.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p140_s0", "idA": "906709_14_item1_p92_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 study design.", "sentB": "Following a series of formal meetings and communications between the drug sponsor and the regulatory agencies, the results of product development, preclinical studies and clinical studies are submitted to the FDA as an NDA or BLA for approval of the marketing and commercial shipment of the drug product.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design.", "<tag2>", "Following", "a", "series", "of", "formal", "meetings", "and", "communications", "between", "the", "drug", "sponsor", "and", "the", "regulatory", "agencies,", "the", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "studies", "are", "submitted", "to", "the", "FDA", "as", "an", "NDA", "or", "BLA", "for", "approval", "of", "the", "marketing", "and", "commercial", "shipment", "of", "the", "drug", "product.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design."], "wordsB": ["Following", "a", "series", "of", "formal", "meetings", "and", "communications", "between", "the", "drug", "sponsor", "and", "the", "regulatory", "agencies,", "the", "results", "of", "product", "development,", "preclinical", "studies", "and", "clinical", "studies", "are", "submitted", "to", "the", "FDA", "as", "an", "NDA", "or", "BLA", "for", "approval", "of", "the", "marketing", "and", "commercial", "shipment", "of", "the", "drug", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s15", "idA": "906709_14_item1_p92_s0", "sentA": "In December 2013, we met with the FDA to discuss the results of the Phase 2 clinical study and certain preliminary considerations for the Phase 3 study design.", "sentB": "We enrolled the first patient in this first Phase 3 study on February 24, 2015.", "type": 2, "words": ["<tag1>", "In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015.", "<tag3>"], "wordsA": ["In", "December", "2013,", "we", "met", "with", "the", "FDA", "to", "discuss", "the", "results", "of", "the", "Phase", "2", "clinical", "study", "and", "certain", "preliminary", "considerations", "for", "the", "Phase", "3", "study", "design."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p65_s6", "idA": "906709_14_item1_p92_s1", "sentA": "We are currently evaluating the appropriate Phase 3 clinical trial design for NKTR-181 and plan to start a Phase 3 clinical study in mid-2014, following the completion of an end-of-Phase 2 meeting with the FDA planned to occur in the first half of 2014.", "sentB": "We plan to submit a manuscript describing the results of this study in the first half of 2015.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "trial", "design", "for", "NKTR-181", "and", "plan", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014.", "<tag2>", "We", "plan", "to", "submit", "a", "manuscript", "describing", "the", "results", "of", "this", "study", "in", "the", "first", "half", "of", "2015.", "<tag3>"], "wordsA": ["We", "are", "currently", "evaluating", "the", "appropriate", "Phase", "3", "clinical", "trial", "design", "for", "NKTR-181", "and", "plan", "to", "start", "a", "Phase", "3", "clinical", "study", "in", "mid-2014,", "following", "the", "completion", "of", "an", "end-of-Phase", "2", "meeting", "with", "the", "FDA", "planned", "to", "occur", "in", "the", "first", "half", "of", "2014."], "wordsB": ["We", "plan", "to", "submit", "a", "manuscript", "describing", "the", "results", "of", "this", "study", "in", "the", "first", "half", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p75_s1", "idA": "906709_14_item1_p94_s4", "sentA": "In this study, NKTR-181 was rated similar to placebo in drug liking and feeling high scores and had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "In this study, NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "type": 2, "words": ["<tag1>", "In", "this", "study,", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag3>"], "wordsA": ["In", "this", "study,", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p142_s0", "idA": "906709_14_item1_p97_s0", "sentA": "Opioids are considered to be the most effective therapeutic option for pain.", "sentB": "For product candidates currently under development utilizing pulmonary technology, the pulmonary inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molecule.", "type": 2, "words": ["<tag1>", "Opioids", "are", "considered", "to", "be", "the", "most", "effective", "therapeutic", "option", "for", "pain.", "<tag2>", "For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molecule.", "<tag3>"], "wordsA": ["Opioids", "are", "considered", "to", "be", "the", "most", "effective", "therapeutic", "option", "for", "pain."], "wordsB": ["For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molecule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p130_s1", "idA": "906709_14_item1_p98_s0", "sentA": "The FDA has cited prescription opioid analgesics as being at the center of a major public health crisis of addiction, misuse, abuse, overdose and death.", "sentB": "The FDA has been notified by Affymax of 19 reports of anaphylaxis with 3 of those cases resulting in death.", "type": 2, "words": ["<tag1>", "The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death.", "<tag2>", "The", "FDA", "has", "been", "notified", "by", "Affymax", "of", "19", "reports", "of", "anaphylaxis", "with", "3", "of", "those", "cases", "resulting", "in", "death.", "<tag3>"], "wordsA": ["The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death."], "wordsB": ["The", "FDA", "has", "been", "notified", "by", "Affymax", "of", "19", "reports", "of", "anaphylaxis", "with", "3", "of", "those", "cases", "resulting", "in", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p79_s0", "idA": "906709_14_item1_p98_s0", "sentA": "The FDA has cited prescription opioid analgesics as being at the center of a major public health crisis of addiction, misuse, abuse, overdose and death.", "sentB": "crisis of addiction, misuse, abuse, overdose and death.", "type": 2, "words": ["<tag1>", "The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death.", "<tag2>", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death.", "<tag3>"], "wordsA": ["The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death."], "wordsB": ["crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p133_s1", "idA": "906709_14_item1_p99_s1", "sentA": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "sentB": "If the product is a new chemical entity that has not been previously approved, the process includes the following:", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag2>", "If", "the", "product", "is", "a", "new", "chemical", "entity", "that", "has", "not", "been", "previously", "approved,", "the", "process", "includes", "the", "following:", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "wordsB": ["If", "the", "product", "is", "a", "new", "chemical", "entity", "that", "has", "not", "been", "previously", "approved,", "the", "process", "includes", "the", "following:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p11_s1", "idA": "906709_14_item1_p9_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "In this Phase 3 program for NKTR-181 we plan to include two separate efficacy studies in patients with chronic lower back pain, a long-term safety study, and a human abuse liability study.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "In", "this", "Phase", "3", "program", "for", "NKTR-181", "we", "plan", "to", "include", "two", "separate", "efficacy", "studies", "in", "patients", "with", "chronic", "lower", "back", "pain,", "a", "long-term", "safety", "study,", "and", "a", "human", "abuse", "liability", "study.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["In", "this", "Phase", "3", "program", "for", "NKTR-181", "we", "plan", "to", "include", "two", "separate", "efficacy", "studies", "in", "patients", "with", "chronic", "lower", "back", "pain,", "a", "long-term", "safety", "study,", "and", "a", "human", "abuse", "liability", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p74_s14", "idA": "906709_14_item1_p9_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "In this Phase 3 program for NKTR-181 we plan to include two separate efficacy studies in patients with chronic lower back pain, a long-term safety study, and a human abuse liability study.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "In", "this", "Phase", "3", "program", "for", "NKTR-181", "we", "plan", "to", "include", "two", "separate", "efficacy", "studies", "in", "patients", "with", "chronic", "lower", "back", "pain,", "a", "long-term", "safety", "study,", "and", "a", "human", "abuse", "liability", "study.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["In", "this", "Phase", "3", "program", "for", "NKTR-181", "we", "plan", "to", "include", "two", "separate", "efficacy", "studies", "in", "patients", "with", "chronic", "lower", "back", "pain,", "a", "long-term", "safety", "study,", "and", "a", "human", "abuse", "liability", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p10_s1", "idA": "906709_14_item1_p9_s1", "sentA": "On June 19, 2013, we announced results from that HAL study demonstrated that NKTR-181 was rated similar to placebo in drug liking and feeling high scores and had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "In June 2013, we announced results from a human abuse liability study that demonstrated that NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested.", "type": 2, "words": ["<tag1>", "On", "June", "19,", "2013,", "we", "announced", "results", "from", "that", "HAL", "study", "demonstrated", "that", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "In", "June", "2013,", "we", "announced", "results", "from", "a", "human", "abuse", "liability", "study", "that", "demonstrated", "that", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested.", "<tag3>"], "wordsA": ["On", "June", "19,", "2013,", "we", "announced", "results", "from", "that", "HAL", "study", "demonstrated", "that", "NKTR-181", "was", "rated", "similar", "to", "placebo", "in", "drug", "liking", "and", "feeling", "high", "scores", "and", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["In", "June", "2013,", "we", "announced", "results", "from", "a", "human", "abuse", "liability", "study", "that", "demonstrated", "that", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_15_item1_p10_s2", "idA": "906709_14_item1_p9_s2", "sentA": "On September 26, 2013, we announced preliminary topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "In September 2013, we announced topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "type": 2, "words": ["<tag1>", "On", "September", "26,", "2013,", "we", "announced", "preliminary", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "In", "September", "2013,", "we", "announced", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag3>"], "wordsA": ["On", "September", "26,", "2013,", "we", "announced", "preliminary", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["In", "September", "2013,", "we", "announced", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p0_s0", "idA": "906709_15_item1_p0_s0", "sentA": "new molecular entities that target known mechanisms of action.", "sentB": "We are a biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.", "type": 2, "words": ["<tag1>", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag2>", "We", "are", "a", "biopharmaceutical", "company", "developing", "a", "pipeline", "of", "drug", "candidates", "that", "utilize", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag3>"], "wordsA": ["new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "wordsB": ["We", "are", "a", "biopharmaceutical", "company", "developing", "a", "pipeline", "of", "drug", "candidates", "that", "utilize", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p102_s1", "idA": "906709_15_item1_p100_s0", "sentA": "In December 2006, we entered into a license agreement with Halozyme, Inc. (Halozyme) under which we granted Halozyme a worldwide, limited exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation reagent linked only with certain qualifying hyaluronidase protein molecules including PEGPH20.", "sentB": "In December 2006, we entered into a license agreement with Halozyme Therapeutics, Inc. (Halozyme), under which we granted Halozyme a worldwide, limited exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation materials linked only with certain qualifying hyaluronidase protein molecules including PEGPH20.", "type": 2, "words": ["<tag1>", "In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme,", "Inc.", "(Halozyme)", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20.", "<tag2>", "In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "(Halozyme),", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "materials", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20.", "<tag3>"], "wordsA": ["In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme,", "Inc.", "(Halozyme)", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "reagent", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20."], "wordsB": ["In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "(Halozyme),", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "materials", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p11_s1", "idA": "906709_15_item1_p103_s0", "sentA": "On October 2, 2014, the FDA granted Orphan Drug designation for PEGPH20 for the treatment of pancreatic cancer.", "sentB": "We have a license, manufacturing and supply agreement with Halozyme Therapeutics, Inc. for PEG-PH20, which is entering Phase 3 development for the treatment of pancreatic cancer.", "type": 2, "words": ["<tag1>", "On", "October", "2,", "2014,", "the", "FDA", "granted", "Orphan", "Drug", "designation", "for", "PEGPH20", "for", "the", "treatment", "of", "pancreatic", "cancer.", "<tag2>", "We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "for", "PEG-PH20,", "which", "is", "entering", "Phase", "3", "development", "for", "the", "treatment", "of", "pancreatic", "cancer.", "<tag3>"], "wordsA": ["On", "October", "2,", "2014,", "the", "FDA", "granted", "Orphan", "Drug", "designation", "for", "PEGPH20", "for", "the", "treatment", "of", "pancreatic", "cancer."], "wordsB": ["We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "for", "PEG-PH20,", "which", "is", "entering", "Phase", "3", "development", "for", "the", "treatment", "of", "pancreatic", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p55_s2", "idA": "906709_15_item1_p104_s0", "sentA": "We are entitled to future development milestones and royalties on net sales subject to reduction in the absence of patent coverage.", "sentB": "Additional patents owned by Nektar Therapeutics provide further layers of patent coverage for Adynovate TM .", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "future", "development", "milestones", "and", "royalties", "on", "net", "sales", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage.", "<tag2>", "Additional", "patents", "owned", "by", "Nektar", "Therapeutics", "provide", "further", "layers", "of", "patent", "coverage", "for", "Adynovate", "TM", ".", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "future", "development", "milestones", "and", "royalties", "on", "net", "sales", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage."], "wordsB": ["Additional", "patents", "owned", "by", "Nektar", "Therapeutics", "provide", "further", "layers", "of", "patent", "coverage", "for", "Adynovate", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p106_s2", "idA": "906709_15_item1_p105_s1", "sentA": "We also manufacture and supply Halozyme with clinical and future commercial supply of our proprietary PEGylation reagent used in the manufacture of PEGPH20.", "sentB": "We also manufacture and supply Halozyme with clinical and future commercial supply of our proprietary PEGylation materials used in the manufacture of PEGPH20.", "type": 2, "words": ["<tag1>", "We", "also", "manufacture", "and", "supply", "Halozyme", "with", "clinical", "and", "future", "commercial", "supply", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "PEGPH20.", "<tag2>", "We", "also", "manufacture", "and", "supply", "Halozyme", "with", "clinical", "and", "future", "commercial", "supply", "of", "our", "proprietary", "PEGylation", "materials", "used", "in", "the", "manufacture", "of", "PEGPH20.", "<tag3>"], "wordsA": ["We", "also", "manufacture", "and", "supply", "Halozyme", "with", "clinical", "and", "future", "commercial", "supply", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "PEGPH20."], "wordsB": ["We", "also", "manufacture", "and", "supply", "Halozyme", "with", "clinical", "and", "future", "commercial", "supply", "of", "our", "proprietary", "PEGylation", "materials", "used", "in", "the", "manufacture", "of", "PEGPH20."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p108_s0", "idA": "906709_15_item1_p106_s2", "sentA": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of SEMPRANA .", "sentB": "agreement, we have the right to receive certain milestone payments based on development criteria that are solely t he responsibility of MAP and royalties based on net sales of SEMPRANA .", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag2>", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "t", "he", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "wordsB": ["agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "t", "he", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s4", "idA": "906709_15_item1_p106_s2", "sentA": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of SEMPRANA .", "sentB": "Our revenue is derived from our collaboration agreements with partners, under which we may receive contract research payments, milestone payments based on clinical progress, regulatory progress or net sales achievements, royalties or product sales revenue.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag2>", "Our", "revenue", "is", "derived", "from", "our", "collaboration", "agreements", "with", "partners,", "under", "which", "we", "may", "receive", "contract", "research", "payments,", "milestone", "payments", "based", "on", "clinical", "progress,", "regulatory", "progress", "or", "net", "sales", "achievements,", "royalties", "or", "product", "sales", "revenue.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "wordsB": ["Our", "revenue", "is", "derived", "from", "our", "collaboration", "agreements", "with", "partners,", "under", "which", "we", "may", "receive", "contract", "research", "payments,", "milestone", "payments", "based", "on", "clinical", "progress,", "regulatory", "progress", "or", "net", "sales", "achievements,", "royalties", "or", "product", "sales", "revenue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p108_s1", "idA": "906709_15_item1_p106_s3", "sentA": "Our right to receive royalties for the net sales of SEMPRANA under the license agreement in any particular country will expire upon the later of (i) 10 years after first commercial sale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "sentB": "Our right to receive royalties for the net sales of SEMPRANA under the license agreement in any particular country will expire upon the later of (i) 10 years after first commercial s ale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag2>", "Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "s", "ale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "wordsB": ["Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "s", "ale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p108_s2", "idA": "906709_15_item1_p106_s4", "sentA": "Either party may terminate the agreement upon a material, uncured default of the other party.", "sentB": "Either party may terminate the agreement upon a material, uncured de fault of the other party.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party.", "<tag2>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "de", "fault", "of", "the", "other", "party.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party."], "wordsB": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "de", "fault", "of", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p4_s0", "idA": "906709_15_item1_p107_s0", "sentA": "SEMPRANA is a self-administered formulation of DHE using an inhaler device that is currently under review by the FDA.", "sentB": "ADYNOVATE TM is currently under regulatory review in Japan, Canada and Switzerland.", "type": 2, "words": ["<tag1>", "SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA.", "<tag2>", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland.", "<tag3>"], "wordsA": ["SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA."], "wordsB": ["ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p91_s0", "idA": "906709_15_item1_p107_s0", "sentA": "SEMPRANA is a self-administered formulation of DHE using an inhaler device that is currently under review by the FDA.", "sentB": "ADYNOVATE TM is currently under regulatory review in Japan, Canada and Switzerland.", "type": 2, "words": ["<tag1>", "SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA.", "<tag2>", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland.", "<tag3>"], "wordsA": ["SEMPRANA", "is", "a", "self-administered", "formulation", "of", "DHE", "using", "an", "inhaler", "device", "that", "is", "currently", "under", "review", "by", "the", "FDA."], "wordsB": ["ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p109_s5", "idA": "906709_15_item1_p107_s5", "sentA": "Allergan has responded to the FDA s latest complete response letter and has stated that it expects a response from the FDA on the NDA for SEMPRANA in the second half of 2015.", "sentB": "Allergan has responded to the FDA s latest complete response letter and has stated that it continues to work with the FDA to resolve outstanding CMC issues.", "type": 2, "words": ["<tag1>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "SEMPRANA", "in", "the", "second", "half", "of", "2015.", "<tag2>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "continues", "to", "work", "with", "the", "FDA", "to", "resolve", "outstanding", "CMC", "issues.", "<tag3>"], "wordsA": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "expects", "a", "response", "from", "the", "FDA", "on", "the", "NDA", "for", "SEMPRANA", "in", "the", "second", "half", "of", "2015."], "wordsB": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "continues", "to", "work", "with", "the", "FDA", "to", "resolve", "outstanding", "CMC", "issues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p112_s4", "idA": "906709_15_item1_p10_s2", "sentA": "In September 2013, we announced topline results from a Phase 2 clinical study of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "Based on the results of this clinical study, Biogen and UCB announced that they planned to initiate a Phase 2 clinical study in 2016 in patients with SLE.", "type": 2, "words": ["<tag1>", "In", "September", "2013,", "we", "announced", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "Based", "on", "the", "results", "of", "this", "clinical", "study,", "Biogen", "and", "UCB", "announced", "that", "they", "planned", "to", "initiate", "a", "Phase", "2", "clinical", "study", "in", "2016", "in", "patients", "with", "SLE.", "<tag3>"], "wordsA": ["In", "September", "2013,", "we", "announced", "topline", "results", "from", "a", "Phase", "2", "clinical", "study", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["Based", "on", "the", "results", "of", "this", "clinical", "study,", "Biogen", "and", "UCB", "announced", "that", "they", "planned", "to", "initiate", "a", "Phase", "2", "clinical", "study", "in", "2016", "in", "patients", "with", "SLE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p160_s2", "idA": "906709_15_item1_p112_s1", "sentA": "Under the terms of the 2010 Agreement, we guarantee the manufacture and supply of our proprietary PEGylation materials (Polymer Materials) to Amgen in an existing manufacturing suite to be used exclusively for the manufacture of Polymer Materials for Amgen in our manufacturing facility in Huntsville, Alabama.", "sentB": "The volume of our proprietary PEGylation materials actually ordered by our customers, as well as shipment schedules, are subject to frequent revisions that reflect changes in both the customers needs and our manufacturing capacity.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "guarantee", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "(Polymer", "Materials)", "to", "Amgen", "in", "an", "existing", "manufacturing", "suite", "to", "be", "used", "exclusively", "for", "the", "manufacture", "of", "Polymer", "Materials", "for", "Amgen", "in", "our", "manufacturing", "facility", "in", "Huntsville,", "Alabama.", "<tag2>", "The", "volume", "of", "our", "proprietary", "PEGylation", "materials", "actually", "ordered", "by", "our", "customers,", "as", "well", "as", "shipment", "schedules,", "are", "subject", "to", "frequent", "revisions", "that", "reflect", "changes", "in", "both", "the", "customers", "needs", "and", "our", "manufacturing", "capacity.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "guarantee", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "(Polymer", "Materials)", "to", "Amgen", "in", "an", "existing", "manufacturing", "suite", "to", "be", "used", "exclusively", "for", "the", "manufacture", "of", "Polymer", "Materials", "for", "Amgen", "in", "our", "manufacturing", "facility", "in", "Huntsville,", "Alabama."], "wordsB": ["The", "volume", "of", "our", "proprietary", "PEGylation", "materials", "actually", "ordered", "by", "our", "customers,", "as", "well", "as", "shipment", "schedules,", "are", "subject", "to", "frequent", "revisions", "that", "reflect", "changes", "in", "both", "the", "customers", "needs", "and", "our", "manufacturing", "capacity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p116_s2", "idA": "906709_15_item1_p113_s0", "sentA": "arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from any other third party.", "sentB": "This supply arrangement is on a non-exclusive basis (other than the use of the manufacturing suite and certain equipment) whereby we are free to manufacture and supply the Polymer Materials to any other third party and Amgen is free to procure the Polymer Materials from any other third party.", "type": 2, "words": ["<tag1>", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party.", "<tag2>", "This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party.", "<tag3>"], "wordsA": ["arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party."], "wordsB": ["This", "supply", "arrangement", "is", "on", "a", "non-exclusive", "basis", "(other", "than", "the", "use", "of", "the", "manufacturing", "suite", "and", "certain", "equipment)", "whereby", "we", "are", "free", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "to", "any", "other", "third", "party", "and", "Amgen", "is", "free", "to", "procure", "the", "Polymer", "Materials", "from", "any", "other", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p117_s1", "idA": "906709_15_item1_p113_s5", "sentA": "In the event we become subject to a bankruptcy or insolvency proceeding, we cease to own or control the manufacturing facility in Huntsville, Alabama, we fail to manufacture and supply the Polymer Materials or certain other events occur, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the dedicated equipment and access the manufacturing facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "sentB": "In the event we become subject to a bankruptcy or insolvency proceeding, we cease to own or control the manufacturing facility in Huntsville, Al abama, we fail to manufacture and supply the Polymer Materials or certain other events occur, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the dedicated equipment and access the manufacturi ng facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "type": 2, "words": ["<tag1>", "In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Alabama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag2>", "In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Al", "abama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturi", "ng", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag3>"], "wordsA": ["In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Alabama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "wordsB": ["In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Al", "abama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturi", "ng", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p119_s0", "idA": "906709_15_item1_p115_s0", "sentA": "PEGASYS is approved in the U.S., E.U. and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "sentB": "PEGASYS is approved in the U.S., EU and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "type": 2, "words": ["<tag1>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag2>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "EU", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag3>"], "wordsA": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "E.U.", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "wordsB": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "EU", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s5", "idA": "906709_15_item1_p115_s3", "sentA": "The agreement expires on the later of December 31, 2015 or the expiration of our last relevant patent containing a valid claim.", "sentB": "AstraZeneca and UCB represented 57% and 13% of our revenue, respectively, for the year ended December 31, 2015.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "on", "the", "later", "of", "December", "31,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "AstraZeneca", "and", "UCB", "represented", "57%", "and", "13%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2015.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "on", "the", "later", "of", "December", "31,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["AstraZeneca", "and", "UCB", "represented", "57%", "and", "13%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s6", "idA": "906709_15_item1_p115_s3", "sentA": "The agreement expires on the later of December 31, 2015 or the expiration of our last relevant patent containing a valid claim.", "sentB": "No other collaboration partner accounted for more than 10% of our total revenue during the year ended December 31, 2015.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "on", "the", "later", "of", "December", "31,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2015.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "on", "the", "later", "of", "December", "31,", "2015", "or", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p102_s0", "idA": "906709_15_item1_p116_s0", "sentA": "Somavert , Agreement with Pfizer, Inc.", "sentB": "PEGPH20, Agreement with Halozyme Therapeutics, Inc.", "type": 2, "words": ["<tag1>", "Somavert", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag2>", "PEGPH20,", "Agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "<tag3>"], "wordsA": ["Somavert", ",", "Agreement", "with", "Pfizer,", "Inc."], "wordsB": ["PEGPH20,", "Agreement", "with", "Halozyme", "Therapeutics,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p11_s2", "idA": "906709_15_item1_p117_s0", "sentA": "In January 2000, we entered into a license, manufacturing and supply agreement with Sensus Drug Development Corporation (subsequently acquired by Pharmacia Corp. in 2001 and then acquired by Pfizer, Inc. in 2003), for the PEGylation of Somavert (pegvisomant), a human growth hormone receptor antagonist for the treatment of acromegaly.", "sentB": "We have a license, manufacturing and supply agreement with UCB Pharma for dapirolizumab pegol, a monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L), being developed for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) for which the candidate is entering Phase 2 development with UCB partner Biogen.", "type": 2, "words": ["<tag1>", "In", "January", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Sensus", "Drug", "Development", "Corporation", "(subsequently", "acquired", "by", "Pharmacia", "Corp.", "in", "2001", "and", "then", "acquired", "by", "Pfizer,", "Inc.", "in", "2003),", "for", "the", "PEGylation", "of", "Somavert", "(pegvisomant),", "a", "human", "growth", "hormone", "receptor", "antagonist", "for", "the", "treatment", "of", "acromegaly.", "<tag2>", "We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "for", "dapirolizumab", "pegol,", "a", "monovalent", "pegylated", "Fab", "antibody", "fragment", "against", "the", "CD40", "ligand", "(CD40L),", "being", "developed", "for", "the", "treatment", "of", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE)", "for", "which", "the", "candidate", "is", "entering", "Phase", "2", "development", "with", "UCB", "partner", "Biogen.", "<tag3>"], "wordsA": ["In", "January", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Sensus", "Drug", "Development", "Corporation", "(subsequently", "acquired", "by", "Pharmacia", "Corp.", "in", "2001", "and", "then", "acquired", "by", "Pfizer,", "Inc.", "in", "2003),", "for", "the", "PEGylation", "of", "Somavert", "(pegvisomant),", "a", "human", "growth", "hormone", "receptor", "antagonist", "for", "the", "treatment", "of", "acromegaly."], "wordsB": ["We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "for", "dapirolizumab", "pegol,", "a", "monovalent", "pegylated", "Fab", "antibody", "fragment", "against", "the", "CD40", "ligand", "(CD40L),", "being", "developed", "for", "the", "treatment", "of", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE)", "for", "which", "the", "candidate", "is", "entering", "Phase", "2", "development", "with", "UCB", "partner", "Biogen."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p122_s0", "idA": "906709_15_item1_p118_s0", "sentA": "production of a PEGylated recombinant human interferon-alpha (PEG-Intron).", "sentB": "In February 2000, we entered into a manufacturing and supply agreement with Schering-Plough Corporation (Schering) for the manufacture and supply of our proprietary PEGylation materials to be used by Schering in production of a PEGylated recombinant human interferon-alpha (PEG-Intron).", "type": 2, "words": ["<tag1>", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron).", "<tag2>", "In", "February", "2000,", "we", "entered", "into", "a", "manufacturing", "and", "supply", "agreement", "with", "Schering-Plough", "Corporation", "(Schering)", "for", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "to", "be", "used", "by", "Schering", "in", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron).", "<tag3>"], "wordsA": ["production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron)."], "wordsB": ["In", "February", "2000,", "we", "entered", "into", "a", "manufacturing", "and", "supply", "agreement", "with", "Schering-Plough", "Corporation", "(Schering)", "for", "the", "manufacture", "and", "supply", "of", "our", "proprietary", "PEGylation", "materials", "to", "be", "used", "by", "Schering", "in", "production", "of", "a", "PEGylated", "recombinant", "human", "interferon-alpha", "(PEG-Intron)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p165_s0", "idA": "906709_15_item1_p118_s1", "sentA": "PEG-Intron is a treatment for patients with Hepatitis C. Schering was acquired by, and became a wholly-owned subsidiary of, Merck Co., Inc.", "sentB": "Potential competitors include Merck Co., Inc., GlaxoSmithKline plc, Ironwood Pharmaceuticals, Inc. in collaboration with Actavis plc, Mundipharma Int.", "type": 2, "words": ["<tag1>", "PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc.", "<tag2>", "Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Mundipharma", "Int.", "<tag3>"], "wordsA": ["PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc."], "wordsB": ["Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Mundipharma", "Int."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s8", "idA": "906709_15_item1_p118_s1", "sentA": "PEG-Intron is a treatment for patients with Hepatitis C. Schering was acquired by, and became a wholly-owned subsidiary of, Merck Co., Inc.", "sentB": "Based on the outcome of these meetings, we believe that there is a path forward to file an MAA for conditional approval of NKTR-102 for patients with advanced breast cancer having brain metastases.", "type": 2, "words": ["<tag1>", "PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc.", "<tag2>", "Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases.", "<tag3>"], "wordsA": ["PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc."], "wordsB": ["Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s10", "idA": "906709_15_item1_p118_s1", "sentA": "PEG-Intron is a treatment for patients with Hepatitis C. Schering was acquired by, and became a wholly-owned subsidiary of, Merck Co., Inc.", "sentB": "Based on the outcome of these meetings, we believe that there is a path forward to file an MAA for conditional approval of NKTR-102 for patients with advanced breast cancer having brain metastases.", "type": 2, "words": ["<tag1>", "PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc.", "<tag2>", "Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases.", "<tag3>"], "wordsA": ["PEG-Intron", "is", "a", "treatment", "for", "patients", "with", "Hepatitis", "C.", "Schering", "was", "acquired", "by,", "and", "became", "a", "wholly-owned", "subsidiary", "of,", "Merck", "Co.,", "Inc."], "wordsB": ["Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s6", "idA": "906709_15_item1_p118_s4", "sentA": "The amended agreement provided for a one-time payment and milestone payments as well as increased pricing for any future manufacturing performed by us.", "sentB": "These individuals include scientific advisors as well as independent consultants.", "type": 2, "words": ["<tag1>", "The", "amended", "agreement", "provided", "for", "a", "one-time", "payment", "and", "milestone", "payments", "as", "well", "as", "increased", "pricing", "for", "any", "future", "manufacturing", "performed", "by", "us.", "<tag2>", "These", "individuals", "include", "scientific", "advisors", "as", "well", "as", "independent", "consultants.", "<tag3>"], "wordsA": ["The", "amended", "agreement", "provided", "for", "a", "one-time", "payment", "and", "milestone", "payments", "as", "well", "as", "increased", "pricing", "for", "any", "future", "manufacturing", "performed", "by", "us."], "wordsB": ["These", "individuals", "include", "scientific", "advisors", "as", "well", "as", "independent", "consultants."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s13", "idA": "906709_15_item1_p11_s10", "sentA": "This year we plan to advance NKTR-214, an engineered immune-stimulatory cytokine being developed for the treatment of solid tumors, into a Phase 1 clinical study.", "sentB": "At this time, we do not plan to advance development of NKTR-102 without a collaboration partner.", "type": 2, "words": ["<tag1>", "This", "year", "we", "plan", "to", "advance", "NKTR-214,", "an", "engineered", "immune-stimulatory", "cytokine", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors,", "into", "a", "Phase", "1", "clinical", "study.", "<tag2>", "At", "this", "time,", "we", "do", "not", "plan", "to", "advance", "development", "of", "NKTR-102", "without", "a", "collaboration", "partner.", "<tag3>"], "wordsA": ["This", "year", "we", "plan", "to", "advance", "NKTR-214,", "an", "engineered", "immune-stimulatory", "cytokine", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors,", "into", "a", "Phase", "1", "clinical", "study."], "wordsB": ["At", "this", "time,", "we", "do", "not", "plan", "to", "advance", "development", "of", "NKTR-102", "without", "a", "collaboration", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s15", "idA": "906709_15_item1_p11_s10", "sentA": "This year we plan to advance NKTR-214, an engineered immune-stimulatory cytokine being developed for the treatment of solid tumors, into a Phase 1 clinical study.", "sentB": "At this time, we do not plan to advance development of NKTR-102 without a collaboration partner.", "type": 2, "words": ["<tag1>", "This", "year", "we", "plan", "to", "advance", "NKTR-214,", "an", "engineered", "immune-stimulatory", "cytokine", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors,", "into", "a", "Phase", "1", "clinical", "study.", "<tag2>", "At", "this", "time,", "we", "do", "not", "plan", "to", "advance", "development", "of", "NKTR-102", "without", "a", "collaboration", "partner.", "<tag3>"], "wordsA": ["This", "year", "we", "plan", "to", "advance", "NKTR-214,", "an", "engineered", "immune-stimulatory", "cytokine", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors,", "into", "a", "Phase", "1", "clinical", "study."], "wordsB": ["At", "this", "time,", "we", "do", "not", "plan", "to", "advance", "development", "of", "NKTR-102", "without", "a", "collaboration", "partner."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p3_s0", "idA": "906709_15_item1_p11_s13", "sentA": "We have a collaboration with Baxter Healthcare (Baxter), to identify and develop PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients.", "sentB": "We have a collaboration with certain subsidiaries of Baxalta Incorporated (Baxalta), formerly Baxter International Inc. (Baxter) before the separation of Baxalta from Baxter in July 2015, to identify and develop PEGylated drug candidates with the objective of providing new longer-acting therapies for hemophilia patients.", "type": 2, "words": ["<tag1>", "We", "have", "a", "collaboration", "with", "Baxter", "Healthcare", "(Baxter),", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients.", "<tag2>", "We", "have", "a", "collaboration", "with", "certain", "subsidiaries", "of", "Baxalta", "Incorporated", "(Baxalta),", "formerly", "Baxter", "International", "Inc.", "(Baxter)", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "longer-acting", "therapies", "for", "hemophilia", "patients.", "<tag3>"], "wordsA": ["We", "have", "a", "collaboration", "with", "Baxter", "Healthcare", "(Baxter),", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients."], "wordsB": ["We", "have", "a", "collaboration", "with", "certain", "subsidiaries", "of", "Baxalta", "Incorporated", "(Baxalta),", "formerly", "Baxter", "International", "Inc.", "(Baxter)", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "longer-acting", "therapies", "for", "hemophilia", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p5_s1", "idA": "906709_15_item1_p11_s2", "sentA": "We enrolled the first patient in this first Phase 3 study on February 24, 2015.", "sentB": "We enrolled the first patient in the first Phase 3 efficacy study in February 2015 and the study continues to enroll patients.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p171_s0", "idA": "906709_15_item1_p11_s8", "sentA": "We also have additional proprietary preclinical and clinical drug candidates in research and development.", "sentB": "Research and Development Our total research and development expenditures can be disaggregated into the following significant types of expenses (in millions):", "type": 2, "words": ["<tag1>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "in", "research", "and", "development.", "<tag2>", "Research", "and", "Development", "Our", "total", "research", "and", "development", "expenditures", "can", "be", "disaggregated", "into", "the", "following", "significant", "types", "of", "expenses", "(in", "millions):", "<tag3>"], "wordsA": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "in", "research", "and", "development."], "wordsB": ["Research", "and", "Development", "Our", "total", "research", "and", "development", "expenditures", "can", "be", "disaggregated", "into", "the", "following", "significant", "types", "of", "expenses", "(in", "millions):"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s0", "idA": "906709_15_item1_p11_s8", "sentA": "We also have additional proprietary preclinical and clinical drug candidates in research and development.", "sentB": "Employees and Consultants As of December 31, 2015 we had 425 employees, of which 322 employees were engaged in research and development, commercial operations and quality activities and 103 employees were engaged in general administration and business development.", "type": 2, "words": ["<tag1>", "We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "in", "research", "and", "development.", "<tag2>", "Employees", "and", "Consultants", "As", "of", "December", "31,", "2015", "we", "had", "425", "employees,", "of", "which", "322", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "103", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development.", "<tag3>"], "wordsA": ["We", "also", "have", "additional", "proprietary", "preclinical", "and", "clinical", "drug", "candidates", "in", "research", "and", "development."], "wordsB": ["Employees", "and", "Consultants", "As", "of", "December", "31,", "2015", "we", "had", "425", "employees,", "of", "which", "322", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "103", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p11_s0", "idA": "906709_15_item1_p120_s0", "sentA": "In 2002, we entered into a license, manufacturing and supply agreement with Eyetech, Inc. (subsequently acquired by Valeant Pharmaceuticals International, Inc. or Valeant), pursuant to which we license certain intellectual property related to our proprietary PEGylation technology for the development and commercialization of Macugen , a PEGylated anti-vascular endothelial growth factor aptamer currently approved in the U.S. and E.U. for age-related macular degeneration.", "sentB": "We have a license, manufacturing and supply agreement with Ophthotech Corporation for Fovista , an anti-platelet-derived growth factor (anti-PDGF) agent , currently in Phase 3 development for the treatment of wet age-related macular degeneration.", "type": 2, "words": ["<tag1>", "In", "2002,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Eyetech,", "Inc.", "(subsequently", "acquired", "by", "Valeant", "Pharmaceuticals", "International,", "Inc.", "or", "Valeant),", "pursuant", "to", "which", "we", "license", "certain", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "technology", "for", "the", "development", "and", "commercialization", "of", "Macugen", ",", "a", "PEGylated", "anti-vascular", "endothelial", "growth", "factor", "aptamer", "currently", "approved", "in", "the", "U.S.", "and", "E.U.", "for", "age-related", "macular", "degeneration.", "<tag2>", "We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Ophthotech", "Corporation", "for", "Fovista", ",", "an", "anti-platelet-derived", "growth", "factor", "(anti-PDGF)", "agent", ",", "currently", "in", "Phase", "3", "development", "for", "the", "treatment", "of", "wet", "age-related", "macular", "degeneration.", "<tag3>"], "wordsA": ["In", "2002,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Eyetech,", "Inc.", "(subsequently", "acquired", "by", "Valeant", "Pharmaceuticals", "International,", "Inc.", "or", "Valeant),", "pursuant", "to", "which", "we", "license", "certain", "intellectual", "property", "related", "to", "our", "proprietary", "PEGylation", "technology", "for", "the", "development", "and", "commercialization", "of", "Macugen", ",", "a", "PEGylated", "anti-vascular", "endothelial", "growth", "factor", "aptamer", "currently", "approved", "in", "the", "U.S.", "and", "E.U.", "for", "age-related", "macular", "degeneration."], "wordsB": ["We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Ophthotech", "Corporation", "for", "Fovista", ",", "an", "anti-platelet-derived", "growth", "factor", "(anti-PDGF)", "agent", ",", "currently", "in", "Phase", "3", "development", "for", "the", "treatment", "of", "wet", "age-related", "macular", "degeneration."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p172_s0", "idA": "906709_15_item1_p120_s1", "sentA": "We currently manufacture our proprietary PEGylation materials for Valeant on a price per gram basis.", "sentB": "Manufacturing and Supply We have a manufacturing facility located in Huntsville, Alabama that is capable of manufacturing our proprietary PEGylation materials for active pharmaceutical ingredients (APIs).", "type": 2, "words": ["<tag1>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis.", "<tag2>", "Manufacturing", "and", "Supply", "We", "have", "a", "manufacturing", "facility", "located", "in", "Huntsville,", "Alabama", "that", "is", "capable", "of", "manufacturing", "our", "proprietary", "PEGylation", "materials", "for", "active", "pharmaceutical", "ingredients", "(APIs).", "<tag3>"], "wordsA": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis."], "wordsB": ["Manufacturing", "and", "Supply", "We", "have", "a", "manufacturing", "facility", "located", "in", "Huntsville,", "Alabama", "that", "is", "capable", "of", "manufacturing", "our", "proprietary", "PEGylation", "materials", "for", "active", "pharmaceutical", "ingredients", "(APIs)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p163_s3", "idA": "906709_15_item1_p120_s3", "sentA": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc.", "sentB": "There is also a subcutaneous treatment known as RELISTOR Subjectaneous Injection (methylnaltrexone bromide) marketed by Valeant Pharmaceuticals, Ltd (formerly Salix) under a license from Progenics Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag2>", "There", "is", "also", "a", "subcutaneous", "treatment", "known", "as", "RELISTOR", "Subjectaneous", "Injection", "(methylnaltrexone", "bromide)", "marketed", "by", "Valeant", "Pharmaceuticals,", "Ltd", "(formerly", "Salix)", "under", "a", "license", "from", "Progenics", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc."], "wordsB": ["There", "is", "also", "a", "subcutaneous", "treatment", "known", "as", "RELISTOR", "Subjectaneous", "Injection", "(methylnaltrexone", "bromide)", "marketed", "by", "Valeant", "Pharmaceuticals,", "Ltd", "(formerly", "Salix)", "under", "a", "license", "from", "Progenics", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p182_s8", "idA": "906709_15_item1_p120_s3", "sentA": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc.", "sentB": "Prior to joining Endo Pharmaceuticals, he was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc.", "type": 2, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag2>", "Prior", "to", "joining", "Endo", "Pharmaceuticals,", "he", "was", "Senior", "Vice", "President", "of", "Scientific", "Affairs", "and", "President", "of", "the", "Forest", "Research", "Institute", "of", "Forest", "Laboratories", "Inc.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc."], "wordsB": ["Prior", "to", "joining", "Endo", "Pharmaceuticals,", "he", "was", "Senior", "Vice", "President", "of", "Scientific", "Affairs", "and", "President", "of", "the", "Forest", "Research", "Institute", "of", "Forest", "Laboratories", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p119_s4", "idA": "906709_15_item1_p120_s4", "sentA": "The agreement expires upon the expiration of our last relevant patent containing a valid claim.", "sentB": "The agreement expires on the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "The", "agreement", "expires", "on", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["The", "agreement", "expires", "on", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p186_s0", "idA": "906709_15_item1_p121_s1", "sentA": "Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses.", "sentB": "Gil M. Labrucherie has served as our Senior Vice President, General Counsel and Secretary since April 2007, responsible for all aspects of our legal affairs.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag2>", "Gil", "M.", "Labrucherie", "has", "served", "as", "our", "Senior", "Vice", "President,", "General", "Counsel", "and", "Secretary", "since", "April", "2007,", "responsible", "for", "all", "aspects", "of", "our", "legal", "affairs.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "wordsB": ["Gil", "M.", "Labrucherie", "has", "served", "as", "our", "Senior", "Vice", "President,", "General", "Counsel", "and", "Secretary", "since", "April", "2007,", "responsible", "for", "all", "aspects", "of", "our", "legal", "affairs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p169_s1", "idA": "906709_15_item1_p123_s0", "sentA": "MIRCERA is a novel continuous erythropoietin receptor activator indicated for the treatment of anemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis.", "sentB": "The current standard of care includes approved intravenous antibiotics which are partially effective for the treatment of either hospital-acquired pneumonia or ventilator-associated pneumonia in patients on mechanical ventilators.", "type": 2, "words": ["<tag1>", "MIRCERA", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis.", "<tag2>", "The", "current", "standard", "of", "care", "includes", "approved", "intravenous", "antibiotics", "which", "are", "partially", "effective", "for", "the", "treatment", "of", "either", "hospital-acquired", "pneumonia", "or", "ventilator-associated", "pneumonia", "in", "patients", "on", "mechanical", "ventilators.", "<tag3>"], "wordsA": ["MIRCERA", "is", "a", "novel", "continuous", "erythropoietin", "receptor", "activator", "indicated", "for", "the", "treatment", "of", "anemia", "associated", "with", "chronic", "kidney", "disease", "in", "patients", "on", "dialysis", "and", "patients", "not", "on", "dialysis."], "wordsB": ["The", "current", "standard", "of", "care", "includes", "approved", "intravenous", "antibiotics", "which", "are", "partially", "effective", "for", "the", "treatment", "of", "either", "hospital-acquired", "pneumonia", "or", "ventilator-associated", "pneumonia", "in", "patients", "on", "mechanical", "ventilators."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p119_s5", "idA": "906709_15_item1_p124_s0", "sentA": "As of the end of 2006, we were no longer required to manufacture and supply our proprietary PEGylation materials for MIRCERA under our original agreement.", "sentB": "As of December 31, 2015, we no longer have any continuing manufacturing or supply obligations under this PEGASYS agreement.", "type": 2, "words": ["<tag1>", "As", "of", "the", "end", "of", "2006,", "we", "were", "no", "longer", "required", "to", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "for", "MIRCERA", "under", "our", "original", "agreement.", "<tag2>", "As", "of", "December", "31,", "2015,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement.", "<tag3>"], "wordsA": ["As", "of", "the", "end", "of", "2006,", "we", "were", "no", "longer", "required", "to", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "for", "MIRCERA", "under", "our", "original", "agreement."], "wordsB": ["As", "of", "December", "31,", "2015,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p128_s2", "idA": "906709_15_item1_p125_s0", "sentA": "a secondary back-up source on a non-exclusive basis through December 31, 2016.", "sentB": "Roche entered into the toll-manufacturing agreement with the objective of establishing us as a secondary back-up source on a non-exclusive basis through December 31, 2016.", "type": 2, "words": ["<tag1>", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016.", "<tag2>", "Roche", "entered", "into", "the", "toll-manufacturing", "agreement", "with", "the", "objective", "of", "establishing", "us", "as", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016.", "<tag3>"], "wordsA": ["a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016."], "wordsB": ["Roche", "entered", "into", "the", "toll-manufacturing", "agreement", "with", "the", "objective", "of", "establishing", "us", "as", "a", "secondary", "back-up", "source", "on", "a", "non-exclusive", "basis", "through", "December", "31,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p112_s0", "idA": "906709_15_item1_p126_s1", "sentA": "In April 2004, we entered into a license, manufacturing and supply agreement with Affymax, Inc. (Affymax), under which we granted Affymax a worldwide, non-exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize OMONTYS .", "sentB": "In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEFylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE).", "type": 2, "words": ["<tag1>", "In", "April", "2004,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Affymax,", "Inc.", "(Affymax),", "under", "which", "we", "granted", "Affymax", "a", "worldwide,", "non-exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "OMONTYS", ".", "<tag2>", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEFylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE).", "<tag3>"], "wordsA": ["In", "April", "2004,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "Affymax,", "Inc.", "(Affymax),", "under", "which", "we", "granted", "Affymax", "a", "worldwide,", "non-exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "OMONTYS", "."], "wordsB": ["In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEFylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p163_s2", "idA": "906709_15_item1_p128_s0", "sentA": "The compound was discovered by Affymax and is being co-developed and marketed by Affymax and Takeda Pharmaceutical Company Limited (Takeda).", "sentB": "AMITIZA is marketed by Sucampo Pharmaceuticals and Takeda.", "type": 2, "words": ["<tag1>", "The", "compound", "was", "discovered", "by", "Affymax", "and", "is", "being", "co-developed", "and", "marketed", "by", "Affymax", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda).", "<tag2>", "AMITIZA", "is", "marketed", "by", "Sucampo", "Pharmaceuticals", "and", "Takeda.", "<tag3>"], "wordsA": ["The", "compound", "was", "discovered", "by", "Affymax", "and", "is", "being", "co-developed", "and", "marketed", "by", "Affymax", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)."], "wordsB": ["AMITIZA", "is", "marketed", "by", "Sucampo", "Pharmaceuticals", "and", "Takeda."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p165_s1", "idA": "906709_15_item1_p128_s0", "sentA": "The compound was discovered by Affymax and is being co-developed and marketed by Affymax and Takeda Pharmaceutical Company Limited (Takeda).", "sentB": "Limited, Theravance, Inc., Develco Pharma, Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.", "type": 2, "words": ["<tag1>", "The", "compound", "was", "discovered", "by", "Affymax", "and", "is", "being", "co-developed", "and", "marketed", "by", "Affymax", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda).", "<tag2>", "Limited,", "Theravance,", "Inc.,", "Develco", "Pharma,", "Sucampo", "Pharmaceuticals,", "Inc.,", "and", "Takeda", "Pharmaceutical", "Company", "Limited.", "<tag3>"], "wordsA": ["The", "compound", "was", "discovered", "by", "Affymax", "and", "is", "being", "co-developed", "and", "marketed", "by", "Affymax", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)."], "wordsB": ["Limited,", "Theravance,", "Inc.,", "Develco", "Pharma,", "Sucampo", "Pharmaceuticals,", "Inc.,", "and", "Takeda", "Pharmaceutical", "Company", "Limited."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s1", "idA": "906709_15_item1_p129_s1", "sentA": "OMONTYS is the first once-monthly ESA for anemia in CKD for dialysis patients available in the U.S.", "sentB": "Of the 425 employees, 347 were located in the U.S. and 78 were located in India.", "type": 2, "words": ["<tag1>", "OMONTYS", "is", "the", "first", "once-monthly", "ESA", "for", "anemia", "in", "CKD", "for", "dialysis", "patients", "available", "in", "the", "U.S.", "<tag2>", "Of", "the", "425", "employees,", "347", "were", "located", "in", "the", "U.S.", "and", "78", "were", "located", "in", "India.", "<tag3>"], "wordsA": ["OMONTYS", "is", "the", "first", "once-monthly", "ESA", "for", "anemia", "in", "CKD", "for", "dialysis", "patients", "available", "in", "the", "U.S."], "wordsB": ["Of", "the", "425", "employees,", "347", "were", "located", "in", "the", "U.S.", "and", "78", "were", "located", "in", "India."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p191_s0", "idA": "906709_15_item1_p129_s1", "sentA": "OMONTYS is the first once-monthly ESA for anemia in CKD for dialysis patients available in the U.S.", "sentB": "Dr. Hora served as a key member of various teams that successfully registered ten drugs or vaccines in the U.S. and Europe during his professional career.", "type": 2, "words": ["<tag1>", "OMONTYS", "is", "the", "first", "once-monthly", "ESA", "for", "anemia", "in", "CKD", "for", "dialysis", "patients", "available", "in", "the", "U.S.", "<tag2>", "Dr.", "Hora", "served", "as", "a", "key", "member", "of", "various", "teams", "that", "successfully", "registered", "ten", "drugs", "or", "vaccines", "in", "the", "U.S.", "and", "Europe", "during", "his", "professional", "career.", "<tag3>"], "wordsA": ["OMONTYS", "is", "the", "first", "once-monthly", "ESA", "for", "anemia", "in", "CKD", "for", "dialysis", "patients", "available", "in", "the", "U.S."], "wordsB": ["Dr.", "Hora", "served", "as", "a", "key", "member", "of", "various", "teams", "that", "successfully", "registered", "ten", "drugs", "or", "vaccines", "in", "the", "U.S.", "and", "Europe", "during", "his", "professional", "career."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p3_s1", "idA": "906709_15_item1_p12_s0", "sentA": "The first drug candidate in this collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "sentB": "Under this collaboration, we worked with Baxter to develop ADYNOVATE TM (previously referred to as BAX 855), an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "type": 2, "words": ["<tag1>", "The", "first", "drug", "candidate", "in", "this", "collaboration", "is", "BAX", "855,", "an", "investigational,", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag2>", "Under", "this", "collaboration,", "we", "worked", "with", "Baxter", "to", "develop", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag3>"], "wordsA": ["The", "first", "drug", "candidate", "in", "this", "collaboration", "is", "BAX", "855,", "an", "investigational,", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "wordsB": ["Under", "this", "collaboration,", "we", "worked", "with", "Baxter", "to", "develop", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p52_s0", "idA": "906709_15_item1_p12_s0", "sentA": "The first drug candidate in this collaboration is BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "sentB": "ADYNOVATE TM (previously referred to as BAX 855, PEGylated rFVIII) ADYNOVATE TM is an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "type": 2, "words": ["<tag1>", "The", "first", "drug", "candidate", "in", "this", "collaboration", "is", "BAX", "855,", "an", "investigational,", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag2>", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855,", "PEGylated", "rFVIII)", "ADYNOVATE", "TM", "is", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag3>"], "wordsA": ["The", "first", "drug", "candidate", "in", "this", "collaboration", "is", "BAX", "855,", "an", "investigational,", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "wordsB": ["ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855,", "PEGylated", "rFVIII)", "ADYNOVATE", "TM", "is", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p52_s2", "idA": "906709_15_item1_p12_s2", "sentA": "This regulatory submission was based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients.", "sentB": "This regulatory submission was based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of ADYNOVATE TM (previously referred to as BAX 855) in 137 previously treated patients.", "type": 2, "words": ["<tag1>", "This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients.", "<tag2>", "This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855)", "in", "137", "previously", "treated", "patients.", "<tag3>"], "wordsA": ["This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients."], "wordsB": ["This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855)", "in", "137", "previously", "treated", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s11", "idA": "906709_15_item1_p12_s2", "sentA": "This regulatory submission was based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients.", "sentB": "However, the FDA staff also indicated that positive results from a completed confirmatory trial for the MAA could also support an NDA filing.", "type": 2, "words": ["<tag1>", "This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients.", "<tag2>", "However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "also", "support", "an", "NDA", "filing.", "<tag3>"], "wordsA": ["This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients."], "wordsB": ["However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "also", "support", "an", "NDA", "filing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s13", "idA": "906709_15_item1_p12_s2", "sentA": "This regulatory submission was based on positive results from a prospective, global, multi-center, open-label, two-arm Phase 3 study of BAX 855 in 137 previously treated patients.", "sentB": "However, the FDA staff also indicated that positive results from a completed confirmatory trial for the MAA could support an NDA filing.", "type": 2, "words": ["<tag1>", "This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients.", "<tag2>", "However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "support", "an", "NDA", "filing.", "<tag3>"], "wordsA": ["This", "regulatory", "submission", "was", "based", "on", "positive", "results", "from", "a", "prospective,", "global,", "multi-center,", "open-label,", "two-arm", "Phase", "3", "study", "of", "BAX", "855", "in", "137", "previously", "treated", "patients."], "wordsB": ["However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "support", "an", "NDA", "filing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p166_s0", "idA": "906709_15_item1_p12_s3", "sentA": "Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older.", "sentB": "[Antihemophilic Factor (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with Hemophilia A. ELOCTATE is intended to be an extended half-life Factor VIII therapy with prolonged circulation in the body with the potential to extend the interval between prophylactic infusions.", "type": 2, "words": ["<tag1>", "Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag2>", "[Antihemophilic", "Factor", "(Recombinant),", "Fc", "Fusion", "Protein]", "for", "the", "control", "and", "prevention", "of", "bleeding", "episodes,", "perioperative", "(surgical)", "management", "and", "routine", "prophylaxis", "in", "adults", "and", "children", "with", "Hemophilia", "A.", "ELOCTATE", "is", "intended", "to", "be", "an", "extended", "half-life", "Factor", "VIII", "therapy", "with", "prolonged", "circulation", "in", "the", "body", "with", "the", "potential", "to", "extend", "the", "interval", "between", "prophylactic", "infusions.", "<tag3>"], "wordsA": ["Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older."], "wordsB": ["[Antihemophilic", "Factor", "(Recombinant),", "Fc", "Fusion", "Protein]", "for", "the", "control", "and", "prevention", "of", "bleeding", "episodes,", "perioperative", "(surgical)", "management", "and", "routine", "prophylaxis", "in", "adults", "and", "children", "with", "Hemophilia", "A.", "ELOCTATE", "is", "intended", "to", "be", "an", "extended", "half-life", "Factor", "VIII", "therapy", "with", "prolonged", "circulation", "in", "the", "body", "with", "the", "potential", "to", "extend", "the", "interval", "between", "prophylactic", "infusions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p52_s3", "idA": "906709_15_item1_p12_s3", "sentA": "Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older.", "sentB": "Baxalta reported that the results demonstrated that ADYNOVATE TM met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older.", "type": 2, "words": ["<tag1>", "Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag2>", "Baxalta", "reported", "that", "the", "results", "demonstrated", "that", "ADYNOVATE", "TM", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag3>"], "wordsA": ["Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older."], "wordsB": ["Baxalta", "reported", "that", "the", "results", "demonstrated", "that", "ADYNOVATE", "TM", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s8", "idA": "906709_15_item1_p12_s3", "sentA": "Baxter reported that the results demonstrated that BAX 855 met its primary endpoint in the control and prevention of bleeding episodes and routine prophylaxis for patients who were 12 years or older.", "sentB": "ADYNOVATE TM met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE TM .", "type": 2, "words": ["<tag1>", "Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag2>", "ADYNOVATE", "TM", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "TM", ".", "<tag3>"], "wordsA": ["Baxter", "reported", "that", "the", "results", "demonstrated", "that", "BAX", "855", "met", "its", "primary", "endpoint", "in", "the", "control", "and", "prevention", "of", "bleeding", "episodes", "and", "routine", "prophylaxis", "for", "patients", "who", "were", "12", "years", "or", "older."], "wordsB": ["ADYNOVATE", "TM", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p3_s2", "idA": "906709_15_item1_p133_s0", "sentA": "The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S. depends on whether the chemical composition of the product has previously been approved for use in other dosage forms.", "sentB": "In November 2015, ADYNOVATE TM was approved by the U.S. Food and Drug Administration (FDA) for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Baxalta announced the launch and first shipments of ADYNOVATE TM in the U.S. on November 30, 2015.", "type": 2, "words": ["<tag1>", "The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms.", "<tag2>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "on", "November", "30,", "2015.", "<tag3>"], "wordsA": ["The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms."], "wordsB": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "on", "November", "30,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p52_s4", "idA": "906709_15_item1_p133_s0", "sentA": "The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S. depends on whether the chemical composition of the product has previously been approved for use in other dosage forms.", "sentB": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE TM in the U.S. ADYNOVATE TM is currently under regulatory review in Japan, Canada and Switzerland.", "type": 2, "words": ["<tag1>", "The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms.", "<tag2>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland.", "<tag3>"], "wordsA": ["The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms."], "wordsB": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s4", "idA": "906709_15_item1_p133_s0", "sentA": "The approval process required by the FDA before a product using any of our technologies may be marketed in the U.S. depends on whether the chemical composition of the product has previously been approved for use in other dosage forms.", "sentB": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE TM in the U.S.", "type": 2, "words": ["<tag1>", "The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms.", "<tag2>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "<tag3>"], "wordsA": ["The", "approval", "process", "required", "by", "the", "FDA", "before", "a", "product", "using", "any", "of", "our", "technologies", "may", "be", "marketed", "in", "the", "U.S.", "depends", "on", "whether", "the", "chemical", "composition", "of", "the", "product", "has", "previously", "been", "approved", "for", "use", "in", "other", "dosage", "forms."], "wordsB": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p132_s0", "idA": "906709_15_item1_p134_s1", "sentA": "If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests relating to systemic toxicity normally required for the IND and NDA or BLA may not be necessary if the company has a right of reference to such data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section 505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.", "sentB": "If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests , including those relating to systemic toxicity normally required for the IND and NDA or BLA , and clinical trials, may not be necessary if the company has a right of reference to existing preclinical or clinical data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section 505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.", "type": 2, "words": ["<tag1>", "If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "such", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act.", "<tag2>", "If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests", ",", "including", "those", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA", ",", "and", "clinical", "trials,", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "existing", "preclinical", "or", "clinical", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act.", "<tag3>"], "wordsA": ["If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "such", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act."], "wordsB": ["If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests", ",", "including", "those", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA", ",", "and", "clinical", "trials,", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "existing", "preclinical", "or", "clinical", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s5", "idA": "906709_15_item1_p134_s2", "sentA": "Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation.", "sentB": "In December 2015, Baxalta announced positive study results from its prospective, uncontrolled, open-label, multi-center Phase 3 study designed to assess the safety and immunogenicity of ADYNOVATE TM .", "type": 2, "words": ["<tag1>", "Preclinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "animal", "studies", "to", "assess", "the", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "chosen", "formulation.", "<tag2>", "In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", ".", "<tag3>"], "wordsA": ["Preclinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "animal", "studies", "to", "assess", "the", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "chosen", "formulation."], "wordsB": ["In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p174_s2", "idA": "906709_15_item1_p134_s3", "sentA": "Preclinical safety tests must be conducted by laboratories that comply with FDA good laboratory practices (GLP) regulations.", "sentB": "We would be subject to significant penalties for failure to comply with these laws and regulations.", "type": 2, "words": ["<tag1>", "Preclinical", "safety", "tests", "must", "be", "conducted", "by", "laboratories", "that", "comply", "with", "FDA", "good", "laboratory", "practices", "(GLP)", "regulations.", "<tag2>", "We", "would", "be", "subject", "to", "significant", "penalties", "for", "failure", "to", "comply", "with", "these", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["Preclinical", "safety", "tests", "must", "be", "conducted", "by", "laboratories", "that", "comply", "with", "FDA", "good", "laboratory", "practices", "(GLP)", "regulations."], "wordsB": ["We", "would", "be", "subject", "to", "significant", "penalties", "for", "failure", "to", "comply", "with", "these", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p92_s2", "idA": "906709_15_item1_p135_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "There are about 20,000 people with hemophilia in the US.", "type": 2, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "There", "are", "about", "20,000", "people", "with", "hemophilia", "in", "the", "US.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["There", "are", "about", "20,000", "people", "with", "hemophilia", "in", "the", "US."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s12", "idA": "906709_15_item1_p139_s1", "sentA": "In some cases, the FDA and the drug sponsor may determine that Phase 2 trials are not needed prior to entering Phase 3 trials.", "sentB": "In the United States, we met with the FDA and the Oncology Division indicated that we would not be able to use the BEACON data to support an accelerated approval for a new drug application (NDA).", "type": 2, "words": ["<tag1>", "In", "some", "cases,", "the", "FDA", "and", "the", "drug", "sponsor", "may", "determine", "that", "Phase", "2", "trials", "are", "not", "needed", "prior", "to", "entering", "Phase", "3", "trials.", "<tag2>", "In", "the", "United", "States,", "we", "met", "with", "the", "FDA", "and", "the", "Oncology", "Division", "indicated", "that", "we", "would", "not", "be", "able", "to", "use", "the", "BEACON", "data", "to", "support", "an", "accelerated", "approval", "for", "a", "new", "drug", "application", "(NDA).", "<tag3>"], "wordsA": ["In", "some", "cases,", "the", "FDA", "and", "the", "drug", "sponsor", "may", "determine", "that", "Phase", "2", "trials", "are", "not", "needed", "prior", "to", "entering", "Phase", "3", "trials."], "wordsB": ["In", "the", "United", "States,", "we", "met", "with", "the", "FDA", "and", "the", "Oncology", "Division", "indicated", "that", "we", "would", "not", "be", "able", "to", "use", "the", "BEACON", "data", "to", "support", "an", "accelerated", "approval", "for", "a", "new", "drug", "application", "(NDA)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p10_s0", "idA": "906709_15_item1_p13_s0", "sentA": "We also have a collaboration with Bayer Healthcare LLC (Bayer), to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "We have a collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer),", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer),", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p10_s2", "idA": "906709_15_item1_p13_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "sentB": "Bayer is currently enrolling patients in a Phase 3 clinical program for Amikacin Inhale.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag2>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "wordsB": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s0", "idA": "906709_15_item1_p13_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "sentB": "On March 17, 2015, we announced topline data from the BEACON Phase 3 clinical study for NKTR-102.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag2>", "On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "the", "BEACON", "Phase", "3", "clinical", "study", "for", "NKTR-102.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "wordsB": ["On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "the", "BEACON", "Phase", "3", "clinical", "study", "for", "NKTR-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p7_s0", "idA": "906709_15_item1_p13_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "sentB": "In December 2015, we dosed the first patient in a Phase 1/2 clinical study for NKTR-214, which is our engineered immunostimulatory CD122-biased cytokine designed to preferentially activate the beta and gamma sub-units of the IL-2 receptor in orde r to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag2>", "In", "December", "2015,", "we", "dosed", "the", "first", "patient", "in", "a", "Phase", "1/2", "clinical", "study", "for", "NKTR-214,", "which", "is", "our", "engineered", "immunostimulatory", "CD122-biased", "cytokine", "designed", "to", "preferentially", "activate", "the", "beta", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "orde", "r", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "wordsB": ["In", "December", "2015,", "we", "dosed", "the", "first", "patient", "in", "a", "Phase", "1/2", "clinical", "study", "for", "NKTR-214,", "which", "is", "our", "engineered", "immunostimulatory", "CD122-biased", "cytokine", "designed", "to", "preferentially", "activate", "the", "beta", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "orde", "r", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p11_s3", "idA": "906709_15_item1_p13_s4", "sentA": "We also have a number of license, manufacturing and supply agreements with leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Halozyme Therapeutics, Inc., Merck Co., Inc., Ophthotech Corporation, Pfizer, Inc., F. Hoffmann-La Roche Ltd (Roche), and UCB Pharma.", "sentB": "We also have a number of license, manufacturing and supply agreements with other leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Merck Co., Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd (Roche).", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma.", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche).", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Halozyme", "Therapeutics,", "Inc.,", "Merck", "Co.,", "Inc.,", "Ophthotech", "Corporation,", "Pfizer,", "Inc.,", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche),", "and", "UCB", "Pharma."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s1", "idA": "906709_15_item1_p141_s0", "sentA": "Each manufacturing establishment producing the active pharmaceutical ingredient and finished drug product for the U.S. market must be registered with the FDA and typically is inspected by the FDA prior to NDA or BLA approval of a drug product manufactured by such establishment.", "sentB": "As we do not maintain the capability to manufacture APIs (including biologics) nor finished drug products for all of our development programs, we primarily utilize contract manufacturers to manufacture active pharmaceutical ingredients and finished drug product for us.", "type": 2, "words": ["<tag1>", "Each", "manufacturing", "establishment", "producing", "the", "active", "pharmaceutical", "ingredient", "and", "finished", "drug", "product", "for", "the", "U.S.", "market", "must", "be", "registered", "with", "the", "FDA", "and", "typically", "is", "inspected", "by", "the", "FDA", "prior", "to", "NDA", "or", "BLA", "approval", "of", "a", "drug", "product", "manufactured", "by", "such", "establishment.", "<tag2>", "As", "we", "do", "not", "maintain", "the", "capability", "to", "manufacture", "APIs", "(including", "biologics)", "nor", "finished", "drug", "products", "for", "all", "of", "our", "development", "programs,", "we", "primarily", "utilize", "contract", "manufacturers", "to", "manufacture", "active", "pharmaceutical", "ingredients", "and", "finished", "drug", "product", "for", "us.", "<tag3>"], "wordsA": ["Each", "manufacturing", "establishment", "producing", "the", "active", "pharmaceutical", "ingredient", "and", "finished", "drug", "product", "for", "the", "U.S.", "market", "must", "be", "registered", "with", "the", "FDA", "and", "typically", "is", "inspected", "by", "the", "FDA", "prior", "to", "NDA", "or", "BLA", "approval", "of", "a", "drug", "product", "manufactured", "by", "such", "establishment."], "wordsB": ["As", "we", "do", "not", "maintain", "the", "capability", "to", "manufacture", "APIs", "(including", "biologics)", "nor", "finished", "drug", "products", "for", "all", "of", "our", "development", "programs,", "we", "primarily", "utilize", "contract", "manufacturers", "to", "manufacture", "active", "pharmaceutical", "ingredients", "and", "finished", "drug", "product", "for", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p141_s0", "idA": "906709_15_item1_p141_s4", "sentA": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance controls, among others.", "sentB": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, e nvironmental protection and hazardous and controlled substance controls, among others.", "type": 2, "words": ["<tag1>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag2>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "e", "nvironmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag3>"], "wordsA": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "wordsB": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "e", "nvironmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s7", "idA": "906709_15_item1_p141_s4", "sentA": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance controls, among others.", "sentB": "As a manufacturer of PEG reagents for the U.S. market, we are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others.", "type": 2, "words": ["<tag1>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag2>", "As", "a", "manufacturer", "of", "PEG", "reagents", "for", "the", "U.S.", "market,", "we", "are", "subject", "to", "inspections", "by", "the", "FDA", "for", "compliance", "with", "cGMP", "and", "other", "U.S.", "regulatory", "requirements,", "including", "U.S.", "federal,", "state", "and", "local", "regulations", "regarding", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag3>"], "wordsA": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "wordsB": ["As", "a", "manufacturer", "of", "PEG", "reagents", "for", "the", "U.S.", "market,", "we", "are", "subject", "to", "inspections", "by", "the", "FDA", "for", "compliance", "with", "cGMP", "and", "other", "U.S.", "regulatory", "requirements,", "including", "U.S.", "federal,", "state", "and", "local", "regulations", "regarding", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p146_s0", "idA": "906709_15_item1_p145_s5", "sentA": "To date, our partners have generally been responsible for clinical and regulatory approval procedures, but we may participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device, PEGylation materials or drug.", "sentB": "In situations where our partners are responsible for clinical and regulatory approval procedures, but we may participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device, PEGylation materials or drug.", "type": 2, "words": ["<tag1>", "To", "date,", "our", "partners", "have", "generally", "been", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug.", "<tag2>", "In", "situations", "where", "our", "partners", "are", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug.", "<tag3>"], "wordsA": ["To", "date,", "our", "partners", "have", "generally", "been", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug."], "wordsB": ["In", "situations", "where", "our", "partners", "are", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p160_s4", "idA": "906709_15_item1_p14_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "The backlog at a particular time is affected by a number of factors, including scheduled date of manufacture and delivery and development program status.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "The", "backlog", "at", "a", "particular", "time", "is", "affected", "by", "a", "number", "of", "factors,", "including", "scheduled", "date", "of", "manufacture", "and", "delivery", "and", "development", "program", "status.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["The", "backlog", "at", "a", "particular", "time", "is", "affected", "by", "a", "number", "of", "factors,", "including", "scheduled", "date", "of", "manufacture", "and", "delivery", "and", "development", "program", "status."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p51_s0", "idA": "906709_15_item1_p14_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "There are a number of patents relevant to Movantik TM , some of which are listed in the FDA s Orange Book.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "There", "are", "a", "number", "of", "patents", "relevant", "to", "Movantik", "TM", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["There", "are", "a", "number", "of", "patents", "relevant", "to", "Movantik", "TM", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p54_s0", "idA": "906709_15_item1_p14_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "There are a number of patents relevant to Adynovate TM .", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "There", "are", "a", "number", "of", "patents", "relevant", "to", "Adynovate", "TM", ".", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["There", "are", "a", "number", "of", "patents", "relevant", "to", "Adynovate", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p150_s0", "idA": "906709_15_item1_p150_s0", "sentA": "Similar incentives also are available for orphan drugs in the E.U.", "sentB": "Similar incentives also are available for orphan drugs in the EU.", "type": 2, "words": ["<tag1>", "Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "E.U.", "<tag2>", "Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "EU.", "<tag3>"], "wordsA": ["Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "E.U."], "wordsB": ["Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p151_s0", "idA": "906709_15_item1_p151_s0", "sentA": "In the U.S., the FDA may grant Fast Track or Breakthrough designation to a product candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.", "sentB": "In the U.S., the FDA may grant Fast Track or Breakthrough Therapy designation to a product candidate, which allows the FDA to expedite the review of new drugs that are intended for serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.", "type": 2, "words": ["<tag1>", "In", "the", "U.S.,", "the", "FDA", "may", "grant", "Fast", "Track", "or", "Breakthrough", "designation", "to", "a", "product", "candidate,", "which", "allows", "the", "FDA", "to", "expedite", "the", "review", "of", "new", "drugs", "that", "are", "intended", "for", "serious", "or", "life-threatening", "conditions", "and", "that", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs.", "<tag2>", "In", "the", "U.S.,", "the", "FDA", "may", "grant", "Fast", "Track", "or", "Breakthrough", "Therapy", "designation", "to", "a", "product", "candidate,", "which", "allows", "the", "FDA", "to", "expedite", "the", "review", "of", "new", "drugs", "that", "are", "intended", "for", "serious", "or", "life-threatening", "conditions", "and", "that", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs.", "<tag3>"], "wordsA": ["In", "the", "U.S.,", "the", "FDA", "may", "grant", "Fast", "Track", "or", "Breakthrough", "designation", "to", "a", "product", "candidate,", "which", "allows", "the", "FDA", "to", "expedite", "the", "review", "of", "new", "drugs", "that", "are", "intended", "for", "serious", "or", "life-threatening", "conditions", "and", "that", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs."], "wordsB": ["In", "the", "U.S.,", "the", "FDA", "may", "grant", "Fast", "Track", "or", "Breakthrough", "Therapy", "designation", "to", "a", "product", "candidate,", "which", "allows", "the", "FDA", "to", "expedite", "the", "review", "of", "new", "drugs", "that", "are", "intended", "for", "serious", "or", "life-threatening", "conditions", "and", "that", "demonstrate", "the", "potential", "to", "address", "unmet", "medical", "needs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p151_s1", "idA": "906709_15_item1_p151_s1", "sentA": "Important features of Fast Track or Breakthrough designation include a potentially reduced clinical program and close, early communication between the FDA and the sponsor company to improve the efficiency of product development.", "sentB": "Important features of Fast Track or Breakthrough Therapy designation include a potentially reduced clinical program and close, early communication between the FDA and the sponsor company to improve the efficiency of product development.", "type": 2, "words": ["<tag1>", "Important", "features", "of", "Fast", "Track", "or", "Breakthrough", "designation", "include", "a", "potentially", "reduced", "clinical", "program", "and", "close,", "early", "communication", "between", "the", "FDA", "and", "the", "sponsor", "company", "to", "improve", "the", "efficiency", "of", "product", "development.", "<tag2>", "Important", "features", "of", "Fast", "Track", "or", "Breakthrough", "Therapy", "designation", "include", "a", "potentially", "reduced", "clinical", "program", "and", "close,", "early", "communication", "between", "the", "FDA", "and", "the", "sponsor", "company", "to", "improve", "the", "efficiency", "of", "product", "development.", "<tag3>"], "wordsA": ["Important", "features", "of", "Fast", "Track", "or", "Breakthrough", "designation", "include", "a", "potentially", "reduced", "clinical", "program", "and", "close,", "early", "communication", "between", "the", "FDA", "and", "the", "sponsor", "company", "to", "improve", "the", "efficiency", "of", "product", "development."], "wordsB": ["Important", "features", "of", "Fast", "Track", "or", "Breakthrough", "Therapy", "designation", "include", "a", "potentially", "reduced", "clinical", "program", "and", "close,", "early", "communication", "between", "the", "FDA", "and", "the", "sponsor", "company", "to", "improve", "the", "efficiency", "of", "product", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p161_s0", "idA": "906709_15_item1_p152_s4", "sentA": "Our patent strategy is to file patent applications on innovations and improvements to cover a significant majority of the major pharmaceutical markets in the world.", "sentB": "Competition Competition in the pharmaceutical and biotechnology industry is intense and characterized by aggressive research and development and rapidly-evolving science, technology, and standards of medical care throughout the world.", "type": 2, "words": ["<tag1>", "Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world.", "<tag2>", "Competition", "Competition", "in", "the", "pharmaceutical", "and", "biotechnology", "industry", "is", "intense", "and", "characterized", "by", "aggressive", "research", "and", "development", "and", "rapidly-evolving", "science,", "technology,", "and", "standards", "of", "medical", "care", "throughout", "the", "world.", "<tag3>"], "wordsA": ["Our", "patent", "strategy", "is", "to", "file", "patent", "applications", "on", "innovations", "and", "improvements", "to", "cover", "a", "significant", "majority", "of", "the", "major", "pharmaceutical", "markets", "in", "the", "world."], "wordsB": ["Competition", "Competition", "in", "the", "pharmaceutical", "and", "biotechnology", "industry", "is", "intense", "and", "characterized", "by", "aggressive", "research", "and", "development", "and", "rapidly-evolving", "science,", "technology,", "and", "standards", "of", "medical", "care", "throughout", "the", "world."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p153_s0", "idA": "906709_15_item1_p152_s5", "sentA": "Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "sentB": "have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "type": 2, "words": ["<tag1>", "Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag2>", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag3>"], "wordsA": ["Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "wordsB": ["have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p153_s1", "idA": "906709_15_item1_p152_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "In some instances, patent terms can be increased or decreased, depending on the laws an d regulations of the country or jurisdiction that issued the patent.", "type": 2, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "an", "d", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "an", "d", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s0", "idA": "906709_15_item1_p152_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "The facility and associated equipment are designed and operated to be consistent with all applicable laws and regulations.", "type": 2, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "The", "facility", "and", "associated", "equipment", "are", "designed", "and", "operated", "to", "be", "consistent", "with", "all", "applicable", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["The", "facility", "and", "associated", "equipment", "are", "designed", "and", "operated", "to", "be", "consistent", "with", "all", "applicable", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p174_s0", "idA": "906709_15_item1_p152_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time.", "type": 2, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "Environmental", "laws", "and", "regulations", "are", "complex,", "change", "frequently", "and", "have", "tended", "to", "become", "more", "stringent", "over", "time.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["Environmental", "laws", "and", "regulations", "are", "complex,", "change", "frequently", "and", "have", "tended", "to", "become", "more", "stringent", "over", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p176_s3", "idA": "906709_15_item1_p152_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "Information on the operation of the Public Reference Room can be obtained by calling 1-800-SEC-0330.", "type": 2, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "Information", "on", "the", "operation", "of", "the", "Public", "Reference", "Room", "can", "be", "obtained", "by", "calling", "1-800-SEC-0330.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["Information", "on", "the", "operation", "of", "the", "Public", "Reference", "Room", "can", "be", "obtained", "by", "calling", "1-800-SEC-0330."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s9", "idA": "906709_15_item1_p154_s1", "sentA": "In connection with the Novartis Pulmonary Asset Sale, as of December 31, 2008, we entered into an exclusive license agreement with Novartis Pharma AG.", "sentB": "In connection with any MAA filing, the EMA has informed us that we would be required to start a confirmatory trial in conjunction with the MAA review.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "of", "December", "31,", "2008,", "we", "entered", "into", "an", "exclusive", "license", "agreement", "with", "Novartis", "Pharma", "AG.", "<tag2>", "In", "connection", "with", "any", "MAA", "filing,", "the", "EMA", "has", "informed", "us", "that", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review.", "<tag3>"], "wordsA": ["In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "of", "December", "31,", "2008,", "we", "entered", "into", "an", "exclusive", "license", "agreement", "with", "Novartis", "Pharma", "AG."], "wordsB": ["In", "connection", "with", "any", "MAA", "filing,", "the", "EMA", "has", "informed", "us", "that", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s11", "idA": "906709_15_item1_p154_s1", "sentA": "In connection with the Novartis Pulmonary Asset Sale, as of December 31, 2008, we entered into an exclusive license agreement with Novartis Pharma AG.", "sentB": "In connection with any MAA filing, we would be required to start a confirmatory trial in conjunction with the MAA review.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "of", "December", "31,", "2008,", "we", "entered", "into", "an", "exclusive", "license", "agreement", "with", "Novartis", "Pharma", "AG.", "<tag2>", "In", "connection", "with", "any", "MAA", "filing,", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review.", "<tag3>"], "wordsA": ["In", "connection", "with", "the", "Novartis", "Pulmonary", "Asset", "Sale,", "as", "of", "December", "31,", "2008,", "we", "entered", "into", "an", "exclusive", "license", "agreement", "with", "Novartis", "Pharma", "AG."], "wordsB": ["In", "connection", "with", "any", "MAA", "filing,", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p155_s3", "idA": "906709_15_item1_p155_s0", "sentA": "program for inhaled vancomycin or are necessary for us to satisfy certain continuing contractual obligations to third parties, including in connection with development, manufacture, sale, and commercialization activities related to BAY41-6551 partnered with Bayer Healthcare LLC.", "sentB": "Certain of such patent rights and other related intellectual property rights relate to our development program for inhaled vancomycin or are necessary for us to satisfy certain continuing contractual obligations to third parties, including in connection with development, manufacture, sale, and commercialization activities related to BAY41-6551 partnered with Bayer Healthcare LLC.", "type": 2, "words": ["<tag1>", "program", "for", "inhaled", "vancomycin", "or", "are", "necessary", "for", "us", "to", "satisfy", "certain", "continuing", "contractual", "obligations", "to", "third", "parties,", "including", "in", "connection", "with", "development,", "manufacture,", "sale,", "and", "commercialization", "activities", "related", "to", "BAY41-6551", "partnered", "with", "Bayer", "Healthcare", "LLC.", "<tag2>", "Certain", "of", "such", "patent", "rights", "and", "other", "related", "intellectual", "property", "rights", "relate", "to", "our", "development", "program", "for", "inhaled", "vancomycin", "or", "are", "necessary", "for", "us", "to", "satisfy", "certain", "continuing", "contractual", "obligations", "to", "third", "parties,", "including", "in", "connection", "with", "development,", "manufacture,", "sale,", "and", "commercialization", "activities", "related", "to", "BAY41-6551", "partnered", "with", "Bayer", "Healthcare", "LLC.", "<tag3>"], "wordsA": ["program", "for", "inhaled", "vancomycin", "or", "are", "necessary", "for", "us", "to", "satisfy", "certain", "continuing", "contractual", "obligations", "to", "third", "parties,", "including", "in", "connection", "with", "development,", "manufacture,", "sale,", "and", "commercialization", "activities", "related", "to", "BAY41-6551", "partnered", "with", "Bayer", "Healthcare", "LLC."], "wordsB": ["Certain", "of", "such", "patent", "rights", "and", "other", "related", "intellectual", "property", "rights", "relate", "to", "our", "development", "program", "for", "inhaled", "vancomycin", "or", "are", "necessary", "for", "us", "to", "satisfy", "certain", "continuing", "contractual", "obligations", "to", "third", "parties,", "including", "in", "connection", "with", "development,", "manufacture,", "sale,", "and", "commercialization", "activities", "related", "to", "BAY41-6551", "partnered", "with", "Bayer", "Healthcare", "LLC."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p159_s3", "idA": "906709_15_item1_p155_s2", "sentA": "No assurance can be given that we can meaningfully protect our trade secrets.", "sentB": "There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.", "type": 2, "words": ["<tag1>", "No", "assurance", "can", "be", "given", "that", "we", "can", "meaningfully", "protect", "our", "trade", "secrets.", "<tag2>", "There", "can", "be", "no", "assurance,", "however,", "that", "these", "agreements", "will", "provide", "meaningful", "protection", "or", "adequate", "remedies", "for", "our", "trade", "secrets", "in", "the", "event", "of", "unauthorized", "use", "or", "disclosure", "of", "such", "information.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "given", "that", "we", "can", "meaningfully", "protect", "our", "trade", "secrets."], "wordsB": ["There", "can", "be", "no", "assurance,", "however,", "that", "these", "agreements", "will", "provide", "meaningful", "protection", "or", "adequate", "remedies", "for", "our", "trade", "secrets", "in", "the", "event", "of", "unauthorized", "use", "or", "disclosure", "of", "such", "information."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p158_s3", "idA": "906709_15_item1_p156_s7", "sentA": "Please refer to Item 1A, Risk Factors, including without limitation, If any of our pending patent applications do not issue, or are deemed invalid following issuance, we may lose valuable intellectual property protection.", "sentB": "Please refer to Item 1A, Risk Factors, including without limitation, We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, if at all.", "type": 2, "words": ["<tag1>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "any", "of", "our", "pending", "patent", "applications", "do", "not", "issue,", "or", "are", "deemed", "invalid", "following", "issuance,", "we", "may", "lose", "valuable", "intellectual", "property", "protection.", "<tag2>", "Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "may", "not", "be", "able", "to", "obtain", "intellectual", "property", "licenses", "related", "to", "the", "development", "of", "our", "drug", "candidates", "on", "a", "commercially", "reasonable", "basis,", "if", "at", "all.", "<tag3>"], "wordsA": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "If", "any", "of", "our", "pending", "patent", "applications", "do", "not", "issue,", "or", "are", "deemed", "invalid", "following", "issuance,", "we", "may", "lose", "valuable", "intellectual", "property", "protection."], "wordsB": ["Please", "refer", "to", "Item", "1A,", "Risk", "Factors,", "including", "without", "limitation,", "We", "may", "not", "be", "able", "to", "obtain", "intellectual", "property", "licenses", "related", "to", "the", "development", "of", "our", "drug", "candidates", "on", "a", "commercially", "reasonable", "basis,", "if", "at", "all."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p13_s1", "idA": "906709_15_item1_p15_s1", "sentA": "We retained all of our rights to Amikacin Inhale and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transaction.", "sentB": "We retai ned all of our rights to Amikacin Inhale and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transa ction.", "type": 2, "words": ["<tag1>", "We", "retained", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction.", "<tag2>", "We", "retai", "ned", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transa", "ction.", "<tag3>"], "wordsA": ["We", "retained", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transaction."], "wordsB": ["We", "retai", "ned", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transa", "ction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p13_s3", "idA": "906709_15_item1_p16_s1", "sentA": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 patients and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "sentB": "The two placebo-controlled trials, RESPIRE-1 and RESPIRE-2, are enrolling up to 600 pati ents and will evaluate Cipro DPI as a chronic, intermittent therapy over a period of 48 weeks.", "type": 2, "words": ["<tag1>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag2>", "The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "pati", "ents", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks.", "<tag3>"], "wordsA": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "patients", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "wordsB": ["The", "two", "placebo-controlled", "trials,", "RESPIRE-1", "and", "RESPIRE-2,", "are", "enrolling", "up", "to", "600", "pati", "ents", "and", "will", "evaluate", "Cipro", "DPI", "as", "a", "chronic,", "intermittent", "therapy", "over", "a", "period", "of", "48", "weeks."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p176_s0", "idA": "906709_15_item1_p17_s2", "sentA": "Our website is located at www.nektar.com.", "sentB": "Our website address is http://www.nektar.com .", "type": 2, "words": ["<tag1>", "Our", "website", "is", "located", "at", "www.nektar.com.", "<tag2>", "Our", "website", "address", "is", "http://www.nektar.com", ".", "<tag3>"], "wordsA": ["Our", "website", "is", "located", "at", "www.nektar.com."], "wordsB": ["Our", "website", "address", "is", "http://www.nektar.com", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p176_s1", "idA": "906709_15_item1_p17_s3", "sentA": "The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report.", "sentB": "The information in, or that can be accessed through, our website is not part of this annual report on Form 10-K. Our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K and amendments to those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities Exchange Commission (SEC).", "type": 2, "words": ["<tag1>", "The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report.", "<tag2>", "The", "information", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of", "this", "annual", "report", "on", "Form", "10-K.", "Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q", "and", "current", "reports", "on", "Form", "8-K", "and", "amendments", "to", "those", "reports", "are", "available,", "free", "of", "charge,", "on", "or", "through", "our", "website", "as", "soon", "as", "reasonably", "practicable", "after", "we", "electronically", "file", "such", "material", "with,", "or", "furnish", "it", "to,", "the", "Securities", "Exchange", "Commission", "(SEC).", "<tag3>"], "wordsA": ["The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report."], "wordsB": ["The", "information", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of", "this", "annual", "report", "on", "Form", "10-K.", "Our", "annual", "reports", "on", "Form", "10-K,", "quarterly", "reports", "on", "Form", "10-Q", "and", "current", "reports", "on", "Form", "8-K", "and", "amendments", "to", "those", "reports", "are", "available,", "free", "of", "charge,", "on", "or", "through", "our", "website", "as", "soon", "as", "reasonably", "practicable", "after", "we", "electronically", "file", "such", "material", "with,", "or", "furnish", "it", "to,", "the", "Securities", "Exchange", "Commission", "(SEC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s2", "idA": "906709_15_item1_p18_s1", "sentA": "Nearly all of the PEGylated drugs approved over the last fifteen years were enabled with our PEGylation technology through our collaborations and licensing partnerships with a number of well-known biotechnology and pharmaceutical companies.", "sentB": "A number of the drug candidates in our pipeline have direct and indirect competition from large pharmaceutical companies and biopharmaceutical companies.", "type": 2, "words": ["<tag1>", "Nearly", "all", "of", "the", "PEGylated", "drugs", "approved", "over", "the", "last", "fifteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "well-known", "biotechnology", "and", "pharmaceutical", "companies.", "<tag2>", "A", "number", "of", "the", "drug", "candidates", "in", "our", "pipeline", "have", "direct", "and", "indirect", "competition", "from", "large", "pharmaceutical", "companies", "and", "biopharmaceutical", "companies.", "<tag3>"], "wordsA": ["Nearly", "all", "of", "the", "PEGylated", "drugs", "approved", "over", "the", "last", "fifteen", "years", "were", "enabled", "with", "our", "PEGylation", "technology", "through", "our", "collaborations", "and", "licensing", "partnerships", "with", "a", "number", "of", "well-known", "biotechnology", "and", "pharmaceutical", "companies."], "wordsB": ["A", "number", "of", "the", "drug", "candidates", "in", "our", "pipeline", "have", "direct", "and", "indirect", "competition", "from", "large", "pharmaceutical", "companies", "and", "biopharmaceutical", "companies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p164_s1", "idA": "906709_15_item1_p19_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "sentB": "These therapies do not address the underlying cause of constipation as a result of opioid use and are generally viewed as ineffective or only partially effective to treat the symptoms of OIC and OBD.", "type": 2, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag2>", "These", "therapies", "do", "not", "address", "the", "underlying", "cause", "of", "constipation", "as", "a", "result", "of", "opioid", "use", "and", "are", "generally", "viewed", "as", "ineffective", "or", "only", "partially", "effective", "to", "treat", "the", "symptoms", "of", "OIC", "and", "OBD.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "wordsB": ["These", "therapies", "do", "not", "address", "the", "underlying", "cause", "of", "constipation", "as", "a", "result", "of", "opioid", "use", "and", "are", "generally", "viewed", "as", "ineffective", "or", "only", "partially", "effective", "to", "treat", "the", "symptoms", "of", "OIC", "and", "OBD."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p0_s2", "idA": "906709_15_item1_p1_s1", "sentA": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "sentB": "Our research and development activities involve small molecule drugs, peptides and protein biologic drug candidates.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag2>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "protein", "biologic", "drug", "candidates.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "wordsB": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "protein", "biologic", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p161_s1", "idA": "906709_15_item1_p1_s1", "sentA": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "sentB": "We frequently compete with pharmaceutical companies and other institutions with greater financial, research and development, marketing and sales, manufacturing and managerial capabilities.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag2>", "We", "frequently", "compete", "with", "pharmaceutical", "companies", "and", "other", "institutions", "with", "greater", "financial,", "research", "and", "development,", "marketing", "and", "sales,", "manufacturing", "and", "managerial", "capabilities.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "wordsB": ["We", "frequently", "compete", "with", "pharmaceutical", "companies", "and", "other", "institutions", "with", "greater", "financial,", "research", "and", "development,", "marketing", "and", "sales,", "manufacturing", "and", "managerial", "capabilities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s7", "idA": "906709_15_item1_p1_s1", "sentA": "Our research and development activities involve small molecule drugs, peptides and other biologic drug candidates.", "sentB": "Some of these companies license intellectual property or PEGylation materials to other companies, while others apply the technology to create their own drug candidates.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates.", "<tag2>", "Some", "of", "these", "companies", "license", "intellectual", "property", "or", "PEGylation", "materials", "to", "other", "companies,", "while", "others", "apply", "the", "technology", "to", "create", "their", "own", "drug", "candidates.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "other", "biologic", "drug", "candidates."], "wordsB": ["Some", "of", "these", "companies", "license", "intellectual", "property", "or", "PEGylation", "materials", "to", "other", "companies,", "while", "others", "apply", "the", "technology", "to", "create", "their", "own", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s0", "idA": "906709_15_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "Science and Technology Competition We believe that our proprietary and partnered products will compete with others in the market on the basis of one or more of the following parameters: efficacy, safety, ease of use and cost.", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "Science", "and", "Technology", "Competition", "We", "believe", "that", "our", "proprietary", "and", "partnered", "products", "will", "compete", "with", "others", "in", "the", "market", "on", "the", "basis", "of", "one", "or", "more", "of", "the", "following", "parameters:", "efficacy,", "safety,", "ease", "of", "use", "and", "cost.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["Science", "and", "Technology", "Competition", "We", "believe", "that", "our", "proprietary", "and", "partnered", "products", "will", "compete", "with", "others", "in", "the", "market", "on", "the", "basis", "of", "one", "or", "more", "of", "the", "following", "parameters:", "efficacy,", "safety,", "ease", "of", "use", "and", "cost."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s3", "idA": "906709_15_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "With our PEGylation and advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules.", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "With", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "we", "believe", "we", "have", "competitive", "advantages", "relating", "to", "factors", "such", "as", "efficacy,", "safety,", "ease", "of", "use", "and", "cost", "for", "certain", "applications", "and", "molecules.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["With", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "we", "believe", "we", "have", "competitive", "advantages", "relating", "to", "factors", "such", "as", "efficacy,", "safety,", "ease", "of", "use", "and", "cost", "for", "certain", "applications", "and", "molecules."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s5", "idA": "906709_15_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "In the fields of PEGylation and advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr. Reddy s Laboratories, Ltd., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.).", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "In", "the", "fields", "of", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "our", "competitors", "include", "Biogen", "Idec", "Inc.,", "Savient", "Pharmaceuticals,", "Inc.,", "Dr.", "Reddy", "s", "Laboratories,", "Ltd.,", "Mountain", "View", "Pharmaceuticals,", "Inc.,", "SunBio", "Corporation,", "NOF", "Corporation,", "and", "Novo", "Nordisk", "A/S", "(assets", "formerly", "held", "by", "Neose", "Technologies,", "Inc.).", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["In", "the", "fields", "of", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "our", "competitors", "include", "Biogen", "Idec", "Inc.,", "Savient", "Pharmaceuticals,", "Inc.,", "Dr.", "Reddy", "s", "Laboratories,", "Ltd.,", "Mountain", "View", "Pharmaceuticals,", "Inc.,", "SunBio", "Corporation,", "NOF", "Corporation,", "and", "Novo", "Nordisk", "A/S", "(assets", "formerly", "held", "by", "Neose", "Technologies,", "Inc.)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s6", "idA": "906709_15_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "Several other chemical, biotechnology and pharmaceutical companies may also be developing PEGylation technology, advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits.", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "Several", "other", "chemical,", "biotechnology", "and", "pharmaceutical", "companies", "may", "also", "be", "developing", "PEGylation", "technology,", "advanced", "polymer", "conjugate", "technology", "or", "technologies", "intended", "to", "deliver", "similar", "scientific", "and", "medical", "benefits.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["Several", "other", "chemical,", "biotechnology", "and", "pharmaceutical", "companies", "may", "also", "be", "developing", "PEGylation", "technology,", "advanced", "polymer", "conjugate", "technology", "or", "technologies", "intended", "to", "deliver", "similar", "scientific", "and", "medical", "benefits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s2", "idA": "906709_15_item1_p21_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We source drug starting materials for our manufacturing activities from one or more suppliers.", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "source", "drug", "starting", "materials", "for", "our", "manufacturing", "activities", "from", "one", "or", "more", "suppliers.", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "source", "drug", "starting", "materials", "for", "our", "manufacturing", "activities", "from", "one", "or", "more", "suppliers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p20_s3", "idA": "906709_15_item1_p24_s0", "sentA": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that is currently in Phase 3 development.", "sentB": "An example of reducing transport across the blood-brain barrier is MOVANTIK TM , an orally-available peripherally-acting opioid antagonist that is approved in the United States and European Union.", "type": 2, "words": ["<tag1>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "development.", "<tag2>", "An", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "MOVANTIK", "TM", ",", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "approved", "in", "the", "United", "States", "and", "European", "Union.", "<tag3>"], "wordsA": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "development."], "wordsB": ["An", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "MOVANTIK", "TM", ",", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "approved", "in", "the", "United", "States", "and", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s5", "idA": "906709_15_item1_p25_s1", "sentA": "We are currently using this platform with oncolytics, which typically have sub-optimal half-lives that can limit their therapeutic efficacy.", "sentB": "We are currently exploring various future regulatory paths forward for NKTR-102 with the EU and U.S. regulatory authorities.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy.", "<tag2>", "We", "are", "currently", "exploring", "various", "future", "regulatory", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities.", "<tag3>"], "wordsA": ["We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy."], "wordsB": ["We", "are", "currently", "exploring", "various", "future", "regulatory", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s7", "idA": "906709_15_item1_p25_s1", "sentA": "We are currently using this platform with oncolytics, which typically have sub-optimal half-lives that can limit their therapeutic efficacy.", "sentB": "We are currently exploring various future regulatory and development paths forward for NKTR-102 with the EU and U.S. regulatory authorities.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy.", "<tag2>", "We", "are", "currently", "exploring", "various", "future", "regulatory", "and", "development", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities.", "<tag3>"], "wordsA": ["We", "are", "currently", "using", "this", "platform", "with", "oncolytics,", "which", "typically", "have", "sub-optimal", "half-lives", "that", "can", "limit", "their", "therapeutic", "efficacy."], "wordsB": ["We", "are", "currently", "exploring", "various", "future", "regulatory", "and", "development", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p21_s3", "idA": "906709_15_item1_p25_s3", "sentA": "We are using this approach with our lead oncolytic drug candidate, etirinotecan pegol, a next-generation topoisomerase I-inhibitor currently in the Phase 3 BEACON clinical study for treatment of metastatic breast cancer.", "sentB": "We are using this approach with our lead oncolytic drug candidate, NKTR-102, a next-generation topoisomerase I-inhibitor currently in the Phase 3 BEACON clinical study for treatment of metastatic breast cancer.", "type": 2, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer.", "<tag2>", "We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "etirinotecan", "pegol,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer."], "wordsB": ["We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p21_s7", "idA": "906709_15_item1_p25_s4", "sentA": "Our customized approaches with large molecule polymer conjugates have enabled numerous successful PEGylated biologics on the market today.", "sentB": "Our customized approaches with large molecule polymer conjugates have expanded to include a new approach with biologics, in particular cytokines, which utilizes the polymer as a means to bias action to a certain receptor or receptor sub-type.", "type": 2, "words": ["<tag1>", "Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "enabled", "numerous", "successful", "PEGylated", "biologics", "on", "the", "market", "today.", "<tag2>", "Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "expanded", "to", "include", "a", "new", "approach", "with", "biologics,", "in", "particular", "cytokines,", "which", "utilizes", "the", "polymer", "as", "a", "means", "to", "bias", "action", "to", "a", "certain", "receptor", "or", "receptor", "sub-type.", "<tag3>"], "wordsA": ["Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "enabled", "numerous", "successful", "PEGylated", "biologics", "on", "the", "market", "today."], "wordsB": ["Our", "customized", "approaches", "with", "large", "molecule", "polymer", "conjugates", "have", "expanded", "to", "include", "a", "new", "approach", "with", "biologics,", "in", "particular", "cytokines,", "which", "utilizes", "the", "polymer", "as", "a", "means", "to", "bias", "action", "to", "a", "certain", "receptor", "or", "receptor", "sub-type."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p21_s8", "idA": "906709_15_item1_p25_s6", "sentA": "Through rational drug design, a protein or peptide s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "sentB": "In addition, a cytokine s pharmacokinetics and pharmacodynamics can be substantially improved and its half-life can be significantly extended.", "type": 2, "words": ["<tag1>", "Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag2>", "In", "addition,", "a", "cytokine", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended.", "<tag3>"], "wordsA": ["Through", "rational", "drug", "design,", "a", "protein", "or", "peptide", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "wordsB": ["In", "addition,", "a", "cytokine", "s", "pharmacokinetics", "and", "pharmacodynamics", "can", "be", "substantially", "improved", "and", "its", "half-life", "can", "be", "significantly", "extended."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p21_s9", "idA": "906709_15_item1_p25_s7", "sentA": "An example of this is BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, for which Baxter filed a biologic license application with the United States Food and Drug Administration on December 1, 2014.", "sentB": "An example of this is NKTR-214, which is a CD122-biased immune-stimulatory cytokine with an every two or every three-week dosing schedule.", "type": 2, "words": ["<tag1>", "An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014.", "<tag2>", "An", "example", "of", "this", "is", "NKTR-214,", "which", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "with", "an", "every", "two", "or", "every", "three-week", "dosing", "schedule.", "<tag3>"], "wordsA": ["An", "example", "of", "this", "is", "BAX", "855,", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "for", "which", "Baxter", "filed", "a", "biologic", "license", "application", "with", "the", "United", "States", "Food", "and", "Drug", "Administration", "on", "December", "1,", "2014."], "wordsB": ["An", "example", "of", "this", "is", "NKTR-214,", "which", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "with", "an", "every", "two", "or", "every", "three-week", "dosing", "schedule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p23_s0", "idA": "906709_15_item1_p26_s0", "sentA": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease, psoriatic arthritis and ankylosing spondylitis in the U.S. and rheumatoid arthritis in the U.S. and E.U.", "sentB": "There is currently one approved product on the market that utilizes our technology with an antibody fragment, CIMZIA (certoluzimab pegol), which was developed by our partner UCB Pharma and is approved for the treatment of Crohn s Disease, psoriatic arthritis and ankylosing spondylitis in the U.S. and rheumatoid arthritis in the U.S. and EU.", "type": 2, "words": ["<tag1>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease,", "psoriatic", "arthritis", "and", "ankylosing", "spondylitis", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U.", "<tag2>", "There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease,", "psoriatic", "arthritis", "and", "ankylosing", "spondylitis", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "EU.", "<tag3>"], "wordsA": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease,", "psoriatic", "arthritis", "and", "ankylosing", "spondylitis", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "E.U."], "wordsB": ["There", "is", "currently", "one", "approved", "product", "on", "the", "market", "that", "utilizes", "our", "technology", "with", "an", "antibody", "fragment,", "CIMZIA", "(certoluzimab", "pegol),", "which", "was", "developed", "by", "our", "partner", "UCB", "Pharma", "and", "is", "approved", "for", "the", "treatment", "of", "Crohn", "s", "Disease,", "psoriatic", "arthritis", "and", "ankylosing", "spondylitis", "in", "the", "U.S.", "and", "rheumatoid", "arthritis", "in", "the", "U.S.", "and", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p172_s1", "idA": "906709_15_item1_p28_s0", "sentA": "Our objective is to create value by advancing our lead drug candidates through various stages of clinical development.", "sentB": "The facility is also used to produce APIs and finished drug products to support the early phases of clinical development of our proprietary drug candidates.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "create", "value", "by", "advancing", "our", "lead", "drug", "candidates", "through", "various", "stages", "of", "clinical", "development.", "<tag2>", "The", "facility", "is", "also", "used", "to", "produce", "APIs", "and", "finished", "drug", "products", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "create", "value", "by", "advancing", "our", "lead", "drug", "candidates", "through", "various", "stages", "of", "clinical", "development."], "wordsB": ["The", "facility", "is", "also", "used", "to", "produce", "APIs", "and", "finished", "drug", "products", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s5", "idA": "906709_15_item1_p28_s0", "sentA": "Our objective is to create value by advancing our lead drug candidates through various stages of clinical development.", "sentB": "To complement our own expert professional staff, we utilize specialists in regulatory affairs, pharmacovigilance, process engineering, manufacturing, quality assurance, clinical development and business development.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "create", "value", "by", "advancing", "our", "lead", "drug", "candidates", "through", "various", "stages", "of", "clinical", "development.", "<tag2>", "To", "complement", "our", "own", "expert", "professional", "staff,", "we", "utilize", "specialists", "in", "regulatory", "affairs,", "pharmacovigilance,", "process", "engineering,", "manufacturing,", "quality", "assurance,", "clinical", "development", "and", "business", "development.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "create", "value", "by", "advancing", "our", "lead", "drug", "candidates", "through", "various", "stages", "of", "clinical", "development."], "wordsB": ["To", "complement", "our", "own", "expert", "professional", "staff,", "we", "utilize", "specialists", "in", "regulatory", "affairs,", "pharmacovigilance,", "process", "engineering,", "manufacturing,", "quality", "assurance,", "clinical", "development", "and", "business", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p25_s2", "idA": "906709_15_item1_p28_s2", "sentA": "A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of approved drugs as well as established pharmacologic targets and drugs directed to those targets.", "sentB": "A key component of our development strategy is to potentially reduce the risks and time associated with drug development by capitalizing on the known safety and efficacy of existing drugs and drug candidates as well as established pharmacologic targets and drugs directed to those targets.", "type": 2, "words": ["<tag1>", "A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets.", "<tag2>", "A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "existing", "drugs", "and", "drug", "candidates", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets.", "<tag3>"], "wordsA": ["A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "approved", "drugs", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets."], "wordsB": ["A", "key", "component", "of", "our", "development", "strategy", "is", "to", "potentially", "reduce", "the", "risks", "and", "time", "associated", "with", "drug", "development", "by", "capitalizing", "on", "the", "known", "safety", "and", "efficacy", "of", "existing", "drugs", "and", "drug", "candidates", "as", "well", "as", "established", "pharmacologic", "targets", "and", "drugs", "directed", "to", "those", "targets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s4", "idA": "906709_15_item1_p29_s1", "sentA": "We believe that the improved characteristics of our drug candidates will provide meaningful benefit to patients compared to the existing therapies.", "sentB": "We believe that we maintain good relations with our employees.", "type": 2, "words": ["<tag1>", "We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies.", "<tag2>", "We", "believe", "that", "we", "maintain", "good", "relations", "with", "our", "employees.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "improved", "characteristics", "of", "our", "drug", "candidates", "will", "provide", "meaningful", "benefit", "to", "patients", "compared", "to", "the", "existing", "therapies."], "wordsB": ["We", "believe", "that", "we", "maintain", "good", "relations", "with", "our", "employees."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p2_s0", "idA": "906709_15_item1_p2_s2", "sentA": "Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life, bioavailability and mechanism of action.", "sentB": "Our drug candidates are designed to improve the overall benefits and use of a drug for patients by improving the metabolism, distribution, pharmacokinetics, pharmacodynamics, half-life and/or bioavailability of drugs.", "type": 2, "words": ["<tag1>", "Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life,", "bioavailability", "and", "mechanism", "of", "action.", "<tag2>", "Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life", "and/or", "bioavailability", "of", "drugs.", "<tag3>"], "wordsA": ["Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life,", "bioavailability", "and", "mechanism", "of", "action."], "wordsB": ["Our", "drug", "candidates", "are", "designed", "to", "improve", "the", "overall", "benefits", "and", "use", "of", "a", "drug", "for", "patients", "by", "improving", "the", "metabolism,", "distribution,", "pharmacokinetics,", "pharmacodynamics,", "half-life", "and/or", "bioavailability", "of", "drugs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p2_s1", "idA": "906709_15_item1_p2_s3", "sentA": "Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas.", "sentB": "Our objective is to apply our advanced polymer conjugate technology platform to create new drug candidates in multiple therapeutic areas that address large potential markets.", "type": 2, "words": ["<tag1>", "Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas.", "<tag2>", "Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas", "that", "address", "large", "potential", "markets.", "<tag3>"], "wordsA": ["Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas."], "wordsB": ["Our", "objective", "is", "to", "apply", "our", "advanced", "polymer", "conjugate", "technology", "platform", "to", "create", "new", "drug", "candidates", "in", "multiple", "therapeutic", "areas", "that", "address", "large", "potential", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p2_s2", "idA": "906709_15_item1_p2_s4", "sentA": "In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK (previously referred to as naloxegol and NKTR-118), under a global license agreement with AstraZeneca AB (AstraZeneca).", "sentB": "In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK TM (previously referred to as naloxegol and NKTR-118), under a global license agreement with AstraZeneca AB (AstraZeneca).", "type": 2, "words": ["<tag1>", "In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca).", "<tag2>", "In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "TM", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca).", "<tag3>"], "wordsA": ["In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)."], "wordsB": ["In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "TM", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p2_s3", "idA": "906709_15_item1_p2_s5", "sentA": "MOVANTIK is an oral peripherally-acting mu-opioid antagonist (PAMORA), approved in both the U.S. and Europe for the treatment of opioid-induced constipation, or OIC, a common side effect caused by chronic administration of prescription opioid pain medicines.", "sentB": "MOVANTIK TM is an oral peripherally-acting mu-opioid antagonist (PAMORA), approved in both the U.S. and Europe for the treatment of opioid-induced constipation, or OIC, a common side effect caused by chronic administration of prescription opioid pain medicines.", "type": 2, "words": ["<tag1>", "MOVANTIK", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag2>", "MOVANTIK", "TM", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag3>"], "wordsA": ["MOVANTIK", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "wordsB": ["MOVANTIK", "TM", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p45_s0", "idA": "906709_15_item1_p2_s5", "sentA": "MOVANTIK is an oral peripherally-acting mu-opioid antagonist (PAMORA), approved in both the U.S. and Europe for the treatment of opioid-induced constipation, or OIC, a common side effect caused by chronic administration of prescription opioid pain medicines.", "sentB": "MOVANTIK TM is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications.", "type": 2, "words": ["<tag1>", "MOVANTIK", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag2>", "MOVANTIK", "TM", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag3>"], "wordsA": ["MOVANTIK", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "wordsB": ["MOVANTIK", "TM", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p48_s2", "idA": "906709_15_item1_p2_s9", "sentA": "The EC s approval applies to all 28 European Union member countries plus Iceland and Norway.", "sentB": "The EC s approval applies to all 28 EU member countries plus Iceland and Norway.", "type": 2, "words": ["<tag1>", "The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway.", "<tag2>", "The", "EC", "s", "approval", "applies", "to", "all", "28", "EU", "member", "countries", "plus", "Iceland", "and", "Norway.", "<tag3>"], "wordsA": ["The", "EC", "s", "approval", "applies", "to", "all", "28", "European", "Union", "member", "countries", "plus", "Iceland", "and", "Norway."], "wordsB": ["The", "EC", "s", "approval", "applies", "to", "all", "28", "EU", "member", "countries", "plus", "Iceland", "and", "Norway."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p26_s3", "idA": "906709_15_item1_p30_s0", "sentA": "Ensure Future Growth of our Proprietary Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "sentB": "We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "type": 2, "words": ["<tag1>", "Ensure", "Future", "Growth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag2>", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag3>"], "wordsA": ["Ensure", "Future", "Growth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "wordsB": ["We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p160_s3", "idA": "906709_15_item1_p31_s3", "sentA": "The table includes the type of molecule or drug, the target indications for the drug candidate, and the status of the clinical development program.", "sentB": "In our partnered programs where we provide contract research services, those services are typically provided under a work plan that is subject to frequent revisions that change based on the development needs and status of the program.", "type": 2, "words": ["<tag1>", "The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program.", "<tag2>", "In", "our", "partnered", "programs", "where", "we", "provide", "contract", "research", "services,", "those", "services", "are", "typically", "provided", "under", "a", "work", "plan", "that", "is", "subject", "to", "frequent", "revisions", "that", "change", "based", "on", "the", "development", "needs", "and", "status", "of", "the", "program.", "<tag3>"], "wordsA": ["The", "table", "includes", "the", "type", "of", "molecule", "or", "drug,", "the", "target", "indications", "for", "the", "drug", "candidate,", "and", "the", "status", "of", "the", "clinical", "development", "program."], "wordsB": ["In", "our", "partnered", "programs", "where", "we", "provide", "contract", "research", "services,", "those", "services", "are", "typically", "provided", "under", "a", "work", "plan", "that", "is", "subject", "to", "frequent", "revisions", "that", "change", "based", "on", "the", "development", "needs", "and", "status", "of", "the", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p12_s0", "idA": "906709_15_item1_p37_s0", "sentA": "A total of nine products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "A total of ten products using our PEGylation technology have received regulatory approval in the U.S. or EU.", "type": 2, "words": ["<tag1>", "A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU.", "<tag3>"], "wordsA": ["A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p34_s0", "idA": "906709_15_item1_p37_s0", "sentA": "A total of nine products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "A total of ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "type": 2, "words": ["<tag1>", "A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag3>"], "wordsA": ["A", "total", "of", "nine", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p164_s2", "idA": "906709_15_item1_p37_s1", "sentA": "There are also a number of other candidates that have been filed for approval or are in various stages of clinical development.", "sentB": "There are a number of companies developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "candidates", "that", "have", "been", "filed", "for", "approval", "or", "are", "in", "various", "stages", "of", "clinical", "development.", "<tag2>", "There", "are", "a", "number", "of", "companies", "developing", "potential", "products", "which", "are", "in", "various", "stages", "of", "clinical", "development", "and", "are", "being", "evaluated", "for", "the", "treatment", "of", "OIC", "and", "OBD", "in", "different", "patient", "populations.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "candidates", "that", "have", "been", "filed", "for", "approval", "or", "are", "in", "various", "stages", "of", "clinical", "development."], "wordsB": ["There", "are", "a", "number", "of", "companies", "developing", "potential", "products", "which", "are", "in", "various", "stages", "of", "clinical", "development", "and", "are", "being", "evaluated", "for", "the", "treatment", "of", "OIC", "and", "OBD", "in", "different", "patient", "populations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p168_s0", "idA": "906709_15_item1_p37_s1", "sentA": "There are also a number of other candidates that have been filed for approval or are in various stages of clinical development.", "sentB": "There are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for breast and ovarian cancers including but not limited to: Abraxane (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Afinitor (everolimus), Doxil (doxorubicin HCl), Ellence (epirubicin), Gemzar (gemcitabine), Halaven (eribulin), Herceptin (trastuzumab), Hycamtin (topotecan), Ibrance (palbociclib), Ixempra (ixabepilone), Navelbine (vinolrebine), Paraplatin (carboplatin), Taxol (paclitaxel), Xeloda (capecitabine) and Taxotere (docetaxel).", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "candidates", "that", "have", "been", "filed", "for", "approval", "or", "are", "in", "various", "stages", "of", "clinical", "development.", "<tag2>", "There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "breast", "and", "ovarian", "cancers", "including", "but", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Doxil", "(doxorubicin", "HCl),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Hycamtin", "(topotecan),", "Ibrance", "(palbociclib),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Paraplatin", "(carboplatin),", "Taxol", "(paclitaxel),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel).", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "candidates", "that", "have", "been", "filed", "for", "approval", "or", "are", "in", "various", "stages", "of", "clinical", "development."], "wordsB": ["There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "breast", "and", "ovarian", "cancers", "including", "but", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Doxil", "(doxorubicin", "HCl),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Hycamtin", "(topotecan),", "Ibrance", "(palbociclib),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Paraplatin", "(carboplatin),", "Taxol", "(paclitaxel),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p55_s0", "idA": "906709_15_item1_p38_s0", "sentA": "Phase 3 ongoing and filed for approval in U.S.", "sentB": "Among other patents, U.S. Patent Nos.", "type": 2, "words": ["<tag1>", "Phase", "3", "ongoing", "and", "filed", "for", "approval", "in", "U.S.", "<tag2>", "Among", "other", "patents,", "U.S.", "Patent", "Nos.", "<tag3>"], "wordsA": ["Phase", "3", "ongoing", "and", "filed", "for", "approval", "in", "U.S."], "wordsB": ["Among", "other", "patents,", "U.S.", "Patent", "Nos."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p35_s0", "idA": "906709_15_item1_p39_s0", "sentA": "(1) Status definitions are: Approved regulatory approval to market and sell product obtained in one or more of the U.S., E.U. or other countries.", "sentB": "Approved regulatory approval to market and sell product obtained in one or more of the U.S., EU or other countries.", "type": 2, "words": ["<tag1>", "(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries.", "<tag2>", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "EU", "or", "other", "countries.", "<tag3>"], "wordsA": ["(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries."], "wordsB": ["Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "EU", "or", "other", "countries."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p75_s6", "idA": "906709_15_item1_p39_s0", "sentA": "(1) Status definitions are: Approved regulatory approval to market and sell product obtained in one or more of the U.S., E.U. or other countries.", "sentB": "In the U.S., our royalty on annual net sales is a flat 30% and outside of the U.S. our royalty on annual net sales is an escalating royalty equal to an approximate average of 22%.", "type": 2, "words": ["<tag1>", "(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries.", "<tag2>", "In", "the", "U.S.,", "our", "royalty", "on", "annual", "net", "sales", "is", "a", "flat", "30%", "and", "outside", "of", "the", "U.S.", "our", "royalty", "on", "annual", "net", "sales", "is", "an", "escalating", "royalty", "equal", "to", "an", "approximate", "average", "of", "22%.", "<tag3>"], "wordsA": ["(1)", "Status", "definitions", "are:", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "E.U.", "or", "other", "countries."], "wordsB": ["In", "the", "U.S.,", "our", "royalty", "on", "annual", "net", "sales", "is", "a", "flat", "30%", "and", "outside", "of", "the", "U.S.", "our", "royalty", "on", "annual", "net", "sales", "is", "an", "escalating", "royalty", "equal", "to", "an", "approximate", "average", "of", "22%."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p39_s0", "idA": "906709_15_item1_p42_s0", "sentA": "* In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012.", "sentB": "In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012.", "type": 2, "words": ["<tag1>", "*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012.", "<tag2>", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012.", "<tag3>"], "wordsA": ["*", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012."], "wordsB": ["In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p40_s0", "idA": "906709_15_item1_p43_s0", "sentA": "** Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche was prevented from marketing MIRCERA in the U.S. until July 2014.", "sentB": "Amgen Inc. prevailed in a patent lawsuit against F. Hoffmann-La Roche Ltd (Roche) and as a result of this legal ruling Roche was prevented from marketing MIRCERA in the U.S. until July 2014.", "type": 2, "words": ["<tag1>", "**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag2>", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014.", "<tag3>"], "wordsA": ["**", "Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "wordsB": ["Amgen", "Inc.", "prevailed", "in", "a", "patent", "lawsuit", "against", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)", "and", "as", "a", "result", "of", "this", "legal", "ruling", "Roche", "was", "prevented", "from", "marketing", "MIRCERA", "in", "the", "U.S.", "until", "July", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p163_s1", "idA": "906709_15_item1_p49_s0", "sentA": "OIC is a result of decreased fluid absorption and lower gastrointestinal motility due to opioid receptor binding in the gastrointestinal tract.", "sentB": "The only approved oral treatment for opioid-induced constipation in adults with chronic, non-cancer pain is a twice daily oral therapy called AMITIZA (lubiprostone), which acts by specifically activating CIC-2 chloride channels in the gastrointestinal tract to increase secretions.", "type": 2, "words": ["<tag1>", "OIC", "is", "a", "result", "of", "decreased", "fluid", "absorption", "and", "lower", "gastrointestinal", "motility", "due", "to", "opioid", "receptor", "binding", "in", "the", "gastrointestinal", "tract.", "<tag2>", "The", "only", "approved", "oral", "treatment", "for", "opioid-induced", "constipation", "in", "adults", "with", "chronic,", "non-cancer", "pain", "is", "a", "twice", "daily", "oral", "therapy", "called", "AMITIZA", "(lubiprostone),", "which", "acts", "by", "specifically", "activating", "CIC-2", "chloride", "channels", "in", "the", "gastrointestinal", "tract", "to", "increase", "secretions.", "<tag3>"], "wordsA": ["OIC", "is", "a", "result", "of", "decreased", "fluid", "absorption", "and", "lower", "gastrointestinal", "motility", "due", "to", "opioid", "receptor", "binding", "in", "the", "gastrointestinal", "tract."], "wordsB": ["The", "only", "approved", "oral", "treatment", "for", "opioid-induced", "constipation", "in", "adults", "with", "chronic,", "non-cancer", "pain", "is", "a", "twice", "daily", "oral", "therapy", "called", "AMITIZA", "(lubiprostone),", "which", "acts", "by", "specifically", "activating", "CIC-2", "chloride", "channels", "in", "the", "gastrointestinal", "tract", "to", "increase", "secretions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p163_s0", "idA": "906709_15_item1_p50_s0", "sentA": "On September 16, 2014, the FDA approved MOVANTIK TM as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "sentB": "There are no other once-daily oral drugs that act specifically to block or reverse the action of opioids on receptors in the gastrointestinal tract which are approved specifically for the treatment of opioid-induced constipation (OIC) or opioid bowel dysfunction (OBD) in patients with chronic, non-cancer pain.", "type": 2, "words": ["<tag1>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag2>", "There", "are", "no", "other", "once-daily", "oral", "drugs", "that", "act", "specifically", "to", "block", "or", "reverse", "the", "action", "of", "opioids", "on", "receptors", "in", "the", "gastrointestinal", "tract", "which", "are", "approved", "specifically", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "or", "opioid", "bowel", "dysfunction", "(OBD)", "in", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag3>"], "wordsA": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "wordsB": ["There", "are", "no", "other", "once-daily", "oral", "drugs", "that", "act", "specifically", "to", "block", "or", "reverse", "the", "action", "of", "opioids", "on", "receptors", "in", "the", "gastrointestinal", "tract", "which", "are", "approved", "specifically", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC)", "or", "opioid", "bowel", "dysfunction", "(OBD)", "in", "patients", "with", "chronic,", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p163_s4", "idA": "906709_15_item1_p50_s0", "sentA": "On September 16, 2014, the FDA approved MOVANTIK TM as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "sentB": "In 2014, RELISTOR Subjectaneous Injection was approved by the FDA for adult patients with chronic non-cancer pain.", "type": 2, "words": ["<tag1>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag2>", "In", "2014,", "RELISTOR", "Subjectaneous", "Injection", "was", "approved", "by", "the", "FDA", "for", "adult", "patients", "with", "chronic", "non-cancer", "pain.", "<tag3>"], "wordsA": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "wordsB": ["In", "2014,", "RELISTOR", "Subjectaneous", "Injection", "was", "approved", "by", "the", "FDA", "for", "adult", "patients", "with", "chronic", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p163_s5", "idA": "906709_15_item1_p50_s0", "sentA": "On September 16, 2014, the FDA approved MOVANTIK TM as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "sentB": "On June 23, 2015, Valeant submitted an NDA to the FDA for Relistor (methylnaltrexone bromide) oral tablets for the treatment of OCI in adult patients with chronic non-cancer pain.", "type": 2, "words": ["<tag1>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag2>", "On", "June", "23,", "2015,", "Valeant", "submitted", "an", "NDA", "to", "the", "FDA", "for", "Relistor", "(methylnaltrexone", "bromide)", "oral", "tablets", "for", "the", "treatment", "of", "OCI", "in", "adult", "patients", "with", "chronic", "non-cancer", "pain.", "<tag3>"], "wordsA": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "wordsB": ["On", "June", "23,", "2015,", "Valeant", "submitted", "an", "NDA", "to", "the", "FDA", "for", "Relistor", "(methylnaltrexone", "bromide)", "oral", "tablets", "for", "the", "treatment", "of", "OCI", "in", "adult", "patients", "with", "chronic", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p49_s0", "idA": "906709_15_item1_p51_s0", "sentA": "On January 23, 2015, the DEA published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled Substances Act.", "sentB": "On January 23, 2015, the Drug Enforcement Administration published the final rule in the Federal Register, effective immediately on the date it was published, removing naloxegol and its salts from the schedules of the Controlled Substances Act.", "type": 2, "words": ["<tag1>", "On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act.", "<tag2>", "On", "January", "23,", "2015,", "the", "Drug", "Enforcement", "Administration", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act.", "<tag3>"], "wordsA": ["On", "January", "23,", "2015,", "the", "DEA", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act."], "wordsB": ["On", "January", "23,", "2015,", "the", "Drug", "Enforcement", "Administration", "published", "the", "final", "rule", "in", "the", "Federal", "Register,", "effective", "immediately", "on", "the", "date", "it", "was", "published,", "removing", "naloxegol", "and", "its", "salts", "from", "the", "schedules", "of", "the", "Controlled", "Substances", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p2_s5", "idA": "906709_15_item1_p52_s0", "sentA": "AstraZeneca is planning the commercial launch of MOVANTIK in the United States late in the first quarter of 2015 and MOVENTIG in the second half of 2015.", "sentB": "On March 31, 2015, AstraZeneca announced that it launched MOVANTIK TM in the United States, as a result of which we received a $100 million commercial launch milestone on March 31, 2015.", "type": 2, "words": ["<tag1>", "AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "second", "half", "of", "2015.", "<tag2>", "On", "March", "31,", "2015,", "AstraZeneca", "announced", "that", "it", "launched", "MOVANTIK", "TM", "in", "the", "United", "States,", "as", "a", "result", "of", "which", "we", "received", "a", "$100", "million", "commercial", "launch", "milestone", "on", "March", "31,", "2015.", "<tag3>"], "wordsA": ["AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "second", "half", "of", "2015."], "wordsB": ["On", "March", "31,", "2015,", "AstraZeneca", "announced", "that", "it", "launched", "MOVANTIK", "TM", "in", "the", "United", "States,", "as", "a", "result", "of", "which", "we", "received", "a", "$100", "million", "commercial", "launch", "milestone", "on", "March", "31,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p49_s1", "idA": "906709_15_item1_p52_s0", "sentA": "AstraZeneca is planning the commercial launch of MOVANTIK in the United States late in the first quarter of 2015 and MOVENTIG in the second half of 2015.", "sentB": "AstraZeneca launched the commercial sales of MOVANTIK TM in the United States in March 2015 and MOVENTIG in Germany, the first EU member country, in August 2015.", "type": 2, "words": ["<tag1>", "AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "second", "half", "of", "2015.", "<tag2>", "AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "TM", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015.", "<tag3>"], "wordsA": ["AstraZeneca", "is", "planning", "the", "commercial", "launch", "of", "MOVANTIK", "in", "the", "United", "States", "late", "in", "the", "first", "quarter", "of", "2015", "and", "MOVENTIG", "in", "the", "second", "half", "of", "2015."], "wordsB": ["AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "TM", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p49_s2", "idA": "906709_15_item1_p52_s1", "sentA": "Under the terms of our license agreement, AstraZeneca made an initial license payment to us of $125.0 million and AstraZeneca has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK TM and MOVANTIK TM fixed-dose combination products.", "sentB": "Under the terms of our license agreement, AstraZeneca made an initial license payment of $125.0 million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK TM and MOVANTIK TM fixed-dose combination products.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products.", "<tag2>", "Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "to", "us", "of", "$125.0", "million", "and", "AstraZeneca", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products."], "wordsB": ["Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p49_s3", "idA": "906709_15_item1_p52_s2", "sentA": "We received $70.0 million and $25.0 million upon the acceptance for review of MOVANTIK TM regulatory approval applications filed with the FDA and European Medicines Agency (EMA), respectively, in 2013.", "sentB": "We received milestone payments of $70.0 million and $25.0 million upon the acceptance of regulatory approval applications of MOVANTIK TM by the FDA and European Medicines Agency (EMA), respectively, in 2013.", "type": 2, "words": ["<tag1>", "We", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "MOVANTIK", "TM", "regulatory", "approval", "applications", "filed", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag2>", "We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "TM", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag3>"], "wordsA": ["We", "received", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "for", "review", "of", "MOVANTIK", "TM", "regulatory", "approval", "applications", "filed", "with", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "wordsB": ["We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "TM", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p2_s6", "idA": "906709_15_item1_p52_s3", "sentA": "In 2014, we received an additional $35.0 million payment upon the FDA s approval of MOVANTIK TM .", "sentB": "In August 2015, we received an additional $40.0 million payment triggered by the first commercial sale of MOVENTIG by AstraZeneca in Germany.", "type": 2, "words": ["<tag1>", "In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", ".", "<tag2>", "In", "August", "2015,", "we", "received", "an", "additional", "$40.0", "million", "payment", "triggered", "by", "the", "first", "commercial", "sale", "of", "MOVENTIG", "by", "AstraZeneca", "in", "Germany.", "<tag3>"], "wordsA": ["In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "."], "wordsB": ["In", "August", "2015,", "we", "received", "an", "additional", "$40.0", "million", "payment", "triggered", "by", "the", "first", "commercial", "sale", "of", "MOVENTIG", "by", "AstraZeneca", "in", "Germany."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p49_s4", "idA": "906709_15_item1_p52_s3", "sentA": "In 2014, we received an additional $35.0 million payment upon the FDA s approval of MOVANTIK TM .", "sentB": "We received an additional milestone payment of $35.0 million upon the FDA s approval of MOVANTIK TM in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK TM in the U.S. and $40.0 million for MOVENTIG in Germany.", "type": 2, "words": ["<tag1>", "In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", ".", "<tag2>", "We", "received", "an", "additional", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "TM", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany.", "<tag3>"], "wordsA": ["In", "2014,", "we", "received", "an", "additional", "$35.0", "million", "payment", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "."], "wordsB": ["We", "received", "an", "additional", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "TM", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p49_s7", "idA": "906709_15_item1_p52_s7", "sentA": "For both MOVANTIK TM and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sales in the U.S. and 18% of net sales in the E.U. and rest of world, varying by country of sale and level of annual net sales.", "sentB": "For both MOVANTIK TM and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sales in the U.S. and 18% of net sales in the EU and rest of world, varying by country of sale and level of annual net sales.", "type": 2, "words": ["<tag1>", "For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "E.U.", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag3>"], "wordsA": ["For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "E.U.", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p64_s0", "idA": "906709_15_item1_p54_s0", "sentA": "We are developing etirinotecan pegol (also known as NKTR-102), a next generation topoisomerase I (topo I) inhibitor which was designed using our PEGylation technology.", "sentB": "We are developing NKTR-102, a next generation topoisomerase I (topo I) inhibitor which was designed using our PEGylation technology.", "type": 2, "words": ["<tag1>", "We", "are", "developing", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology.", "<tag2>", "We", "are", "developing", "NKTR-102,", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology.", "<tag3>"], "wordsA": ["We", "are", "developing", "etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology."], "wordsB": ["We", "are", "developing", "NKTR-102,", "a", "next", "generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "which", "was", "designed", "using", "our", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p64_s1", "idA": "906709_15_item1_p54_s1", "sentA": "Etirinotecan pegol is a novel macromolecular chemotherapeutic designed to enhance the anti-cancer effects of topo I inhibition while minimizing its toxicities.", "sentB": "NKTR-102 is a novel macromolecular chemotherapeutic designed to enhance the anti-cancer effects of topo I inhibition while minimizing its toxicities.", "type": 2, "words": ["<tag1>", "Etirinotecan", "pegol", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities.", "<tag2>", "NKTR-102", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities.", "<tag3>"], "wordsA": ["Etirinotecan", "pegol", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities."], "wordsB": ["NKTR-102", "is", "a", "novel", "macromolecular", "chemotherapeutic", "designed", "to", "enhance", "the", "anti-cancer", "effects", "of", "topo", "I", "inhibition", "while", "minimizing", "its", "toxicities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p64_s2", "idA": "906709_15_item1_p54_s2", "sentA": "Unlike irinotecan, which is a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, etirinotecan pegol s pro-drug design results in a lower initial peak concentration of active topo I inhibitor in the blood.", "sentB": "Unlike irinotecan, which is a first generation topo I inhibitor that exhibits a high initial peak concentration and short half-life, NKTR-102 s pro-drug design results in a lower initial peak concentration of active topo I inhibitor in the blood.", "type": 2, "words": ["<tag1>", "Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "etirinotecan", "pegol", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood.", "<tag2>", "Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "NKTR-102", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood.", "<tag3>"], "wordsA": ["Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "etirinotecan", "pegol", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood."], "wordsB": ["Unlike", "irinotecan,", "which", "is", "a", "first", "generation", "topo", "I", "inhibitor", "that", "exhibits", "a", "high", "initial", "peak", "concentration", "and", "short", "half-life,", "NKTR-102", "s", "pro-drug", "design", "results", "in", "a", "lower", "initial", "peak", "concentration", "of", "active", "topo", "I", "inhibitor", "in", "the", "blood."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p65_s0", "idA": "906709_15_item1_p55_s0", "sentA": "The large etirinotecan pegol molecule is inactive when administered.", "sentB": "The large NKTR-102 molecule is inactive when administered.", "type": 2, "words": ["<tag1>", "The", "large", "etirinotecan", "pegol", "molecule", "is", "inactive", "when", "administered.", "<tag2>", "The", "large", "NKTR-102", "molecule", "is", "inactive", "when", "administered.", "<tag3>"], "wordsA": ["The", "large", "etirinotecan", "pegol", "molecule", "is", "inactive", "when", "administered."], "wordsB": ["The", "large", "NKTR-102", "molecule", "is", "inactive", "when", "administered."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p66_s0", "idA": "906709_15_item1_p56_s0", "sentA": "In preclinical models, etirinotecan pegol achieved a 300-fold increase in tumor concentration as compared to irinotecan.", "sentB": "In preclinical models, NKTR-102 achieved a 300-fold increase in tumor concentration as compared to irinotecan.", "type": 2, "words": ["<tag1>", "In", "preclinical", "models,", "etirinotecan", "pegol", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan.", "<tag2>", "In", "preclinical", "models,", "NKTR-102", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan.", "<tag3>"], "wordsA": ["In", "preclinical", "models,", "etirinotecan", "pegol", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan."], "wordsB": ["In", "preclinical", "models,", "NKTR-102", "achieved", "a", "300-fold", "increase", "in", "tumor", "concentration", "as", "compared", "to", "irinotecan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p66_s1", "idA": "906709_15_item1_p56_s1", "sentA": "Because etirinotecan pegol is a large molecule, based on preclinical studies we believe that it may penetrate the leaky vasculature within the tumor environment more readily than normal vasculature, concentrating and trapping etirinotecan pegol in tumor tissue.", "sentB": "Because NKTR-102 is a large molecule, based on preclinical studies we believe that it may penetrate the leaky vasculature within the tumor environment more readily than normal vasculature, concentrating and trapping NKTR-102 in tumor tissue.", "type": 2, "words": ["<tag1>", "Because", "etirinotecan", "pegol", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "etirinotecan", "pegol", "in", "tumor", "tissue.", "<tag2>", "Because", "NKTR-102", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "NKTR-102", "in", "tumor", "tissue.", "<tag3>"], "wordsA": ["Because", "etirinotecan", "pegol", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "etirinotecan", "pegol", "in", "tumor", "tissue."], "wordsB": ["Because", "NKTR-102", "is", "a", "large", "molecule,", "based", "on", "preclinical", "studies", "we", "believe", "that", "it", "may", "penetrate", "the", "leaky", "vasculature", "within", "the", "tumor", "environment", "more", "readily", "than", "normal", "vasculature,", "concentrating", "and", "trapping", "NKTR-102", "in", "tumor", "tissue."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p67_s0", "idA": "906709_15_item1_p57_s0", "sentA": "Clinical studies have shown that etirinotecan pegol has an extended pharmacokinetic profile and remains in circulation throughout the entire chemotherapy cycle, providing sustained exposure to topo I inhibition.", "sentB": "Clinical studies have shown that NKTR-102 has an extended pharmacokinetic profile and remains in circulation throughout the entire chemotherapy cycle, providing sustained exposure to topo I inhibition.", "type": 2, "words": ["<tag1>", "Clinical", "studies", "have", "shown", "that", "etirinotecan", "pegol", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition.", "<tag2>", "Clinical", "studies", "have", "shown", "that", "NKTR-102", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition.", "<tag3>"], "wordsA": ["Clinical", "studies", "have", "shown", "that", "etirinotecan", "pegol", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition."], "wordsB": ["Clinical", "studies", "have", "shown", "that", "NKTR-102", "has", "an", "extended", "pharmacokinetic", "profile", "and", "remains", "in", "circulation", "throughout", "the", "entire", "chemotherapy", "cycle,", "providing", "sustained", "exposure", "to", "topo", "I", "inhibition."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p68_s0", "idA": "906709_15_item1_p58_s0", "sentA": "Etirinotecan pegol is currently being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "sentB": "NKTR-102 is currently being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "type": 2, "words": ["<tag1>", "Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "NKTR-102", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["Etirinotecan", "pegol", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["NKTR-102", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p68_s1", "idA": "906709_15_item1_p59_s0", "sentA": "clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "type": 2, "words": ["<tag1>", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag3>"], "wordsA": ["clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s3", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Secondary endpoints in the BEACON study included objective response rate and progression-free survival, which did not achieve statistical significance in the study.", "type": 2, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Secondary", "endpoints", "in", "the", "BEACON", "study", "included", "objective", "response", "rate", "and", "progression-free", "survival,", "which", "did", "not", "achieve", "statistical", "significance", "in", "the", "study.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Secondary", "endpoints", "in", "the", "BEACON", "study", "included", "objective", "response", "rate", "and", "progression-free", "survival,", "which", "did", "not", "achieve", "statistical", "significance", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s5", "idA": "906709_15_item1_p59_s1", "sentA": "We completed enrollment in the BEACON study in late July 2013.", "sentB": "Secondary endpoints in the BEACON study included objective response rate and progression-free survival, which did not achieve statistical significance in the study.", "type": 2, "words": ["<tag1>", "We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013.", "<tag2>", "Secondary", "endpoints", "in", "the", "BEACON", "study", "included", "objective", "response", "rate", "and", "progression-free", "survival,", "which", "did", "not", "achieve", "statistical", "significance", "in", "the", "study.", "<tag3>"], "wordsA": ["We", "completed", "enrollment", "in", "the", "BEACON", "study", "in", "late", "July", "2013."], "wordsB": ["Secondary", "endpoints", "in", "the", "BEACON", "study", "included", "objective", "response", "rate", "and", "progression-free", "survival,", "which", "did", "not", "achieve", "statistical", "significance", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p68_s3", "idA": "906709_15_item1_p59_s2", "sentA": "This study randomized patients on a 1:1 basis to receive single-agent etirinotecan pegol or a single agent chosen from a defined set of physician s choice alternatives.", "sentB": "This study randomized patients on a 1:1 basis to receive single-agent NKTR-102 or a single agent chosen from a defined set of physician s choice alternatives.", "type": 2, "words": ["<tag1>", "This", "study", "randomized", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives.", "<tag2>", "This", "study", "randomized", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "NKTR-102", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives.", "<tag3>"], "wordsA": ["This", "study", "randomized", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives."], "wordsB": ["This", "study", "randomized", "patients", "on", "a", "1:1", "basis", "to", "receive", "single-agent", "NKTR-102", "or", "a", "single", "agent", "chosen", "from", "a", "defined", "set", "of", "physician", "s", "choice", "alternatives."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s0", "idA": "906709_15_item1_p5_s0", "sentA": "Etirinotecan pegol (also known as NKTR-102), is a next-generation topoisomerase I (topo I) inhibitor currently being evaluated in a Phase 3 open-label, randomized, multicenter clinical study as a single-agent therapy for women with metastatic breast cancer.", "sentB": "NKTR-102 (also known as etirinotecan pegol) is our next-generation topoisomerase I inhibitor proprietary drug candidate.", "type": 2, "words": ["<tag1>", "Etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "currently", "being", "evaluated", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "women", "with", "metastatic", "breast", "cancer.", "<tag2>", "NKTR-102", "(also", "known", "as", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate.", "<tag3>"], "wordsA": ["Etirinotecan", "pegol", "(also", "known", "as", "NKTR-102),", "is", "a", "next-generation", "topoisomerase", "I", "(topo", "I)", "inhibitor", "currently", "being", "evaluated", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "as", "a", "single-agent", "therapy", "for", "women", "with", "metastatic", "breast", "cancer."], "wordsB": ["NKTR-102", "(also", "known", "as", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s1", "idA": "906709_15_item1_p5_s1", "sentA": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), has completed enrollment of approximately 850 women with locally recurrent or metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "On March 17, 2015, we announced topline data from a Phase 3 clinical study for NKTR-102, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), as a single-agent therapy for women with advanced metastatic breast cancer.", "type": 2, "words": ["<tag1>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "has", "completed", "enrollment", "of", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "NKTR-102,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "has", "completed", "enrollment", "of", "approximately", "850", "women", "with", "locally", "recurrent", "or", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "NKTR-102,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s2", "idA": "906709_15_item1_p5_s2", "sentA": "Patients in the BEACON study were randomized on a 1:1 basis to receive either single-agent etirinotecan pegol or a single agent of physician s choice.", "sentB": "The BEACON study compared NKTR-102 to an active control arm comprised of a single chemotherapy agent of physician s choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease.", "type": 2, "words": ["<tag1>", "Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice.", "<tag2>", "The", "BEACON", "study", "compared", "NKTR-102", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease.", "<tag3>"], "wordsA": ["Patients", "in", "the", "BEACON", "study", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "single-agent", "etirinotecan", "pegol", "or", "a", "single", "agent", "of", "physician", "s", "choice."], "wordsB": ["The", "BEACON", "study", "compared", "NKTR-102", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p8_s1", "idA": "906709_15_item1_p5_s3", "sentA": "The primary endpoint of the BEACON study is overall survival, and secondary endpoints include progression-free survival and objective tumor response rate.", "sentB": "In addition to a determination of the recommended Phase 2 dose, the study will assess preliminary anti-tumor activity, includi ng objective response rate .", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate.", "<tag2>", "In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "preliminary", "anti-tumor", "activity,", "includi", "ng", "objective", "response", "rate", ".", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "BEACON", "study", "is", "overall", "survival,", "and", "secondary", "endpoints", "include", "progression-free", "survival", "and", "objective", "tumor", "response", "rate."], "wordsB": ["In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "preliminary", "anti-tumor", "activity,", "includi", "ng", "objective", "response", "rate", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p63_s3", "idA": "906709_15_item1_p62_s0", "sentA": "According to the American Cancer Society and World Health Organization, more than 1.4 million women worldwide are diagnosed with breast cancer globally every year.", "sentB": "According to the American Society of Addiction Medicine 2016 report, there are 1.9 million Americans which have a substance use disorder involving prescription pain relievers.", "type": 2, "words": ["<tag1>", "According", "to", "the", "American", "Cancer", "Society", "and", "World", "Health", "Organization,", "more", "than", "1.4", "million", "women", "worldwide", "are", "diagnosed", "with", "breast", "cancer", "globally", "every", "year.", "<tag2>", "According", "to", "the", "American", "Society", "of", "Addiction", "Medicine", "2016", "report,", "there", "are", "1.9", "million", "Americans", "which", "have", "a", "substance", "use", "disorder", "involving", "prescription", "pain", "relievers.", "<tag3>"], "wordsA": ["According", "to", "the", "American", "Cancer", "Society", "and", "World", "Health", "Organization,", "more", "than", "1.4", "million", "women", "worldwide", "are", "diagnosed", "with", "breast", "cancer", "globally", "every", "year."], "wordsB": ["According", "to", "the", "American", "Society", "of", "Addiction", "Medicine", "2016", "report,", "there", "are", "1.9", "million", "Americans", "which", "have", "a", "substance", "use", "disorder", "involving", "prescription", "pain", "relievers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p70_s2", "idA": "906709_15_item1_p63_s0", "sentA": "In 2015, the American Cancer Society estimates there will be 231,840 new cases of breast cancer in the U.S. Metastatic breast cancer refers to cancer that has spread from the breast to distant sites in the body.", "sentB": "In 2016, the American Cancer Society estima tes there will be 246,660 new cases of invasive breast cancer diagnosed in the U.S. and about 40,450 women will die from breast cancer.", "type": 2, "words": ["<tag1>", "In", "2015,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "231,840", "new", "cases", "of", "breast", "cancer", "in", "the", "U.S.", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body.", "<tag2>", "In", "2016,", "the", "American", "Cancer", "Society", "estima", "tes", "there", "will", "be", "246,660", "new", "cases", "of", "invasive", "breast", "cancer", "diagnosed", "in", "the", "U.S.", "and", "about", "40,450", "women", "will", "die", "from", "breast", "cancer.", "<tag3>"], "wordsA": ["In", "2015,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "231,840", "new", "cases", "of", "breast", "cancer", "in", "the", "U.S.", "Metastatic", "breast", "cancer", "refers", "to", "cancer", "that", "has", "spread", "from", "the", "breast", "to", "distant", "sites", "in", "the", "body."], "wordsB": ["In", "2016,", "the", "American", "Cancer", "Society", "estima", "tes", "there", "will", "be", "246,660", "new", "cases", "of", "invasive", "breast", "cancer", "diagnosed", "in", "the", "U.S.", "and", "about", "40,450", "women", "will", "die", "from", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p169_s0", "idA": "906709_15_item1_p65_s0", "sentA": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "sentB": "There are currently no approved drugs on the market for adjunctive treatment or prevention of gram-negative pneumonias in mechanically ventilated patients which are also administered via the pulmonary route.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag2>", "There", "are", "currently", "no", "approved", "drugs", "on", "the", "market", "for", "adjunctive", "treatment", "or", "prevention", "of", "gram-negative", "pneumonias", "in", "mechanically", "ventilated", "patients", "which", "are", "also", "administered", "via", "the", "pulmonary", "route.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "wordsB": ["There", "are", "currently", "no", "approved", "drugs", "on", "the", "market", "for", "adjunctive", "treatment", "or", "prevention", "of", "gram-negative", "pneumonias", "in", "mechanically", "ventilated", "patients", "which", "are", "also", "administered", "via", "the", "pulmonary", "route."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p170_s0", "idA": "906709_15_item1_p65_s0", "sentA": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "sentB": "There are numerous companies engaged in developing immunotherapies to be used alone, or in combination, to treat a wide range of oncology indications targeting both solid and liquid tumors.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag2>", "There", "are", "numerous", "companies", "engaged", "in", "developing", "immunotherapies", "to", "be", "used", "alone,", "or", "in", "combination,", "to", "treat", "a", "wide", "range", "of", "oncology", "indications", "targeting", "both", "solid", "and", "liquid", "tumors.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "wordsB": ["There", "are", "numerous", "companies", "engaged", "in", "developing", "immunotherapies", "to", "be", "used", "alone,", "or", "in", "combination,", "to", "treat", "a", "wide", "range", "of", "oncology", "indications", "targeting", "both", "solid", "and", "liquid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p72_s0", "idA": "906709_15_item1_p65_s0", "sentA": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "sentB": "There are currently no FDA-approved topoi somerase I inhibitors indicated to treat breast cancer.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag2>", "There", "are", "currently", "no", "FDA-approved", "topoi", "somerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "wordsB": ["There", "are", "currently", "no", "FDA-approved", "topoi", "somerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p72_s1", "idA": "906709_15_item1_p65_s1", "sentA": "We have also conducted clinical studies for etirinotecan pegol in other solid tumor settings.", "sentB": "We have also conducted clinical studies for NKTR-102 in other solid tumor settings.", "type": 2, "words": ["<tag1>", "We", "have", "also", "conducted", "clinical", "studies", "for", "etirinotecan", "pegol", "in", "other", "solid", "tumor", "settings.", "<tag2>", "We", "have", "also", "conducted", "clinical", "studies", "for", "NKTR-102", "in", "other", "solid", "tumor", "settings.", "<tag3>"], "wordsA": ["We", "have", "also", "conducted", "clinical", "studies", "for", "etirinotecan", "pegol", "in", "other", "solid", "tumor", "settings."], "wordsB": ["We", "have", "also", "conducted", "clinical", "studies", "for", "NKTR-102", "in", "other", "solid", "tumor", "settings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p74_s0", "idA": "906709_15_item1_p65_s10", "sentA": "In addition to the clinical study of etirinotecan pegol being conducted by us, we are also providing support for four investigator-initiated Phase 2 studies being conducted for etirinotecan pegol.", "sentB": "In addition to the clinical study of NKTR-102 being conducted by us, we have also provided support for four investigator-initiated Phase 2 studies being conducted for NKTR-102.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "study", "of", "etirinotecan", "pegol", "being", "conducted", "by", "us,", "we", "are", "also", "providing", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol.", "<tag2>", "In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "study", "of", "etirinotecan", "pegol", "being", "conducted", "by", "us,", "we", "are", "also", "providing", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "etirinotecan", "pegol."], "wordsB": ["In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p74_s1", "idA": "906709_15_item1_p65_s11", "sentA": "On August 7, 2012, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "On August 7, 2012, we announced a Phase 2 investigator-initiated clinical study of NKTR-102 in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "type": 2, "words": ["<tag1>", "On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag3>"], "wordsA": ["On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p112_s1", "idA": "906709_15_item1_p65_s2", "sentA": "In 2013, we completed a Phase 2 clinical study for etirinotecan pegol in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "sentB": "In 2014, UCB and Biogen completed a Phase 1b randomized, double-blind, placebo-controlled clinical study in approximately 24 patients with SLE.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "In", "2014,", "UCB", "and", "Biogen", "completed", "a", "Phase", "1b", "randomized,", "double-blind,", "placebo-controlled", "clinical", "study", "in", "approximately", "24", "patients", "with", "SLE.", "<tag3>"], "wordsA": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["In", "2014,", "UCB", "and", "Biogen", "completed", "a", "Phase", "1b", "randomized,", "double-blind,", "placebo-controlled", "clinical", "study", "in", "approximately", "24", "patients", "with", "SLE."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p168_s1", "idA": "906709_15_item1_p65_s2", "sentA": "In 2013, we completed a Phase 2 clinical study for etirinotecan pegol in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "sentB": "These therapies are only partially effective in treating breast and ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "These", "therapies", "are", "only", "partially", "effective", "in", "treating", "breast", "and", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["These", "therapies", "are", "only", "partially", "effective", "in", "treating", "breast", "and", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p72_s2", "idA": "906709_15_item1_p65_s2", "sentA": "In 2013, we completed a Phase 2 clinical study for etirinotecan pegol in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "sentB": "In 2013, we completed a Phase 2 clinical study for NKTR-102 in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "NKTR-102", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "etirinotecan", "pegol", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "NKTR-102", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s7", "idA": "906709_15_item1_p65_s3", "sentA": "We also initiated a Phase 2 clinical study of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "We also met with the EMA to discuss filing an MAA.", "type": 2, "words": ["<tag1>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "We", "also", "met", "with", "the", "EMA", "to", "discuss", "filing", "an", "MAA.", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["We", "also", "met", "with", "the", "EMA", "to", "discuss", "filing", "an", "MAA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p72_s3", "idA": "906709_15_item1_p65_s3", "sentA": "We also initiated a Phase 2 clinical study of etirinotecan pegol monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "We also initiated a Phase 2 clinical study of NKTR-102 monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "type": 2, "words": ["<tag1>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "etirinotecan", "pegol", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p8_s0", "idA": "906709_15_item1_p65_s4", "sentA": "The Phase 2 clinical study was designed to enroll 174 patients with metastatic colorectal cancer.", "sentB": "The dose-escalation stage of the Phase 1/2 study is designed to evaluate safety, efficacy, and define the recommended Phase 2 dose of NKTR-214 in approximately 20 patients with solid tu mors.", "type": 2, "words": ["<tag1>", "The", "Phase", "2", "clinical", "study", "was", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer.", "<tag2>", "The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety,", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "approximately", "20", "patients", "with", "solid", "tu", "mors.", "<tag3>"], "wordsA": ["The", "Phase", "2", "clinical", "study", "was", "designed", "to", "enroll", "174", "patients", "with", "metastatic", "colorectal", "cancer."], "wordsB": ["The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety,", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "approximately", "20", "patients", "with", "solid", "tu", "mors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p72_s5", "idA": "906709_15_item1_p65_s5", "sentA": "In February 2014, we decided to close enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or E.U.", "sentB": "In February 2014, we decided to close enrollment in this study after 80 patients were randomized due to challenges in recruiting new patients because the comparator arm of this study, single-agent irinotecan, is not the common standard of care for second line metastatic colorectal therapy in the U.S. or EU.", "type": 2, "words": ["<tag1>", "In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U.", "<tag2>", "In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "EU.", "<tag3>"], "wordsA": ["In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "E.U."], "wordsB": ["In", "February", "2014,", "we", "decided", "to", "close", "enrollment", "in", "this", "study", "after", "80", "patients", "were", "randomized", "due", "to", "challenges", "in", "recruiting", "new", "patients", "because", "the", "comparator", "arm", "of", "this", "study,", "single-agent", "irinotecan,", "is", "not", "the", "common", "standard", "of", "care", "for", "second", "line", "metastatic", "colorectal", "therapy", "in", "the", "U.S.", "or", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p84_s5", "idA": "906709_15_item1_p65_s6", "sentA": "We plan to submit a manuscript describing the results of this study in the first half of 2015.", "sentB": "Although the results of these studies showed NKTR-171 was well-tolerated, as a result of pipeline prioritization, at this time we do not plan to advance NKTR-171 into any further clinical studies.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "submit", "a", "manuscript", "describing", "the", "results", "of", "this", "study", "in", "the", "first", "half", "of", "2015.", "<tag2>", "Although", "the", "results", "of", "these", "studies", "showed", "NKTR-171", "was", "well-tolerated,", "as", "a", "result", "of", "pipeline", "prioritization,", "at", "this", "time", "we", "do", "not", "plan", "to", "advance", "NKTR-171", "into", "any", "further", "clinical", "studies.", "<tag3>"], "wordsA": ["We", "plan", "to", "submit", "a", "manuscript", "describing", "the", "results", "of", "this", "study", "in", "the", "first", "half", "of", "2015."], "wordsB": ["Although", "the", "results", "of", "these", "studies", "showed", "NKTR-171", "was", "well-tolerated,", "as", "a", "result", "of", "pipeline", "prioritization,", "at", "this", "time", "we", "do", "not", "plan", "to", "advance", "NKTR-171", "into", "any", "further", "clinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p72_s6", "idA": "906709_15_item1_p65_s7", "sentA": "We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate etirinotecan pegol in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.", "sentB": "We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate NKTR-102 in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.", "type": 2, "words": ["<tag1>", "We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers.", "<tag2>", "We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "NKTR-102", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers.", "<tag3>"], "wordsA": ["We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers."], "wordsB": ["We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "NKTR-102", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p82_s0", "idA": "906709_15_item1_p65_s7", "sentA": "We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate etirinotecan pegol in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.", "sentB": "In June 2015, we and The University of Texas MD Anderson Cancer Center announced a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214 in a variety of tumor types as a monotherapy and in combination with other therapies, including PD-1 pathway inhibitors.", "type": 2, "words": ["<tag1>", "We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers.", "<tag2>", "In", "June", "2015,", "we", "and", "The", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center", "announced", "a", "research", "collaboration", "that", "includes", "a", "Phase", "1/2", "clinical", "study", "to", "evaluate", "NKTR-214", "in", "a", "variety", "of", "tumor", "types", "as", "a", "monotherapy", "and", "in", "combination", "with", "other", "therapies,", "including", "PD-1", "pathway", "inhibitors.", "<tag3>"], "wordsA": ["We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "etirinotecan", "pegol", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers."], "wordsB": ["In", "June", "2015,", "we", "and", "The", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center", "announced", "a", "research", "collaboration", "that", "includes", "a", "Phase", "1/2", "clinical", "study", "to", "evaluate", "NKTR-214", "in", "a", "variety", "of", "tumor", "types", "as", "a", "monotherapy", "and", "in", "combination", "with", "other", "therapies,", "including", "PD-1", "pathway", "inhibitors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p74_s3", "idA": "906709_15_item1_p66_s0", "sentA": "to evaluate etirinotecan pegol in patients with brain metastasis from primary lung cancer.", "sentB": "A separate investigator-initiated clinical study is also being conducted at Stanford to evaluate NKTR-102 in patients with brain metastasis from primary lung cancer.", "type": 2, "words": ["<tag1>", "to", "evaluate", "etirinotecan", "pegol", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer.", "<tag2>", "A", "separate", "investigator-initiated", "clinical", "study", "is", "also", "being", "conducted", "at", "Stanford", "to", "evaluate", "NKTR-102", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer.", "<tag3>"], "wordsA": ["to", "evaluate", "etirinotecan", "pegol", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer."], "wordsB": ["A", "separate", "investigator-initiated", "clinical", "study", "is", "also", "being", "conducted", "at", "Stanford", "to", "evaluate", "NKTR-102", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p8_s3", "idA": "906709_15_item1_p66_s0", "sentA": "to evaluate etirinotecan pegol in patients with brain metastasis from primary lung cancer.", "sentB": "Following the dose-escalation stage of the study, dose expansion cohorts are planned to evaluate NKTR-214 in specific tumor types, which may include melanoma, renal cell carcinoma an d non-small cell lung cancer .", "type": 2, "words": ["<tag1>", "to", "evaluate", "etirinotecan", "pegol", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer.", "<tag2>", "Following", "the", "dose-escalation", "stage", "of", "the", "study,", "dose", "expansion", "cohorts", "are", "planned", "to", "evaluate", "NKTR-214", "in", "specific", "tumor", "types,", "which", "may", "include", "melanoma,", "renal", "cell", "carcinoma", "an", "d", "non-small", "cell", "lung", "cancer", ".", "<tag3>"], "wordsA": ["to", "evaluate", "etirinotecan", "pegol", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer."], "wordsB": ["Following", "the", "dose-escalation", "stage", "of", "the", "study,", "dose", "expansion", "cohorts", "are", "planned", "to", "evaluate", "NKTR-214", "in", "specific", "tumor", "types,", "which", "may", "include", "melanoma,", "renal", "cell", "carcinoma", "an", "d", "non-small", "cell", "lung", "cancer", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p183_s0", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "Dr. Gergel received his M.D. from the Royal Free Medical School of the University of London and an MBA from the Wharton School.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "Dr.", "Gergel", "received", "his", "M.D.", "from", "the", "Royal", "Free", "Medical", "School", "of", "the", "University", "of", "London", "and", "an", "MBA", "from", "the", "Wharton", "School.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["Dr.", "Gergel", "received", "his", "M.D.", "from", "the", "Royal", "Free", "Medical", "School", "of", "the", "University", "of", "London", "and", "an", "MBA", "from", "the", "Wharton", "School."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p185_s2", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "Prior to working at Exelixis, Dr. Doberstein was a Howard Hughes Postdoctoral Fellow and a Muscular Dystrophy Association Senior Postdoctoral Fellow at the University of California, Berkeley.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "Prior", "to", "working", "at", "Exelixis,", "Dr.", "Doberstein", "was", "a", "Howard", "Hughes", "Postdoctoral", "Fellow", "and", "a", "Muscular", "Dystrophy", "Association", "Senior", "Postdoctoral", "Fellow", "at", "the", "University", "of", "California,", "Berkeley.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["Prior", "to", "working", "at", "Exelixis,", "Dr.", "Doberstein", "was", "a", "Howard", "Hughes", "Postdoctoral", "Fellow", "and", "a", "Muscular", "Dystrophy", "Association", "Senior", "Postdoctoral", "Fellow", "at", "the", "University", "of", "California,", "Berkeley."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p74_s4", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of NKTR-102 in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p7_s1", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "The study is being conducted initially at two primary investigator sites: the University of Texas MD Anderson Cancer Center and Yale Cancer Center.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "The", "study", "is", "being", "conducted", "initially", "at", "two", "primary", "investigator", "sites:", "the", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center", "and", "Yale", "Cancer", "Center.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["The", "study", "is", "being", "conducted", "initially", "at", "two", "primary", "investigator", "sites:", "the", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center", "and", "Yale", "Cancer", "Center."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p82_s1", "idA": "906709_15_item1_p66_s1", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "In December 2015, we announced that dosing had commenced in the Phase 1/2 clinical study evaluating the safety, tolerability and efficacy of NKTR-214 in patients with advanced solid tumors, including melanoma, renal cell carcinoma and non-small cell lung cancer.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "In", "December", "2015,", "we", "announced", "that", "dosing", "had", "commenced", "in", "the", "Phase", "1/2", "clinical", "study", "evaluating", "the", "safety,", "tolerability", "and", "efficacy", "of", "NKTR-214", "in", "patients", "with", "advanced", "solid", "tumors,", "including", "melanoma,", "renal", "cell", "carcinoma", "and", "non-small", "cell", "lung", "cancer.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["In", "December", "2015,", "we", "announced", "that", "dosing", "had", "commenced", "in", "the", "Phase", "1/2", "clinical", "study", "evaluating", "the", "safety,", "tolerability", "and", "efficacy", "of", "NKTR-214", "in", "patients", "with", "advanced", "solid", "tumors,", "including", "melanoma,", "renal", "cell", "carcinoma", "and", "non-small", "cell", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p74_s5", "idA": "906709_15_item1_p66_s2", "sentA": "On October 24, 2013, we announced a Phase 2 investigator-initiated clinical study of etirinotecan pegol in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute.", "sentB": "On October 24, 2013, we announced a Phase 2 investigator-initiated clinical study of NKTR-102 in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute.", "type": 2, "words": ["<tag1>", "On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute.", "<tag2>", "On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute.", "<tag3>"], "wordsA": ["On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "etirinotecan", "pegol", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute."], "wordsB": ["On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s6", "idA": "906709_15_item1_p67_s3", "sentA": "We have engaged third party contract manufacturers to perform our device manufacturing activities for this program.", "sentB": "We also utilize the services of contract manufacturers to manufacture APIs required for later phases of clinical development and eventual commercialization for us under all applicable laws and regulations.", "type": 2, "words": ["<tag1>", "We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program.", "<tag2>", "We", "also", "utilize", "the", "services", "of", "contract", "manufacturers", "to", "manufacture", "APIs", "required", "for", "later", "phases", "of", "clinical", "development", "and", "eventual", "commercialization", "for", "us", "under", "all", "applicable", "laws", "and", "regulations.", "<tag3>"], "wordsA": ["We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program."], "wordsB": ["We", "also", "utilize", "the", "services", "of", "contract", "manufacturers", "to", "manufacture", "APIs", "required", "for", "later", "phases", "of", "clinical", "development", "and", "eventual", "commercialization", "for", "us", "under", "all", "applicable", "laws", "and", "regulations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s12", "idA": "906709_15_item1_p67_s3", "sentA": "We have engaged third party contract manufacturers to perform our device manufacturing activities for this program.", "sentB": "We are currently evaluating next steps for this program.", "type": 2, "words": ["<tag1>", "We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program.", "<tag2>", "We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program.", "<tag3>"], "wordsA": ["We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program."], "wordsB": ["We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s14", "idA": "906709_15_item1_p67_s3", "sentA": "We have engaged third party contract manufacturers to perform our device manufacturing activities for this program.", "sentB": "We are currently evaluating next steps for this program.", "type": 2, "words": ["<tag1>", "We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program.", "<tag2>", "We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program.", "<tag3>"], "wordsA": ["We", "have", "engaged", "third", "party", "contract", "manufacturers", "to", "perform", "our", "device", "manufacturing", "activities", "for", "this", "program."], "wordsB": ["We", "are", "currently", "evaluating", "next", "steps", "for", "this", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p79_s0", "idA": "906709_15_item1_p71_s0", "sentA": "In April 2013, Bayer initiated enrollment in a global Phase 3 clinical study, which it calls INHALE, to evaluate the efficacy and safety of Amikacin Inhale versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.", "sentB": "negative pneumonia receiving s tandard of care intravenous antibiotics.", "type": 2, "words": ["<tag1>", "In", "April", "2013,", "Bayer", "initiated", "enrollment", "in", "a", "global", "Phase", "3", "clinical", "study,", "which", "it", "calls", "INHALE,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Amikacin", "Inhale", "versus", "aerosolized", "placebo", "in", "the", "treatment", "of", "intubated", "and", "mechanically", "ventilated", "patients", "with", "Gram-negative", "pneumonia", "receiving", "standard", "of", "care", "intravenous", "antibiotics.", "<tag2>", "negative", "pneumonia", "receiving", "s", "tandard", "of", "care", "intravenous", "antibiotics.", "<tag3>"], "wordsA": ["In", "April", "2013,", "Bayer", "initiated", "enrollment", "in", "a", "global", "Phase", "3", "clinical", "study,", "which", "it", "calls", "INHALE,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Amikacin", "Inhale", "versus", "aerosolized", "placebo", "in", "the", "treatment", "of", "intubated", "and", "mechanically", "ventilated", "patients", "with", "Gram-negative", "pneumonia", "receiving", "standard", "of", "care", "intravenous", "antibiotics."], "wordsB": ["negative", "pneumonia", "receiving", "s", "tandard", "of", "care", "intravenous", "antibiotics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p80_s0", "idA": "906709_15_item1_p71_s1", "sentA": "The global INHALE development program is comprised of two prospective, randomized, double-blind, placebo-controlled, large multi-center global programs involving centers in North America, South America, Europe, Japan, Australia and Asia.", "sentB": "The global INHALE development program is comprised of two prospective, randomized, double-blind, placebo-controlled, large multi-center global programs involving centers in North America, South America, Europe, Jap an, Australia and Asia.", "type": 2, "words": ["<tag1>", "The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Japan,", "Australia", "and", "Asia.", "<tag2>", "The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Jap", "an,", "Australia", "and", "Asia.", "<tag3>"], "wordsA": ["The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Japan,", "Australia", "and", "Asia."], "wordsB": ["The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Jap", "an,", "Australia", "and", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s10", "idA": "906709_15_item1_p71_s2", "sentA": "The INHALE development program is being conducted by Bayer under a Special Protocol Assessment agreement with the FDA that is intended to support the submission of an NDA if the INHALE clinical studies are successful.", "sentB": "In the United States, we met with the FDA and the Oncology Division indicated that we would not be able to use the BEACON data to support an accelerated approval for an NDA.", "type": 2, "words": ["<tag1>", "The", "INHALE", "development", "program", "is", "being", "conducted", "by", "Bayer", "under", "a", "Special", "Protocol", "Assessment", "agreement", "with", "the", "FDA", "that", "is", "intended", "to", "support", "the", "submission", "of", "an", "NDA", "if", "the", "INHALE", "clinical", "studies", "are", "successful.", "<tag2>", "In", "the", "United", "States,", "we", "met", "with", "the", "FDA", "and", "the", "Oncology", "Division", "indicated", "that", "we", "would", "not", "be", "able", "to", "use", "the", "BEACON", "data", "to", "support", "an", "accelerated", "approval", "for", "an", "NDA.", "<tag3>"], "wordsA": ["The", "INHALE", "development", "program", "is", "being", "conducted", "by", "Bayer", "under", "a", "Special", "Protocol", "Assessment", "agreement", "with", "the", "FDA", "that", "is", "intended", "to", "support", "the", "submission", "of", "an", "NDA", "if", "the", "INHALE", "clinical", "studies", "are", "successful."], "wordsB": ["In", "the", "United", "States,", "we", "met", "with", "the", "FDA", "and", "the", "Oncology", "Division", "indicated", "that", "we", "would", "not", "be", "able", "to", "use", "the", "BEACON", "data", "to", "support", "an", "accelerated", "approval", "for", "an", "NDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p56_s1", "idA": "906709_15_item1_p73_s0", "sentA": "serious central nervous system (CNS) side effects associated with current opioid therapies.", "sentB": "NKTR-181 is designed with the objective to address the abuse liability and serious central nervous system (CNS) side effects associated with current opioid therapies.", "type": 2, "words": ["<tag1>", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag2>", "NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies.", "<tag3>"], "wordsA": ["serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "wordsB": ["NKTR-181", "is", "designed", "with", "the", "objective", "to", "address", "the", "abuse", "liability", "and", "serious", "central", "nervous", "system", "(CNS)", "side", "effects", "associated", "with", "current", "opioid", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p173_s5", "idA": "906709_15_item1_p73_s2", "sentA": "NKTR-181 s abuse deterrent properties are inherent to its novel molecular structure and do not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "sentB": "In addition, we typically order raw materials and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements.", "type": 2, "words": ["<tag1>", "NKTR-181", "s", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag2>", "In", "addition,", "we", "typically", "order", "raw", "materials", "and", "services", "on", "a", "purchase", "order", "basis", "and", "do", "not", "enter", "into", "long-term", "dedicated", "capacity", "or", "minimum", "supply", "arrangements.", "<tag3>"], "wordsA": ["NKTR-181", "s", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "wordsB": ["In", "addition,", "we", "typically", "order", "raw", "materials", "and", "services", "on", "a", "purchase", "order", "basis", "and", "do", "not", "enter", "into", "long-term", "dedicated", "capacity", "or", "minimum", "supply", "arrangements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p162_s1", "idA": "906709_15_item1_p74_s1", "sentA": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "We face intense science and technology competition from a multitude of technologies seeking to enhance the efficacy, safety and ease of use of approved drugs and new drug molecule candidates.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "We", "face", "intense", "science", "and", "technology", "competition", "from", "a", "multitude", "of", "technologies", "seeking", "to", "enhance", "the", "efficacy,", "safety", "and", "ease", "of", "use", "of", "approved", "drugs", "and", "new", "drug", "molecule", "candidates.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["We", "face", "intense", "science", "and", "technology", "competition", "from", "a", "multitude", "of", "technologies", "seeking", "to", "enhance", "the", "efficacy,", "safety", "and", "ease", "of", "use", "of", "approved", "drugs", "and", "new", "drug", "molecule", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p69_s2", "idA": "906709_15_item1_p74_s12", "sentA": "This unusual lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study.", "sentB": "Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio (HR) for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance.", "type": 2, "words": ["<tag1>", "This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study.", "<tag2>", "Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance.", "<tag3>"], "wordsA": ["This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study."], "wordsB": ["Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p9_s4", "idA": "906709_15_item1_p74_s12", "sentA": "This unusual lack of a placebo rebound caused the Phase 2 study to miss the primary endpoint in the study.", "sentB": "Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio (HR) for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance.", "type": 2, "words": ["<tag1>", "This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study.", "<tag2>", "Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance.", "<tag3>"], "wordsA": ["This", "unusual", "lack", "of", "a", "placebo", "rebound", "caused", "the", "Phase", "2", "study", "to", "miss", "the", "primary", "endpoint", "in", "the", "study."], "wordsB": ["Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p60_s0", "idA": "906709_15_item1_p74_s13", "sentA": "In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of the design of the Phase 3 clinical study program.", "sentB": "In October 2014, we engaged in an end-of-Phase 2 meeting for NKTR-181 with the FDA , which included discuss ions of the design of the Phase 3 clinical study program .", "type": 2, "words": ["<tag1>", "In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program.", "<tag2>", "In", "October", "2014,", "we", "engaged", "in", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA", ",", "which", "included", "discuss", "ions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program", ".", "<tag3>"], "wordsA": ["In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program."], "wordsB": ["In", "October", "2014,", "we", "engaged", "in", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA", ",", "which", "included", "discuss", "ions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p82_s2", "idA": "906709_15_item1_p74_s13", "sentA": "In October 2014, we had an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of the design of the Phase 3 clinical study program.", "sentB": "As part of the Phase 1/2 clinical study program, we will also evaluate NKTR-214 in combination with a checkpoint inhibitor.", "type": 2, "words": ["<tag1>", "In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program.", "<tag2>", "As", "part", "of", "the", "Phase", "1/2", "clinical", "study", "program,", "we", "will", "also", "evaluate", "NKTR-214", "in", "combination", "with", "a", "checkpoint", "inhibitor.", "<tag3>"], "wordsA": ["In", "October", "2014,", "we", "had", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program."], "wordsB": ["As", "part", "of", "the", "Phase", "1/2", "clinical", "study", "program,", "we", "will", "also", "evaluate", "NKTR-214", "in", "combination", "with", "a", "checkpoint", "inhibitor."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p60_s2", "idA": "906709_15_item1_p74_s15", "sentA": "We enrolled the first patient in this first Phase 3 study on February 24, 2015.", "sentB": "We enrolled the first patient in this first Phase 3 study in February 2015 .", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "in", "February", "2015", ".", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "on", "February", "24,", "2015."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "this", "first", "Phase", "3", "study", "in", "February", "2015", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p5_s2", "idA": "906709_15_item1_p74_s16", "sentA": "In this first efficacy study, we plan to enroll approximately 416 patients in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "sentB": "In this study, we are randomizing patients with chronic low back pain in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "type": 2, "words": ["<tag1>", "In", "this", "first", "efficacy", "study,", "we", "plan", "to", "enroll", "approximately", "416", "patients", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag2>", "In", "this", "study,", "we", "are", "randomizing", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag3>"], "wordsA": ["In", "this", "first", "efficacy", "study,", "we", "plan", "to", "enroll", "approximately", "416", "patients", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "wordsB": ["In", "this", "study,", "we", "are", "randomizing", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p6_s0", "idA": "906709_15_item1_p74_s17", "sentA": "The study design also includes a single interim analysis for sample size reassessment which will be conducted by an independent data monitoring committee.", "sentB": "The NKTR-181 Phase 3 study design includes a single interim sample size assessment to be conducted by an independent analysis center (IAC) after approximately fifty percent of the initially planned 416 patients completed the study.", "type": 2, "words": ["<tag1>", "The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee.", "<tag2>", "The", "NKTR-181", "Phase", "3", "study", "design", "includes", "a", "single", "interim", "sample", "size", "assessment", "to", "be", "conducted", "by", "an", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study.", "<tag3>"], "wordsA": ["The", "study", "design", "also", "includes", "a", "single", "interim", "analysis", "for", "sample", "size", "reassessment", "which", "will", "be", "conducted", "by", "an", "independent", "data", "monitoring", "committee."], "wordsB": ["The", "NKTR-181", "Phase", "3", "study", "design", "includes", "a", "single", "interim", "sample", "size", "assessment", "to", "be", "conducted", "by", "an", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p61_s1", "idA": "906709_15_item1_p74_s18", "sentA": "The primary endpoint will be change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints will include percentage of responders ( 30% reduction in pain score) and patient impression of change.", "sentB": "The primary endpoint is a change in weekly pain score in the double-blind randomized period relative to the baseline pain score and the key secondary endpoints include percentage of re sponders ( 30% reduction in pain score) and patient impression of change.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change.", "<tag2>", "The", "primary", "endpoint", "is", "a", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "include", "percentage", "of", "re", "sponders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "will", "be", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "will", "include", "percentage", "of", "responders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change."], "wordsB": ["The", "primary", "endpoint", "is", "a", "change", "in", "weekly", "pain", "score", "in", "the", "double-blind", "randomized", "period", "relative", "to", "the", "baseline", "pain", "score", "and", "the", "key", "secondary", "endpoints", "include", "percentage", "of", "re", "sponders", "(", "30%", "reduction", "in", "pain", "score)", "and", "patient", "impression", "of", "change."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p57_s3", "idA": "906709_15_item1_p74_s3", "sentA": "The study enrolled 213 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication.", "sentB": "The study enrolled 295 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication.", "type": 2, "words": ["<tag1>", "The", "study", "enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag2>", "The", "study", "enrolled", "295", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag3>"], "wordsA": ["The", "study", "enrolled", "213", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication."], "wordsB": ["The", "study", "enrolled", "295", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p112_s2", "idA": "906709_15_item1_p74_s6", "sentA": "The primary endpoint of the study was the average change in a patient s pain score from baseline to the end of the double-blind, randomized treatment period.", "sentB": "Data from the study was published in September 2015 at the Annual American College of Rheumatology Meeting and showed that multiple administrations of dapirolizumab pegol given over 12 weeks were well-tolerated and the safety profile supported further development of the compound.", "type": 2, "words": ["<tag1>", "The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period.", "<tag2>", "Data", "from", "the", "study", "was", "published", "in", "September", "2015", "at", "the", "Annual", "American", "College", "of", "Rheumatology", "Meeting", "and", "showed", "that", "multiple", "administrations", "of", "dapirolizumab", "pegol", "given", "over", "12", "weeks", "were", "well-tolerated", "and", "the", "safety", "profile", "supported", "further", "development", "of", "the", "compound.", "<tag3>"], "wordsA": ["The", "primary", "endpoint", "of", "the", "study", "was", "the", "average", "change", "in", "a", "patient", "s", "pain", "score", "from", "baseline", "to", "the", "end", "of", "the", "double-blind,", "randomized", "treatment", "period."], "wordsB": ["Data", "from", "the", "study", "was", "published", "in", "September", "2015", "at", "the", "Annual", "American", "College", "of", "Rheumatology", "Meeting", "and", "showed", "that", "multiple", "administrations", "of", "dapirolizumab", "pegol", "given", "over", "12", "weeks", "were", "well-tolerated", "and", "the", "safety", "profile", "supported", "further", "development", "of", "the", "compound."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p59_s2", "idA": "906709_15_item1_p74_s8", "sentA": "Of the 295 patients that entered the study, only 9 (3%) patients were unable to achieve meaningful pain relief with NKTR-181.", "sentB": "Of the 295 patients that entered the study, only 9 patients (representing 3% of the patient population) were unable to achieve meaningful pain relief with NKTR-181.", "type": 2, "words": ["<tag1>", "Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "(3%)", "patients", "were", "unable", "to", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181.", "<tag2>", "Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "patients", "(representing", "3%", "of", "the", "patient", "population)", "were", "unable", "to", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181.", "<tag3>"], "wordsA": ["Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "(3%)", "patients", "were", "unable", "to", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181."], "wordsB": ["Of", "the", "295", "patients", "that", "entered", "the", "study,", "only", "9", "patients", "(representing", "3%", "of", "the", "patient", "population)", "were", "unable", "to", "achieve", "meaningful", "pain", "relief", "with", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p58_s1", "idA": "906709_15_item1_p75_s1", "sentA": "In this study, NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "In this study, NKTR-181 had highly statistically significant lower \"drug liking\" scores and reduced \"feeling high\" scores as compared to oxycodone at all doses tested (p 0.0001).", "type": 2, "words": ["<tag1>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "\"drug", "liking\"", "scores", "and", "reduced", "\"feeling", "high\"", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag3>"], "wordsA": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "\"drug", "liking\"", "scores", "and", "reduced", "\"feeling", "high\"", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p63_s2", "idA": "906709_15_item1_p79_s0", "sentA": "crisis of addiction, misuse, abuse, overdose and death.", "sentB": "The FDA has cited prescription opioid analgesics as being at the center of a major public health crisis of addiction, misuse, abuse, overdose and death.", "type": 2, "words": ["<tag1>", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death.", "<tag2>", "The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death.", "<tag3>"], "wordsA": ["crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death."], "wordsB": ["The", "FDA", "has", "cited", "prescription", "opioid", "analgesics", "as", "being", "at", "the", "center", "of", "a", "major", "public", "health", "crisis", "of", "addiction,", "misuse,", "abuse,", "overdose", "and", "death."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p53_s1", "idA": "906709_15_item1_p79_s1", "sentA": "A 2010 report from the Center for Disease Control and Prevention notes that emergency room visits tied to the abuse of prescription painkillers was at an all-time high at that point, having increased 111 percent over the preceding five-year period.", "sentB": "According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately 1 in 5,000 live births.", "type": 2, "words": ["<tag1>", "A", "2010", "report", "from", "the", "Center", "for", "Disease", "Control", "and", "Prevention", "notes", "that", "emergency", "room", "visits", "tied", "to", "the", "abuse", "of", "prescription", "painkillers", "was", "at", "an", "all-time", "high", "at", "that", "point,", "having", "increased", "111", "percent", "over", "the", "preceding", "five-year", "period.", "<tag2>", "According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "1", "in", "5,000", "live", "births.", "<tag3>"], "wordsA": ["A", "2010", "report", "from", "the", "Center", "for", "Disease", "Control", "and", "Prevention", "notes", "that", "emergency", "room", "visits", "tied", "to", "the", "abuse", "of", "prescription", "painkillers", "was", "at", "an", "all-time", "high", "at", "that", "point,", "having", "increased", "111", "percent", "over", "the", "preceding", "five-year", "period."], "wordsB": ["According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "1", "in", "5,000", "live", "births."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p92_s1", "idA": "906709_15_item1_p79_s1", "sentA": "A 2010 report from the Center for Disease Control and Prevention notes that emergency room visits tied to the abuse of prescription painkillers was at an all-time high at that point, having increased 111 percent over the preceding five-year period.", "sentB": "According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately one in 5,000 live births.", "type": 2, "words": ["<tag1>", "A", "2010", "report", "from", "the", "Center", "for", "Disease", "Control", "and", "Prevention", "notes", "that", "emergency", "room", "visits", "tied", "to", "the", "abuse", "of", "prescription", "painkillers", "was", "at", "an", "all-time", "high", "at", "that", "point,", "having", "increased", "111", "percent", "over", "the", "preceding", "five-year", "period.", "<tag2>", "According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "one", "in", "5,000", "live", "births.", "<tag3>"], "wordsA": ["A", "2010", "report", "from", "the", "Center", "for", "Disease", "Control", "and", "Prevention", "notes", "that", "emergency", "room", "visits", "tied", "to", "the", "abuse", "of", "prescription", "painkillers", "was", "at", "an", "all-time", "high", "at", "that", "point,", "having", "increased", "111", "percent", "over", "the", "preceding", "five-year", "period."], "wordsB": ["According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "one", "in", "5,000", "live", "births."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p81_s0", "idA": "906709_15_item1_p82_s0", "sentA": "NKTR-214 is an engineered immunostimulatory cytokine and is being developed for the treatment of solid tumors.", "sentB": "NKTR-214 is a CD122-biased immune-stimulatory cytokine designed for the treatment of solid tumors.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors.", "<tag2>", "NKTR-214", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "designed", "for", "the", "treatment", "of", "solid", "tumors.", "<tag3>"], "wordsA": ["NKTR-214", "is", "an", "engineered", "immunostimulatory", "cytokine", "and", "is", "being", "developed", "for", "the", "treatment", "of", "solid", "tumors."], "wordsB": ["NKTR-214", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "designed", "for", "the", "treatment", "of", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p82_s3", "idA": "906709_15_item1_p83_s0", "sentA": "On June 1, 2014, we announced positive preclinical data for NKTR-214 at the ASCO Annual Meeting in Chicago.", "sentB": "On February 1, 2016, we announced positive preclinical data was published in a manuscript in Clinical Cancer Research for NKTR-214.", "type": 2, "words": ["<tag1>", "On", "June", "1,", "2014,", "we", "announced", "positive", "preclinical", "data", "for", "NKTR-214", "at", "the", "ASCO", "Annual", "Meeting", "in", "Chicago.", "<tag2>", "On", "February", "1,", "2016,", "we", "announced", "positive", "preclinical", "data", "was", "published", "in", "a", "manuscript", "in", "Clinical", "Cancer", "Research", "for", "NKTR-214.", "<tag3>"], "wordsA": ["On", "June", "1,", "2014,", "we", "announced", "positive", "preclinical", "data", "for", "NKTR-214", "at", "the", "ASCO", "Annual", "Meeting", "in", "Chicago."], "wordsB": ["On", "February", "1,", "2016,", "we", "announced", "positive", "preclinical", "data", "was", "published", "in", "a", "manuscript", "in", "Clinical", "Cancer", "Research", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p83_s2", "idA": "906709_15_item1_p83_s3", "sentA": "In both the breast and colon tumor models, the combination dosing regimens of NKTR-214 therapy with anti-PD-1 therapy or anti-CTLA-4 therapy resulted in significant tumor growth inhibition.", "sentB": "In both the breast and colon tumor models, the combination dosing regimens of NKTR-214 therapy with anti-PD-1 therapy or anti-CTLA-4 therapy resulted in significant tumor growth inhibition as well as complete regression of tumors in some animals.", "type": 2, "words": ["<tag1>", "In", "both", "the", "breast", "and", "colon", "tumor", "models,", "the", "combination", "dosing", "regimens", "of", "NKTR-214", "therapy", "with", "anti-PD-1", "therapy", "or", "anti-CTLA-4", "therapy", "resulted", "in", "significant", "tumor", "growth", "inhibition.", "<tag2>", "In", "both", "the", "breast", "and", "colon", "tumor", "models,", "the", "combination", "dosing", "regimens", "of", "NKTR-214", "therapy", "with", "anti-PD-1", "therapy", "or", "anti-CTLA-4", "therapy", "resulted", "in", "significant", "tumor", "growth", "inhibition", "as", "well", "as", "complete", "regression", "of", "tumors", "in", "some", "animals.", "<tag3>"], "wordsA": ["In", "both", "the", "breast", "and", "colon", "tumor", "models,", "the", "combination", "dosing", "regimens", "of", "NKTR-214", "therapy", "with", "anti-PD-1", "therapy", "or", "anti-CTLA-4", "therapy", "resulted", "in", "significant", "tumor", "growth", "inhibition."], "wordsB": ["In", "both", "the", "breast", "and", "colon", "tumor", "models,", "the", "combination", "dosing", "regimens", "of", "NKTR-214", "therapy", "with", "anti-PD-1", "therapy", "or", "anti-CTLA-4", "therapy", "resulted", "in", "significant", "tumor", "growth", "inhibition", "as", "well", "as", "complete", "regression", "of", "tumors", "in", "some", "animals."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p83_s3", "idA": "906709_15_item1_p83_s4", "sentA": "In the aggressive EMT6 breast tumor model where activity with single-agent anti-PD-1 therapy or single-agent anti-CTLA-4 therapy was not observed, pre-dosing of NKTR-214 followed by anti-PD-1 demonstrated better efficacy (tumor growth inhibition of 74%) as compared to a concomitant dosing regimen of anti-CTLA-4 and anti-PD-1 therapies (tumor growth inhibition of 23%).", "sentB": "In the aggressive EMT6 breast tumor model where activity with single-agent anti-PD-1 therapy or single-agent anti-CTLA-4 therapy was not observed, combination of NKTR-214 plus either anti-PD-1 or anti-CTLA-4 demonstrated substantial efficacy.", "type": 2, "words": ["<tag1>", "In", "the", "aggressive", "EMT6", "breast", "tumor", "model", "where", "activity", "with", "single-agent", "anti-PD-1", "therapy", "or", "single-agent", "anti-CTLA-4", "therapy", "was", "not", "observed,", "pre-dosing", "of", "NKTR-214", "followed", "by", "anti-PD-1", "demonstrated", "better", "efficacy", "(tumor", "growth", "inhibition", "of", "74%)", "as", "compared", "to", "a", "concomitant", "dosing", "regimen", "of", "anti-CTLA-4", "and", "anti-PD-1", "therapies", "(tumor", "growth", "inhibition", "of", "23%).", "<tag2>", "In", "the", "aggressive", "EMT6", "breast", "tumor", "model", "where", "activity", "with", "single-agent", "anti-PD-1", "therapy", "or", "single-agent", "anti-CTLA-4", "therapy", "was", "not", "observed,", "combination", "of", "NKTR-214", "plus", "either", "anti-PD-1", "or", "anti-CTLA-4", "demonstrated", "substantial", "efficacy.", "<tag3>"], "wordsA": ["In", "the", "aggressive", "EMT6", "breast", "tumor", "model", "where", "activity", "with", "single-agent", "anti-PD-1", "therapy", "or", "single-agent", "anti-CTLA-4", "therapy", "was", "not", "observed,", "pre-dosing", "of", "NKTR-214", "followed", "by", "anti-PD-1", "demonstrated", "better", "efficacy", "(tumor", "growth", "inhibition", "of", "74%)", "as", "compared", "to", "a", "concomitant", "dosing", "regimen", "of", "anti-CTLA-4", "and", "anti-PD-1", "therapies", "(tumor", "growth", "inhibition", "of", "23%)."], "wordsB": ["In", "the", "aggressive", "EMT6", "breast", "tumor", "model", "where", "activity", "with", "single-agent", "anti-PD-1", "therapy", "or", "single-agent", "anti-CTLA-4", "therapy", "was", "not", "observed,", "combination", "of", "NKTR-214", "plus", "either", "anti-PD-1", "or", "anti-CTLA-4", "demonstrated", "substantial", "efficacy."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p83_s5", "idA": "906709_15_item1_p83_s5", "sentA": "NKTR-214 was also very well-tolerated when co-dosed with either antibody in these preclinical studies.", "sentB": "NKTR-214 was also very well-tolerated when co-administered with either antibody in these preclinical studies.", "type": 2, "words": ["<tag1>", "NKTR-214", "was", "also", "very", "well-tolerated", "when", "co-dosed", "with", "either", "antibody", "in", "these", "preclinical", "studies.", "<tag2>", "NKTR-214", "was", "also", "very", "well-tolerated", "when", "co-administered", "with", "either", "antibody", "in", "these", "preclinical", "studies.", "<tag3>"], "wordsA": ["NKTR-214", "was", "also", "very", "well-tolerated", "when", "co-dosed", "with", "either", "antibody", "in", "these", "preclinical", "studies."], "wordsB": ["NKTR-214", "was", "also", "very", "well-tolerated", "when", "co-administered", "with", "either", "antibody", "in", "these", "preclinical", "studies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p175_s2", "idA": "906709_15_item1_p84_s0", "sentA": "Overview of Select Technology Licensing Collaborations and Programs We have a number of product candidates in clinical development and approved products in collaboration with our partners that use our technology or involve rights over which we have patents or other proprietary intellectual property.", "sentB": "We have a number of employees who hold advanced degrees, such as Ph.D.s.", "type": 2, "words": ["<tag1>", "Overview", "of", "Select", "Technology", "Licensing", "Collaborations", "and", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "that", "use", "our", "technology", "or", "involve", "rights", "over", "which", "we", "have", "patents", "or", "other", "proprietary", "intellectual", "property.", "<tag2>", "We", "have", "a", "number", "of", "employees", "who", "hold", "advanced", "degrees,", "such", "as", "Ph.D.s.", "<tag3>"], "wordsA": ["Overview", "of", "Select", "Technology", "Licensing", "Collaborations", "and", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "that", "use", "our", "technology", "or", "involve", "rights", "over", "which", "we", "have", "patents", "or", "other", "proprietary", "intellectual", "property."], "wordsB": ["We", "have", "a", "number", "of", "employees", "who", "hold", "advanced", "degrees,", "such", "as", "Ph.D.s."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p160_s0", "idA": "906709_15_item1_p84_s2", "sentA": "In certain cases, we also manufacture and supply our proprietary PEGylation materials to our partners.", "sentB": "Backlog Pursuant to our collaboration agreements, we manufacture and supply our proprietary PEGylation materials.", "type": 2, "words": ["<tag1>", "In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners.", "<tag2>", "Backlog", "Pursuant", "to", "our", "collaboration", "agreements,", "we", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials.", "<tag3>"], "wordsA": ["In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners."], "wordsB": ["Backlog", "Pursuant", "to", "our", "collaboration", "agreements,", "we", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p86_s0", "idA": "906709_15_item1_p86_s0", "sentA": "In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with Baxter Healthcare SA and Baxter Healthcare Corporation (Baxter) to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "sentB": "ADYNOVATE TM (previously referred to as BAX 855) and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of Baxalta In corporated In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with certain subsidiaries of Baxalta, formerly Baxter before the separation of Baxalta from Baxter in July 2015, to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "type": 2, "words": ["<tag1>", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "Baxter", "Healthcare", "SA", "and", "Baxter", "Healthcare", "Corporation", "(Baxter)", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag2>", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "In", "corporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag3>"], "wordsA": ["In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "Baxter", "Healthcare", "SA", "and", "Baxter", "Healthcare", "Corporation", "(Baxter)", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "wordsB": ["ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "In", "corporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p53_s0", "idA": "906709_15_item1_p86_s1", "sentA": "The first product in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "sentB": "Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein.", "type": 2, "words": ["<tag1>", "The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag2>", "Hemophilia", "A,", "also", "called", "factor", "VIII", "(FVIII)", "deficiency", "or", "classic", "hemophilia,", "is", "a", "genetic", "disorder", "caused", "by", "missing", "or", "defective", "factor", "VIII,", "a", "clotting", "protein.", "<tag3>"], "wordsA": ["The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "wordsB": ["Hemophilia", "A,", "also", "called", "factor", "VIII", "(FVIII)", "deficiency", "or", "classic", "hemophilia,", "is", "a", "genetic", "disorder", "caused", "by", "missing", "or", "defective", "factor", "VIII,", "a", "clotting", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p86_s1", "idA": "906709_15_item1_p86_s1", "sentA": "The first product in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "sentB": "The first product in this collaboration, ADYNOVATE TM (previously referred to as BAX 855), is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "type": 2, "words": ["<tag1>", "The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag2>", "The", "first", "product", "in", "this", "collaboration,", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag3>"], "wordsA": ["The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "wordsB": ["The", "first", "product", "in", "this", "collaboration,", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p92_s0", "idA": "906709_15_item1_p86_s1", "sentA": "The first product in this collaboration, BAX 855, is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "sentB": "Hemophilia A, also called factor VIII (FVIII) deficiency or classic hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein.", "type": 2, "words": ["<tag1>", "The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag2>", "Hemophilia", "A,", "also", "called", "factor", "VIII", "(FVIII)", "deficiency", "or", "classic", "hemophilia,", "is", "a", "genetic", "disorder", "caused", "by", "missing", "or", "defective", "factor", "VIII,", "a", "clotting", "protein.", "<tag3>"], "wordsA": ["The", "first", "product", "in", "this", "collaboration,", "BAX", "855,", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "wordsB": ["Hemophilia", "A,", "also", "called", "factor", "VIII", "(FVIII)", "deficiency", "or", "classic", "hemophilia,", "is", "a", "genetic", "disorder", "caused", "by", "missing", "or", "defective", "factor", "VIII,", "a", "clotting", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p6_s3", "idA": "906709_15_item1_p87_s0", "sentA": "BAX 855 is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "sentB": "On February 29, 2016, the IAC instructed Nektar to increase the sample size by about 200 patients.", "type": 2, "words": ["<tag1>", "BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag2>", "On", "February", "29,", "2016,", "the", "IAC", "instructed", "Nektar", "to", "increase", "the", "sample", "size", "by", "about", "200", "patients.", "<tag3>"], "wordsA": ["BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "wordsB": ["On", "February", "29,", "2016,", "the", "IAC", "instructed", "Nektar", "to", "increase", "the", "sample", "size", "by", "about", "200", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p87_s0", "idA": "906709_15_item1_p87_s0", "sentA": "BAX 855 is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "sentB": "ADYNOVATE TM is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "type": 2, "words": ["<tag1>", "BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag2>", "ADYNOVATE", "TM", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag3>"], "wordsA": ["BAX", "855", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "wordsB": ["ADYNOVATE", "TM", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p88_s0", "idA": "906709_15_item1_p88_s0", "sentA": "We are entitled to up to $65.0 million in total development and sales milestone payments, as well as royalties on net sales varying by product and country of sale.", "sentB": "We are entitled to up to $55.0 million in total development and sales milestone payments, as well as royalties on net sales varying by product and country of sale.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$65.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale.", "<tag2>", "We", "are", "entitled", "to", "up", "to", "$55.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$65.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale."], "wordsB": ["We", "are", "entitled", "to", "up", "to", "$55.0", "million", "in", "total", "development", "and", "sales", "milestone", "payments,", "as", "well", "as", "royalties", "on", "net", "sales", "varying", "by", "product", "and", "country", "of", "sale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p88_s1", "idA": "906709_15_item1_p88_s1", "sentA": "The royalties start in the mid-single digits for net sales of BAX 855 up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion.", "sentB": "The royalties start in the mid-single digits for net sales of ADYNOVATE TM up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion.", "type": 2, "words": ["<tag1>", "The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "BAX", "855", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion.", "<tag2>", "The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "ADYNOVATE", "TM", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion.", "<tag3>"], "wordsA": ["The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "BAX", "855", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion."], "wordsB": ["The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "ADYNOVATE", "TM", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p89_s0", "idA": "906709_15_item1_p89_s0", "sentA": "In 2012, Baxter completed a Phase 1 clinical study for BAX 855 that was a prospective, open-label study assessing the safety, tolerability and pharmacokinetics of BAX 855 in 19 previously treated patients age 18 years or older with severe hemophilia A.", "sentB": "In 2012, Baxalta completed a Phase 1 clinical study for ADYNOVATE TM that was a prospective, open-label study assessing the safety, tolerability and pharmacokinetics of ADYNOVATE TM in 19 previously treated patients age 18 years or older with severe Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "2012,", "Baxter", "completed", "a", "Phase", "1", "clinical", "study", "for", "BAX", "855", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "hemophilia", "A.", "<tag2>", "In", "2012,", "Baxalta", "completed", "a", "Phase", "1", "clinical", "study", "for", "ADYNOVATE", "TM", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "2012,", "Baxter", "completed", "a", "Phase", "1", "clinical", "study", "for", "BAX", "855", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "BAX", "855", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "hemophilia", "A."], "wordsB": ["In", "2012,", "Baxalta", "completed", "a", "Phase", "1", "clinical", "study", "for", "ADYNOVATE", "TM", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p89_s1", "idA": "906709_15_item1_p89_s1", "sentA": "In January 2013, Baxter announced the top level results from this Phase 1 clinical study.", "sentB": "In January 2013, Baxalta announced the top level results from this Phase 1 clinical study.", "type": 2, "words": ["<tag1>", "In", "January", "2013,", "Baxter", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study.", "<tag2>", "In", "January", "2013,", "Baxalta", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study.", "<tag3>"], "wordsA": ["In", "January", "2013,", "Baxter", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study."], "wordsB": ["In", "January", "2013,", "Baxalta", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p89_s2", "idA": "906709_15_item1_p89_s2", "sentA": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of BAX 855 was approximately 1.5-fold higher compared to ADVATE.", "sentB": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of ADYNOVATE TM was approximately 1.5-fold higher compared to ADVATE .", "type": 2, "words": ["<tag1>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE.", "<tag2>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "TM", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", ".", "<tag3>"], "wordsA": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "BAX", "855", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE."], "wordsB": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "TM", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p89_s3", "idA": "906709_15_item1_p89_s3", "sentA": "A longer half-life was achieved in all patients in the study using BAX 855, no patients developed inhibitors to either base molecule, BAX 855 or PEG, and no patients had allergic reactions.", "sentB": "A longer half-life was achieved in all patients in the study using ADYNOVATE TM , no patients developed inhibitors to either base molecule, ADYNOVATE TM or PEG, and no patients had allergic reactions.", "type": 2, "words": ["<tag1>", "A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "BAX", "855,", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "BAX", "855", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions.", "<tag2>", "A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "ADYNOVATE", "TM", ",", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "ADYNOVATE", "TM", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions.", "<tag3>"], "wordsA": ["A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "BAX", "855,", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "BAX", "855", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions."], "wordsB": ["A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "ADYNOVATE", "TM", ",", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "ADYNOVATE", "TM", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s9", "idA": "906709_15_item1_p89_s4", "sentA": "Eleven adverse events were reported in eight patients across both treatment arms, but none was serious, treatment-related or resulted in withdrawal from the study.", "sentB": "In addition, no treatment-related serious adverse events were reported.", "type": 2, "words": ["<tag1>", "Eleven", "adverse", "events", "were", "reported", "in", "eight", "patients", "across", "both", "treatment", "arms,", "but", "none", "was", "serious,", "treatment-related", "or", "resulted", "in", "withdrawal", "from", "the", "study.", "<tag2>", "In", "addition,", "no", "treatment-related", "serious", "adverse", "events", "were", "reported.", "<tag3>"], "wordsA": ["Eleven", "adverse", "events", "were", "reported", "in", "eight", "patients", "across", "both", "treatment", "arms,", "but", "none", "was", "serious,", "treatment-related", "or", "resulted", "in", "withdrawal", "from", "the", "study."], "wordsB": ["In", "addition,", "no", "treatment-related", "serious", "adverse", "events", "were", "reported."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p3_s3", "idA": "906709_15_item1_p90_s0", "sentA": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "In December 2015, Baxalta announced positive Phase 3 study results of ADYNOVATE TM in patients younger than 12 years of age with severe Hemophilia A. With the study results, Baxalta announced that it plans to file for marketing authorization in the European Union and aims to file for a pediatric indication in the U.S. in early 2016.", "type": 2, "words": ["<tag1>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "In", "December", "2015,", "Baxalta", "announced", "positive", "Phase", "3", "study", "results", "of", "ADYNOVATE", "TM", "in", "patients", "younger", "than", "12", "years", "of", "age", "with", "severe", "Hemophilia", "A.", "With", "the", "study", "results,", "Baxalta", "announced", "that", "it", "plans", "to", "file", "for", "marketing", "authorization", "in", "the", "European", "Union", "and", "aims", "to", "file", "for", "a", "pediatric", "indication", "in", "the", "U.S.", "in", "early", "2016.", "<tag3>"], "wordsA": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["In", "December", "2015,", "Baxalta", "announced", "positive", "Phase", "3", "study", "results", "of", "ADYNOVATE", "TM", "in", "patients", "younger", "than", "12", "years", "of", "age", "with", "severe", "Hemophilia", "A.", "With", "the", "study", "results,", "Baxalta", "announced", "that", "it", "plans", "to", "file", "for", "marketing", "authorization", "in", "the", "European", "Union", "and", "aims", "to", "file", "for", "a", "pediatric", "indication", "in", "the", "U.S.", "in", "early", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s0", "idA": "906709_15_item1_p90_s0", "sentA": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "Baxalta commenced patient enrollment in a Phase 3 clinical study of ADYNOVATE TM in the U.S. in February 2013 and completed enrollment in November 2013.", "type": 2, "words": ["<tag1>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag3>"], "wordsA": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s10", "idA": "906709_15_item1_p90_s0", "sentA": "Baxter commenced patient enrollment in a Phase 3 clinical study of BAX 855 in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "With the study results, Baxalta announced that it plans to file for marketing authorization in Europe and aims to file for a pediatric indication in the U.S. in early 2016.", "type": 2, "words": ["<tag1>", "Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "With", "the", "study", "results,", "Baxalta", "announced", "that", "it", "plans", "to", "file", "for", "marketing", "authorization", "in", "Europe", "and", "aims", "to", "file", "for", "a", "pediatric", "indication", "in", "the", "U.S.", "in", "early", "2016.", "<tag3>"], "wordsA": ["Baxter", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "BAX", "855", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["With", "the", "study", "results,", "Baxalta", "announced", "that", "it", "plans", "to", "file", "for", "marketing", "authorization", "in", "Europe", "and", "aims", "to", "file", "for", "a", "pediatric", "indication", "in", "the", "U.S.", "in", "early", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s1", "idA": "906709_15_item1_p90_s1", "sentA": "The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146 previously treated adult patients with severe hemophilia A in order to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146 previously treated adult patients with severe Hemophilia A in order to assess the efficacy, safety and pharmacokinetics of ADYNOVATE TM for prophylaxis and on-demand treatment of bleeding.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "Hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag3>"], "wordsA": ["The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "Hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s6", "idA": "906709_15_item1_p90_s1", "sentA": "The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146 previously treated adult patients with severe hemophilia A in order to assess the efficacy, safety and pharmacokinetics of BAX 855 for prophylaxis and on-demand treatment of bleeding.", "sentB": "The study enrolled 73 previously-treated patients (PTPs) with severe Hemophilia A younger than 12 years of age and assessed the treatment s hemostatic efficacy in prophylaxis and treatment of bleeding episodes.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "The", "study", "enrolled", "73", "previously-treated", "patients", "(PTPs)", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes.", "<tag3>"], "wordsA": ["The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "BAX", "855", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["The", "study", "enrolled", "73", "previously-treated", "patients", "(PTPs)", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s2", "idA": "906709_15_item1_p90_s2", "sentA": "In August 2014, Baxter announced positive top-line results from the PROLONG-ATE clinical study which met the primary endpoint for the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older.", "sentB": "In August 2014, Baxalta announced positive top-line results from the PROLONG-ATE clinical study which met the primary endpoint for the control and prevention of bleeding, routine prophylaxis and perioperative management for patients who were 12 years or older.", "type": 2, "words": ["<tag1>", "In", "August", "2014,", "Baxter", "announced", "positive", "top-line", "results", "from", "the", "PROLONG-ATE", "clinical", "study", "which", "met", "the", "primary", "endpoint", "for", "the", "control", "and", "prevention", "of", "bleeding,", "routine", "prophylaxis", "and", "perioperative", "management", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag2>", "In", "August", "2014,", "Baxalta", "announced", "positive", "top-line", "results", "from", "the", "PROLONG-ATE", "clinical", "study", "which", "met", "the", "primary", "endpoint", "for", "the", "control", "and", "prevention", "of", "bleeding,", "routine", "prophylaxis", "and", "perioperative", "management", "for", "patients", "who", "were", "12", "years", "or", "older.", "<tag3>"], "wordsA": ["In", "August", "2014,", "Baxter", "announced", "positive", "top-line", "results", "from", "the", "PROLONG-ATE", "clinical", "study", "which", "met", "the", "primary", "endpoint", "for", "the", "control", "and", "prevention", "of", "bleeding,", "routine", "prophylaxis", "and", "perioperative", "management", "for", "patients", "who", "were", "12", "years", "or", "older."], "wordsB": ["In", "August", "2014,", "Baxalta", "announced", "positive", "top-line", "results", "from", "the", "PROLONG-ATE", "clinical", "study", "which", "met", "the", "primary", "endpoint", "for", "the", "control", "and", "prevention", "of", "bleeding,", "routine", "prophylaxis", "and", "perioperative", "management", "for", "patients", "who", "were", "12", "years", "or", "older."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p52_s1", "idA": "906709_15_item1_p90_s3", "sentA": "In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855.", "sentB": "In December 2014, Baxalta announced that it filed a biologic license application with the FDA for ADYNOVATE TM .", "type": 2, "words": ["<tag1>", "In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855.", "<tag2>", "In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "TM", ".", "<tag3>"], "wordsA": ["In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855."], "wordsB": ["In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p90_s3", "idA": "906709_15_item1_p90_s3", "sentA": "In December 2014, Baxter announced that it filed a biologic license application with the FDA for BAX 855.", "sentB": "In December 2014, Baxalta announced that it filed a biologic license application with the FDA for ADYNOVATE TM .", "type": 2, "words": ["<tag1>", "In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855.", "<tag2>", "In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "TM", ".", "<tag3>"], "wordsA": ["In", "December", "2014,", "Baxter", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "BAX", "855."], "wordsB": ["In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p166_s4", "idA": "906709_15_item1_p91_s2", "sentA": "However, we retained our economic interest in the future potential net sales royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer.", "sentB": "These programs, if developed successfully and approved by health authorities, would be competitors in the longer acting Factor VIII market.", "type": 2, "words": ["<tag1>", "However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer.", "<tag2>", "These", "programs,", "if", "developed", "successfully", "and", "approved", "by", "health", "authorities,", "would", "be", "competitors", "in", "the", "longer", "acting", "Factor", "VIII", "market.", "<tag3>"], "wordsA": ["However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer."], "wordsB": ["These", "programs,", "if", "developed", "successfully", "and", "approved", "by", "health", "authorities,", "would", "be", "competitors", "in", "the", "longer", "acting", "Factor", "VIII", "market."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p166_s3", "idA": "906709_15_item1_p92_s1", "sentA": "In August 2012, Bayer initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis.", "sentB": "Bayer Healthcare and Novo Nordisk have ongoing Phase 3 clinical development programs for longer acting Factor VIII proteins based on pegylation technology approaches.", "type": 2, "words": ["<tag1>", "In", "August", "2012,", "Bayer", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag2>", "Bayer", "Healthcare", "and", "Novo", "Nordisk", "have", "ongoing", "Phase", "3", "clinical", "development", "programs", "for", "longer", "acting", "Factor", "VIII", "proteins", "based", "on", "pegylation", "technology", "approaches.", "<tag3>"], "wordsA": ["In", "August", "2012,", "Bayer", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "wordsB": ["Bayer", "Healthcare", "and", "Novo", "Nordisk", "have", "ongoing", "Phase", "3", "clinical", "development", "programs", "for", "longer", "acting", "Factor", "VIII", "proteins", "based", "on", "pegylation", "technology", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p97_s1", "idA": "906709_15_item1_p95_s1", "sentA": "Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are eligible for fast-track designation, priority review by FDA and a five-year extension of market exclusivity.", "sentB": "Antimicrobial drugs designed to treat serious and life-threatening infections, designated as QIDP, are eligible for fast-track des ignation, priority review by FDA and a five-year extension of market exclusivity.", "type": 2, "words": ["<tag1>", "Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "designation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity.", "<tag2>", "Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "des", "ignation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity.", "<tag3>"], "wordsA": ["Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "designation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity."], "wordsB": ["Antimicrobial", "drugs", "designed", "to", "treat", "serious", "and", "life-threatening", "infections,", "designated", "as", "QIDP,", "are", "eligible", "for", "fast-track", "des", "ignation,", "priority", "review", "by", "FDA", "and", "a", "five-year", "extension", "of", "market", "exclusivity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p99_s2", "idA": "906709_15_item1_p97_s2", "sentA": "Under our agreement with Ophthotech, in June 2014 we received a $19.75 million payment in connection with this licensing agreement.", "sentB": "Under our agreement with Ophthotech, we received a $19.75 million payment in June 2014 in connection with this licensing agreement.", "type": 2, "words": ["<tag1>", "Under", "our", "agreement", "with", "Ophthotech,", "in", "June", "2014", "we", "received", "a", "$19.75", "million", "payment", "in", "connection", "with", "this", "licensing", "agreement.", "<tag2>", "Under", "our", "agreement", "with", "Ophthotech,", "we", "received", "a", "$19.75", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement.", "<tag3>"], "wordsA": ["Under", "our", "agreement", "with", "Ophthotech,", "in", "June", "2014", "we", "received", "a", "$19.75", "million", "payment", "in", "connection", "with", "this", "licensing", "agreement."], "wordsB": ["Under", "our", "agreement", "with", "Ophthotech,", "we", "received", "a", "$19.75", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p106_s1", "idA": "906709_15_item1_p97_s4", "sentA": "Our right to receive royalties in any particular country will expire upon the later of ten years after first commercial sale of the product or expiration of patent rights in the particular country.", "sentB": "Our right to receive royalties in any particular country will expire upon the later of twelve years after first commercial sale of the product or expiration of patent rights in the particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "twelve", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "twelve", "years", "after", "first", "commercial", "sale", "of", "the", "product", "or", "expiration", "of", "patent", "rights", "in", "the", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p99_s5", "idA": "906709_15_item1_p97_s5", "sentA": "We are the exclusive supplier for all of Ophthotech s clinical and future commercial requirements of our proprietary PEGylation reagent used in the manufacture of Fovista .", "sentB": "We are the exclusive supplier for all of Ophthotech s clinical and future commercial requirements of our proprietary PEGylation materials used in the manufacture of Fovista .", "type": 2, "words": ["<tag1>", "We", "are", "the", "exclusive", "supplier", "for", "all", "of", "Ophthotech", "s", "clinical", "and", "future", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", ".", "<tag2>", "We", "are", "the", "exclusive", "supplier", "for", "all", "of", "Ophthotech", "s", "clinical", "and", "future", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "materials", "used", "in", "the", "manufacture", "of", "Fovista", ".", "<tag3>"], "wordsA": ["We", "are", "the", "exclusive", "supplier", "for", "all", "of", "Ophthotech", "s", "clinical", "and", "future", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "reagent", "used", "in", "the", "manufacture", "of", "Fovista", "."], "wordsB": ["We", "are", "the", "exclusive", "supplier", "for", "all", "of", "Ophthotech", "s", "clinical", "and", "future", "commercial", "requirements", "of", "our", "proprietary", "PEGylation", "materials", "used", "in", "the", "manufacture", "of", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p6_s2", "idA": "906709_15_item1_p98_s1", "sentA": "Fovista met the pre-specified primary efficacy endpoint of mean vision gain.", "sentB": "The IAC s determination is nondiscretionary and was based upon our determination of pre-defined acceptable power to detect a statistically significant difference between NKTR-181 and placebo based on the primary efficacy endpoint.", "type": 2, "words": ["<tag1>", "Fovista", "met", "the", "pre-specified", "primary", "efficacy", "endpoint", "of", "mean", "vision", "gain.", "<tag2>", "The", "IAC", "s", "determination", "is", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint.", "<tag3>"], "wordsA": ["Fovista", "met", "the", "pre-specified", "primary", "efficacy", "endpoint", "of", "mean", "vision", "gain."], "wordsB": ["The", "IAC", "s", "determination", "is", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_16_item1_p5_s0", "idA": "906709_15_item1_p9_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions.", "sentB": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions.", "<tag2>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions."], "wordsB": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p0_s3", "idA": "906709_16_item1_p0_s0", "sentA": "We are a biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.", "sentB": "These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.", "type": 2, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "developing", "a", "pipeline", "of", "drug", "candidates", "that", "utilize", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag2>", "These", "drug", "candidates", "utilize", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "developing", "a", "pipeline", "of", "drug", "candidates", "that", "utilize", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "wordsB": ["These", "drug", "candidates", "utilize", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "which", "are", "designed", "to", "enable", "the", "development", "of", "new", "molecular", "entities", "that", "target", "known", "mechanisms", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p0_s1", "idA": "906709_16_item1_p0_s2", "sentA": "Our research and development activities involve small molecule drugs, peptides and protein biologic drug candidates.", "sentB": "Our research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "protein", "biologic", "drug", "candidates.", "<tag2>", "Our", "research", "and", "development", "pipeline", "of", "new", "investigational", "drugs", "includes", "treatments", "for", "cancer,", "auto-immune", "disease", "and", "chronic", "pain.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "activities", "involve", "small", "molecule", "drugs,", "peptides", "and", "protein", "biologic", "drug", "candidates."], "wordsB": ["Our", "research", "and", "development", "pipeline", "of", "new", "investigational", "drugs", "includes", "treatments", "for", "cancer,", "auto-immune", "disease", "and", "chronic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p103_s2", "idA": "906709_16_item1_p101_s0", "sentA": "In September 2013, Ophthotech announced the initiation of patient enrollment in the first of three planned pivotal Phase 3 clinical studies of Fovista in combination with anti-VEGF therapy for the treatment of newly diagnosed patients with wet AMD.", "sentB": "In December 2016, Ophthotech announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista (pegpleranib) anti-PDGF therapy in combination with Lucentis (ranibizumab) anti-VEGF therapy compared to Lucentis monotherapy for the treatment of wet age-related macular degeneration (AMD).", "type": 2, "words": ["<tag1>", "In", "September", "2013,", "Ophthotech", "announced", "the", "initiation", "of", "patient", "enrollment", "in", "the", "first", "of", "three", "planned", "pivotal", "Phase", "3", "clinical", "studies", "of", "Fovista", "in", "combination", "with", "anti-VEGF", "therapy", "for", "the", "treatment", "of", "newly", "diagnosed", "patients", "with", "wet", "AMD.", "<tag2>", "In", "December", "2016,", "Ophthotech", "announced", "that", "the", "pre-specified", "primary", "endpoint", "of", "mean", "change", "in", "visual", "acuity", "at", "12", "months", "was", "not", "achieved", "in", "its", "two", "pivotal", "Phase", "3", "clinical", "trials", "investigating", "the", "superiority", "of", "Fovista", "(pegpleranib)", "anti-PDGF", "therapy", "in", "combination", "with", "Lucentis", "(ranibizumab)", "anti-VEGF", "therapy", "compared", "to", "Lucentis", "monotherapy", "for", "the", "treatment", "of", "wet", "age-related", "macular", "degeneration", "(AMD).", "<tag3>"], "wordsA": ["In", "September", "2013,", "Ophthotech", "announced", "the", "initiation", "of", "patient", "enrollment", "in", "the", "first", "of", "three", "planned", "pivotal", "Phase", "3", "clinical", "studies", "of", "Fovista", "in", "combination", "with", "anti-VEGF", "therapy", "for", "the", "treatment", "of", "newly", "diagnosed", "patients", "with", "wet", "AMD."], "wordsB": ["In", "December", "2016,", "Ophthotech", "announced", "that", "the", "pre-specified", "primary", "endpoint", "of", "mean", "change", "in", "visual", "acuity", "at", "12", "months", "was", "not", "achieved", "in", "its", "two", "pivotal", "Phase", "3", "clinical", "trials", "investigating", "the", "superiority", "of", "Fovista", "(pegpleranib)", "anti-PDGF", "therapy", "in", "combination", "with", "Lucentis", "(ranibizumab)", "anti-VEGF", "therapy", "compared", "to", "Lucentis", "monotherapy", "for", "the", "treatment", "of", "wet", "age-related", "macular", "degeneration", "(AMD)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p103_s1", "idA": "906709_16_item1_p101_s1", "sentA": "These three studies plan to enroll a total of approximately 1,866 patients to evaluate the efficacy and safety of Fovista .", "sentB": "These three studies were to enroll a total of approximately 1,866 patients to evaluate the efficacy and safety of Fovista .", "type": 2, "words": ["<tag1>", "These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", ".", "<tag2>", "These", "three", "studies", "were", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", ".", "<tag3>"], "wordsA": ["These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", "."], "wordsB": ["These", "three", "studies", "were", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p113_s4", "idA": "906709_16_item1_p101_s1", "sentA": "These three studies plan to enroll a total of approximately 1,866 patients to evaluate the efficacy and safety of Fovista .", "sentB": "In 2016, UCB initiated a multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging Phase 2 clinical study followed by an observational period to evaluate the efficacy and safety of patients with moderately to severely active SLE receiving stable standard of care medications.", "type": 2, "words": ["<tag1>", "These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", ".", "<tag2>", "In", "2016,", "UCB", "initiated", "a", "multi-center,", "randomized,", "double-blind,", "placebo-controlled,", "parallel-group,", "dose-ranging", "Phase", "2", "clinical", "study", "followed", "by", "an", "observational", "period", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "patients", "with", "moderately", "to", "severely", "active", "SLE", "receiving", "stable", "standard", "of", "care", "medications.", "<tag3>"], "wordsA": ["These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", "."], "wordsB": ["In", "2016,", "UCB", "initiated", "a", "multi-center,", "randomized,", "double-blind,", "placebo-controlled,", "parallel-group,", "dose-ranging", "Phase", "2", "clinical", "study", "followed", "by", "an", "observational", "period", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "patients", "with", "moderately", "to", "severely", "active", "SLE", "receiving", "stable", "standard", "of", "care", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p94_s0", "idA": "906709_16_item1_p101_s1", "sentA": "These three studies plan to enroll a total of approximately 1,866 patients to evaluate the efficacy and safety of Fovista .", "sentB": "In April 2013, Bayer initiated enrollment in a global Phase 3 clinical study, which it calls INHALE, to evaluate the efficacy and safety of Amikacin Inhale versus aerosolized placebo in the treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia receiving standard of care intravenous antibiotics.", "type": 2, "words": ["<tag1>", "These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", ".", "<tag2>", "In", "April", "2013,", "Bayer", "initiated", "enrollment", "in", "a", "global", "Phase", "3", "clinical", "study,", "which", "it", "calls", "INHALE,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Amikacin", "Inhale", "versus", "aerosolized", "placebo", "in", "the", "treatment", "of", "intubated", "and", "mechanically", "ventilated", "patients", "with", "Gram-negative", "pneumonia", "receiving", "standard", "of", "care", "intravenous", "antibiotics.", "<tag3>"], "wordsA": ["These", "three", "studies", "plan", "to", "enroll", "a", "total", "of", "approximately", "1,866", "patients", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Fovista", "."], "wordsB": ["In", "April", "2013,", "Bayer", "initiated", "enrollment", "in", "a", "global", "Phase", "3", "clinical", "study,", "which", "it", "calls", "INHALE,", "to", "evaluate", "the", "efficacy", "and", "safety", "of", "Amikacin", "Inhale", "versus", "aerosolized", "placebo", "in", "the", "treatment", "of", "intubated", "and", "mechanically", "ventilated", "patients", "with", "Gram-negative", "pneumonia", "receiving", "standard", "of", "care", "intravenous", "antibiotics."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p104_s1", "idA": "906709_16_item1_p102_s1", "sentA": "In December 2006, we entered into a license agreement with Halozyme Therapeutics, Inc. (Halozyme), under which we granted Halozyme a worldwide, limited exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation materials linked only with certain qualifying hyaluronidase protein molecules including PEGPH20.", "sentB": "In December 2006, we entered into a license agreement with Halozyme pursuant to which we granted Halozyme a worldwide, limited exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize particular products that use our proprietary PEGylation materials linked only with certain qualifying hyaluronidase protein molecules including PEGPH20.", "type": 2, "words": ["<tag1>", "In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "(Halozyme),", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "materials", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20.", "<tag2>", "In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme", "pursuant", "to", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "materials", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20.", "<tag3>"], "wordsA": ["In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme", "Therapeutics,", "Inc.", "(Halozyme),", "under", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "materials", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20."], "wordsB": ["In", "December", "2006,", "we", "entered", "into", "a", "license", "agreement", "with", "Halozyme", "pursuant", "to", "which", "we", "granted", "Halozyme", "a", "worldwide,", "limited", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "particular", "products", "that", "use", "our", "proprietary", "PEGylation", "materials", "linked", "only", "with", "certain", "qualifying", "hyaluronidase", "protein", "molecules", "including", "PEGPH20."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p3_s2", "idA": "906709_16_item1_p103_s0", "sentA": "According to Halozyme, certain cancers, including pancreatic, breast, colon and prostate, have been shown to accumulate high levels of hyaluronan (HA).", "sentB": "NKTR-255 has also been shown to stimulate NK cell development.", "type": 2, "words": ["<tag1>", "According", "to", "Halozyme,", "certain", "cancers,", "including", "pancreatic,", "breast,", "colon", "and", "prostate,", "have", "been", "shown", "to", "accumulate", "high", "levels", "of", "hyaluronan", "(HA).", "<tag2>", "NKTR-255", "has", "also", "been", "shown", "to", "stimulate", "NK", "cell", "development.", "<tag3>"], "wordsA": ["According", "to", "Halozyme,", "certain", "cancers,", "including", "pancreatic,", "breast,", "colon", "and", "prostate,", "have", "been", "shown", "to", "accumulate", "high", "levels", "of", "hyaluronan", "(HA)."], "wordsB": ["NKTR-255", "has", "also", "been", "shown", "to", "stimulate", "NK", "cell", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p106_s2", "idA": "906709_16_item1_p104_s1", "sentA": "Halozyme is currently evaluating PEGPH20 in a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer.", "sentB": "On January 5, 2017 Halozyme announced positive topline results from the Phase 2 clinical trial of PEGPH20 in combination with ABRAXANE in stage IV pancreas cancer patients.", "type": 2, "words": ["<tag1>", "Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer.", "<tag2>", "On", "January", "5,", "2017", "Halozyme", "announced", "positive", "topline", "results", "from", "the", "Phase", "2", "clinical", "trial", "of", "PEGPH20", "in", "combination", "with", "ABRAXANE", "in", "stage", "IV", "pancreas", "cancer", "patients.", "<tag3>"], "wordsA": ["Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer."], "wordsB": ["On", "January", "5,", "2017", "Halozyme", "announced", "positive", "topline", "results", "from", "the", "Phase", "2", "clinical", "trial", "of", "PEGPH20", "in", "combination", "with", "ABRAXANE", "in", "stage", "IV", "pancreas", "cancer", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p113_s5", "idA": "906709_16_item1_p104_s1", "sentA": "Halozyme is currently evaluating PEGPH20 in a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer.", "sentB": "This Phase 2 clinical trial is currently recruiting participants.", "type": 2, "words": ["<tag1>", "Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer.", "<tag2>", "This", "Phase", "2", "clinical", "trial", "is", "currently", "recruiting", "participants.", "<tag3>"], "wordsA": ["Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer."], "wordsB": ["This", "Phase", "2", "clinical", "trial", "is", "currently", "recruiting", "participants."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p74_s2", "idA": "906709_16_item1_p106_s0", "sentA": "We are entitled to future development milestones and royalties on net sales subject to reduction in the absence of patent coverage.", "sentB": "We typically receive consideration from our collaboration partners in the form of upfront payments, or milestone payment and royalties on sales.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "future", "development", "milestones", "and", "royalties", "on", "net", "sales", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage.", "<tag2>", "We", "typically", "receive", "consideration", "from", "our", "collaboration", "partners", "in", "the", "form", "of", "upfront", "payments,", "or", "milestone", "payment", "and", "royalties", "on", "sales.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "future", "development", "milestones", "and", "royalties", "on", "net", "sales", "subject", "to", "reduction", "in", "the", "absence", "of", "patent", "coverage."], "wordsB": ["We", "typically", "receive", "consideration", "from", "our", "collaboration", "partners", "in", "the", "form", "of", "upfront", "payments,", "or", "milestone", "payment", "and", "royalties", "on", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p109_s2", "idA": "906709_16_item1_p108_s0", "sentA": "agreement, we have the right to receive certain milestone payments based on development criteria that are solely t he responsibility of MAP and royalties based on net sales of SEMPRANA .", "sentB": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of SEMPRANA .", "type": 2, "words": ["<tag1>", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "t", "he", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag3>"], "wordsA": ["agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "t", "he", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p109_s3", "idA": "906709_16_item1_p108_s1", "sentA": "Our right to receive royalties for the net sales of SEMPRANA under the license agreement in any particular country will expire upon the later of (i) 10 years after first commercial s ale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "sentB": "Our right to receive royalties for the net sales of SEMPRANA under the license agreement in any particular country will expire upon the later of (i) 10 years after first commercial sale in that country, (ii) the date upon which the licensed know-how becomes known to the general public, and (iii) expiration of certain patent claims, each on a country-by-country basis.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "s", "ale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag2>", "Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "s", "ale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "wordsB": ["Our", "right", "to", "receive", "royalties", "for", "the", "net", "sales", "of", "SEMPRANA", "under", "the", "license", "agreement", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(i)", "10", "years", "after", "first", "commercial", "sale", "in", "that", "country,", "(ii)", "the", "date", "upon", "which", "the", "licensed", "know-how", "becomes", "known", "to", "the", "general", "public,", "and", "(iii)", "expiration", "of", "certain", "patent", "claims,", "each", "on", "a", "country-by-country", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p109_s4", "idA": "906709_16_item1_p108_s2", "sentA": "Either party may terminate the agreement upon a material, uncured de fault of the other party.", "sentB": "Either party may terminate the agreement upon a material, uncured default of the other party.", "type": 2, "words": ["<tag1>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "de", "fault", "of", "the", "other", "party.", "<tag2>", "Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party.", "<tag3>"], "wordsA": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "de", "fault", "of", "the", "other", "party."], "wordsB": ["Either", "party", "may", "terminate", "the", "agreement", "upon", "a", "material,", "uncured", "default", "of", "the", "other", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p110_s5", "idA": "906709_16_item1_p109_s5", "sentA": "Allergan has responded to the FDA s latest complete response letter and has stated that it continues to work with the FDA to resolve outstanding CMC issues.", "sentB": "Allergan has responded to the FDA s latest complete response letter and has stated that it continues to work with the FDA to resolve outstanding Chemistry, Manufacturing and Controls (CMC) issues.", "type": 2, "words": ["<tag1>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "continues", "to", "work", "with", "the", "FDA", "to", "resolve", "outstanding", "CMC", "issues.", "<tag2>", "Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "continues", "to", "work", "with", "the", "FDA", "to", "resolve", "outstanding", "Chemistry,", "Manufacturing", "and", "Controls", "(CMC)", "issues.", "<tag3>"], "wordsA": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "continues", "to", "work", "with", "the", "FDA", "to", "resolve", "outstanding", "CMC", "issues."], "wordsB": ["Allergan", "has", "responded", "to", "the", "FDA", "s", "latest", "complete", "response", "letter", "and", "has", "stated", "that", "it", "continues", "to", "work", "with", "the", "FDA", "to", "resolve", "outstanding", "Chemistry,", "Manufacturing", "and", "Controls", "(CMC)", "issues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p16_s0", "idA": "906709_16_item1_p10_s0", "sentA": "We have a collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "We also have two significant drug development programs with Bayer Healthcare LLC (Bayer).", "type": 2, "words": ["<tag1>", "We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "We", "also", "have", "two", "significant", "drug", "development", "programs", "with", "Bayer", "Healthcare", "LLC", "(Bayer).", "<tag3>"], "wordsA": ["We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["We", "also", "have", "two", "significant", "drug", "development", "programs", "with", "Bayer", "Healthcare", "LLC", "(Bayer)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p16_s1", "idA": "906709_16_item1_p10_s0", "sentA": "We have a collaboration with Bayer Healthcare LLC (Bayer) to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "sentB": "The first is a collaboration to develop BAY41-6551 (Amikacin Inhale, formerly known as NKTR-061), which is an inhaled solution of amikacin, an aminoglycoside antibiotic.", "type": 2, "words": ["<tag1>", "We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag2>", "The", "first", "is", "a", "collaboration", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic.", "<tag3>"], "wordsA": ["We", "have", "a", "collaboration", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "wordsB": ["The", "first", "is", "a", "collaboration", "to", "develop", "BAY41-6551", "(Amikacin", "Inhale,", "formerly", "known", "as", "NKTR-061),", "which", "is", "an", "inhaled", "solution", "of", "amikacin,", "an", "aminoglycoside", "antibiotic."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p16_s2", "idA": "906709_16_item1_p10_s1", "sentA": "We originally developed the NKTR-061 drug candidate and the associated liquid aerosol inhalation platform and entered into a collaboration agreement with Bayer to advance the drug candidate into further clinical development and potential commercialization.", "sentB": "We originally developed the liquid aerosol inhalation platform and the NKTR-061 drug candidate and entered into a collaboration agreement with Bayer to further advance the drug candidate s development and potential commercialization.", "type": 2, "words": ["<tag1>", "We", "originally", "developed", "the", "NKTR-061", "drug", "candidate", "and", "the", "associated", "liquid", "aerosol", "inhalation", "platform", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "advance", "the", "drug", "candidate", "into", "further", "clinical", "development", "and", "potential", "commercialization.", "<tag2>", "We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "the", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "further", "advance", "the", "drug", "candidate", "s", "development", "and", "potential", "commercialization.", "<tag3>"], "wordsA": ["We", "originally", "developed", "the", "NKTR-061", "drug", "candidate", "and", "the", "associated", "liquid", "aerosol", "inhalation", "platform", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "advance", "the", "drug", "candidate", "into", "further", "clinical", "development", "and", "potential", "commercialization."], "wordsB": ["We", "originally", "developed", "the", "liquid", "aerosol", "inhalation", "platform", "and", "the", "NKTR-061", "drug", "candidate", "and", "entered", "into", "a", "collaboration", "agreement", "with", "Bayer", "to", "further", "advance", "the", "drug", "candidate", "s", "development", "and", "potential", "commercialization."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p11_s3", "idA": "906709_16_item1_p10_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical program for Amikacin Inhale.", "sentB": "The Phase 3 program for NKTR-181 is anticipated to also include a Phase 3 efficacy and safety trial in people who are opioid-experienced.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale.", "<tag2>", "The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale."], "wordsB": ["The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p16_s3", "idA": "906709_16_item1_p10_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical program for Amikacin Inhale.", "sentB": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale.", "<tag2>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale."], "wordsB": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p55_s1", "idA": "906709_16_item1_p10_s2", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical program for Amikacin Inhale.", "sentB": "The Phase 3 program for NKTR-181 is anticipated to also include a Phase 3 efficacy and safety trial in people who are opioid-experienced.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale.", "<tag2>", "The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "program", "for", "Amikacin", "Inhale."], "wordsB": ["The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p113_s0", "idA": "906709_16_item1_p112_s0", "sentA": "In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEFylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE).", "sentB": "Dapirolizumab Pegol In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., (UCB) under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEGylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE).", "type": 2, "words": ["<tag1>", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEFylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE).", "<tag2>", "Dapirolizumab", "Pegol", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "(UCB)", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEGylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE).", "<tag3>"], "wordsA": ["In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEFylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE)."], "wordsB": ["Dapirolizumab", "Pegol", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "(UCB)", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEGylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p114_s0", "idA": "906709_16_item1_p113_s0", "sentA": "Overview of Select Licensing Partnerships for Approved Products Neulasta , Agreement with Amgen, Inc.", "sentB": "Neulasta , Agreement with Amgen, Inc.", "type": 2, "words": ["<tag1>", "Overview", "of", "Select", "Licensing", "Partnerships", "for", "Approved", "Products", "Neulasta", ",", "Agreement", "with", "Amgen,", "Inc.", "<tag2>", "Neulasta", ",", "Agreement", "with", "Amgen,", "Inc.", "<tag3>"], "wordsA": ["Overview", "of", "Select", "Licensing", "Partnerships", "for", "Approved", "Products", "Neulasta", ",", "Agreement", "with", "Amgen,", "Inc."], "wordsB": ["Neulasta", ",", "Agreement", "with", "Amgen,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p116_s7", "idA": "906709_16_item1_p117_s1", "sentA": "In the event we become subject to a bankruptcy or insolvency proceeding, we cease to own or control the manufacturing facility in Huntsville, Al abama, we fail to manufacture and supply the Polymer Materials or certain other events occur, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the dedicated equipment and access the manufacturi ng facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "sentB": "In the event we become subject to a bankruptcy or insolvency proceeding, we cease to own or control the manufacturing facility in Huntsville, Alabama, we fail to manufacture and supply the Polymer Materials or certain other events occur, Amgen or its designated third party will have the right to elect, among certain other options, to take title to the dedicated equipment and access the manufacturing facility to operate the manufacturing suite solely for the purpose of manufacturing the Polymer Materials (Additional Rights).", "type": 2, "words": ["<tag1>", "In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Al", "abama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturi", "ng", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag2>", "In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Alabama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights).", "<tag3>"], "wordsA": ["In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Al", "abama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturi", "ng", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "wordsB": ["In", "the", "event", "we", "become", "subject", "to", "a", "bankruptcy", "or", "insolvency", "proceeding,", "we", "cease", "to", "own", "or", "control", "the", "manufacturing", "facility", "in", "Huntsville,", "Alabama,", "we", "fail", "to", "manufacture", "and", "supply", "the", "Polymer", "Materials", "or", "certain", "other", "events", "occur,", "Amgen", "or", "its", "designated", "third", "party", "will", "have", "the", "right", "to", "elect,", "among", "certain", "other", "options,", "to", "take", "title", "to", "the", "dedicated", "equipment", "and", "access", "the", "manufacturing", "facility", "to", "operate", "the", "manufacturing", "suite", "solely", "for", "the", "purpose", "of", "manufacturing", "the", "Polymer", "Materials", "(Additional", "Rights)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p3_s1", "idA": "906709_16_item1_p119_s0", "sentA": "PEGASYS is approved in the U.S., EU and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "sentB": "Signaling of the IL-15 pathway induces the proliferation and growth of CD8 memory T cells so the body s immune system retains the ability to identify cancer cells if they re-grow in the body.", "type": 2, "words": ["<tag1>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "EU", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag2>", "Signaling", "of", "the", "IL-15", "pathway", "induces", "the", "proliferation", "and", "growth", "of", "CD8", "memory", "T", "cells", "so", "the", "body", "s", "immune", "system", "retains", "the", "ability", "to", "identify", "cancer", "cells", "if", "they", "re-grow", "in", "the", "body.", "<tag3>"], "wordsA": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "EU", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "wordsB": ["Signaling", "of", "the", "IL-15", "pathway", "induces", "the", "proliferation", "and", "growth", "of", "CD8", "memory", "T", "cells", "so", "the", "body", "s", "immune", "system", "retains", "the", "ability", "to", "identify", "cancer", "cells", "if", "they", "re-grow", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p46_s0", "idA": "906709_16_item1_p119_s0", "sentA": "PEGASYS is approved in the U.S., EU and other countries for the treatment of Hepatitis C and is designed to help the patient s immune system fight the Hepatitis C virus.", "sentB": "Immunology NKTR-358 is designed to correct the underlying immune system imbalance in the body which occurs in patients with auto-immune disease.", "type": 2, "words": ["<tag1>", "PEGASYS", "is", "approved", "in", "the", "U.S.,", "EU", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus.", "<tag2>", "Immunology", "NKTR-358", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease.", "<tag3>"], "wordsA": ["PEGASYS", "is", "approved", "in", "the", "U.S.,", "EU", "and", "other", "countries", "for", "the", "treatment", "of", "Hepatitis", "C", "and", "is", "designed", "to", "help", "the", "patient", "s", "immune", "system", "fight", "the", "Hepatitis", "C", "virus."], "wordsB": ["Immunology", "NKTR-358", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p118_s3", "idA": "906709_16_item1_p119_s3", "sentA": "In August 2013, we agreed to deliver additional quantities of PEGylation materials used by Roche to produce PEGASYS and MIRCERA , all of which were delivered in the last quarter of 2013, for total consideration of approximately $18.6 million.", "sentB": "In 2013, we delivered additional quantities of PEGylation materials used by Roche to produce PEGASYS and MIRCERA for total consideration of approximately $18.6 million.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million.", "<tag2>", "In", "2013,", "we", "delivered", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", "for", "total", "consideration", "of", "approximately", "$18.6", "million.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million."], "wordsB": ["In", "2013,", "we", "delivered", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", "for", "total", "consideration", "of", "approximately", "$18.6", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p129_s4", "idA": "906709_16_item1_p119_s3", "sentA": "In August 2013, we agreed to deliver additional quantities of PEGylation materials used by Roche to produce PEGASYS and MIRCERA , all of which were delivered in the last quarter of 2013, for total consideration of approximately $18.6 million.", "sentB": "In 2013, we delivered additional quantities of PEGylation materials used by Roche to produce PEGASYS and MIRCERA for total consideration of approximately $18.6 million.", "type": 2, "words": ["<tag1>", "In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million.", "<tag2>", "In", "2013,", "we", "delivered", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", "for", "total", "consideration", "of", "approximately", "$18.6", "million.", "<tag3>"], "wordsA": ["In", "August", "2013,", "we", "agreed", "to", "deliver", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", ",", "all", "of", "which", "were", "delivered", "in", "the", "last", "quarter", "of", "2013,", "for", "total", "consideration", "of", "approximately", "$18.6", "million."], "wordsB": ["In", "2013,", "we", "delivered", "additional", "quantities", "of", "PEGylation", "materials", "used", "by", "Roche", "to", "produce", "PEGASYS", "and", "MIRCERA", "for", "total", "consideration", "of", "approximately", "$18.6", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p129_s8", "idA": "906709_16_item1_p119_s5", "sentA": "As of December 31, 2015, we no longer have any continuing manufacturing or supply obligations under this PEGASYS agreement.", "sentB": "As of December 31, 2016, we no longer have any continuing manufacturing or supply obligations under this MIRCERA agreement.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2015,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement.", "<tag2>", "As", "of", "December", "31,", "2016,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2015,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement."], "wordsB": ["As", "of", "December", "31,", "2016,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p17_s5", "idA": "906709_16_item1_p11_s3", "sentA": "We also have a number of license, manufacturing and supply agreements with other leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Merck Co., Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd (Roche).", "sentB": "We also have a number of license, manufacturing and supply agreements with other leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Opthotech Corporation (Fovista), Merck Co., Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd (Roche).", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche).", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Opthotech", "Corporation", "(Fovista),", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche).", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Opthotech", "Corporation", "(Fovista),", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p119_s0", "idA": "906709_16_item1_p120_s0", "sentA": "Somavert , Agreement with Pfizer, Inc.", "sentB": "Somave rt , Agreement with Pfizer, Inc.", "type": 2, "words": ["<tag1>", "Somavert", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag2>", "Somave", "rt", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag3>"], "wordsA": ["Somavert", ",", "Agreement", "with", "Pfizer,", "Inc."], "wordsB": ["Somave", "rt", ",", "Agreement", "with", "Pfizer,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p120_s3", "idA": "906709_16_item1_p121_s1", "sentA": "We currently manufacture our proprietary PEGylation reagent for Pfizer, Inc. on a price per gram basis.", "sentB": "It is anticipated that Nektar will continue to supply Pfizer with proprietary PEGylation reagent under a new agreement.", "type": 2, "words": ["<tag1>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "reagent", "for", "Pfizer,", "Inc.", "on", "a", "price", "per", "gram", "basis.", "<tag2>", "It", "is", "anticipated", "that", "Nektar", "will", "continue", "to", "supply", "Pfizer", "with", "proprietary", "PEGylation", "reagent", "under", "a", "new", "agreement.", "<tag3>"], "wordsA": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "reagent", "for", "Pfizer,", "Inc.", "on", "a", "price", "per", "gram", "basis."], "wordsB": ["It", "is", "anticipated", "that", "Nektar", "will", "continue", "to", "supply", "Pfizer", "with", "proprietary", "PEGylation", "reagent", "under", "a", "new", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p123_s3", "idA": "906709_16_item1_p124_s3", "sentA": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc.", "sentB": "We share a portion of the payments received under this agreement with Enzon Pharmaceuticals, Inc. pursuant to the terms of the Cross-License and Option Agreement we have with them.", "type": 2, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag2>", "We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "pursuant", "to", "the", "terms", "of", "the", "Cross-License", "and", "Option", "Agreement", "we", "have", "with", "them.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc."], "wordsB": ["We", "share", "a", "portion", "of", "the", "payments", "received", "under", "this", "agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "pursuant", "to", "the", "terms", "of", "the", "Cross-License", "and", "Option", "Agreement", "we", "have", "with", "them."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p123_s4", "idA": "906709_16_item1_p124_s4", "sentA": "The agreement expires upon the expiration of our last relevant patent containing a valid claim.", "sentB": "Our Agreement expires upon the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "Our", "Agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["Our", "Agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p42_s0", "idA": "906709_16_item1_p125_s1", "sentA": "Under the terms of the agreement, UCB is responsible for all clinical development, regulatory, and commercialization expenses.", "sentB": "Under the BMS Agreement, BMS is responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organization, laboratories, clinical sites and institutional review boards.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses.", "<tag2>", "Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "UCB", "is", "responsible", "for", "all", "clinical", "development,", "regulatory,", "and", "commercialization", "expenses."], "wordsB": ["Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p125_s0", "idA": "906709_16_item1_p125_s6", "sentA": "We share a portion of the payments we receive from UCB with Enzon Pharmaceuticals, Inc.", "sentB": "We share a portion of the payments we receive from UCB with Enzon Pharmaceuticals, Inc. pursuant to the terms of the Cross-License and Option Agreement we have with them.", "type": 2, "words": ["<tag1>", "We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "<tag2>", "We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "pursuant", "to", "the", "terms", "of", "the", "Cross-License", "and", "Option", "Agreement", "we", "have", "with", "them.", "<tag3>"], "wordsA": ["We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc."], "wordsB": ["We", "share", "a", "portion", "of", "the", "payments", "we", "receive", "from", "UCB", "with", "Enzon", "Pharmaceuticals,", "Inc.", "pursuant", "to", "the", "terms", "of", "the", "Cross-License", "and", "Option", "Agreement", "we", "have", "with", "them."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p125_s1", "idA": "906709_16_item1_p125_s7", "sentA": "The agreement expires upon the expiration of all of UCB s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties.", "sentB": "Our agreement with UCB Pharma expires upon the expiration of all of UCB s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties.", "type": 2, "words": ["<tag1>", "The", "agreement", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag2>", "Our", "agreement", "with", "UCB", "Pharma", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag3>"], "wordsA": ["The", "agreement", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties."], "wordsB": ["Our", "agreement", "with", "UCB", "Pharma", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p126_s0", "idA": "906709_16_item1_p126_s0", "sentA": "In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), which was amended and restated in its entirety in December 2005.", "sentB": "MIRCERA (C.E.R.A.) (Continuous Erythropoietin Receptor Activator), Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.", "type": 2, "words": ["<tag1>", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005.", "<tag2>", "MIRCERA", "(C.E.R.A.)", "(Continuous", "Erythropoietin", "Receptor", "Activator),", "Agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "<tag3>"], "wordsA": ["In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005."], "wordsB": ["MIRCERA", "(C.E.R.A.)", "(Continuous", "Erythropoietin", "Receptor", "Activator),", "Agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p18_s1", "idA": "906709_16_item1_p12_s1", "sentA": "There are also a number of other products in clinical development that incorporate our advanced PEGylation and advanced polymer conjugate technologies.", "sentB": "There are also a number of other products in clinical development that incorporate our advanced polymer conjugate technologies.", "type": 2, "words": ["<tag1>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies.", "<tag2>", "There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "polymer", "conjugate", "technologies.", "<tag3>"], "wordsA": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies."], "wordsB": ["There", "are", "also", "a", "number", "of", "other", "products", "in", "clinical", "development", "that", "incorporate", "our", "advanced", "polymer", "conjugate", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p132_s0", "idA": "906709_16_item1_p131_s0", "sentA": "submission to the FDA of an NDA for approval of a drug, a Biological License Application (BLA) for approval of a biological product or a Premarket Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)).", "sentB": "submission to the FDA of a New Drug Application (NDA) for approval of a drug, a Biological License Application (BLA) for approval of a biological product or a Premarket Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)).", "type": 2, "words": ["<tag1>", "submission", "to", "the", "FDA", "of", "an", "NDA", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k)).", "<tag2>", "submission", "to", "the", "FDA", "of", "a", "New", "Drug", "Application", "(NDA)", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k)).", "<tag3>"], "wordsA": ["submission", "to", "the", "FDA", "of", "an", "NDA", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k))."], "wordsB": ["submission", "to", "the", "FDA", "of", "a", "New", "Drug", "Application", "(NDA)", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k))."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s6", "idA": "906709_16_item1_p132_s1", "sentA": "Preclinical tests include laboratory evaluation of product chemistry and animal studies to assess the safety and efficacy of the product and its chosen formulation.", "sentB": "The second phase of the expansion cohorts is expected to evaluate the safety and efficacy of combining NKTR-214 with Opdivo .", "type": 2, "words": ["<tag1>", "Preclinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "animal", "studies", "to", "assess", "the", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "chosen", "formulation.", "<tag2>", "The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "expected", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", ".", "<tag3>"], "wordsA": ["Preclinical", "tests", "include", "laboratory", "evaluation", "of", "product", "chemistry", "and", "animal", "studies", "to", "assess", "the", "safety", "and", "efficacy", "of", "the", "product", "and", "its", "chosen", "formulation."], "wordsB": ["The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "expected", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p134_s3", "idA": "906709_16_item1_p132_s4", "sentA": "Clinical trials may begin 30 days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period.", "sentB": "Clinical trials may begin 30 days after receipt of the IND by the FDA, unless the FDA raises objections or requires c larification within that period.", "type": 2, "words": ["<tag1>", "Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "clarification", "within", "that", "period.", "<tag2>", "Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "c", "larification", "within", "that", "period.", "<tag3>"], "wordsA": ["Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "clarification", "within", "that", "period."], "wordsB": ["Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "c", "larification", "within", "that", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p135_s1", "idA": "906709_16_item1_p133_s1", "sentA": "Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP).", "sentB": "Dru g products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP).", "type": 2, "words": ["<tag1>", "Drug", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP).", "<tag2>", "Dru", "g", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP).", "<tag3>"], "wordsA": ["Drug", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP)."], "wordsB": ["Dru", "g", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s12", "idA": "906709_16_item1_p133_s2", "sentA": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "sentB": "The primary endpoint of the ATTAIN study will be overall survival (OS) and the ATTAIN study will include a pre-specified interim analysis for OS which is to be conducted after 130 events have occurred in the study.", "type": 2, "words": ["<tag1>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag2>", "The", "primary", "endpoint", "of", "the", "ATTAIN", "study", "will", "be", "overall", "survival", "(OS)", "and", "the", "ATTAIN", "study", "will", "include", "a", "pre-specified", "interim", "analysis", "for", "OS", "which", "is", "to", "be", "conducted", "after", "130", "events", "have", "occurred", "in", "the", "study.", "<tag3>"], "wordsA": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "wordsB": ["The", "primary", "endpoint", "of", "the", "ATTAIN", "study", "will", "be", "overall", "survival", "(OS)", "and", "the", "ATTAIN", "study", "will", "include", "a", "pre-specified", "interim", "analysis", "for", "OS", "which", "is", "to", "be", "conducted", "after", "130", "events", "have", "occurred", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p135_s2", "idA": "906709_16_item1_p133_s2", "sentA": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "sentB": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to moni tor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "type": 2, "words": ["<tag1>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag2>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "moni", "tor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag3>"], "wordsA": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "wordsB": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "moni", "tor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p59_s1", "idA": "906709_16_item1_p133_s2", "sentA": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "sentB": "The primary endpoint of the ATTAIN Study will be overall survival (OS) and the ATTAIN Study will include a pre-specified interim analysis for OS which is to be conducted after 130 events have occurred in the study .", "type": 2, "words": ["<tag1>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag2>", "The", "primary", "endpoint", "of", "the", "ATTAIN", "Study", "will", "be", "overall", "survival", "(OS)", "and", "the", "ATTAIN", "Study", "will", "include", "a", "pre-specified", "interim", "analysis", "for", "OS", "which", "is", "to", "be", "conducted", "after", "130", "events", "have", "occurred", "in", "the", "study", ".", "<tag3>"], "wordsA": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "wordsB": ["The", "primary", "endpoint", "of", "the", "ATTAIN", "Study", "will", "be", "overall", "survival", "(OS)", "and", "the", "ATTAIN", "Study", "will", "include", "a", "pre-specified", "interim", "analysis", "for", "OS", "which", "is", "to", "be", "conducted", "after", "130", "events", "have", "occurred", "in", "the", "study", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p29_s2", "idA": "906709_16_item1_p133_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "We have engineered different novel conjugates of IL-2 with optimized differential receptor binding to the IL-2 receptor categories in the immune system.", "type": 2, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "We", "have", "engineered", "different", "novel", "conjugates", "of", "IL-2", "with", "optimized", "differential", "receptor", "binding", "to", "the", "IL-2", "receptor", "categories", "in", "the", "immune", "system.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["We", "have", "engineered", "different", "novel", "conjugates", "of", "IL-2", "with", "optimized", "differential", "receptor", "binding", "to", "the", "IL-2", "receptor", "categories", "in", "the", "immune", "system."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p8_s2", "idA": "906709_16_item1_p133_s3", "sentA": "Each protocol is submitted to the FDA in the IND.", "sentB": "We submitted an IND for NKTR-358 with the FDA in February 2017.", "type": 2, "words": ["<tag1>", "Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND.", "<tag2>", "We", "submitted", "an", "IND", "for", "NKTR-358", "with", "the", "FDA", "in", "February", "2017.", "<tag3>"], "wordsA": ["Each", "protocol", "is", "submitted", "to", "the", "FDA", "in", "the", "IND."], "wordsB": ["We", "submitted", "an", "IND", "for", "NKTR-358", "with", "the", "FDA", "in", "February", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p17_s0", "idA": "906709_16_item1_p13_s1", "sentA": "We retai ned all of our rights to Amikacin Inhale and our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG that we transferred to Novartis as part of the transa ction.", "sentB": "The second program is the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG (Bayer Schering) that we transferred to Novartis as part of the 2008 pulmonary asset divestiture transaction.", "type": 2, "words": ["<tag1>", "We", "retai", "ned", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transa", "ction.", "<tag2>", "The", "second", "program", "is", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering)", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "2008", "pulmonary", "asset", "divestiture", "transaction.", "<tag3>"], "wordsA": ["We", "retai", "ned", "all", "of", "our", "rights", "to", "Amikacin", "Inhale", "and", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "transa", "ction."], "wordsB": ["The", "second", "program", "is", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering)", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "2008", "pulmonary", "asset", "divestiture", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p17_s1", "idA": "906709_16_item1_p13_s2", "sentA": "In August 2012, Bayer initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis.", "sentB": "In August 2012, Bayer Schering initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis.", "type": 2, "words": ["<tag1>", "In", "August", "2012,", "Bayer", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag2>", "In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag3>"], "wordsA": ["In", "August", "2012,", "Bayer", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "wordsB": ["In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p142_s4", "idA": "906709_16_item1_p141_s0", "sentA": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, e nvironmental protection and hazardous and controlled substance controls, among others.", "sentB": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance controls, among others.", "type": 2, "words": ["<tag1>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "e", "nvironmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag2>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag3>"], "wordsA": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "e", "nvironmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "wordsB": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p143_s0", "idA": "906709_16_item1_p142_s0", "sentA": "For product candidates currently under development utilizing pulmonary technology, the pulmonary inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molecule.", "sentB": "For product candidates currently under development utilizing pulmonary technology, the pulmonary inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molec ule.", "type": 2, "words": ["<tag1>", "For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molecule.", "<tag2>", "For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molec", "ule.", "<tag3>"], "wordsA": ["For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molecule."], "wordsB": ["For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molec", "ule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p144_s0", "idA": "906709_16_item1_p143_s0", "sentA": "The FDA will make a determination as to the most appropriate center and division within the agency that will assume primary responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBER are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction.", "sentB": "The FDA will make a determination as to the most appropriate center and division within the agency that will assume primary responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBE R are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction.", "type": 2, "words": ["<tag1>", "The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBER", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction.", "<tag2>", "The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBE", "R", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction.", "<tag3>"], "wordsA": ["The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBER", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction."], "wordsB": ["The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBE", "R", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p147_s0", "idA": "906709_16_item1_p146_s0", "sentA": "In situations where our partners are responsible for clinical and regulatory approval procedures, but we may participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device, PEGylation materials or drug.", "sentB": "In situations where our partners are responsible for clinical and regulatory approval procedures, we may still participate in this process by submitting to the FDA a drug master file developed and maintained by us which contains data concerning the manufacturing processes for the inhaler device, polymer conjugation materials or drug.", "type": 2, "words": ["<tag1>", "In", "situations", "where", "our", "partners", "are", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug.", "<tag2>", "In", "situations", "where", "our", "partners", "are", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "we", "may", "still", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "polymer", "conjugation", "materials", "or", "drug.", "<tag3>"], "wordsA": ["In", "situations", "where", "our", "partners", "are", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "but", "we", "may", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "PEGylation", "materials", "or", "drug."], "wordsB": ["In", "situations", "where", "our", "partners", "are", "responsible", "for", "clinical", "and", "regulatory", "approval", "procedures,", "we", "may", "still", "participate", "in", "this", "process", "by", "submitting", "to", "the", "FDA", "a", "drug", "master", "file", "developed", "and", "maintained", "by", "us", "which", "contains", "data", "concerning", "the", "manufacturing", "processes", "for", "the", "inhaler", "device,", "polymer", "conjugation", "materials", "or", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p19_s4", "idA": "906709_16_item1_p14_s4", "sentA": "Our Technology Platform As a leader in the PEGylation field, we have advanced our technology platform to include new advanced polymer conjugate chemistries and polymer technologies that can be tailored in specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs targeting numerous disease areas.", "sentB": "Our Technology Platform As a leader in the polymer conjugation field, we have advanced our technology platform to include new advanced polymer technologies that can be tailored in specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs targeting numerous disease areas.", "type": 2, "words": ["<tag1>", "Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "conjugate", "chemistries", "and", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas.", "<tag2>", "Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "polymer", "conjugation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas.", "<tag3>"], "wordsA": ["Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "PEGylation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "conjugate", "chemistries", "and", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas."], "wordsB": ["Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "polymer", "conjugation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p153_s1", "idA": "906709_16_item1_p152_s1", "sentA": "We have filed patent applications, and plan to file additional patent applications, covering various aspects of our PEGylation and advanced polymer conjugate technologies and our proprietary product candidates.", "sentB": "We have filed patent applications, and plan to file additional patent applications, covering various aspects of our advanced polymer conjugate technologies and our proprietary product candidates.", "type": 2, "words": ["<tag1>", "We", "have", "filed", "patent", "applications,", "and", "plan", "to", "file", "additional", "patent", "applications,", "covering", "various", "aspects", "of", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies", "and", "our", "proprietary", "product", "candidates.", "<tag2>", "We", "have", "filed", "patent", "applications,", "and", "plan", "to", "file", "additional", "patent", "applications,", "covering", "various", "aspects", "of", "our", "advanced", "polymer", "conjugate", "technologies", "and", "our", "proprietary", "product", "candidates.", "<tag3>"], "wordsA": ["We", "have", "filed", "patent", "applications,", "and", "plan", "to", "file", "additional", "patent", "applications,", "covering", "various", "aspects", "of", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies", "and", "our", "proprietary", "product", "candidates."], "wordsB": ["We", "have", "filed", "patent", "applications,", "and", "plan", "to", "file", "additional", "patent", "applications,", "covering", "various", "aspects", "of", "our", "advanced", "polymer", "conjugate", "technologies", "and", "our", "proprietary", "product", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p153_s3", "idA": "906709_16_item1_p152_s3", "sentA": "Our patent portfolio contains patents and patent applications that encompass our PEGylation and advanced polymer conjugate technology platforms, some of which we acquired in our acquisition of Shearwater Corporation in June 2001.", "sentB": "Our patent portfolio contains patents and patent applications that encompass our advanced polymer conjugate technology platforms, some of which we acquired in our acquisition of Shearwater Corporation in June 2001.", "type": 2, "words": ["<tag1>", "Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001.", "<tag2>", "Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001.", "<tag3>"], "wordsA": ["Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001."], "wordsB": ["Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p153_s5", "idA": "906709_16_item1_p153_s0", "sentA": "have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "sentB": "Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "type": 2, "words": ["<tag1>", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag2>", "Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag3>"], "wordsA": ["have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "wordsB": ["Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p153_s6", "idA": "906709_16_item1_p153_s1", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws an d regulations of the country or jurisdiction that issued the patent.", "sentB": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "type": 2, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "an", "d", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "an", "d", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s5", "idA": "906709_16_item1_p154_s0", "sentA": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "sentB": "On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement (BMS Agreement) with Bristol-Myers Squibb Company (BMS), pursuant to which we and BMS are collaborating to conduct Phase 1/2 clinical trials evaluating NKTR-214 and BMS human monoclonal antibody that binds PD-1, known as Opdivo (nivolumab), as a potential combination treatment regimen in five tumor types and eight potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon by the parties (each, a Combined Therapy Trial).", "type": 2, "words": ["<tag1>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag2>", "On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial).", "<tag3>"], "wordsA": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "wordsB": ["On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s3", "idA": "906709_16_item1_p154_s0", "sentA": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "sentB": "On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement (BMS Agreement) with Bristol-Myers Squibb Company (BMS), pursuant to which we and BMS are collaborating to conduct Phase 1/2 clinical trials evaluating NKTR-214 and BMS human monoclonal antibody that binds PD-1, known as Opdivo (nivolumab), as a potential combination treatment regimen in five tumor types and eight potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon by the parties (each, a Combined Therapy Trial).", "type": 2, "words": ["<tag1>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag2>", "On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial).", "<tag3>"], "wordsA": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "wordsB": ["On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p154_s1", "idA": "906709_16_item1_p154_s1", "sentA": "In certain cases, we have the option to license certain of Enzon s PEGylation patents for use in our proprietary products or for sublicenses to third parties in each case in exchange for payments to Enzon based on manufacturing profits, revenue share or royalties on net sales if a designated product candidate is approved in one or more markets.", "sentB": "In certain cases, we have the option to license certain of Enzon s PEGylation patents for use in our proprietary products or for sublicenses to third parties in each case in exchange for payments to Enzon based on manufacturing profits, revenue share or royalties on net sa les if a designated product candidate is approved in one or more markets.", "type": 2, "words": ["<tag1>", "In", "certain", "cases,", "we", "have", "the", "option", "to", "license", "certain", "of", "Enzon", "s", "PEGylation", "patents", "for", "use", "in", "our", "proprietary", "products", "or", "for", "sublicenses", "to", "third", "parties", "in", "each", "case", "in", "exchange", "for", "payments", "to", "Enzon", "based", "on", "manufacturing", "profits,", "revenue", "share", "or", "royalties", "on", "net", "sales", "if", "a", "designated", "product", "candidate", "is", "approved", "in", "one", "or", "more", "markets.", "<tag2>", "In", "certain", "cases,", "we", "have", "the", "option", "to", "license", "certain", "of", "Enzon", "s", "PEGylation", "patents", "for", "use", "in", "our", "proprietary", "products", "or", "for", "sublicenses", "to", "third", "parties", "in", "each", "case", "in", "exchange", "for", "payments", "to", "Enzon", "based", "on", "manufacturing", "profits,", "revenue", "share", "or", "royalties", "on", "net", "sa", "les", "if", "a", "designated", "product", "candidate", "is", "approved", "in", "one", "or", "more", "markets.", "<tag3>"], "wordsA": ["In", "certain", "cases,", "we", "have", "the", "option", "to", "license", "certain", "of", "Enzon", "s", "PEGylation", "patents", "for", "use", "in", "our", "proprietary", "products", "or", "for", "sublicenses", "to", "third", "parties", "in", "each", "case", "in", "exchange", "for", "payments", "to", "Enzon", "based", "on", "manufacturing", "profits,", "revenue", "share", "or", "royalties", "on", "net", "sales", "if", "a", "designated", "product", "candidate", "is", "approved", "in", "one", "or", "more", "markets."], "wordsB": ["In", "certain", "cases,", "we", "have", "the", "option", "to", "license", "certain", "of", "Enzon", "s", "PEGylation", "patents", "for", "use", "in", "our", "proprietary", "products", "or", "for", "sublicenses", "to", "third", "parties", "in", "each", "case", "in", "exchange", "for", "payments", "to", "Enzon", "based", "on", "manufacturing", "profits,", "revenue", "share", "or", "royalties", "on", "net", "sa", "les", "if", "a", "designated", "product", "candidate", "is", "approved", "in", "one", "or", "more", "markets."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p29_s0", "idA": "906709_16_item1_p155_s5", "sentA": "No assurance can be given that we can meaningfully protect our trade secrets.", "sentB": "More recently, our scientists have shown that we can also optimize relative receptor binding characteristics of large molecule conjugates.", "type": 2, "words": ["<tag1>", "No", "assurance", "can", "be", "given", "that", "we", "can", "meaningfully", "protect", "our", "trade", "secrets.", "<tag2>", "More", "recently,", "our", "scientists", "have", "shown", "that", "we", "can", "also", "optimize", "relative", "receptor", "binding", "characteristics", "of", "large", "molecule", "conjugates.", "<tag3>"], "wordsA": ["No", "assurance", "can", "be", "given", "that", "we", "can", "meaningfully", "protect", "our", "trade", "secrets."], "wordsB": ["More", "recently,", "our", "scientists", "have", "shown", "that", "we", "can", "also", "optimize", "relative", "receptor", "binding", "characteristics", "of", "large", "molecule", "conjugates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p159_s0", "idA": "906709_16_item1_p159_s0", "sentA": "It is our policy to require our employees and consultants, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us.", "sentB": "It is our policy to require our employees and consulta nts, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us.", "type": 2, "words": ["<tag1>", "It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consultants,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us.", "<tag2>", "It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consulta", "nts,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us.", "<tag3>"], "wordsA": ["It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consultants,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us."], "wordsB": ["It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consulta", "nts,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p159_s1", "idA": "906709_16_item1_p159_s1", "sentA": "These agreements provide that all confidential information developed or made known to the individual during the course of the individual s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.", "sentB": "These agreements pro vide that all confidential information developed or made known to the individual during the course of the individual s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.", "type": 2, "words": ["<tag1>", "These", "agreements", "provide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances.", "<tag2>", "These", "agreements", "pro", "vide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances.", "<tag3>"], "wordsA": ["These", "agreements", "provide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances."], "wordsB": ["These", "agreements", "pro", "vide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p160_s0", "idA": "906709_16_item1_p159_s2", "sentA": "The agreements provide that all inventions conceived by an employee shall be our property.", "sentB": "The agreements provi de that all inventions conceived by an employee shall be our property.", "type": 2, "words": ["<tag1>", "The", "agreements", "provide", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property.", "<tag2>", "The", "agreements", "provi", "de", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property.", "<tag3>"], "wordsA": ["The", "agreements", "provide", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property."], "wordsB": ["The", "agreements", "provi", "de", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p160_s3", "idA": "906709_16_item1_p159_s5", "sentA": "AstraZeneca and UCB represented 57% and 13% of our revenue, respectively, for the year ended December 31, 2015.", "sentB": "AstraZeneca, UCB, Ophthotech and Roche represented 29%, 21%, 19% and 11% of our revenue, respectively, for the year ended December 31, 2016.", "type": 2, "words": ["<tag1>", "AstraZeneca", "and", "UCB", "represented", "57%", "and", "13%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2015.", "<tag2>", "AstraZeneca,", "UCB,", "Ophthotech", "and", "Roche", "represented", "29%,", "21%,", "19%", "and", "11%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2016.", "<tag3>"], "wordsA": ["AstraZeneca", "and", "UCB", "represented", "57%", "and", "13%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2015."], "wordsB": ["AstraZeneca,", "UCB,", "Ophthotech", "and", "Roche", "represented", "29%,", "21%,", "19%", "and", "11%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p160_s4", "idA": "906709_16_item1_p159_s6", "sentA": "No other collaboration partner accounted for more than 10% of our total revenue during the year ended December 31, 2015.", "sentB": "No other collaboration partner accounted for more than 10% of our total revenue during the year ended December 31, 2016.", "type": 2, "words": ["<tag1>", "No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2015.", "<tag2>", "No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2016.", "<tag3>"], "wordsA": ["No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2015."], "wordsB": ["No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p20_s0", "idA": "906709_16_item1_p15_s0", "sentA": "PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen s Neulasta (pegfilgrastim) and Roche s PEGASYS (PEG-interferon alfa-2a).", "sentB": "Polymer conjugation or PEGylation has been a highly effective technology platform for the development of therapeutics with significant commercial success, such as Amgen s Neulasta (pegfilgrastim) and Roche s PEGASYS (PEG-interferon alfa-2a).", "type": 2, "words": ["<tag1>", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a).", "<tag2>", "Polymer", "conjugation", "or", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a).", "<tag3>"], "wordsA": ["PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)."], "wordsB": ["Polymer", "conjugation", "or", "PEGylation", "has", "been", "a", "highly", "effective", "technology", "platform", "for", "the", "development", "of", "therapeutics", "with", "significant", "commercial", "success,", "such", "as", "Amgen", "s", "Neulasta", "(pegfilgrastim)", "and", "Roche", "s", "PEGASYS", "(PEG-interferon", "alfa-2a)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p161_s0", "idA": "906709_16_item1_p160_s0", "sentA": "Backlog Pursuant to our collaboration agreements, we manufacture and supply our proprietary PEGylation materials.", "sentB": "Backlog Pursuant to our collaboration agreements, we manufacture and supply our proprietary polymer conjugation materials.", "type": 2, "words": ["<tag1>", "Backlog", "Pursuant", "to", "our", "collaboration", "agreements,", "we", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials.", "<tag2>", "Backlog", "Pursuant", "to", "our", "collaboration", "agreements,", "we", "manufacture", "and", "supply", "our", "proprietary", "polymer", "conjugation", "materials.", "<tag3>"], "wordsA": ["Backlog", "Pursuant", "to", "our", "collaboration", "agreements,", "we", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials."], "wordsB": ["Backlog", "Pursuant", "to", "our", "collaboration", "agreements,", "we", "manufacture", "and", "supply", "our", "proprietary", "polymer", "conjugation", "materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p161_s2", "idA": "906709_16_item1_p160_s2", "sentA": "The volume of our proprietary PEGylation materials actually ordered by our customers, as well as shipment schedules, are subject to frequent revisions that reflect changes in both the customers needs and our manufacturing capacity.", "sentB": "The volume of our proprietary polymer conjugation materials actually ordered by our customers, as well as shipment schedules, are subject to frequent revisions that reflect changes in both the customers needs and our manufacturing capacity.", "type": 2, "words": ["<tag1>", "The", "volume", "of", "our", "proprietary", "PEGylation", "materials", "actually", "ordered", "by", "our", "customers,", "as", "well", "as", "shipment", "schedules,", "are", "subject", "to", "frequent", "revisions", "that", "reflect", "changes", "in", "both", "the", "customers", "needs", "and", "our", "manufacturing", "capacity.", "<tag2>", "The", "volume", "of", "our", "proprietary", "polymer", "conjugation", "materials", "actually", "ordered", "by", "our", "customers,", "as", "well", "as", "shipment", "schedules,", "are", "subject", "to", "frequent", "revisions", "that", "reflect", "changes", "in", "both", "the", "customers", "needs", "and", "our", "manufacturing", "capacity.", "<tag3>"], "wordsA": ["The", "volume", "of", "our", "proprietary", "PEGylation", "materials", "actually", "ordered", "by", "our", "customers,", "as", "well", "as", "shipment", "schedules,", "are", "subject", "to", "frequent", "revisions", "that", "reflect", "changes", "in", "both", "the", "customers", "needs", "and", "our", "manufacturing", "capacity."], "wordsB": ["The", "volume", "of", "our", "proprietary", "polymer", "conjugation", "materials", "actually", "ordered", "by", "our", "customers,", "as", "well", "as", "shipment", "schedules,", "are", "subject", "to", "frequent", "revisions", "that", "reflect", "changes", "in", "both", "the", "customers", "needs", "and", "our", "manufacturing", "capacity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p163_s3", "idA": "906709_16_item1_p162_s3", "sentA": "With our PEGylation and advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules.", "sentB": "With our advanced polymer conjugate technologies, we believe we have competitive advantages relating to factors such as efficacy, safety, ease of use and cost for certain applications and molecules.", "type": 2, "words": ["<tag1>", "With", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "we", "believe", "we", "have", "competitive", "advantages", "relating", "to", "factors", "such", "as", "efficacy,", "safety,", "ease", "of", "use", "and", "cost", "for", "certain", "applications", "and", "molecules.", "<tag2>", "With", "our", "advanced", "polymer", "conjugate", "technologies,", "we", "believe", "we", "have", "competitive", "advantages", "relating", "to", "factors", "such", "as", "efficacy,", "safety,", "ease", "of", "use", "and", "cost", "for", "certain", "applications", "and", "molecules.", "<tag3>"], "wordsA": ["With", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "we", "believe", "we", "have", "competitive", "advantages", "relating", "to", "factors", "such", "as", "efficacy,", "safety,", "ease", "of", "use", "and", "cost", "for", "certain", "applications", "and", "molecules."], "wordsB": ["With", "our", "advanced", "polymer", "conjugate", "technologies,", "we", "believe", "we", "have", "competitive", "advantages", "relating", "to", "factors", "such", "as", "efficacy,", "safety,", "ease", "of", "use", "and", "cost", "for", "certain", "applications", "and", "molecules."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p163_s5", "idA": "906709_16_item1_p162_s5", "sentA": "In the fields of PEGylation and advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr. Reddy s Laboratories, Ltd., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.).", "sentB": "In the fields of advanced polymer conjugate technologies, our competitors include Biogen Idec Inc., Savient Pharmaceuticals, Inc., Dr. Reddy s Laboratories, Ltd., Mountain View Pharmaceuticals, Inc., SunBio Corporation, NOF Corporation, and Novo Nordisk A/S (assets formerly held by Neose Technologies, Inc.).", "type": 2, "words": ["<tag1>", "In", "the", "fields", "of", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "our", "competitors", "include", "Biogen", "Idec", "Inc.,", "Savient", "Pharmaceuticals,", "Inc.,", "Dr.", "Reddy", "s", "Laboratories,", "Ltd.,", "Mountain", "View", "Pharmaceuticals,", "Inc.,", "SunBio", "Corporation,", "NOF", "Corporation,", "and", "Novo", "Nordisk", "A/S", "(assets", "formerly", "held", "by", "Neose", "Technologies,", "Inc.).", "<tag2>", "In", "the", "fields", "of", "advanced", "polymer", "conjugate", "technologies,", "our", "competitors", "include", "Biogen", "Idec", "Inc.,", "Savient", "Pharmaceuticals,", "Inc.,", "Dr.", "Reddy", "s", "Laboratories,", "Ltd.,", "Mountain", "View", "Pharmaceuticals,", "Inc.,", "SunBio", "Corporation,", "NOF", "Corporation,", "and", "Novo", "Nordisk", "A/S", "(assets", "formerly", "held", "by", "Neose", "Technologies,", "Inc.).", "<tag3>"], "wordsA": ["In", "the", "fields", "of", "PEGylation", "and", "advanced", "polymer", "conjugate", "technologies,", "our", "competitors", "include", "Biogen", "Idec", "Inc.,", "Savient", "Pharmaceuticals,", "Inc.,", "Dr.", "Reddy", "s", "Laboratories,", "Ltd.,", "Mountain", "View", "Pharmaceuticals,", "Inc.,", "SunBio", "Corporation,", "NOF", "Corporation,", "and", "Novo", "Nordisk", "A/S", "(assets", "formerly", "held", "by", "Neose", "Technologies,", "Inc.)."], "wordsB": ["In", "the", "fields", "of", "advanced", "polymer", "conjugate", "technologies,", "our", "competitors", "include", "Biogen", "Idec", "Inc.,", "Savient", "Pharmaceuticals,", "Inc.,", "Dr.", "Reddy", "s", "Laboratories,", "Ltd.,", "Mountain", "View", "Pharmaceuticals,", "Inc.,", "SunBio", "Corporation,", "NOF", "Corporation,", "and", "Novo", "Nordisk", "A/S", "(assets", "formerly", "held", "by", "Neose", "Technologies,", "Inc.)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p163_s6", "idA": "906709_16_item1_p162_s6", "sentA": "Several other chemical, biotechnology and pharmaceutical companies may also be developing PEGylation technology, advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits.", "sentB": "Several other chemical, biotechnology and pharmaceutical companies may also be developing advanced polymer conjugate technology or technologies intended to deliver similar scientific and medical benefits.", "type": 2, "words": ["<tag1>", "Several", "other", "chemical,", "biotechnology", "and", "pharmaceutical", "companies", "may", "also", "be", "developing", "PEGylation", "technology,", "advanced", "polymer", "conjugate", "technology", "or", "technologies", "intended", "to", "deliver", "similar", "scientific", "and", "medical", "benefits.", "<tag2>", "Several", "other", "chemical,", "biotechnology", "and", "pharmaceutical", "companies", "may", "also", "be", "developing", "advanced", "polymer", "conjugate", "technology", "or", "technologies", "intended", "to", "deliver", "similar", "scientific", "and", "medical", "benefits.", "<tag3>"], "wordsA": ["Several", "other", "chemical,", "biotechnology", "and", "pharmaceutical", "companies", "may", "also", "be", "developing", "PEGylation", "technology,", "advanced", "polymer", "conjugate", "technology", "or", "technologies", "intended", "to", "deliver", "similar", "scientific", "and", "medical", "benefits."], "wordsB": ["Several", "other", "chemical,", "biotechnology", "and", "pharmaceutical", "companies", "may", "also", "be", "developing", "advanced", "polymer", "conjugate", "technology", "or", "technologies", "intended", "to", "deliver", "similar", "scientific", "and", "medical", "benefits."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p164_s3", "idA": "906709_16_item1_p163_s3", "sentA": "There is also a subcutaneous treatment known as RELISTOR Subjectaneous Injection (methylnaltrexone bromide) marketed by Valeant Pharmaceuticals, Ltd (formerly Salix) under a license from Progenics Pharmaceuticals, Inc.", "sentB": "There is also a subcutaneous treatment and an oral treatment known as RELISTOR which is marketed by Valeant Pharmaceuticals, Ltd (formerly Salix) under a license from Progenics Pharmaceuticals, Inc.", "type": 2, "words": ["<tag1>", "There", "is", "also", "a", "subcutaneous", "treatment", "known", "as", "RELISTOR", "Subjectaneous", "Injection", "(methylnaltrexone", "bromide)", "marketed", "by", "Valeant", "Pharmaceuticals,", "Ltd", "(formerly", "Salix)", "under", "a", "license", "from", "Progenics", "Pharmaceuticals,", "Inc.", "<tag2>", "There", "is", "also", "a", "subcutaneous", "treatment", "and", "an", "oral", "treatment", "known", "as", "RELISTOR", "which", "is", "marketed", "by", "Valeant", "Pharmaceuticals,", "Ltd", "(formerly", "Salix)", "under", "a", "license", "from", "Progenics", "Pharmaceuticals,", "Inc.", "<tag3>"], "wordsA": ["There", "is", "also", "a", "subcutaneous", "treatment", "known", "as", "RELISTOR", "Subjectaneous", "Injection", "(methylnaltrexone", "bromide)", "marketed", "by", "Valeant", "Pharmaceuticals,", "Ltd", "(formerly", "Salix)", "under", "a", "license", "from", "Progenics", "Pharmaceuticals,", "Inc."], "wordsB": ["There", "is", "also", "a", "subcutaneous", "treatment", "and", "an", "oral", "treatment", "known", "as", "RELISTOR", "which", "is", "marketed", "by", "Valeant", "Pharmaceuticals,", "Ltd", "(formerly", "Salix)", "under", "a", "license", "from", "Progenics", "Pharmaceuticals,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p164_s5", "idA": "906709_16_item1_p163_s5", "sentA": "On June 23, 2015, Valeant submitted an NDA to the FDA for Relistor (methylnaltrexone bromide) oral tablets for the treatment of OCI in adult patients with chronic non-cancer pain.", "sentB": "On July 22, 2016, Relistor (methylnaltrexone bromide) oral tablets for the treatment of OCI in adult patients with chronic non-cancer pain was approved by FDA.", "type": 2, "words": ["<tag1>", "On", "June", "23,", "2015,", "Valeant", "submitted", "an", "NDA", "to", "the", "FDA", "for", "Relistor", "(methylnaltrexone", "bromide)", "oral", "tablets", "for", "the", "treatment", "of", "OCI", "in", "adult", "patients", "with", "chronic", "non-cancer", "pain.", "<tag2>", "On", "July", "22,", "2016,", "Relistor", "(methylnaltrexone", "bromide)", "oral", "tablets", "for", "the", "treatment", "of", "OCI", "in", "adult", "patients", "with", "chronic", "non-cancer", "pain", "was", "approved", "by", "FDA.", "<tag3>"], "wordsA": ["On", "June", "23,", "2015,", "Valeant", "submitted", "an", "NDA", "to", "the", "FDA", "for", "Relistor", "(methylnaltrexone", "bromide)", "oral", "tablets", "for", "the", "treatment", "of", "OCI", "in", "adult", "patients", "with", "chronic", "non-cancer", "pain."], "wordsB": ["On", "July", "22,", "2016,", "Relistor", "(methylnaltrexone", "bromide)", "oral", "tablets", "for", "the", "treatment", "of", "OCI", "in", "adult", "patients", "with", "chronic", "non-cancer", "pain", "was", "approved", "by", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p172_s0", "idA": "906709_16_item1_p164_s2", "sentA": "There are a number of companies developing potential products which are in various stages of clinical development and are being evaluated for the treatment of OIC and OBD in different patient populations.", "sentB": "There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to auto-immune disease.", "type": 2, "words": ["<tag1>", "There", "are", "a", "number", "of", "companies", "developing", "potential", "products", "which", "are", "in", "various", "stages", "of", "clinical", "development", "and", "are", "being", "evaluated", "for", "the", "treatment", "of", "OIC", "and", "OBD", "in", "different", "patient", "populations.", "<tag2>", "There", "are", "a", "number", "of", "competitors", "in", "various", "stages", "of", "clinical", "development", "that", "are", "working", "on", "programs", "which", "are", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "due", "to", "auto-immune", "disease.", "<tag3>"], "wordsA": ["There", "are", "a", "number", "of", "companies", "developing", "potential", "products", "which", "are", "in", "various", "stages", "of", "clinical", "development", "and", "are", "being", "evaluated", "for", "the", "treatment", "of", "OIC", "and", "OBD", "in", "different", "patient", "populations."], "wordsB": ["There", "are", "a", "number", "of", "competitors", "in", "various", "stages", "of", "clinical", "development", "that", "are", "working", "on", "programs", "which", "are", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "due", "to", "auto-immune", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p165_s0", "idA": "906709_16_item1_p165_s0", "sentA": "Potential competitors include Merck Co., Inc., GlaxoSmithKline plc, Ironwood Pharmaceuticals, Inc. in collaboration with Actavis plc, Mundipharma Int.", "sentB": "Potential competitors include Merck Co., Inc., GlaxoSmithKline plc, Ironwood Pharmaceuticals, Inc. in collaboration with Actavis plc, Purdue Pharma L.P. in collaboration with Shionogi Co., Ltd., Mundipharma Int.", "type": 2, "words": ["<tag1>", "Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Mundipharma", "Int.", "<tag2>", "Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Purdue", "Pharma", "L.P.", "in", "collaboration", "with", "Shionogi", "Co.,", "Ltd.,", "Mundipharma", "Int.", "<tag3>"], "wordsA": ["Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Mundipharma", "Int."], "wordsB": ["Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Purdue", "Pharma", "L.P.", "in", "collaboration", "with", "Shionogi", "Co.,", "Ltd.,", "Mundipharma", "Int."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p167_s1", "idA": "906709_16_item1_p165_s0", "sentA": "Potential competitors include Merck Co., Inc., GlaxoSmithKline plc, Ironwood Pharmaceuticals, Inc. in collaboration with Actavis plc, Mundipharma Int.", "sentB": "Potential competitors include Acura Pharmaceuticals, Inc., Cara Therapeutics, Inc., Collegium Pharmaceutical, Inc., Egalet Ltd, Elite Pharmaceuticals, Inc., Endo Health Solutions Inc., KemPharm, Inc., Pfizer, Inc., Purdue Pharma L.P., and Teva Pharmaceutical Industries Ltd.", "type": 2, "words": ["<tag1>", "Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Mundipharma", "Int.", "<tag2>", "Potential", "competitors", "include", "Acura", "Pharmaceuticals,", "Inc.,", "Cara", "Therapeutics,", "Inc.,", "Collegium", "Pharmaceutical,", "Inc.,", "Egalet", "Ltd,", "Elite", "Pharmaceuticals,", "Inc.,", "Endo", "Health", "Solutions", "Inc.,", "KemPharm,", "Inc.,", "Pfizer,", "Inc.,", "Purdue", "Pharma", "L.P.,", "and", "Teva", "Pharmaceutical", "Industries", "Ltd.", "<tag3>"], "wordsA": ["Potential", "competitors", "include", "Merck", "Co.,", "Inc.,", "GlaxoSmithKline", "plc,", "Ironwood", "Pharmaceuticals,", "Inc.", "in", "collaboration", "with", "Actavis", "plc,", "Mundipharma", "Int."], "wordsB": ["Potential", "competitors", "include", "Acura", "Pharmaceuticals,", "Inc.,", "Cara", "Therapeutics,", "Inc.,", "Collegium", "Pharmaceutical,", "Inc.,", "Egalet", "Ltd,", "Elite", "Pharmaceuticals,", "Inc.,", "Endo", "Health", "Solutions", "Inc.,", "KemPharm,", "Inc.,", "Pfizer,", "Inc.,", "Purdue", "Pharma", "L.P.,", "and", "Teva", "Pharmaceutical", "Industries", "Ltd."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p168_s0", "idA": "906709_16_item1_p168_s0", "sentA": "There are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for breast and ovarian cancers including but not limited to: Abraxane (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Afinitor (everolimus), Doxil (doxorubicin HCl), Ellence (epirubicin), Gemzar (gemcitabine), Halaven (eribulin), Herceptin (trastuzumab), Hycamtin (topotecan), Ibrance (palbociclib), Ixempra (ixabepilone), Navelbine (vinolrebine), Paraplatin (carboplatin), Taxol (paclitaxel), Xeloda (capecitabine) and Taxotere (docetaxel).", "sentB": "There are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for advanced breast cancer.", "type": 2, "words": ["<tag1>", "There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "breast", "and", "ovarian", "cancers", "including", "but", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Doxil", "(doxorubicin", "HCl),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Hycamtin", "(topotecan),", "Ibrance", "(palbociclib),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Paraplatin", "(carboplatin),", "Taxol", "(paclitaxel),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel).", "<tag2>", "There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "advanced", "breast", "cancer.", "<tag3>"], "wordsA": ["There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "breast", "and", "ovarian", "cancers", "including", "but", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Doxil", "(doxorubicin", "HCl),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Hycamtin", "(topotecan),", "Ibrance", "(palbociclib),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Paraplatin", "(carboplatin),", "Taxol", "(paclitaxel),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel)."], "wordsB": ["There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "advanced", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p168_s2", "idA": "906709_16_item1_p168_s0", "sentA": "There are a number of chemotherapies and cancer therapies approved today and in various stages of clinical development for breast and ovarian cancers including but not limited to: Abraxane (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Afinitor (everolimus), Doxil (doxorubicin HCl), Ellence (epirubicin), Gemzar (gemcitabine), Halaven (eribulin), Herceptin (trastuzumab), Hycamtin (topotecan), Ibrance (palbociclib), Ixempra (ixabepilone), Navelbine (vinolrebine), Paraplatin (carboplatin), Taxol (paclitaxel), Xeloda (capecitabine) and Taxotere (docetaxel).", "sentB": "These therapies include but are not limited to: Abraxane (paclitaxel protein-bound particles for injectable suspension (albumin bound)), Afinitor (everolimus), Ellence (epirubicin), Gemzar (gemcitabine), Halaven (eribulin), Herceptin (trastuzumab), Ixempra (ixabepilone), Navelbine (vinolrebine), Xeloda (capecitabine) and Taxotere (docetaxel).", "type": 2, "words": ["<tag1>", "There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "breast", "and", "ovarian", "cancers", "including", "but", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Doxil", "(doxorubicin", "HCl),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Hycamtin", "(topotecan),", "Ibrance", "(palbociclib),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Paraplatin", "(carboplatin),", "Taxol", "(paclitaxel),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel).", "<tag2>", "These", "therapies", "include", "but", "are", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel).", "<tag3>"], "wordsA": ["There", "are", "a", "number", "of", "chemotherapies", "and", "cancer", "therapies", "approved", "today", "and", "in", "various", "stages", "of", "clinical", "development", "for", "breast", "and", "ovarian", "cancers", "including", "but", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Doxil", "(doxorubicin", "HCl),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Hycamtin", "(topotecan),", "Ibrance", "(palbociclib),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Paraplatin", "(carboplatin),", "Taxol", "(paclitaxel),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel)."], "wordsB": ["These", "therapies", "include", "but", "are", "not", "limited", "to:", "Abraxane", "(paclitaxel", "protein-bound", "particles", "for", "injectable", "suspension", "(albumin", "bound)),", "Afinitor", "(everolimus),", "Ellence", "(epirubicin),", "Gemzar", "(gemcitabine),", "Halaven", "(eribulin),", "Herceptin", "(trastuzumab),", "Ixempra", "(ixabepilone),", "Navelbine", "(vinolrebine),", "Xeloda", "(capecitabine)", "and", "Taxotere", "(docetaxel)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p168_s1", "idA": "906709_16_item1_p168_s1", "sentA": "These therapies are only partially effective in treating breast and ovarian cancer.", "sentB": "These therapies are only partially effective in treating advanced or metastatic breast cancer and none have a specific indication in either the U.S. or Europe for treatment of patients with advanced breast cancer and co-existing brain metastases.", "type": 2, "words": ["<tag1>", "These", "therapies", "are", "only", "partially", "effective", "in", "treating", "breast", "and", "ovarian", "cancer.", "<tag2>", "These", "therapies", "are", "only", "partially", "effective", "in", "treating", "advanced", "or", "metastatic", "breast", "cancer", "and", "none", "have", "a", "specific", "indication", "in", "either", "the", "U.S.", "or", "Europe", "for", "treatment", "of", "patients", "with", "advanced", "breast", "cancer", "and", "co-existing", "brain", "metastases.", "<tag3>"], "wordsA": ["These", "therapies", "are", "only", "partially", "effective", "in", "treating", "breast", "and", "ovarian", "cancer."], "wordsB": ["These", "therapies", "are", "only", "partially", "effective", "in", "treating", "advanced", "or", "metastatic", "breast", "cancer", "and", "none", "have", "a", "specific", "indication", "in", "either", "the", "U.S.", "or", "Europe", "for", "treatment", "of", "patients", "with", "advanced", "breast", "cancer", "and", "co-existing", "brain", "metastases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p169_s0", "idA": "906709_16_item1_p168_s2", "sentA": "Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include Bristol-Meyers Squibb Company, Eisai, Inc., Roche Holding Group (including its Genentech subsidiary), GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly Co., Johnson Johnson, Sanofi Aventis S.A., and many others.", "sentB": "Major pharmaceutical or biotechnology companies with approved drugs or drugs in development for these cancers include Bristol-Myers Squibb Company, Eisai, Inc., Roche Holding Group (including its Genentech subsidiary), GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly Co., Sanofi Aventis S.A., and others.", "type": 2, "words": ["<tag1>", "Major", "pharmaceutical", "or", "biotechnology", "companies", "with", "approved", "drugs", "or", "drugs", "in", "development", "for", "these", "cancers", "include", "Bristol-Meyers", "Squibb", "Company,", "Eisai,", "Inc.,", "Roche", "Holding", "Group", "(including", "its", "Genentech", "subsidiary),", "GlaxoSmithKline", "plc,", "Pfizer,", "Inc.,", "Eli", "Lilly", "Co.,", "Johnson", "Johnson,", "Sanofi", "Aventis", "S.A.,", "and", "many", "others.", "<tag2>", "Major", "pharmaceutical", "or", "biotechnology", "companies", "with", "approved", "drugs", "or", "drugs", "in", "development", "for", "these", "cancers", "include", "Bristol-Myers", "Squibb", "Company,", "Eisai,", "Inc.,", "Roche", "Holding", "Group", "(including", "its", "Genentech", "subsidiary),", "GlaxoSmithKline", "plc,", "Pfizer,", "Inc.,", "Eli", "Lilly", "Co.,", "Sanofi", "Aventis", "S.A.,", "and", "others.", "<tag3>"], "wordsA": ["Major", "pharmaceutical", "or", "biotechnology", "companies", "with", "approved", "drugs", "or", "drugs", "in", "development", "for", "these", "cancers", "include", "Bristol-Meyers", "Squibb", "Company,", "Eisai,", "Inc.,", "Roche", "Holding", "Group", "(including", "its", "Genentech", "subsidiary),", "GlaxoSmithKline", "plc,", "Pfizer,", "Inc.,", "Eli", "Lilly", "Co.,", "Johnson", "Johnson,", "Sanofi", "Aventis", "S.A.,", "and", "many", "others."], "wordsB": ["Major", "pharmaceutical", "or", "biotechnology", "companies", "with", "approved", "drugs", "or", "drugs", "in", "development", "for", "these", "cancers", "include", "Bristol-Myers", "Squibb", "Company,", "Eisai,", "Inc.,", "Roche", "Holding", "Group", "(including", "its", "Genentech", "subsidiary),", "GlaxoSmithKline", "plc,", "Pfizer,", "Inc.,", "Eli", "Lilly", "Co.,", "Sanofi", "Aventis", "S.A.,", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p22_s1", "idA": "906709_16_item1_p16_s3", "sentA": "These techniques cannot be used successfully to create small molecule drugs which could potentially benefit from the application of the technology.", "sentB": "For example, these techniques cannot be used successfully to create small molecule drugs which could potentially benefit from t he application of the technology.", "type": 2, "words": ["<tag1>", "These", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology.", "<tag2>", "For", "example,", "these", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "t", "he", "application", "of", "the", "technology.", "<tag3>"], "wordsA": ["These", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology."], "wordsB": ["For", "example,", "these", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "t", "he", "application", "of", "the", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p172_s1", "idA": "906709_16_item1_p170_s1", "sentA": "In particular, we expect to compete with therapies with tumor infiltrating lymphocytes, or TILS, chimeric antigen receptor-expressing T cells, or CAR-T, cytokine-based therapies, and checkpoint inhibitors.", "sentB": "In particular, we expect to compete with therapies that could be cytokine-based therapies (Symbiotix, LLC and Tizona Therapeutics), T regulatory cell therapies (Targazyme, Inc., Juno Therapeutics and Tract Therapeutics, Inc.), or IL-2-based and toleragen-based therapies (Celgene Corporation, Amgen Inc., Tolera Therapeutics, Inc., and Caladrius BioSciences, Inc.).", "type": 2, "words": ["<tag1>", "In", "particular,", "we", "expect", "to", "compete", "with", "therapies", "with", "tumor", "infiltrating", "lymphocytes,", "or", "TILS,", "chimeric", "antigen", "receptor-expressing", "T", "cells,", "or", "CAR-T,", "cytokine-based", "therapies,", "and", "checkpoint", "inhibitors.", "<tag2>", "In", "particular,", "we", "expect", "to", "compete", "with", "therapies", "that", "could", "be", "cytokine-based", "therapies", "(Symbiotix,", "LLC", "and", "Tizona", "Therapeutics),", "T", "regulatory", "cell", "therapies", "(Targazyme,", "Inc.,", "Juno", "Therapeutics", "and", "Tract", "Therapeutics,", "Inc.),", "or", "IL-2-based", "and", "toleragen-based", "therapies", "(Celgene", "Corporation,", "Amgen", "Inc.,", "Tolera", "Therapeutics,", "Inc.,", "and", "Caladrius", "BioSciences,", "Inc.).", "<tag3>"], "wordsA": ["In", "particular,", "we", "expect", "to", "compete", "with", "therapies", "with", "tumor", "infiltrating", "lymphocytes,", "or", "TILS,", "chimeric", "antigen", "receptor-expressing", "T", "cells,", "or", "CAR-T,", "cytokine-based", "therapies,", "and", "checkpoint", "inhibitors."], "wordsB": ["In", "particular,", "we", "expect", "to", "compete", "with", "therapies", "that", "could", "be", "cytokine-based", "therapies", "(Symbiotix,", "LLC", "and", "Tizona", "Therapeutics),", "T", "regulatory", "cell", "therapies", "(Targazyme,", "Inc.,", "Juno", "Therapeutics", "and", "Tract", "Therapeutics,", "Inc.),", "or", "IL-2-based", "and", "toleragen-based", "therapies", "(Celgene", "Corporation,", "Amgen", "Inc.,", "Tolera", "Therapeutics,", "Inc.,", "and", "Caladrius", "BioSciences,", "Inc.)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p0_s2", "idA": "906709_16_item1_p172_s1", "sentA": "The facility is also used to produce APIs and finished drug products to support the early phases of clinical development of our proprietary drug candidates.", "sentB": "We leverage our proprietary and proven chemistry platform to discover and design new drug candidates.", "type": 2, "words": ["<tag1>", "The", "facility", "is", "also", "used", "to", "produce", "APIs", "and", "finished", "drug", "products", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates.", "<tag2>", "We", "leverage", "our", "proprietary", "and", "proven", "chemistry", "platform", "to", "discover", "and", "design", "new", "drug", "candidates.", "<tag3>"], "wordsA": ["The", "facility", "is", "also", "used", "to", "produce", "APIs", "and", "finished", "drug", "products", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates."], "wordsB": ["We", "leverage", "our", "proprietary", "and", "proven", "chemistry", "platform", "to", "discover", "and", "design", "new", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p177_s0", "idA": "906709_16_item1_p175_s0", "sentA": "Employees and Consultants As of December 31, 2015 we had 425 employees, of which 322 employees were engaged in research and development, commercial operations and quality activities and 103 employees were engaged in general administration and business development.", "sentB": "Employees and Consultants As of December 31, 2016 we had 468 employees, of which 358 employees were engaged in research and development, commercial operations and quality activities and 110 employees were engaged in general administration and business development.", "type": 2, "words": ["<tag1>", "Employees", "and", "Consultants", "As", "of", "December", "31,", "2015", "we", "had", "425", "employees,", "of", "which", "322", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "103", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development.", "<tag2>", "Employees", "and", "Consultants", "As", "of", "December", "31,", "2016", "we", "had", "468", "employees,", "of", "which", "358", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "110", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development.", "<tag3>"], "wordsA": ["Employees", "and", "Consultants", "As", "of", "December", "31,", "2015", "we", "had", "425", "employees,", "of", "which", "322", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "103", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development."], "wordsB": ["Employees", "and", "Consultants", "As", "of", "December", "31,", "2016", "we", "had", "468", "employees,", "of", "which", "358", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "110", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p178_s0", "idA": "906709_16_item1_p175_s1", "sentA": "Of the 425 employees, 347 were located in the U.S. and 78 were located in India.", "sentB": "Of the 468 employees, 392 were located in the U.S. and 76 were located in India.", "type": 2, "words": ["<tag1>", "Of", "the", "425", "employees,", "347", "were", "located", "in", "the", "U.S.", "and", "78", "were", "located", "in", "India.", "<tag2>", "Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India.", "<tag3>"], "wordsA": ["Of", "the", "425", "employees,", "347", "were", "located", "in", "the", "U.S.", "and", "78", "were", "located", "in", "India."], "wordsB": ["Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p179_s0", "idA": "906709_16_item1_p177_s0", "sentA": "EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth the names, ages and positions of our executive officers as of February 15, 2016:", "sentB": "EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth the names, ages and positions of our executive officers as of February 13, 2017:", "type": 2, "words": ["<tag1>", "EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "15,", "2016:", "<tag2>", "EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "13,", "2017:", "<tag3>"], "wordsA": ["EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "15,", "2016:"], "wordsB": ["EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "13,", "2017:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p23_s0", "idA": "906709_16_item1_p17_s0", "sentA": "With our expertise and proprietary technology in PEGylation, we have created the next generation of PEGylation technology.", "sentB": "With our expertise and proprietary technology in polymer conjugation, we have created the next generation of PEGylation technology.", "type": 2, "words": ["<tag1>", "With", "our", "expertise", "and", "proprietary", "technology", "in", "PEGylation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology.", "<tag2>", "With", "our", "expertise", "and", "proprietary", "technology", "in", "polymer", "conjugation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology.", "<tag3>"], "wordsA": ["With", "our", "expertise", "and", "proprietary", "technology", "in", "PEGylation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology."], "wordsB": ["With", "our", "expertise", "and", "proprietary", "technology", "in", "polymer", "conjugation,", "we", "have", "created", "the", "next", "generation", "of", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p43_s1", "idA": "906709_16_item1_p17_s1", "sentA": "Our advanced polymer conjugate technology platform is designed to overcome the limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "sentB": "NKTR-262 is designed to overcome the body s dysfunction of antigen-presenting cells (APC), such as dendritic cells, which are critical to induce the body s adaptive immunity and create antigen-specific cytotoxic T cells.", "type": 2, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag2>", "NKTR-262", "is", "designed", "to", "overcome", "the", "body", "s", "dysfunction", "of", "antigen-presenting", "cells", "(APC),", "such", "as", "dendritic", "cells,", "which", "are", "critical", "to", "induce", "the", "body", "s", "adaptive", "immunity", "and", "create", "antigen-specific", "cytotoxic", "T", "cells.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "wordsB": ["NKTR-262", "is", "designed", "to", "overcome", "the", "body", "s", "dysfunction", "of", "antigen-presenting", "cells", "(APC),", "such", "as", "dendritic", "cells,", "which", "are", "critical", "to", "induce", "the", "body", "s", "adaptive", "immunity", "and", "create", "antigen-specific", "cytotoxic", "T", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p23_s3", "idA": "906709_16_item1_p17_s3", "sentA": "Both our PEGylation and advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "type": 2, "words": ["<tag1>", "Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag3>"], "wordsA": ["Both", "our", "PEGylation", "and", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p184_s0", "idA": "906709_16_item1_p182_s0", "sentA": "John Nicholson has served as our Senior Vice President and Chief Financial Officer since December 2007.", "sentB": "John Nicholson has served as our Senior Vice President and Chief Operating Officer since June 2016.", "type": 2, "words": ["<tag1>", "John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "December", "2007.", "<tag2>", "John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Operating", "Officer", "since", "June", "2016.", "<tag3>"], "wordsA": ["John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "December", "2007."], "wordsB": ["John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Operating", "Officer", "since", "June", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p185_s0", "idA": "906709_16_item1_p182_s0", "sentA": "John Nicholson has served as our Senior Vice President and Chief Financial Officer since December 2007.", "sentB": "Gil M. Labrucherie has served as our Senior Vice President and Chief Financial Officer since June 2016.", "type": 2, "words": ["<tag1>", "John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "December", "2007.", "<tag2>", "Gil", "M.", "Labrucherie", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "June", "2016.", "<tag3>"], "wordsA": ["John", "Nicholson", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "December", "2007."], "wordsB": ["Gil", "M.", "Labrucherie", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "since", "June", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p184_s1", "idA": "906709_16_item1_p182_s1", "sentA": "Mr. Nicholson joined the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007.", "sentB": "Mr. Nicholson joined the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007 and served as our Chief Financial Officer until June 2016 when he was promoted to Senior Vice President and Chief Operating Officer.", "type": 2, "words": ["<tag1>", "Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007.", "<tag2>", "Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007", "and", "served", "as", "our", "Chief", "Financial", "Officer", "until", "June", "2016", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President", "and", "Chief", "Operating", "Officer.", "<tag3>"], "wordsA": ["Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007."], "wordsB": ["Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007", "and", "served", "as", "our", "Chief", "Financial", "Officer", "until", "June", "2016", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President", "and", "Chief", "Operating", "Officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p0_s0", "idA": "906709_16_item1_p182_s11", "sentA": "Dr. Gergel is a member of the Board of Directors of Corium International, Inc., a commercial-stage biopharmaceutical company.", "sentB": "Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need.", "type": 2, "words": ["<tag1>", "Dr.", "Gergel", "is", "a", "member", "of", "the", "Board", "of", "Directors", "of", "Corium", "International,", "Inc.,", "a", "commercial-stage", "biopharmaceutical", "company.", "<tag2>", "Nektar", "Therapeutics", "is", "a", "research-based", "biopharmaceutical", "company", "that", "discovers", "and", "develops", "innovative", "medicines", "in", "areas", "of", "high", "unmet", "medical", "need.", "<tag3>"], "wordsA": ["Dr.", "Gergel", "is", "a", "member", "of", "the", "Board", "of", "Directors", "of", "Corium", "International,", "Inc.,", "a", "commercial-stage", "biopharmaceutical", "company."], "wordsB": ["Nektar", "Therapeutics", "is", "a", "research-based", "biopharmaceutical", "company", "that", "discovers", "and", "develops", "innovative", "medicines", "in", "areas", "of", "high", "unmet", "medical", "need."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p189_s0", "idA": "906709_16_item1_p185_s0", "sentA": "From September 2001 until July 2004, D r. Doberstein was Vice President, Research at privately held Xencor, Inc., a clinical stage biotechnology company.", "sentB": "From September 2001 until July 2004, Dr. Doberstein was Vice President, Research at privately held Xencor, Inc., a clinical stage biotechnology company.", "type": 2, "words": ["<tag1>", "From", "September", "2001", "until", "July", "2004,", "D", "r.", "Doberstein", "was", "Vice", "President,", "Research", "at", "privately", "held", "Xencor,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company.", "<tag2>", "From", "September", "2001", "until", "July", "2004,", "Dr.", "Doberstein", "was", "Vice", "President,", "Research", "at", "privately", "held", "Xencor,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company.", "<tag3>"], "wordsA": ["From", "September", "2001", "until", "July", "2004,", "D", "r.", "Doberstein", "was", "Vice", "President,", "Research", "at", "privately", "held", "Xencor,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company."], "wordsB": ["From", "September", "2001", "until", "July", "2004,", "Dr.", "Doberstein", "was", "Vice", "President,", "Research", "at", "privately", "held", "Xencor,", "Inc.,", "a", "clinical", "stage", "biotechnology", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p189_s1", "idA": "906709_16_item1_p185_s1", "sentA": "From 1997 to 2000, he held various pharmaceutical research positions at Exelixis, Inc. (Exelixis), a publicly traded clinical stage biotechno logy company.", "sentB": "From 1997 to 2000, he held various pharmaceutical research positions at Exelixis, Inc. (Exelixis), a publicly traded clinical stage biotechnology company.", "type": 2, "words": ["<tag1>", "From", "1997", "to", "2000,", "he", "held", "various", "pharmaceutical", "research", "positions", "at", "Exelixis,", "Inc.", "(Exelixis),", "a", "publicly", "traded", "clinical", "stage", "biotechno", "logy", "company.", "<tag2>", "From", "1997", "to", "2000,", "he", "held", "various", "pharmaceutical", "research", "positions", "at", "Exelixis,", "Inc.", "(Exelixis),", "a", "publicly", "traded", "clinical", "stage", "biotechnology", "company.", "<tag3>"], "wordsA": ["From", "1997", "to", "2000,", "he", "held", "various", "pharmaceutical", "research", "positions", "at", "Exelixis,", "Inc.", "(Exelixis),", "a", "publicly", "traded", "clinical", "stage", "biotechno", "logy", "company."], "wordsB": ["From", "1997", "to", "2000,", "he", "held", "various", "pharmaceutical", "research", "positions", "at", "Exelixis,", "Inc.", "(Exelixis),", "a", "publicly", "traded", "clinical", "stage", "biotechnology", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p185_s1", "idA": "906709_16_item1_p186_s1", "sentA": "Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007.", "sentB": "Mr. Labrucherie served as our Vice President, Corporate Legal from October 2005 through April 2007 and served as our Senior Vice President, General Counsel and Secretary from April 2007 through June 2016 when he was promoted to Senior Vice President and Chief Financial Officer.", "type": 2, "words": ["<tag1>", "Mr.", "Labrucherie", "served", "as", "our", "Vice", "President,", "Corporate", "Legal", "from", "October", "2005", "through", "April", "2007.", "<tag2>", "Mr.", "Labrucherie", "served", "as", "our", "Vice", "President,", "Corporate", "Legal", "from", "October", "2005", "through", "April", "2007", "and", "served", "as", "our", "Senior", "Vice", "President,", "General", "Counsel", "and", "Secretary", "from", "April", "2007", "through", "June", "2016", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer.", "<tag3>"], "wordsA": ["Mr.", "Labrucherie", "served", "as", "our", "Vice", "President,", "Corporate", "Legal", "from", "October", "2005", "through", "April", "2007."], "wordsB": ["Mr.", "Labrucherie", "served", "as", "our", "Vice", "President,", "Corporate", "Legal", "from", "October", "2005", "through", "April", "2007", "and", "served", "as", "our", "Senior", "Vice", "President,", "General", "Counsel", "and", "Secretary", "from", "April", "2007", "through", "June", "2016", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p187_s0", "idA": "906709_16_item1_p187_s2", "sentA": "Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions.", "sentB": "the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions.", "type": 2, "words": ["<tag1>", "Prior", "to", "E2open,", "he", "was", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions.", "<tag2>", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions.", "<tag3>"], "wordsA": ["Prior", "to", "E2open,", "he", "was", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions."], "wordsB": ["the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p26_s3", "idA": "906709_16_item1_p20_s3", "sentA": "An example of reducing transport across the blood-brain barrier is MOVANTIK TM , an orally-available peripherally-acting opioid antagonist that is approved in the United States and European Union.", "sentB": "An example of reducing transport across the blood-brain barrier is MOVANTIK , an orally-available peripherally-acting opioid antagonist that is approved in the United States and European Union.", "type": 2, "words": ["<tag1>", "An", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "MOVANTIK", "TM", ",", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "approved", "in", "the", "United", "States", "and", "European", "Union.", "<tag2>", "An", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "MOVANTIK", ",", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "approved", "in", "the", "United", "States", "and", "European", "Union.", "<tag3>"], "wordsA": ["An", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "MOVANTIK", "TM", ",", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "approved", "in", "the", "United", "States", "and", "European", "Union."], "wordsB": ["An", "example", "of", "reducing", "transport", "across", "the", "blood-brain", "barrier", "is", "MOVANTIK", ",", "an", "orally-available", "peripherally-acting", "opioid", "antagonist", "that", "is", "approved", "in", "the", "United", "States", "and", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p26_s4", "idA": "906709_16_item1_p20_s4", "sentA": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that is currently in Phase 3 development.", "sentB": "An additional example of the application of membrane transport, specifically slowing transport across the blood-brain barrier is NKTR-181, an orally-available mu-opioid analgesic molecule that is currently in Phase 3 clinical development.", "type": 2, "words": ["<tag1>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "development.", "<tag2>", "An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag3>"], "wordsA": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "development."], "wordsB": ["An", "additional", "example", "of", "the", "application", "of", "membrane", "transport,", "specifically", "slowing", "transport", "across", "the", "blood-brain", "barrier", "is", "NKTR-181,", "an", "orally-available", "mu-opioid", "analgesic", "molecule", "that", "is", "currently", "in", "Phase", "3", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p2_s0", "idA": "906709_16_item1_p21_s2", "sentA": "With our releasable polymer conjugate technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body.", "type": 2, "words": ["<tag1>", "With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "NKTR-262", "is", "a", "small", "molecule", "agonist", "that", "targets", "toll-like", "receptors", "(TLRs)", "found", "on", "innate", "immune", "cells", "in", "the", "body.", "<tag3>"], "wordsA": ["With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["NKTR-262", "is", "a", "small", "molecule", "agonist", "that", "targets", "toll-like", "receptors", "(TLRs)", "found", "on", "innate", "immune", "cells", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p43_s0", "idA": "906709_16_item1_p21_s2", "sentA": "With our releasable polymer conjugate technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "NKTR-262 NKTR-262 is a small molecule agonist that targets toll-like receptors (TLRs) found on innate immune cells in the body.", "type": 2, "words": ["<tag1>", "With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "NKTR-262", "NKTR-262", "is", "a", "small", "molecule", "agonist", "that", "targets", "toll-like", "receptors", "(TLRs)", "found", "on", "innate", "immune", "cells", "in", "the", "body.", "<tag3>"], "wordsA": ["With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["NKTR-262", "NKTR-262", "is", "a", "small", "molecule", "agonist", "that", "targets", "toll-like", "receptors", "(TLRs)", "found", "on", "innate", "immune", "cells", "in", "the", "body."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p5_s0", "idA": "906709_16_item1_p21_s2", "sentA": "With our releasable polymer conjugate technology platform, we believe that these drugs can be modulated for programmed release within the body, optimized bioactivity and increased sustained exposure of active drug to tumor cells in the body.", "sentB": "By increasing the number of T regulatory cells (which are specific immune cells in the body that modul ate the immune system and prevent auto-immune disease by maintaining self-tolerance), these pathogenic auto reactive T cells can be reduced and the proper balance of effector and regulatory T cells can be achieved to restore the body's self-tolerance mecha nisms.", "type": 2, "words": ["<tag1>", "With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body.", "<tag2>", "By", "increasing", "the", "number", "of", "T", "regulatory", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modul", "ate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mecha", "nisms.", "<tag3>"], "wordsA": ["With", "our", "releasable", "polymer", "conjugate", "technology", "platform,", "we", "believe", "that", "these", "drugs", "can", "be", "modulated", "for", "programmed", "release", "within", "the", "body,", "optimized", "bioactivity", "and", "increased", "sustained", "exposure", "of", "active", "drug", "to", "tumor", "cells", "in", "the", "body."], "wordsB": ["By", "increasing", "the", "number", "of", "T", "regulatory", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modul", "ate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mecha", "nisms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p27_s3", "idA": "906709_16_item1_p21_s3", "sentA": "We are using this approach with our lead oncolytic drug candidate, NKTR-102, a next-generation topoisomerase I-inhibitor currently in the Phase 3 BEACON clinical study for treatment of metastatic breast cancer.", "sentB": "We are using this approach with our lead oncolytic drug candidate, ONZEALD TM next-generation topoisomerase I-inhibitor currently in Phase 3 clinical development.", "type": 2, "words": ["<tag1>", "We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer.", "<tag2>", "We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "ONZEALD", "TM", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "Phase", "3", "clinical", "development.", "<tag3>"], "wordsA": ["We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "NKTR-102,", "a", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "the", "Phase", "3", "BEACON", "clinical", "study", "for", "treatment", "of", "metastatic", "breast", "cancer."], "wordsB": ["We", "are", "using", "this", "approach", "with", "our", "lead", "oncolytic", "drug", "candidate,", "ONZEALD", "TM", "next-generation", "topoisomerase", "I-inhibitor", "currently", "in", "Phase", "3", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p43_s3", "idA": "906709_16_item1_p26_s5", "sentA": "We continue to advance our most promising research drug candidates into preclinical development with the objective of advancing these early stage research programs to human clinical studies over the next several years.", "sentB": "NKTR-262 is currently advancing through preclinical development with the objective of filing an IND and beginning clinical development.", "type": 2, "words": ["<tag1>", "We", "continue", "to", "advance", "our", "most", "promising", "research", "drug", "candidates", "into", "preclinical", "development", "with", "the", "objective", "of", "advancing", "these", "early", "stage", "research", "programs", "to", "human", "clinical", "studies", "over", "the", "next", "several", "years.", "<tag2>", "NKTR-262", "is", "currently", "advancing", "through", "preclinical", "development", "with", "the", "objective", "of", "filing", "an", "IND", "and", "beginning", "clinical", "development.", "<tag3>"], "wordsA": ["We", "continue", "to", "advance", "our", "most", "promising", "research", "drug", "candidates", "into", "preclinical", "development", "with", "the", "objective", "of", "advancing", "these", "early", "stage", "research", "programs", "to", "human", "clinical", "studies", "over", "the", "next", "several", "years."], "wordsB": ["NKTR-262", "is", "currently", "advancing", "through", "preclinical", "development", "with", "the", "objective", "of", "filing", "an", "IND", "and", "beginning", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p34_s0", "idA": "906709_16_item1_p26_s6", "sentA": "Enter into Strategic and High-Value Partnerships to Bring Certain of Our Drug Candidates to Market We decide on a drug candidate-by-drug candidate basis how far to advance clinical development (e.g. Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "sentB": "Enter int o Strategic and High-Value Partnerships to Bring Certain of Our Drug Candidates to Market We decide on a drug candidate-by-drug candidate basis how far to advance clinical development (e.g. Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "type": 2, "words": ["<tag1>", "Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag2>", "Enter", "int", "o", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag3>"], "wordsA": ["Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "wordsB": ["Enter", "int", "o", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p35_s0", "idA": "906709_16_item1_p27_s0", "sentA": "We are committed to continuing to build on our intellectual property position in the field of PEGylation and polymer conjugate chemistry.", "sentB": "We are committed to continuing to build on our intellectual property position in the field of polymer conjugate chemistry.", "type": 2, "words": ["<tag1>", "We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "PEGylation", "and", "polymer", "conjugate", "chemistry.", "<tag2>", "We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "polymer", "conjugate", "chemistry.", "<tag3>"], "wordsA": ["We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "PEGylation", "and", "polymer", "conjugate", "chemistry."], "wordsB": ["We", "are", "committed", "to", "continuing", "to", "build", "on", "our", "intellectual", "property", "position", "in", "the", "field", "of", "polymer", "conjugate", "chemistry."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p13_s0", "idA": "906709_16_item1_p2_s2", "sentA": "In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK TM (previously referred to as naloxegol and NKTR-118), under a global license agreement with AstraZeneca AB (AstraZeneca).", "sentB": "Collaboration Partner Programs In 2014, we achieved the first approval of one of our proprietary drug candidates, MOVANTIK (naloxegol), under a global license agreement with AstraZeneca AB (AstraZeneca).", "type": 2, "words": ["<tag1>", "In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "TM", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca).", "<tag2>", "Collaboration", "Partner", "Programs", "In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "(naloxegol),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca).", "<tag3>"], "wordsA": ["In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "TM", "(previously", "referred", "to", "as", "naloxegol", "and", "NKTR-118),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)."], "wordsB": ["Collaboration", "Partner", "Programs", "In", "2014,", "we", "achieved", "the", "first", "approval", "of", "one", "of", "our", "proprietary", "drug", "candidates,", "MOVANTIK", "(naloxegol),", "under", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p14_s0", "idA": "906709_16_item1_p2_s3", "sentA": "MOVANTIK TM is an oral peripherally-acting mu-opioid antagonist (PAMORA), approved in both the U.S. and Europe for the treatment of opioid-induced constipation, or OIC, a common side effect caused by chronic administration of prescription opioid pain medicines.", "sentB": "MOVANTIK is an oral peripherally-acting opioid antagonist, for the treatment of opioid-induced constipation, or OIC, a side effect caused by chronic administration of prescription opioid pain medicines.", "type": 2, "words": ["<tag1>", "MOVANTIK", "TM", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag2>", "MOVANTIK", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines.", "<tag3>"], "wordsA": ["MOVANTIK", "TM", "is", "an", "oral", "peripherally-acting", "mu-opioid", "antagonist", "(PAMORA),", "approved", "in", "both", "the", "U.S.", "and", "Europe", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "common", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "wordsB": ["MOVANTIK", "is", "an", "oral", "peripherally-acting", "opioid", "antagonist,", "for", "the", "treatment", "of", "opioid-induced", "constipation,", "or", "OIC,", "a", "side", "effect", "caused", "by", "chronic", "administration", "of", "prescription", "opioid", "pain", "medicines."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p74_s1", "idA": "906709_16_item1_p34_s2", "sentA": "These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.", "sentB": "Our agreements with collaboration partners may involve several elements including a technology license as well as the development, commercialization, and manufacturing and supply obligations.", "type": 2, "words": ["<tag1>", "These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products.", "<tag2>", "Our", "agreements", "with", "collaboration", "partners", "may", "involve", "several", "elements", "including", "a", "technology", "license", "as", "well", "as", "the", "development,", "commercialization,", "and", "manufacturing", "and", "supply", "obligations.", "<tag3>"], "wordsA": ["These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products."], "wordsB": ["Our", "agreements", "with", "collaboration", "partners", "may", "involve", "several", "elements", "including", "a", "technology", "license", "as", "well", "as", "the", "development,", "commercialization,", "and", "manufacturing", "and", "supply", "obligations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s2", "idA": "906709_16_item1_p3_s0", "sentA": "We have a collaboration with certain subsidiaries of Baxalta Incorporated (Baxalta), formerly Baxter International Inc. (Baxter) before the separation of Baxalta from Baxter in July 2015, to identify and develop PEGylated drug candidates with the objective of providing new longer-acting therapies for hemophilia patients.", "sentB": "We have a collaboration with Baxalta Incorporated, (a wholly-owned, indirect subsidiary of Shire plc) to develop and commercialize PEGylated drug candidates with the objective of providing new long-acting therapies for hemophilia patients.", "type": 2, "words": ["<tag1>", "We", "have", "a", "collaboration", "with", "certain", "subsidiaries", "of", "Baxalta", "Incorporated", "(Baxalta),", "formerly", "Baxter", "International", "Inc.", "(Baxter)", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "longer-acting", "therapies", "for", "hemophilia", "patients.", "<tag2>", "We", "have", "a", "collaboration", "with", "Baxalta", "Incorporated,", "(a", "wholly-owned,", "indirect", "subsidiary", "of", "Shire", "plc)", "to", "develop", "and", "commercialize", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients.", "<tag3>"], "wordsA": ["We", "have", "a", "collaboration", "with", "certain", "subsidiaries", "of", "Baxalta", "Incorporated", "(Baxalta),", "formerly", "Baxter", "International", "Inc.", "(Baxter)", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "identify", "and", "develop", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "longer-acting", "therapies", "for", "hemophilia", "patients."], "wordsB": ["We", "have", "a", "collaboration", "with", "Baxalta", "Incorporated,", "(a", "wholly-owned,", "indirect", "subsidiary", "of", "Shire", "plc)", "to", "develop", "and", "commercialize", "PEGylated", "drug", "candidates", "with", "the", "objective", "of", "providing", "new", "long-acting", "therapies", "for", "hemophilia", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s3", "idA": "906709_16_item1_p3_s1", "sentA": "Under this collaboration, we worked with Baxter to develop ADYNOVATE TM (previously referred to as BAX 855), an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "sentB": "Under this collaboration, we worked with Baxalta to develop ADYNOVATE (previously referred to as BAX 855), an extended half-life recombinant factor VIII (rFVIII) treatment for Hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].", "type": 2, "words": ["<tag1>", "Under", "this", "collaboration,", "we", "worked", "with", "Baxter", "to", "develop", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag2>", "Under", "this", "collaboration,", "we", "worked", "with", "Baxalta", "to", "develop", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855),", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)].", "<tag3>"], "wordsA": ["Under", "this", "collaboration,", "we", "worked", "with", "Baxter", "to", "develop", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "wordsB": ["Under", "this", "collaboration,", "we", "worked", "with", "Baxalta", "to", "develop", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855),", "an", "extended", "half-life", "recombinant", "factor", "VIII", "(rFVIII)", "treatment", "for", "Hemophilia", "A", "based", "on", "ADVATE", "[Antihemophilic", "Factor", "(Recombinant)]."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s4", "idA": "906709_16_item1_p3_s2", "sentA": "In November 2015, ADYNOVATE TM was approved by the U.S. Food and Drug Administration (FDA) for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Baxalta announced the launch and first shipments of ADYNOVATE TM in the U.S. on November 30, 2015.", "sentB": "In November 2015, ADYNOVATE was approved by the U.S. Food and Drug Administration (FDA) for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Baxalta announced the launch and first shipments of ADYNOVATE in the U.S. on November 30, 2015.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "on", "November", "30,", "2015.", "<tag2>", "In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "in", "the", "U.S.", "on", "November", "30,", "2015.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "on", "November", "30,", "2015."], "wordsB": ["In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "in", "the", "U.S.", "on", "November", "30,", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p74_s4", "idA": "906709_16_item1_p43_s0", "sentA": "In September 2009, we entered into a global license agreement with AstraZeneca AB pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell MOVANTIK TM and MOVANTIK TM fixed-dose combination products.", "sentB": "In September 2009, we entered into a global license agreement with AstraZeneca AB (AstraZeneca) pursuant to which we granted AstraZeneca a worldwide, exclusive, perpetual, royalty-bearing license under our patents and other intellectual property to develop, market and sell MOVANTIK and MOVANTIK fixed-dose combination products.", "type": 2, "words": ["<tag1>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products.", "<tag2>", "In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products."], "wordsB": ["In", "September", "2009,", "we", "entered", "into", "a", "global", "license", "agreement", "with", "AstraZeneca", "AB", "(AstraZeneca)", "pursuant", "to", "which", "we", "granted", "AstraZeneca", "a", "worldwide,", "exclusive,", "perpetual,", "royalty-bearing", "license", "under", "our", "patents", "and", "other", "intellectual", "property", "to", "develop,", "market", "and", "sell", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p75_s0", "idA": "906709_16_item1_p45_s0", "sentA": "MOVANTIK TM is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications.", "sentB": "MOVANTIK is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications.", "type": 2, "words": ["<tag1>", "MOVANTIK", "TM", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag2>", "MOVANTIK", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag3>"], "wordsA": ["MOVANTIK", "TM", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "wordsB": ["MOVANTIK", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s0", "idA": "906709_16_item1_p48_s0", "sentA": "On September 16, 2014, the FDA approved MOVANTIK TM as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "sentB": "On September 16, 2014, the FDA approved MOVAN TIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "type": 2, "words": ["<tag1>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag2>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVAN", "TIK", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag3>"], "wordsA": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "TM", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "wordsB": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVAN", "TIK", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s1", "idA": "906709_16_item1_p48_s1", "sentA": "On December 9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG (the naloxegol brand name in the European Union, or EU) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "sentB": "Kyowa Hakko Kirin Co. Ltd. (Kirin) has exclusive marketing rights to MOVENTIG (the naloxegol brand name in the EU) in the EU, Iceland, Liechtenstein, Norway and Switzerland.", "type": 2, "words": ["<tag1>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag2>", "Kyowa", "Hakko", "Kirin", "Co.", "Ltd.", "(Kirin)", "has", "exclusive", "marketing", "rights", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "EU)", "in", "the", "EU,", "Iceland,", "Liechtenstein,", "Norway", "and", "Switzerland.", "<tag3>"], "wordsA": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "wordsB": ["Kyowa", "Hakko", "Kirin", "Co.", "Ltd.", "(Kirin)", "has", "exclusive", "marketing", "rights", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "EU)", "in", "the", "EU,", "Iceland,", "Liechtenstein,", "Norway", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s1", "idA": "906709_16_item1_p48_s1", "sentA": "On December 9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG (the naloxegol brand name in the European Union, or EU) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "sentB": "On December 9, 2014, the European Commission, or EC, granted Marketing Author isation to MOVENTIG (the naloxegol brand name in the European Union) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "type": 2, "words": ["<tag1>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag2>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Author", "isation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag3>"], "wordsA": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union,", "or", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "wordsB": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Author", "isation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s0", "idA": "906709_16_item1_p49_s1", "sentA": "AstraZeneca launched the commercial sales of MOVANTIK TM in the United States in March 2015 and MOVENTIG in Germany, the first EU member country, in August 2015.", "sentB": "AstraZeneca markets and sells MOVANTIK in the United States in collaboration with Daiichi Sankyo, Inc. (Daiichi).", "type": 2, "words": ["<tag1>", "AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "TM", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015.", "<tag2>", "AstraZeneca", "markets", "and", "sells", "MOVANTIK", "in", "the", "United", "States", "in", "collaboration", "with", "Daiichi", "Sankyo,", "Inc.", "(Daiichi).", "<tag3>"], "wordsA": ["AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "TM", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015."], "wordsB": ["AstraZeneca", "markets", "and", "sells", "MOVANTIK", "in", "the", "United", "States", "in", "collaboration", "with", "Daiichi", "Sankyo,", "Inc.", "(Daiichi)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s3", "idA": "906709_16_item1_p49_s1", "sentA": "AstraZeneca launched the commercial sales of MOVANTIK TM in the United States in March 2015 and MOVENTIG in Germany, the first EU member country, in August 2015.", "sentB": "AstraZeneca launched the commercial sales of MOVANTIK in the United States in March 2015 and MOVENTIG in Germany, the first EU member country, in August 2015.", "type": 2, "words": ["<tag1>", "AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "TM", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015.", "<tag2>", "AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015.", "<tag3>"], "wordsA": ["AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "TM", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015."], "wordsB": ["AstraZeneca", "launched", "the", "commercial", "sales", "of", "MOVANTIK", "in", "the", "United", "States", "in", "March", "2015", "and", "MOVENTIG", "in", "Germany,", "the", "first", "EU", "member", "country,", "in", "August", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s4", "idA": "906709_16_item1_p49_s2", "sentA": "Under the terms of our license agreement, AstraZeneca made an initial license payment of $125.0 million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK TM and MOVANTIK TM fixed-dose combination products.", "sentB": "Under the terms of our license agreement with AstraZeneca, AstraZeneca made an initial license payment of $125.0 million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK and MOVANTIK fixed-dose combinati on products.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products.", "<tag2>", "Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combinati", "on", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "license", "agreement,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "TM", "and", "MOVANTIK", "TM", "fixed-dose", "combination", "products."], "wordsB": ["Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combinati", "on", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s5", "idA": "906709_16_item1_p49_s3", "sentA": "We received milestone payments of $70.0 million and $25.0 million upon the acceptance of regulatory approval applications of MOVANTIK TM by the FDA and European Medicines Agency (EMA), respectively, in 2013.", "sentB": "We received milestone payments of $70.0 million and $25.0 million upon the acceptance of regulatory approval applications of MOVANTIK by the FDA and European Medicines Agency (EMA), respectively, in 2013.", "type": 2, "words": ["<tag1>", "We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "TM", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag2>", "We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag3>"], "wordsA": ["We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "TM", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "wordsB": ["We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s6", "idA": "906709_16_item1_p49_s4", "sentA": "We received an additional milestone payment of $35.0 million upon the FDA s approval of MOVANTIK TM in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK TM in the U.S. and $40.0 million for MOVENTIG in Germany.", "sentB": "We received an additional developmen tal milestone payment of $35.0 million upon the FDA s approval of MOVANTIK in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK in the U.S. and $40.0 million for MOVENTIG in Germany.", "type": 2, "words": ["<tag1>", "We", "received", "an", "additional", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "TM", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany.", "<tag2>", "We", "received", "an", "additional", "developmen", "tal", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany.", "<tag3>"], "wordsA": ["We", "received", "an", "additional", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "TM", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "TM", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany."], "wordsB": ["We", "received", "an", "additional", "developmen", "tal", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s7", "idA": "906709_16_item1_p49_s5", "sentA": "We are also entitled to up to $375.0 million in sales milestones for MOVANTIK TM if the program achieves certain annual commercial sales levels.", "sentB": "We are also e ntitled to up to $375.0 million in sales milestones for MOVANTIK if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "We", "are", "also", "entitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "TM", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "are", "also", "e", "ntitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["We", "are", "also", "entitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "TM", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "are", "also", "e", "ntitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s8", "idA": "906709_16_item1_p49_s6", "sentA": "For the MOVANTIK TM fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "sentB": "For the MOVANTIK fixed-dose combination products, we are also eligible to receive significant development milestones as well as significant sales milestone payments if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "For", "the", "MOVANTIK", "TM", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "For", "the", "MOVANTIK", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["For", "the", "MOVANTIK", "TM", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["For", "the", "MOVANTIK", "fixed-dose", "combination", "products,", "we", "are", "also", "eligible", "to", "receive", "significant", "development", "milestones", "as", "well", "as", "significant", "sales", "milestone", "payments", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s9", "idA": "906709_16_item1_p49_s7", "sentA": "For both MOVANTIK TM and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sales in the U.S. and 18% of net sales in the EU and rest of world, varying by country of sale and level of annual net sales.", "sentB": "For both MOVANTIK and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sa les in the U.S. and 18% of net sales in the EU and rest of world, varying by country of sale and level of annual net sales.", "type": 2, "words": ["<tag1>", "For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sa", "les", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag3>"], "wordsA": ["For", "both", "MOVANTIK", "TM", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sa", "les", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p78_s10", "idA": "906709_16_item1_p49_s8", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) a specified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) a specif ied period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "a", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "a", "specif", "ied", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "a", "specified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "a", "specif", "ied", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p42_s2", "idA": "906709_16_item1_p50_s0", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK TM fixed-dose combination product and has the right to develop multiple products which combine MOVANTIK TM with opioids.", "sentB": "Nektar and BMS will use commercially reasonable efforts to manufacture and supply its compound for each Combined Therapy Trial and will bear the costs related thereto.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "TM", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "TM", "with", "opioids.", "<tag2>", "Nektar", "and", "BMS", "will", "use", "commercially", "reasonable", "efforts", "to", "manufacture", "and", "supply", "its", "compound", "for", "each", "Combined", "Therapy", "Trial", "and", "will", "bear", "the", "costs", "related", "thereto.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "TM", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "TM", "with", "opioids."], "wordsB": ["Nektar", "and", "BMS", "will", "use", "commercially", "reasonable", "efforts", "to", "manufacture", "and", "supply", "its", "compound", "for", "each", "Combined", "Therapy", "Trial", "and", "will", "bear", "the", "costs", "related", "thereto."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p79_s0", "idA": "906709_16_item1_p50_s0", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK TM fixed-dose combination product and has the right to develop multiple products which combine MOVANTIK TM with opioids.", "sentB": "AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK fixed-dose combinati on product and has the right to develop multiple products which combine MOVANTIK with opioids.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "TM", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "TM", "with", "opioids.", "<tag2>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "fixed-dose", "combinati", "on", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "with", "opioids.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "TM", "fixed-dose", "combination", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "TM", "with", "opioids."], "wordsB": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "fixed-dose", "combinati", "on", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "with", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p80_s0", "idA": "906709_16_item1_p51_s0", "sentA": "There are a number of patents relevant to Movantik TM , some of which are listed in the FDA s Orange Book.", "sentB": "There are a number of patents relevant to MOVANTIK , some of which are listed in the FDA s Orange Book.", "type": 2, "words": ["<tag1>", "There", "are", "a", "number", "of", "patents", "relevant", "to", "Movantik", "TM", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book.", "<tag2>", "There", "are", "a", "number", "of", "patents", "relevant", "to", "MOVANTIK", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book.", "<tag3>"], "wordsA": ["There", "are", "a", "number", "of", "patents", "relevant", "to", "Movantik", "TM", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book."], "wordsB": ["There", "are", "a", "number", "of", "patents", "relevant", "to", "MOVANTIK", ",", "some", "of", "which", "are", "listed", "in", "the", "FDA", "s", "Orange", "Book."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p80_s1", "idA": "906709_16_item1_p51_s1", "sentA": "The Orange Book currently lists six patents for Movantik TM .", "sentB": "The Orange Book currently lists six patents for MOVANTIK .", "type": 2, "words": ["<tag1>", "The", "Orange", "Book", "currently", "lists", "six", "patents", "for", "Movantik", "TM", ".", "<tag2>", "The", "Orange", "Book", "currently", "lists", "six", "patents", "for", "MOVANTIK", ".", "<tag3>"], "wordsA": ["The", "Orange", "Book", "currently", "lists", "six", "patents", "for", "Movantik", "TM", "."], "wordsB": ["The", "Orange", "Book", "currently", "lists", "six", "patents", "for", "MOVANTIK", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s5", "idA": "906709_16_item1_p57_s1", "sentA": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "In the first phase of the PIVOT study, we expect to evaluate the clinical benefit, safety, and tolerability of combining NKTR-214 with Opdivo in patients.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "In", "the", "first", "phase", "of", "the", "PIVOT", "study,", "we", "expect", "to", "evaluate", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "patients.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["In", "the", "first", "phase", "of", "the", "PIVOT", "study,", "we", "expect", "to", "evaluate", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p59_s0", "idA": "906709_16_item1_p57_s1", "sentA": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "In 2016 we initiated a randomized Phase 3 confirmatory study to evaluate ONZEALD TM as compared to treatment of physician s choice (TPC) in approximately 350 adult patients with advanced breast cancer who have brain metastases (ATTAIN Study).", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "In", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician", "s", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "(ATTAIN", "Study).", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["In", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician", "s", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "(ATTAIN", "Study)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p11_s0", "idA": "906709_16_item1_p58_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "In 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181 dose levels that were included in SUMMIT-07.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "In", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181", "dose", "levels", "that", "were", "included", "in", "SUMMIT-07.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["In", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181", "dose", "levels", "that", "were", "included", "in", "SUMMIT-07."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p54_s0", "idA": "906709_16_item1_p58_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "In 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181 dose levels that were included in SUMMIT-07.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "In", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181", "dose", "levels", "that", "were", "included", "in", "SUMMIT-07.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["In", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181", "dose", "levels", "that", "were", "included", "in", "SUMMIT-07."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p11_s1", "idA": "906709_16_item1_p58_s1", "sentA": "In this study, NKTR-181 had highly statistically significant lower \"drug liking\" scores and reduced \"feeling high\" scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "In this study, NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "type": 2, "words": ["<tag1>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "\"drug", "liking\"", "scores", "and", "reduced", "\"feeling", "high\"", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag3>"], "wordsA": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "\"drug", "liking\"", "scores", "and", "reduced", "\"feeling", "high\"", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p54_s1", "idA": "906709_16_item1_p58_s1", "sentA": "In this study, NKTR-181 had highly statistically significant lower \"drug liking\" scores and reduced \"feeling high\" scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "In this study, NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "type": 2, "words": ["<tag1>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "\"drug", "liking\"", "scores", "and", "reduced", "\"feeling", "high\"", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag3>"], "wordsA": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "\"drug", "liking\"", "scores", "and", "reduced", "\"feeling", "high\"", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p17_s2", "idA": "906709_16_item1_p59_s0", "sentA": "On June 19, 2013, we presented data from the HAL study at the 2013 Annual Meeting of The College on Problems of Drug Dependence in San Diego, California.", "sentB": "In September 2016, Bayer Schering presented data from the first Phase 3 trail (RESPIRE 1) at the 2016 European Respiratory Society Annual Meeting which showed that the study met its co-primary endpoints for the every 14-day dosing arm of Cipro DPI.", "type": 2, "words": ["<tag1>", "On", "June", "19,", "2013,", "we", "presented", "data", "from", "the", "HAL", "study", "at", "the", "2013", "Annual", "Meeting", "of", "The", "College", "on", "Problems", "of", "Drug", "Dependence", "in", "San", "Diego,", "California.", "<tag2>", "In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI.", "<tag3>"], "wordsA": ["On", "June", "19,", "2013,", "we", "presented", "data", "from", "the", "HAL", "study", "at", "the", "2013", "Annual", "Meeting", "of", "The", "College", "on", "Problems", "of", "Drug", "Dependence", "in", "San", "Diego,", "California."], "wordsB": ["In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p99_s0", "idA": "906709_16_item1_p59_s0", "sentA": "On June 19, 2013, we presented data from the HAL study at the 2013 Annual Meeting of The College on Problems of Drug Dependence in San Diego, California.", "sentB": "In September 2016, Bayer Schering presented data from the first Phase 3 trail (RESPIRE 1) at the 2016 European Respiratory Society Annual Meeting which showed that the study met its co-primary endpoints for the every 14-day dosing arm of Cip ro DPI.", "type": 2, "words": ["<tag1>", "On", "June", "19,", "2013,", "we", "presented", "data", "from", "the", "HAL", "study", "at", "the", "2013", "Annual", "Meeting", "of", "The", "College", "on", "Problems", "of", "Drug", "Dependence", "in", "San", "Diego,", "California.", "<tag2>", "In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cip", "ro", "DPI.", "<tag3>"], "wordsA": ["On", "June", "19,", "2013,", "we", "presented", "data", "from", "the", "HAL", "study", "at", "the", "2013", "Annual", "Meeting", "of", "The", "College", "on", "Problems", "of", "Drug", "Dependence", "in", "San", "Diego,", "California."], "wordsB": ["In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cip", "ro", "DPI."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p2_s3", "idA": "906709_16_item1_p5_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "sentB": "NKTR-262 is currently advancing through preclinical development.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag2>", "NKTR-262", "is", "currently", "advancing", "through", "preclinical", "development.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "wordsB": ["NKTR-262", "is", "currently", "advancing", "through", "preclinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p3_s3", "idA": "906709_16_item1_p5_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "sentB": "NKTR-255 is currently advancing through preclinical development.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag2>", "NKTR-255", "is", "currently", "advancing", "through", "preclinical", "development.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "wordsB": ["NKTR-255", "is", "currently", "advancing", "through", "preclinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p9_s0", "idA": "906709_16_item1_p5_s0", "sentA": "NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "sentB": "Pain - NKTR-181 NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "type": 2, "words": ["<tag1>", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag2>", "Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag3>"], "wordsA": ["NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "wordsB": ["Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s4", "idA": "906709_16_item1_p5_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study in February 2015 and the study continues to enroll patients.", "sentB": "meeting in November 2016 and the ASCO-GU meeting in February 2017.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients.", "<tag2>", "meeting", "in", "November", "2016", "and", "the", "ASCO-GU", "meeting", "in", "February", "2017.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients."], "wordsB": ["meeting", "in", "November", "2016", "and", "the", "ASCO-GU", "meeting", "in", "February", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p53_s1", "idA": "906709_16_item1_p5_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study in February 2015 and the study continues to enroll patients.", "sentB": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in the fourth quarter of 2016.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "the", "fourth", "quarter", "of", "2016.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "the", "fourth", "quarter", "of", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p9_s1", "idA": "906709_16_item1_p5_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study in February 2015 and the study continues to enroll patients.", "sentB": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in late 2016.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study", "in", "February", "2015", "and", "the", "study", "continues", "to", "enroll", "patients."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p10_s0", "idA": "906709_16_item1_p5_s2", "sentA": "In this study, we are randomizing patients with chronic low back pain in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "sentB": "In this study, we randomized patients with chronic low back pain in an enriched enrollment randomized withdrawal design which included a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12-week double-blind randomized period where subjects were randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "type": 2, "words": ["<tag1>", "In", "this", "study,", "we", "are", "randomizing", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag2>", "In", "this", "study,", "we", "randomized", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "included", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12-week", "double-blind", "randomized", "period", "where", "subjects", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag3>"], "wordsA": ["In", "this", "study,", "we", "are", "randomizing", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "wordsB": ["In", "this", "study,", "we", "randomized", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "included", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12-week", "double-blind", "randomized", "period", "where", "subjects", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p53_s2", "idA": "906709_16_item1_p5_s2", "sentA": "In this study, we are randomizing patients with chronic low back pain in an enriched enrollment randomized withdrawal design which will include a qualifying screening period, an open-label titration period where NKTR-181 is given to all patients, followed by a 12 week double-blind randomized period where subjects will be randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "sentB": "In this study, we randomized patients with chronic low back pain in an enriched enrollment randomized withdrawal design which included a qualifying screening period, an open-label titration period where NKTR-181 was given to all patients, followed by a 12-week double-blind randomized period where subjects were randomized on a 1:1 basis to receive either NKTR-181 or placebo.", "type": 2, "words": ["<tag1>", "In", "this", "study,", "we", "are", "randomizing", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag2>", "In", "this", "study,", "we", "randomized", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "included", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "was", "given", "to", "all", "patients,", "followed", "by", "a", "12-week", "double-blind", "randomized", "period", "where", "subjects", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo.", "<tag3>"], "wordsA": ["In", "this", "study,", "we", "are", "randomizing", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "will", "include", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "is", "given", "to", "all", "patients,", "followed", "by", "a", "12", "week", "double-blind", "randomized", "period", "where", "subjects", "will", "be", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "wordsB": ["In", "this", "study,", "we", "randomized", "patients", "with", "chronic", "low", "back", "pain", "in", "an", "enriched", "enrollment", "randomized", "withdrawal", "design", "which", "included", "a", "qualifying", "screening", "period,", "an", "open-label", "titration", "period", "where", "NKTR-181", "was", "given", "to", "all", "patients,", "followed", "by", "a", "12-week", "double-blind", "randomized", "period", "where", "subjects", "were", "randomized", "on", "a", "1:1", "basis", "to", "receive", "either", "NKTR-181", "or", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p53_s0", "idA": "906709_16_item1_p60_s0", "sentA": "In October 2014, we engaged in an end-of-Phase 2 meeting for NKTR-181 with the FDA , which included discuss ions of the design of the Phase 3 clinical study program .", "sentB": "In October 2014, we engaged in an end-of-Phase 2 meeting for NKTR-181 with the FDA, which included discussions of the design of the Phase 3 clinical study program.", "type": 2, "words": ["<tag1>", "In", "October", "2014,", "we", "engaged", "in", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA", ",", "which", "included", "discuss", "ions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program", ".", "<tag2>", "In", "October", "2014,", "we", "engaged", "in", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program.", "<tag3>"], "wordsA": ["In", "October", "2014,", "we", "engaged", "in", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA", ",", "which", "included", "discuss", "ions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program", "."], "wordsB": ["In", "October", "2014,", "we", "engaged", "in", "an", "end-of-Phase", "2", "meeting", "for", "NKTR-181", "with", "the", "FDA,", "which", "included", "discussions", "of", "the", "design", "of", "the", "Phase", "3", "clinical", "study", "program."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s3", "idA": "906709_16_item1_p68_s0", "sentA": "NKTR-102 is currently being evaluated as a single-agent therapy (145 mg/m2 every 21 days) in a Phase 3 open-label, randomized, multicenter clinical study in patients with metastatic breast cancer.", "sentB": "A Phase 1 trial for NKTR-214 as a single-agent in cancer patients with solid tumors has completed recruitment.", "type": 2, "words": ["<tag1>", "NKTR-102", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer.", "<tag2>", "A", "Phase", "1", "trial", "for", "NKTR-214", "as", "a", "single-agent", "in", "cancer", "patients", "with", "solid", "tumors", "has", "completed", "recruitment.", "<tag3>"], "wordsA": ["NKTR-102", "is", "currently", "being", "evaluated", "as", "a", "single-agent", "therapy", "(145", "mg/m2", "every", "21", "days)", "in", "a", "Phase", "3", "open-label,", "randomized,", "multicenter", "clinical", "study", "in", "patients", "with", "metastatic", "breast", "cancer."], "wordsB": ["A", "Phase", "1", "trial", "for", "NKTR-214", "as", "a", "single-agent", "in", "cancer", "patients", "with", "solid", "tumors", "has", "completed", "recruitment."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s11", "idA": "906709_16_item1_p68_s1", "sentA": "This Phase 3 clinical study, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), enrolled approximately 850 patients with metastatic breast cancer who have had prior treatment with anthracycline, taxane and capecitabine in either the adjuvant or metastatic setting.", "sentB": "(Daiichi Europe) and in connection with MAA filing for ONZEALD TM , in the fourth quarter of 2016 we initiated a randomized Phase 3 confirmatory study to evaluate ONZEALD TM as compared to treatment of physician's choice (TPC) in approximately 350 adult patients with advanced breast cancer who have brain metastases, which we call the ATTAIN study.", "type": 2, "words": ["<tag1>", "This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting.", "<tag2>", "(Daiichi", "Europe)", "and", "in", "connection", "with", "MAA", "filing", "for", "ONZEALD", "TM", ",", "in", "the", "fourth", "quarter", "of", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician's", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases,", "which", "we", "call", "the", "ATTAIN", "study.", "<tag3>"], "wordsA": ["This", "Phase", "3", "clinical", "study,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "enrolled", "approximately", "850", "patients", "with", "metastatic", "breast", "cancer", "who", "have", "had", "prior", "treatment", "with", "anthracycline,", "taxane", "and", "capecitabine", "in", "either", "the", "adjuvant", "or", "metastatic", "setting."], "wordsB": ["(Daiichi", "Europe)", "and", "in", "connection", "with", "MAA", "filing", "for", "ONZEALD", "TM", ",", "in", "the", "fourth", "quarter", "of", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician's", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases,", "which", "we", "call", "the", "ATTAIN", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s3", "idA": "906709_16_item1_p69_s1", "sentA": "In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC).", "sentB": "In a topline analysis of 852 patients from the trial, ONZEALD TM provided a 2.1 month improvement in median overall survival over TPC (12.4 months for patients receiving ONZEALD TM compared to 10.3 months for patients receiving TPC).", "type": 2, "words": ["<tag1>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag2>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "wordsB": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s3", "idA": "906709_16_item1_p69_s1", "sentA": "In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival (OS) over TPC (12.4 months for patients receiving NKTR-102 compared to 10.3 months for patients receiving TPC).", "sentB": "In a topline analysis of 852 patients from the trial, ONZEALD T M provided a 2.1 month improvement in median overall survival over TPC (12.4 months for patients receiving ONZEALD TM compared to 10.3 months for patients receiving TPC).", "type": 2, "words": ["<tag1>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag2>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "T", "M", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "NKTR-102", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "(OS)", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "NKTR-102", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "wordsB": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "T", "M", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s4", "idA": "906709_16_item1_p69_s2", "sentA": "Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio (HR) for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance.", "sentB": "Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio (HR) for survival in the ONZEALD TM group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance.", "type": 2, "words": ["<tag1>", "Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance.", "<tag2>", "Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "ONZEALD", "TM", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance.", "<tag3>"], "wordsA": ["Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance."], "wordsB": ["Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "ONZEALD", "TM", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s4", "idA": "906709_16_item1_p69_s2", "sentA": "Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio (HR) for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance.", "sentB": "Based on a stratified log-rank analysis, the primary endpoint measuring the hazard ratio for survival in the ONZEALD TM group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance.", "type": 2, "words": ["<tag1>", "Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance.", "<tag2>", "Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "hazard", "ratio", "for", "survival", "in", "the", "ONZEALD", "TM", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance.", "<tag3>"], "wordsA": ["Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "Hazard", "Ratio", "(HR)", "for", "survival", "in", "the", "NKTR-102", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance."], "wordsB": ["Based", "on", "a", "stratified", "log-rank", "analysis,", "the", "primary", "endpoint", "measuring", "the", "hazard", "ratio", "for", "survival", "in", "the", "ONZEALD", "TM", "group", "compared", "to", "the", "active", "control", "arm", "was", "0.87", "with", "a", "p-value", "of", "0.08,", "which", "did", "not", "achieve", "statistical", "significance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s8", "idA": "906709_16_item1_p69_s6", "sentA": "In Europe, we have met with the National Authorities in Sweden (MPA) and the United Kingdom (MHRA) to discuss the BEACON data.", "sentB": "In Europe, we met with the National Authorities in Sweden and the United Kingdom, as well as the European Medicines Agency (EMA) to discuss the BEACON data.", "type": 2, "words": ["<tag1>", "In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data.", "<tag2>", "In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data.", "<tag3>"], "wordsA": ["In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data."], "wordsB": ["In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s8", "idA": "906709_16_item1_p69_s6", "sentA": "In Europe, we have met with the National Authorities in Sweden (MPA) and the United Kingdom (MHRA) to discuss the BEACON data.", "sentB": "In Europe, we met with the National Authorities in Sweden and the United Kingdom, as well as the European Medicines Agency (EMA) to discuss the BEACON data.", "type": 2, "words": ["<tag1>", "In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data.", "<tag2>", "In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data.", "<tag3>"], "wordsA": ["In", "Europe,", "we", "have", "met", "with", "the", "National", "Authorities", "in", "Sweden", "(MPA)", "and", "the", "United", "Kingdom", "(MHRA)", "to", "discuss", "the", "BEACON", "data."], "wordsB": ["In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s10", "idA": "906709_16_item1_p69_s9", "sentA": "In connection with any MAA filing, the EMA has informed us that we would be required to start a confirmatory trial in conjunction with the MAA review.", "sentB": "On July 14, 2016, we received a letter from the EMA notifying us that the ONZEALD TM MAA successfully passed validation to be accepted for review.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "any", "MAA", "filing,", "the", "EMA", "has", "informed", "us", "that", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review.", "<tag2>", "On", "July", "14,", "2016,", "we", "received", "a", "letter", "from", "the", "EMA", "notifying", "us", "that", "the", "ONZEALD", "TM", "MAA", "successfully", "passed", "validation", "to", "be", "accepted", "for", "review.", "<tag3>"], "wordsA": ["In", "connection", "with", "any", "MAA", "filing,", "the", "EMA", "has", "informed", "us", "that", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review."], "wordsB": ["On", "July", "14,", "2016,", "we", "received", "a", "letter", "from", "the", "EMA", "notifying", "us", "that", "the", "ONZEALD", "TM", "MAA", "successfully", "passed", "validation", "to", "be", "accepted", "for", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s10", "idA": "906709_16_item1_p69_s9", "sentA": "In connection with any MAA filing, the EMA has informed us that we would be required to start a confirmatory trial in conjunction with the MAA review.", "sentB": "On July 14, 2016, we received a letter from the EMA notifying us that the ONZEALD TM MAA successfully passed validation to be accepted for review.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "any", "MAA", "filing,", "the", "EMA", "has", "informed", "us", "that", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review.", "<tag2>", "On", "July", "14,", "2016,", "we", "received", "a", "letter", "from", "the", "EMA", "notifying", "us", "that", "the", "ONZEALD", "TM", "MAA", "successfully", "passed", "validation", "to", "be", "accepted", "for", "review.", "<tag3>"], "wordsA": ["In", "connection", "with", "any", "MAA", "filing,", "the", "EMA", "has", "informed", "us", "that", "we", "would", "be", "required", "to", "start", "a", "confirmatory", "trial", "in", "conjunction", "with", "the", "MAA", "review."], "wordsB": ["On", "July", "14,", "2016,", "we", "received", "a", "letter", "from", "the", "EMA", "notifying", "us", "that", "the", "ONZEALD", "TM", "MAA", "successfully", "passed", "validation", "to", "be", "accepted", "for", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p10_s1", "idA": "906709_16_item1_p6_s0", "sentA": "The NKTR-181 Phase 3 study design includes a single interim sample size assessment to be conducted by an independent analysis center (IAC) after approximately fifty percent of the initially planned 416 patients completed the study.", "sentB": "In 2016, we increased the sample size of this trial by approximately 200 patients following a pre-specified sample size assessment by the independent analysis center (IAC) after approximately fifty percent of the initially planned 416 patients completed the study.", "type": 2, "words": ["<tag1>", "The", "NKTR-181", "Phase", "3", "study", "design", "includes", "a", "single", "interim", "sample", "size", "assessment", "to", "be", "conducted", "by", "an", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study.", "<tag2>", "In", "2016,", "we", "increased", "the", "sample", "size", "of", "this", "trial", "by", "approximately", "200", "patients", "following", "a", "pre-specified", "sample", "size", "assessment", "by", "the", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study.", "<tag3>"], "wordsA": ["The", "NKTR-181", "Phase", "3", "study", "design", "includes", "a", "single", "interim", "sample", "size", "assessment", "to", "be", "conducted", "by", "an", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study."], "wordsB": ["In", "2016,", "we", "increased", "the", "sample", "size", "of", "this", "trial", "by", "approximately", "200", "patients", "following", "a", "pre-specified", "sample", "size", "assessment", "by", "the", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p53_s3", "idA": "906709_16_item1_p6_s0", "sentA": "The NKTR-181 Phase 3 study design includes a single interim sample size assessment to be conducted by an independent analysis center (IAC) after approximately fifty percent of the initially planned 416 patients completed the study.", "sentB": "On February 29, 2016, we increased the sample size of this trial by approximately 200 patients following a pre-specified sample size assessment by the independent analysis center (IAC) after approximately fifty percent of the initially planned 416 patients completed the study.", "type": 2, "words": ["<tag1>", "The", "NKTR-181", "Phase", "3", "study", "design", "includes", "a", "single", "interim", "sample", "size", "assessment", "to", "be", "conducted", "by", "an", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study.", "<tag2>", "On", "February", "29,", "2016,", "we", "increased", "the", "sample", "size", "of", "this", "trial", "by", "approximately", "200", "patients", "following", "a", "pre-specified", "sample", "size", "assessment", "by", "the", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study.", "<tag3>"], "wordsA": ["The", "NKTR-181", "Phase", "3", "study", "design", "includes", "a", "single", "interim", "sample", "size", "assessment", "to", "be", "conducted", "by", "an", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study."], "wordsB": ["On", "February", "29,", "2016,", "we", "increased", "the", "sample", "size", "of", "this", "trial", "by", "approximately", "200", "patients", "following", "a", "pre-specified", "sample", "size", "assessment", "by", "the", "independent", "analysis", "center", "(IAC)", "after", "approximately", "fifty", "percent", "of", "the", "initially", "planned", "416", "patients", "completed", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p53_s5", "idA": "906709_16_item1_p6_s2", "sentA": "The IAC s determination is nondiscretionary and was based upon our determination of pre-defined acceptable power to detect a statistically significant difference between NKTR-181 and placebo based on the primary efficacy endpoint.", "sentB": "The IAC s determination was nondiscretionary and was based upon our determination of pre-defined acceptable power to detect a statistically significant difference between NKTR-181 and placebo based on the primary efficacy endpoint.", "type": 2, "words": ["<tag1>", "The", "IAC", "s", "determination", "is", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint.", "<tag2>", "The", "IAC", "s", "determination", "was", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint.", "<tag3>"], "wordsA": ["The", "IAC", "s", "determination", "is", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint."], "wordsB": ["The", "IAC", "s", "determination", "was", "nondiscretionary", "and", "was", "based", "upon", "our", "determination", "of", "pre-defined", "acceptable", "power", "to", "detect", "a", "statistically", "significant", "difference", "between", "NKTR-181", "and", "placebo", "based", "on", "the", "primary", "efficacy", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p60_s1", "idA": "906709_16_item1_p70_s1", "sentA": "The chance of developing invasive breast cancer at some time in a woman s life is a little less than one in eight (12%).", "sentB": "The chance of developing invasive breast cancer at some time in a woman s life is a little less than one in eight (approximately 12%).", "type": 2, "words": ["<tag1>", "The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(12%).", "<tag2>", "The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(approximately", "12%).", "<tag3>"], "wordsA": ["The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(12%)."], "wordsB": ["The", "chance", "of", "developing", "invasive", "breast", "cancer", "at", "some", "time", "in", "a", "woman", "s", "life", "is", "a", "little", "less", "than", "one", "in", "eight", "(approximately", "12%)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p60_s2", "idA": "906709_16_item1_p70_s2", "sentA": "In 2016, the American Cancer Society estima tes there will be 246,660 new cases of invasive breast cancer diagnosed in the U.S. and about 40,450 women will die from breast cancer.", "sentB": "In 2017, the American Cancer Society estimates there will be 252,710 new cases of invasive breast cancer diagnosed in the U.S. and about 40,610 women will die from breast cancer.", "type": 2, "words": ["<tag1>", "In", "2016,", "the", "American", "Cancer", "Society", "estima", "tes", "there", "will", "be", "246,660", "new", "cases", "of", "invasive", "breast", "cancer", "diagnosed", "in", "the", "U.S.", "and", "about", "40,450", "women", "will", "die", "from", "breast", "cancer.", "<tag2>", "In", "2017,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "252,710", "new", "cases", "of", "invasive", "breast", "cancer", "diagnosed", "in", "the", "U.S.", "and", "about", "40,610", "women", "will", "die", "from", "breast", "cancer.", "<tag3>"], "wordsA": ["In", "2016,", "the", "American", "Cancer", "Society", "estima", "tes", "there", "will", "be", "246,660", "new", "cases", "of", "invasive", "breast", "cancer", "diagnosed", "in", "the", "U.S.", "and", "about", "40,450", "women", "will", "die", "from", "breast", "cancer."], "wordsB": ["In", "2017,", "the", "American", "Cancer", "Society", "estimates", "there", "will", "be", "252,710", "new", "cases", "of", "invasive", "breast", "cancer", "diagnosed", "in", "the", "U.S.", "and", "about", "40,610", "women", "will", "die", "from", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p62_s0", "idA": "906709_16_item1_p72_s0", "sentA": "There are currently no FDA-approved topoi somerase I inhibitors indicated to treat breast cancer.", "sentB": "There are currently no FDA-approved topoisomerase I inhibitors indicated to treat breast cancer.", "type": 2, "words": ["<tag1>", "There", "are", "currently", "no", "FDA-approved", "topoi", "somerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag2>", "There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer.", "<tag3>"], "wordsA": ["There", "are", "currently", "no", "FDA-approved", "topoi", "somerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "wordsB": ["There", "are", "currently", "no", "FDA-approved", "topoisomerase", "I", "inhibitors", "indicated", "to", "treat", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p62_s1", "idA": "906709_16_item1_p72_s1", "sentA": "We have also conducted clinical studies for NKTR-102 in other solid tumor settings.", "sentB": "We have also conducted clinical studies for ONZEALD TM in other solid tumor settings.", "type": 2, "words": ["<tag1>", "We", "have", "also", "conducted", "clinical", "studies", "for", "NKTR-102", "in", "other", "solid", "tumor", "settings.", "<tag2>", "We", "have", "also", "conducted", "clinical", "studies", "for", "ONZEALD", "TM", "in", "other", "solid", "tumor", "settings.", "<tag3>"], "wordsA": ["We", "have", "also", "conducted", "clinical", "studies", "for", "NKTR-102", "in", "other", "solid", "tumor", "settings."], "wordsB": ["We", "have", "also", "conducted", "clinical", "studies", "for", "ONZEALD", "TM", "in", "other", "solid", "tumor", "settings."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p62_s2", "idA": "906709_16_item1_p72_s2", "sentA": "In 2013, we completed a Phase 2 clinical study for NKTR-102 in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "sentB": "In 2013, we completed a Phase 2 clinical study for ONZEALD TM in approximately 170 patients with platinum-resistant/refractory ovarian cancer.", "type": 2, "words": ["<tag1>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "NKTR-102", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag2>", "In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "ONZEALD", "TM", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer.", "<tag3>"], "wordsA": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "NKTR-102", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "wordsB": ["In", "2013,", "we", "completed", "a", "Phase", "2", "clinical", "study", "for", "ONZEALD", "TM", "in", "approximately", "170", "patients", "with", "platinum-resistant/refractory", "ovarian", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p62_s3", "idA": "906709_16_item1_p72_s3", "sentA": "We also initiated a Phase 2 clinical study of NKTR-102 monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "sentB": "We also initiated a Phase 2 clinical study of ONZEALD TM monotherapy versus irinotecan in second-line metastatic colorectal cancer patients with the KRAS mutant gene.", "type": 2, "words": ["<tag1>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag2>", "We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "ONZEALD", "TM", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene.", "<tag3>"], "wordsA": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "NKTR-102", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "wordsB": ["We", "also", "initiated", "a", "Phase", "2", "clinical", "study", "of", "ONZEALD", "TM", "monotherapy", "versus", "irinotecan", "in", "second-line", "metastatic", "colorectal", "cancer", "patients", "with", "the", "KRAS", "mutant", "gene."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p62_s6", "idA": "906709_16_item1_p72_s6", "sentA": "We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate NKTR-102 in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.", "sentB": "We also conducted a Phase 1 dose-escalation clinical study which enrolled 26 patients to evaluate ONZEALD TM in combination with 5-Fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers.", "type": 2, "words": ["<tag1>", "We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "NKTR-102", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers.", "<tag2>", "We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "ONZEALD", "TM", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers.", "<tag3>"], "wordsA": ["We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "NKTR-102", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers."], "wordsB": ["We", "also", "conducted", "a", "Phase", "1", "dose-escalation", "clinical", "study", "which", "enrolled", "26", "patients", "to", "evaluate", "ONZEALD", "TM", "in", "combination", "with", "5-Fluorouracil", "(5-FU)/leucovorin", "in", "refractory", "solid", "tumor", "cancers."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s9", "idA": "906709_16_item1_p74_s0", "sentA": "In addition to the clinical study of NKTR-102 being conducted by us, we have also provided support for four investigator-initiated Phase 2 studies being conducted for NKTR-102.", "sentB": "In addition to the clinical program in collaboration with BMS, we also plan to initiate a broad clinical development program, both on our own or in collaboration with other potential partners, to explore the potential of combining NKTR-214 with therapies such as cancer vaccines, adoptive cell therapy, small molecules, and other biological agents in order to generate novel immune-oncology approaches.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102.", "<tag2>", "In", "addition", "to", "the", "clinical", "program", "in", "collaboration", "with", "BMS,", "we", "also", "plan", "to", "initiate", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102."], "wordsB": ["In", "addition", "to", "the", "clinical", "program", "in", "collaboration", "with", "BMS,", "we", "also", "plan", "to", "initiate", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p42_s3", "idA": "906709_16_item1_p74_s0", "sentA": "In addition to the clinical study of NKTR-102 being conducted by us, we have also provided support for four investigator-initiated Phase 2 studies being conducted for NKTR-102.", "sentB": "In addition to the clinical trials in collaboration with BMS, we also plan to initiate a broad clinical development program, both on our own or in collaboration with other potential partners, to explore the potential of combining NKTR-214 with therapies such as cancer vaccines, adoptive cell therapy, small molecules, and other biological agents in order to generate novel immune-oncology approaches.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102.", "<tag2>", "In", "addition", "to", "the", "clinical", "trials", "in", "collaboration", "with", "BMS,", "we", "also", "plan", "to", "initiate", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102."], "wordsB": ["In", "addition", "to", "the", "clinical", "trials", "in", "collaboration", "with", "BMS,", "we", "also", "plan", "to", "initiate", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p64_s1", "idA": "906709_16_item1_p74_s0", "sentA": "In addition to the clinical study of NKTR-102 being conducted by us, we have also provided support for four investigator-initiated Phase 2 studies being conducted for NKTR-102.", "sentB": "In addition to the clinical study of ONZEALD TM being conducted by us, we have also provided support for f our investigator-initiated Phase 2 studies being conducted for ONZEALD TM .", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102.", "<tag2>", "In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "f", "our", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", ".", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "study", "of", "NKTR-102", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "NKTR-102."], "wordsB": ["In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "f", "our", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p64_s2", "idA": "906709_16_item1_p74_s1", "sentA": "On August 7, 2012, we announced a Phase 2 investigator-initiated clinical study of NKTR-102 in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "sentB": "On August 7, 2012, we announced a Phase 2 investigator-initiated clinical study of ONZEALD TM in patients with bevacizumab (Avastin)-resistant high-grade glioma being conducted at the Stanford Cancer Institute.", "type": 2, "words": ["<tag1>", "On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag2>", "On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "ONZEALD", "TM", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute.", "<tag3>"], "wordsA": ["On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "wordsB": ["On", "August", "7,", "2012,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "ONZEALD", "TM", "in", "patients", "with", "bevacizumab", "(Avastin)-resistant", "high-grade", "glioma", "being", "conducted", "at", "the", "Stanford", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p64_s4", "idA": "906709_16_item1_p74_s3", "sentA": "A separate investigator-initiated clinical study is also being conducted at Stanford to evaluate NKTR-102 in patients with brain metastasis from primary lung cancer.", "sentB": "A separate investigator-initiated clinical study is also being conducted at Stanford to evaluate ONZEALD TM in patients with brain metastasis from primary lung cancer.", "type": 2, "words": ["<tag1>", "A", "separate", "investigator-initiated", "clinical", "study", "is", "also", "being", "conducted", "at", "Stanford", "to", "evaluate", "NKTR-102", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer.", "<tag2>", "A", "separate", "investigator-initiated", "clinical", "study", "is", "also", "being", "conducted", "at", "Stanford", "to", "evaluate", "ONZEALD", "TM", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer.", "<tag3>"], "wordsA": ["A", "separate", "investigator-initiated", "clinical", "study", "is", "also", "being", "conducted", "at", "Stanford", "to", "evaluate", "NKTR-102", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer."], "wordsB": ["A", "separate", "investigator-initiated", "clinical", "study", "is", "also", "being", "conducted", "at", "Stanford", "to", "evaluate", "ONZEALD", "TM", "in", "patients", "with", "brain", "metastasis", "from", "primary", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p64_s5", "idA": "906709_16_item1_p74_s4", "sentA": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of NKTR-102 in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "sentB": "On February 5, 2013, we announced a Phase 2 investigator-initiated clinical study of ONZEALD TM in patients with metastatic and recurrent non-small cell lung cancer being conducted at the Abramson Cancer Center of the University of Pennsylvania.", "type": 2, "words": ["<tag1>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag2>", "On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "ONZEALD", "TM", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania.", "<tag3>"], "wordsA": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "wordsB": ["On", "February", "5,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "ONZEALD", "TM", "in", "patients", "with", "metastatic", "and", "recurrent", "non-small", "cell", "lung", "cancer", "being", "conducted", "at", "the", "Abramson", "Cancer", "Center", "of", "the", "University", "of", "Pennsylvania."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p64_s6", "idA": "906709_16_item1_p74_s5", "sentA": "On October 24, 2013, we announced a Phase 2 investigator-initiated clinical study of NKTR-102 in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute.", "sentB": "On October 24, 2013, we announced a Phase 2 investigator-initiated clinical study of ONZEALD TM in patients with relapsed or refractory small-cell lung cancer at the Roswell Park Cancer Institute.", "type": 2, "words": ["<tag1>", "On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute.", "<tag2>", "On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "ONZEALD", "TM", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute.", "<tag3>"], "wordsA": ["On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "NKTR-102", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute."], "wordsB": ["On", "October", "24,", "2013,", "we", "announced", "a", "Phase", "2", "investigator-initiated", "clinical", "study", "of", "ONZEALD", "TM", "in", "patients", "with", "relapsed", "or", "refractory", "small-cell", "lung", "cancer", "at", "the", "Roswell", "Park", "Cancer", "Institute."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p40_s0", "idA": "906709_16_item1_p7_s0", "sentA": "In December 2015, we dosed the first patient in a Phase 1/2 clinical study for NKTR-214, which is our engineered immunostimulatory CD122-biased cytokine designed to preferentially activate the beta and gamma sub-units of the IL-2 receptor in orde r to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "We are currently conducting a Phase 1/2 clinical study for NKTR-214, which is our engineered immunostimulatory CD122-biased cytokine designed to preferentially activate the beta and gamma sub-units of the IL-2 receptor with the objective to induce proliferation and accumulation of tumor-killing lymphocyte cells within the body (CD8-positive effector T cells and natural killer T cells) with limited activity on regulatory T cells (CD4-positive T cells).", "type": 2, "words": ["<tag1>", "In", "December", "2015,", "we", "dosed", "the", "first", "patient", "in", "a", "Phase", "1/2", "clinical", "study", "for", "NKTR-214,", "which", "is", "our", "engineered", "immunostimulatory", "CD122-biased", "cytokine", "designed", "to", "preferentially", "activate", "the", "beta", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "orde", "r", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "We", "are", "currently", "conducting", "a", "Phase", "1/2", "clinical", "study", "for", "NKTR-214,", "which", "is", "our", "engineered", "immunostimulatory", "CD122-biased", "cytokine", "designed", "to", "preferentially", "activate", "the", "beta", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "with", "the", "objective", "to", "induce", "proliferation", "and", "accumulation", "of", "tumor-killing", "lymphocyte", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "with", "limited", "activity", "on", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag3>"], "wordsA": ["In", "December", "2015,", "we", "dosed", "the", "first", "patient", "in", "a", "Phase", "1/2", "clinical", "study", "for", "NKTR-214,", "which", "is", "our", "engineered", "immunostimulatory", "CD122-biased", "cytokine", "designed", "to", "preferentially", "activate", "the", "beta", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "orde", "r", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["We", "are", "currently", "conducting", "a", "Phase", "1/2", "clinical", "study", "for", "NKTR-214,", "which", "is", "our", "engineered", "immunostimulatory", "CD122-biased", "cytokine", "designed", "to", "preferentially", "activate", "the", "beta", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "with", "the", "objective", "to", "induce", "proliferation", "and", "accumulation", "of", "tumor-killing", "lymphocyte", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "with", "limited", "activity", "on", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p40_s1", "idA": "906709_16_item1_p7_s1", "sentA": "The study is being conducted initially at two primary investigator sites: the University of Texas MD Anderson Cancer Center and Yale Cancer Center.", "sentB": "The study is being conducted initially at three primary investigator sites: the University of Texas MD Anderson Cancer Center, Yale Cancer Center and the Providence Cancer Center in Portland, Oregon.", "type": 2, "words": ["<tag1>", "The", "study", "is", "being", "conducted", "initially", "at", "two", "primary", "investigator", "sites:", "the", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center", "and", "Yale", "Cancer", "Center.", "<tag2>", "The", "study", "is", "being", "conducted", "initially", "at", "three", "primary", "investigator", "sites:", "the", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center,", "Yale", "Cancer", "Center", "and", "the", "Providence", "Cancer", "Center", "in", "Portland,", "Oregon.", "<tag3>"], "wordsA": ["The", "study", "is", "being", "conducted", "initially", "at", "two", "primary", "investigator", "sites:", "the", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center", "and", "Yale", "Cancer", "Center."], "wordsB": ["The", "study", "is", "being", "conducted", "initially", "at", "three", "primary", "investigator", "sites:", "the", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center,", "Yale", "Cancer", "Center", "and", "the", "Providence", "Cancer", "Center", "in", "Portland,", "Oregon."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p94_s1", "idA": "906709_16_item1_p80_s0", "sentA": "The global INHALE development program is comprised of two prospective, randomized, double-blind, placebo-controlled, large multi-center global programs involving centers in North America, South America, Europe, Jap an, Australia and Asia.", "sentB": "The global INHALE development program is comprised of two prospective, randomized, double-blind, placebo-controlled, large multi-center global programs involving centers in North America, South America, Europe, Japan, Australia and Asia.", "type": 2, "words": ["<tag1>", "The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Jap", "an,", "Australia", "and", "Asia.", "<tag2>", "The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Japan,", "Australia", "and", "Asia.", "<tag3>"], "wordsA": ["The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Jap", "an,", "Australia", "and", "Asia."], "wordsB": ["The", "global", "INHALE", "development", "program", "is", "comprised", "of", "two", "prospective,", "randomized,", "double-blind,", "placebo-controlled,", "large", "multi-center", "global", "programs", "involving", "centers", "in", "North", "America,", "South", "America,", "Europe,", "Japan,", "Australia", "and", "Asia."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p48_s1", "idA": "906709_16_item1_p81_s0", "sentA": "NKTR-214 is a CD122-biased immune-stimulatory cytokine designed for the treatment of solid tumors.", "sentB": "We plan to evaluate NKTR-358 in clinical studies for the treatment of systemic lupus erythematosus and other indications.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "designed", "for", "the", "treatment", "of", "solid", "tumors.", "<tag2>", "We", "plan", "to", "evaluate", "NKTR-358", "in", "clinical", "studies", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus", "and", "other", "indications.", "<tag3>"], "wordsA": ["NKTR-214", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "designed", "for", "the", "treatment", "of", "solid", "tumors."], "wordsB": ["We", "plan", "to", "evaluate", "NKTR-358", "in", "clinical", "studies", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus", "and", "other", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s0", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "In the area of I-O, we are developing medicines that target biological pathways which stimulate and sustain the body s immune response in order to fight cancer.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "In", "the", "area", "of", "I-O,", "we", "are", "developing", "medicines", "that", "target", "biological", "pathways", "which", "stimulate", "and", "sustain", "the", "body", "s", "immune", "response", "in", "order", "to", "fight", "cancer.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["In", "the", "area", "of", "I-O,", "we", "are", "developing", "medicines", "that", "target", "biological", "pathways", "which", "stimulate", "and", "sustain", "the", "body", "s", "immune", "response", "in", "order", "to", "fight", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p2_s1", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "NKTR-262 is designed to stimulate the innate immune system and promote maturation and activation of antigen-presenting cells (APC), such as dendritic cells, which are critical to induce the body s adaptive immunity and create antigen-specific cytotoxic T cells.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "NKTR-262", "is", "designed", "to", "stimulate", "the", "innate", "immune", "system", "and", "promote", "maturation", "and", "activation", "of", "antigen-presenting", "cells", "(APC),", "such", "as", "dendritic", "cells,", "which", "are", "critical", "to", "induce", "the", "body", "s", "adaptive", "immunity", "and", "create", "antigen-specific", "cytotoxic", "T", "cells.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["NKTR-262", "is", "designed", "to", "stimulate", "the", "innate", "immune", "system", "and", "promote", "maturation", "and", "activation", "of", "antigen-presenting", "cells", "(APC),", "such", "as", "dendritic", "cells,", "which", "are", "critical", "to", "induce", "the", "body", "s", "adaptive", "immunity", "and", "create", "antigen-specific", "cytotoxic", "T", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p3_s0", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "NKTR-255 is a biologic that targets the interleukin-15 pathway in order to activate the body s innate and adaptive immunity.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "NKTR-255", "is", "a", "biologic", "that", "targets", "the", "interleukin-15", "pathway", "in", "order", "to", "activate", "the", "body", "s", "innate", "and", "adaptive", "immunity.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["NKTR-255", "is", "a", "biologic", "that", "targets", "the", "interleukin-15", "pathway", "in", "order", "to", "activate", "the", "body", "s", "innate", "and", "adaptive", "immunity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p7_s0", "idA": "906709_16_item1_p81_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "NKTR-358 is designed to optimally target the IL-2 receptor complex in order to stimulate proliferation and growth of T regulatory cells.", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "NKTR-358", "is", "designed", "to", "optimally", "target", "the", "IL-2", "receptor", "complex", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "T", "regulatory", "cells.", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["NKTR-358", "is", "designed", "to", "optimally", "target", "the", "IL-2", "receptor", "complex", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "T", "regulatory", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s8", "idA": "906709_16_item1_p82_s1", "sentA": "In December 2015, we announced that dosing had commenced in the Phase 1/2 clinical study evaluating the safety, tolerability and efficacy of NKTR-214 in patients with advanced solid tumors, including melanoma, renal cell carcinoma and non-small cell lung cancer.", "sentB": "This clinical program will explore eight potential indications in five solid tumor types: melanoma, kidney, triple-negative breast cancer, bladder and non-small cell lung cancer.", "type": 2, "words": ["<tag1>", "In", "December", "2015,", "we", "announced", "that", "dosing", "had", "commenced", "in", "the", "Phase", "1/2", "clinical", "study", "evaluating", "the", "safety,", "tolerability", "and", "efficacy", "of", "NKTR-214", "in", "patients", "with", "advanced", "solid", "tumors,", "including", "melanoma,", "renal", "cell", "carcinoma", "and", "non-small", "cell", "lung", "cancer.", "<tag2>", "This", "clinical", "program", "will", "explore", "eight", "potential", "indications", "in", "five", "solid", "tumor", "types:", "melanoma,", "kidney,", "triple-negative", "breast", "cancer,", "bladder", "and", "non-small", "cell", "lung", "cancer.", "<tag3>"], "wordsA": ["In", "December", "2015,", "we", "announced", "that", "dosing", "had", "commenced", "in", "the", "Phase", "1/2", "clinical", "study", "evaluating", "the", "safety,", "tolerability", "and", "efficacy", "of", "NKTR-214", "in", "patients", "with", "advanced", "solid", "tumors,", "including", "melanoma,", "renal", "cell", "carcinoma", "and", "non-small", "cell", "lung", "cancer."], "wordsB": ["This", "clinical", "program", "will", "explore", "eight", "potential", "indications", "in", "five", "solid", "tumor", "types:", "melanoma,", "kidney,", "triple-negative", "breast", "cancer,", "bladder", "and", "non-small", "cell", "lung", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s2", "idA": "906709_16_item1_p82_s2", "sentA": "As part of the Phase 1/2 clinical study program, we will also evaluate NKTR-214 in combination with a checkpoint inhibitor.", "sentB": "We plan to study NKTR-214 in combination with a number of therapeutic approaches where we believe there is a strong biologic rationale for complimentary mechanisms of action.", "type": 2, "words": ["<tag1>", "As", "part", "of", "the", "Phase", "1/2", "clinical", "study", "program,", "we", "will", "also", "evaluate", "NKTR-214", "in", "combination", "with", "a", "checkpoint", "inhibitor.", "<tag2>", "We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action.", "<tag3>"], "wordsA": ["As", "part", "of", "the", "Phase", "1/2", "clinical", "study", "program,", "we", "will", "also", "evaluate", "NKTR-214", "in", "combination", "with", "a", "checkpoint", "inhibitor."], "wordsB": ["We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s4", "idA": "906709_16_item1_p82_s2", "sentA": "As part of the Phase 1/2 clinical study program, we will also evaluate NKTR-214 in combination with a checkpoint inhibitor.", "sentB": "The dose escalation stage of the Phase 1/2 program evaluating NKTR-214 in combination with Opdivo , which we call the PIVOT study is currently enrolling patients at multiple clinical sites.", "type": 2, "words": ["<tag1>", "As", "part", "of", "the", "Phase", "1/2", "clinical", "study", "program,", "we", "will", "also", "evaluate", "NKTR-214", "in", "combination", "with", "a", "checkpoint", "inhibitor.", "<tag2>", "The", "dose", "escalation", "stage", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", ",", "which", "we", "call", "the", "PIVOT", "study", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites.", "<tag3>"], "wordsA": ["As", "part", "of", "the", "Phase", "1/2", "clinical", "study", "program,", "we", "will", "also", "evaluate", "NKTR-214", "in", "combination", "with", "a", "checkpoint", "inhibitor."], "wordsB": ["The", "dose", "escalation", "stage", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", ",", "which", "we", "call", "the", "PIVOT", "study", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p2_s2", "idA": "906709_16_item1_p84_s0", "sentA": "NKTR-171 (neuropathic pain) NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "NKTR-262 is being developed as a single intra-tumoral injection in combination with systemic NKTR-214 in order to induce an abscopal response and achieve the goal of complete tumor regression in cancer patients treated with both therapies.", "type": 2, "words": ["<tag1>", "NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "NKTR-262", "is", "being", "developed", "as", "a", "single", "intra-tumoral", "injection", "in", "combination", "with", "systemic", "NKTR-214", "in", "order", "to", "induce", "an", "abscopal", "response", "and", "achieve", "the", "goal", "of", "complete", "tumor", "regression", "in", "cancer", "patients", "treated", "with", "both", "therapies.", "<tag3>"], "wordsA": ["NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["NKTR-262", "is", "being", "developed", "as", "a", "single", "intra-tumoral", "injection", "in", "combination", "with", "systemic", "NKTR-214", "in", "order", "to", "induce", "an", "abscopal", "response", "and", "achieve", "the", "goal", "of", "complete", "tumor", "regression", "in", "cancer", "patients", "treated", "with", "both", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p43_s2", "idA": "906709_16_item1_p84_s0", "sentA": "NKTR-171 (neuropathic pain) NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "NKTR-262 is being developed as a single intra-tumoral injection to be administered at the start of therapy with NKTR-214 in order to induce an abscopal response and achieve the goal of complete tumor regression in cancer patients treated with both therapies.", "type": 2, "words": ["<tag1>", "NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "NKTR-262", "is", "being", "developed", "as", "a", "single", "intra-tumoral", "injection", "to", "be", "administered", "at", "the", "start", "of", "therapy", "with", "NKTR-214", "in", "order", "to", "induce", "an", "abscopal", "response", "and", "achieve", "the", "goal", "of", "complete", "tumor", "regression", "in", "cancer", "patients", "treated", "with", "both", "therapies.", "<tag3>"], "wordsA": ["NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["NKTR-262", "is", "being", "developed", "as", "a", "single", "intra-tumoral", "injection", "to", "be", "administered", "at", "the", "start", "of", "therapy", "with", "NKTR-214", "in", "order", "to", "induce", "an", "abscopal", "response", "and", "achieve", "the", "goal", "of", "complete", "tumor", "regression", "in", "cancer", "patients", "treated", "with", "both", "therapies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p8_s0", "idA": "906709_16_item1_p84_s0", "sentA": "NKTR-171 (neuropathic pain) NKTR-171 is a novel, orally-available sodium channel blocker and is being developed as a treatment for neuropathic pain.", "sentB": "NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of auto-immune diseases.", "type": 2, "words": ["<tag1>", "NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain.", "<tag2>", "NKTR-358", "is", "being", "developed", "as", "a", "once", "or", "twice", "monthly", "self-administered", "injection", "for", "a", "number", "of", "auto-immune", "diseases.", "<tag3>"], "wordsA": ["NKTR-171", "(neuropathic", "pain)", "NKTR-171", "is", "a", "novel,", "orally-available", "sodium", "channel", "blocker", "and", "is", "being", "developed", "as", "a", "treatment", "for", "neuropathic", "pain."], "wordsB": ["NKTR-358", "is", "being", "developed", "as", "a", "once", "or", "twice", "monthly", "self-administered", "injection", "for", "a", "number", "of", "auto-immune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p3_s4", "idA": "906709_16_item1_p84_s1", "sentA": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "sentB": "Immunology We are developing a new biologic, NKTR-358, which is designed to correct the underlying immune system imbalance in the body which occurs in patients with auto-immune disease.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag2>", "Immunology", "We", "are", "developing", "a", "new", "biologic,", "NKTR-358,", "which", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "wordsB": ["Immunology", "We", "are", "developing", "a", "new", "biologic,", "NKTR-358,", "which", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p44_s0", "idA": "906709_16_item1_p84_s1", "sentA": "NKTR-171 is a new molecular entity that is designed to treat neuropathic pain by blocking hyperactive neuronal sodium channels associated with damaged nerves in the peripheral nervous system.", "sentB": "NKTR-255 NKTR-255 is a memory T cell stimulating cytokine designed to engage the IL-15 pathway to induce long-term T cell activation and improve the quality of T cell memory response to treat cancer.", "type": 2, "words": ["<tag1>", "NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system.", "<tag2>", "NKTR-255", "NKTR-255", "is", "a", "memory", "T", "cell", "stimulating", "cytokine", "designed", "to", "engage", "the", "IL-15", "pathway", "to", "induce", "long-term", "T", "cell", "activation", "and", "improve", "the", "quality", "of", "T", "cell", "memory", "response", "to", "treat", "cancer.", "<tag3>"], "wordsA": ["NKTR-171", "is", "a", "new", "molecular", "entity", "that", "is", "designed", "to", "treat", "neuropathic", "pain", "by", "blocking", "hyperactive", "neuronal", "sodium", "channels", "associated", "with", "damaged", "nerves", "in", "the", "peripheral", "nervous", "system."], "wordsB": ["NKTR-255", "NKTR-255", "is", "a", "memory", "T", "cell", "stimulating", "cytokine", "designed", "to", "engage", "the", "IL-15", "pathway", "to", "induce", "long-term", "T", "cell", "activation", "and", "improve", "the", "quality", "of", "T", "cell", "memory", "response", "to", "treat", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p74_s0", "idA": "906709_16_item1_p85_s0", "sentA": "Overview of Select Technology Licensing Collaborations and Programs We have a number of product candidates in clinical development and approved products in collaboration with our partners that use our technology or involve rights over which we have patents or other proprietary intellectual property.", "sentB": "Overview of Collaboration Partner Programs We have a number of product candidates in clinical development and approved products in collaboration with our partners where we invented the drug candidate or where our collaboration partners have licensed our proprietary intellectual property to enable one of their drug candidates.", "type": 2, "words": ["<tag1>", "Overview", "of", "Select", "Technology", "Licensing", "Collaborations", "and", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "that", "use", "our", "technology", "or", "involve", "rights", "over", "which", "we", "have", "patents", "or", "other", "proprietary", "intellectual", "property.", "<tag2>", "Overview", "of", "Collaboration", "Partner", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "where", "we", "invented", "the", "drug", "candidate", "or", "where", "our", "collaboration", "partners", "have", "licensed", "our", "proprietary", "intellectual", "property", "to", "enable", "one", "of", "their", "drug", "candidates.", "<tag3>"], "wordsA": ["Overview", "of", "Select", "Technology", "Licensing", "Collaborations", "and", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "that", "use", "our", "technology", "or", "involve", "rights", "over", "which", "we", "have", "patents", "or", "other", "proprietary", "intellectual", "property."], "wordsB": ["Overview", "of", "Collaboration", "Partner", "Programs", "We", "have", "a", "number", "of", "product", "candidates", "in", "clinical", "development", "and", "approved", "products", "in", "collaboration", "with", "our", "partners", "where", "we", "invented", "the", "drug", "candidate", "or", "where", "our", "collaboration", "partners", "have", "licensed", "our", "proprietary", "intellectual", "property", "to", "enable", "one", "of", "their", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p74_s3", "idA": "906709_16_item1_p85_s2", "sentA": "In certain cases, we also manufacture and supply our proprietary PEGylation materials to our partners.", "sentB": "In certain cases, we also manufacture and supply our proprietary polymer materials to our partners.", "type": 2, "words": ["<tag1>", "In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners.", "<tag2>", "In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "polymer", "materials", "to", "our", "partners.", "<tag3>"], "wordsA": ["In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "PEGylation", "materials", "to", "our", "partners."], "wordsB": ["In", "certain", "cases,", "we", "also", "manufacture", "and", "supply", "our", "proprietary", "polymer", "materials", "to", "our", "partners."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p81_s0", "idA": "906709_16_item1_p86_s0", "sentA": "ADYNOVATE TM (previously referred to as BAX 855) and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of Baxalta In corporated In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with certain subsidiaries of Baxalta, formerly Baxter before the separation of Baxalta from Baxter in July 2015, to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "sentB": "ADYNOVATE (previously referred to as BAX 855) and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of Baxalta Incorporated In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with certain subsidiaries of Baxalta, formerly Baxter before the separation of Baxalta from Baxter in July 2015, to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "type": 2, "words": ["<tag1>", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "In", "corporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag2>", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "Incorporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag3>"], "wordsA": ["ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "In", "corporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "wordsB": ["ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "Incorporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p81_s1", "idA": "906709_16_item1_p86_s1", "sentA": "The first product in this collaboration, ADYNOVATE TM (previously referred to as BAX 855), is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "sentB": "The first product in this collaboration, ADYNOVATE (previously referred to as BAX 855), is a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.", "type": 2, "words": ["<tag1>", "The", "first", "product", "in", "this", "collaboration,", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag2>", "The", "first", "product", "in", "this", "collaboration,", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855),", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein.", "<tag3>"], "wordsA": ["The", "first", "product", "in", "this", "collaboration,", "ADYNOVATE", "TM", "(previously", "referred", "to", "as", "BAX", "855),", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "wordsB": ["The", "first", "product", "in", "this", "collaboration,", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855),", "is", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p82_s0", "idA": "906709_16_item1_p87_s0", "sentA": "ADYNOVATE TM is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "sentB": "ADYNOVATE is a full-length PEGylated longer-acting recombinant factor VIII (rFVIII) that was developed to increase the half-life of ADVATE (Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method).", "type": 2, "words": ["<tag1>", "ADYNOVATE", "TM", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag2>", "ADYNOVATE", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method).", "<tag3>"], "wordsA": ["ADYNOVATE", "TM", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "wordsB": ["ADYNOVATE", "is", "a", "full-length", "PEGylated", "longer-acting", "recombinant", "factor", "VIII", "(rFVIII)", "that", "was", "developed", "to", "increase", "the", "half-life", "of", "ADVATE", "(Antihemophilic", "Factor", "(Recombinant)", "Plasma/Albumin-Free", "Method)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p83_s1", "idA": "906709_16_item1_p88_s1", "sentA": "The royalties start in the mid-single digits for net sales of ADYNOVATE TM up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion.", "sentB": "The royalties start in the mid-single digits for net sales of ADYNOVATE up to $1.2 billion and then in the low teens for net sales exceeding $1.2 billion.", "type": 2, "words": ["<tag1>", "The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "ADYNOVATE", "TM", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion.", "<tag2>", "The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "ADYNOVATE", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion.", "<tag3>"], "wordsA": ["The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "ADYNOVATE", "TM", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion."], "wordsB": ["The", "royalties", "start", "in", "the", "mid-single", "digits", "for", "net", "sales", "of", "ADYNOVATE", "up", "to", "$1.2", "billion", "and", "then", "in", "the", "low", "teens", "for", "net", "sales", "exceeding", "$1.2", "billion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p84_s0", "idA": "906709_16_item1_p89_s0", "sentA": "In 2012, Baxalta completed a Phase 1 clinical study for ADYNOVATE TM that was a prospective, open-label study assessing the safety, tolerability and pharmacokinetics of ADYNOVATE TM in 19 previously treated patients age 18 years or older with severe Hemophilia A.", "sentB": "In 2012, Baxalta completed a Phase 1 clinical study for ADYNOVATE that was a prospective, open-label study assessing the safety, tolerability and pharmacokinetics of ADYNOVATE in 19 previously treated patients age 18 years or older with severe Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "2012,", "Baxalta", "completed", "a", "Phase", "1", "clinical", "study", "for", "ADYNOVATE", "TM", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "Hemophilia", "A.", "<tag2>", "In", "2012,", "Baxalta", "completed", "a", "Phase", "1", "clinical", "study", "for", "ADYNOVATE", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "ADYNOVATE", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "2012,", "Baxalta", "completed", "a", "Phase", "1", "clinical", "study", "for", "ADYNOVATE", "TM", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "Hemophilia", "A."], "wordsB": ["In", "2012,", "Baxalta", "completed", "a", "Phase", "1", "clinical", "study", "for", "ADYNOVATE", "that", "was", "a", "prospective,", "open-label", "study", "assessing", "the", "safety,", "tolerability", "and", "pharmacokinetics", "of", "ADYNOVATE", "in", "19", "previously", "treated", "patients", "age", "18", "years", "or", "older", "with", "severe", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p84_s2", "idA": "906709_16_item1_p89_s2", "sentA": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of ADYNOVATE TM was approximately 1.5-fold higher compared to ADVATE .", "sentB": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of ADYNOVATE was approximately 1.5-fold higher compared to ADVATE .", "type": 2, "words": ["<tag1>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "TM", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", ".", "<tag2>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", ".", "<tag3>"], "wordsA": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "TM", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", "."], "wordsB": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p84_s3", "idA": "906709_16_item1_p89_s3", "sentA": "A longer half-life was achieved in all patients in the study using ADYNOVATE TM , no patients developed inhibitors to either base molecule, ADYNOVATE TM or PEG, and no patients had allergic reactions.", "sentB": "A longer half-life was achieved in all patients in the study using ADYNOVATE , no patients developed inhibitors to either base molecule, ADYNOVATE or PEG, and no patients had allergic reactions.", "type": 2, "words": ["<tag1>", "A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "ADYNOVATE", "TM", ",", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "ADYNOVATE", "TM", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions.", "<tag2>", "A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "ADYNOVATE", ",", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "ADYNOVATE", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions.", "<tag3>"], "wordsA": ["A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "ADYNOVATE", "TM", ",", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "ADYNOVATE", "TM", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions."], "wordsB": ["A", "longer", "half-life", "was", "achieved", "in", "all", "patients", "in", "the", "study", "using", "ADYNOVATE", ",", "no", "patients", "developed", "inhibitors", "to", "either", "base", "molecule,", "ADYNOVATE", "or", "PEG,", "and", "no", "patients", "had", "allergic", "reactions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s7", "idA": "906709_16_item1_p8_s0", "sentA": "The dose-escalation stage of the Phase 1/2 study is designed to evaluate safety, efficacy, and define the recommended Phase 2 dose of NKTR-214 in approximately 20 patients with solid tu mors.", "sentB": "The first stage of the large Phase 1/2 clinical program for NKTR-214 is underway with BMS and is evaluating a potential combination treatment regimen of NKTR-214 with BMS PD-1 immune checkpoint inhibitor, Opdivo in up to 260 patients.", "type": 2, "words": ["<tag1>", "The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety,", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "approximately", "20", "patients", "with", "solid", "tu", "mors.", "<tag2>", "The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients.", "<tag3>"], "wordsA": ["The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety,", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "approximately", "20", "patients", "with", "solid", "tu", "mors."], "wordsB": ["The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s0", "idA": "906709_16_item1_p8_s0", "sentA": "The dose-escalation stage of the Phase 1/2 study is designed to evaluate safety, efficacy, and define the recommended Phase 2 dose of NKTR-214 in approximately 20 patients with solid tu mors.", "sentB": "The dose-escalation stage of the Phase 1/2 study is designed to evaluate safety and efficacy, and define the recommended Phase 2 dose of NKTR-214 in patients with solid tumors.", "type": 2, "words": ["<tag1>", "The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety,", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "approximately", "20", "patients", "with", "solid", "tu", "mors.", "<tag2>", "The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors.", "<tag3>"], "wordsA": ["The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety,", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "approximately", "20", "patients", "with", "solid", "tu", "mors."], "wordsB": ["The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p41_s1", "idA": "906709_16_item1_p8_s1", "sentA": "In addition to a determination of the recommended Phase 2 dose, the study will assess preliminary anti-tumor activity, includi ng objective response rate .", "sentB": "In addition to a determination of the recommended Phase 2 dose, the study will assess the safety profile of NKTR-214, the immunologic effect of NKTR-214 on tumor-infiltrating lymphocytes and other immune activation markers in both blood and tumor tissue, the pharmacokinetic/pharmacodynamic profile as well as preliminary anti-tumor activity based on objective response rate.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "preliminary", "anti-tumor", "activity,", "includi", "ng", "objective", "response", "rate", ".", "<tag2>", "In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "the", "safety", "profile", "of", "NKTR-214,", "the", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrating", "lymphocytes", "and", "other", "immune", "activation", "markers", "in", "both", "blood", "and", "tumor", "tissue,", "the", "pharmacokinetic/pharmacodynamic", "profile", "as", "well", "as", "preliminary", "anti-tumor", "activity", "based", "on", "objective", "response", "rate.", "<tag3>"], "wordsA": ["In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "preliminary", "anti-tumor", "activity,", "includi", "ng", "objective", "response", "rate", "."], "wordsB": ["In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "the", "safety", "profile", "of", "NKTR-214,", "the", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrating", "lymphocytes", "and", "other", "immune", "activation", "markers", "in", "both", "blood", "and", "tumor", "tissue,", "the", "pharmacokinetic/pharmacodynamic", "profile", "as", "well", "as", "preliminary", "anti-tumor", "activity", "based", "on", "objective", "response", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p85_s0", "idA": "906709_16_item1_p90_s0", "sentA": "Baxalta commenced patient enrollment in a Phase 3 clinical study of ADYNOVATE TM in the U.S. in February 2013 and completed enrollment in November 2013.", "sentB": "Baxalta commenced patient enrollment in a Phase 3 clinical study of ADYNOVATE in the U.S. in February 2013 and completed enrollment in November 2013.", "type": 2, "words": ["<tag1>", "Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag2>", "Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013.", "<tag3>"], "wordsA": ["Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "wordsB": ["Baxalta", "commenced", "patient", "enrollment", "in", "a", "Phase", "3", "clinical", "study", "of", "ADYNOVATE", "in", "the", "U.S.", "in", "February", "2013", "and", "completed", "enrollment", "in", "November", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p85_s1", "idA": "906709_16_item1_p90_s1", "sentA": "The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146 previously treated adult patients with severe Hemophilia A in order to assess the efficacy, safety and pharmacokinetics of ADYNOVATE TM for prophylaxis and on-demand treatment of bleeding.", "sentB": "The Phase 3 clinical study, a multi-center, open-label study called PROLONG-ATE, enrolled 146 previously treated adult patients with severe Hemophilia A in order to assess the efficacy, safety and pharmacokinetics of ADYNOVATE for prophylaxis and on-demand treatment of bleeding.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "Hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag2>", "The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "Hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "ADYNOVATE", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding.", "<tag3>"], "wordsA": ["The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "Hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "ADYNOVATE", "TM", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "wordsB": ["The", "Phase", "3", "clinical", "study,", "a", "multi-center,", "open-label", "study", "called", "PROLONG-ATE,", "enrolled", "146", "previously", "treated", "adult", "patients", "with", "severe", "Hemophilia", "A", "in", "order", "to", "assess", "the", "efficacy,", "safety", "and", "pharmacokinetics", "of", "ADYNOVATE", "for", "prophylaxis", "and", "on-demand", "treatment", "of", "bleeding."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p85_s3", "idA": "906709_16_item1_p90_s3", "sentA": "In December 2014, Baxalta announced that it filed a biologic license application with the FDA for ADYNOVATE TM .", "sentB": "In December 2014, Baxalta announced that it filed a biologic license application with the FDA for ADYNOVATE .", "type": 2, "words": ["<tag1>", "In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "TM", ".", "<tag2>", "In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", ".", "<tag3>"], "wordsA": ["In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "TM", "."], "wordsB": ["In", "December", "2014,", "Baxalta", "announced", "that", "it", "filed", "a", "biologic", "license", "application", "with", "the", "FDA", "for", "ADYNOVATE", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s5", "idA": "906709_16_item1_p90_s4", "sentA": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE TM in the U.S.", "sentB": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "<tag2>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S."], "wordsB": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p28_s3", "idA": "906709_16_item1_p90_s4", "sentA": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE TM in the U.S.", "sentB": "An example of this is Baxalta s ADYNOVATE , a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein, which was approved by the FDA in November 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "<tag2>", "An", "example", "of", "this", "is", "Baxalta", "s", "ADYNOVATE", ",", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "was", "approved", "by", "the", "FDA", "in", "November", "2015", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S."], "wordsB": ["An", "example", "of", "this", "is", "Baxalta", "s", "ADYNOVATE", ",", "a", "longer-acting", "(PEGylated)", "form", "of", "a", "full-length", "recombinant", "factor", "VIII", "(rFVIII)", "protein,", "which", "was", "approved", "by", "the", "FDA", "in", "November", "2015", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p85_s4", "idA": "906709_16_item1_p90_s4", "sentA": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE TM in the U.S.", "sentB": "In November 2015, ADYNOVATE was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE in the U.S.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "<tag2>", "In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S."], "wordsB": ["In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p86_s5", "idA": "906709_16_item1_p90_s4", "sentA": "In November 2015, ADYNOVATE TM was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE TM in the U.S.", "sentB": "On April 4, 2016, Baxalta ann ounced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adu lt and pediatric patients and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S.", "<tag2>", "On", "April", "4,", "2016,", "Baxalta", "ann", "ounced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adu", "lt", "and", "pediatric", "patients", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "TM", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "TM", "in", "the", "U.S."], "wordsB": ["On", "April", "4,", "2016,", "Baxalta", "ann", "ounced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adu", "lt", "and", "pediatric", "patients", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p86_s0", "idA": "906709_16_item1_p90_s5", "sentA": "In December 2015, Baxalta announced positive study results from its prospective, uncontrolled, open-label, multi-center Phase 3 study designed to assess the safety and immunogenicity of ADYNOVATE TM .", "sentB": "In December 2015, Baxalta (a wholl y owned, indirect subsidiary of Shire plc) announced positive study results from its prospective, uncontrolled, open-label, multi-center Phase 3 clinical study designed to assess the safety and immunogenicity of ADYNOVATE .", "type": 2, "words": ["<tag1>", "In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", ".", "<tag2>", "In", "December", "2015,", "Baxalta", "(a", "wholl", "y", "owned,", "indirect", "subsidiary", "of", "Shire", "plc)", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "clinical", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", ".", "<tag3>"], "wordsA": ["In", "December", "2015,", "Baxalta", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "TM", "."], "wordsB": ["In", "December", "2015,", "Baxalta", "(a", "wholl", "y", "owned,", "indirect", "subsidiary", "of", "Shire", "plc)", "announced", "positive", "study", "results", "from", "its", "prospective,", "uncontrolled,", "open-label,", "multi-center", "Phase", "3", "clinical", "study", "designed", "to", "assess", "the", "safety", "and", "immunogenicity", "of", "ADYNOVATE", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p28_s4", "idA": "906709_16_item1_p90_s6", "sentA": "The study enrolled 73 previously-treated patients (PTPs) with severe Hemophilia A younger than 12 years of age and assessed the treatment s hemostatic efficacy in prophylaxis and treatment of bleeding episodes.", "sentB": "In December 2016, Shire plc announced the FDA approved ADYNOVATE for use in surgical settings for both adults and pediatric patients, and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "type": 2, "words": ["<tag1>", "The", "study", "enrolled", "73", "previously-treated", "patients", "(PTPs)", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes.", "<tag2>", "In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag3>"], "wordsA": ["The", "study", "enrolled", "73", "previously-treated", "patients", "(PTPs)", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes."], "wordsB": ["In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p86_s1", "idA": "906709_16_item1_p90_s6", "sentA": "The study enrolled 73 previously-treated patients (PTPs) with severe Hemophilia A younger than 12 years of age and assessed the treatment s hemostatic efficacy in prophylaxis and treatment of bleeding episodes.", "sentB": "The study enrolled 73 previously -treated patients with severe Hemophilia A younger than 12 years of age and assessed the treatment s hemostatic efficacy in prophylaxis and treatment of bleeding episodes.", "type": 2, "words": ["<tag1>", "The", "study", "enrolled", "73", "previously-treated", "patients", "(PTPs)", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes.", "<tag2>", "The", "study", "enrolled", "73", "previously", "-treated", "patients", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes.", "<tag3>"], "wordsA": ["The", "study", "enrolled", "73", "previously-treated", "patients", "(PTPs)", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes."], "wordsB": ["The", "study", "enrolled", "73", "previously", "-treated", "patients", "with", "severe", "Hemophilia", "A", "younger", "than", "12", "years", "of", "age", "and", "assessed", "the", "treatment", "s", "hemostatic", "efficacy", "in", "prophylaxis", "and", "treatment", "of", "bleeding", "episodes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p86_s2", "idA": "906709_16_item1_p90_s7", "sentA": "All participants received prophylactic ADYNOVATE TM treatment (median 1.9 infusions per week) and were followed for six months.", "sentB": "All participants received prophylactic ADYNOVATE treatment (median 1.9 infusions p er week) and were followed for six months.", "type": 2, "words": ["<tag1>", "All", "participants", "received", "prophylactic", "ADYNOVATE", "TM", "treatment", "(median", "1.9", "infusions", "per", "week)", "and", "were", "followed", "for", "six", "months.", "<tag2>", "All", "participants", "received", "prophylactic", "ADYNOVATE", "treatment", "(median", "1.9", "infusions", "p", "er", "week)", "and", "were", "followed", "for", "six", "months.", "<tag3>"], "wordsA": ["All", "participants", "received", "prophylactic", "ADYNOVATE", "TM", "treatment", "(median", "1.9", "infusions", "per", "week)", "and", "were", "followed", "for", "six", "months."], "wordsB": ["All", "participants", "received", "prophylactic", "ADYNOVATE", "treatment", "(median", "1.9", "infusions", "p", "er", "week)", "and", "were", "followed", "for", "six", "months."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p86_s3", "idA": "906709_16_item1_p90_s8", "sentA": "ADYNOVATE TM met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE TM .", "sentB": "ADYNOVATE met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE .", "type": 2, "words": ["<tag1>", "ADYNOVATE", "TM", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "TM", ".", "<tag2>", "ADYNOVATE", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", ".", "<tag3>"], "wordsA": ["ADYNOVATE", "TM", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "TM", "."], "wordsB": ["ADYNOVATE", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p15_s6", "idA": "906709_16_item1_p91_s0", "sentA": "ADYNOVATE TM is currently under regulatory review in Japan, Canada and Switzerland.", "sentB": "ADYNOVATE is also under regulatory review in the European Union, Switzerland and Canada.", "type": 2, "words": ["<tag1>", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland.", "<tag2>", "ADYNOVATE", "is", "also", "under", "regulatory", "review", "in", "the", "European", "Union,", "Switzerland", "and", "Canada.", "<tag3>"], "wordsA": ["ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland."], "wordsB": ["ADYNOVATE", "is", "also", "under", "regulatory", "review", "in", "the", "European", "Union,", "Switzerland", "and", "Canada."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p86_s6", "idA": "906709_16_item1_p91_s0", "sentA": "ADYNOVATE TM is currently under regulatory review in Japan, Canada and Switzerland.", "sentB": "ADYNOVATE is also under regulatory review in the European Union, Canada, and Switzerland.", "type": 2, "words": ["<tag1>", "ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland.", "<tag2>", "ADYNOVATE", "is", "also", "under", "regulatory", "review", "in", "the", "European", "Union,", "Canada,", "and", "Switzerland.", "<tag3>"], "wordsA": ["ADYNOVATE", "TM", "is", "currently", "under", "regulatory", "review", "in", "Japan,", "Canada", "and", "Switzerland."], "wordsB": ["ADYNOVATE", "is", "also", "under", "regulatory", "review", "in", "the", "European", "Union,", "Canada,", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p88_s0", "idA": "906709_16_item1_p92_s1", "sentA": "According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately one in 5,000 live births.", "sentB": "According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately one in 5,000 live births and there are about 20,000 people with hemophilia in the US.", "type": 2, "words": ["<tag1>", "According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "one", "in", "5,000", "live", "births.", "<tag2>", "According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "one", "in", "5,000", "live", "births", "and", "there", "are", "about", "20,000", "people", "with", "hemophilia", "in", "the", "US.", "<tag3>"], "wordsA": ["According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "one", "in", "5,000", "live", "births."], "wordsB": ["According", "to", "the", "US", "Centers", "for", "Disease", "Control", "and", "Prevention,", "hemophilia", "occurs", "in", "approximately", "one", "in", "5,000", "live", "births", "and", "there", "are", "about", "20,000", "people", "with", "hemophilia", "in", "the", "US."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p95_s0", "idA": "906709_16_item1_p94_s0", "sentA": "Cipro DPI (formerly known as Cipro Inhale), Agreement with Bayer Schering Pharma AG Assigned to Novartis as of December 31, 2008 We were a party to a collaborative research, development and commercialization agreement with Bayer Schering Pharma AG (Bayer), related to the development of an inhaled powder formulation of ciprofloxacin delivered by way of a dry powder inhaler, Cipro DPI (formerly known as Cipro Inhale) for the treatment of chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.", "sentB": "We were a party to a collaborative research, development and commercialization agreement with Bayer Schering Pharma AG (Bayer Schering), related to the development of an inhaled powder formulation of ciprofloxacin delivered by way of a dry powder inhaler, Cipro DPI (formerly known as Cipro Inhale) for the treatment of chronic lung infections caused by Pseudomonas aeruginosa in cystic fibrosis patients.", "type": 2, "words": ["<tag1>", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale),", "Agreement", "with", "Bayer", "Schering", "Pharma", "AG", "Assigned", "to", "Novartis", "as", "of", "December", "31,", "2008", "We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer),", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "ciprofloxacin", "delivered", "by", "way", "of", "a", "dry", "powder", "inhaler,", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients.", "<tag2>", "We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering),", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "ciprofloxacin", "delivered", "by", "way", "of", "a", "dry", "powder", "inhaler,", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients.", "<tag3>"], "wordsA": ["Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale),", "Agreement", "with", "Bayer", "Schering", "Pharma", "AG", "Assigned", "to", "Novartis", "as", "of", "December", "31,", "2008", "We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer),", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "ciprofloxacin", "delivered", "by", "way", "of", "a", "dry", "powder", "inhaler,", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients."], "wordsB": ["We", "were", "a", "party", "to", "a", "collaborative", "research,", "development", "and", "commercialization", "agreement", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering),", "related", "to", "the", "development", "of", "an", "inhaled", "powder", "formulation", "of", "ciprofloxacin", "delivered", "by", "way", "of", "a", "dry", "powder", "inhaler,", "Cipro", "DPI", "(formerly", "known", "as", "Cipro", "Inhale)", "for", "the", "treatment", "of", "chronic", "lung", "infections", "caused", "by", "Pseudomonas", "aeruginosa", "in", "cystic", "fibrosis", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p1_s6", "idA": "906709_16_item1_p94_s1", "sentA": "On December 31, 2008, we assigned the agreement to Novartis Pharma AG in connection with the completion of the pulmonary asset sale transaction.", "sentB": "Under the BMS Agreement, BMS will supply nivolumab and be responsible for 50% of all out-of-pocket costs reasonably incurred in connection with the Combined Therapy Trials.", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction.", "<tag2>", "Under", "the", "BMS", "Agreement,", "BMS", "will", "supply", "nivolumab", "and", "be", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "the", "Combined", "Therapy", "Trials.", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction."], "wordsB": ["Under", "the", "BMS", "Agreement,", "BMS", "will", "supply", "nivolumab", "and", "be", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "the", "Combined", "Therapy", "Trials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p96_s0", "idA": "906709_16_item1_p94_s2", "sentA": "However, we retained our economic interest in the future potential net sales royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer.", "sentB": "royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer Schering.", "type": 2, "words": ["<tag1>", "However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer.", "<tag2>", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer", "Schering.", "<tag3>"], "wordsA": ["However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer."], "wordsB": ["royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer", "Schering."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p97_s1", "idA": "906709_16_item1_p95_s1", "sentA": "In August 2012, Bayer initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis.", "sentB": "In August 2012, Bayer Scherin g initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis.", "type": 2, "words": ["<tag1>", "In", "August", "2012,", "Bayer", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag2>", "In", "August", "2012,", "Bayer", "Scherin", "g", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag3>"], "wordsA": ["In", "August", "2012,", "Bayer", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "wordsB": ["In", "August", "2012,", "Bayer", "Scherin", "g", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p120_s2", "idA": "906709_16_item1_p98_s2", "sentA": "As a result of this transaction, Ophthotech assumed the license, manufacturing and supply agreement between Eyetech and us.", "sentB": "In June 2016, Nektar terminated the license, manufacturing and supply agreement effective as of July 6, 2017.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us.", "<tag2>", "In", "June", "2016,", "Nektar", "terminated", "the", "license,", "manufacturing", "and", "supply", "agreement", "effective", "as", "of", "July", "6,", "2017.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us."], "wordsB": ["In", "June", "2016,", "Nektar", "terminated", "the", "license,", "manufacturing", "and", "supply", "agreement", "effective", "as", "of", "July", "6,", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p42_s1", "idA": "906709_16_item1_p99_s2", "sentA": "Under our agreement with Ophthotech, we received a $19.75 million payment in June 2014 in connection with this licensing agreement.", "sentB": "Each party will otherwise be responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combined Therapy Trial.", "type": 2, "words": ["<tag1>", "Under", "our", "agreement", "with", "Ophthotech,", "we", "received", "a", "$19.75", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement.", "<tag2>", "Each", "party", "will", "otherwise", "be", "responsible", "for", "its", "own", "internal", "costs,", "including", "internal", "personnel", "costs,", "incurred", "in", "connection", "with", "each", "Combined", "Therapy", "Trial.", "<tag3>"], "wordsA": ["Under", "our", "agreement", "with", "Ophthotech,", "we", "received", "a", "$19.75", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement."], "wordsB": ["Each", "party", "will", "otherwise", "be", "responsible", "for", "its", "own", "internal", "costs,", "including", "internal", "personnel", "costs,", "incurred", "in", "connection", "with", "each", "Combined", "Therapy", "Trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s0", "idA": "906709_16_item1_p9_s0", "sentA": "NKTR-102 (also known as etirinotecan pegol) is our next-generation topoisomerase I inhibitor proprietary drug candidate.", "sentB": "Oncology - ONZEALD TM ONZEALD TM (also known as NKTR-102, etirinotecan pegol) is our next-generation topoisomerase I inhibitor proprietary drug candidate.", "type": 2, "words": ["<tag1>", "NKTR-102", "(also", "known", "as", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate.", "<tag2>", "Oncology", "-", "ONZEALD", "TM", "ONZEALD", "TM", "(also", "known", "as", "NKTR-102,", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate.", "<tag3>"], "wordsA": ["NKTR-102", "(also", "known", "as", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate."], "wordsB": ["Oncology", "-", "ONZEALD", "TM", "ONZEALD", "TM", "(also", "known", "as", "NKTR-102,", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s0", "idA": "906709_16_item1_p9_s0", "sentA": "NKTR-102 (also known as etirinotecan pegol) is our next-generation topoisomerase I inhibitor proprietary drug candidate.", "sentB": "ONZEALD TM (previously known as NKTR-102 or etirinotecan pegol) is our next-generation topoisomerase I inhibitor proprietary drug candidate.", "type": 2, "words": ["<tag1>", "NKTR-102", "(also", "known", "as", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate.", "<tag2>", "ONZEALD", "TM", "(previously", "known", "as", "NKTR-102", "or", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate.", "<tag3>"], "wordsA": ["NKTR-102", "(also", "known", "as", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate."], "wordsB": ["ONZEALD", "TM", "(previously", "known", "as", "NKTR-102", "or", "etirinotecan", "pegol)", "is", "our", "next-generation", "topoisomerase", "I", "inhibitor", "proprietary", "drug", "candidate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s1", "idA": "906709_16_item1_p9_s1", "sentA": "On March 17, 2015, we announced topline data from a Phase 3 clinical study for NKTR-102, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), as a single-agent therapy for women with advanced metastatic breast cancer.", "sentB": "On March 17, 2015, we announced topline data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), as a single-agent therapy for women with advanced metastatic breast cancer.", "type": 2, "words": ["<tag1>", "On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "NKTR-102,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag2>", "On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "NKTR-102,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "wordsB": ["On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s1", "idA": "906709_16_item1_p9_s1", "sentA": "On March 17, 2015, we announced topline data from a Phase 3 clinical study for NKTR-102, which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), as a single-agent therapy for women with advanced metastatic breast cancer.", "sentB": "In 2015, we announced topline data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with ONZEALD TM ), as a single-agent therapy for women with advanced metastatic breast cancer.", "type": 2, "words": ["<tag1>", "On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "NKTR-102,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag2>", "In", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "NKTR-102,", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "wordsB": ["In", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s9", "idA": "906709_16_item1_p9_s10", "sentA": "Based on the outcome of these meetings, we believe that there is a path forward to file an MAA for conditional approval of NKTR-102 for patients with advanced breast cancer having brain metastases.", "sentB": "In June 2016, we filed an MAA for conditional approval of ONZEALD TM for adult patients with advanced breast cancer who have brain metastases.", "type": 2, "words": ["<tag1>", "Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases.", "<tag2>", "In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases.", "<tag3>"], "wordsA": ["Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases."], "wordsB": ["In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s9", "idA": "906709_16_item1_p9_s10", "sentA": "Based on the outcome of these meetings, we believe that there is a path forward to file an MAA for conditional approval of NKTR-102 for patients with advanced breast cancer having brain metastases.", "sentB": "In June 2016, we filed an MAA for conditional approval of ONZEALD TM for adult patients with advanced breast cancer who have brain metastases .", "type": 2, "words": ["<tag1>", "Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases.", "<tag2>", "In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", ".", "<tag3>"], "wordsA": ["Based", "on", "the", "outcome", "of", "these", "meetings,", "we", "believe", "that", "there", "is", "a", "path", "forward", "to", "file", "an", "MAA", "for", "conditional", "approval", "of", "NKTR-102", "for", "patients", "with", "advanced", "breast", "cancer", "having", "brain", "metastases."], "wordsB": ["In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s13", "idA": "906709_16_item1_p9_s13", "sentA": "However, the FDA staff also indicated that positive results from a completed confirmatory trial for the MAA could support an NDA filing.", "sentB": "In addition, based on our meetings with the FDA s Oncology Division, the FDA staff has indicated that positive results from the ATTAIN study could potentially support a New Drug Application (NDA) filing in the U.S. where Nektar has retained all rights to ONZEALD TM .", "type": 2, "words": ["<tag1>", "However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "support", "an", "NDA", "filing.", "<tag2>", "In", "addition,", "based", "on", "our", "meetings", "with", "the", "FDA", "s", "Oncology", "Division,", "the", "FDA", "staff", "has", "indicated", "that", "positive", "results", "from", "the", "ATTAIN", "study", "could", "potentially", "support", "a", "New", "Drug", "Application", "(NDA)", "filing", "in", "the", "U.S.", "where", "Nektar", "has", "retained", "all", "rights", "to", "ONZEALD", "TM", ".", "<tag3>"], "wordsA": ["However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "support", "an", "NDA", "filing."], "wordsB": ["In", "addition,", "based", "on", "our", "meetings", "with", "the", "FDA", "s", "Oncology", "Division,", "the", "FDA", "staff", "has", "indicated", "that", "positive", "results", "from", "the", "ATTAIN", "study", "could", "potentially", "support", "a", "New", "Drug", "Application", "(NDA)", "filing", "in", "the", "U.S.", "where", "Nektar", "has", "retained", "all", "rights", "to", "ONZEALD", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p59_s2", "idA": "906709_16_item1_p9_s13", "sentA": "However, the FDA staff also indicated that positive results from a completed confirmatory trial for the MAA could support an NDA filing.", "sentB": "In addition, based on our meetings with the FDA s Oncology Division, the FDA staff has indicated that positive results from the ATTAIN Study could potentially support a New Drug Application (NDA) filing in the U.S. where Nektar has retained all rights to ONZEALD TM .", "type": 2, "words": ["<tag1>", "However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "support", "an", "NDA", "filing.", "<tag2>", "In", "addition,", "based", "on", "our", "meetings", "with", "the", "FDA", "s", "Oncology", "Division,", "the", "FDA", "staff", "has", "indicated", "that", "positive", "results", "from", "the", "ATTAIN", "Study", "could", "potentially", "support", "a", "New", "Drug", "Application", "(NDA)", "filing", "in", "the", "U.S.", "where", "Nektar", "has", "retained", "all", "rights", "to", "ONZEALD", "TM", ".", "<tag3>"], "wordsA": ["However,", "the", "FDA", "staff", "also", "indicated", "that", "positive", "results", "from", "a", "completed", "confirmatory", "trial", "for", "the", "MAA", "could", "support", "an", "NDA", "filing."], "wordsB": ["In", "addition,", "based", "on", "our", "meetings", "with", "the", "FDA", "s", "Oncology", "Division,", "the", "FDA", "staff", "has", "indicated", "that", "positive", "results", "from", "the", "ATTAIN", "Study", "could", "potentially", "support", "a", "New", "Drug", "Application", "(NDA)", "filing", "in", "the", "U.S.", "where", "Nektar", "has", "retained", "all", "rights", "to", "ONZEALD", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p11_s4", "idA": "906709_16_item1_p9_s15", "sentA": "At this time, we do not plan to advance development of NKTR-102 without a collaboration partner.", "sentB": "If the top-line data from the SUMMIT-07 study is positive, we plan to seek a collaboration partner for this program to support further development investments and commercialize NKTR-181.", "type": 2, "words": ["<tag1>", "At", "this", "time,", "we", "do", "not", "plan", "to", "advance", "development", "of", "NKTR-102", "without", "a", "collaboration", "partner.", "<tag2>", "If", "the", "top-line", "data", "from", "the", "SUMMIT-07", "study", "is", "positive,", "we", "plan", "to", "seek", "a", "collaboration", "partner", "for", "this", "program", "to", "support", "further", "development", "investments", "and", "commercialize", "NKTR-181.", "<tag3>"], "wordsA": ["At", "this", "time,", "we", "do", "not", "plan", "to", "advance", "development", "of", "NKTR-102", "without", "a", "collaboration", "partner."], "wordsB": ["If", "the", "top-line", "data", "from", "the", "SUMMIT-07", "study", "is", "positive,", "we", "plan", "to", "seek", "a", "collaboration", "partner", "for", "this", "program", "to", "support", "further", "development", "investments", "and", "commercialize", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s2", "idA": "906709_16_item1_p9_s2", "sentA": "The BEACON study compared NKTR-102 to an active control arm comprised of a single chemotherapy agent of physician s choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease.", "sentB": "The BEACON study compared ONZEALD TM to an active control arm comprised of a single chemotherapy agent of physician s choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "compared", "NKTR-102", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease.", "<tag2>", "The", "BEACON", "study", "compared", "ONZEALD", "TM", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "compared", "NKTR-102", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease."], "wordsB": ["The", "BEACON", "study", "compared", "ONZEALD", "TM", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s2", "idA": "906709_16_item1_p9_s2", "sentA": "The BEACON study compared NKTR-102 to an active control arm comprised of a single chemotherapy agent of physician s choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease.", "sentB": "The BEACON study compared ONZEALD TM to an active control arm comprised of a single chemotherapy agent of physician s choice (TPC) in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease.", "type": 2, "words": ["<tag1>", "The", "BEACON", "study", "compared", "NKTR-102", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease.", "<tag2>", "The", "BEACON", "study", "compared", "ONZEALD", "TM", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease.", "<tag3>"], "wordsA": ["The", "BEACON", "study", "compared", "NKTR-102", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease."], "wordsB": ["The", "BEACON", "study", "compared", "ONZEALD", "TM", "to", "an", "active", "control", "arm", "comprised", "of", "a", "single", "chemotherapy", "agent", "of", "physician", "s", "choice", "(TPC)", "in", "patients", "who", "were", "heavily", "pre-treated", "with", "a", "median", "of", "three", "prior", "therapies", "for", "metastatic", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p12_s7", "idA": "906709_16_item1_p9_s7", "sentA": "We are currently exploring various future regulatory and development paths forward for NKTR-102 with the EU and U.S. regulatory authorities.", "sentB": "We have explored future regulatory and development paths forward for ONZEALD TM with the EU and U.S. health authorities.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "exploring", "various", "future", "regulatory", "and", "development", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities.", "<tag2>", "We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "EU", "and", "U.S.", "health", "authorities.", "<tag3>"], "wordsA": ["We", "are", "currently", "exploring", "various", "future", "regulatory", "and", "development", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities."], "wordsB": ["We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "EU", "and", "U.S.", "health", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_17_item1_p58_s7", "idA": "906709_16_item1_p9_s7", "sentA": "We are currently exploring various future regulatory and development paths forward for NKTR-102 with the EU and U.S. regulatory authorities.", "sentB": "We have explored future regulatory and development paths forward for ONZEALD TM with the EU and U.S. health authorities.", "type": 2, "words": ["<tag1>", "We", "are", "currently", "exploring", "various", "future", "regulatory", "and", "development", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities.", "<tag2>", "We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "EU", "and", "U.S.", "health", "authorities.", "<tag3>"], "wordsA": ["We", "are", "currently", "exploring", "various", "future", "regulatory", "and", "development", "paths", "forward", "for", "NKTR-102", "with", "the", "EU", "and", "U.S.", "regulatory", "authorities."], "wordsB": ["We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "EU", "and", "U.S.", "health", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p0_s1", "idA": "906709_17_item1_p0_s1", "sentA": "Our research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain.", "sentB": "Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain.", "type": 2, "words": ["<tag1>", "Our", "research", "and", "development", "pipeline", "of", "new", "investigational", "drugs", "includes", "treatments", "for", "cancer,", "auto-immune", "disease", "and", "chronic", "pain.", "<tag2>", "Our", "research", "and", "development", "pipeline", "of", "new", "investigational", "drugs", "includes", "treatments", "for", "cancer,", "autoimmune", "disease", "and", "chronic", "pain.", "<tag3>"], "wordsA": ["Our", "research", "and", "development", "pipeline", "of", "new", "investigational", "drugs", "includes", "treatments", "for", "cancer,", "auto-immune", "disease", "and", "chronic", "pain."], "wordsB": ["Our", "research", "and", "development", "pipeline", "of", "new", "investigational", "drugs", "includes", "treatments", "for", "cancer,", "autoimmune", "disease", "and", "chronic", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p18_s1", "idA": "906709_17_item1_p100_s2", "sentA": "As a result of this transaction, Ophthotech assumed the license, manufacturing and supply agreement between Eyetech and us.", "sentB": "As a result of the termination, we made a $12.5 million termination payment to Daiichi in December 2017, and all rights and licenses granted to Daiichi under t he Daiichi Collaboration Agreement reverted exclusively to Nektar.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us.", "<tag2>", "As", "a", "result", "of", "the", "termination,", "we", "made", "a", "$12.5", "million", "termination", "payment", "to", "Daiichi", "in", "December", "2017,", "and", "all", "rights", "and", "licenses", "granted", "to", "Daiichi", "under", "t", "he", "Daiichi", "Collaboration", "Agreement", "reverted", "exclusively", "to", "Nektar.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us."], "wordsB": ["As", "a", "result", "of", "the", "termination,", "we", "made", "a", "$12.5", "million", "termination", "payment", "to", "Daiichi", "in", "December", "2017,", "and", "all", "rights", "and", "licenses", "granted", "to", "Daiichi", "under", "t", "he", "Daiichi", "Collaboration", "Agreement", "reverted", "exclusively", "to", "Nektar."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s12", "idA": "906709_17_item1_p100_s2", "sentA": "As a result of this transaction, Ophthotech assumed the license, manufacturing and supply agreement between Eyetech and us.", "sentB": "As a result of the termination, we made a $12.5 million termination payment to Daiichi in December 2017, and all rights and licenses granted to Daiichi under the Daiichi Collaboration Agreement reverted exclusively to Nektar.", "type": 2, "words": ["<tag1>", "As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us.", "<tag2>", "As", "a", "result", "of", "the", "termination,", "we", "made", "a", "$12.5", "million", "termination", "payment", "to", "Daiichi", "in", "December", "2017,", "and", "all", "rights", "and", "licenses", "granted", "to", "Daiichi", "under", "the", "Daiichi", "Collaboration", "Agreement", "reverted", "exclusively", "to", "Nektar.", "<tag3>"], "wordsA": ["As", "a", "result", "of", "this", "transaction,", "Ophthotech", "assumed", "the", "license,", "manufacturing", "and", "supply", "agreement", "between", "Eyetech", "and", "us."], "wordsB": ["As", "a", "result", "of", "the", "termination,", "we", "made", "a", "$12.5", "million", "termination", "payment", "to", "Daiichi", "in", "December", "2017,", "and", "all", "rights", "and", "licenses", "granted", "to", "Daiichi", "under", "the", "Daiichi", "Collaboration", "Agreement", "reverted", "exclusively", "to", "Nektar."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p98_s7", "idA": "906709_17_item1_p101_s2", "sentA": "Under our agreement with Ophthotech, we received a $19.75 million payment in June 2014 in connection with this licensing agreement.", "sentB": "Under the original license and supply agreement entered into between us and Ophthotech, we received a $19.8 million payment in June 2014 in connection with this licensing agreement.", "type": 2, "words": ["<tag1>", "Under", "our", "agreement", "with", "Ophthotech,", "we", "received", "a", "$19.75", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement.", "<tag2>", "Under", "the", "original", "license", "and", "supply", "agreement", "entered", "into", "between", "us", "and", "Ophthotech,", "we", "received", "a", "$19.8", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement.", "<tag3>"], "wordsA": ["Under", "our", "agreement", "with", "Ophthotech,", "we", "received", "a", "$19.75", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement."], "wordsB": ["Under", "the", "original", "license", "and", "supply", "agreement", "entered", "into", "between", "us", "and", "Ophthotech,", "we", "received", "a", "$19.8", "million", "payment", "in", "June", "2014", "in", "connection", "with", "this", "licensing", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s7", "idA": "906709_17_item1_p102_s1", "sentA": "Fovista met the pre-specified primary efficacy endpoint of mean vision gain.", "sentB": "The primary efficacy endpoint of the study demonstrated significantly improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019).", "type": 2, "words": ["<tag1>", "Fovista", "met", "the", "pre-specified", "primary", "efficacy", "endpoint", "of", "mean", "vision", "gain.", "<tag2>", "The", "primary", "efficacy", "endpoint", "of", "the", "study", "demonstrated", "significantly", "improved", "chronic", "back", "pain", "relief", "with", "NKTR-181", "compared", "to", "placebo", "(p=0.0019).", "<tag3>"], "wordsA": ["Fovista", "met", "the", "pre-specified", "primary", "efficacy", "endpoint", "of", "mean", "vision", "gain."], "wordsB": ["The", "primary", "efficacy", "endpoint", "of", "the", "study", "demonstrated", "significantly", "improved", "chronic", "back", "pain", "relief", "with", "NKTR-181", "compared", "to", "placebo", "(p=0.0019)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p99_s0", "idA": "906709_17_item1_p103_s2", "sentA": "In December 2016, Ophthotech announced that the pre-specified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal Phase 3 clinical trials investigating the superiority of Fovista (pegpleranib) anti-PDGF therapy in combination with Lucentis (ranibizumab) anti-VEGF therapy compared to Lucentis monotherapy for the treatment of wet age-related macular degeneration (AMD).", "sentB": "In December 2016 Ophthotech announced that two pivotal Phase 3 clinical trials for Fovista failed to meet their primary endpoints.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "Ophthotech", "announced", "that", "the", "pre-specified", "primary", "endpoint", "of", "mean", "change", "in", "visual", "acuity", "at", "12", "months", "was", "not", "achieved", "in", "its", "two", "pivotal", "Phase", "3", "clinical", "trials", "investigating", "the", "superiority", "of", "Fovista", "(pegpleranib)", "anti-PDGF", "therapy", "in", "combination", "with", "Lucentis", "(ranibizumab)", "anti-VEGF", "therapy", "compared", "to", "Lucentis", "monotherapy", "for", "the", "treatment", "of", "wet", "age-related", "macular", "degeneration", "(AMD).", "<tag2>", "In", "December", "2016", "Ophthotech", "announced", "that", "two", "pivotal", "Phase", "3", "clinical", "trials", "for", "Fovista", "failed", "to", "meet", "their", "primary", "endpoints.", "<tag3>"], "wordsA": ["In", "December", "2016,", "Ophthotech", "announced", "that", "the", "pre-specified", "primary", "endpoint", "of", "mean", "change", "in", "visual", "acuity", "at", "12", "months", "was", "not", "achieved", "in", "its", "two", "pivotal", "Phase", "3", "clinical", "trials", "investigating", "the", "superiority", "of", "Fovista", "(pegpleranib)", "anti-PDGF", "therapy", "in", "combination", "with", "Lucentis", "(ranibizumab)", "anti-VEGF", "therapy", "compared", "to", "Lucentis", "monotherapy", "for", "the", "treatment", "of", "wet", "age-related", "macular", "degeneration", "(AMD)."], "wordsB": ["In", "December", "2016", "Ophthotech", "announced", "that", "two", "pivotal", "Phase", "3", "clinical", "trials", "for", "Fovista", "failed", "to", "meet", "their", "primary", "endpoints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p101_s1", "idA": "906709_17_item1_p106_s1", "sentA": "Halozyme is currently evaluating PEGPH20 in a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer.", "sentB": "Halozyme is currently evaluating PEGPH20 in a Phase 3 clinical study combining PEGPH20 with ABRAXANE (nab-paclitaxel) and gemcitabine in stage IV pancreatic ductal adenocarcinoma (PDA) (HALO 109-301), in Phase 1b clinical testing for PEGPH20 with KEYTRUDA (pembrolizumab) in non-small cell lung cancer and gastric cancer (HALO 107-101), in Phase 1b/2 clinical testing for PEGPH20 with HALAVEN (eribulin) in patients treated with up to two lines of prior therapy for HER2-negative metastatic breast cancer, in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq (atezolizumab) in patients with previously treated metastatic PDA, in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with gastric cancer and in Phase 1b/2 clinical testing for PEGPH20 with Tecentriq in patients with cholangiocarcinoma and gall bladder cancer (HALO 110-101/MATRIX).", "type": 2, "words": ["<tag1>", "Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer.", "<tag2>", "Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "3", "clinical", "study", "combining", "PEGPH20", "with", "ABRAXANE", "(nab-paclitaxel)", "and", "gemcitabine", "in", "stage", "IV", "pancreatic", "ductal", "adenocarcinoma", "(PDA)", "(HALO", "109-301),", "in", "Phase", "1b", "clinical", "testing", "for", "PEGPH20", "with", "KEYTRUDA", "(pembrolizumab)", "in", "non-small", "cell", "lung", "cancer", "and", "gastric", "cancer", "(HALO", "107-101),", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "HALAVEN", "(eribulin)", "in", "patients", "treated", "with", "up", "to", "two", "lines", "of", "prior", "therapy", "for", "HER2-negative", "metastatic", "breast", "cancer,", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "Tecentriq", "(atezolizumab)", "in", "patients", "with", "previously", "treated", "metastatic", "PDA,", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "Tecentriq", "in", "patients", "with", "gastric", "cancer", "and", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "Tecentriq", "in", "patients", "with", "cholangiocarcinoma", "and", "gall", "bladder", "cancer", "(HALO", "110-101/MATRIX).", "<tag3>"], "wordsA": ["Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "2", "multicenter,", "randomized", "clinical", "trial", "evaluating", "PEGPH20", "as", "a", "first-line", "therapy", "for", "patients", "with", "stage", "IV", "metastatic", "pancreatic", "cancer."], "wordsB": ["Halozyme", "is", "currently", "evaluating", "PEGPH20", "in", "a", "Phase", "3", "clinical", "study", "combining", "PEGPH20", "with", "ABRAXANE", "(nab-paclitaxel)", "and", "gemcitabine", "in", "stage", "IV", "pancreatic", "ductal", "adenocarcinoma", "(PDA)", "(HALO", "109-301),", "in", "Phase", "1b", "clinical", "testing", "for", "PEGPH20", "with", "KEYTRUDA", "(pembrolizumab)", "in", "non-small", "cell", "lung", "cancer", "and", "gastric", "cancer", "(HALO", "107-101),", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "HALAVEN", "(eribulin)", "in", "patients", "treated", "with", "up", "to", "two", "lines", "of", "prior", "therapy", "for", "HER2-negative", "metastatic", "breast", "cancer,", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "Tecentriq", "(atezolizumab)", "in", "patients", "with", "previously", "treated", "metastatic", "PDA,", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "Tecentriq", "in", "patients", "with", "gastric", "cancer", "and", "in", "Phase", "1b/2", "clinical", "testing", "for", "PEGPH20", "with", "Tecentriq", "in", "patients", "with", "cholangiocarcinoma", "and", "gall", "bladder", "cancer", "(HALO", "110-101/MATRIX)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s13", "idA": "906709_17_item1_p109_s2", "sentA": "Under the terms of the agreement, we have the right to receive certain milestone payments based on development criteria that are solely the responsibility of MAP and royalties based on net sales of SEMPRANA .", "sentB": "Under the right to sublicense agreement, Baxalta paid us $12.0 million in November 2017 and agreed to pay us single digit royalty payments based upon net sales of the third party products covered under the sublicense throughout the term of the right to sublicense agreement.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", ".", "<tag2>", "Under", "the", "right", "to", "sublicense", "agreement,", "Baxalta", "paid", "us", "$12.0", "million", "in", "November", "2017", "and", "agreed", "to", "pay", "us", "single", "digit", "royalty", "payments", "based", "upon", "net", "sales", "of", "the", "third", "party", "products", "covered", "under", "the", "sublicense", "throughout", "the", "term", "of", "the", "right", "to", "sublicense", "agreement.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "we", "have", "the", "right", "to", "receive", "certain", "milestone", "payments", "based", "on", "development", "criteria", "that", "are", "solely", "the", "responsibility", "of", "MAP", "and", "royalties", "based", "on", "net", "sales", "of", "SEMPRANA", "."], "wordsB": ["Under", "the", "right", "to", "sublicense", "agreement,", "Baxalta", "paid", "us", "$12.0", "million", "in", "November", "2017", "and", "agreed", "to", "pay", "us", "single", "digit", "royalty", "payments", "based", "upon", "net", "sales", "of", "the", "third", "party", "products", "covered", "under", "the", "sublicense", "throughout", "the", "term", "of", "the", "right", "to", "sublicense", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p104_s4", "idA": "906709_17_item1_p110_s4", "sentA": "In June 2014, Allergan announced that it had received a third complete response letter from the FDA related to specifications around content uniformity on the improved canister filling process and on standards for device actuation.", "sentB": "In June 2014, Allergan which acquired MAP as described below, announced that it had received a third complete response letter from the FDA related to specifications around content uniformity on the improved canister filling process and on standards for device actuation.", "type": 2, "words": ["<tag1>", "In", "June", "2014,", "Allergan", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation.", "<tag2>", "In", "June", "2014,", "Allergan", "which", "acquired", "MAP", "as", "described", "below,", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation.", "<tag3>"], "wordsA": ["In", "June", "2014,", "Allergan", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation."], "wordsB": ["In", "June", "2014,", "Allergan", "which", "acquired", "MAP", "as", "described", "below,", "announced", "that", "it", "had", "received", "a", "third", "complete", "response", "letter", "from", "the", "FDA", "related", "to", "specifications", "around", "content", "uniformity", "on", "the", "improved", "canister", "filling", "process", "and", "on", "standards", "for", "device", "actuation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p105_s0", "idA": "906709_17_item1_p111_s0", "sentA": "On January 28, 2011, MAP entered into a Collaboration Agreement with Allergan, Inc. pursuant to which Allergan received a co-exclusive license to market and promote SEMPRANA to neurologists and pain specialists in the U.S. Under this arrangement, Allergan paid MAP an upfront payment of $60 million and MAP was also entitled to receive up to an additional $97 million in the form of regulatory milestones, which includes milestones for acceptance of filing of the SEMPRANA NDA and first commercial sale associated with the initial acute migraine indication.", "sentB": "On January 28, 2011, MAP entered into a Collaboration Agreement with Allergan, Inc. (Allergan), pursuant to which Allergan received a co-exclusive license to market and promote SEMPRANA to neurologists and pain specialists in the U.S.", "type": 2, "words": ["<tag1>", "On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication.", "<tag2>", "On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "(Allergan),", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "<tag3>"], "wordsA": ["On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication."], "wordsB": ["On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "(Allergan),", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p105_s1", "idA": "906709_17_item1_p111_s0", "sentA": "On January 28, 2011, MAP entered into a Collaboration Agreement with Allergan, Inc. pursuant to which Allergan received a co-exclusive license to market and promote SEMPRANA to neurologists and pain specialists in the U.S. Under this arrangement, Allergan paid MAP an upfront payment of $60 million and MAP was also entitled to receive up to an additional $97 million in the form of regulatory milestones, which includes milestones for acceptance of filing of the SEMPRANA NDA and first commercial sale associated with the initial acute migraine indication.", "sentB": "Under this arrangement, Allergan paid MAP an upfront payment of $60.0 million.", "type": 2, "words": ["<tag1>", "On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication.", "<tag2>", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60.0", "million.", "<tag3>"], "wordsA": ["On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication."], "wordsB": ["Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p105_s2", "idA": "906709_17_item1_p111_s0", "sentA": "On January 28, 2011, MAP entered into a Collaboration Agreement with Allergan, Inc. pursuant to which Allergan received a co-exclusive license to market and promote SEMPRANA to neurologists and pain specialists in the U.S. Under this arrangement, Allergan paid MAP an upfront payment of $60 million and MAP was also entitled to receive up to an additional $97 million in the form of regulatory milestones, which includes milestones for acceptance of filing of the SEMPRANA NDA and first commercial sale associated with the initial acute migraine indication.", "sentB": "MAP was also entitled to receive up to an additional $97.0 million in the form of regulatory milestones, which includes milestones for the FDA s acceptance of filing of the SEMPRANA NDA and first commercial sale associated with the initial acute migraine indication.", "type": 2, "words": ["<tag1>", "On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication.", "<tag2>", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97.0", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "the", "FDA", "s", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication.", "<tag3>"], "wordsA": ["On", "January", "28,", "2011,", "MAP", "entered", "into", "a", "Collaboration", "Agreement", "with", "Allergan,", "Inc.", "pursuant", "to", "which", "Allergan", "received", "a", "co-exclusive", "license", "to", "market", "and", "promote", "SEMPRANA", "to", "neurologists", "and", "pain", "specialists", "in", "the", "U.S.", "Under", "this", "arrangement,", "Allergan", "paid", "MAP", "an", "upfront", "payment", "of", "$60", "million", "and", "MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication."], "wordsB": ["MAP", "was", "also", "entitled", "to", "receive", "up", "to", "an", "additional", "$97.0", "million", "in", "the", "form", "of", "regulatory", "milestones,", "which", "includes", "milestones", "for", "the", "FDA", "s", "acceptance", "of", "filing", "of", "the", "SEMPRANA", "NDA", "and", "first", "commercial", "sale", "associated", "with", "the", "initial", "acute", "migraine", "indication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p105_s3", "idA": "906709_17_item1_p111_s1", "sentA": "On March 1, 2013, Allergan, Inc. completed a merger and acquisition transaction with MAP pursuant to which MAP become a wholly-owned subsidiary of Allergan.", "sentB": "On March 1, 2013, Allergan completed a merger and acquisition transaction with MAP pursuant to which MAP become a wholly-owned subsidiary of Allergan.", "type": 2, "words": ["<tag1>", "On", "March", "1,", "2013,", "Allergan,", "Inc.", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan.", "<tag2>", "On", "March", "1,", "2013,", "Allergan", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan.", "<tag3>"], "wordsA": ["On", "March", "1,", "2013,", "Allergan,", "Inc.", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan."], "wordsB": ["On", "March", "1,", "2013,", "Allergan", "completed", "a", "merger", "and", "acquisition", "transaction", "with", "MAP", "pursuant", "to", "which", "MAP", "become", "a", "wholly-owned", "subsidiary", "of", "Allergan."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p106_s0", "idA": "906709_17_item1_p113_s0", "sentA": "Dapirolizumab Pegol In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., (UCB) under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEGylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE).", "sentB": "In 2010, we entered into a license, manufacturing and supply agreement with UCB Pharma S.A., (UCB) under which we granted UCB a worldwide, exclusive license to certain of our proprietary PEGylation technology to develop, manufacture and commercialize an anti-CD40L PEGylated Fab being developed by UCB and their partner Biogen Idec, for the treatment of autoimmune disorders, including systemic lupus erythemastosus (SLE).", "type": 2, "words": ["<tag1>", "Dapirolizumab", "Pegol", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "(UCB)", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEGylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE).", "<tag2>", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "(UCB)", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEGylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE).", "<tag3>"], "wordsA": ["Dapirolizumab", "Pegol", "In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "(UCB)", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEGylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE)."], "wordsB": ["In", "2010,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "S.A.,", "(UCB)", "under", "which", "we", "granted", "UCB", "a", "worldwide,", "exclusive", "license", "to", "certain", "of", "our", "proprietary", "PEGylation", "technology", "to", "develop,", "manufacture", "and", "commercialize", "an", "anti-CD40L", "PEGylated", "Fab", "being", "developed", "by", "UCB", "and", "their", "partner", "Biogen", "Idec,", "for", "the", "treatment", "of", "autoimmune", "disorders,", "including", "systemic", "lupus", "erythemastosus", "(SLE)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p106_s5", "idA": "906709_17_item1_p113_s5", "sentA": "This Phase 2 clinical trial is currently recruiting participants.", "sentB": "This Phase 2 clinical trial is currently recruiting patients.", "type": 2, "words": ["<tag1>", "This", "Phase", "2", "clinical", "trial", "is", "currently", "recruiting", "participants.", "<tag2>", "This", "Phase", "2", "clinical", "trial", "is", "currently", "recruiting", "patients.", "<tag3>"], "wordsA": ["This", "Phase", "2", "clinical", "trial", "is", "currently", "recruiting", "participants."], "wordsB": ["This", "Phase", "2", "clinical", "trial", "is", "currently", "recruiting", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p110_s0", "idA": "906709_17_item1_p116_s3", "sentA": "Under the terms of the 2010 Agreement, we received a $50.0 million upfront payment in return for guaranteeing supply of certain quantities of Polymer Materials to Amgen and the Additional Rights described below, and Amgen will pay manufacturing fees calculated based on fixed and variable components applicable to the Polymer Materials ordered by Amgen and delivered by us.", "sentB": "described below, and Amgen will pay manufacturing fees calculated based on fixed and variable components applicable to the Polymer Materials ord ered by Amgen and delivered by us.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "received", "a", "$50.0", "million", "upfront", "payment", "in", "return", "for", "guaranteeing", "supply", "of", "certain", "quantities", "of", "Polymer", "Materials", "to", "Amgen", "and", "the", "Additional", "Rights", "described", "below,", "and", "Amgen", "will", "pay", "manufacturing", "fees", "calculated", "based", "on", "fixed", "and", "variable", "components", "applicable", "to", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "and", "delivered", "by", "us.", "<tag2>", "described", "below,", "and", "Amgen", "will", "pay", "manufacturing", "fees", "calculated", "based", "on", "fixed", "and", "variable", "components", "applicable", "to", "the", "Polymer", "Materials", "ord", "ered", "by", "Amgen", "and", "delivered", "by", "us.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "2010", "Agreement,", "we", "received", "a", "$50.0", "million", "upfront", "payment", "in", "return", "for", "guaranteeing", "supply", "of", "certain", "quantities", "of", "Polymer", "Materials", "to", "Amgen", "and", "the", "Additional", "Rights", "described", "below,", "and", "Amgen", "will", "pay", "manufacturing", "fees", "calculated", "based", "on", "fixed", "and", "variable", "components", "applicable", "to", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "and", "delivered", "by", "us."], "wordsB": ["described", "below,", "and", "Amgen", "will", "pay", "manufacturing", "fees", "calculated", "based", "on", "fixed", "and", "variable", "components", "applicable", "to", "the", "Polymer", "Materials", "ord", "ered", "by", "Amgen", "and", "delivered", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p110_s2", "idA": "906709_17_item1_p116_s5", "sentA": "If quantities of the Polymer Materials ordered by Amgen exceed specified quantities (with each specified quantity representing a small portion of the quantity that we historically supplied to Amgen), significant additional payments become payable to us in return for guaranteeing supply of additional quantities of the Polymer Materials.", "sentB": "If quantities of the Polymer Materials ordered by Amgen exceed specified quantities (with each specified quantity representing a small portion of the quantity that we historicall y supplied to Amgen), significant additional payments become payable to us in return for guaranteeing supply of additional quantities of the Polymer Materials.", "type": 2, "words": ["<tag1>", "If", "quantities", "of", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "exceed", "specified", "quantities", "(with", "each", "specified", "quantity", "representing", "a", "small", "portion", "of", "the", "quantity", "that", "we", "historically", "supplied", "to", "Amgen),", "significant", "additional", "payments", "become", "payable", "to", "us", "in", "return", "for", "guaranteeing", "supply", "of", "additional", "quantities", "of", "the", "Polymer", "Materials.", "<tag2>", "If", "quantities", "of", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "exceed", "specified", "quantities", "(with", "each", "specified", "quantity", "representing", "a", "small", "portion", "of", "the", "quantity", "that", "we", "historicall", "y", "supplied", "to", "Amgen),", "significant", "additional", "payments", "become", "payable", "to", "us", "in", "return", "for", "guaranteeing", "supply", "of", "additional", "quantities", "of", "the", "Polymer", "Materials.", "<tag3>"], "wordsA": ["If", "quantities", "of", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "exceed", "specified", "quantities", "(with", "each", "specified", "quantity", "representing", "a", "small", "portion", "of", "the", "quantity", "that", "we", "historically", "supplied", "to", "Amgen),", "significant", "additional", "payments", "become", "payable", "to", "us", "in", "return", "for", "guaranteeing", "supply", "of", "additional", "quantities", "of", "the", "Polymer", "Materials."], "wordsB": ["If", "quantities", "of", "the", "Polymer", "Materials", "ordered", "by", "Amgen", "exceed", "specified", "quantities", "(with", "each", "specified", "quantity", "representing", "a", "small", "portion", "of", "the", "quantity", "that", "we", "historicall", "y", "supplied", "to", "Amgen),", "significant", "additional", "payments", "become", "payable", "to", "us", "in", "return", "for", "guaranteeing", "supply", "of", "additional", "quantities", "of", "the", "Polymer", "Materials."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s4", "idA": "906709_17_item1_p116_s8", "sentA": "Amgen may terminate the 2010 Agreement for convenience or due to an uncured material default by us.", "sentB": "We will also share Phase 2 development costs with Lilly, with 75% of those costs borne by Lilly and 25% of the costs borne by us.", "type": 2, "words": ["<tag1>", "Amgen", "may", "terminate", "the", "2010", "Agreement", "for", "convenience", "or", "due", "to", "an", "uncured", "material", "default", "by", "us.", "<tag2>", "We", "will", "also", "share", "Phase", "2", "development", "costs", "with", "Lilly,", "with", "75%", "of", "those", "costs", "borne", "by", "Lilly", "and", "25%", "of", "the", "costs", "borne", "by", "us.", "<tag3>"], "wordsA": ["Amgen", "may", "terminate", "the", "2010", "Agreement", "for", "convenience", "or", "due", "to", "an", "uncured", "material", "default", "by", "us."], "wordsB": ["We", "will", "also", "share", "Phase", "2", "development", "costs", "with", "Lilly,", "with", "75%", "of", "those", "costs", "borne", "by", "Lilly", "and", "25%", "of", "the", "costs", "borne", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s4", "idA": "906709_17_item1_p116_s8", "sentA": "Amgen may terminate the 2010 Agreement for convenience or due to an uncured material default by us.", "sentB": "We will also share Phase 2 development costs with Lilly, with 75% of those costs borne by Lilly and 25% of the costs borne by us.", "type": 2, "words": ["<tag1>", "Amgen", "may", "terminate", "the", "2010", "Agreement", "for", "convenience", "or", "due", "to", "an", "uncured", "material", "default", "by", "us.", "<tag2>", "We", "will", "also", "share", "Phase", "2", "development", "costs", "with", "Lilly,", "with", "75%", "of", "those", "costs", "borne", "by", "Lilly", "and", "25%", "of", "the", "costs", "borne", "by", "us.", "<tag3>"], "wordsA": ["Amgen", "may", "terminate", "the", "2010", "Agreement", "for", "convenience", "or", "due", "to", "an", "uncured", "material", "default", "by", "us."], "wordsB": ["We", "will", "also", "share", "Phase", "2", "development", "costs", "with", "Lilly,", "with", "75%", "of", "those", "costs", "borne", "by", "Lilly", "and", "25%", "of", "the", "costs", "borne", "by", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s18", "idA": "906709_17_item1_p118_s2", "sentA": "In connection with Roche s exercise of the license extension option in December 2009, we received a payment of $31.0 million.", "sentB": "Nektar s share of such development costs are limited to an annual cap of $125.0 million.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million.", "<tag2>", "Nektar", "s", "share", "of", "such", "development", "costs", "are", "limited", "to", "an", "annual", "cap", "of", "$125.0", "million.", "<tag3>"], "wordsA": ["In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million."], "wordsB": ["Nektar", "s", "share", "of", "such", "development", "costs", "are", "limited", "to", "an", "annual", "cap", "of", "$125.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s14", "idA": "906709_17_item1_p118_s2", "sentA": "In connection with Roche s exercise of the license extension option in December 2009, we received a payment of $31.0 million.", "sentB": "Nektar s share of such development costs are limited to an annual cap of $125.0 million.", "type": 2, "words": ["<tag1>", "In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million.", "<tag2>", "Nektar", "s", "share", "of", "such", "development", "costs", "are", "limited", "to", "an", "annual", "cap", "of", "$125.0", "million.", "<tag3>"], "wordsA": ["In", "connection", "with", "Roche", "s", "exercise", "of", "the", "license", "extension", "option", "in", "December", "2009,", "we", "received", "a", "payment", "of", "$31.0", "million."], "wordsB": ["Nektar", "s", "share", "of", "such", "development", "costs", "are", "limited", "to", "an", "annual", "cap", "of", "$125.0", "million."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p113_s4", "idA": "906709_17_item1_p118_s5", "sentA": "As of December 31, 2015, we no longer have any continuing manufacturing or supply obligations under this PEGASYS agreement.", "sentB": "As of December 31, 2015, we no longer had any continuing manufacturing or supply obligations under this PEGASYS agreement.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2015,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement.", "<tag2>", "As", "of", "December", "31,", "2015,", "we", "no", "longer", "had", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2015,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement."], "wordsB": ["As", "of", "December", "31,", "2015,", "we", "no", "longer", "had", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "PEGASYS", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p114_s0", "idA": "906709_17_item1_p119_s0", "sentA": "Somave rt , Agreement with Pfizer, Inc.", "sentB": "Somavert , Agreement with Pfizer, Inc.", "type": 2, "words": ["<tag1>", "Somave", "rt", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag2>", "Somavert", ",", "Agreement", "with", "Pfizer,", "Inc.", "<tag3>"], "wordsA": ["Somave", "rt", ",", "Agreement", "with", "Pfizer,", "Inc."], "wordsB": ["Somavert", ",", "Agreement", "with", "Pfizer,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s12", "idA": "906709_17_item1_p11_s1", "sentA": "In this study, NKTR-181 had highly statistically significant lower drug liking scores and reduced feeling high scores as compared to oxycodone at all doses tested (p 0.0001).", "sentB": "For the primary endpoint of Drug Liking, NKTR-181 (400 mg and 600 mg) rated less likable compared to oxycodone 40 mg and 60 mg (p 0.0001), and a supratherapeutic dose of NKTR-181 (1200 mg) rated less likable than oxycodone 60 mg (p=0.0071).", "type": 2, "words": ["<tag1>", "In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001).", "<tag2>", "For", "the", "primary", "endpoint", "of", "Drug", "Liking,", "NKTR-181", "(400", "mg", "and", "600", "mg)", "rated", "less", "likable", "compared", "to", "oxycodone", "40", "mg", "and", "60", "mg", "(p", "0.0001),", "and", "a", "supratherapeutic", "dose", "of", "NKTR-181", "(1200", "mg)", "rated", "less", "likable", "than", "oxycodone", "60", "mg", "(p=0.0071).", "<tag3>"], "wordsA": ["In", "this", "study,", "NKTR-181", "had", "highly", "statistically", "significant", "lower", "drug", "liking", "scores", "and", "reduced", "feeling", "high", "scores", "as", "compared", "to", "oxycodone", "at", "all", "doses", "tested", "(p", "0.0001)."], "wordsB": ["For", "the", "primary", "endpoint", "of", "Drug", "Liking,", "NKTR-181", "(400", "mg", "and", "600", "mg)", "rated", "less", "likable", "compared", "to", "oxycodone", "40", "mg", "and", "60", "mg", "(p", "0.0001),", "and", "a", "supratherapeutic", "dose", "of", "NKTR-181", "(1200", "mg)", "rated", "less", "likable", "than", "oxycodone", "60", "mg", "(p=0.0071)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p62_s6", "idA": "906709_17_item1_p11_s2", "sentA": "In January 2017, we started enrollment in a second HAL study where we are assessing abuse liability of supra-therapeutic doses of NKTR-181 in order to further evaluate NKTR-181 for labeling and scheduling purposes.", "sentB": "In January 2017, we started enrollment in a second human abuse liability study where we are assessing abuse liability of supra-therapeutic doses of NKTR-181 in order to further evaluate NKTR-181 for labeling and scheduling purposes.", "type": 2, "words": ["<tag1>", "In", "January", "2017,", "we", "started", "enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "purposes.", "<tag2>", "In", "January", "2017,", "we", "started", "enrollment", "in", "a", "second", "human", "abuse", "liability", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "purposes.", "<tag3>"], "wordsA": ["In", "January", "2017,", "we", "started", "enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "purposes."], "wordsB": ["In", "January", "2017,", "we", "started", "enrollment", "in", "a", "second", "human", "abuse", "liability", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "purposes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p16_s0", "idA": "906709_17_item1_p11_s3", "sentA": "The Phase 3 program for NKTR-181 is anticipated to also include a Phase 3 efficacy and safety trial in people who are opioid-experienced.", "sentB": "Following our success of the SUMMIT-07 Phase 3 efficacy study and the HAP study, we are seeking a partner to support future development and commercialization activities for NKTR-181.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced.", "<tag2>", "Following", "our", "success", "of", "the", "SUMMIT-07", "Phase", "3", "efficacy", "study", "and", "the", "HAP", "study,", "we", "are", "seeking", "a", "partner", "to", "support", "future", "development", "and", "commercialization", "activities", "for", "NKTR-181.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced."], "wordsB": ["Following", "our", "success", "of", "the", "SUMMIT-07", "Phase", "3", "efficacy", "study", "and", "the", "HAP", "study,", "we", "are", "seeking", "a", "partner", "to", "support", "future", "development", "and", "commercialization", "activities", "for", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p64_s0", "idA": "906709_17_item1_p11_s3", "sentA": "The Phase 3 program for NKTR-181 is anticipated to also include a Phase 3 efficacy and safety trial in people who are opioid-experienced.", "sentB": "Following our success of the SUMMIT-07 Phase 3 efficacy study and the HAP study, we are seeking a partner to support future development and commercialization activities for NKTR-181.", "type": 2, "words": ["<tag1>", "The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced.", "<tag2>", "Following", "our", "success", "of", "the", "SUMMIT-07", "Phase", "3", "efficacy", "study", "and", "the", "HAP", "study,", "we", "are", "seeking", "a", "partner", "to", "support", "future", "development", "and", "commercialization", "activities", "for", "NKTR-181.", "<tag3>"], "wordsA": ["The", "Phase", "3", "program", "for", "NKTR-181", "is", "anticipated", "to", "also", "include", "a", "Phase", "3", "efficacy", "and", "safety", "trial", "in", "people", "who", "are", "opioid-experienced."], "wordsB": ["Following", "our", "success", "of", "the", "SUMMIT-07", "Phase", "3", "efficacy", "study", "and", "the", "HAP", "study,", "we", "are", "seeking", "a", "partner", "to", "support", "future", "development", "and", "commercialization", "activities", "for", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s5", "idA": "906709_17_item1_p11_s4", "sentA": "If the top-line data from the SUMMIT-07 study is positive, we plan to seek a collaboration partner for this program to support further development investments and commercialize NKTR-181.", "sentB": "This study is not impacted by the BMS Collaboration Agreement and we plan to continue this study through completion.", "type": 2, "words": ["<tag1>", "If", "the", "top-line", "data", "from", "the", "SUMMIT-07", "study", "is", "positive,", "we", "plan", "to", "seek", "a", "collaboration", "partner", "for", "this", "program", "to", "support", "further", "development", "investments", "and", "commercialize", "NKTR-181.", "<tag2>", "This", "study", "is", "not", "impacted", "by", "the", "BMS", "Collaboration", "Agreement", "and", "we", "plan", "to", "continue", "this", "study", "through", "completion.", "<tag3>"], "wordsA": ["If", "the", "top-line", "data", "from", "the", "SUMMIT-07", "study", "is", "positive,", "we", "plan", "to", "seek", "a", "collaboration", "partner", "for", "this", "program", "to", "support", "further", "development", "investments", "and", "commercialize", "NKTR-181."], "wordsB": ["This", "study", "is", "not", "impacted", "by", "the", "BMS", "Collaboration", "Agreement", "and", "we", "plan", "to", "continue", "this", "study", "through", "completion."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p117_s0", "idA": "906709_17_item1_p121_s2", "sentA": "We currently manufacture our proprietary PEGylation materials for Schering on a price per gram basis.", "sentB": "We manufactured our proprietary PEGylation materials for Schering on a price per gram basis.", "type": 2, "words": ["<tag1>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis.", "<tag2>", "We", "manufactured", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis.", "<tag3>"], "wordsA": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis."], "wordsB": ["We", "manufactured", "our", "proprietary", "PEGylation", "materials", "for", "Schering", "on", "a", "price", "per", "gram", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p117_s1", "idA": "906709_17_item1_p121_s3", "sentA": "In December 2010, the parties amended the manufacturing and supply agreement to provide for a transition plan to an alternative manufacturer and extension of the term through the successful manufacturing transition or December 31, 2018 at the latest.", "sentB": "In December 2010, the parties amended the manufacturing and supply agreement to provide for a transition plan to an alternative manufacturer and extension of the term through December 31, 2017.", "type": 2, "words": ["<tag1>", "In", "December", "2010,", "the", "parties", "amended", "the", "manufacturing", "and", "supply", "agreement", "to", "provide", "for", "a", "transition", "plan", "to", "an", "alternative", "manufacturer", "and", "extension", "of", "the", "term", "through", "the", "successful", "manufacturing", "transition", "or", "December", "31,", "2018", "at", "the", "latest.", "<tag2>", "In", "December", "2010,", "the", "parties", "amended", "the", "manufacturing", "and", "supply", "agreement", "to", "provide", "for", "a", "transition", "plan", "to", "an", "alternative", "manufacturer", "and", "extension", "of", "the", "term", "through", "December", "31,", "2017.", "<tag3>"], "wordsA": ["In", "December", "2010,", "the", "parties", "amended", "the", "manufacturing", "and", "supply", "agreement", "to", "provide", "for", "a", "transition", "plan", "to", "an", "alternative", "manufacturer", "and", "extension", "of", "the", "term", "through", "the", "successful", "manufacturing", "transition", "or", "December", "31,", "2018", "at", "the", "latest."], "wordsB": ["In", "December", "2010,", "the", "parties", "amended", "the", "manufacturing", "and", "supply", "agreement", "to", "provide", "for", "a", "transition", "plan", "to", "an", "alternative", "manufacturer", "and", "extension", "of", "the", "term", "through", "December", "31,", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s8", "idA": "906709_17_item1_p123_s1", "sentA": "We currently manufacture our proprietary PEGylation materials for Valeant on a price per gram basis.", "sentB": "The parties have agreed to jointly commercialize NKTR-214 on a worldwide basis.", "type": 2, "words": ["<tag1>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis.", "<tag2>", "The", "parties", "have", "agreed", "to", "jointly", "commercialize", "NKTR-214", "on", "a", "worldwide", "basis.", "<tag3>"], "wordsA": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis."], "wordsB": ["The", "parties", "have", "agreed", "to", "jointly", "commercialize", "NKTR-214", "on", "a", "worldwide", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s4", "idA": "906709_17_item1_p123_s1", "sentA": "We currently manufacture our proprietary PEGylation materials for Valeant on a price per gram basis.", "sentB": "The parties have agreed to jointly commercialize NKTR-214 on a worldwide basis.", "type": 2, "words": ["<tag1>", "We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis.", "<tag2>", "The", "parties", "have", "agreed", "to", "jointly", "commercialize", "NKTR-214", "on", "a", "worldwide", "basis.", "<tag3>"], "wordsA": ["We", "currently", "manufacture", "our", "proprietary", "PEGylation", "materials", "for", "Valeant", "on", "a", "price", "per", "gram", "basis."], "wordsB": ["The", "parties", "have", "agreed", "to", "jointly", "commercialize", "NKTR-214", "on", "a", "worldwide", "basis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p119_s3", "idA": "906709_17_item1_p123_s4", "sentA": "Our Agreement expires upon the expiration of our last relevant patent containing a valid claim.", "sentB": "Our agreement with Valeant expires upon the expiration of our last relevant patent containing a valid claim.", "type": 2, "words": ["<tag1>", "Our", "Agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag2>", "Our", "agreement", "with", "Valeant", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim.", "<tag3>"], "wordsA": ["Our", "Agreement", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "wordsB": ["Our", "agreement", "with", "Valeant", "expires", "upon", "the", "expiration", "of", "our", "last", "relevant", "patent", "containing", "a", "valid", "claim."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s16", "idA": "906709_17_item1_p125_s1", "sentA": "Our agreement with UCB Pharma expires upon the expiration of all of UCB s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties.", "sentB": "Under the BMS Collaboration Agreement, we and BMS will collaborate to develop and conduct clinical studies of NKTR-214 pursuant to a joint development plan, which initially includes a series of registration-enabling trials in more than 20 indications in nine tumor types and may be updated and expanded only upon mutual agreement of the parties.", "type": 2, "words": ["<tag1>", "Our", "agreement", "with", "UCB", "Pharma", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag2>", "Under", "the", "BMS", "Collaboration", "Agreement,", "we", "and", "BMS", "will", "collaborate", "to", "develop", "and", "conduct", "clinical", "studies", "of", "NKTR-214", "pursuant", "to", "a", "joint", "development", "plan,", "which", "initially", "includes", "a", "series", "of", "registration-enabling", "trials", "in", "more", "than", "20", "indications", "in", "nine", "tumor", "types", "and", "may", "be", "updated", "and", "expanded", "only", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag3>"], "wordsA": ["Our", "agreement", "with", "UCB", "Pharma", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties."], "wordsB": ["Under", "the", "BMS", "Collaboration", "Agreement,", "we", "and", "BMS", "will", "collaborate", "to", "develop", "and", "conduct", "clinical", "studies", "of", "NKTR-214", "pursuant", "to", "a", "joint", "development", "plan,", "which", "initially", "includes", "a", "series", "of", "registration-enabling", "trials", "in", "more", "than", "20", "indications", "in", "nine", "tumor", "types", "and", "may", "be", "updated", "and", "expanded", "only", "upon", "mutual", "agreement", "of", "the", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s12", "idA": "906709_17_item1_p125_s1", "sentA": "Our agreement with UCB Pharma expires upon the expiration of all of UCB s royalty obligations, provided that the agreement can be extended for successive two year renewal periods upon mutual agreement of the parties.", "sentB": "Under the BMS Collaboration Agreement, we and BMS will collaborate to develop and conduct clinical studies of NKTR-214 pursuant to a joint development plan, which initially includes a series of registration-enabling trials in more than 20 indications in nine tumor types and may be updated and expanded only upon mutual agreement of the parties.", "type": 2, "words": ["<tag1>", "Our", "agreement", "with", "UCB", "Pharma", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag2>", "Under", "the", "BMS", "Collaboration", "Agreement,", "we", "and", "BMS", "will", "collaborate", "to", "develop", "and", "conduct", "clinical", "studies", "of", "NKTR-214", "pursuant", "to", "a", "joint", "development", "plan,", "which", "initially", "includes", "a", "series", "of", "registration-enabling", "trials", "in", "more", "than", "20", "indications", "in", "nine", "tumor", "types", "and", "may", "be", "updated", "and", "expanded", "only", "upon", "mutual", "agreement", "of", "the", "parties.", "<tag3>"], "wordsA": ["Our", "agreement", "with", "UCB", "Pharma", "expires", "upon", "the", "expiration", "of", "all", "of", "UCB", "s", "royalty", "obligations,", "provided", "that", "the", "agreement", "can", "be", "extended", "for", "successive", "two", "year", "renewal", "periods", "upon", "mutual", "agreement", "of", "the", "parties."], "wordsB": ["Under", "the", "BMS", "Collaboration", "Agreement,", "we", "and", "BMS", "will", "collaborate", "to", "develop", "and", "conduct", "clinical", "studies", "of", "NKTR-214", "pursuant", "to", "a", "joint", "development", "plan,", "which", "initially", "includes", "a", "series", "of", "registration-enabling", "trials", "in", "more", "than", "20", "indications", "in", "nine", "tumor", "types", "and", "may", "be", "updated", "and", "expanded", "only", "upon", "mutual", "agreement", "of", "the", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p105_s4", "idA": "906709_17_item1_p127_s0", "sentA": "In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), which was amended and restated in its entirety in December 2005.", "sentB": "In December 2017, we, MAP and Allergan entered into a Settlement Agreement and Release.", "type": 2, "words": ["<tag1>", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005.", "<tag2>", "In", "December", "2017,", "we,", "MAP", "and", "Allergan", "entered", "into", "a", "Settlement", "Agreement", "and", "Release.", "<tag3>"], "wordsA": ["In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005."], "wordsB": ["In", "December", "2017,", "we,", "MAP", "and", "Allergan", "entered", "into", "a", "Settlement", "Agreement", "and", "Release."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p99_s2", "idA": "906709_17_item1_p127_s0", "sentA": "In December 2000, we entered into a license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche), which was amended and restated in its entirety in December 2005.", "sentB": "On October 27, 2017, we agreed to terminate our license and supply agreement with Ophthotech.", "type": 2, "words": ["<tag1>", "In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005.", "<tag2>", "On", "October", "27,", "2017,", "we", "agreed", "to", "terminate", "our", "license", "and", "supply", "agreement", "with", "Ophthotech.", "<tag3>"], "wordsA": ["In", "December", "2000,", "we", "entered", "into", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "F.", "Hoffmann-La", "Roche", "Ltd", "and", "Hoffmann-La", "Roche", "Inc.", "(Roche),", "which", "was", "amended", "and", "restated", "in", "its", "entirety", "in", "December", "2005."], "wordsB": ["On", "October", "27,", "2017,", "we", "agreed", "to", "terminate", "our", "license", "and", "supply", "agreement", "with", "Ophthotech."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s1", "idA": "906709_17_item1_p129_s1", "sentA": "In February 2012, we entered into a toll-manufacturing agreement with Roche under which we manufactured our proprietary PEGylation material for MIRCERA .", "sentB": "On July 23, 2017, we entered into a worldwide license agreement with Eli Lilly and Company (Lilly) to co-develop NKTR-358.", "type": 2, "words": ["<tag1>", "In", "February", "2012,", "we", "entered", "into", "a", "toll-manufacturing", "agreement", "with", "Roche", "under", "which", "we", "manufactured", "our", "proprietary", "PEGylation", "material", "for", "MIRCERA", ".", "<tag2>", "On", "July", "23,", "2017,", "we", "entered", "into", "a", "worldwide", "license", "agreement", "with", "Eli", "Lilly", "and", "Company", "(Lilly)", "to", "co-develop", "NKTR-358.", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "entered", "into", "a", "toll-manufacturing", "agreement", "with", "Roche", "under", "which", "we", "manufactured", "our", "proprietary", "PEGylation", "material", "for", "MIRCERA", "."], "wordsB": ["On", "July", "23,", "2017,", "we", "entered", "into", "a", "worldwide", "license", "agreement", "with", "Eli", "Lilly", "and", "Company", "(Lilly)", "to", "co-develop", "NKTR-358."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s12", "idA": "906709_17_item1_p129_s1", "sentA": "In February 2012, we entered into a toll-manufacturing agreement with Roche under which we manufactured our proprietary PEGylation material for MIRCERA .", "sentB": "In October 2017, we entered into a right to sublicense agreement with Baxalta, under which we granted to Baxalta the right to grant a nonexclusive sublicense to certain patents to a third party that were previously exclusively licensed to Baxalta under the Baxalta License Agreement.", "type": 2, "words": ["<tag1>", "In", "February", "2012,", "we", "entered", "into", "a", "toll-manufacturing", "agreement", "with", "Roche", "under", "which", "we", "manufactured", "our", "proprietary", "PEGylation", "material", "for", "MIRCERA", ".", "<tag2>", "In", "October", "2017,", "we", "entered", "into", "a", "right", "to", "sublicense", "agreement", "with", "Baxalta,", "under", "which", "we", "granted", "to", "Baxalta", "the", "right", "to", "grant", "a", "nonexclusive", "sublicense", "to", "certain", "patents", "to", "a", "third", "party", "that", "were", "previously", "exclusively", "licensed", "to", "Baxalta", "under", "the", "Baxalta", "License", "Agreement.", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "entered", "into", "a", "toll-manufacturing", "agreement", "with", "Roche", "under", "which", "we", "manufactured", "our", "proprietary", "PEGylation", "material", "for", "MIRCERA", "."], "wordsB": ["In", "October", "2017,", "we", "entered", "into", "a", "right", "to", "sublicense", "agreement", "with", "Baxalta,", "under", "which", "we", "granted", "to", "Baxalta", "the", "right", "to", "grant", "a", "nonexclusive", "sublicense", "to", "certain", "patents", "to", "a", "third", "party", "that", "were", "previously", "exclusively", "licensed", "to", "Baxalta", "under", "the", "Baxalta", "License", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p117_s3", "idA": "906709_17_item1_p129_s8", "sentA": "As of December 31, 2016, we no longer have any continuing manufacturing or supply obligations under this MIRCERA agreement.", "sentB": "As of December 31, 2017, we no longer have any continuing manufacturing or supply obligations under this agreement.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2016,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement.", "<tag2>", "As", "of", "December", "31,", "2017,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "agreement.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2016,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement."], "wordsB": ["As", "of", "December", "31,", "2017,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p125_s8", "idA": "906709_17_item1_p129_s8", "sentA": "As of December 31, 2016, we no longer have any continuing manufacturing or supply obligations under this MIRCERA agreement.", "sentB": "As of December 31, 2016, we no longer had any continuing manufacturing or supply obligations under this MIRCERA agreement.", "type": 2, "words": ["<tag1>", "As", "of", "December", "31,", "2016,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement.", "<tag2>", "As", "of", "December", "31,", "2016,", "we", "no", "longer", "had", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement.", "<tag3>"], "wordsA": ["As", "of", "December", "31,", "2016,", "we", "no", "longer", "have", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement."], "wordsB": ["As", "of", "December", "31,", "2016,", "we", "no", "longer", "had", "any", "continuing", "manufacturing", "or", "supply", "obligations", "under", "this", "MIRCERA", "agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p17_s1", "idA": "906709_17_item1_p12_s1", "sentA": "On March 17, 2015, we announced topline data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), as a single-agent therapy for women with advanced metastatic breast cancer.", "sentB": "On March 17, 2015, we announced top-line data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with NKTR-102), as a single-agent therapy for women with advanced metastatic breast cancer.", "type": 2, "words": ["<tag1>", "On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag2>", "On", "March", "17,", "2015,", "we", "announced", "top-line", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["On", "March", "17,", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "wordsB": ["On", "March", "17,", "2015,", "we", "announced", "top-line", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "NKTR-102),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p17_s3", "idA": "906709_17_item1_p12_s3", "sentA": "In a topline analysis of 852 patients from the trial, ONZEALD TM provided a 2.1 month improvement in median overall survival over TPC (12.4 months for patients receiving ONZEALD TM compared to 10.3 months for patients receiving TPC).", "sentB": "In a top-line analysis of 852 patients from the trial, ONZEALD TM provided a 2.1 month improvement in median overall survival over TPC (12.4 months for patients receiving ONZEALD TM compared to 10.3 months for patients receiving TPC).", "type": 2, "words": ["<tag1>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag2>", "In", "a", "top-line", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "wordsB": ["In", "a", "top-line", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p67_s3", "idA": "906709_17_item1_p12_s3", "sentA": "In a topline analysis of 852 patients from the trial, ONZEALD TM provided a 2.1 month improvement in median overall survival over TPC (12.4 months for patients receiving ONZEALD TM compared to 10.3 months for patients receiving TPC).", "sentB": "In a top-line analysis of 852 patients from the trial, ONZEALD TM provided a 2.1 month improvement in median overall survival over TPC (12.4 months for patients receiving ONZEALD TM compared to 10.3 months for patients receiving TPC).", "type": 2, "words": ["<tag1>", "In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag2>", "In", "a", "top-line", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC).", "<tag3>"], "wordsA": ["In", "a", "topline", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "wordsB": ["In", "a", "top-line", "analysis", "of", "852", "patients", "from", "the", "trial,", "ONZEALD", "TM", "provided", "a", "2.1", "month", "improvement", "in", "median", "overall", "survival", "over", "TPC", "(12.4", "months", "for", "patients", "receiving", "ONZEALD", "TM", "compared", "to", "10.3", "months", "for", "patients", "receiving", "TPC)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p17_s7", "idA": "906709_17_item1_p12_s7", "sentA": "We have explored future regulatory and development paths forward for ONZEALD TM with the EU and U.S. health authorities.", "sentB": "We have explored future regulatory and development paths forward for ONZEALD TM with the European Union (EU) and U.S. health authorities.", "type": 2, "words": ["<tag1>", "We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "EU", "and", "U.S.", "health", "authorities.", "<tag2>", "We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "European", "Union", "(EU)", "and", "U.S.", "health", "authorities.", "<tag3>"], "wordsA": ["We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "EU", "and", "U.S.", "health", "authorities."], "wordsB": ["We", "have", "explored", "future", "regulatory", "and", "development", "paths", "forward", "for", "ONZEALD", "TM", "with", "the", "European", "Union", "(EU)", "and", "U.S.", "health", "authorities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p17_s9", "idA": "906709_17_item1_p12_s9", "sentA": "In June 2016, we filed an MAA for conditional approval of ONZEALD TM for adult patients with advanced breast cancer who have brain metastases.", "sentB": "In June 2016, we filed a Marketing Authorization Application (MAA) for conditional approval of ONZEALD TM for adult patients with advanced breast cancer who have brain metastases and began enrolling in the ATTAIN study, which compares the overall survival in patients with breast cancer and brain metastases treated with ONZEALD TM versus physicians treatment of choice.", "type": 2, "words": ["<tag1>", "In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases.", "<tag2>", "In", "June", "2016,", "we", "filed", "a", "Marketing", "Authorization", "Application", "(MAA)", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "and", "began", "enrolling", "in", "the", "ATTAIN", "study,", "which", "compares", "the", "overall", "survival", "in", "patients", "with", "breast", "cancer", "and", "brain", "metastases", "treated", "with", "ONZEALD", "TM", "versus", "physicians", "treatment", "of", "choice.", "<tag3>"], "wordsA": ["In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases."], "wordsB": ["In", "June", "2016,", "we", "filed", "a", "Marketing", "Authorization", "Application", "(MAA)", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "and", "began", "enrolling", "in", "the", "ATTAIN", "study,", "which", "compares", "the", "overall", "survival", "in", "patients", "with", "breast", "cancer", "and", "brain", "metastases", "treated", "with", "ONZEALD", "TM", "versus", "physicians", "treatment", "of", "choice."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p150_s0", "idA": "906709_17_item1_p131_s1", "sentA": "If the product is a new chemical entity that has not been previously approved, the process includes the following:", "sentB": "The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product.", "type": 2, "words": ["<tag1>", "If", "the", "product", "is", "a", "new", "chemical", "entity", "that", "has", "not", "been", "previously", "approved,", "the", "process", "includes", "the", "following:", "<tag2>", "The", "process", "for", "determining", "whether", "a", "payor", "will", "provide", "coverage", "for", "a", "product", "is", "typically", "separate", "from", "the", "process", "for", "setting", "the", "reimbursement", "rate", "that", "the", "payor", "will", "pay", "for", "the", "product.", "<tag3>"], "wordsA": ["If", "the", "product", "is", "a", "new", "chemical", "entity", "that", "has", "not", "been", "previously", "approved,", "the", "process", "includes", "the", "following:"], "wordsB": ["The", "process", "for", "determining", "whether", "a", "payor", "will", "provide", "coverage", "for", "a", "product", "is", "typically", "separate", "from", "the", "process", "for", "setting", "the", "reimbursement", "rate", "that", "the", "payor", "will", "pay", "for", "the", "product."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p128_s0", "idA": "906709_17_item1_p132_s0", "sentA": "submission to the FDA of a New Drug Application (NDA) for approval of a drug, a Biological License Application (BLA) for approval of a biological product or a Premarket Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)).", "sentB": "submission to the FDA of an NDA for approval of a drug, a Biological License Application (BLA) for approval of a biological product or a Premarket Approval Application (PMA) or Premarket Notification 510(k) for a medical device product (a 510(k)).", "type": 2, "words": ["<tag1>", "submission", "to", "the", "FDA", "of", "a", "New", "Drug", "Application", "(NDA)", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k)).", "<tag2>", "submission", "to", "the", "FDA", "of", "an", "NDA", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k)).", "<tag3>"], "wordsA": ["submission", "to", "the", "FDA", "of", "a", "New", "Drug", "Application", "(NDA)", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k))."], "wordsB": ["submission", "to", "the", "FDA", "of", "an", "NDA", "for", "approval", "of", "a", "drug,", "a", "Biological", "License", "Application", "(BLA)", "for", "approval", "of", "a", "biological", "product", "or", "a", "Premarket", "Approval", "Application", "(PMA)", "or", "Premarket", "Notification", "510(k)", "for", "a", "medical", "device", "product", "(a", "510(k))."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p129_s0", "idA": "906709_17_item1_p133_s0", "sentA": "If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests, including those relating to systemic toxicity normally required for the IND and NDA or BLA, and clinical trials, may not be necessary if the company has a right of reference to existing preclinical or clinical data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section 505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Services Act.", "sentB": "If the active chemical ingredient has been previously approved by the FDA, the approval process is similar, except that certain preclinical tests, including those relating to systemic toxicity normally required for the IND and NDA or BLA, and clinical trials, may not be necessary if the company ha s a right of reference to existing preclinical or clinical data under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA) or is eligible for approval under Section 505(b)(2) of the FDCA or the biosimilars provisions of the Public Health Serv ices Act.", "type": 2, "words": ["<tag1>", "If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests,", "including", "those", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA,", "and", "clinical", "trials,", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "existing", "preclinical", "or", "clinical", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act.", "<tag2>", "If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests,", "including", "those", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA,", "and", "clinical", "trials,", "may", "not", "be", "necessary", "if", "the", "company", "ha", "s", "a", "right", "of", "reference", "to", "existing", "preclinical", "or", "clinical", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Serv", "ices", "Act.", "<tag3>"], "wordsA": ["If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests,", "including", "those", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA,", "and", "clinical", "trials,", "may", "not", "be", "necessary", "if", "the", "company", "has", "a", "right", "of", "reference", "to", "existing", "preclinical", "or", "clinical", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Services", "Act."], "wordsB": ["If", "the", "active", "chemical", "ingredient", "has", "been", "previously", "approved", "by", "the", "FDA,", "the", "approval", "process", "is", "similar,", "except", "that", "certain", "preclinical", "tests,", "including", "those", "relating", "to", "systemic", "toxicity", "normally", "required", "for", "the", "IND", "and", "NDA", "or", "BLA,", "and", "clinical", "trials,", "may", "not", "be", "necessary", "if", "the", "company", "ha", "s", "a", "right", "of", "reference", "to", "existing", "preclinical", "or", "clinical", "data", "under", "section", "505(j)", "of", "the", "Federal", "Food,", "Drug,", "and", "Cosmetic", "Act", "(FDCA)", "or", "is", "eligible", "for", "approval", "under", "Section", "505(b)(2)", "of", "the", "FDCA", "or", "the", "biosimilars", "provisions", "of", "the", "Public", "Health", "Serv", "ices", "Act."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p129_s4", "idA": "906709_17_item1_p134_s3", "sentA": "Clinical trials may begin 30 days after receipt of the IND by the FDA, unless the FDA raises objections or requires c larification within that period.", "sentB": "Clinical trials may begin 30 days after receipt of the IND by the FDA, unless the FDA raises objections or requires clarification within that period.", "type": 2, "words": ["<tag1>", "Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "c", "larification", "within", "that", "period.", "<tag2>", "Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "clarification", "within", "that", "period.", "<tag3>"], "wordsA": ["Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "c", "larification", "within", "that", "period."], "wordsB": ["Clinical", "trials", "may", "begin", "30", "days", "after", "receipt", "of", "the", "IND", "by", "the", "FDA,", "unless", "the", "FDA", "raises", "objections", "or", "requires", "clarification", "within", "that", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p130_s1", "idA": "906709_17_item1_p135_s1", "sentA": "Dru g products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP).", "sentB": "Drug products to be used in clinical trials must be manufactured according to current good manufacturing practices (cGMP).", "type": 2, "words": ["<tag1>", "Dru", "g", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP).", "<tag2>", "Drug", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP).", "<tag3>"], "wordsA": ["Dru", "g", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP)."], "wordsB": ["Drug", "products", "to", "be", "used", "in", "clinical", "trials", "must", "be", "manufactured", "according", "to", "current", "good", "manufacturing", "practices", "(cGMP)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p130_s2", "idA": "906709_17_item1_p135_s2", "sentA": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to moni tor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "sentB": "Clinical trials are conducted in accordance with protocols that detail the objectives of the study and the parameters to be used to monitor participant safety and product efficacy as well as other criteria to be evaluated in the study.", "type": 2, "words": ["<tag1>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "moni", "tor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag2>", "Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study.", "<tag3>"], "wordsA": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "moni", "tor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "wordsB": ["Clinical", "trials", "are", "conducted", "in", "accordance", "with", "protocols", "that", "detail", "the", "objectives", "of", "the", "study", "and", "the", "parameters", "to", "be", "used", "to", "monitor", "participant", "safety", "and", "product", "efficacy", "as", "well", "as", "other", "criteria", "to", "be", "evaluated", "in", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s13", "idA": "906709_17_item1_p135_s5", "sentA": "The IRB considers, among other things, ethical factors, the potential risks to subjects participating in the trial and the possible liability to the institution where the trial is conducted.", "sentB": "These laws may impact, among other things, our proposed sales and marketing programs.", "type": 2, "words": ["<tag1>", "The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted.", "<tag2>", "These", "laws", "may", "impact,", "among", "other", "things,", "our", "proposed", "sales", "and", "marketing", "programs.", "<tag3>"], "wordsA": ["The", "IRB", "considers,", "among", "other", "things,", "ethical", "factors,", "the", "potential", "risks", "to", "subjects", "participating", "in", "the", "trial", "and", "the", "possible", "liability", "to", "the", "institution", "where", "the", "trial", "is", "conducted."], "wordsB": ["These", "laws", "may", "impact,", "among", "other", "things,", "our", "proposed", "sales", "and", "marketing", "programs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p138_s0", "idA": "906709_17_item1_p142_s4", "sentA": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and controlled substance controls, among others.", "sentB": "They are also subject to U.S. federal, state, and local regulations regarding workplace safety, environmental protection and hazardous and control led substance controls, among others.", "type": 2, "words": ["<tag1>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others.", "<tag2>", "They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "control", "led", "substance", "controls,", "among", "others.", "<tag3>"], "wordsA": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "controlled", "substance", "controls,", "among", "others."], "wordsB": ["They", "are", "also", "subject", "to", "U.S.", "federal,", "state,", "and", "local", "regulations", "regarding", "workplace", "safety,", "environmental", "protection", "and", "hazardous", "and", "control", "led", "substance", "controls,", "among", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p139_s0", "idA": "906709_17_item1_p143_s0", "sentA": "For product candidates currently under development utilizing pulmonary technology, the pulmonary inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molec ule.", "sentB": "For product candidates currently under development utilizing pulmonary technology, the pulmonary inhaler devices are considered to be part of a drug and device combination for deep lung delivery of each specific molecule.", "type": 2, "words": ["<tag1>", "For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molec", "ule.", "<tag2>", "For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molecule.", "<tag3>"], "wordsA": ["For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molec", "ule."], "wordsB": ["For", "product", "candidates", "currently", "under", "development", "utilizing", "pulmonary", "technology,", "the", "pulmonary", "inhaler", "devices", "are", "considered", "to", "be", "part", "of", "a", "drug", "and", "device", "combination", "for", "deep", "lung", "delivery", "of", "each", "specific", "molecule."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p140_s0", "idA": "906709_17_item1_p144_s0", "sentA": "The FDA will make a determination as to the most appropriate center and division within the agency that will assume primary responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBE R are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction.", "sentB": "The FDA will make a determination as to the most appropriate center and division within the agency that will assume primary responsibility for the review of the applicable applications, which would consist of an IND and an NDA or BLA where CDER or CBER are determined to have primary jurisdiction or an investigational device exemption application and PMA or 510(k) where the Center for Devices and Radiological Health (CDRH) is determined to have primary jurisdiction.", "type": 2, "words": ["<tag1>", "The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBE", "R", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction.", "<tag2>", "The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBER", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction.", "<tag3>"], "wordsA": ["The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBE", "R", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction."], "wordsB": ["The", "FDA", "will", "make", "a", "determination", "as", "to", "the", "most", "appropriate", "center", "and", "division", "within", "the", "agency", "that", "will", "assume", "primary", "responsibility", "for", "the", "review", "of", "the", "applicable", "applications,", "which", "would", "consist", "of", "an", "IND", "and", "an", "NDA", "or", "BLA", "where", "CDER", "or", "CBER", "are", "determined", "to", "have", "primary", "jurisdiction", "or", "an", "investigational", "device", "exemption", "application", "and", "PMA", "or", "510(k)", "where", "the", "Center", "for", "Devices", "and", "Radiological", "Health", "(CDRH)", "is", "determined", "to", "have", "primary", "jurisdiction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p156_s2", "idA": "906709_17_item1_p148_s2", "sentA": "Sales of our products outside the U.S. are subject to local regulatory requirements governing clinical trials and marketing approval for drugs.", "sentB": "In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state, and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under this law.", "type": 2, "words": ["<tag1>", "Sales", "of", "our", "products", "outside", "the", "U.S.", "are", "subject", "to", "local", "regulatory", "requirements", "governing", "clinical", "trials", "and", "marketing", "approval", "for", "drugs.", "<tag2>", "In", "addition,", "our", "future", "activities", "relating", "to", "the", "reporting", "of", "wholesaler", "or", "estimated", "retail", "prices", "for", "our", "products,", "the", "reporting", "of", "prices", "used", "to", "calculate", "Medicaid", "rebate", "information", "and", "other", "information", "affecting", "federal,", "state,", "and", "third-party", "reimbursement", "for", "our", "products,", "and", "the", "sale", "and", "marketing", "of", "our", "products,", "are", "subject", "to", "scrutiny", "under", "this", "law.", "<tag3>"], "wordsA": ["Sales", "of", "our", "products", "outside", "the", "U.S.", "are", "subject", "to", "local", "regulatory", "requirements", "governing", "clinical", "trials", "and", "marketing", "approval", "for", "drugs."], "wordsB": ["In", "addition,", "our", "future", "activities", "relating", "to", "the", "reporting", "of", "wholesaler", "or", "estimated", "retail", "prices", "for", "our", "products,", "the", "reporting", "of", "prices", "used", "to", "calculate", "Medicaid", "rebate", "information", "and", "other", "information", "affecting", "federal,", "state,", "and", "third-party", "reimbursement", "for", "our", "products,", "and", "the", "sale", "and", "marketing", "of", "our", "products,", "are", "subject", "to", "scrutiny", "under", "this", "law."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s9", "idA": "906709_17_item1_p151_s0", "sentA": "Similar incentives also are available for orphan drugs in the EU.", "sentB": "On July 21, 2017, we were informed by the EMA s Committee for Medicinal Products for Human Use (CHMP) that it had adopted a negative opinion for the conditional marketing authorization application for ONZEALD in the EU.", "type": 2, "words": ["<tag1>", "Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "EU.", "<tag2>", "On", "July", "21,", "2017,", "we", "were", "informed", "by", "the", "EMA", "s", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "that", "it", "had", "adopted", "a", "negative", "opinion", "for", "the", "conditional", "marketing", "authorization", "application", "for", "ONZEALD", "in", "the", "EU.", "<tag3>"], "wordsA": ["Similar", "incentives", "also", "are", "available", "for", "orphan", "drugs", "in", "the", "EU."], "wordsB": ["On", "July", "21,", "2017,", "we", "were", "informed", "by", "the", "EMA", "s", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "that", "it", "had", "adopted", "a", "negative", "opinion", "for", "the", "conditional", "marketing", "authorization", "application", "for", "ONZEALD", "in", "the", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p158_s0", "idA": "906709_17_item1_p153_s0", "sentA": "Patents and Proprietary Rights We own more than 215 U.S. and 750 foreign patents and a number of pending patent applications that cover various aspects of our technologies.", "sentB": "Patents and Proprietary Rights We own more than 250 U.S. and 800 foreign patents and a number of pending patent applications that cover various aspects of our technologies.", "type": 2, "words": ["<tag1>", "Patents", "and", "Proprietary", "Rights", "We", "own", "more", "than", "215", "U.S.", "and", "750", "foreign", "patents", "and", "a", "number", "of", "pending", "patent", "applications", "that", "cover", "various", "aspects", "of", "our", "technologies.", "<tag2>", "Patents", "and", "Proprietary", "Rights", "We", "own", "more", "than", "250", "U.S.", "and", "800", "foreign", "patents", "and", "a", "number", "of", "pending", "patent", "applications", "that", "cover", "various", "aspects", "of", "our", "technologies.", "<tag3>"], "wordsA": ["Patents", "and", "Proprietary", "Rights", "We", "own", "more", "than", "215", "U.S.", "and", "750", "foreign", "patents", "and", "a", "number", "of", "pending", "patent", "applications", "that", "cover", "various", "aspects", "of", "our", "technologies."], "wordsB": ["Patents", "and", "Proprietary", "Rights", "We", "own", "more", "than", "250", "U.S.", "and", "800", "foreign", "patents", "and", "a", "number", "of", "pending", "patent", "applications", "that", "cover", "various", "aspects", "of", "our", "technologies."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p159_s0", "idA": "906709_17_item1_p153_s2", "sentA": "More specifically, our patents and patent applications cover polymer architecture, drug conjugates, formulations, methods of making polymers and polymer conjugates, methods of administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates.", "sentB": "methods of administering polymer conjugates, and methods of manufacturing polymers and polymer conjugates.", "type": 2, "words": ["<tag1>", "More", "specifically,", "our", "patents", "and", "patent", "applications", "cover", "polymer", "architecture,", "drug", "conjugates,", "formulations,", "methods", "of", "making", "polymers", "and", "polymer", "conjugates,", "methods", "of", "administering", "polymer", "conjugates,", "and", "methods", "of", "manufacturing", "polymers", "and", "polymer", "conjugates.", "<tag2>", "methods", "of", "administering", "polymer", "conjugates,", "and", "methods", "of", "manufacturing", "polymers", "and", "polymer", "conjugates.", "<tag3>"], "wordsA": ["More", "specifically,", "our", "patents", "and", "patent", "applications", "cover", "polymer", "architecture,", "drug", "conjugates,", "formulations,", "methods", "of", "making", "polymers", "and", "polymer", "conjugates,", "methods", "of", "administering", "polymer", "conjugates,", "and", "methods", "of", "manufacturing", "polymers", "and", "polymer", "conjugates."], "wordsB": ["methods", "of", "administering", "polymer", "conjugates,", "and", "methods", "of", "manufacturing", "polymers", "and", "polymer", "conjugates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p159_s1", "idA": "906709_17_item1_p153_s3", "sentA": "Our patent portfolio contains patents and patent applications that encompass our advanced polymer conjugate technology platforms, some of which we acquired in our acquisition of Shearwater Corporation in June 2001.", "sentB": "Our patent portfolio contains patents and patent applications that encompass our advanced polymer conjugate technology platforms, some of w hich we acquired in our acquisition of Shearwater Corporation in June 2001.", "type": 2, "words": ["<tag1>", "Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001.", "<tag2>", "Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "w", "hich", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001.", "<tag3>"], "wordsA": ["Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "which", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001."], "wordsB": ["Our", "patent", "portfolio", "contains", "patents", "and", "patent", "applications", "that", "encompass", "our", "advanced", "polymer", "conjugate", "technology", "platforms,", "some", "of", "w", "hich", "we", "acquired", "in", "our", "acquisition", "of", "Shearwater", "Corporation", "in", "June", "2001."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p159_s3", "idA": "906709_17_item1_p153_s5", "sentA": "Generally, patents have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "sentB": "Generally, pate nts have a term of twenty years from the earliest priority date (assuming all maintenance fees are paid).", "type": 2, "words": ["<tag1>", "Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag2>", "Generally,", "pate", "nts", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid).", "<tag3>"], "wordsA": ["Generally,", "patents", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "wordsB": ["Generally,", "pate", "nts", "have", "a", "term", "of", "twenty", "years", "from", "the", "earliest", "priority", "date", "(assuming", "all", "maintenance", "fees", "are", "paid)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p159_s4", "idA": "906709_17_item1_p153_s6", "sentA": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the patent.", "sentB": "In some instances, patent terms can be increased or decreased, depending on the laws and regulations of the country or jurisdiction that issued the pa tent.", "type": 2, "words": ["<tag1>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent.", "<tag2>", "In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "pa", "tent.", "<tag3>"], "wordsA": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "patent."], "wordsB": ["In", "some", "instances,", "patent", "terms", "can", "be", "increased", "or", "decreased,", "depending", "on", "the", "laws", "and", "regulations", "of", "the", "country", "or", "jurisdiction", "that", "issued", "the", "pa", "tent."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p160_s0", "idA": "906709_17_item1_p154_s0", "sentA": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "sentB": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon, pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "type": 2, "words": ["<tag1>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag2>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon,", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag3>"], "wordsA": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "wordsB": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon,", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s7", "idA": "906709_17_item1_p154_s0", "sentA": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "sentB": "On February 13, 2018, we entered into a Strategic Collaboration Agreement (the BMS Collaboration Agreement) with BMS, pursuant to which we and BMS will jointly develop NKTR-214, including, without limitation, in combination with BMS s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab), and other compounds of BMS, us or any third party.", "type": 2, "words": ["<tag1>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag2>", "On", "February", "13,", "2018,", "we", "entered", "into", "a", "Strategic", "Collaboration", "Agreement", "(the", "BMS", "Collaboration", "Agreement)", "with", "BMS,", "pursuant", "to", "which", "we", "and", "BMS", "will", "jointly", "develop", "NKTR-214,", "including,", "without", "limitation,", "in", "combination", "with", "BMS", "s", "Opdivo", "(nivolumab)", "and", "Opdivo", "plus", "Yervoy", "(ipilimumab),", "and", "other", "compounds", "of", "BMS,", "us", "or", "any", "third", "party.", "<tag3>"], "wordsA": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "wordsB": ["On", "February", "13,", "2018,", "we", "entered", "into", "a", "Strategic", "Collaboration", "Agreement", "(the", "BMS", "Collaboration", "Agreement)", "with", "BMS,", "pursuant", "to", "which", "we", "and", "BMS", "will", "jointly", "develop", "NKTR-214,", "including,", "without", "limitation,", "in", "combination", "with", "BMS", "s", "Opdivo", "(nivolumab)", "and", "Opdivo", "plus", "Yervoy", "(ipilimumab),", "and", "other", "compounds", "of", "BMS,", "us", "or", "any", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s3", "idA": "906709_17_item1_p154_s0", "sentA": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "sentB": "On February 13, 2018, we entered into the BMS Collaboration Agreement with BMS, pursuant to which we and BMS will jointly develop NKTR-214, including, without limitation, in combination with BMS s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab), and other compounds of BMS, us or any third party.", "type": 2, "words": ["<tag1>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag2>", "On", "February", "13,", "2018,", "we", "entered", "into", "the", "BMS", "Collaboration", "Agreement", "with", "BMS,", "pursuant", "to", "which", "we", "and", "BMS", "will", "jointly", "develop", "NKTR-214,", "including,", "without", "limitation,", "in", "combination", "with", "BMS", "s", "Opdivo", "(nivolumab)", "and", "Opdivo", "plus", "Yervoy", "(ipilimumab),", "and", "other", "compounds", "of", "BMS,", "us", "or", "any", "third", "party.", "<tag3>"], "wordsA": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "wordsB": ["On", "February", "13,", "2018,", "we", "entered", "into", "the", "BMS", "Collaboration", "Agreement", "with", "BMS,", "pursuant", "to", "which", "we", "and", "BMS", "will", "jointly", "develop", "NKTR-214,", "including,", "without", "limitation,", "in", "combination", "with", "BMS", "s", "Opdivo", "(nivolumab)", "and", "Opdivo", "plus", "Yervoy", "(ipilimumab),", "and", "other", "compounds", "of", "BMS,", "us", "or", "any", "third", "party."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s1", "idA": "906709_17_item1_p154_s0", "sentA": "In January 2002, we entered into a Cross-License and Option Agreement with Enzon Pharmaceuticals, Inc. (Enzon), pursuant to which we and Enzon provided certain licenses to selected portions of each party s PEGylation patent portfolio.", "sentB": "On July 23, 2017, we entered into the Lilly Agreement, pursuant to which we and Lilly will co develop NKTR-358.", "type": 2, "words": ["<tag1>", "In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio.", "<tag2>", "On", "July", "23,", "2017,", "we", "entered", "into", "the", "Lilly", "Agreement,", "pursuant", "to", "which", "we", "and", "Lilly", "will", "co", "develop", "NKTR-358.", "<tag3>"], "wordsA": ["In", "January", "2002,", "we", "entered", "into", "a", "Cross-License", "and", "Option", "Agreement", "with", "Enzon", "Pharmaceuticals,", "Inc.", "(Enzon),", "pursuant", "to", "which", "we", "and", "Enzon", "provided", "certain", "licenses", "to", "selected", "portions", "of", "each", "party", "s", "PEGylation", "patent", "portfolio."], "wordsB": ["On", "July", "23,", "2017,", "we", "entered", "into", "the", "Lilly", "Agreement,", "pursuant", "to", "which", "we", "and", "Lilly", "will", "co", "develop", "NKTR-358."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s9", "idA": "906709_17_item1_p155_s0", "sentA": "On December 31, 2008, we completed the sale of certain assets related to our pulmonary business, associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation (together referred to as Novartis) for a purchase price of $115.0 million in cash (Novartis Pulmonary Asset Sale).", "sentB": "BMS will pay us a non-refundable upfront cash payment of $1.0 billion and purchase $850.0 million of shares of our common stock at a purchase price of $102.60 per share pursuant to a Share Purchase Agreement (Purchase Agreement).", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "of", "certain", "assets", "related", "to", "our", "pulmonary", "business,", "associated", "technology", "and", "intellectual", "property", "to", "Novartis", "Pharma", "AG", "and", "Novartis", "Pharmaceuticals", "Corporation", "(together", "referred", "to", "as", "Novartis)", "for", "a", "purchase", "price", "of", "$115.0", "million", "in", "cash", "(Novartis", "Pulmonary", "Asset", "Sale).", "<tag2>", "BMS", "will", "pay", "us", "a", "non-refundable", "upfront", "cash", "payment", "of", "$1.0", "billion", "and", "purchase", "$850.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "a", "purchase", "price", "of", "$102.60", "per", "share", "pursuant", "to", "a", "Share", "Purchase", "Agreement", "(Purchase", "Agreement).", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "of", "certain", "assets", "related", "to", "our", "pulmonary", "business,", "associated", "technology", "and", "intellectual", "property", "to", "Novartis", "Pharma", "AG", "and", "Novartis", "Pharmaceuticals", "Corporation", "(together", "referred", "to", "as", "Novartis)", "for", "a", "purchase", "price", "of", "$115.0", "million", "in", "cash", "(Novartis", "Pulmonary", "Asset", "Sale)."], "wordsB": ["BMS", "will", "pay", "us", "a", "non-refundable", "upfront", "cash", "payment", "of", "$1.0", "billion", "and", "purchase", "$850.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "a", "purchase", "price", "of", "$102.60", "per", "share", "pursuant", "to", "a", "Share", "Purchase", "Agreement", "(Purchase", "Agreement)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s5", "idA": "906709_17_item1_p155_s0", "sentA": "On December 31, 2008, we completed the sale of certain assets related to our pulmonary business, associated technology and intellectual property to Novartis Pharma AG and Novartis Pharmaceuticals Corporation (together referred to as Novartis) for a purchase price of $115.0 million in cash (Novartis Pulmonary Asset Sale).", "sentB": "BMS will pay us a non-refundable upfront cash payment of $1 billion and purchase $850.0 million of shares of our common stock at a purchase price of $102.60 per share pursuant to a Share Purchase Agreement (Purchase Agreement).", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "completed", "the", "sale", "of", "certain", "assets", "related", "to", "our", "pulmonary", "business,", "associated", "technology", "and", "intellectual", "property", "to", "Novartis", "Pharma", "AG", "and", "Novartis", "Pharmaceuticals", "Corporation", "(together", "referred", "to", "as", "Novartis)", "for", "a", "purchase", "price", "of", "$115.0", "million", "in", "cash", "(Novartis", "Pulmonary", "Asset", "Sale).", "<tag2>", "BMS", "will", "pay", "us", "a", "non-refundable", "upfront", "cash", "payment", "of", "$1", "billion", "and", "purchase", "$850.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "a", "purchase", "price", "of", "$102.60", "per", "share", "pursuant", "to", "a", "Share", "Purchase", "Agreement", "(Purchase", "Agreement).", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "completed", "the", "sale", "of", "certain", "assets", "related", "to", "our", "pulmonary", "business,", "associated", "technology", "and", "intellectual", "property", "to", "Novartis", "Pharma", "AG", "and", "Novartis", "Pharmaceuticals", "Corporation", "(together", "referred", "to", "as", "Novartis)", "for", "a", "purchase", "price", "of", "$115.0", "million", "in", "cash", "(Novartis", "Pulmonary", "Asset", "Sale)."], "wordsB": ["BMS", "will", "pay", "us", "a", "non-refundable", "upfront", "cash", "payment", "of", "$1", "billion", "and", "purchase", "$850.0", "million", "of", "shares", "of", "our", "common", "stock", "at", "a", "purchase", "price", "of", "$102.60", "per", "share", "pursuant", "to", "a", "Share", "Purchase", "Agreement", "(Purchase", "Agreement)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s11", "idA": "906709_17_item1_p155_s8", "sentA": "In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs.", "sentB": "Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.", "type": 2, "words": ["<tag1>", "In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs.", "<tag2>", "Even", "if", "favorable", "coverage", "and", "reimbursement", "status", "is", "attained", "for", "one", "or", "more", "products", "for", "which", "we", "receive", "regulatory", "approval,", "less", "favorable", "coverage", "policies", "and", "reimbursement", "rates", "may", "be", "implemented", "in", "the", "future.", "<tag3>"], "wordsA": ["In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs."], "wordsB": ["Even", "if", "favorable", "coverage", "and", "reimbursement", "status", "is", "attained", "for", "one", "or", "more", "products", "for", "which", "we", "receive", "regulatory", "approval,", "less", "favorable", "coverage", "policies", "and", "reimbursement", "rates", "may", "be", "implemented", "in", "the", "future."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s14", "idA": "906709_17_item1_p155_s8", "sentA": "In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs.", "sentB": "In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business.", "type": 2, "words": ["<tag1>", "In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs.", "<tag2>", "In", "addition,", "we", "may", "be", "subject", "to", "patient", "privacy", "regulation", "by", "both", "the", "federal", "government", "and", "the", "states", "in", "which", "we", "conduct", "our", "business.", "<tag3>"], "wordsA": ["In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs."], "wordsB": ["In", "addition,", "we", "may", "be", "subject", "to", "patient", "privacy", "regulation", "by", "both", "the", "federal", "government", "and", "the", "states", "in", "which", "we", "conduct", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p151_s15", "idA": "906709_17_item1_p155_s8", "sentA": "In certain situations in which we work with drugs covered by one or more patents, our ability to develop and commercialize our technologies may be affected by limitations in our access to these proprietary drugs.", "sentB": "The laws that may affect our ability to operate include:", "type": 2, "words": ["<tag1>", "In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs.", "<tag2>", "The", "laws", "that", "may", "affect", "our", "ability", "to", "operate", "include:", "<tag3>"], "wordsA": ["In", "certain", "situations", "in", "which", "we", "work", "with", "drugs", "covered", "by", "one", "or", "more", "patents,", "our", "ability", "to", "develop", "and", "commercialize", "our", "technologies", "may", "be", "affected", "by", "limitations", "in", "our", "access", "to", "these", "proprietary", "drugs."], "wordsB": ["The", "laws", "that", "may", "affect", "our", "ability", "to", "operate", "include:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s15", "idA": "906709_17_item1_p156_s1", "sentA": "There can be no assurance that patents that have issued will be held valid and enforceable in a court of law.", "sentB": "NKTR-214 will be sold on a stand-alone basis and there will be no fixed-dose combinations or co-packaging without the consent of both parties.", "type": 2, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law.", "<tag2>", "NKTR-214", "will", "be", "sold", "on", "a", "stand-alone", "basis", "and", "there", "will", "be", "no", "fixed-dose", "combinations", "or", "co-packaging", "without", "the", "consent", "of", "both", "parties.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law."], "wordsB": ["NKTR-214", "will", "be", "sold", "on", "a", "stand-alone", "basis", "and", "there", "will", "be", "no", "fixed-dose", "combinations", "or", "co-packaging", "without", "the", "consent", "of", "both", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s11", "idA": "906709_17_item1_p156_s1", "sentA": "There can be no assurance that patents that have issued will be held valid and enforceable in a court of law.", "sentB": "NKTR-214 will be sold on a stand-alone basis and there will be no fixed-dose combinations or co-packaging without the consent of both parties.", "type": 2, "words": ["<tag1>", "There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law.", "<tag2>", "NKTR-214", "will", "be", "sold", "on", "a", "stand-alone", "basis", "and", "there", "will", "be", "no", "fixed-dose", "combinations", "or", "co-packaging", "without", "the", "consent", "of", "both", "parties.", "<tag3>"], "wordsA": ["There", "can", "be", "no", "assurance", "that", "patents", "that", "have", "issued", "will", "be", "held", "valid", "and", "enforceable", "in", "a", "court", "of", "law."], "wordsB": ["NKTR-214", "will", "be", "sold", "on", "a", "stand-alone", "basis", "and", "there", "will", "be", "no", "fixed-dose", "combinations", "or", "co-packaging", "without", "the", "consent", "of", "both", "parties."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p165_s0", "idA": "906709_17_item1_p159_s0", "sentA": "It is our policy to require our employees and consulta nts, outside scientific collaborators, sponsored researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us.", "sentB": "It is our policy to require our employees and consultants, outside scientific collaborators, sponso red researchers and other advisors who receive confidential information from us to execute confidentiality agreements upon the commencement of employment or consulting relationships with us.", "type": 2, "words": ["<tag1>", "It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consulta", "nts,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us.", "<tag2>", "It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consultants,", "outside", "scientific", "collaborators,", "sponso", "red", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us.", "<tag3>"], "wordsA": ["It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consulta", "nts,", "outside", "scientific", "collaborators,", "sponsored", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us."], "wordsB": ["It", "is", "our", "policy", "to", "require", "our", "employees", "and", "consultants,", "outside", "scientific", "collaborators,", "sponso", "red", "researchers", "and", "other", "advisors", "who", "receive", "confidential", "information", "from", "us", "to", "execute", "confidentiality", "agreements", "upon", "the", "commencement", "of", "employment", "or", "consulting", "relationships", "with", "us."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p165_s1", "idA": "906709_17_item1_p159_s1", "sentA": "These agreements pro vide that all confidential information developed or made known to the individual during the course of the individual s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.", "sentB": "These agreements provide that all confidential information develo ped or made known to the individual during the course of the individual s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances.", "type": 2, "words": ["<tag1>", "These", "agreements", "pro", "vide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances.", "<tag2>", "These", "agreements", "provide", "that", "all", "confidential", "information", "develo", "ped", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances.", "<tag3>"], "wordsA": ["These", "agreements", "pro", "vide", "that", "all", "confidential", "information", "developed", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances."], "wordsB": ["These", "agreements", "provide", "that", "all", "confidential", "information", "develo", "ped", "or", "made", "known", "to", "the", "individual", "during", "the", "course", "of", "the", "individual", "s", "relationship", "with", "us", "is", "to", "be", "kept", "confidential", "and", "not", "disclosed", "to", "third", "parties", "except", "in", "specific", "circumstances."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p85_s0", "idA": "906709_17_item1_p15_s1", "sentA": "Kyowa Hakko Kirin Co. Ltd. (Kirin) has exclusive marketing rights to MOVENTIG (the naloxegol brand name in the EU) in the EU, Iceland, Liechtenstein, Norway and Switzerland.", "sentB": "On March 1, 2016, AstraZeneca announced that it had entered into an agreement with Kyowa Hakko Kirin Co. Ltd. (Kirin), granting Kirin exclusive marketing rights to MOVENTIG in the EU, Iceland, Liechtenstein, Norway and Switzerland.", "type": 2, "words": ["<tag1>", "Kyowa", "Hakko", "Kirin", "Co.", "Ltd.", "(Kirin)", "has", "exclusive", "marketing", "rights", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "EU)", "in", "the", "EU,", "Iceland,", "Liechtenstein,", "Norway", "and", "Switzerland.", "<tag2>", "On", "March", "1,", "2016,", "AstraZeneca", "announced", "that", "it", "had", "entered", "into", "an", "agreement", "with", "Kyowa", "Hakko", "Kirin", "Co.", "Ltd.", "(Kirin),", "granting", "Kirin", "exclusive", "marketing", "rights", "to", "MOVENTIG", "in", "the", "EU,", "Iceland,", "Liechtenstein,", "Norway", "and", "Switzerland.", "<tag3>"], "wordsA": ["Kyowa", "Hakko", "Kirin", "Co.", "Ltd.", "(Kirin)", "has", "exclusive", "marketing", "rights", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "EU)", "in", "the", "EU,", "Iceland,", "Liechtenstein,", "Norway", "and", "Switzerland."], "wordsB": ["On", "March", "1,", "2016,", "AstraZeneca", "announced", "that", "it", "had", "entered", "into", "an", "agreement", "with", "Kyowa", "Hakko", "Kirin", "Co.", "Ltd.", "(Kirin),", "granting", "Kirin", "exclusive", "marketing", "rights", "to", "MOVENTIG", "in", "the", "EU,", "Iceland,", "Liechtenstein,", "Norway", "and", "Switzerland."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s4", "idA": "906709_17_item1_p15_s4", "sentA": "In November 2015, ADYNOVATE was approved by the U.S. Food and Drug Administration (FDA) for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Baxalta announced the launch and first shipments of ADYNOVATE in the U.S. on November 30, 2015.", "sentB": "ADYNOVATE , was first approved by the United States Food and Drug Administration (FDA) in late 2015 for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "in", "the", "U.S.", "on", "November", "30,", "2015.", "<tag2>", "ADYNOVATE", ",", "was", "first", "approved", "by", "the", "United", "States", "Food", "and", "Drug", "Administration", "(FDA)", "in", "late", "2015", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "U.S.", "Food", "and", "Drug", "Administration", "(FDA)", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "Baxalta", "announced", "the", "launch", "and", "first", "shipments", "of", "ADYNOVATE", "in", "the", "U.S.", "on", "November", "30,", "2015."], "wordsB": ["ADYNOVATE", ",", "was", "first", "approved", "by", "the", "United", "States", "Food", "and", "Drug", "Administration", "(FDA)", "in", "late", "2015", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s6", "idA": "906709_17_item1_p15_s5", "sentA": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In March 2016, ADYNOVATE was approved in Japan for p atients aged 12 years and older with Hemophilia A and in November 2017 that approval was extended to include pediatric patients under 12 years of age, and those undergoing surgery.", "type": 2, "words": ["<tag1>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "March", "2016,", "ADYNOVATE", "was", "approved", "in", "Japan", "for", "p", "atients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A", "and", "in", "November", "2017", "that", "approval", "was", "extended", "to", "include", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "those", "undergoing", "surgery.", "<tag3>"], "wordsA": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "March", "2016,", "ADYNOVATE", "was", "approved", "in", "Japan", "for", "p", "atients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A", "and", "in", "November", "2017", "that", "approval", "was", "extended", "to", "include", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "those", "undergoing", "surgery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s7", "idA": "906709_17_item1_p15_s5", "sentA": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In late 2016, ADYNOVATE (marketed as ADYNOVI) was approved in Switzerland for use in Hemophilia A patients aged 12 years and older and in March 2017, ADYNOVI was approved for use in pediatric patients.", "type": 2, "words": ["<tag1>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "late", "2016,", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "Switzerland", "for", "use", "in", "Hemophilia", "A", "patients", "aged", "12", "years", "and", "older", "and", "in", "March", "2017,", "ADYNOVI", "was", "approved", "for", "use", "in", "pediatric", "patients.", "<tag3>"], "wordsA": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "late", "2016,", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "Switzerland", "for", "use", "in", "Hemophilia", "A", "patients", "aged", "12", "years", "and", "older", "and", "in", "March", "2017,", "ADYNOVI", "was", "approved", "for", "use", "in", "pediatric", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s9", "idA": "906709_17_item1_p15_s5", "sentA": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In March 2017, ADYNOVATE was approved in Australia for use in adult and pediatric patients with Hemophilia A.", "type": 2, "words": ["<tag1>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "March", "2017,", "ADYNOVATE", "was", "approved", "in", "Australia", "for", "use", "in", "adult", "and", "pediatric", "patients", "with", "Hemophilia", "A.", "<tag3>"], "wordsA": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "March", "2017,", "ADYNOVATE", "was", "approved", "in", "Australia", "for", "use", "in", "adult", "and", "pediatric", "patients", "with", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s5", "idA": "906709_17_item1_p15_s5", "sentA": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In March 2016, ADYNOVATE was approved in Japan for patients aged 12 years and older with Hemophilia A and in November 2017 that approval was extended to include pediatric patients under 12 years of age, and those undergoing surgery.", "type": 2, "words": ["<tag1>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "March", "2016,", "ADYNOVATE", "was", "approved", "in", "Japan", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A", "and", "in", "November", "2017", "that", "approval", "was", "extended", "to", "include", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "those", "undergoing", "surgery.", "<tag3>"], "wordsA": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "March", "2016,", "ADYNOVATE", "was", "approved", "in", "Japan", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A", "and", "in", "November", "2017", "that", "approval", "was", "extended", "to", "include", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "those", "undergoing", "surgery."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s6", "idA": "906709_17_item1_p15_s5", "sentA": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In late 2016, ADYNOVATE (marketed as ADYNOVI) was approved in Switzerland for use in Hemophilia A patients aged 12 years and older and in March 2017, ADYNOVI was approved for use in pediatric patients.", "type": 2, "words": ["<tag1>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "late", "2016,", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "Switzerland", "for", "use", "in", "Hemophilia", "A", "patients", "aged", "12", "years", "and", "older", "and", "in", "March", "2017,", "ADYNOVI", "was", "approved", "for", "use", "in", "pediatric", "patients.", "<tag3>"], "wordsA": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "late", "2016,", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "Switzerland", "for", "use", "in", "Hemophilia", "A", "patients", "aged", "12", "years", "and", "older", "and", "in", "March", "2017,", "ADYNOVI", "was", "approved", "for", "use", "in", "pediatric", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s8", "idA": "906709_17_item1_p15_s5", "sentA": "On April 4, 2016, Baxalta announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE for patients aged 12 years and older with Hemophilia A. On December 27, 2016, Shire plc announced that the FDA approved ADYNOVATE for use in surgical settings for both adult and pediatric patients and the FDA also approved ADYNOVATE for the treatment for Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In March 2017, ADYNOVATE was approved in Australia for use in adult and pediatric patients with Hemophilia A.", "type": 2, "words": ["<tag1>", "On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "March", "2017,", "ADYNOVATE", "was", "approved", "in", "Australia", "for", "use", "in", "adult", "and", "pediatric", "patients", "with", "Hemophilia", "A.", "<tag3>"], "wordsA": ["On", "April", "4,", "2016,", "Baxalta", "announced", "that", "the", "Ministry", "of", "Health,", "Labour", "and", "Welfare", "in", "Japan", "approved", "ADYNOVATE", "for", "patients", "aged", "12", "years", "and", "older", "with", "Hemophilia", "A.", "On", "December", "27,", "2016,", "Shire", "plc", "announced", "that", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients", "and", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "for", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "March", "2017,", "ADYNOVATE", "was", "approved", "in", "Australia", "for", "use", "in", "adult", "and", "pediatric", "patients", "with", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p165_s2", "idA": "906709_17_item1_p160_s0", "sentA": "The agreements provi de that all inventions conceived by an employee shall be our property.", "sentB": "The agreements provide that all inventions conceived by an employ ee shall be our property.", "type": 2, "words": ["<tag1>", "The", "agreements", "provi", "de", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property.", "<tag2>", "The", "agreements", "provide", "that", "all", "inventions", "conceived", "by", "an", "employ", "ee", "shall", "be", "our", "property.", "<tag3>"], "wordsA": ["The", "agreements", "provi", "de", "that", "all", "inventions", "conceived", "by", "an", "employee", "shall", "be", "our", "property."], "wordsB": ["The", "agreements", "provide", "that", "all", "inventions", "conceived", "by", "an", "employ", "ee", "shall", "be", "our", "property."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p165_s5", "idA": "906709_17_item1_p160_s3", "sentA": "AstraZeneca, UCB, Ophthotech and Roche represented 29%, 21%, 19% and 11% of our revenue, respectively, for the year ended December 31, 2016.", "sentB": "The revenue generated under the Lilly Agreement and the license, manufacturing and supply agreement with UCB represented 42% and 12% of our revenue, respectively, for the year ended December 31, 2017.", "type": 2, "words": ["<tag1>", "AstraZeneca,", "UCB,", "Ophthotech", "and", "Roche", "represented", "29%,", "21%,", "19%", "and", "11%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2016.", "<tag2>", "The", "revenue", "generated", "under", "the", "Lilly", "Agreement", "and", "the", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "represented", "42%", "and", "12%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2017.", "<tag3>"], "wordsA": ["AstraZeneca,", "UCB,", "Ophthotech", "and", "Roche", "represented", "29%,", "21%,", "19%", "and", "11%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2016."], "wordsB": ["The", "revenue", "generated", "under", "the", "Lilly", "Agreement", "and", "the", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "represented", "42%", "and", "12%", "of", "our", "revenue,", "respectively,", "for", "the", "year", "ended", "December", "31,", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p165_s6", "idA": "906709_17_item1_p160_s4", "sentA": "No other collaboration partner accounted for more than 10% of our total revenue during the year ended December 31, 2016.", "sentB": "No other collaboration partner accounted for more than 10% of our total revenue during the year ended December 31, 2017.", "type": 2, "words": ["<tag1>", "No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2016.", "<tag2>", "No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2017.", "<tag3>"], "wordsA": ["No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2016."], "wordsB": ["No", "other", "collaboration", "partner", "accounted", "for", "more", "than", "10%", "of", "our", "total", "revenue", "during", "the", "year", "ended", "December", "31,", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s2", "idA": "906709_17_item1_p165_s1", "sentA": "Limited, Theravance, Inc., Develco Pharma, Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.", "sentB": "On May 22, 2017, we announced a research collaboration that is currently underway bewteen Nektar and Takeda Pharmaceutical Company Limited (Takeda) to evaluate NKTR-214 with five compounds from Takeda s cancer portfolio.", "type": 2, "words": ["<tag1>", "Limited,", "Theravance,", "Inc.,", "Develco", "Pharma,", "Sucampo", "Pharmaceuticals,", "Inc.,", "and", "Takeda", "Pharmaceutical", "Company", "Limited.", "<tag2>", "On", "May", "22,", "2017,", "we", "announced", "a", "research", "collaboration", "that", "is", "currently", "underway", "bewteen", "Nektar", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)", "to", "evaluate", "NKTR-214", "with", "five", "compounds", "from", "Takeda", "s", "cancer", "portfolio.", "<tag3>"], "wordsA": ["Limited,", "Theravance,", "Inc.,", "Develco", "Pharma,", "Sucampo", "Pharmaceuticals,", "Inc.,", "and", "Takeda", "Pharmaceutical", "Company", "Limited."], "wordsB": ["On", "May", "22,", "2017,", "we", "announced", "a", "research", "collaboration", "that", "is", "currently", "underway", "bewteen", "Nektar", "and", "Takeda", "Pharmaceutical", "Company", "Limited", "(Takeda)", "to", "evaluate", "NKTR-214", "with", "five", "compounds", "from", "Takeda", "s", "cancer", "portfolio."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p174_s0", "idA": "906709_17_item1_p166_s0", "sentA": "[Antihemophilic Factor (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with Hemophilia A. ELOCTATE is intended to be an extended half-life Factor VIII therapy with prolonged circulation in the body with the potential to extend the interval between prophylactic infusions.", "sentB": "On June 6, 2014, the FDA approved Biogen Idec s ELOCTATE TM [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with Hemophilia A. ELOCTATE TM is intended to be an extended half-life Factor VIII therapy with prolonged circulation in the body with the potential to extend the interval between prophylactic infusions.", "type": 2, "words": ["<tag1>", "[Antihemophilic", "Factor", "(Recombinant),", "Fc", "Fusion", "Protein]", "for", "the", "control", "and", "prevention", "of", "bleeding", "episodes,", "perioperative", "(surgical)", "management", "and", "routine", "prophylaxis", "in", "adults", "and", "children", "with", "Hemophilia", "A.", "ELOCTATE", "is", "intended", "to", "be", "an", "extended", "half-life", "Factor", "VIII", "therapy", "with", "prolonged", "circulation", "in", "the", "body", "with", "the", "potential", "to", "extend", "the", "interval", "between", "prophylactic", "infusions.", "<tag2>", "On", "June", "6,", "2014,", "the", "FDA", "approved", "Biogen", "Idec", "s", "ELOCTATE", "TM", "[Antihemophilic", "Factor", "(Recombinant),", "Fc", "Fusion", "Protein]", "for", "the", "control", "and", "prevention", "of", "bleeding", "episodes,", "perioperative", "(surgical)", "management", "and", "routine", "prophylaxis", "in", "adults", "and", "children", "with", "Hemophilia", "A.", "ELOCTATE", "TM", "is", "intended", "to", "be", "an", "extended", "half-life", "Factor", "VIII", "therapy", "with", "prolonged", "circulation", "in", "the", "body", "with", "the", "potential", "to", "extend", "the", "interval", "between", "prophylactic", "infusions.", "<tag3>"], "wordsA": ["[Antihemophilic", "Factor", "(Recombinant),", "Fc", "Fusion", "Protein]", "for", "the", "control", "and", "prevention", "of", "bleeding", "episodes,", "perioperative", "(surgical)", "management", "and", "routine", "prophylaxis", "in", "adults", "and", "children", "with", "Hemophilia", "A.", "ELOCTATE", "is", "intended", "to", "be", "an", "extended", "half-life", "Factor", "VIII", "therapy", "with", "prolonged", "circulation", "in", "the", "body", "with", "the", "potential", "to", "extend", "the", "interval", "between", "prophylactic", "infusions."], "wordsB": ["On", "June", "6,", "2014,", "the", "FDA", "approved", "Biogen", "Idec", "s", "ELOCTATE", "TM", "[Antihemophilic", "Factor", "(Recombinant),", "Fc", "Fusion", "Protein]", "for", "the", "control", "and", "prevention", "of", "bleeding", "episodes,", "perioperative", "(surgical)", "management", "and", "routine", "prophylaxis", "in", "adults", "and", "children", "with", "Hemophilia", "A.", "ELOCTATE", "TM", "is", "intended", "to", "be", "an", "extended", "half-life", "Factor", "VIII", "therapy", "with", "prolonged", "circulation", "in", "the", "body", "with", "the", "potential", "to", "extend", "the", "interval", "between", "prophylactic", "infusions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p174_s1", "idA": "906709_17_item1_p166_s1", "sentA": "Prior to its 2014 approval, the fusion protein in ELOCTATE was not used outside of the clinical trial setting for Hemophilia A patients.", "sentB": "Prior to its 2014 approval, the fusion protein in ELOCTATE TM was not used outside of the clinical trial setting for Hemophilia A patients.", "type": 2, "words": ["<tag1>", "Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients.", "<tag2>", "Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "TM", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients.", "<tag3>"], "wordsA": ["Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients."], "wordsB": ["Prior", "to", "its", "2014", "approval,", "the", "fusion", "protein", "in", "ELOCTATE", "TM", "was", "not", "used", "outside", "of", "the", "clinical", "trial", "setting", "for", "Hemophilia", "A", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p175_s1", "idA": "906709_17_item1_p168_s1", "sentA": "These therapies are only partially effective in treating advanced or metastatic breast cancer and none have a specific indication in either the U.S. or Europe for treatment of patients with advanced breast cancer and co-existing brain metastases.", "sentB": "These therapies are only partially effective in treating advanced or metastatic breast cancer and none of them have a specific indication in either the U.S. or Europe for treatment of patients with advanced breast cancer and co-existing brain metastases.", "type": 2, "words": ["<tag1>", "These", "therapies", "are", "only", "partially", "effective", "in", "treating", "advanced", "or", "metastatic", "breast", "cancer", "and", "none", "have", "a", "specific", "indication", "in", "either", "the", "U.S.", "or", "Europe", "for", "treatment", "of", "patients", "with", "advanced", "breast", "cancer", "and", "co-existing", "brain", "metastases.", "<tag2>", "These", "therapies", "are", "only", "partially", "effective", "in", "treating", "advanced", "or", "metastatic", "breast", "cancer", "and", "none", "of", "them", "have", "a", "specific", "indication", "in", "either", "the", "U.S.", "or", "Europe", "for", "treatment", "of", "patients", "with", "advanced", "breast", "cancer", "and", "co-existing", "brain", "metastases.", "<tag3>"], "wordsA": ["These", "therapies", "are", "only", "partially", "effective", "in", "treating", "advanced", "or", "metastatic", "breast", "cancer", "and", "none", "have", "a", "specific", "indication", "in", "either", "the", "U.S.", "or", "Europe", "for", "treatment", "of", "patients", "with", "advanced", "breast", "cancer", "and", "co-existing", "brain", "metastases."], "wordsB": ["These", "therapies", "are", "only", "partially", "effective", "in", "treating", "advanced", "or", "metastatic", "breast", "cancer", "and", "none", "of", "them", "have", "a", "specific", "indication", "in", "either", "the", "U.S.", "or", "Europe", "for", "treatment", "of", "patients", "with", "advanced", "breast", "cancer", "and", "co-existing", "brain", "metastases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p95_s1", "idA": "906709_17_item1_p16_s3", "sentA": "Bayer is currently enrolling patients in a Phase 3 clinical study for Amikacin Inhale.", "sentB": "On November 24, 2017, Bayer announced that the Phase 3 Amikacin Inhale clinical program did not meet its primary endpoint or key secondary endpoints.", "type": 2, "words": ["<tag1>", "Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale.", "<tag2>", "On", "November", "24,", "2017,", "Bayer", "announced", "that", "the", "Phase", "3", "Amikacin", "Inhale", "clinical", "program", "did", "not", "meet", "its", "primary", "endpoint", "or", "key", "secondary", "endpoints.", "<tag3>"], "wordsA": ["Bayer", "is", "currently", "enrolling", "patients", "in", "a", "Phase", "3", "clinical", "study", "for", "Amikacin", "Inhale."], "wordsB": ["On", "November", "24,", "2017,", "Bayer", "announced", "that", "the", "Phase", "3", "Amikacin", "Inhale", "clinical", "program", "did", "not", "meet", "its", "primary", "endpoint", "or", "key", "secondary", "endpoints."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p170_s0", "idA": "906709_17_item1_p172_s0", "sentA": "There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to auto-immune disease.", "sentB": "There are a number of competitors in various stages of clinical development that are working on programs which are designed to correct the underlying immune system imbalance in the body due to autoimmune disease.", "type": 2, "words": ["<tag1>", "There", "are", "a", "number", "of", "competitors", "in", "various", "stages", "of", "clinical", "development", "that", "are", "working", "on", "programs", "which", "are", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "due", "to", "auto-immune", "disease.", "<tag2>", "There", "are", "a", "number", "of", "competitors", "in", "various", "stages", "of", "clinical", "development", "that", "are", "working", "on", "programs", "which", "are", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "due", "to", "autoimmune", "disease.", "<tag3>"], "wordsA": ["There", "are", "a", "number", "of", "competitors", "in", "various", "stages", "of", "clinical", "development", "that", "are", "working", "on", "programs", "which", "are", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "due", "to", "auto-immune", "disease."], "wordsB": ["There", "are", "a", "number", "of", "competitors", "in", "various", "stages", "of", "clinical", "development", "that", "are", "working", "on", "programs", "which", "are", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "due", "to", "autoimmune", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p178_s1", "idA": "906709_17_item1_p174_s1", "sentA": "The facility is also used to produce APIs and finished drug products to support the early phases of clinical development of our proprietary drug candidates.", "sentB": "The facility is also used to produce APIs to support the early phases of clinical development of our proprietary drug candidates.", "type": 2, "words": ["<tag1>", "The", "facility", "is", "also", "used", "to", "produce", "APIs", "and", "finished", "drug", "products", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates.", "<tag2>", "The", "facility", "is", "also", "used", "to", "produce", "APIs", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates.", "<tag3>"], "wordsA": ["The", "facility", "is", "also", "used", "to", "produce", "APIs", "and", "finished", "drug", "products", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates."], "wordsB": ["The", "facility", "is", "also", "used", "to", "produce", "APIs", "to", "support", "the", "early", "phases", "of", "clinical", "development", "of", "our", "proprietary", "drug", "candidates."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p181_s0", "idA": "906709_17_item1_p177_s0", "sentA": "Employees and Consultants As of December 31, 2016 we had 468 employees, of which 358 employees were engaged in research and development, commercial operations and quality activities and 110 employees were engaged in general administration and business development.", "sentB": "Employees and Consultants As of December 31, 2017 we had 509 employees, of which 396 employees were engaged in research and development, commercial operations and quality activities and 113 employees were engaged in general administration and business development.", "type": 2, "words": ["<tag1>", "Employees", "and", "Consultants", "As", "of", "December", "31,", "2016", "we", "had", "468", "employees,", "of", "which", "358", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "110", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development.", "<tag2>", "Employees", "and", "Consultants", "As", "of", "December", "31,", "2017", "we", "had", "509", "employees,", "of", "which", "396", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "113", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development.", "<tag3>"], "wordsA": ["Employees", "and", "Consultants", "As", "of", "December", "31,", "2016", "we", "had", "468", "employees,", "of", "which", "358", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "110", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development."], "wordsB": ["Employees", "and", "Consultants", "As", "of", "December", "31,", "2017", "we", "had", "509", "employees,", "of", "which", "396", "employees", "were", "engaged", "in", "research", "and", "development,", "commercial", "operations", "and", "quality", "activities", "and", "113", "employees", "were", "engaged", "in", "general", "administration", "and", "business", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s7", "idA": "906709_17_item1_p178_s0", "sentA": "Of the 468 employees, 392 were located in the U.S. and 76 were located in India.", "sentB": "Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions.", "type": 2, "words": ["<tag1>", "Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India.", "<tag2>", "Lilly", "will", "be", "responsible", "for", "all", "costs", "of", "global", "commercialization", "and", "we", "will", "have", "an", "option", "to", "co-promote", "in", "the", "U.S.", "under", "certain", "conditions.", "<tag3>"], "wordsA": ["Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India."], "wordsB": ["Lilly", "will", "be", "responsible", "for", "all", "costs", "of", "global", "commercialization", "and", "we", "will", "have", "an", "option", "to", "co-promote", "in", "the", "U.S.", "under", "certain", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p181_s1", "idA": "906709_17_item1_p178_s0", "sentA": "Of the 468 employees, 392 were located in the U.S. and 76 were located in India.", "sentB": "Of the 509 employees, 432 were located in the U.S. and 77 were located in India.", "type": 2, "words": ["<tag1>", "Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India.", "<tag2>", "Of", "the", "509", "employees,", "432", "were", "located", "in", "the", "U.S.", "and", "77", "were", "located", "in", "India.", "<tag3>"], "wordsA": ["Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India."], "wordsB": ["Of", "the", "509", "employees,", "432", "were", "located", "in", "the", "U.S.", "and", "77", "were", "located", "in", "India."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s7", "idA": "906709_17_item1_p178_s0", "sentA": "Of the 468 employees, 392 were located in the U.S. and 76 were located in India.", "sentB": "Lilly will be responsible for all costs of global commercialization and we will have an option to co-promote in the U.S. under certain conditions.", "type": 2, "words": ["<tag1>", "Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India.", "<tag2>", "Lilly", "will", "be", "responsible", "for", "all", "costs", "of", "global", "commercialization", "and", "we", "will", "have", "an", "option", "to", "co-promote", "in", "the", "U.S.", "under", "certain", "conditions.", "<tag3>"], "wordsA": ["Of", "the", "468", "employees,", "392", "were", "located", "in", "the", "U.S.", "and", "76", "were", "located", "in", "India."], "wordsB": ["Lilly", "will", "be", "responsible", "for", "all", "costs", "of", "global", "commercialization", "and", "we", "will", "have", "an", "option", "to", "co-promote", "in", "the", "U.S.", "under", "certain", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p181_s2", "idA": "906709_17_item1_p178_s2", "sentA": "None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages.", "sentB": "We have a number of employees who hold advanced degrees, such as Ph.D. None of our employees are covered by a collective bargaining agreement, and we have experienced no work stoppages.", "type": 2, "words": ["<tag1>", "None", "of", "our", "employees", "are", "covered", "by", "a", "collective", "bargaining", "agreement,", "and", "we", "have", "experienced", "no", "work", "stoppages.", "<tag2>", "We", "have", "a", "number", "of", "employees", "who", "hold", "advanced", "degrees,", "such", "as", "Ph.D.", "None", "of", "our", "employees", "are", "covered", "by", "a", "collective", "bargaining", "agreement,", "and", "we", "have", "experienced", "no", "work", "stoppages.", "<tag3>"], "wordsA": ["None", "of", "our", "employees", "are", "covered", "by", "a", "collective", "bargaining", "agreement,", "and", "we", "have", "experienced", "no", "work", "stoppages."], "wordsB": ["We", "have", "a", "number", "of", "employees", "who", "hold", "advanced", "degrees,", "such", "as", "Ph.D.", "None", "of", "our", "employees", "are", "covered", "by", "a", "collective", "bargaining", "agreement,", "and", "we", "have", "experienced", "no", "work", "stoppages."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p182_s0", "idA": "906709_17_item1_p178_s4", "sentA": "To complement our own expert professional staff, we utilize specialists in regulatory affairs, pharmacovigilance, process engineering, manufacturing, quality assurance, clinical development and business development.", "sentB": "To complement our own expert professional staff, we utilize specialists in regulatory affairs, pharmacovi gilance, process engineering, manufacturing, quality assurance, clinical development and business development.", "type": 2, "words": ["<tag1>", "To", "complement", "our", "own", "expert", "professional", "staff,", "we", "utilize", "specialists", "in", "regulatory", "affairs,", "pharmacovigilance,", "process", "engineering,", "manufacturing,", "quality", "assurance,", "clinical", "development", "and", "business", "development.", "<tag2>", "To", "complement", "our", "own", "expert", "professional", "staff,", "we", "utilize", "specialists", "in", "regulatory", "affairs,", "pharmacovi", "gilance,", "process", "engineering,", "manufacturing,", "quality", "assurance,", "clinical", "development", "and", "business", "development.", "<tag3>"], "wordsA": ["To", "complement", "our", "own", "expert", "professional", "staff,", "we", "utilize", "specialists", "in", "regulatory", "affairs,", "pharmacovigilance,", "process", "engineering,", "manufacturing,", "quality", "assurance,", "clinical", "development", "and", "business", "development."], "wordsB": ["To", "complement", "our", "own", "expert", "professional", "staff,", "we", "utilize", "specialists", "in", "regulatory", "affairs,", "pharmacovi", "gilance,", "process", "engineering,", "manufacturing,", "quality", "assurance,", "clinical", "development", "and", "business", "development."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p183_s0", "idA": "906709_17_item1_p179_s0", "sentA": "EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth the names, ages and positions of our executive officers as of February 13, 2017:", "sentB": "EXECUTIVE OFFICERS OF THE REGISTRANT The following table sets forth the names, ages and positions of our executive officers as of February 22, 2018:", "type": 2, "words": ["<tag1>", "EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "13,", "2017:", "<tag2>", "EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "22,", "2018:", "<tag3>"], "wordsA": ["EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "13,", "2017:"], "wordsB": ["EXECUTIVE", "OFFICERS", "OF", "THE", "REGISTRANT", "The", "following", "table", "sets", "forth", "the", "names,", "ages", "and", "positions", "of", "our", "executive", "officers", "as", "of", "February", "22,", "2018:"], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s11", "idA": "906709_17_item1_p17_s0", "sentA": "The second program is the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale) program with Bayer Schering Pharma AG (Bayer Schering) that we transferred to Novartis as part of the 2008 pulmonary asset divestiture transaction.", "sentB": "In January 2018, ADYNOVATE was also approved in S. Korea for use in children and adults with Hemophilia A. We retained our right to receive royalties on net sales of the Cipro DPI (Cipro Dry Powder Inhaler, previously called Cipro Inhale), pursuant to a drug development program with Bayer Schering Pharma AG (Bayer Schering) that we transferred to Novartis as part of the 2008 pulmonary asset divestiture transaction.", "type": 2, "words": ["<tag1>", "The", "second", "program", "is", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering)", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "2008", "pulmonary", "asset", "divestiture", "transaction.", "<tag2>", "In", "January", "2018,", "ADYNOVATE", "was", "also", "approved", "in", "S.", "Korea", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A.", "We", "retained", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale),", "pursuant", "to", "a", "drug", "development", "program", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering)", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "2008", "pulmonary", "asset", "divestiture", "transaction.", "<tag3>"], "wordsA": ["The", "second", "program", "is", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale)", "program", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering)", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "2008", "pulmonary", "asset", "divestiture", "transaction."], "wordsB": ["In", "January", "2018,", "ADYNOVATE", "was", "also", "approved", "in", "S.", "Korea", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A.", "We", "retained", "our", "right", "to", "receive", "royalties", "on", "net", "sales", "of", "the", "Cipro", "DPI", "(Cipro", "Dry", "Powder", "Inhaler,", "previously", "called", "Cipro", "Inhale),", "pursuant", "to", "a", "drug", "development", "program", "with", "Bayer", "Schering", "Pharma", "AG", "(Bayer", "Schering)", "that", "we", "transferred", "to", "Novartis", "as", "part", "of", "the", "2008", "pulmonary", "asset", "divestiture", "transaction."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p23_s0", "idA": "906709_17_item1_p17_s1", "sentA": "In August 2012, Bayer Schering initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis.", "sentB": "In August 2012, Bayer Schering initiated a global Phase 3 program called RESPIRE for the Cipro DPI product candidate in patients with non-cystic fibrosis bronchiectasis (NCFB).", "type": 2, "words": ["<tag1>", "In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag2>", "In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis", "(NCFB).", "<tag3>"], "wordsA": ["In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "wordsB": ["In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "global", "Phase", "3", "program", "called", "RESPIRE", "for", "the", "Cipro", "DPI", "product", "candidate", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis", "(NCFB)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p23_s1", "idA": "906709_17_item1_p17_s2", "sentA": "In September 2016, Bayer Schering presented data from the first Phase 3 trail (RESPIRE 1) at the 2016 European Respiratory Society Annual Meeting which showed that the study met its co-primary endpoints for the every 14-day dosing arm of Cipro DPI.", "sentB": "In September 2016, Bayer Schering presented data from the first Phase 3 trail (RESPIRE 1) at the 2016 European Respiratory Society Annual Meeting which showed in the 14 days on/off regimen, the RESPIRE 1 trial met its primary endpoints of significantly prolonged time to first exacerbation and significantly reduced frequency of exacerbations versus placebo.", "type": 2, "words": ["<tag1>", "In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI.", "<tag2>", "In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "in", "the", "14", "days", "on/off", "regimen,", "the", "RESPIRE", "1", "trial", "met", "its", "primary", "endpoints", "of", "significantly", "prolonged", "time", "to", "first", "exacerbation", "and", "significantly", "reduced", "frequency", "of", "exacerbations", "versus", "placebo.", "<tag3>"], "wordsA": ["In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI."], "wordsB": ["In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "in", "the", "14", "days", "on/off", "regimen,", "the", "RESPIRE", "1", "trial", "met", "its", "primary", "endpoints", "of", "significantly", "prolonged", "time", "to", "first", "exacerbation", "and", "significantly", "reduced", "frequency", "of", "exacerbations", "versus", "placebo."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p23_s5", "idA": "906709_17_item1_p17_s2", "sentA": "In September 2016, Bayer Schering presented data from the first Phase 3 trail (RESPIRE 1) at the 2016 European Respiratory Society Annual Meeting which showed that the study met its co-primary endpoints for the every 14-day dosing arm of Cipro DPI.", "sentB": "Bayer Schering has informed us that they are discontinuing development of Cipro DPI in NCFB for the time being as they evaluate possible future options for this asset.", "type": 2, "words": ["<tag1>", "In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI.", "<tag2>", "Bayer", "Schering", "has", "informed", "us", "that", "they", "are", "discontinuing", "development", "of", "Cipro", "DPI", "in", "NCFB", "for", "the", "time", "being", "as", "they", "evaluate", "possible", "future", "options", "for", "this", "asset.", "<tag3>"], "wordsA": ["In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI."], "wordsB": ["Bayer", "Schering", "has", "informed", "us", "that", "they", "are", "discontinuing", "development", "of", "Cipro", "DPI", "in", "NCFB", "for", "the", "time", "being", "as", "they", "evaluate", "possible", "future", "options", "for", "this", "asset."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p98_s5", "idA": "906709_17_item1_p17_s2", "sentA": "In September 2016, Bayer Schering presented data from the first Phase 3 trail (RESPIRE 1) at the 2016 European Respiratory Society Annual Meeting which showed that the study met its co-primary endpoints for the every 14-day dosing arm of Cipro DPI.", "sentB": "Bayer Schering has informed us that they are discontinuing development of Cipro DPI in NCFB for the time being as they evaluate possible future options for this asset.", "type": 2, "words": ["<tag1>", "In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI.", "<tag2>", "Bayer", "Schering", "has", "informed", "us", "that", "they", "are", "discontinuing", "development", "of", "Cipro", "DPI", "in", "NCFB", "for", "the", "time", "being", "as", "they", "evaluate", "possible", "future", "options", "for", "this", "asset.", "<tag3>"], "wordsA": ["In", "September", "2016,", "Bayer", "Schering", "presented", "data", "from", "the", "first", "Phase", "3", "trail", "(RESPIRE", "1)", "at", "the", "2016", "European", "Respiratory", "Society", "Annual", "Meeting", "which", "showed", "that", "the", "study", "met", "its", "co-primary", "endpoints", "for", "the", "every", "14-day", "dosing", "arm", "of", "Cipro", "DPI."], "wordsB": ["Bayer", "Schering", "has", "informed", "us", "that", "they", "are", "discontinuing", "development", "of", "Cipro", "DPI", "in", "NCFB", "for", "the", "time", "being", "as", "they", "evaluate", "possible", "future", "options", "for", "this", "asset."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p23_s2", "idA": "906709_17_item1_p17_s3", "sentA": "The second Phase 3 trial (RESPIRE 2) completed recruitment in September 2016 and Bayer Schering has not yet reported the results from RESPIRE 2.", "sentB": "The top-line results of the second Phase 3 trial (RESPIRE 2) were presented at the American Thoracic Society 2017 International Conference.", "type": 2, "words": ["<tag1>", "The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2.", "<tag2>", "The", "top-line", "results", "of", "the", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "were", "presented", "at", "the", "American", "Thoracic", "Society", "2017", "International", "Conference.", "<tag3>"], "wordsA": ["The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2."], "wordsB": ["The", "top-line", "results", "of", "the", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "were", "presented", "at", "the", "American", "Thoracic", "Society", "2017", "International", "Conference."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p98_s1", "idA": "906709_17_item1_p17_s3", "sentA": "The second Phase 3 trial (RESPIRE 2) completed recruitment in September 2016 and Bayer Schering has not yet reported the results from RESPIRE 2.", "sentB": "The second Phase 3 trial (RESPIRE 2) completed recruitment in September 2016.", "type": 2, "words": ["<tag1>", "The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2.", "<tag2>", "The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016.", "<tag3>"], "wordsA": ["The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2."], "wordsB": ["The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p24_s0", "idA": "906709_17_item1_p17_s4", "sentA": "We have a license, manufacturing and supply agreement with UCB Pharma for dapirolizumab pegol, a monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L), being developed for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) for which the candidate is entering Phase 2 development with UCB partner Biogen.", "sentB": "We have a license, manufacturing and supply agreement with UCB Pharma (UCB) for dapirolizumab pegol, a monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L), being developed for the treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) for which the candidate is entering Phase 2 development with UCB partner Biogen Inc.", "type": 2, "words": ["<tag1>", "We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "for", "dapirolizumab", "pegol,", "a", "monovalent", "pegylated", "Fab", "antibody", "fragment", "against", "the", "CD40", "ligand", "(CD40L),", "being", "developed", "for", "the", "treatment", "of", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE)", "for", "which", "the", "candidate", "is", "entering", "Phase", "2", "development", "with", "UCB", "partner", "Biogen.", "<tag2>", "We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "(UCB)", "for", "dapirolizumab", "pegol,", "a", "monovalent", "pegylated", "Fab", "antibody", "fragment", "against", "the", "CD40", "ligand", "(CD40L),", "being", "developed", "for", "the", "treatment", "of", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE)", "for", "which", "the", "candidate", "is", "entering", "Phase", "2", "development", "with", "UCB", "partner", "Biogen", "Inc.", "<tag3>"], "wordsA": ["We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "for", "dapirolizumab", "pegol,", "a", "monovalent", "pegylated", "Fab", "antibody", "fragment", "against", "the", "CD40", "ligand", "(CD40L),", "being", "developed", "for", "the", "treatment", "of", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE)", "for", "which", "the", "candidate", "is", "entering", "Phase", "2", "development", "with", "UCB", "partner", "Biogen."], "wordsB": ["We", "have", "a", "license,", "manufacturing", "and", "supply", "agreement", "with", "UCB", "Pharma", "(UCB)", "for", "dapirolizumab", "pegol,", "a", "monovalent", "pegylated", "Fab", "antibody", "fragment", "against", "the", "CD40", "ligand", "(CD40L),", "being", "developed", "for", "the", "treatment", "of", "autoimmune", "diseases,", "including", "systemic", "lupus", "erythematosus", "(SLE)", "for", "which", "the", "candidate", "is", "entering", "Phase", "2", "development", "with", "UCB", "partner", "Biogen", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p24_s1", "idA": "906709_17_item1_p17_s5", "sentA": "We also have a number of license, manufacturing and supply agreements with other leading biotechnology and pharmaceutical companies, including Amgen Inc., Allergan, Inc., Opthotech Corporation (Fovista), Merck Co., Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd (Roche).", "sentB": "We also have a number of license, manufacturing and supply agreements with other leading biotechnology and pharmaceutical companies, including Amgen, Inc., Allergan, Inc., Merck Co., Inc. and Pfizer, Inc.", "type": 2, "words": ["<tag1>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Opthotech", "Corporation", "(Fovista),", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche).", "<tag2>", "We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen,", "Inc.,", "Allergan,", "Inc.,", "Merck", "Co.,", "Inc.", "and", "Pfizer,", "Inc.", "<tag3>"], "wordsA": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen", "Inc.,", "Allergan,", "Inc.,", "Opthotech", "Corporation", "(Fovista),", "Merck", "Co.,", "Inc.,", "Pfizer,", "Inc.", "and", "F.", "Hoffmann-La", "Roche", "Ltd", "(Roche)."], "wordsB": ["We", "also", "have", "a", "number", "of", "license,", "manufacturing", "and", "supply", "agreements", "with", "other", "leading", "biotechnology", "and", "pharmaceutical", "companies,", "including", "Amgen,", "Inc.,", "Allergan,", "Inc.,", "Merck", "Co.,", "Inc.", "and", "Pfizer,", "Inc."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p188_s1", "idA": "906709_17_item1_p184_s1", "sentA": "Mr. Nicholson joined the Company as Senior Vice President of Corporate Development and Business Operations in October 2007 and was appointed Senior Vice President and Chief Financial Officer in December 2007 and served as our Chief Financial Officer until June 2016 when he was promoted to Senior Vice President and Chief Operating Officer.", "sentB": "Dr. Doberstein served as Senior Vice President and Chief Scientific Officer from January 2010 to November 2017 when he was promoted to Senior Vice President, Research Development and Chief Research Development Officer .", "type": 2, "words": ["<tag1>", "Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007", "and", "served", "as", "our", "Chief", "Financial", "Officer", "until", "June", "2016", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President", "and", "Chief", "Operating", "Officer.", "<tag2>", "Dr.", "Doberstein", "served", "as", "Senior", "Vice", "President", "and", "Chief", "Scientific", "Officer", "from", "January", "2010", "to", "November", "2017", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President,", "Research", "Development", "and", "Chief", "Research", "Development", "Officer", ".", "<tag3>"], "wordsA": ["Mr.", "Nicholson", "joined", "the", "Company", "as", "Senior", "Vice", "President", "of", "Corporate", "Development", "and", "Business", "Operations", "in", "October", "2007", "and", "was", "appointed", "Senior", "Vice", "President", "and", "Chief", "Financial", "Officer", "in", "December", "2007", "and", "served", "as", "our", "Chief", "Financial", "Officer", "until", "June", "2016", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President", "and", "Chief", "Operating", "Officer."], "wordsB": ["Dr.", "Doberstein", "served", "as", "Senior", "Vice", "President", "and", "Chief", "Scientific", "Officer", "from", "January", "2010", "to", "November", "2017", "when", "he", "was", "promoted", "to", "Senior", "Vice", "President,", "Research", "Development", "and", "Chief", "Research", "Development", "Officer", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p194_s2", "idA": "906709_17_item1_p187_s0", "sentA": "the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions.", "sentB": "Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for strategic partnerships and mergers and acquisitions.", "type": 2, "words": ["<tag1>", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions.", "<tag2>", "Prior", "to", "E2open,", "he", "was", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions.", "<tag3>"], "wordsA": ["the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions."], "wordsB": ["Prior", "to", "E2open,", "he", "was", "the", "Senior", "Director", "of", "Corporate", "Development", "at", "AltaVista", "Company,", "an", "Internet", "search", "company,", "where", "he", "was", "responsible", "for", "strategic", "partnerships", "and", "mergers", "and", "acquisitions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p188_s0", "idA": "906709_17_item1_p188_s1", "sentA": "Stephen K. Doberstein, Ph.D. has served as our Senior Vice President and Chief Scientific Officer since January 2010.", "sentB": "Stephen K. Doberstein, Ph.D. has served as our Senior Vice President, Research Development and Chief Research Development Officer since November 2017.", "type": 2, "words": ["<tag1>", "Stephen", "K.", "Doberstein,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Scientific", "Officer", "since", "January", "2010.", "<tag2>", "Stephen", "K.", "Doberstein,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Research", "Development", "and", "Chief", "Research", "Development", "Officer", "since", "November", "2017.", "<tag3>"], "wordsA": ["Stephen", "K.", "Doberstein,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President", "and", "Chief", "Scientific", "Officer", "since", "January", "2010."], "wordsB": ["Stephen", "K.", "Doberstein,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Research", "Development", "and", "Chief", "Research", "Development", "Officer", "since", "November", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p24_s2", "idA": "906709_17_item1_p18_s0", "sentA": "A total of ten products using our PEGylation technology have received regulatory approval in the U.S. or EU.", "sentB": "More than 10 products using our PEGylation technology have received regulatory approval in the U.S. or the EU.", "type": 2, "words": ["<tag1>", "A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU.", "<tag2>", "More", "than", "10", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "the", "EU.", "<tag3>"], "wordsA": ["A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "EU."], "wordsB": ["More", "than", "10", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "the", "EU."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p190_s4", "idA": "906709_17_item1_p191_s1", "sentA": "Maninder Hora, Ph.D. has served as our Senior Vice President, Pharmaceutical Development and Manufacturing Operations since August 2010.", "sentB": "Maninder Hora, Ph.D. has served as our Senior Vice President, Pharmaceutical Development and Chief Technical Operations Officer since August 2010.", "type": 2, "words": ["<tag1>", "Maninder", "Hora,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Pharmaceutical", "Development", "and", "Manufacturing", "Operations", "since", "August", "2010.", "<tag2>", "Maninder", "Hora,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Pharmaceutical", "Development", "and", "Chief", "Technical", "Operations", "Officer", "since", "August", "2010.", "<tag3>"], "wordsA": ["Maninder", "Hora,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Pharmaceutical", "Development", "and", "Manufacturing", "Operations", "since", "August", "2010."], "wordsB": ["Maninder", "Hora,", "Ph.D.", "has", "served", "as", "our", "Senior", "Vice", "President,", "Pharmaceutical", "Development", "and", "Chief", "Technical", "Operations", "Officer", "since", "August", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p192_s0", "idA": "906709_17_item1_p193_s0", "sentA": "Dr. Hora served as a key member of various teams that successfully registered ten drugs or vaccines in the U.S. and Europe during his professional career.", "sentB": "or vaccines in the U.S. and Europe du ring his professional career.", "type": 2, "words": ["<tag1>", "Dr.", "Hora", "served", "as", "a", "key", "member", "of", "various", "teams", "that", "successfully", "registered", "ten", "drugs", "or", "vaccines", "in", "the", "U.S.", "and", "Europe", "during", "his", "professional", "career.", "<tag2>", "or", "vaccines", "in", "the", "U.S.", "and", "Europe", "du", "ring", "his", "professional", "career.", "<tag3>"], "wordsA": ["Dr.", "Hora", "served", "as", "a", "key", "member", "of", "various", "teams", "that", "successfully", "registered", "ten", "drugs", "or", "vaccines", "in", "the", "U.S.", "and", "Europe", "during", "his", "professional", "career."], "wordsB": ["or", "vaccines", "in", "the", "U.S.", "and", "Europe", "du", "ring", "his", "professional", "career."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p192_s1", "idA": "906709_17_item1_p194_s0", "sentA": "Dr. Hora completed his Ph.D. in Bioengineering from the Indian Institute of Technology, Delhi, India, and was a Fulbright Scholar at the University of Washington, and received his B.S. in chemistry from the University of Jabalpur.", "sentB": "Dr. Hora completed his Ph.D. in Bioengineering from the Indian Institute of Technology, Delhi, India, and was a Fulbright Scholar at the University of Washington, and received his B.S. in chemistry from the University of Jabal pur.", "type": 2, "words": ["<tag1>", "Dr.", "Hora", "completed", "his", "Ph.D.", "in", "Bioengineering", "from", "the", "Indian", "Institute", "of", "Technology,", "Delhi,", "India,", "and", "was", "a", "Fulbright", "Scholar", "at", "the", "University", "of", "Washington,", "and", "received", "his", "B.S.", "in", "chemistry", "from", "the", "University", "of", "Jabalpur.", "<tag2>", "Dr.", "Hora", "completed", "his", "Ph.D.", "in", "Bioengineering", "from", "the", "Indian", "Institute", "of", "Technology,", "Delhi,", "India,", "and", "was", "a", "Fulbright", "Scholar", "at", "the", "University", "of", "Washington,", "and", "received", "his", "B.S.", "in", "chemistry", "from", "the", "University", "of", "Jabal", "pur.", "<tag3>"], "wordsA": ["Dr.", "Hora", "completed", "his", "Ph.D.", "in", "Bioengineering", "from", "the", "Indian", "Institute", "of", "Technology,", "Delhi,", "India,", "and", "was", "a", "Fulbright", "Scholar", "at", "the", "University", "of", "Washington,", "and", "received", "his", "B.S.", "in", "chemistry", "from", "the", "University", "of", "Jabalpur."], "wordsB": ["Dr.", "Hora", "completed", "his", "Ph.D.", "in", "Bioengineering", "from", "the", "Indian", "Institute", "of", "Technology,", "Delhi,", "India,", "and", "was", "a", "Fulbright", "Scholar", "at", "the", "University", "of", "Washington,", "and", "received", "his", "B.S.", "in", "chemistry", "from", "the", "University", "of", "Jabal", "pur."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p25_s3", "idA": "906709_17_item1_p19_s3", "sentA": "The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report.", "sentB": "The information contained in, or that can be accessed through, our website is not part of, and is not incorporated in, this Annual Report on Form 10-K.", "type": 2, "words": ["<tag1>", "The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report.", "<tag2>", "The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report", "on", "Form", "10-K.", "<tag3>"], "wordsA": ["The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report."], "wordsB": ["The", "information", "contained", "in,", "or", "that", "can", "be", "accessed", "through,", "our", "website", "is", "not", "part", "of,", "and", "is", "not", "incorporated", "in,", "this", "Annual", "Report", "on", "Form", "10-K."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p26_s0", "idA": "906709_17_item1_p19_s4", "sentA": "Our Technology Platform As a leader in the polymer conjugation field, we have advanced our technology platform to include new advanced polymer technologies that can be tailored in specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules including many classes of drugs targeting numerous disease areas.", "sentB": "Our Techn ology Platform As a leader in the polymer conjugation field, we have advanced our technology platform to include new advanced polymer technologies that can be tailored in specific and customized ways with the objective of optimizing and significantly improving the profile of a wide range of molecules, including many classes of drugs targeting numerous disease areas.", "type": 2, "words": ["<tag1>", "Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "polymer", "conjugation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas.", "<tag2>", "Our", "Techn", "ology", "Platform", "As", "a", "leader", "in", "the", "polymer", "conjugation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules,", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas.", "<tag3>"], "wordsA": ["Our", "Technology", "Platform", "As", "a", "leader", "in", "the", "polymer", "conjugation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas."], "wordsB": ["Our", "Techn", "ology", "Platform", "As", "a", "leader", "in", "the", "polymer", "conjugation", "field,", "we", "have", "advanced", "our", "technology", "platform", "to", "include", "new", "advanced", "polymer", "technologies", "that", "can", "be", "tailored", "in", "specific", "and", "customized", "ways", "with", "the", "objective", "of", "optimizing", "and", "significantly", "improving", "the", "profile", "of", "a", "wide", "range", "of", "molecules,", "including", "many", "classes", "of", "drugs", "targeting", "numerous", "disease", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s4", "idA": "906709_17_item1_p1_s4", "sentA": "meeting in November 2016 and the ASCO-GU meeting in February 2017.", "sentB": "Interim data from the dose-escalation phase of the trial was presented at the 2017 SITC meeting in November 2017.", "type": 2, "words": ["<tag1>", "meeting", "in", "November", "2016", "and", "the", "ASCO-GU", "meeting", "in", "February", "2017.", "<tag2>", "Interim", "data", "from", "the", "dose-escalation", "phase", "of", "the", "trial", "was", "presented", "at", "the", "2017", "SITC", "meeting", "in", "November", "2017.", "<tag3>"], "wordsA": ["meeting", "in", "November", "2016", "and", "the", "ASCO-GU", "meeting", "in", "February", "2017."], "wordsB": ["Interim", "data", "from", "the", "dose-escalation", "phase", "of", "the", "trial", "was", "presented", "at", "the", "2017", "SITC", "meeting", "in", "November", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s1", "idA": "906709_17_item1_p1_s5", "sentA": "On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement (BMS Agreement) with Bristol-Myers Squibb Company (BMS), pursuant to which we and BMS are collaborating to conduct Phase 1/2 clinical trials evaluating NKTR-214 and BMS human monoclonal antibody that binds PD-1, known as Opdivo (nivolumab), as a potential combination treatment regimen in five tumor types and eight potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon by the parties (each, a Combined Therapy Trial).", "sentB": "On September 21, 2016, we entered into a Clinical Trial Collaboration Agreement with BMS, pursuant to which we and BMS are collaborating to conduct Phase 1/2 clinical trials evaluating NKTR-214 and BMS human monoclonal antibody that binds PD-1, known as Opdivo (nivolumab), as a potential combination treatment regimen in five tumor types and eight potential indications, and such other clinical trials evaluating the combined therapy as may be mutually agreed upon by the parties (each, a Combined Therapy Trial).", "type": 2, "words": ["<tag1>", "On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial).", "<tag2>", "On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "with", "BMS,", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial).", "<tag3>"], "wordsA": ["On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "(BMS", "Agreement)", "with", "Bristol-Myers", "Squibb", "Company", "(BMS),", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial)."], "wordsB": ["On", "September", "21,", "2016,", "we", "entered", "into", "a", "Clinical", "Trial", "Collaboration", "Agreement", "with", "BMS,", "pursuant", "to", "which", "we", "and", "BMS", "are", "collaborating", "to", "conduct", "Phase", "1/2", "clinical", "trials", "evaluating", "NKTR-214", "and", "BMS", "human", "monoclonal", "antibody", "that", "binds", "PD-1,", "known", "as", "Opdivo", "(nivolumab),", "as", "a", "potential", "combination", "treatment", "regimen", "in", "five", "tumor", "types", "and", "eight", "potential", "indications,", "and", "such", "other", "clinical", "trials", "evaluating", "the", "combined", "therapy", "as", "may", "be", "mutually", "agreed", "upon", "by", "the", "parties", "(each,", "a", "Combined", "Therapy", "Trial)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s13", "idA": "906709_17_item1_p1_s7", "sentA": "The first stage of the large Phase 1/2 clinical program for NKTR-214 is underway with BMS and is evaluating a potential combination treatment regimen of NKTR-214 with BMS PD-1 immune checkpoint inhibitor, Opdivo in up to 260 patients.", "sentB": "BMS will lead commercialization for combinations of NKTR-214 with BMS proprietary medicines, and we will lead all other commercialization efforts for NKTR-214.", "type": 2, "words": ["<tag1>", "The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients.", "<tag2>", "BMS", "will", "lead", "commercialization", "for", "combinations", "of", "NKTR-214", "with", "BMS", "proprietary", "medicines,", "and", "we", "will", "lead", "all", "other", "commercialization", "efforts", "for", "NKTR-214.", "<tag3>"], "wordsA": ["The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients."], "wordsB": ["BMS", "will", "lead", "commercialization", "for", "combinations", "of", "NKTR-214", "with", "BMS", "proprietary", "medicines,", "and", "we", "will", "lead", "all", "other", "commercialization", "efforts", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s9", "idA": "906709_17_item1_p1_s7", "sentA": "The first stage of the large Phase 1/2 clinical program for NKTR-214 is underway with BMS and is evaluating a potential combination treatment regimen of NKTR-214 with BMS PD-1 immune checkpoint inhibitor, Opdivo in up to 260 patients.", "sentB": "BMS will lead commercialization for combinations of NKTR-214 with BMS proprietary medicines, and we will lead all other commercialization efforts for NKTR-214.", "type": 2, "words": ["<tag1>", "The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients.", "<tag2>", "BMS", "will", "lead", "commercialization", "for", "combinations", "of", "NKTR-214", "with", "BMS", "proprietary", "medicines,", "and", "we", "will", "lead", "all", "other", "commercialization", "efforts", "for", "NKTR-214.", "<tag3>"], "wordsA": ["The", "first", "stage", "of", "the", "large", "Phase", "1/2", "clinical", "program", "for", "NKTR-214", "is", "underway", "with", "BMS", "and", "is", "evaluating", "a", "potential", "combination", "treatment", "regimen", "of", "NKTR-214", "with", "BMS", "PD-1", "immune", "checkpoint", "inhibitor,", "Opdivo", "in", "up", "to", "260", "patients."], "wordsB": ["BMS", "will", "lead", "commercialization", "for", "combinations", "of", "NKTR-214", "with", "BMS", "proprietary", "medicines,", "and", "we", "will", "lead", "all", "other", "commercialization", "efforts", "for", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p95_s3", "idA": "906709_17_item1_p21_s0", "sentA": "PEGylation is a versatile technology as a result of polyethylene glycol (PEG) being a water soluble, amphiphilic, non-toxic, non-immunogenic compound that has been shown to safely clear from the body.", "sentB": "No payment obligations to Bayer arose as a result of the termination of the Bayer Agreement.", "type": 2, "words": ["<tag1>", "PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body.", "<tag2>", "No", "payment", "obligations", "to", "Bayer", "arose", "as", "a", "result", "of", "the", "termination", "of", "the", "Bayer", "Agreement.", "<tag3>"], "wordsA": ["PEGylation", "is", "a", "versatile", "technology", "as", "a", "result", "of", "polyethylene", "glycol", "(PEG)", "being", "a", "water", "soluble,", "amphiphilic,", "non-toxic,", "non-immunogenic", "compound", "that", "has", "been", "shown", "to", "safely", "clear", "from", "the", "body."], "wordsB": ["No", "payment", "obligations", "to", "Bayer", "arose", "as", "a", "result", "of", "the", "termination", "of", "the", "Bayer", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p27_s3", "idA": "906709_17_item1_p22_s1", "sentA": "For example, these techniques cannot be used successfully to create small molecule drugs which could potentially benefit from t he application of the technology.", "sentB": "For example, these techniques cannot be used successfully to create small molecule drugs which could potentially benefit from the application of the technology.", "type": 2, "words": ["<tag1>", "For", "example,", "these", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "t", "he", "application", "of", "the", "technology.", "<tag2>", "For", "example,", "these", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology.", "<tag3>"], "wordsA": ["For", "example,", "these", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "t", "he", "application", "of", "the", "technology."], "wordsB": ["For", "example,", "these", "techniques", "cannot", "be", "used", "successfully", "to", "create", "small", "molecule", "drugs", "which", "could", "potentially", "benefit", "from", "the", "application", "of", "the", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p28_s1", "idA": "906709_17_item1_p23_s1", "sentA": "Our advanced polymer conjugate technology platform is designed to overcome the limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "sentB": "Our advanced polymer conjugation technology platform is designed to overcome the limitations of the first generation of the technology platform and to allow the platform to be utilized with a broader range of molecules across many therapeutic areas.", "type": 2, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag2>", "Our", "advanced", "polymer", "conjugation", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "wordsB": ["Our", "advanced", "polymer", "conjugation", "technology", "platform", "is", "designed", "to", "overcome", "the", "limitations", "of", "the", "first", "generation", "of", "the", "technology", "platform", "and", "to", "allow", "the", "platform", "to", "be", "utilized", "with", "a", "broader", "range", "of", "molecules", "across", "many", "therapeutic", "areas."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s5", "idA": "906709_17_item1_p23_s3", "sentA": "Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the global Phase 3 development costs.", "type": 2, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "will", "have", "the", "option", "to", "contribute", "funding", "to", "Phase", "3", "development", "on", "an", "indication-by-indication", "basis,", "ranging", "from", "zero", "to", "25%", "of", "the", "global", "Phase", "3", "development", "costs.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "will", "have", "the", "option", "to", "contribute", "funding", "to", "Phase", "3", "development", "on", "an", "indication-by-indication", "basis,", "ranging", "from", "zero", "to", "25%", "of", "the", "global", "Phase", "3", "development", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s5", "idA": "906709_17_item1_p23_s3", "sentA": "Our advanced polymer conjugate technology platforms have the potential to offer one or more of the following benefits:", "sentB": "We will have the option to contribute funding to Phase 3 development on an indication-by-indication basis, ranging from zero to 25% of the global Phase 3 development costs.", "type": 2, "words": ["<tag1>", "Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:", "<tag2>", "We", "will", "have", "the", "option", "to", "contribute", "funding", "to", "Phase", "3", "development", "on", "an", "indication-by-indication", "basis,", "ranging", "from", "zero", "to", "25%", "of", "the", "global", "Phase", "3", "development", "costs.", "<tag3>"], "wordsA": ["Our", "advanced", "polymer", "conjugate", "technology", "platforms", "have", "the", "potential", "to", "offer", "one", "or", "more", "of", "the", "following", "benefits:"], "wordsB": ["We", "will", "have", "the", "option", "to", "contribute", "funding", "to", "Phase", "3", "development", "on", "an", "indication-by-indication", "basis,", "ranging", "from", "zero", "to", "25%", "of", "the", "global", "Phase", "3", "development", "costs."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s5", "idA": "906709_17_item1_p28_s4", "sentA": "In December 2016, Shire plc announced the FDA approved ADYNOVATE for use in surgical settings for both adults and pediatric patients, and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In December 2016 the FDA expanded the approval of ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age, and for the use in surgical settings for both adult and pediatric patients.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "December", "2016", "the", "FDA", "expanded", "the", "approval", "of", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "for", "the", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients.", "<tag3>"], "wordsA": ["In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "December", "2016", "the", "FDA", "expanded", "the", "approval", "of", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "for", "the", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s8", "idA": "906709_17_item1_p28_s4", "sentA": "In December 2016, Shire plc announced the FDA approved ADYNOVATE for use in surgical settings for both adults and pediatric patients, and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In November 2016, ADYNOVATE was approved in Canada for patients 12 years of age and older for the treatment of Hemophilia A, including for perioperative management.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "November", "2016,", "ADYNOVATE", "was", "approved", "in", "Canada", "for", "patients", "12", "years", "of", "age", "and", "older", "for", "the", "treatment", "of", "Hemophilia", "A,", "including", "for", "perioperative", "management.", "<tag3>"], "wordsA": ["In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "November", "2016,", "ADYNOVATE", "was", "approved", "in", "Canada", "for", "patients", "12", "years", "of", "age", "and", "older", "for", "the", "treatment", "of", "Hemophilia", "A,", "including", "for", "perioperative", "management."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s11", "idA": "906709_17_item1_p28_s4", "sentA": "In December 2016, Shire plc announced the FDA approved ADYNOVATE for use in surgical settings for both adults and pediatric patients, and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In January 2018, ADYNOVATE was also approved in S. Korea for use in children and adults with Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "January", "2018,", "ADYNOVATE", "was", "also", "approved", "in", "S.", "Korea", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "January", "2018,", "ADYNOVATE", "was", "also", "approved", "in", "S.", "Korea", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s4", "idA": "906709_17_item1_p28_s4", "sentA": "In December 2016, Shire plc announced the FDA approved ADYNOVATE for use in surgical settings for both adults and pediatric patients, and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In December 2016 the FDA expanded the approval of ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age, and for the use in surgical settings for both adult and pediatric patients.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "December", "2016", "the", "FDA", "expanded", "the", "approval", "of", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "for", "the", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients.", "<tag3>"], "wordsA": ["In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "December", "2016", "the", "FDA", "expanded", "the", "approval", "of", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age,", "and", "for", "the", "use", "in", "surgical", "settings", "for", "both", "adult", "and", "pediatric", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s7", "idA": "906709_17_item1_p28_s4", "sentA": "In December 2016, Shire plc announced the FDA approved ADYNOVATE for use in surgical settings for both adults and pediatric patients, and that the FDA also approved ADYNOVATE for the treatment of Hemophilia A in pediatric patients under 12 years of age.", "sentB": "In November 2016, ADYNOVATE was approved in Canada for patients 12 years of age and older for the treatment of Hemophilia A, including for perioperative management.", "type": 2, "words": ["<tag1>", "In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age.", "<tag2>", "In", "November", "2016,", "ADYNOVATE", "was", "approved", "in", "Canada", "for", "patients", "12", "years", "of", "age", "and", "older", "for", "the", "treatment", "of", "Hemophilia", "A,", "including", "for", "perioperative", "management.", "<tag3>"], "wordsA": ["In", "December", "2016,", "Shire", "plc", "announced", "the", "FDA", "approved", "ADYNOVATE", "for", "use", "in", "surgical", "settings", "for", "both", "adults", "and", "pediatric", "patients,", "and", "that", "the", "FDA", "also", "approved", "ADYNOVATE", "for", "the", "treatment", "of", "Hemophilia", "A", "in", "pediatric", "patients", "under", "12", "years", "of", "age."], "wordsB": ["In", "November", "2016,", "ADYNOVATE", "was", "approved", "in", "Canada", "for", "patients", "12", "years", "of", "age", "and", "older", "for", "the", "treatment", "of", "Hemophilia", "A,", "including", "for", "perioperative", "management."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p38_s0", "idA": "906709_17_item1_p33_s3", "sentA": "We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "sentB": "Ensure Future Gro wth of our Proprietary Pipeline through Internal Research Efforts and Advancement of our Preclinical Drug Candidates into Clinical Trials We believe it is important to maintain a diverse pipeline of new drug candidates to continue to build on the value of our business.", "type": 2, "words": ["<tag1>", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag2>", "Ensure", "Future", "Gro", "wth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business.", "<tag3>"], "wordsA": ["We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "wordsB": ["Ensure", "Future", "Gro", "wth", "of", "our", "Proprietary", "Pipeline", "through", "Internal", "Research", "Efforts", "and", "Advancement", "of", "our", "Preclinical", "Drug", "Candidates", "into", "Clinical", "Trials", "We", "believe", "it", "is", "important", "to", "maintain", "a", "diverse", "pipeline", "of", "new", "drug", "candidates", "to", "continue", "to", "build", "on", "the", "value", "of", "our", "business."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p38_s3", "idA": "906709_17_item1_p34_s0", "sentA": "Enter int o Strategic and High-Value Partnerships to Bring Certain of Our Drug Candidates to Market We decide on a drug candidate-by-drug candidate basis how far to advance clinical development (e.g. Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "sentB": "Enter into Strategic and High-Value Partnerships to Bring Certain of Our Drug Candidates to Market We decide on a drug candidate-by-drug candidate basis, how far to advance clinical development (e.g. Phase 1, 2 or 3) and whether to commercialize products on our own, or seek a partner, or pursue a combination of these approaches.", "type": 2, "words": ["<tag1>", "Enter", "int", "o", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag2>", "Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis,", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches.", "<tag3>"], "wordsA": ["Enter", "int", "o", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "wordsB": ["Enter", "into", "Strategic", "and", "High-Value", "Partnerships", "to", "Bring", "Certain", "of", "Our", "Drug", "Candidates", "to", "Market", "We", "decide", "on", "a", "drug", "candidate-by-drug", "candidate", "basis,", "how", "far", "to", "advance", "clinical", "development", "(e.g.", "Phase", "1,", "2", "or", "3)", "and", "whether", "to", "commercialize", "products", "on", "our", "own,", "or", "seek", "a", "partner,", "or", "pursue", "a", "combination", "of", "these", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p42_s0", "idA": "906709_17_item1_p38_s1", "sentA": "NKTR-214 is designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "sentB": "NKTR-214 is a CD122-biased immune-stimulatory cytokine designed to preferentially activate the IL-2 beta sub-receptors and gamma sub-units of the IL-2 receptor in order to proliferate tumor-killing T cells within the body (CD8-positive effector T cells and natural killer T cells) without stimulating regulatory T cells (CD4-positive T cells).", "type": 2, "words": ["<tag1>", "NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag2>", "NKTR-214", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells).", "<tag3>"], "wordsA": ["NKTR-214", "is", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "wordsB": ["NKTR-214", "is", "a", "CD122-biased", "immune-stimulatory", "cytokine", "designed", "to", "preferentially", "activate", "the", "IL-2", "beta", "sub-receptors", "and", "gamma", "sub-units", "of", "the", "IL-2", "receptor", "in", "order", "to", "proliferate", "tumor-killing", "T", "cells", "within", "the", "body", "(CD8-positive", "effector", "T", "cells", "and", "natural", "killer", "T", "cells)", "without", "stimulating", "regulatory", "T", "cells", "(CD4-positive", "T", "cells)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s3", "idA": "906709_17_item1_p39_s1", "sentA": "In December 2015, we announced that dosing had commenced in the Phase 1/2 clinical study evaluating the safety, tolerability and efficacy of NKTR-214 in patients with advanced solid tumors, including melanoma, renal cell carcinoma and non-small cell lung cancer.", "sentB": "On September 12, 2017, we announced that we had begun dosing in a clinical study evaluating the efficacy and safety of NKTR-214 in combination with approved checkpoint inhibitors, TECENTRIQ (atezolizumab) and KEYTRUDA (pembrolizumab).", "type": 2, "words": ["<tag1>", "In", "December", "2015,", "we", "announced", "that", "dosing", "had", "commenced", "in", "the", "Phase", "1/2", "clinical", "study", "evaluating", "the", "safety,", "tolerability", "and", "efficacy", "of", "NKTR-214", "in", "patients", "with", "advanced", "solid", "tumors,", "including", "melanoma,", "renal", "cell", "carcinoma", "and", "non-small", "cell", "lung", "cancer.", "<tag2>", "On", "September", "12,", "2017,", "we", "announced", "that", "we", "had", "begun", "dosing", "in", "a", "clinical", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "NKTR-214", "in", "combination", "with", "approved", "checkpoint", "inhibitors,", "TECENTRIQ", "(atezolizumab)", "and", "KEYTRUDA", "(pembrolizumab).", "<tag3>"], "wordsA": ["In", "December", "2015,", "we", "announced", "that", "dosing", "had", "commenced", "in", "the", "Phase", "1/2", "clinical", "study", "evaluating", "the", "safety,", "tolerability", "and", "efficacy", "of", "NKTR-214", "in", "patients", "with", "advanced", "solid", "tumors,", "including", "melanoma,", "renal", "cell", "carcinoma", "and", "non-small", "cell", "lung", "cancer."], "wordsB": ["On", "September", "12,", "2017,", "we", "announced", "that", "we", "had", "begun", "dosing", "in", "a", "clinical", "study", "evaluating", "the", "efficacy", "and", "safety", "of", "NKTR-214", "in", "combination", "with", "approved", "checkpoint", "inhibitors,", "TECENTRIQ", "(atezolizumab)", "and", "KEYTRUDA", "(pembrolizumab)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p6_s4", "idA": "906709_17_item1_p3_s4", "sentA": "Immunology We are developing a new biologic, NKTR-358, which is designed to correct the underlying immune system imbalance in the body which occurs in patients with auto-immune disease.", "sentB": "In February 2017 we submitted an investigational new drug application (IND) for a new biologic that we are developing, NKTR-358, which is designed to correct the underlying immune system imbalance in the body that occurs in patients with autoimmune disease.", "type": 2, "words": ["<tag1>", "Immunology", "We", "are", "developing", "a", "new", "biologic,", "NKTR-358,", "which", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease.", "<tag2>", "In", "February", "2017", "we", "submitted", "an", "investigational", "new", "drug", "application", "(IND)", "for", "a", "new", "biologic", "that", "we", "are", "developing,", "NKTR-358,", "which", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "that", "occurs", "in", "patients", "with", "autoimmune", "disease.", "<tag3>"], "wordsA": ["Immunology", "We", "are", "developing", "a", "new", "biologic,", "NKTR-358,", "which", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease."], "wordsB": ["In", "February", "2017", "we", "submitted", "an", "investigational", "new", "drug", "application", "(IND)", "for", "a", "new", "biologic", "that", "we", "are", "developing,", "NKTR-358,", "which", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "that", "occurs", "in", "patients", "with", "autoimmune", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p43_s0", "idA": "906709_17_item1_p41_s0", "sentA": "The dose-escalation stage of the Phase 1/2 study is designed to evaluate safety and efficacy, and define the recommended Phase 2 dose of NKTR-214 in patients with solid tumors.", "sentB": "Under a research collaboration with The University of Texas MD Anderson Cancer Center, in December 2015 we commenced a Phase 1 study to evaluate NKTR-214 as a monotherapy in a variety of tumor types to evaluate safety and efficacy, and define the recommended Phase 2 dose of NKTR-214 in patients with solid tumors.", "type": 2, "words": ["<tag1>", "The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors.", "<tag2>", "Under", "a", "research", "collaboration", "with", "The", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center,", "in", "December", "2015", "we", "commenced", "a", "Phase", "1", "study", "to", "evaluate", "NKTR-214", "as", "a", "monotherapy", "in", "a", "variety", "of", "tumor", "types", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors.", "<tag3>"], "wordsA": ["The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors."], "wordsB": ["Under", "a", "research", "collaboration", "with", "The", "University", "of", "Texas", "MD", "Anderson", "Cancer", "Center,", "in", "December", "2015", "we", "commenced", "a", "Phase", "1", "study", "to", "evaluate", "NKTR-214", "as", "a", "monotherapy", "in", "a", "variety", "of", "tumor", "types", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s5", "idA": "906709_17_item1_p41_s0", "sentA": "The dose-escalation stage of the Phase 1/2 study is designed to evaluate safety and efficacy, and define the recommended Phase 2 dose of NKTR-214 in patients with solid tumors.", "sentB": "We identified the recommended Phase 2 dose for NKTR-214 in combination with Opdivo and are currently enrolling subjects in the expansion phase of the study.", "type": 2, "words": ["<tag1>", "The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors.", "<tag2>", "We", "identified", "the", "recommended", "Phase", "2", "dose", "for", "NKTR-214", "in", "combination", "with", "Opdivo", "and", "are", "currently", "enrolling", "subjects", "in", "the", "expansion", "phase", "of", "the", "study.", "<tag3>"], "wordsA": ["The", "dose-escalation", "stage", "of", "the", "Phase", "1/2", "study", "is", "designed", "to", "evaluate", "safety", "and", "efficacy,", "and", "define", "the", "recommended", "Phase", "2", "dose", "of", "NKTR-214", "in", "patients", "with", "solid", "tumors."], "wordsB": ["We", "identified", "the", "recommended", "Phase", "2", "dose", "for", "NKTR-214", "in", "combination", "with", "Opdivo", "and", "are", "currently", "enrolling", "subjects", "in", "the", "expansion", "phase", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p43_s1", "idA": "906709_17_item1_p41_s1", "sentA": "In addition to a determination of the recommended Phase 2 dose, the study will assess the safety profile of NKTR-214, the immunologic effect of NKTR-214 on tumor-infiltrating lymphocytes and other immune activation markers in both blood and tumor tissue, the pharmacokinetic/pharmacodynamic profile as well as preliminary anti-tumor activity based on objective response rate.", "sentB": "In addition, the study also assessed the safety profile of NKTR-214, the immunologic effect of NKTR-214 on tumor-infiltrating lymphocytes and other immune activation markers in both blood and tumor tissue, the pharmacokinetic and pharmacodynamic profile of NKTR-214.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "the", "safety", "profile", "of", "NKTR-214,", "the", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrating", "lymphocytes", "and", "other", "immune", "activation", "markers", "in", "both", "blood", "and", "tumor", "tissue,", "the", "pharmacokinetic/pharmacodynamic", "profile", "as", "well", "as", "preliminary", "anti-tumor", "activity", "based", "on", "objective", "response", "rate.", "<tag2>", "In", "addition,", "the", "study", "also", "assessed", "the", "safety", "profile", "of", "NKTR-214,", "the", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrating", "lymphocytes", "and", "other", "immune", "activation", "markers", "in", "both", "blood", "and", "tumor", "tissue,", "the", "pharmacokinetic", "and", "pharmacodynamic", "profile", "of", "NKTR-214.", "<tag3>"], "wordsA": ["In", "addition", "to", "a", "determination", "of", "the", "recommended", "Phase", "2", "dose,", "the", "study", "will", "assess", "the", "safety", "profile", "of", "NKTR-214,", "the", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrating", "lymphocytes", "and", "other", "immune", "activation", "markers", "in", "both", "blood", "and", "tumor", "tissue,", "the", "pharmacokinetic/pharmacodynamic", "profile", "as", "well", "as", "preliminary", "anti-tumor", "activity", "based", "on", "objective", "response", "rate."], "wordsB": ["In", "addition,", "the", "study", "also", "assessed", "the", "safety", "profile", "of", "NKTR-214,", "the", "immunologic", "effect", "of", "NKTR-214", "on", "tumor-infiltrating", "lymphocytes", "and", "other", "immune", "activation", "markers", "in", "both", "blood", "and", "tumor", "tissue,", "the", "pharmacokinetic", "and", "pharmacodynamic", "profile", "of", "NKTR-214."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s0", "idA": "906709_17_item1_p41_s2", "sentA": "We plan to study NKTR-214 in combination with a number of therapeutic approaches where we believe there is a strong biologic rationale for complimentary mechanisms of action.", "sentB": "The development program for NKTR-214 includes combinations with a number of therapeutic approaches where we believe there is a strong biologic rationale for complimentary mechanisms of action.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action.", "<tag2>", "The", "development", "program", "for", "NKTR-214", "includes", "combinations", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action.", "<tag3>"], "wordsA": ["We", "plan", "to", "study", "NKTR-214", "in", "combination", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action."], "wordsB": ["The", "development", "program", "for", "NKTR-214", "includes", "combinations", "with", "a", "number", "of", "therapeutic", "approaches", "where", "we", "believe", "there", "is", "a", "strong", "biologic", "rationale", "for", "complimentary", "mechanisms", "of", "action."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s2", "idA": "906709_17_item1_p41_s4", "sentA": "The dose escalation stage of the Phase 1/2 program evaluating NKTR-214 in combination with Opdivo , which we call the PIVOT study is currently enrolling patients at multiple clinical sites.", "sentB": "The dose expansion portion of the Phase 1/2 program evaluating NKTR-214 in combination with Opdivo is currently enrolling patients at multiple clinical sites.", "type": 2, "words": ["<tag1>", "The", "dose", "escalation", "stage", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", ",", "which", "we", "call", "the", "PIVOT", "study", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites.", "<tag2>", "The", "dose", "expansion", "portion", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites.", "<tag3>"], "wordsA": ["The", "dose", "escalation", "stage", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", ",", "which", "we", "call", "the", "PIVOT", "study", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites."], "wordsB": ["The", "dose", "expansion", "portion", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s4", "idA": "906709_17_item1_p41_s4", "sentA": "The dose escalation stage of the Phase 1/2 program evaluating NKTR-214 in combination with Opdivo , which we call the PIVOT study is currently enrolling patients at multiple clinical sites.", "sentB": "This study is planned to enroll patients into two separate arms concurrently with the first arm evaluating NKTR-214 in combination with atezolizumab in up to 30 patients, and the second arm evaluating NKTR-214 in combination with pembrolizumab in up to 30 patients.", "type": 2, "words": ["<tag1>", "The", "dose", "escalation", "stage", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", ",", "which", "we", "call", "the", "PIVOT", "study", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites.", "<tag2>", "This", "study", "is", "planned", "to", "enroll", "patients", "into", "two", "separate", "arms", "concurrently", "with", "the", "first", "arm", "evaluating", "NKTR-214", "in", "combination", "with", "atezolizumab", "in", "up", "to", "30", "patients,", "and", "the", "second", "arm", "evaluating", "NKTR-214", "in", "combination", "with", "pembrolizumab", "in", "up", "to", "30", "patients.", "<tag3>"], "wordsA": ["The", "dose", "escalation", "stage", "of", "the", "Phase", "1/2", "program", "evaluating", "NKTR-214", "in", "combination", "with", "Opdivo", ",", "which", "we", "call", "the", "PIVOT", "study", "is", "currently", "enrolling", "patients", "at", "multiple", "clinical", "sites."], "wordsB": ["This", "study", "is", "planned", "to", "enroll", "patients", "into", "two", "separate", "arms", "concurrently", "with", "the", "first", "arm", "evaluating", "NKTR-214", "in", "combination", "with", "atezolizumab", "in", "up", "to", "30", "patients,", "and", "the", "second", "arm", "evaluating", "NKTR-214", "in", "combination", "with", "pembrolizumab", "in", "up", "to", "30", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p12_s0", "idA": "906709_17_item1_p41_s5", "sentA": "In the first phase of the PIVOT study, we expect to evaluate the clinical benefit, safety, and tolerability of combining NKTR-214 with Opdivo in patients.", "sentB": "In March 2017, we began the first Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR-358 in approximately 50 healthy patients.", "type": 2, "words": ["<tag1>", "In", "the", "first", "phase", "of", "the", "PIVOT", "study,", "we", "expect", "to", "evaluate", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "patients.", "<tag2>", "In", "March", "2017,", "we", "began", "the", "first", "Phase", "1", "dose-finding", "trial", "of", "NKTR-358", "to", "evaluate", "single-ascending", "doses", "of", "NKTR-358", "in", "approximately", "50", "healthy", "patients.", "<tag3>"], "wordsA": ["In", "the", "first", "phase", "of", "the", "PIVOT", "study,", "we", "expect", "to", "evaluate", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "patients."], "wordsB": ["In", "March", "2017,", "we", "began", "the", "first", "Phase", "1", "dose-finding", "trial", "of", "NKTR-358", "to", "evaluate", "single-ascending", "doses", "of", "NKTR-358", "in", "approximately", "50", "healthy", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s3", "idA": "906709_17_item1_p41_s5", "sentA": "In the first phase of the PIVOT study, we expect to evaluate the clinical benefit, safety, and tolerability of combining NKTR-214 with Opdivo in patients.", "sentB": "In the first phase of the PIVOT-02 study, we evaluated the clinical benefit, safety, and tolerability of combining NKTR-214 with Opdivo in thirty-eight patients.", "type": 2, "words": ["<tag1>", "In", "the", "first", "phase", "of", "the", "PIVOT", "study,", "we", "expect", "to", "evaluate", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "patients.", "<tag2>", "In", "the", "first", "phase", "of", "the", "PIVOT-02", "study,", "we", "evaluated", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "thirty-eight", "patients.", "<tag3>"], "wordsA": ["In", "the", "first", "phase", "of", "the", "PIVOT", "study,", "we", "expect", "to", "evaluate", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "patients."], "wordsB": ["In", "the", "first", "phase", "of", "the", "PIVOT-02", "study,", "we", "evaluated", "the", "clinical", "benefit,", "safety,", "and", "tolerability", "of", "combining", "NKTR-214", "with", "Opdivo", "in", "thirty-eight", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p44_s6", "idA": "906709_17_item1_p41_s6", "sentA": "The second phase of the expansion cohorts is expected to evaluate the safety and efficacy of combining NKTR-214 with Opdivo .", "sentB": "The second phase of the expansion cohorts is evaluating the safety and efficacy of combining NKTR-214 with Opdivo .", "type": 2, "words": ["<tag1>", "The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "expected", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", ".", "<tag2>", "The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "evaluating", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", ".", "<tag3>"], "wordsA": ["The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "expected", "to", "evaluate", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", "."], "wordsB": ["The", "second", "phase", "of", "the", "expansion", "cohorts", "is", "evaluating", "the", "safety", "and", "efficacy", "of", "combining", "NKTR-214", "with", "Opdivo", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s4", "idA": "906709_17_item1_p42_s0", "sentA": "Under the BMS Agreement, BMS is responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organization, laboratories, clinical sites and institutional review boards.", "sentB": "Under the BMS Agreement, BMS is responsible for 50% of all out-of-pocket costs reasonably incurred by us in connection with third party contract research organizations, laboratories, clinical sites and institutional review boards.", "type": 2, "words": ["<tag1>", "Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards.", "<tag2>", "Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "by", "us", "in", "connection", "with", "third", "party", "contract", "research", "organizations,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards.", "<tag3>"], "wordsA": ["Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards."], "wordsB": ["Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "by", "us", "in", "connection", "with", "third", "party", "contract", "research", "organizations,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s0", "idA": "906709_17_item1_p42_s0", "sentA": "Under the BMS Agreement, BMS is responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organization, laboratories, clinical sites and institutional review boards.", "sentB": "Under the Clinical Trial Collaboration Agreement, BMS is responsible for 50% of all out-of-pocket costs reasonably incurred in connection with third party contract research organization, laboratories, clinical sites and institutional review boards.", "type": 2, "words": ["<tag1>", "Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards.", "<tag2>", "Under", "the", "Clinical", "Trial", "Collaboration", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards.", "<tag3>"], "wordsA": ["Under", "the", "BMS", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards."], "wordsB": ["Under", "the", "Clinical", "Trial", "Collaboration", "Agreement,", "BMS", "is", "responsible", "for", "50%", "of", "all", "out-of-pocket", "costs", "reasonably", "incurred", "in", "connection", "with", "third", "party", "contract", "research", "organization,", "laboratories,", "clinical", "sites", "and", "institutional", "review", "boards."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s5", "idA": "906709_17_item1_p42_s1", "sentA": "Each party will otherwise be responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combined Therapy Trial.", "sentB": "Each party is otherwise responsible for its own internal costs, including internal personnel costs, incurred in connection with each Combination Therapy Trial.", "type": 2, "words": ["<tag1>", "Each", "party", "will", "otherwise", "be", "responsible", "for", "its", "own", "internal", "costs,", "including", "internal", "personnel", "costs,", "incurred", "in", "connection", "with", "each", "Combined", "Therapy", "Trial.", "<tag2>", "Each", "party", "is", "otherwise", "responsible", "for", "its", "own", "internal", "costs,", "including", "internal", "personnel", "costs,", "incurred", "in", "connection", "with", "each", "Combination", "Therapy", "Trial.", "<tag3>"], "wordsA": ["Each", "party", "will", "otherwise", "be", "responsible", "for", "its", "own", "internal", "costs,", "including", "internal", "personnel", "costs,", "incurred", "in", "connection", "with", "each", "Combined", "Therapy", "Trial."], "wordsB": ["Each", "party", "is", "otherwise", "responsible", "for", "its", "own", "internal", "costs,", "including", "internal", "personnel", "costs,", "incurred", "in", "connection", "with", "each", "Combination", "Therapy", "Trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p4_s6", "idA": "906709_17_item1_p42_s3", "sentA": "In addition to the clinical trials in collaboration with BMS, we also plan to initiate a broad clinical development program, both on our own or in collaboration with other potential partners, to explore the potential of combining NKTR-214 with therapies such as cancer vaccines, adoptive cell therapy, small molecules, and other biological agents in order to generate novel immune-oncology approaches.", "sentB": "In addition to the existing clinical programs, we plan to continue to advance a broad clinical development program, both on our own or in collaboration with other potential partners, to explore the potential of combining NKTR-214 with therapies such as cancer vaccines, adoptive cell therapy, small molecules, and other biological agents in order to generate novel immune-oncology approaches.", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "trials", "in", "collaboration", "with", "BMS,", "we", "also", "plan", "to", "initiate", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches.", "<tag2>", "In", "addition", "to", "the", "existing", "clinical", "programs,", "we", "plan", "to", "continue", "to", "advance", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches.", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "trials", "in", "collaboration", "with", "BMS,", "we", "also", "plan", "to", "initiate", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches."], "wordsB": ["In", "addition", "to", "the", "existing", "clinical", "programs,", "we", "plan", "to", "continue", "to", "advance", "a", "broad", "clinical", "development", "program,", "both", "on", "our", "own", "or", "in", "collaboration", "with", "other", "potential", "partners,", "to", "explore", "the", "potential", "of", "combining", "NKTR-214", "with", "therapies", "such", "as", "cancer", "vaccines,", "adoptive", "cell", "therapy,", "small", "molecules,", "and", "other", "biological", "agents", "in", "order", "to", "generate", "novel", "immune-oncology", "approaches."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p52_s0", "idA": "906709_17_item1_p45_s0", "sentA": "body and must be administered frequently and in high doses limiting its utility due to toxicity.", "sentB": "Native rhIL-15 is rapidly cleared from the body and must be administered frequently and in high doses limiting its utility due to toxicity.", "type": 2, "words": ["<tag1>", "body", "and", "must", "be", "administered", "frequently", "and", "in", "high", "doses", "limiting", "its", "utility", "due", "to", "toxicity.", "<tag2>", "Native", "rhIL-15", "is", "rapidly", "cleared", "from", "the", "body", "and", "must", "be", "administered", "frequently", "and", "in", "high", "doses", "limiting", "its", "utility", "due", "to", "toxicity.", "<tag3>"], "wordsA": ["body", "and", "must", "be", "administered", "frequently", "and", "in", "high", "doses", "limiting", "its", "utility", "due", "to", "toxicity."], "wordsB": ["Native", "rhIL-15", "is", "rapidly", "cleared", "from", "the", "body", "and", "must", "be", "administered", "frequently", "and", "in", "high", "doses", "limiting", "its", "utility", "due", "to", "toxicity."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p53_s0", "idA": "906709_17_item1_p45_s1", "sentA": "NKTR-255 is designed with IL-15 receptor alpha specificity to optimize biological a ctivity and is uniquely engineered to provide optimal exposure and an improved safety profile.", "sentB": "NKTR-255 is designed with IL-15 receptor alpha specificity to optimize biological activity and is uniquely engineered to provide optimal exposure and an improved safety profile.", "type": 2, "words": ["<tag1>", "NKTR-255", "is", "designed", "with", "IL-15", "receptor", "alpha", "specificity", "to", "optimize", "biological", "a", "ctivity", "and", "is", "uniquely", "engineered", "to", "provide", "optimal", "exposure", "and", "an", "improved", "safety", "profile.", "<tag2>", "NKTR-255", "is", "designed", "with", "IL-15", "receptor", "alpha", "specificity", "to", "optimize", "biological", "activity", "and", "is", "uniquely", "engineered", "to", "provide", "optimal", "exposure", "and", "an", "improved", "safety", "profile.", "<tag3>"], "wordsA": ["NKTR-255", "is", "designed", "with", "IL-15", "receptor", "alpha", "specificity", "to", "optimize", "biological", "a", "ctivity", "and", "is", "uniquely", "engineered", "to", "provide", "optimal", "exposure", "and", "an", "improved", "safety", "profile."], "wordsB": ["NKTR-255", "is", "designed", "with", "IL-15", "receptor", "alpha", "specificity", "to", "optimize", "biological", "activity", "and", "is", "uniquely", "engineered", "to", "provide", "optimal", "exposure", "and", "an", "improved", "safety", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p54_s0", "idA": "906709_17_item1_p46_s0", "sentA": "Immunology NKTR-358 is designed to correct the underlying immune system imbalance in the body which occurs in patients with auto-immune disease.", "sentB": "Immunology NKTR-358 is designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.", "type": 2, "words": ["<tag1>", "Immunology", "NKTR-358", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease.", "<tag2>", "Immunology", "NKTR-358", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "autoimmune", "disease.", "<tag3>"], "wordsA": ["Immunology", "NKTR-358", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "auto-immune", "disease."], "wordsB": ["Immunology", "NKTR-358", "is", "designed", "to", "correct", "the", "underlying", "immune", "system", "imbalance", "in", "the", "body", "which", "occurs", "in", "patients", "with", "autoimmune", "disease."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s0", "idA": "906709_17_item1_p48_s0", "sentA": "NKTR-358 targets the CD25 sub-receptor in the interleukin-2 pathway in order to stimulate proliferation and growth of T regulatory cells, which are specific immune cells in the body that modulate the immune system and prevent auto-immune disease by maintaining self-tolerance.", "sentB": "NKTR-358 targets the CD25 sub-receptor in the interleukin-2 pathway in order to stimulate proliferation and growth of regulatory T cells, which are specific immune cells in the body that modulate the immune system and prevent autoimmune disease by maintaining self-tolerance.", "type": 2, "words": ["<tag1>", "NKTR-358", "targets", "the", "CD25", "sub-receptor", "in", "the", "interleukin-2", "pathway", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "T", "regulatory", "cells,", "which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance.", "<tag2>", "NKTR-358", "targets", "the", "CD25", "sub-receptor", "in", "the", "interleukin-2", "pathway", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "regulatory", "T", "cells,", "which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "autoimmune", "disease", "by", "maintaining", "self-tolerance.", "<tag3>"], "wordsA": ["NKTR-358", "targets", "the", "CD25", "sub-receptor", "in", "the", "interleukin-2", "pathway", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "T", "regulatory", "cells,", "which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance."], "wordsB": ["NKTR-358", "targets", "the", "CD25", "sub-receptor", "in", "the", "interleukin-2", "pathway", "in", "order", "to", "stimulate", "proliferation", "and", "growth", "of", "regulatory", "T", "cells,", "which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "autoimmune", "disease", "by", "maintaining", "self-tolerance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p13_s0", "idA": "906709_17_item1_p48_s1", "sentA": "We plan to evaluate NKTR-358 in clinical studies for the treatment of systemic lupus erythematosus and other indications.", "sentB": "trial to evaluate NKTR-358 in patients with systemic lupus erythematosus (SLE) is expected to be initiated in the second quarter of 2018.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "evaluate", "NKTR-358", "in", "clinical", "studies", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus", "and", "other", "indications.", "<tag2>", "trial", "to", "evaluate", "NKTR-358", "in", "patients", "with", "systemic", "lupus", "erythematosus", "(SLE)", "is", "expected", "to", "be", "initiated", "in", "the", "second", "quarter", "of", "2018.", "<tag3>"], "wordsA": ["We", "plan", "to", "evaluate", "NKTR-358", "in", "clinical", "studies", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus", "and", "other", "indications."], "wordsB": ["trial", "to", "evaluate", "NKTR-358", "in", "patients", "with", "systemic", "lupus", "erythematosus", "(SLE)", "is", "expected", "to", "be", "initiated", "in", "the", "second", "quarter", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s9", "idA": "906709_17_item1_p48_s1", "sentA": "We plan to evaluate NKTR-358 in clinical studies for the treatment of systemic lupus erythematosus and other indications.", "sentB": "The Phase 1 multiple-ascending dose trial is expected to be initiated in the second quarter of 2018 to evaluate NKTR 358 in patients with systemic lupus erythematosus and other indications.", "type": 2, "words": ["<tag1>", "We", "plan", "to", "evaluate", "NKTR-358", "in", "clinical", "studies", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus", "and", "other", "indications.", "<tag2>", "The", "Phase", "1", "multiple-ascending", "dose", "trial", "is", "expected", "to", "be", "initiated", "in", "the", "second", "quarter", "of", "2018", "to", "evaluate", "NKTR", "358", "in", "patients", "with", "systemic", "lupus", "erythematosus", "and", "other", "indications.", "<tag3>"], "wordsA": ["We", "plan", "to", "evaluate", "NKTR-358", "in", "clinical", "studies", "for", "the", "treatment", "of", "systemic", "lupus", "erythematosus", "and", "other", "indications."], "wordsB": ["The", "Phase", "1", "multiple-ascending", "dose", "trial", "is", "expected", "to", "be", "initiated", "in", "the", "second", "quarter", "of", "2018", "to", "evaluate", "NKTR", "358", "in", "patients", "with", "systemic", "lupus", "erythematosus", "and", "other", "indications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p15_s2", "idA": "906709_17_item1_p48_s2", "sentA": "We filed an IND for Nektar-358 in February 2017.", "sentB": "The study was completed in December 2017.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017.", "<tag2>", "The", "study", "was", "completed", "in", "December", "2017.", "<tag3>"], "wordsA": ["We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017."], "wordsB": ["The", "study", "was", "completed", "in", "December", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p50_s3", "idA": "906709_17_item1_p48_s2", "sentA": "We filed an IND for Nektar-358 in February 2017.", "sentB": "We filed an IND for NKTR-262 in December 2017 and expect to begin enrolling patients in the initial Phase 1 study before the end of the first quarter of 2018.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017.", "<tag2>", "We", "filed", "an", "IND", "for", "NKTR-262", "in", "December", "2017", "and", "expect", "to", "begin", "enrolling", "patients", "in", "the", "initial", "Phase", "1", "study", "before", "the", "end", "of", "the", "first", "quarter", "of", "2018.", "<tag3>"], "wordsA": ["We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017."], "wordsB": ["We", "filed", "an", "IND", "for", "NKTR-262", "in", "December", "2017", "and", "expect", "to", "begin", "enrolling", "patients", "in", "the", "initial", "Phase", "1", "study", "before", "the", "end", "of", "the", "first", "quarter", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s8", "idA": "906709_17_item1_p48_s2", "sentA": "We filed an IND for Nektar-358 in February 2017.", "sentB": "In February 2017 we filed an IND for NKTR-358 and we are currently enrolling patients in the initial Phase 1 dose-finding trial of NKTR-358 to evaluate single-ascending doses of NKTR 358 in approximately 50 healthy patients.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017.", "<tag2>", "In", "February", "2017", "we", "filed", "an", "IND", "for", "NKTR-358", "and", "we", "are", "currently", "enrolling", "patients", "in", "the", "initial", "Phase", "1", "dose-finding", "trial", "of", "NKTR-358", "to", "evaluate", "single-ascending", "doses", "of", "NKTR", "358", "in", "approximately", "50", "healthy", "patients.", "<tag3>"], "wordsA": ["We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017."], "wordsB": ["In", "February", "2017", "we", "filed", "an", "IND", "for", "NKTR-358", "and", "we", "are", "currently", "enrolling", "patients", "in", "the", "initial", "Phase", "1", "dose-finding", "trial", "of", "NKTR-358", "to", "evaluate", "single-ascending", "doses", "of", "NKTR", "358", "in", "approximately", "50", "healthy", "patients."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p5_s3", "idA": "906709_17_item1_p48_s2", "sentA": "We filed an IND for Nektar-358 in February 2017.", "sentB": "We filed an IND for NKTR-262 in December 2017 and a Phase 1 clinical trial is expected to start before the end of the first quarter of 2018.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017.", "<tag2>", "We", "filed", "an", "IND", "for", "NKTR-262", "in", "December", "2017", "and", "a", "Phase", "1", "clinical", "trial", "is", "expected", "to", "start", "before", "the", "end", "of", "the", "first", "quarter", "of", "2018.", "<tag3>"], "wordsA": ["We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017."], "wordsB": ["We", "filed", "an", "IND", "for", "NKTR-262", "in", "December", "2017", "and", "a", "Phase", "1", "clinical", "trial", "is", "expected", "to", "start", "before", "the", "end", "of", "the", "first", "quarter", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p63_s2", "idA": "906709_17_item1_p48_s2", "sentA": "We filed an IND for Nektar-358 in February 2017.", "sentB": "The study was completed in December 2017.", "type": 2, "words": ["<tag1>", "We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017.", "<tag2>", "The", "study", "was", "completed", "in", "December", "2017.", "<tag3>"], "wordsA": ["We", "filed", "an", "IND", "for", "Nektar-358", "in", "February", "2017."], "wordsB": ["The", "study", "was", "completed", "in", "December", "2017."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p57_s3", "idA": "906709_17_item1_p49_s3", "sentA": "NKTR-181 s abuse deterrent properties are inherent to its novel molecular structure and do not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "sentB": "The abuse deterrent properties of NKTR-181 are inherent to its novel molecular structure and do not rely on a formulation approach to prevent its conversion into a more abusable form of an opioid.", "type": 2, "words": ["<tag1>", "NKTR-181", "s", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag2>", "The", "abuse", "deterrent", "properties", "of", "NKTR-181", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid.", "<tag3>"], "wordsA": ["NKTR-181", "s", "abuse", "deterrent", "properties", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "wordsB": ["The", "abuse", "deterrent", "properties", "of", "NKTR-181", "are", "inherent", "to", "its", "novel", "molecular", "structure", "and", "do", "not", "rely", "on", "a", "formulation", "approach", "to", "prevent", "its", "conversion", "into", "a", "more", "abusable", "form", "of", "an", "opioid."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s4", "idA": "906709_17_item1_p50_s1", "sentA": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "The SUMMIT-07 study compared twice-daily dosing of NKTR-181 tablets to placebo in the treatment of over 600 patients with moderate to severe chronic low back pain who were new to opioid therapy (opioid-na ve).", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "The", "SUMMIT-07", "study", "compared", "twice-daily", "dosing", "of", "NKTR-181", "tablets", "to", "placebo", "in", "the", "treatment", "of", "over", "600", "patients", "with", "moderate", "to", "severe", "chronic", "low", "back", "pain", "who", "were", "new", "to", "opioid", "therapy", "(opioid-na", "ve).", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["The", "SUMMIT-07", "study", "compared", "twice-daily", "dosing", "of", "NKTR-181", "tablets", "to", "placebo", "in", "the", "treatment", "of", "over", "600", "patients", "with", "moderate", "to", "severe", "chronic", "low", "back", "pain", "who", "were", "new", "to", "opioid", "therapy", "(opioid-na", "ve)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p15_s1", "idA": "906709_17_item1_p50_s1", "sentA": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "SUMMIT-LTS is evaluating the long-term safety and tolerability of NKTR-181 in 638 patients (opioid-na ve and opioid-experienced) with moderate to severe chronic low pain or chronic non-cancer pain.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "SUMMIT-LTS", "is", "evaluating", "the", "long-term", "safety", "and", "tolerability", "of", "NKTR-181", "in", "638", "patients", "(opioid-na", "ve", "and", "opioid-experienced)", "with", "moderate", "to", "severe", "chronic", "low", "pain", "or", "chronic", "non-cancer", "pain.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["SUMMIT-LTS", "is", "evaluating", "the", "long-term", "safety", "and", "tolerability", "of", "NKTR-181", "in", "638", "patients", "(opioid-na", "ve", "and", "opioid-experienced)", "with", "moderate", "to", "severe", "chronic", "low", "pain", "or", "chronic", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p63_s1", "idA": "906709_17_item1_p50_s1", "sentA": "In June 2012, we initiated a Phase 2 clinical study to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.", "sentB": "SUMMIT-LTS is evaluating the long-term safety and tolerability of NKTR-181 in over 600 patients (opioid-na ve and opioid-experienced) with moderate to severe chronic low pain or chronic non-cancer pain.", "type": 2, "words": ["<tag1>", "In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee.", "<tag2>", "SUMMIT-LTS", "is", "evaluating", "the", "long-term", "safety", "and", "tolerability", "of", "NKTR-181", "in", "over", "600", "patients", "(opioid-na", "ve", "and", "opioid-experienced)", "with", "moderate", "to", "severe", "chronic", "low", "pain", "or", "chronic", "non-cancer", "pain.", "<tag3>"], "wordsA": ["In", "June", "2012,", "we", "initiated", "a", "Phase", "2", "clinical", "study", "to", "evaluate", "the", "efficacy,", "safety", "and", "tolerability", "of", "NKTR-181", "in", "patients", "with", "moderate", "to", "severe", "chronic", "pain", "from", "osteoarthritis", "of", "the", "knee."], "wordsB": ["SUMMIT-LTS", "is", "evaluating", "the", "long-term", "safety", "and", "tolerability", "of", "NKTR-181", "in", "over", "600", "patients", "(opioid-na", "ve", "and", "opioid-experienced)", "with", "moderate", "to", "severe", "chronic", "low", "pain", "or", "chronic", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p59_s2", "idA": "906709_17_item1_p50_s3", "sentA": "The study enrolled 295 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain relief from their current non-opioid pain medication.", "sentB": "The study enrolled 295 opioid-na ve patients with osteoarthritis of the knee who were not getting adequate pain reli ef from their current non-opioid pain medication.", "type": 2, "words": ["<tag1>", "The", "study", "enrolled", "295", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag2>", "The", "study", "enrolled", "295", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "reli", "ef", "from", "their", "current", "non-opioid", "pain", "medication.", "<tag3>"], "wordsA": ["The", "study", "enrolled", "295", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "relief", "from", "their", "current", "non-opioid", "pain", "medication."], "wordsB": ["The", "study", "enrolled", "295", "opioid-na", "ve", "patients", "with", "osteoarthritis", "of", "the", "knee", "who", "were", "not", "getting", "adequate", "pain", "reli", "ef", "from", "their", "current", "non-opioid", "pain", "medication."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s6", "idA": "906709_17_item1_p50_s4", "sentA": "Patients who qualified during the baseline period entered a titration phase, during which they were titrated on NKTR-181 tablets administered orally twice-daily until a dose was reached that provided a reduction of at least 20% in the patient s pain score as compared to the patient s own baseline.", "sentB": "Patients in the trial achieved an average pain score reduction of over 65% (from 6.73 at screening to 2.32 at randomization) during the dose titration period.", "type": 2, "words": ["<tag1>", "Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "reduction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline.", "<tag2>", "Patients", "in", "the", "trial", "achieved", "an", "average", "pain", "score", "reduction", "of", "over", "65%", "(from", "6.73", "at", "screening", "to", "2.32", "at", "randomization)", "during", "the", "dose", "titration", "period.", "<tag3>"], "wordsA": ["Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "reduction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline."], "wordsB": ["Patients", "in", "the", "trial", "achieved", "an", "average", "pain", "score", "reduction", "of", "over", "65%", "(from", "6.73", "at", "screening", "to", "2.32", "at", "randomization)", "during", "the", "dose", "titration", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p59_s3", "idA": "906709_17_item1_p50_s4", "sentA": "Patients who qualified during the baseline period entered a titration phase, during which they were titrated on NKTR-181 tablets administered orally twice-daily until a dose was reached that provided a reduction of at least 20% in the patient s pain score as compared to the patient s own baseline.", "sentB": "Patients who qualified during the baseline period entered a titration phase, during which they were titrated on NKTR-181 tablets administered orally twice-daily until a dose was reached that provided a redu ction of at least 20% in the patient s pain score as compared to the patient s own baseline.", "type": 2, "words": ["<tag1>", "Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "reduction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline.", "<tag2>", "Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "redu", "ction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline.", "<tag3>"], "wordsA": ["Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "reduction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline."], "wordsB": ["Patients", "who", "qualified", "during", "the", "baseline", "period", "entered", "a", "titration", "phase,", "during", "which", "they", "were", "titrated", "on", "NKTR-181", "tablets", "administered", "orally", "twice-daily", "until", "a", "dose", "was", "reached", "that", "provided", "a", "redu", "ction", "of", "at", "least", "20%", "in", "the", "patient", "s", "pain", "score", "as", "compared", "to", "the", "patient", "s", "own", "baseline."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p59_s4", "idA": "906709_17_item1_p50_s5", "sentA": "Patients that achieved this level of analgesia were then randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive placebo for up to 25 days.", "sentB": "Patients that achieved this level of analgesia were then randomized on a 1:1 basis to either continue to receive their analgesic dose of NKTR-181 or to receive pla cebo for up to 25 days.", "type": 2, "words": ["<tag1>", "Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "up", "to", "25", "days.", "<tag2>", "Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "pla", "cebo", "for", "up", "to", "25", "days.", "<tag3>"], "wordsA": ["Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "placebo", "for", "up", "to", "25", "days."], "wordsB": ["Patients", "that", "achieved", "this", "level", "of", "analgesia", "were", "then", "randomized", "on", "a", "1:1", "basis", "to", "either", "continue", "to", "receive", "their", "analgesic", "dose", "of", "NKTR-181", "or", "to", "receive", "pla", "cebo", "for", "up", "to", "25", "days."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s10", "idA": "906709_17_item1_p51_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "On July 18, 2017, we announced positive top-line data for our pivotal human abuse potential study (HAP) for NKTR-181.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "On", "July", "18,", "2017,", "we", "announced", "positive", "top-line", "data", "for", "our", "pivotal", "human", "abuse", "potential", "study", "(HAP)", "for", "NKTR-181.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["On", "July", "18,", "2017,", "we", "announced", "positive", "top-line", "data", "for", "our", "pivotal", "human", "abuse", "potential", "study", "(HAP)", "for", "NKTR-181."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p16_s1", "idA": "906709_17_item1_p51_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "We have completed pre-NDA meetings with FDA and we are currently planning to file an NDA for NKTR-181 in the first half of 2018.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "We", "have", "completed", "pre-NDA", "meetings", "with", "FDA", "and", "we", "are", "currently", "planning", "to", "file", "an", "NDA", "for", "NKTR-181", "in", "the", "first", "half", "of", "2018.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["We", "have", "completed", "pre-NDA", "meetings", "with", "FDA", "and", "we", "are", "currently", "planning", "to", "file", "an", "NDA", "for", "NKTR-181", "in", "the", "first", "half", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p64_s1", "idA": "906709_17_item1_p51_s0", "sentA": "In the first half of 2013, we conducted a human abuse liability study, or HAL study, for NKTR-181.", "sentB": "We have completed pre-NDA meetings with the FDA to discuss plans for an NDA submission and we are currently planning to file an NDA for NKTR-181 in the first half of 2018.", "type": 2, "words": ["<tag1>", "In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181.", "<tag2>", "We", "have", "completed", "pre-NDA", "meetings", "with", "the", "FDA", "to", "discuss", "plans", "for", "an", "NDA", "submission", "and", "we", "are", "currently", "planning", "to", "file", "an", "NDA", "for", "NKTR-181", "in", "the", "first", "half", "of", "2018.", "<tag3>"], "wordsA": ["In", "the", "first", "half", "of", "2013,", "we", "conducted", "a", "human", "abuse", "liability", "study,", "or", "HAL", "study,", "for", "NKTR-181."], "wordsB": ["We", "have", "completed", "pre-NDA", "meetings", "with", "the", "FDA", "to", "discuss", "plans", "for", "an", "NDA", "submission", "and", "we", "are", "currently", "planning", "to", "file", "an", "NDA", "for", "NKTR-181", "in", "the", "first", "half", "of", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s2", "idA": "906709_17_item1_p52_s1", "sentA": "On September 26, 2013, we announced results from this Phase 2 efficacy study.", "sentB": "On March 20, 2017, we announced that NKTR-181 met its primary and secondary endpoints in the SUMMIT-07 Phase 3 efficacy study.", "type": 2, "words": ["<tag1>", "On", "September", "26,", "2013,", "we", "announced", "results", "from", "this", "Phase", "2", "efficacy", "study.", "<tag2>", "On", "March", "20,", "2017,", "we", "announced", "that", "NKTR-181", "met", "its", "primary", "and", "secondary", "endpoints", "in", "the", "SUMMIT-07", "Phase", "3", "efficacy", "study.", "<tag3>"], "wordsA": ["On", "September", "26,", "2013,", "we", "announced", "results", "from", "this", "Phase", "2", "efficacy", "study."], "wordsB": ["On", "March", "20,", "2017,", "we", "announced", "that", "NKTR-181", "met", "its", "primary", "and", "secondary", "endpoints", "in", "the", "SUMMIT-07", "Phase", "3", "efficacy", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s8", "idA": "906709_17_item1_p52_s3", "sentA": "A total of 213 patients achieved an average 40% reduction in pain and entered the randomized phase of the study.", "sentB": "Key secondary endpoints of the study also achieved high statistical significance.", "type": 2, "words": ["<tag1>", "A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study.", "<tag2>", "Key", "secondary", "endpoints", "of", "the", "study", "also", "achieved", "high", "statistical", "significance.", "<tag3>"], "wordsA": ["A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study."], "wordsB": ["Key", "secondary", "endpoints", "of", "the", "study", "also", "achieved", "high", "statistical", "significance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s6", "idA": "906709_17_item1_p52_s3", "sentA": "A total of 213 patients achieved an average 40% reduction in pain and entered the randomized phase of the study.", "sentB": "and we are currently enrolling subjects in the expansion phase of the study.", "type": 2, "words": ["<tag1>", "A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study.", "<tag2>", "and", "we", "are", "currently", "enrolling", "subjects", "in", "the", "expansion", "phase", "of", "the", "study.", "<tag3>"], "wordsA": ["A", "total", "of", "213", "patients", "achieved", "an", "average", "40%", "reduction", "in", "pain", "and", "entered", "the", "randomized", "phase", "of", "the", "study."], "wordsB": ["and", "we", "are", "currently", "enrolling", "subjects", "in", "the", "expansion", "phase", "of", "the", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s5", "idA": "906709_17_item1_p55_s0", "sentA": "enrollment in a second HAL study where we are assessing abuse liability of supra-therapeutic doses of NKTR-181 in order to further evaluate NKTR-181 for labeling and scheduling p urposes.", "sentB": "SUMMIT-07 evaluated four analgesic doses of NKTR-181 (100 mg, 200 mg, 300 mg and 400 mg).", "type": 2, "words": ["<tag1>", "enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "p", "urposes.", "<tag2>", "SUMMIT-07", "evaluated", "four", "analgesic", "doses", "of", "NKTR-181", "(100", "mg,", "200", "mg,", "300", "mg", "and", "400", "mg).", "<tag3>"], "wordsA": ["enrollment", "in", "a", "second", "HAL", "study", "where", "we", "are", "assessing", "abuse", "liability", "of", "supra-therapeutic", "doses", "of", "NKTR-181", "in", "order", "to", "further", "evaluate", "NKTR-181", "for", "labeling", "and", "scheduling", "p", "urposes."], "wordsB": ["SUMMIT-07", "evaluated", "four", "analgesic", "doses", "of", "NKTR-181", "(100", "mg,", "200", "mg,", "300", "mg", "and", "400", "mg)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p62_s8", "idA": "906709_17_item1_p58_s1", "sentA": "In 2015, we announced topline data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with ONZEALD TM ), as a single-agent therapy for women with advanced metastatic breast cancer.", "sentB": "On July 18, 2017, we announced positive top-line data for our pivotal human abuse potential study for NKTR-181, which we call the HAP study.", "type": 2, "words": ["<tag1>", "In", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag2>", "On", "July", "18,", "2017,", "we", "announced", "positive", "top-line", "data", "for", "our", "pivotal", "human", "abuse", "potential", "study", "for", "NKTR-181,", "which", "we", "call", "the", "HAP", "study.", "<tag3>"], "wordsA": ["In", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "wordsB": ["On", "July", "18,", "2017,", "we", "announced", "positive", "top-line", "data", "for", "our", "pivotal", "human", "abuse", "potential", "study", "for", "NKTR-181,", "which", "we", "call", "the", "HAP", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p67_s1", "idA": "906709_17_item1_p58_s1", "sentA": "In 2015, we announced topline data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with ONZEALD TM ), as a single-agent therapy for women with advanced metastatic breast cancer.", "sentB": "In 2015, we announced top-line data from a Phase 3 clinical study for ONZEALD TM , which we call the BEACON study (BrEAst Cancer Outcomes with ONZEALD TM ), as a single-agent therapy for women with advanced metastatic breast cancer.", "type": 2, "words": ["<tag1>", "In", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag2>", "In", "2015,", "we", "announced", "top-line", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer.", "<tag3>"], "wordsA": ["In", "2015,", "we", "announced", "topline", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "wordsB": ["In", "2015,", "we", "announced", "top-line", "data", "from", "a", "Phase", "3", "clinical", "study", "for", "ONZEALD", "TM", ",", "which", "we", "call", "the", "BEACON", "study", "(BrEAst", "Cancer", "Outcomes", "with", "ONZEALD", "TM", "),", "as", "a", "single-agent", "therapy", "for", "women", "with", "advanced", "metastatic", "breast", "cancer."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p149_s2", "idA": "906709_17_item1_p58_s8", "sentA": "In Europe, we met with the National Authorities in Sweden and the United Kingdom, as well as the European Medicines Agency (EMA) to discuss the BEACON data.", "sentB": "Third-party payors include government programs such as Medicare, Medicaid, TRICARE and the Veterans Administration, as well as managed care providers, private health insurers and other organizations.", "type": 2, "words": ["<tag1>", "In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data.", "<tag2>", "Third-party", "payors", "include", "government", "programs", "such", "as", "Medicare,", "Medicaid,", "TRICARE", "and", "the", "Veterans", "Administration,", "as", "well", "as", "managed", "care", "providers,", "private", "health", "insurers", "and", "other", "organizations.", "<tag3>"], "wordsA": ["In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data."], "wordsB": ["Third-party", "payors", "include", "government", "programs", "such", "as", "Medicare,", "Medicaid,", "TRICARE", "and", "the", "Veterans", "Administration,", "as", "well", "as", "managed", "care", "providers,", "private", "health", "insurers", "and", "other", "organizations."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s7", "idA": "906709_17_item1_p58_s8", "sentA": "In Europe, we met with the National Authorities in Sweden and the United Kingdom, as well as the European Medicines Agency (EMA) to discuss the BEACON data.", "sentB": "In Europe, we met with the National Authorities in Sweden and the United Kingdom, as well as the EMA to discuss the BEACON data.", "type": 2, "words": ["<tag1>", "In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data.", "<tag2>", "In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "EMA", "to", "discuss", "the", "BEACON", "data.", "<tag3>"], "wordsA": ["In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "European", "Medicines", "Agency", "(EMA)", "to", "discuss", "the", "BEACON", "data."], "wordsB": ["In", "Europe,", "we", "met", "with", "the", "National", "Authorities", "in", "Sweden", "and", "the", "United", "Kingdom,", "as", "well", "as", "the", "EMA", "to", "discuss", "the", "BEACON", "data."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s8", "idA": "906709_17_item1_p58_s9", "sentA": "In June 2016, we filed an MAA for conditional approval of ONZEALD TM for adult patients with advanced breast cancer who have brain metastases .", "sentB": "In June 2016, we filed an MAA for conditional approval of ONZEALD TM for adult patients with advanced breast cancer who have brain metastases treated with ONZEALD TM versus physicians treatment of choice in the ATTAIN trial.", "type": 2, "words": ["<tag1>", "In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", ".", "<tag2>", "In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "treated", "with", "ONZEALD", "TM", "versus", "physicians", "treatment", "of", "choice", "in", "the", "ATTAIN", "trial.", "<tag3>"], "wordsA": ["In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "."], "wordsB": ["In", "June", "2016,", "we", "filed", "an", "MAA", "for", "conditional", "approval", "of", "ONZEALD", "TM", "for", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "treated", "with", "ONZEALD", "TM", "versus", "physicians", "treatment", "of", "choice", "in", "the", "ATTAIN", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p19_s0", "idA": "906709_17_item1_p59_s0", "sentA": "In 2016 we initiated a randomized Phase 3 confirmatory study to evaluate ONZEALD TM as compared to treatment of physician s choice (TPC) in approximately 350 adult patients with advanced breast cancer who have brain metastases (ATTAIN Study).", "sentB": "The Phase 3 study (ATTAIN) in breast cancer patients having brain metastases is ongoing.", "type": 2, "words": ["<tag1>", "In", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician", "s", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "(ATTAIN", "Study).", "<tag2>", "The", "Phase", "3", "study", "(ATTAIN)", "in", "breast", "cancer", "patients", "having", "brain", "metastases", "is", "ongoing.", "<tag3>"], "wordsA": ["In", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician", "s", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "(ATTAIN", "Study)."], "wordsB": ["The", "Phase", "3", "study", "(ATTAIN)", "in", "breast", "cancer", "patients", "having", "brain", "metastases", "is", "ongoing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p70_s0", "idA": "906709_17_item1_p59_s0", "sentA": "In 2016 we initiated a randomized Phase 3 confirmatory study to evaluate ONZEALD TM as compared to treatment of physician s choice (TPC) in approximately 350 adult patients with advanced breast cancer who have brain metastases (ATTAIN Study).", "sentB": "The Phase 3 study (ATTAIN) in breast cancer patients having brain metastases is ongoing.", "type": 2, "words": ["<tag1>", "In", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician", "s", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "(ATTAIN", "Study).", "<tag2>", "The", "Phase", "3", "study", "(ATTAIN)", "in", "breast", "cancer", "patients", "having", "brain", "metastases", "is", "ongoing.", "<tag3>"], "wordsA": ["In", "2016", "we", "initiated", "a", "randomized", "Phase", "3", "confirmatory", "study", "to", "evaluate", "ONZEALD", "TM", "as", "compared", "to", "treatment", "of", "physician", "s", "choice", "(TPC)", "in", "approximately", "350", "adult", "patients", "with", "advanced", "breast", "cancer", "who", "have", "brain", "metastases", "(ATTAIN", "Study)."], "wordsB": ["The", "Phase", "3", "study", "(ATTAIN)", "in", "breast", "cancer", "patients", "having", "brain", "metastases", "is", "ongoing."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p8_s0", "idA": "906709_17_item1_p5_s0", "sentA": "By increasing the number of T regulatory cells (which are specific immune cells in the body that modul ate the immune system and prevent auto-immune disease by maintaining self-tolerance), these pathogenic auto reactive T cells can be reduced and the proper balance of effector and regulatory T cells can be achieved to restore the body's self-tolerance mecha nisms.", "sentB": "A failure of the body's self-tolerance mechanisms is known to result from pathogenic auto reactive T lymphocytes.", "type": 2, "words": ["<tag1>", "By", "increasing", "the", "number", "of", "T", "regulatory", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modul", "ate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mecha", "nisms.", "<tag2>", "A", "failure", "of", "the", "body's", "self-tolerance", "mechanisms", "is", "known", "to", "result", "from", "pathogenic", "auto", "reactive", "T", "lymphocytes.", "<tag3>"], "wordsA": ["By", "increasing", "the", "number", "of", "T", "regulatory", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modul", "ate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mecha", "nisms."], "wordsB": ["A", "failure", "of", "the", "body's", "self-tolerance", "mechanisms", "is", "known", "to", "result", "from", "pathogenic", "auto", "reactive", "T", "lymphocytes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p8_s1", "idA": "906709_17_item1_p5_s0", "sentA": "By increasing the number of T regulatory cells (which are specific immune cells in the body that modul ate the immune system and prevent auto-immune disease by maintaining self-tolerance), these pathogenic auto reactive T cells can be reduced and the proper balance of effector and regulatory T cells can be achieved to restore the body's self-tolerance mecha nisms.", "sentB": "By increasing the number of regulatory T cells (which are specific immune cells in the body that modulate the immune system and prevent autoimmune disease by maintaining self-tolerance), these pathogenic auto reactive T cells can be reduced and the proper balance of effector and regulatory T cells can be achieved to restore the body's self-tolerance mechanisms.", "type": 2, "words": ["<tag1>", "By", "increasing", "the", "number", "of", "T", "regulatory", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modul", "ate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mecha", "nisms.", "<tag2>", "By", "increasing", "the", "number", "of", "regulatory", "T", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "autoimmune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mechanisms.", "<tag3>"], "wordsA": ["By", "increasing", "the", "number", "of", "T", "regulatory", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modul", "ate", "the", "immune", "system", "and", "prevent", "auto-immune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mecha", "nisms."], "wordsB": ["By", "increasing", "the", "number", "of", "regulatory", "T", "cells", "(which", "are", "specific", "immune", "cells", "in", "the", "body", "that", "modulate", "the", "immune", "system", "and", "prevent", "autoimmune", "disease", "by", "maintaining", "self-tolerance),", "these", "pathogenic", "auto", "reactive", "T", "cells", "can", "be", "reduced", "and", "the", "proper", "balance", "of", "effector", "and", "regulatory", "T", "cells", "can", "be", "achieved", "to", "restore", "the", "body's", "self-tolerance", "mechanisms."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p17_s10", "idA": "906709_17_item1_p62_s1", "sentA": "We have also conducted clinical studies for ONZEALD TM in other solid tumor settings.", "sentB": "On July 21, 2017, we were informed by the EMA s Committee for Medicinal Products for Human Use (CHMP) that it had adopted a negative opinion for the conditional marketing authorization application for ONZEALD TM in the European Union.", "type": 2, "words": ["<tag1>", "We", "have", "also", "conducted", "clinical", "studies", "for", "ONZEALD", "TM", "in", "other", "solid", "tumor", "settings.", "<tag2>", "On", "July", "21,", "2017,", "we", "were", "informed", "by", "the", "EMA", "s", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "that", "it", "had", "adopted", "a", "negative", "opinion", "for", "the", "conditional", "marketing", "authorization", "application", "for", "ONZEALD", "TM", "in", "the", "European", "Union.", "<tag3>"], "wordsA": ["We", "have", "also", "conducted", "clinical", "studies", "for", "ONZEALD", "TM", "in", "other", "solid", "tumor", "settings."], "wordsB": ["On", "July", "21,", "2017,", "we", "were", "informed", "by", "the", "EMA", "s", "Committee", "for", "Medicinal", "Products", "for", "Human", "Use", "(CHMP)", "that", "it", "had", "adopted", "a", "negative", "opinion", "for", "the", "conditional", "marketing", "authorization", "application", "for", "ONZEALD", "TM", "in", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p69_s0", "idA": "906709_17_item1_p64_s1", "sentA": "In addition to the clinical study of ONZEALD TM being conducted by us, we have also provided support for f our investigator-initiated Phase 2 studies being conducted for ONZEALD TM .", "sentB": "In addition to the clinical study of ONZEALD TM being conducted by us, we have also provided support for four investigator-initiated Phase 2 studies being conducted for ONZEALD TM .", "type": 2, "words": ["<tag1>", "In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "f", "our", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", ".", "<tag2>", "In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", ".", "<tag3>"], "wordsA": ["In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "f", "our", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", "."], "wordsB": ["In", "addition", "to", "the", "clinical", "study", "of", "ONZEALD", "TM", "being", "conducted", "by", "us,", "we", "have", "also", "provided", "support", "for", "four", "investigator-initiated", "Phase", "2", "studies", "being", "conducted", "for", "ONZEALD", "TM", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p74_s1", "idA": "906709_17_item1_p66_s0", "sentA": "A total of ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "sentB": "More than ten products using our PEGylation technology have received regulatory approval in the U.S. or Europe.", "type": 2, "words": ["<tag1>", "A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag2>", "More", "than", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe.", "<tag3>"], "wordsA": ["A", "total", "of", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "wordsB": ["More", "than", "ten", "products", "using", "our", "PEGylation", "technology", "have", "received", "regulatory", "approval", "in", "the", "U.S.", "or", "Europe."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p149_s0", "idA": "906709_17_item1_p66_s2", "sentA": "These collaborations generally contain one or more elements including a license to our intellectual property rights and manufacturing and supply agreements under which we may receive manufacturing revenue, milestone payments, and/or royalties on commercial sales of drug products.", "sentB": "Coverage, Reimbursement, and Pricing Sales of any products for which we may obtain regulatory approval depends, in part, on the coverage and reimbursement status of those products.", "type": 2, "words": ["<tag1>", "These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products.", "<tag2>", "Coverage,", "Reimbursement,", "and", "Pricing", "Sales", "of", "any", "products", "for", "which", "we", "may", "obtain", "regulatory", "approval", "depends,", "in", "part,", "on", "the", "coverage", "and", "reimbursement", "status", "of", "those", "products.", "<tag3>"], "wordsA": ["These", "collaborations", "generally", "contain", "one", "or", "more", "elements", "including", "a", "license", "to", "our", "intellectual", "property", "rights", "and", "manufacturing", "and", "supply", "agreements", "under", "which", "we", "may", "receive", "manufacturing", "revenue,", "milestone", "payments,", "and/or", "royalties", "on", "commercial", "sales", "of", "drug", "products."], "wordsB": ["Coverage,", "Reimbursement,", "and", "Pricing", "Sales", "of", "any", "products", "for", "which", "we", "may", "obtain", "regulatory", "approval", "depends,", "in", "part,", "on", "the", "coverage", "and", "reimbursement", "status", "of", "those", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p149_s1", "idA": "906709_17_item1_p67_s0", "sentA": "Approved regulatory approval to market and sell product obtained in one or more of the U.S., EU or other countries.", "sentB": "In the U.S., sales of any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors.", "type": 2, "words": ["<tag1>", "Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "EU", "or", "other", "countries.", "<tag2>", "In", "the", "U.S.,", "sales", "of", "any", "products", "for", "which", "we", "may", "receive", "regulatory", "approval", "for", "commercial", "sale", "will", "depend", "in", "part", "on", "the", "availability", "of", "coverage", "and", "reimbursement", "from", "third-party", "payors.", "<tag3>"], "wordsA": ["Approved", "regulatory", "approval", "to", "market", "and", "sell", "product", "obtained", "in", "one", "or", "more", "of", "the", "U.S.,", "EU", "or", "other", "countries."], "wordsB": ["In", "the", "U.S.,", "sales", "of", "any", "products", "for", "which", "we", "may", "receive", "regulatory", "approval", "for", "commercial", "sale", "will", "depend", "in", "part", "on", "the", "availability", "of", "coverage", "and", "reimbursement", "from", "third-party", "payors."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p9_s0", "idA": "906709_17_item1_p6_s0", "sentA": "There is consistent evidence that suboptimal T regulatory cell numbers and their lack of activity play a significant role in a myriad of autoimmune diseases.", "sentB": "There is consistent evidence that suboptimal regulatory T cell numbers and their lack of activity play a significant role in a myriad of autoimmune diseases.", "type": 2, "words": ["<tag1>", "There", "is", "consistent", "evidence", "that", "suboptimal", "T", "regulatory", "cell", "numbers", "and", "their", "lack", "of", "activity", "play", "a", "significant", "role", "in", "a", "myriad", "of", "autoimmune", "diseases.", "<tag2>", "There", "is", "consistent", "evidence", "that", "suboptimal", "regulatory", "T", "cell", "numbers", "and", "their", "lack", "of", "activity", "play", "a", "significant", "role", "in", "a", "myriad", "of", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["There", "is", "consistent", "evidence", "that", "suboptimal", "T", "regulatory", "cell", "numbers", "and", "their", "lack", "of", "activity", "play", "a", "significant", "role", "in", "a", "myriad", "of", "autoimmune", "diseases."], "wordsB": ["There", "is", "consistent", "evidence", "that", "suboptimal", "regulatory", "T", "cell", "numbers", "and", "their", "lack", "of", "activity", "play", "a", "significant", "role", "in", "a", "myriad", "of", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p95_s2", "idA": "906709_17_item1_p70_s0", "sentA": "In February 2012, we sold our rights to receive royalties on future worldwide net sales of CIMZIA effective as of January 1, 2012.", "sentB": "On December 14, 2017, we received notice of termination from Bayer of the Bayer Agreement effective as of January 13, 2018.", "type": 2, "words": ["<tag1>", "In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012.", "<tag2>", "On", "December", "14,", "2017,", "we", "received", "notice", "of", "termination", "from", "Bayer", "of", "the", "Bayer", "Agreement", "effective", "as", "of", "January", "13,", "2018.", "<tag3>"], "wordsA": ["In", "February", "2012,", "we", "sold", "our", "rights", "to", "receive", "royalties", "on", "future", "worldwide", "net", "sales", "of", "CIMZIA", "effective", "as", "of", "January", "1,", "2012."], "wordsB": ["On", "December", "14,", "2017,", "we", "received", "notice", "of", "termination", "from", "Bayer", "of", "the", "Bayer", "Agreement", "effective", "as", "of", "January", "13,", "2018."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p82_s0", "idA": "906709_17_item1_p75_s0", "sentA": "MOVANTIK is an orally-available peripherally-acting mu-opioid antagonist being investigated for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications.", "sentB": "MOVANTIK is an orally-available peripherally-acting mu-opioid antagonist which is a medication for the treatment of opioid-induced constipation (OIC), which is a common side effect of prescription opioid medications.", "type": 2, "words": ["<tag1>", "MOVANTIK", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag2>", "MOVANTIK", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "which", "is", "a", "medication", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications.", "<tag3>"], "wordsA": ["MOVANTIK", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "being", "investigated", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "wordsB": ["MOVANTIK", "is", "an", "orally-available", "peripherally-acting", "mu-opioid", "antagonist", "which", "is", "a", "medication", "for", "the", "treatment", "of", "opioid-induced", "constipation", "(OIC),", "which", "is", "a", "common", "side", "effect", "of", "prescription", "opioid", "medications."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s1", "idA": "906709_17_item1_p78_s0", "sentA": "On September 16, 2014, the FDA approved MOVAN TIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "sentB": "On September 16, 2014, the FDA approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of OIC in adult patients with chronic, non-cancer pain.", "type": 2, "words": ["<tag1>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVAN", "TIK", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag2>", "On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain.", "<tag3>"], "wordsA": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVAN", "TIK", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "wordsB": ["On", "September", "16,", "2014,", "the", "FDA", "approved", "MOVANTIK", "as", "the", "first", "once-daily", "oral", "peripherally-acting", "mu-opioid", "receptor", "antagonist", "(PAMORA)", "medication", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "with", "chronic,", "non-cancer", "pain."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s2", "idA": "906709_17_item1_p78_s1", "sentA": "On December 9, 2014, the European Commission, or EC, granted Marketing Author isation to MOVENTIG (the naloxegol brand name in the European Union) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "sentB": "On December 9, 2014, the European Commission, or EC, granted Marketing Authorisation to MOVENTIG (the naloxegol brand name in the EU) as the first once-daily oral PAMORA to be approved in the EU for the treatment of OIC in adult patients who have had an inadequate response to laxative(s).", "type": 2, "words": ["<tag1>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Author", "isation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag2>", "On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s).", "<tag3>"], "wordsA": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Author", "isation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "European", "Union)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "wordsB": ["On", "December", "9,", "2014,", "the", "European", "Commission,", "or", "EC,", "granted", "Marketing", "Authorisation", "to", "MOVENTIG", "(the", "naloxegol", "brand", "name", "in", "the", "EU)", "as", "the", "first", "once-daily", "oral", "PAMORA", "to", "be", "approved", "in", "the", "EU", "for", "the", "treatment", "of", "OIC", "in", "adult", "patients", "who", "have", "had", "an", "inadequate", "response", "to", "laxative(s)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p86_s0", "idA": "906709_17_item1_p78_s10", "sentA": "Our right to receive royalties (subject to certain adjustments) in any particular country will expire upon the later of (a) a specif ied period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "sentB": "spec ified period of time after the first commercial sale of the product in that country or (b) the expiration of patent rights in that particular country.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "a", "specif", "ied", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag2>", "spec", "ified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "royalties", "(subject", "to", "certain", "adjustments)", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "(a)", "a", "specif", "ied", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "wordsB": ["spec", "ified", "period", "of", "time", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "(b)", "the", "expiration", "of", "patent", "rights", "in", "that", "particular", "country."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s2", "idA": "906709_17_item1_p78_s4", "sentA": "Under the terms of our license agreement with AstraZeneca, AstraZeneca made an initial license payment of $125.0 million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK and MOVANTIK fixed-dose combinati on products.", "sentB": "Under the terms of the Lilly Agreement, we received an initial payment of $150.0 million in September 2017 and are eligible for up to $250.0 million in additional development and regulatory milestones.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combinati", "on", "products.", "<tag2>", "Under", "the", "terms", "of", "the", "Lilly", "Agreement,", "we", "received", "an", "initial", "payment", "of", "$150.0", "million", "in", "September", "2017", "and", "are", "eligible", "for", "up", "to", "$250.0", "million", "in", "additional", "development", "and", "regulatory", "milestones.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combinati", "on", "products."], "wordsB": ["Under", "the", "terms", "of", "the", "Lilly", "Agreement,", "we", "received", "an", "initial", "payment", "of", "$150.0", "million", "in", "September", "2017", "and", "are", "eligible", "for", "up", "to", "$250.0", "million", "in", "additional", "development", "and", "regulatory", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s5", "idA": "906709_17_item1_p78_s4", "sentA": "Under the terms of our license agreement with AstraZeneca, AstraZeneca made an initial license payment of $125.0 million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK and MOVANTIK fixed-dose combinati on products.", "sentB": "Under the terms of our license agreement with AstraZeneca, AstraZeneca made an initial license payment of $125.0 million to us and has responsibility for all activities and bears all costs associated with research, development and commercialization for MOVANTIK and MOVANTIK fixed-dose combination products.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combinati", "on", "products.", "<tag2>", "Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combination", "products.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combinati", "on", "products."], "wordsB": ["Under", "the", "terms", "of", "our", "license", "agreement", "with", "AstraZeneca,", "AstraZeneca", "made", "an", "initial", "license", "payment", "of", "$125.0", "million", "to", "us", "and", "has", "responsibility", "for", "all", "activities", "and", "bears", "all", "costs", "associated", "with", "research,", "development", "and", "commercialization", "for", "MOVANTIK", "and", "MOVANTIK", "fixed-dose", "combination", "products."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s6", "idA": "906709_17_item1_p78_s5", "sentA": "We received milestone payments of $70.0 million and $25.0 million upon the acceptance of regulatory approval applications of MOVANTIK by the FDA and European Medicines Agency (EMA), respectively, in 2013.", "sentB": "We received milestone payments of $70.0 million and $25.0 million upon the acceptance of regulatory approval applications of MOVANTIK by the FDA and the EMA, respectively, in 2013.", "type": 2, "words": ["<tag1>", "We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013.", "<tag2>", "We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "by", "the", "FDA", "and", "the", "EMA,", "respectively,", "in", "2013.", "<tag3>"], "wordsA": ["We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "by", "the", "FDA", "and", "European", "Medicines", "Agency", "(EMA),", "respectively,", "in", "2013."], "wordsB": ["We", "received", "milestone", "payments", "of", "$70.0", "million", "and", "$25.0", "million", "upon", "the", "acceptance", "of", "regulatory", "approval", "applications", "of", "MOVANTIK", "by", "the", "FDA", "and", "the", "EMA,", "respectively,", "in", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s2", "idA": "906709_17_item1_p78_s6", "sentA": "We received an additional developmen tal milestone payment of $35.0 million upon the FDA s approval of MOVANTIK in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK in the U.S. and $40.0 million for MOVENTIG in Germany.", "sentB": "We received an initial payment of $150.0 million in September 2017 and are eligible for up to an additional $250.0 million for development and regulatory milestones.", "type": 2, "words": ["<tag1>", "We", "received", "an", "additional", "developmen", "tal", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany.", "<tag2>", "We", "received", "an", "initial", "payment", "of", "$150.0", "million", "in", "September", "2017", "and", "are", "eligible", "for", "up", "to", "an", "additional", "$250.0", "million", "for", "development", "and", "regulatory", "milestones.", "<tag3>"], "wordsA": ["We", "received", "an", "additional", "developmen", "tal", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany."], "wordsB": ["We", "received", "an", "initial", "payment", "of", "$150.0", "million", "in", "September", "2017", "and", "are", "eligible", "for", "up", "to", "an", "additional", "$250.0", "million", "for", "development", "and", "regulatory", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s7", "idA": "906709_17_item1_p78_s6", "sentA": "We received an additional developmen tal milestone payment of $35.0 million upon the FDA s approval of MOVANTIK in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK in the U.S. and $40.0 million for MOVENTIG in Germany.", "sentB": "We received an additional developmental milestone payment of $35.0 million upon the FDA s approval of MOVANTIK in 2014 and a total of $140.0 million upon commercial launches in 2015, including $100.0 million for MOVANTIK in the U.S. and $40.0 million for MOVENTIG in Germany.", "type": 2, "words": ["<tag1>", "We", "received", "an", "additional", "developmen", "tal", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany.", "<tag2>", "We", "received", "an", "additional", "developmental", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany.", "<tag3>"], "wordsA": ["We", "received", "an", "additional", "developmen", "tal", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany."], "wordsB": ["We", "received", "an", "additional", "developmental", "milestone", "payment", "of", "$35.0", "million", "upon", "the", "FDA", "s", "approval", "of", "MOVANTIK", "in", "2014", "and", "a", "total", "of", "$140.0", "million", "upon", "commercial", "launches", "in", "2015,", "including", "$100.0", "million", "for", "MOVANTIK", "in", "the", "U.S.", "and", "$40.0", "million", "for", "MOVENTIG", "in", "Germany."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s8", "idA": "906709_17_item1_p78_s7", "sentA": "We are also e ntitled to up to $375.0 million in sales milestones for MOVANTIK if the program achieves certain annual commercial sales levels.", "sentB": "We are also entitled to up to $375.0 million in sales milestones for MOVANTIK if the program achieves certain annual commercial sales levels.", "type": 2, "words": ["<tag1>", "We", "are", "also", "e", "ntitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag2>", "We", "are", "also", "entitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels.", "<tag3>"], "wordsA": ["We", "are", "also", "e", "ntitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "wordsB": ["We", "are", "also", "entitled", "to", "up", "to", "$375.0", "million", "in", "sales", "milestones", "for", "MOVANTIK", "if", "the", "program", "achieves", "certain", "annual", "commercial", "sales", "levels."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p84_s10", "idA": "906709_17_item1_p78_s9", "sentA": "For both MOVANTIK and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sa les in the U.S. and 18% of net sales in the EU and rest of world, varying by country of sale and level of annual net sales.", "sentB": "For both MOVANTIK and the fixed-dose combination products, we are also entitled to significant double-digit royalty payments starting at 20% of net sales in the U.S. and 18% of net sales in the EU and rest of world, varying by country of sale and level of annual net sales.", "type": 2, "words": ["<tag1>", "For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sa", "les", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag2>", "For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales.", "<tag3>"], "wordsA": ["For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sa", "les", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "wordsB": ["For", "both", "MOVANTIK", "and", "the", "fixed-dose", "combination", "products,", "we", "are", "also", "entitled", "to", "significant", "double-digit", "royalty", "payments", "starting", "at", "20%", "of", "net", "sales", "in", "the", "U.S.", "and", "18%", "of", "net", "sales", "in", "the", "EU", "and", "rest", "of", "world,", "varying", "by", "country", "of", "sale", "and", "level", "of", "annual", "net", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p86_s1", "idA": "906709_17_item1_p79_s0", "sentA": "AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK fixed-dose combinati on product and has the right to develop multiple products which combine MOVANTIK with opioids.", "sentB": "AstraZeneca has agreed to use commercially reasonable efforts to develop one MOVANTIK fixed-dose combina tion product and has the right to develop multiple products which combine MOVANTIK with opioids.", "type": 2, "words": ["<tag1>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "fixed-dose", "combinati", "on", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "with", "opioids.", "<tag2>", "AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "fixed-dose", "combina", "tion", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "with", "opioids.", "<tag3>"], "wordsA": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "fixed-dose", "combinati", "on", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "with", "opioids."], "wordsB": ["AstraZeneca", "has", "agreed", "to", "use", "commercially", "reasonable", "efforts", "to", "develop", "one", "MOVANTIK", "fixed-dose", "combina", "tion", "product", "and", "has", "the", "right", "to", "develop", "multiple", "products", "which", "combine", "MOVANTIK", "with", "opioids."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p88_s0", "idA": "906709_17_item1_p81_s0", "sentA": "ADYNOVATE (previously referred to as BAX 855) and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of Baxalta Incorporated In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement with certain subsidiaries of Baxalta, formerly Baxter before the separation of Baxalta from Baxter in July 2015, to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "sentB": "ADYNOVATE (previously referred to as BAX 855) and Long-Acting Therapies for Hemophilia A, Agreement with Subsidiaries of Baxalta Incorporated In September 2005, we entered into an exclusive research, development, license, manufacturing and supply agreement (Baxalta License Agreement) with certain subsidiaries of Baxalta (which has been acquired by Shire plc), formerly Baxter before the separation of Baxalta from Baxter in July 2015, to develop products with an extended half-life for the treatment and prophylaxis of Hemophilia A patients using our proprietary PEGylation technology.", "type": 2, "words": ["<tag1>", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "Incorporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag2>", "ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "Incorporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "(Baxalta", "License", "Agreement)", "with", "certain", "subsidiaries", "of", "Baxalta", "(which", "has", "been", "acquired", "by", "Shire", "plc),", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology.", "<tag3>"], "wordsA": ["ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "Incorporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "with", "certain", "subsidiaries", "of", "Baxalta,", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "wordsB": ["ADYNOVATE", "(previously", "referred", "to", "as", "BAX", "855)", "and", "Long-Acting", "Therapies", "for", "Hemophilia", "A,", "Agreement", "with", "Subsidiaries", "of", "Baxalta", "Incorporated", "In", "September", "2005,", "we", "entered", "into", "an", "exclusive", "research,", "development,", "license,", "manufacturing", "and", "supply", "agreement", "(Baxalta", "License", "Agreement)", "with", "certain", "subsidiaries", "of", "Baxalta", "(which", "has", "been", "acquired", "by", "Shire", "plc),", "formerly", "Baxter", "before", "the", "separation", "of", "Baxalta", "from", "Baxter", "in", "July", "2015,", "to", "develop", "products", "with", "an", "extended", "half-life", "for", "the", "treatment", "and", "prophylaxis", "of", "Hemophilia", "A", "patients", "using", "our", "proprietary", "PEGylation", "technology."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p46_s0", "idA": "906709_17_item1_p83_s2", "sentA": "Our right to receive these royalties in any particular country will expire upon the later of ten years after the first commercial sale of the product in that country or the expiration of patent rights in certain designated countries or in that particular country.", "sentB": "Neither party will develop any Competing Combination, whether alone or in collaboration with any third party, during a limited exclusivity period from the closing date under the BMS Collaboration Agreement until the later of (i) the first commercial sale of NKTR-214 or (ii) the third anniversary of the closing date, but each party may develop a Competing Combination on its own (but not in collaboration with any third party) during the three years after the end of the foregoing limited exclusivity period.", "type": 2, "words": ["<tag1>", "Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country.", "<tag2>", "Neither", "party", "will", "develop", "any", "Competing", "Combination,", "whether", "alone", "or", "in", "collaboration", "with", "any", "third", "party,", "during", "a", "limited", "exclusivity", "period", "from", "the", "closing", "date", "under", "the", "BMS", "Collaboration", "Agreement", "until", "the", "later", "of", "(i)", "the", "first", "commercial", "sale", "of", "NKTR-214", "or", "(ii)", "the", "third", "anniversary", "of", "the", "closing", "date,", "but", "each", "party", "may", "develop", "a", "Competing", "Combination", "on", "its", "own", "(but", "not", "in", "collaboration", "with", "any", "third", "party)", "during", "the", "three", "years", "after", "the", "end", "of", "the", "foregoing", "limited", "exclusivity", "period.", "<tag3>"], "wordsA": ["Our", "right", "to", "receive", "these", "royalties", "in", "any", "particular", "country", "will", "expire", "upon", "the", "later", "of", "ten", "years", "after", "the", "first", "commercial", "sale", "of", "the", "product", "in", "that", "country", "or", "the", "expiration", "of", "patent", "rights", "in", "certain", "designated", "countries", "or", "in", "that", "particular", "country."], "wordsB": ["Neither", "party", "will", "develop", "any", "Competing", "Combination,", "whether", "alone", "or", "in", "collaboration", "with", "any", "third", "party,", "during", "a", "limited", "exclusivity", "period", "from", "the", "closing", "date", "under", "the", "BMS", "Collaboration", "Agreement", "until", "the", "later", "of", "(i)", "the", "first", "commercial", "sale", "of", "NKTR-214", "or", "(ii)", "the", "third", "anniversary", "of", "the", "closing", "date,", "but", "each", "party", "may", "develop", "a", "Competing", "Combination", "on", "its", "own", "(but", "not", "in", "collaboration", "with", "any", "third", "party)", "during", "the", "three", "years", "after", "the", "end", "of", "the", "foregoing", "limited", "exclusivity", "period."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s3", "idA": "906709_17_item1_p84_s1", "sentA": "In January 2013, Baxalta announced the top level results from this Phase 1 clinical study.", "sentB": "We will be responsible for completing Phase 1 clinical development and certain drug product development and supply activities.", "type": 2, "words": ["<tag1>", "In", "January", "2013,", "Baxalta", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study.", "<tag2>", "We", "will", "be", "responsible", "for", "completing", "Phase", "1", "clinical", "development", "and", "certain", "drug", "product", "development", "and", "supply", "activities.", "<tag3>"], "wordsA": ["In", "January", "2013,", "Baxalta", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study."], "wordsB": ["We", "will", "be", "responsible", "for", "completing", "Phase", "1", "clinical", "development", "and", "certain", "drug", "product", "development", "and", "supply", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s3", "idA": "906709_17_item1_p84_s1", "sentA": "In January 2013, Baxalta announced the top level results from this Phase 1 clinical study.", "sentB": "We will be responsible for completing Phase 1 clinical development and certain drug product development and supply activities.", "type": 2, "words": ["<tag1>", "In", "January", "2013,", "Baxalta", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study.", "<tag2>", "We", "will", "be", "responsible", "for", "completing", "Phase", "1", "clinical", "development", "and", "certain", "drug", "product", "development", "and", "supply", "activities.", "<tag3>"], "wordsA": ["In", "January", "2013,", "Baxalta", "announced", "the", "top", "level", "results", "from", "this", "Phase", "1", "clinical", "study."], "wordsB": ["We", "will", "be", "responsible", "for", "completing", "Phase", "1", "clinical", "development", "and", "certain", "drug", "product", "development", "and", "supply", "activities."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s9", "idA": "906709_17_item1_p84_s2", "sentA": "This study demonstrated that the half-life (measuring the duration of activity of the drug in the body) of ADYNOVATE was approximately 1.5-fold higher compared to ADVATE .", "sentB": "The study demonstrated that NKTR-181 had a favorable safety profile and was well tolerated.", "type": 2, "words": ["<tag1>", "This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", ".", "<tag2>", "The", "study", "demonstrated", "that", "NKTR-181", "had", "a", "favorable", "safety", "profile", "and", "was", "well", "tolerated.", "<tag3>"], "wordsA": ["This", "study", "demonstrated", "that", "the", "half-life", "(measuring", "the", "duration", "of", "activity", "of", "the", "drug", "in", "the", "body)", "of", "ADYNOVATE", "was", "approximately", "1.5-fold", "higher", "compared", "to", "ADVATE", "."], "wordsB": ["The", "study", "demonstrated", "that", "NKTR-181", "had", "a", "favorable", "safety", "profile", "and", "was", "well", "tolerated."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p22_s10", "idA": "906709_17_item1_p85_s4", "sentA": "In November 2015, ADYNOVATE was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE in the U.S.", "sentB": "In September 2017, ADYNOVATE was approved in Colombia for use in children and adults with Hemophilia A I n January 2018, ADYNOVATE (marketed as ADYNOVI) was approved in the European Union for on-demand and prophylactic use in patients 12 years and older with Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S.", "<tag2>", "In", "September", "2017,", "ADYNOVATE", "was", "approved", "in", "Colombia", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A", "I", "n", "January", "2018,", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "the", "European", "Union", "for", "on-demand", "and", "prophylactic", "use", "in", "patients", "12", "years", "and", "older", "with", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S."], "wordsB": ["In", "September", "2017,", "ADYNOVATE", "was", "approved", "in", "Colombia", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A", "I", "n", "January", "2018,", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "the", "European", "Union", "for", "on-demand", "and", "prophylactic", "use", "in", "patients", "12", "years", "and", "older", "with", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s10", "idA": "906709_17_item1_p85_s4", "sentA": "In November 2015, ADYNOVATE was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE in the U.S.", "sentB": "In January 2018 ADYNOVATE (marketed as ADYNOVI) was approved in the European Union for on-demand and prophylactic use in patients 12 years and older with Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S.", "<tag2>", "In", "January", "2018", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "the", "European", "Union", "for", "on-demand", "and", "prophylactic", "use", "in", "patients", "12", "years", "and", "older", "with", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S."], "wordsB": ["In", "January", "2018", "ADYNOVATE", "(marketed", "as", "ADYNOVI)", "was", "approved", "in", "the", "European", "Union", "for", "on-demand", "and", "prophylactic", "use", "in", "patients", "12", "years", "and", "older", "with", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p90_s9", "idA": "906709_17_item1_p85_s4", "sentA": "In November 2015, ADYNOVATE was approved by the FDA for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. On November 30, 2015, Baxalta announced that it had initiated sales of ADYNOVATE in the U.S.", "sentB": "In September 2017, ADYNOVATE was approved in Colombia for use in children and adults with Hemophilia A.", "type": 2, "words": ["<tag1>", "In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S.", "<tag2>", "In", "September", "2017,", "ADYNOVATE", "was", "approved", "in", "Colombia", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A.", "<tag3>"], "wordsA": ["In", "November", "2015,", "ADYNOVATE", "was", "approved", "by", "the", "FDA", "for", "use", "in", "adults", "and", "adolescents,", "aged", "12", "years", "and", "older,", "who", "have", "Hemophilia", "A.", "On", "November", "30,", "2015,", "Baxalta", "announced", "that", "it", "had", "initiated", "sales", "of", "ADYNOVATE", "in", "the", "U.S."], "wordsB": ["In", "September", "2017,", "ADYNOVATE", "was", "approved", "in", "Colombia", "for", "use", "in", "children", "and", "adults", "with", "Hemophilia", "A."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p62_s7", "idA": "906709_17_item1_p86_s3", "sentA": "ADYNOVATE met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE .", "sentB": "On March 20, 2017, we announced that NKTR-181 met its primary and secondary endpoints in the SUMMIT-07 Phase 3 efficacy Study.", "type": 2, "words": ["<tag1>", "ADYNOVATE", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", ".", "<tag2>", "On", "March", "20,", "2017,", "we", "announced", "that", "NKTR-181", "met", "its", "primary", "and", "secondary", "endpoints", "in", "the", "SUMMIT-07", "Phase", "3", "efficacy", "Study.", "<tag3>"], "wordsA": ["ADYNOVATE", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "."], "wordsB": ["On", "March", "20,", "2017,", "we", "announced", "that", "NKTR-181", "met", "its", "primary", "and", "secondary", "endpoints", "in", "the", "SUMMIT-07", "Phase", "3", "efficacy", "Study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p99_s1", "idA": "906709_17_item1_p86_s3", "sentA": "ADYNOVATE met its primary endpoint in the study, as no patients developed inhibitory antibodies to ADYNOVATE .", "sentB": "In August 2017, Opthotech announced that the third Fovista Phase 3 trial also failed to meet its primary endpoint.", "type": 2, "words": ["<tag1>", "ADYNOVATE", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", ".", "<tag2>", "In", "August", "2017,", "Opthotech", "announced", "that", "the", "third", "Fovista", "Phase", "3", "trial", "also", "failed", "to", "meet", "its", "primary", "endpoint.", "<tag3>"], "wordsA": ["ADYNOVATE", "met", "its", "primary", "endpoint", "in", "the", "study,", "as", "no", "patients", "developed", "inhibitory", "antibodies", "to", "ADYNOVATE", "."], "wordsB": ["In", "August", "2017,", "Opthotech", "announced", "that", "the", "third", "Fovista", "Phase", "3", "trial", "also", "failed", "to", "meet", "its", "primary", "endpoint."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p93_s0", "idA": "906709_17_item1_p89_s0", "sentA": "In 2014, according to the Evaluate Group, sales of FVIII replacement products exceeded $6 billion globally.", "sentB": "In 2014, according to the Evaluate Group, sales of FVIII replacement products exceeded $6.0 billion globally.", "type": 2, "words": ["<tag1>", "In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6", "billion", "globally.", "<tag2>", "In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6.0", "billion", "globally.", "<tag3>"], "wordsA": ["In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6", "billion", "globally."], "wordsB": ["In", "2014,", "according", "to", "the", "Evaluate", "Group,", "sales", "of", "FVIII", "replacement", "products", "exceeded", "$6.0", "billion", "globally."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s0", "idA": "906709_17_item1_p8_s0", "sentA": "NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of auto-immune diseases.", "sentB": "NKTR-358 is being developed as a once or twice monthly self-administered injection for a number of autoimmune diseases.", "type": 2, "words": ["<tag1>", "NKTR-358", "is", "being", "developed", "as", "a", "once", "or", "twice", "monthly", "self-administered", "injection", "for", "a", "number", "of", "auto-immune", "diseases.", "<tag2>", "NKTR-358", "is", "being", "developed", "as", "a", "once", "or", "twice", "monthly", "self-administered", "injection", "for", "a", "number", "of", "autoimmune", "diseases.", "<tag3>"], "wordsA": ["NKTR-358", "is", "being", "developed", "as", "a", "once", "or", "twice", "monthly", "self-administered", "injection", "for", "a", "number", "of", "auto-immune", "diseases."], "wordsB": ["NKTR-358", "is", "being", "developed", "as", "a", "once", "or", "twice", "monthly", "self-administered", "injection", "for", "a", "number", "of", "autoimmune", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p94_s0", "idA": "906709_17_item1_p90_s0", "sentA": "Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly called NKTR-061) for the treatment of gram-negative pneumonias.", "sentB": "In August 2007, we entered into a co-development, license and co-promotion agreement (Bayer Agreement) with Bayer Healthcare LLC (Bayer) to develop a specially-formulated Amikacin (BAY41-6551, Amikacin Inhale, formerly called NKTR-061) for the treatment of gram-negative pneumonias.", "type": 2, "words": ["<tag1>", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)", "for", "the", "treatment", "of", "gram-negative", "pneumonias.", "<tag2>", "In", "August", "2007,", "we", "entered", "into", "a", "co-development,", "license", "and", "co-promotion", "agreement", "(Bayer", "Agreement)", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)", "for", "the", "treatment", "of", "gram-negative", "pneumonias.", "<tag3>"], "wordsA": ["Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)", "for", "the", "treatment", "of", "gram-negative", "pneumonias."], "wordsB": ["In", "August", "2007,", "we", "entered", "into", "a", "co-development,", "license", "and", "co-promotion", "agreement", "(Bayer", "Agreement)", "with", "Bayer", "Healthcare", "LLC", "(Bayer)", "to", "develop", "a", "specially-formulated", "Amikacin", "(BAY41-6551,", "Amikacin", "Inhale,", "formerly", "called", "NKTR-061)", "for", "the", "treatment", "of", "gram-negative", "pneumonias."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p94_s1", "idA": "906709_17_item1_p90_s1", "sentA": "Under the terms of the agreement, Bayer is responsible for most future clinical development and commercialization costs, all activities to support worldwide regulatory filings, approvals and related activities, further development of formulated Amikacin and final product packaging for Amikacin Inhale.", "sentB": "Under the terms of the agreement, Bayer was responsible for most future clinical development and commercialization costs, all activities to support worldwide regulatory filings, approvals and related activities, further development of formulated Amikacin and final product packaging for Amikacin Inhale.", "type": 2, "words": ["<tag1>", "Under", "the", "terms", "of", "the", "agreement,", "Bayer", "is", "responsible", "for", "most", "future", "clinical", "development", "and", "commercialization", "costs,", "all", "activities", "to", "support", "worldwide", "regulatory", "filings,", "approvals", "and", "related", "activities,", "further", "development", "of", "formulated", "Amikacin", "and", "final", "product", "packaging", "for", "Amikacin", "Inhale.", "<tag2>", "Under", "the", "terms", "of", "the", "agreement,", "Bayer", "was", "responsible", "for", "most", "future", "clinical", "development", "and", "commercialization", "costs,", "all", "activities", "to", "support", "worldwide", "regulatory", "filings,", "approvals", "and", "related", "activities,", "further", "development", "of", "formulated", "Amikacin", "and", "final", "product", "packaging", "for", "Amikacin", "Inhale.", "<tag3>"], "wordsA": ["Under", "the", "terms", "of", "the", "agreement,", "Bayer", "is", "responsible", "for", "most", "future", "clinical", "development", "and", "commercialization", "costs,", "all", "activities", "to", "support", "worldwide", "regulatory", "filings,", "approvals", "and", "related", "activities,", "further", "development", "of", "formulated", "Amikacin", "and", "final", "product", "packaging", "for", "Amikacin", "Inhale."], "wordsB": ["Under", "the", "terms", "of", "the", "agreement,", "Bayer", "was", "responsible", "for", "most", "future", "clinical", "development", "and", "commercialization", "costs,", "all", "activities", "to", "support", "worldwide", "regulatory", "filings,", "approvals", "and", "related", "activities,", "further", "development", "of", "formulated", "Amikacin", "and", "final", "product", "packaging", "for", "Amikacin", "Inhale."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p94_s2", "idA": "906709_17_item1_p90_s2", "sentA": "We are responsible for all future development, manufacturing and supply of the nebulizer device for clinical and commercial use.", "sentB": "We were responsible for all future development, manufacturing and supply of the nebulizer device for clinical and commercial use.", "type": 2, "words": ["<tag1>", "We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use.", "<tag2>", "We", "were", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use.", "<tag3>"], "wordsA": ["We", "are", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use."], "wordsB": ["We", "were", "responsible", "for", "all", "future", "development,", "manufacturing", "and", "supply", "of", "the", "nebulizer", "device", "for", "clinical", "and", "commercial", "use."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p105_s5", "idA": "906709_17_item1_p90_s4", "sentA": "We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "sentB": "Pursuant to this agreement, Allergan paid Nektar $15.0 million in December 2017 in exchange for relief of any claims related to our share of payments received by MAP from Allergan as well as a specified development milestone payment due to Nektar.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag2>", "Pursuant", "to", "this", "agreement,", "Allergan", "paid", "Nektar", "$15.0", "million", "in", "December", "2017", "in", "exchange", "for", "relief", "of", "any", "claims", "related", "to", "our", "share", "of", "payments", "received", "by", "MAP", "from", "Allergan", "as", "well", "as", "a", "specified", "development", "milestone", "payment", "due", "to", "Nektar.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "wordsB": ["Pursuant", "to", "this", "agreement,", "Allergan", "paid", "Nektar", "$15.0", "million", "in", "December", "2017", "in", "exchange", "for", "relief", "of", "any", "claims", "related", "to", "our", "share", "of", "payments", "received", "by", "MAP", "from", "Allergan", "as", "well", "as", "a", "specified", "development", "milestone", "payment", "due", "to", "Nektar."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p11_s6", "idA": "906709_17_item1_p90_s4", "sentA": "We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "sentB": "We are eligible for tiered royalties on global sales up to the low twenties that escalate based upon our level of our contribution to Phase 3 development costs and the level of global product annual sales.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag2>", "We", "are", "eligible", "for", "tiered", "royalties", "on", "global", "sales", "up", "to", "the", "low", "twenties", "that", "escalate", "based", "upon", "our", "level", "of", "our", "contribution", "to", "Phase", "3", "development", "costs", "and", "the", "level", "of", "global", "product", "annual", "sales.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "wordsB": ["We", "are", "eligible", "for", "tiered", "royalties", "on", "global", "sales", "up", "to", "the", "low", "twenties", "that", "escalate", "based", "upon", "our", "level", "of", "our", "contribution", "to", "Phase", "3", "development", "costs", "and", "the", "level", "of", "global", "product", "annual", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p1_s10", "idA": "906709_17_item1_p90_s4", "sentA": "We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "sentB": "We are eligible to receive additional cash payments of a total of up to $1.43 billion upon achievement of certain development and regulatory milestones and a total of up to $350.0 million upon achievement of certain sales milestones.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag2>", "We", "are", "eligible", "to", "receive", "additional", "cash", "payments", "of", "a", "total", "of", "up", "to", "$1.43", "billion", "upon", "achievement", "of", "certain", "development", "and", "regulatory", "milestones", "and", "a", "total", "of", "up", "to", "$350.0", "million", "upon", "achievement", "of", "certain", "sales", "milestones.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "wordsB": ["We", "are", "eligible", "to", "receive", "additional", "cash", "payments", "of", "a", "total", "of", "up", "to", "$1.43", "billion", "upon", "achievement", "of", "certain", "development", "and", "regulatory", "milestones", "and", "a", "total", "of", "up", "to", "$350.0", "million", "upon", "achievement", "of", "certain", "sales", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p45_s6", "idA": "906709_17_item1_p90_s4", "sentA": "We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "sentB": "We are eligible to receive additional cash payments of a total of up to $1.43 billion upon achievement of certain development and regulatory milestones and a total of up to $350.0 million upon achievement of certain sales milestones.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag2>", "We", "are", "eligible", "to", "receive", "additional", "cash", "payments", "of", "a", "total", "of", "up", "to", "$1.43", "billion", "upon", "achievement", "of", "certain", "development", "and", "regulatory", "milestones", "and", "a", "total", "of", "up", "to", "$350.0", "million", "upon", "achievement", "of", "certain", "sales", "milestones.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "wordsB": ["We", "are", "eligible", "to", "receive", "additional", "cash", "payments", "of", "a", "total", "of", "up", "to", "$1.43", "billion", "upon", "achievement", "of", "certain", "development", "and", "regulatory", "milestones", "and", "a", "total", "of", "up", "to", "$350.0", "million", "upon", "achievement", "of", "certain", "sales", "milestones."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p56_s6", "idA": "906709_17_item1_p90_s4", "sentA": "We are entitled to up to $50.0 million in development milestone payments as well as sales milestone payments upon achievement of certain annual sales targets.", "sentB": "We are eligible to receive up to double-digit sales royalty rates that escalate based upon our contribution to Phase 3 development cost and the level of global product annual sales.", "type": 2, "words": ["<tag1>", "We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets.", "<tag2>", "We", "are", "eligible", "to", "receive", "up", "to", "double-digit", "sales", "royalty", "rates", "that", "escalate", "based", "upon", "our", "contribution", "to", "Phase", "3", "development", "cost", "and", "the", "level", "of", "global", "product", "annual", "sales.", "<tag3>"], "wordsA": ["We", "are", "entitled", "to", "up", "to", "$50.0", "million", "in", "development", "milestone", "payments", "as", "well", "as", "sales", "milestone", "payments", "upon", "achievement", "of", "certain", "annual", "sales", "targets."], "wordsB": ["We", "are", "eligible", "to", "receive", "up", "to", "double-digit", "sales", "royalty", "rates", "that", "escalate", "based", "upon", "our", "contribution", "to", "Phase", "3", "development", "cost", "and", "the", "level", "of", "global", "product", "annual", "sales."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p98_s2", "idA": "906709_17_item1_p95_s1", "sentA": "On December 31, 2008, we assigned the agreement to Novartis Pharma AG in connection with the completion of the pulmonary asset sale transaction.", "sentB": "On April 5, 2017, an abstract with data from the RESPIRE 2 trial was published by the American Thoracic Society in connection with the American Thoracic Society 2017 International Conference.", "type": 2, "words": ["<tag1>", "On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction.", "<tag2>", "On", "April", "5,", "2017,", "an", "abstract", "with", "data", "from", "the", "RESPIRE", "2", "trial", "was", "published", "by", "the", "American", "Thoracic", "Society", "in", "connection", "with", "the", "American", "Thoracic", "Society", "2017", "International", "Conference.", "<tag3>"], "wordsA": ["On", "December", "31,", "2008,", "we", "assigned", "the", "agreement", "to", "Novartis", "Pharma", "AG", "in", "connection", "with", "the", "completion", "of", "the", "pulmonary", "asset", "sale", "transaction."], "wordsB": ["On", "April", "5,", "2017,", "an", "abstract", "with", "data", "from", "the", "RESPIRE", "2", "trial", "was", "published", "by", "the", "American", "Thoracic", "Society", "in", "connection", "with", "the", "American", "Thoracic", "Society", "2017", "International", "Conference."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p96_s2", "idA": "906709_17_item1_p96_s0", "sentA": "royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer Schering.", "sentB": "However, we retained our economic interest in the future potential net sales royalties if Cipro DPI is approved by health authorities and is successfully commercialized by Bayer Schering.", "type": 2, "words": ["<tag1>", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer", "Schering.", "<tag2>", "However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer", "Schering.", "<tag3>"], "wordsA": ["royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer", "Schering."], "wordsB": ["However,", "we", "retained", "our", "economic", "interest", "in", "the", "future", "potential", "net", "sales", "royalties", "if", "Cipro", "DPI", "is", "approved", "by", "health", "authorities", "and", "is", "successfully", "commercialized", "by", "Bayer", "Schering."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p23_s4", "idA": "906709_17_item1_p97_s0", "sentA": "Cipro DPI has completed Phase 2 clinical development for the treatment of chronic lung infections.", "sentB": "On November 16, 2017, the Antimicrobial Drugs Advisory Committee of the FDA voted not to recommend Cipro DPI to be approved for the treatment of non-cystic fibrosis.", "type": 2, "words": ["<tag1>", "Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections.", "<tag2>", "On", "November", "16,", "2017,", "the", "Antimicrobial", "Drugs", "Advisory", "Committee", "of", "the", "FDA", "voted", "not", "to", "recommend", "Cipro", "DPI", "to", "be", "approved", "for", "the", "treatment", "of", "non-cystic", "fibrosis.", "<tag3>"], "wordsA": ["Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections."], "wordsB": ["On", "November", "16,", "2017,", "the", "Antimicrobial", "Drugs", "Advisory", "Committee", "of", "the", "FDA", "voted", "not", "to", "recommend", "Cipro", "DPI", "to", "be", "approved", "for", "the", "treatment", "of", "non-cystic", "fibrosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p98_s4", "idA": "906709_17_item1_p97_s0", "sentA": "Cipro DPI has completed Phase 2 clinical development for the treatment of chronic lung infections.", "sentB": "On November 16, 2017, the Antimicrobial Drugs Advisory Committee of the FDA voted not to recommend Cipro DPI to be approved for the treatment of non-cystic fibrosis.", "type": 2, "words": ["<tag1>", "Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections.", "<tag2>", "On", "November", "16,", "2017,", "the", "Antimicrobial", "Drugs", "Advisory", "Committee", "of", "the", "FDA", "voted", "not", "to", "recommend", "Cipro", "DPI", "to", "be", "approved", "for", "the", "treatment", "of", "non-cystic", "fibrosis.", "<tag3>"], "wordsA": ["Cipro", "DPI", "has", "completed", "Phase", "2", "clinical", "development", "for", "the", "treatment", "of", "chronic", "lung", "infections."], "wordsB": ["On", "November", "16,", "2017,", "the", "Antimicrobial", "Drugs", "Advisory", "Committee", "of", "the", "FDA", "voted", "not", "to", "recommend", "Cipro", "DPI", "to", "be", "approved", "for", "the", "treatment", "of", "non-cystic", "fibrosis."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p97_s0", "idA": "906709_17_item1_p97_s1", "sentA": "In August 2012, Bayer Scherin g initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis.", "sentB": "In August 2012, Bayer Schering initiated a Phase 3 clinical development program which it calls RESPIRE for Cipro DPI in patients with non-cystic fibrosis bronchiectasis (NCFB).", "type": 2, "words": ["<tag1>", "In", "August", "2012,", "Bayer", "Scherin", "g", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis.", "<tag2>", "In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis", "(NCFB).", "<tag3>"], "wordsA": ["In", "August", "2012,", "Bayer", "Scherin", "g", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis."], "wordsB": ["In", "August", "2012,", "Bayer", "Schering", "initiated", "a", "Phase", "3", "clinical", "development", "program", "which", "it", "calls", "RESPIRE", "for", "Cipro", "DPI", "in", "patients", "with", "non-cystic", "fibrosis", "bronchiectasis", "(NCFB)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p97_s1", "idA": "906709_17_item1_p98_s0", "sentA": "In patients with bronchiectasis, the bronchial tubes are enlarged, allowing mucus to pool and making the area prone to infection.", "sentB": "In these patients with NCFB, the bronchial tubes are enlarged, allowing mucus to pool and making the area prone to infection.", "type": 2, "words": ["<tag1>", "In", "patients", "with", "bronchiectasis,", "the", "bronchial", "tubes", "are", "enlarged,", "allowing", "mucus", "to", "pool", "and", "making", "the", "area", "prone", "to", "infection.", "<tag2>", "In", "these", "patients", "with", "NCFB,", "the", "bronchial", "tubes", "are", "enlarged,", "allowing", "mucus", "to", "pool", "and", "making", "the", "area", "prone", "to", "infection.", "<tag3>"], "wordsA": ["In", "patients", "with", "bronchiectasis,", "the", "bronchial", "tubes", "are", "enlarged,", "allowing", "mucus", "to", "pool", "and", "making", "the", "area", "prone", "to", "infection."], "wordsB": ["In", "these", "patients", "with", "NCFB,", "the", "bronchial", "tubes", "are", "enlarged,", "allowing", "mucus", "to", "pool", "and", "making", "the", "area", "prone", "to", "infection."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p23_s3", "idA": "906709_17_item1_p99_s1", "sentA": "The second Phase 3 trial (RESPIRE 2) completed recruitment in September 2016 and Bayer Schering has not yet reported the results from RESPIRE 2.", "sentB": "A pooled analysis of the primary efficacy results from RESPIRE 1 and RESPIRE 2 is positive and the data from both RESPIRE 1 and RESPIRE 2 indicate that Cipro DPI has a positive safety profile.", "type": 2, "words": ["<tag1>", "The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2.", "<tag2>", "A", "pooled", "analysis", "of", "the", "primary", "efficacy", "results", "from", "RESPIRE", "1", "and", "RESPIRE", "2", "is", "positive", "and", "the", "data", "from", "both", "RESPIRE", "1", "and", "RESPIRE", "2", "indicate", "that", "Cipro", "DPI", "has", "a", "positive", "safety", "profile.", "<tag3>"], "wordsA": ["The", "second", "Phase", "3", "trial", "(RESPIRE", "2)", "completed", "recruitment", "in", "September", "2016", "and", "Bayer", "Schering", "has", "not", "yet", "reported", "the", "results", "from", "RESPIRE", "2."], "wordsB": ["A", "pooled", "analysis", "of", "the", "primary", "efficacy", "results", "from", "RESPIRE", "1", "and", "RESPIRE", "2", "is", "positive", "and", "the", "data", "from", "both", "RESPIRE", "1", "and", "RESPIRE", "2", "indicate", "that", "Cipro", "DPI", "has", "a", "positive", "safety", "profile."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s0", "idA": "906709_17_item1_p9_s0", "sentA": "Pain - NKTR-181 NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "sentB": "Pain - NKTR-181 NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions.", "type": 2, "words": ["<tag1>", "Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag2>", "Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions.", "<tag3>"], "wordsA": ["Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "wordsB": ["Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s1", "idA": "906709_17_item1_p9_s0", "sentA": "Pain - NKTR-181 NKTR-181 is a novel mu-opioid analgesic drug candidate for chronic pain conditions and is currently in Phase 3 clinical development.", "sentB": "NKTR-181 is currently in Phase 3 clinical development, which we call the SUMMIT Phase 3 program, which includes the SUMMIT-07 efficacy study, a human abuse potential (HAP) study, and the SUMMIT-LTS long-term safety study.", "type": 2, "words": ["<tag1>", "Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development.", "<tag2>", "NKTR-181", "is", "currently", "in", "Phase", "3", "clinical", "development,", "which", "we", "call", "the", "SUMMIT", "Phase", "3", "program,", "which", "includes", "the", "SUMMIT-07", "efficacy", "study,", "a", "human", "abuse", "potential", "(HAP)", "study,", "and", "the", "SUMMIT-LTS", "long-term", "safety", "study.", "<tag3>"], "wordsA": ["Pain", "-", "NKTR-181", "NKTR-181", "is", "a", "novel", "mu-opioid", "analgesic", "drug", "candidate", "for", "chronic", "pain", "conditions", "and", "is", "currently", "in", "Phase", "3", "clinical", "development."], "wordsB": ["NKTR-181", "is", "currently", "in", "Phase", "3", "clinical", "development,", "which", "we", "call", "the", "SUMMIT", "Phase", "3", "program,", "which", "includes", "the", "SUMMIT-07", "efficacy", "study,", "a", "human", "abuse", "potential", "(HAP)", "study,", "and", "the", "SUMMIT-LTS", "long-term", "safety", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p14_s3", "idA": "906709_17_item1_p9_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in late 2016.", "sentB": "We enrolled the first patient in the first SUMMIT-07 study in February 2015, and we completed enrollment in the study in late 2016.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag2>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "SUMMIT-07", "study", "in", "February", "2015,", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "wordsB": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "SUMMIT-07", "study", "in", "February", "2015,", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p15_s0", "idA": "906709_17_item1_p9_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in late 2016.", "sentB": "The SUMMIT Phase 3 program also includes a 52-week long-term safety study, which we call SUMMIT-LTS.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag2>", "The", "SUMMIT", "Phase", "3", "program", "also", "includes", "a", "52-week", "long-term", "safety", "study,", "which", "we", "call", "SUMMIT-LTS.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "wordsB": ["The", "SUMMIT", "Phase", "3", "program", "also", "includes", "a", "52-week", "long-term", "safety", "study,", "which", "we", "call", "SUMMIT-LTS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "906709_18_item1_p63_s0", "idA": "906709_17_item1_p9_s1", "sentA": "We enrolled the first patient in the first Phase 3 efficacy study, which we call SUMMIT-07 in February 2015 and we completed enrollment in the study in late 2016.", "sentB": "The SUMMIT Phase 3 program also includes a 52-week long-term safety study, which we call SUMMIT-LTS.", "type": 2, "words": ["<tag1>", "We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016.", "<tag2>", "The", "SUMMIT", "Phase", "3", "program", "also", "includes", "a", "52-week", "long-term", "safety", "study,", "which", "we", "call", "SUMMIT-LTS.", "<tag3>"], "wordsA": ["We", "enrolled", "the", "first", "patient", "in", "the", "first", "Phase", "3", "efficacy", "study,", "which", "we", "call", "SUMMIT-07", "in", "February", "2015", "and", "we", "completed", "enrollment", "in", "the", "study", "in", "late", "2016."], "wordsB": ["The", "SUMMIT", "Phase", "3", "program", "also", "includes", "a", "52-week", "long-term", "safety", "study,", "which", "we", "call", "SUMMIT-LTS."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
